

Cervical Cancer Main Database Excluded Studies List

Level 2: Cervical Cancer is not the focus

Case reports. *Clinical Risk*. 2002;8(2):87-88.

CME exam. *Obstetrical and Gynecological Survey*. 2003;58(8):559.

Early warnings. *Nature*. 2009;458(7239):679.

Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes. *Prescrire International*. 2007;16(89):91-94.

Increased risk of pre-term delivery after pre-cancerous growth removal. *South African Journal of Obstetrics and Gynaecology*. 2004;10(2):26.

Minor cervical abnormalities: Call for guidelines review. *Medicine Today*. 2001;2(3):9.

Abdel-Hady, E.S.; Emam, M.; Al-Gohary, A.; Hassan, M.; Farag, M.K.; and Abo-Elkheir, M. Screening for cervical carcinoma using visual inspection with acetic acid. *International Journal of Gynaecology & Obstetrics*. 2006;93(2):118-122.

Abu, J. and Davies, Q. Endocervical curettage at the time of colposcopic assessment of the uterine cervix. *Obstetrical and Gynecological Survey*. 2005;60(5):315-320.

Adjorlolo-Johnson, G.; Unger, E.R.; Boni-Ouattara, E.; Toure-Coulibaly, K.; Maurice, C.; Vernon, S.D.; Sissoko, M.; Greenberg, A.E.; Wiktor, S.Z.; and Chorba, T.L. Assessing the relationship between HIV infection and cervical cancer in Cote d'Ivoire: a case-control study. *BMC Infectious Diseases*. 2010;10:242.

Alibhai, S.M.H. Cancer screening: The importance of outcome measures. *Critical Reviews in Oncology/Hematology*. 2006;57(3):215-224.

Al-Kadri, H.M.; Hajeer, A.H.; Al-Hawashim, N.S.; and Salem, H.H. The significance of documenting clinical appearance of the uterine cervix in the cervical cytology form. *Saudi Medical Journal*. 2006;27(11):1698-1702.

Allen, J.D.; Stoddard, A.M.; Mays, J.; and Sorensen, G. Promoting breast and cervical cancer screening at the workplace: results from the Woman to Woman Study. *American Journal of Public Health*. 2001;91(4):584-590.

Almog, B.; Gamzu, R.; Bornstein, J.; Levin, I.; Fainaru, O.; Niv, J.; Lessing, J.B.; and Bar-Am, A. Clinical and economic benefit of HPV-load testing in follow-up and management of women postcone biopsy for CIN2-3. *British Journal of Cancer*. 7-7-2003;89(1):109-112.

Alvarez, R.D.; Wright, T.C.; Jr.; and Optical Detection Group. Increased detection of high-grade cervical intraepithelial neoplasia utilizing an optical detection system as an adjunct to colposcopy. *Gynecologic Oncology*. 2007;106(1):23-28.

Aragones, A.; Trinh-Shevrin, C.; and Gany, F. Cancer screening practices among physicians serving Chinese immigrants. *Journal of Health Care for the Poor & Underserved*. 2009;20(1):64-73.

Arbyn, M. and Cuzick, J. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention. [Review] *Cancer Letters*. 2009;278(1):1-2.

Arbyn, M.; Anttila, A.; Jordan, J.; Ronco, G.; Schenck, U.; Segnan, N.; Wiener, H.; Herbert, A.; and von, Karsa L. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. *Annals of Oncology*. 2010;21(3):448-458.

- Arbyn, M.; Schenck, U.; Ellison, E.; and Hanselaar, A. Metaanalysis of the accuracy of rapid prescreening relative to full screening of pap smears. *Cancer*. 2003;99(1):9-16.
- Astbury, K.; Martin, C.M.; Ring, M.; Pilkington, L.; Bolger, N.; Sheils, O.M.; and O'Leary, J.J. Future molecular aspects of cervical cytology. *Current Diagnostic Pathology*. 2006;12(2):104-113.
- Austin, R. and Zhao, C. Test group biases and ethical concerns mar New England Journal of Medicine articles promoting HPV screening for cervical cancer in rural India. *CytoJournal*. 2009;6, 2009. Article Number: 12. Date of Publication: 2009.
- Baileff, A. Cervical screening: patients' negative attitudes and experiences. [Review]. *Nursing Standard*. 2000;14(44):35-37.
- Bais, A.G.; Eijkemans, M.J.; Rebolj, M.; Snijders, P.J.; Verheijen, R.H.; van, Ballegooijen M.; Meijer, C.J.; and Helmerhorst, T.J. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. *International Journal of Cancer*. 2009;124(4):889-895.
- Balasubramani, L.; Orbell, S.; Hagger, M.; Brown, V.; and Tidy, J. Can default rates in colposcopy really be reduced?. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2008;115(3):403-408.
- Balasubramanian, A.; Hughes, J.; Mao, C.; Ridder, R.; Herkert, M.; Kiviat, N.B.; and Koutsky, L.A. Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer. *Cancer Epidemiology, Biomarkers & Prevention*. 2009;18(11):3008-3017.
- Barzon, L.; Giorgi, C.; Buonaguro, F.M.; and Palu, G. Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. *Infectious Agents and Cancer*. 2008;3(1).
- Barzon, L.; Pizzighella, S.; Corti, L.; Mengoli, C.; and Palu, G. Vaginal dysplastic lesions in women with hysterectomy and receiving radiotherapy are linked to high-risk human papillomavirus. *Journal of Medical Virology*. 2002;67(3):401-405.
- Basen-Engquist, K.; Paskett, E.D.; Buzaglo, J.; Miller, S.M.; Schover, L.; Wenzel, L.B.; Bodurka, D.C.; and Follen, M. Cervical Cancer: Behavioral Factors Related to Screening, Diagnosis, and Survivors' Quality of Life. *Cancer*. 2003;98(9 SUPPL.):2009-2014.
- Basen-Engquist, K.; Shinn, E.H.; Carla, Warneke A.; De, Moor C.; Le, T.; Richards-Kortum, R.; and Follen, M. Patient distress and satisfaction with optical spectroscopy in cervical dysplasia detection. *American Journal of Obstetrics and Gynecology*. 2003;189(4):1136-1142.
- Bastani, R.; Berman, B.A.; Belin, T.R.; Crane, L.A.; Marcus, A.C.; Nasser, K.; Herman-Shipley, N.; Bernstein, S.; and Henneman, C.E. Increasing cervical cancer screening among underserved women in a large urban county health system: can it be done? What does it take?. *Medical Care*. 2002;40(10):891-907.
- Batal, H.; Biggerstaff, S.; Dunn, T.; and Mehler, P.S. Cervical cancer screening in the urgent care setting. *Journal of General Internal Medicine*. 2000;15(6):389-394.
- Bateson, D.J. and Weisberg, E. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears. *Menopause*. 2009;16(4):765-769.
- Beach, M.L.; Flood, A.B.; Robinson, C.M.; Cassells, A.N.; Tobin, J.N.; Greene, M.A.; and Dietrich, A.J. Can language-concordant prevention care managers improve cancer screening rates?. *Cancer Epidemiology, Biomarkers & Prevention*. 2007;16(10):2058-2064.
- Behbakht, K.; Friedman, J.; Heimler, I.; Aroutcheva, A.; Simoes, J.; and Faro, S. Role of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: a case-control study. *Infectious Diseases in Obstetrics & Gynecology*. 2002;10(4):181-186.

Belinson, J.L.; Hu, S.; Niyazi, M.; Pretorius, R.G.; Wang, H.; Wen, C.; Smith, J.S.; Li, J.; Taddeo, F.J.; Burchette, R.J.; and Qiao, Y.L. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection. *International Journal of Cancer*. 2010;127(5):1151-1157.

Belinson, J.L.; Pretorius, R.G.; Enerson, C.; Garcia, F.; Cruz, E.P.; Belinson, S.E.; Yeverino, Garcia E.; and Brainard, J. The Mexican Cervical Cancer Screening Trial: self-sampling for human papillomavirus with unaided visual inspection as a secondary screen. *International Journal of Gynecological Cancer*. 2009;19(1):27-32.

Ben, Hmid R.; Mourali, M.; Zghal, D.; Mahjoub, S.; Naceur, C.; Sbai, N.; and Zouari, F. [Usefulness of colposcopy in inflammatory cervico-vaginal smears: apropos of 140 cases]. [French]. *Tunisie Medicale*. 2007;85(6):500-504.

Bewtra, C.; Pathan, M.; and Hashish, H. Abnormal Pap smears with negative follow-up biopsies: improving cytohistologic correlations. *Diagnostic Cytopathology*. 2003;29(4):200-202.

Bewtra, C.; Xie, Q.; Soundararajan, S.; Gatalica, Z.; and Hatcher, L. Genital human papillomavirus testing by in situ hybridization in liquid atypical cytologic materials and follow-up biopsies. *Acta Cytologica*. 2005;49(2):127-131.

Bhatla, N. and Joseph, E. Cervical cancer prevention & the role of human papillomavirus vaccines in India. *Indian Journal of Medical Research*. 2009;130(3):334-340.

Birner, P.; Bachtary, B.; Dreier, B.; Schindl, M.; Joura, E.A.; Breitenecker, G.; and Oberhuber, G. Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions. *Modern Pathology*. 2001;14(7):702-709.

Biscotti, C.V.; Dawson, A.E.; Dziura, B.; Galup, L.; Darragh, T.; Rahemtulla, A.; and Wills-Frank, L. Assisted primary screening using the automated ThinPrep Imaging System. *American Journal of Clinical Pathology*. 2005;123(2):281-287.

Bohmer, G.; Van Den Brule, A.J.; Brummer, O.; Meijer, C.L.; and Petry, K.U. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. *American Journal of Obstetrics & Gynecology*. 2003;189(1):118-120.

Bond, S. Is the Pap Test on its Way Out?. *Journal of Midwifery and Women's Health*. 2008;53(2):166-167.

Bosch, F.X. and de, Sanjose S. Human papillomavirus in cervical cancer. [Review]. *Current Oncology Reports*. 2002;4(2):175-183.

Bosze, P. Colposcopy used in a primary setting (routine colposcopy): advantages and concerns. *European Journal of Gynaecological Oncology*. 2006;27(1):5-9.

Boulet, G.A.; Benoy, I.H.; Depuydt, C.E.; Horvath, C.A.; Aerts, M.; Hens, N.; Vereecken, A.J.; and Bogers, J.J. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia ≥ 2 in a liquid-based cytology setting?. *Cancer Epidemiology, Biomarkers & Prevention*. 2009;18(11):2992-2999.

Brabin, L.; Roberts, S.A.; Farzaneh, F.; Fairbrother, E.; and Kitchener, H.C. The second to fourth digit ratio (2D:4D) in women with and without human papillomavirus and cervical dysplasia. *American Journal of Human Biology*. 2008;20(3):337-341.

Brewster, W.R.; Hubbell, F.A.; Largent, J.; Ziogas, A.; Lin, F.; Howe, S.; Ganiats, T.G.; Anton-Culver, H.; and Manetta, A. Feasibility of management of high-grade cervical lesions in a single visit: a randomized controlled trial. *JAMA*. 11-2-2005;294(17):2182-2187.

Brodersen, J. Screening in disease prevention: What works? [2]. *Journal of Epidemiology and Community Health*. 2007;61(2):172-173.

Broughton, S. A review of the literature: interventions to maximize capacity to consent and reduce anxiety of women with learning disabilities preparing for a cervical smear test. [Review] [79 refs]. *Health Services Management Research*. 2002;15(3):173-185.

Burn, R. Managing low-grade cervical lesions [2]. *CMAJ*. 2006;174(6):813.

Cairns, M.; Gray, N.M.; and Cruickshank, M.E. The impact of microinvasive cancer of the cervix on women during follow-up. *International Journal of Gynecological Cancer*. 2008;18(6):1289-1293.

Canavan, T.P. and Doshi, N.R. Cervical cancer. [Review]. *American Family Physician*. 2000;61(5):1369-1376.

Cantor, S.B.; Cardenas-Turanzas, M.; Cox, D.D.; Atkinson, E.N.; Noguerras-Gonzalez, G.M.; Beck, J.R.; Follen, M.; and Benedet, J.L. Accuracy of colposcopy in the diagnostic setting compared with the screening setting. *Obstetrics & Gynecology*. 2008;111(1):7-14.

Cariaggi, M.P.; Confortini, M.; Mirri, F.; and Tinacci, G. Interobserver reproducibility: a new approach to quality control by using digital images (D.I. Test). *Acta Cytologica*. 2001;45(3):488-490.

Castle, P.E.; Schiffman, M.; and Wheeler, C.M. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. *American Journal of Obstetrics and Gynecology*. 2004;191(5):1590-1597.

Castle, P.E.; Schiffman, M.; Burk, R.D.; Wacholder, S.; Hildesheim, A.; Herrero, R.; Bratti, M.C.; Sherman, M.E.; and Lorincz, A. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. *Cancer Epidemiology, Biomarkers & Prevention*. 2002;11(11):1394-1399.

Castle, P.E.; Schiffman, M.; Wheeler, C.M.; Wentzensen, N.; and Gravitt, P.E. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. *Cancer Epidemiology, Biomarkers & Prevention*. 2010;19(7):1675-1681.

Castle, P.E.; Solomon, D.; Wheeler, C.M.; Gravitt, P.E.; Wacholder, S.; and Schiffman, M. Human papillomavirus genotype specificity of hybrid capture 2. *Journal of Clinical Microbiology*. 2008;46(8):2595-2604.

Castle, P. E. The evolving definition of carcinogenic human papillomavirus. *Infectious Agents and Cancer*. 2009;4(1).

Chan, C.; Ho, S. C.; Chan, S. G.; Yip, Y.B.; Wong, F.C.; and Cheng, F. Factors affecting uptake of cervical and breast cancer screening among perimenopausal women in Hong Kong. *Hong Kong Medical Journal*. 2002;8(5):334-341.

Chao, F.Y.; Chao, A.; Huang, C.C.; Hsueh, S.; Yang, J.E.; Huang, H.J.; Wang, L.C.; Lin, C.T.; Chou, H.H.; and Lai, C.H. Defining detection threshold and improving analytical proficiency of HPV testing in clinical specimens. *Gynecologic Oncology*. 2010;117(2):302-307.

Chhieng, D.C.; Talley, L.I.; Roberson, J.; Gatscha, R.M.; Jhala, N.C.; and Elgert, P.A. Interobserver variability: comparison between liquid-based and conventional preparations in gynecologic cytology. *Cancer*. 4-25-2002;96(2):67-73.

Chivukula, M.; Austin, R.M.; and Shidham, V.B. Evaluation and significance of hyperchromatic crowded groups (HCG) in liquid-based paps. *CytoJournal*. 2007;4 , 2007. Article Number: 2. Date of Publication: 2007.

Coe, K.; Martin, L.; Nuvayestewa, L.; Attakai, A.; Papenfuss, M.; De Zapien, J.G.; Seymour, S.S.;

- Hunter, J.; and Giuliano, A. Predictors of Pap test use among women living on the Hopi reservation. *Health Care for Women International*. 2007;28(9):764-781.
- Cohen, D.; Shorie, J.; and Biscotti, C. Glacial acetic acid treatment and atypical endocervical glandular cells: an analysis of 92 cases. *American Journal of Clinical Pathology*. 2010;133(5):799-801.
- Confortini, M.; Bulgaresi, P.; Cariaggi, M.P.; Carozzi, F.M.; Cecchini, S.; Cipparrone, I.; Maddau, C.; Rossi, R.; Troni, G.M.; Zappa, M.; and Ciatto, S. Conventional pap smear and liquid-based cervical cytology smear: comparison from the same patient. *Tumori*. 2002;88(4):288-290.
- Coronado, G.D.; Thompson, B.; and Chen, L. Sociodemographic correlates of cancer screening services among Hispanics and non-Hispanic whites in a rural setting. *American Journal of Health Behavior*. 2009;33(2):181-191.
- Coughlin, S.S. and Wilson, K.M. Breast and cervical cancer screening among migrant and seasonal farmworkers: a review. [Review] [39 refs]. *Cancer Detection & Prevention*. 2002;26(3):203-209.
- Cox, J.T. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. [Review] [59 refs][Erratum appears in *J Clin Virol*. 2010 Mar;47(3):299]. *Journal of Clinical Virology*. 2009;45:Suppl-S12.
- Cremer, M.L.; Peralta, E.I.; Dheming, S.G.; Jimenez, M.E.; Davis-Dao, C.A.; Alonzo, T.A.; Blumenthal, P.D.; and Felix, J.C. Digital assessment of the reproductive tract versus colposcopy for directing biopsies in women with abnormal Pap smears. *Journal of Lower Genital Tract Disease*. 2010;14(1):5-10.
- Cremer, M.; Bullard, K.; Maza, M.; Peralta, E.; Moore, E.; Garcia, L.; Masch, R.; Lerner, V.; Alonzo, T.A.; and Felix, J. Cytology versus visual inspection with acetic acid among women treated previously with cryotherapy in a low-resource setting. *International Journal of Gynecology and Obstetrics*. 2010;111(3):249-252.
- Croll, E.; Rana, D.N.; and Walton, L.J. Hyperchromatic crowded cell groups in gynaecological liquid-based cytology samples. *British Journal of Biomedical Science*. 2010;67(3):154-163.
- Daley, E.M.; Perrin, K.M.; McDermott, R.J.; Vamos, C.A.; Rayko, H.L.; Packing-Ebuen, J.L.; Webb, C.; and McFarlane, M. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV+ women. *Journal of Health Psychology*. 2010;15(2):279-290.
- Dallenbach-Hellweg, G.; Trunk, M.J.; and Von Knebel, Doeberitz M. Traditional and new molecular methods for early detection of cervical cancer. [Review] [47 refs]. *Arkhiv Patologii*. 2004;66(5):35-39.
- De, Costa C. Flora's legacy. *Lancet*. 2001;358(9299):2162-2163.
- Dehbashi, S.; Honarvar, M.; and Riaz, Montazer N. Comparison of cotton swab-spatula and cytobrush-spatula for cervical cytology. *International Journal of Gynaecology & Obstetrics*. 2002;76(2):185-187.
- Dehn, D.; Torkko, K.C.; and Shroyer, K.R. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. [Review] [142 refs]. *Cancer*. 2-25-2007;111(1):1-14.
- Del, Mistro A.; Frayle-Salamanca, H.; Trevisan, R.; Matteucci, M.; Pinarello, A.; Zambenedetti, P.; Buoso, R.; Fantin, G.P.; Zorzi, M.; and Minucci, D. Triage of women with atypical squamous cells of undetermined significance (ASC-US): Results of an Italian multicentric study. *Gynecologic Oncology*. 2010;117(1):77-81.
- Denny, L.; Kuhn, L.; and Wright, TC Jr. Randomized clinical trial of the safety and efficacy of a screen and treat cervical cancer prevention programme [Abstracts 109: Presented for the Thirty-Sixth Society of Gynecologic Oncologist]. *Gynecologic Oncology*. 2005;96(3):958-959.

Denny, L.; Kuhn, L.; De, Souza M.; Pollack, A. E.; Dupree, W.; and Wright, T. C.; Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. *JAMA*. 11-2-2005;294(17):2173-2181.

Denny, L.; Quinn, M.; and Sankaranarayanan, R. Chapter 8: Screening for cervical cancer in developing countries. [Review] [23 refs]. *Vaccine*. 8-31-2006;24:Suppl-7.

Depuydt, C. E.; Vereecken, A. J.; Salembier, G. M.; Vanbrabant, A. S.; Boels, L. A.; van, Herck E.; Arbyn, M.; Segers, K.; and Bogers, J. J. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. *British Journal of Cancer*. 2-24-2003;88(4):560-566.

DeSantis, T.; Chakhtoura, N.; Twiggs, L.; Ferris, D.; Lashgari, M.; Flowers, L.; Faupel, M.; Bambot, S.; Raab, S.; and Wilkinson, E. Spectroscopic imaging as a triage test for cervical disease: a prospective multicenter clinical trial. *Journal of Lower Genital Tract Disease*. 2007;11(1):18-24.

Dey, P.; Gibbs, A.; Arnold, D. F.; Saleh, N.; Hirsch, P. J.; and Woodman, C. B. Loop diathermy excision compared with cervical laser vaporisation for the treatment of intraepithelial neoplasia: a randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2002;109(4):381-385.

Dillner, J. Cervical cancer screening in Sweden. *European Journal of Cancer*. 2000;36(17):2255-2259.

Doh, A. S.; Nkele, N. N.; Achu, P.; Essimbi, F.; Essame, O.; and Nkegoum, B. Visual inspection with acetic acid and cytology as screening methods for cervical lesions in Cameroon. *International Journal of Gynaecology & Obstetrics*. 2005;89(2):167-173.

Doorbar, J. and Cubie, H. Molecular basis for advances in cervical screening. [Review] [93 refs]. *Molecular Diagnosis*. 2005;9(3):129-142.

Doyle, B.; O'Farrell, C.; Mahoney, E.; Turner, L.; Magee, D.; and Gibbons, D. Liquid-based cytology improves productivity in cervical cytology screening. *Cytopathology*. 2006;17(2):60-64.

Dudding, N. and Sutton, J. BSCC terminology conference, koilocytosis and mild dyskaryosis. *Cytopathology*. 2002;13(6):379-381.

Duggan, M. A. Papnet-assisted, primary screening of cervico-vaginal smears. *European Journal of Gynaecological Oncology*. 2000;21(1):35-42.

Dzuba, I. G.; Diaz, E. Y.; Allen, B.; Leonard, Y. F.; Lazcano Ponce, E. C.; Shah, K. V.; Bishai, D.; Lorincz, A.; Ferris, D.; Turnbull, B.; Hernandez, Avila M.; and Salmeron, J. The acceptability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. *Journal of Womens Health & Gender-Based Medicine*. 2002;11(3):265-275.

Edwards, J. B. and Tudiver, F. Women's preventive screening in rural health clinics. *Womens Health Issues*. 2008;18(3):155-166.

Edwards, J. M.; Howat, A. J.; Hermansen, P. J.; and Hillier, V. F. Borderline nuclear change; can a subgroup be identified which is suspicious of high-grade cervical intraepithelial neoplasia, i e CIN 2 or worse?. *Cytopathology*. 2002;13(5):267-272.

Eftekhari, Z.; Rahimi-Moghaddam, P.; Yarandi, F.; and Brojerdi, R. Accuracy of visual inspection with acetic acid (VIA) for early detection of cervical dysplasia in Tehran, Iran. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2005;6(1):69-71.

Eleuterio, J.; Jr.; Giraldo, P. C.; Cavalcante, D. I.; Goncalves, A. K.; Eleuterio, R. M.; and Giraldo, H. P. Papillary squamous cell carcinoma of the uterine cervix, high-risk human papilloma virus infection and p16(INK4a) expression: a case report. *Acta Cytologica*. 2009;53(2):188-190.

- Elit, L. M. Pitfalls in the diagnosis of cervical intraepithelial neoplasia 1. *Journal of Lower Genital Tract Disease*. 2004;8(3):181-187.
- Ell, K.; Vourlekis, B.; Muderspach, L.; Nissly, J.; Padgett, D.; Pineda, D.; Sarabia, O.; and Lee, P. J. Abnormal cervical screen follow-up among low-income Latinas: Project SAFE. *Journal of Womens Health & Gender-Based Medicine*. 2002;11(7):639-651.
- Ell, K.; Vourlekis, B.; Nissly, J.; Padgett, D.; Pineda, D.; Sarabia, O.; Walther, V.; Blumenfield, S.; and Lee, P. J. Integrating mental health screening and abnormal cancer screening follow-up: an intervention to reach low-income women. *Community Mental Health Journal*. 2002;38(4):311-325.
- El-Shalakany, A. H.; Saeed, M. M.; Reda Abdel-Aal, M.; El-Nakeeb, A. H.; Noseirat, N.; Ayyad, S. B.; and El Din, Z. S. Direct visual inspection of the cervix with Lugol iodine for the detection of premalignant lesions. *Journal of Lower Genital Tract Disease*. 2008;12(3):193-198.
- Elsheikh, T. M.; Kirkpatrick, J. L.; Fischer, D.; Herbert, K. D.; and Renshaw, A. A. Does the time of day or weekday affect screening accuracy? A pilot correlation study with cytotechnologist workload and abnormal rate detection using the ThinPrep Imaging System. *Cancer Cytopathology*. 2-25-2010;118(1):41-46.
- Elwood, J. M. Developing areas in cancer in New Zealand. *Japanese Journal of Clinical Oncology*. 2002;32:Suppl-51.
- Fagan, E. J.; Moore, C.; Jenkins, C.; Rossouw, A.; Cubie, H. A.; and James, V. L. External quality assessment for molecular detection of human papillomaviruses. *Journal of Clinical Virology*. 2010;48(4):251-254.
- Fakoya, A.; Lamba, H.; Mackie, N.; Nandwani, R.; Brown, A.; Bernard, E. J.; Gilling-Smith, C.; Lacey, C.; Sherr, L.; Claydon, P.; Wallage, S.; and Gazzard, B. British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. *HIV Medicine*. 2008;9(9):681-720.
- Farley, M.; Golding, J. M.; and Minkoff, J. R. Is a history of trauma associated with a reduced likelihood of cervical cancer screening?. *Journal of Family Practice*. 2002;51(10):827-831.
- Ferrante, J. M.; Mayhew, D. Y.; Goldberg, S.; Woodard, L.; Selleck, C.; and Roetzheim, R. G. Empiric treatment of minimally abnormal papanicolaou smears with 0.75% metronidazole vaginal gel.[Erratum appears in *J Am Board Fam Pract*. 2002 Nov-Dec;15(6):456.]. *Journal of the American Board of Family Practice*. 2002;15(5):347-354.
- Ferris, D. G.; Gilman, P. A.; Leyva Lopez, A. G.; Litaker, M. S.; Miller, J. A.; and Macfee, M. S. Psychological effects women experience before and after a colposcopic examination and primary care appointment. *Journal of Lower Genital Tract Disease*. 2003;7(2):89-94.
- Flores, Y.; Shah, K.; Lazcano, E.; Hernandez, M.; Bishai, D.; Ferris, D. G.; Lorincz, A.; Hernandez, P.; Salmeron, J.; and Morelos HPV, Study Collaborators. Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study. *Salud Publica de Mexico*. 2002;44(4):335-344.
- Flourie, F.; Cherfa, H.; and Bornet, H. [Diagnosis of ruptured fetal membranes by detection of insulin growth factor binding protein-1 (IGFBP-1) in cervical-vaginal secretions: interpretation of weakly positive results]. [French]. *Annales de Biologie Clinique*. 2002;60(5):623-624.
- Forbes, C.; Jepson, R.; and Martin-Hirsch, P. Interventions targeted at women to encourage the uptake of cervical screening. [Review] [82 refs]. *Cochrane Database of Systematic Reviews*. 2002;(3):CD002834.

Frale, W. J. Error reduction and risk management in cytopathology. *Seminars in Diagnostic Pathology*. 2007;24(2):77-88.

Franco, E. L. and Drummond, M. F. Cost-effectiveness analysis: An essential tool to inform public health policy in cervical cancer prevention. *Vaccine*. 2008;26(SUPPL.5):F1-F2.

Franco, E. L. Persistent HPV infection and cervical cancer risk: Is the scientific rationale for changing the screening paradigm enough?. *Journal of the National Cancer Institute*. 2010;102(19):1451-1453.

Freeman-Wang, T. and Walker, P. G. Counselling patients referred for colposcopy. *CME Journal of Gynecologic Oncology*. 2000;5(1):60-63.

Freeman-Wang, T. and Walker, P. Psychological aspects of colposcopy. *CME Journal of Gynecologic Oncology*. 2005;10(2):123-126.

Gage, J. C. and Castle, P. E. Preventing cervical cancer globally by acting locally: if not now, when?. *Journal of the National Cancer Institute*. 10-20-2010;102(20):1524-1527.

Gaikwad, N. L.; Mahajan, N. N.; and Mahajan, K. N. Re: Alternative cervical cancer prevention in low-resource settings: experiences of visual inspection by acetic acid with single-visit approach in the first five provinces of Thailand. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2007;47(3):258-259.

Galaal, K. A.; Deane, K.; Sangal, S.; and Lopes, A. D. Interventions for reducing anxiety in women undergoing colposcopy. [Review] [47 refs]. *Cochrane Database of Systematic Reviews*. 2007;#volume#(3):CD006013.

Galan-Sanchez, F. and Rodriguez-Iglesias, M. A. Use of Cervista HPV HR assay for detection of human papillomavirus in samples with hybrid capture borderline negative results. *APMIS*. 9-1-2010;118(9):681-684.

Gambert, S. R. Ring in the New Year with healthcare screening and preventive strategies. *Clinical Geriatrics*. 2007;15(1):11-12.

Garrido Martinez, J. L.; Diaz, M. M.; and Villarreal, A. Clinical cytohistologic correlations of lesions of the female genital tract: our experience in Panama. *European Journal of Gynaecological Oncology*. 2007;28(3):217-219.

Geisinger, K. R.; Vrbin, C.; Grzybicki, D. M.; Wagner, P.; Garvin, A. J.; and Raab, S. S. Interobserver variability in human papillomavirus test results in cervicovaginal cytologic specimens interpreted as atypical squamous cells. *American Journal of Clinical Pathology*. 2007;128(6):1010-1014.

Giannone, L.; Saab, J.-C.; and Giannone, E. Squamous atypia in the atrophic cervical vaginal smear. *Revue Medicale Libanaise*. 2004;16(1):29-31.

Goel, A.; Gandhi, G.; Batra, S.; Bhambhani, S.; Zutshi, V.; and Sachdeva, P. Visual inspection of the cervix with acetic acid for cervical intraepithelial lesions. *International Journal of Gynaecology & Obstetrics*. 2005;88(1):25-30.

Gok, M.; Heideman, D. A.; van Kemenade, F. J.; Berkhof, J.; Rozendaal, L.; Spruyt, J. W.; Voorhorst, F.; Belien, J. A.; Babovic, M.; Snijders, P. J.; and Meijer, C. J. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. *BMJ*. 2010;340:c1040.

Goldhaber-Fiebert, J. D.; Stout, N. K.; Ortendahl, J.; Kuntz, K. M.; Goldie, S. J.; and Salomon, J. A. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. *Population Health Metrics*. 2007;5, 2007. Article Number: 11. Date of Publication: 29 Oct 2007.

- Grange, G.; Malvy, D.; Lancon, F.; Gaudin, A. F.; and El, Hasnaoui A. Factors associated with regular cervical cancer screening. *International Journal of Gynaecology & Obstetrics*. 2008;102(1):28-33.
- Guido, R. Human papillomavirus and cervical disease in adolescents. *Clinical Obstetrics and Gynecology*. 2008;51(2):290-305.
- Guilfoyle, S.; Franco, R.; and Gorin, S. S. Exploring older women's approaches to cervical cancer screening. *Health Care for Women International*. 2007;28(10):930-950.
- Guillaud, M.; Adler-Storthz, K.; Malpica, A.; Staerckel, G.; Maticic, J.; Van, Niekirk D.; Cox, D.; Poulin, N.; Follen, M.; and Macaulay, C. Subvisual chromatin changes in cervical epithelium measured by texture image analysis and correlated with HPV. *Gynecologic Oncology*. 2005;99(3:Suppl 1):Suppl-23.
- Guo, M.; Hu, L.; Martin, L.; Liu, S.; Baliga, M.; and Hughson, M. D. Accuracy of liquid-based Pap tests: comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal Pap smears. *Acta Cytologica*. 2005;49(2):132-138.
- Gupta, D. K.; Komaromy-Hiller, G.; Raab, S. S.; and Nath, M. E. Interobserver and intraobserver variability in the cytologic diagnosis of normal and abnormal metaplastic squamous cells in pap smears. *Acta Cytologica*. 2001;45(5):697-703.
- Hamashima, C.; Sobue, T.; Muramatsu, Y.; Saito, H.; Moriyama, N.; and Kakizoe, T. Comparison of observed and expected numbers of detected cancers in the Research Center for Cancer Prevention and Screening program. *Japanese Journal of Clinical Oncology*. 2006;36(5):301-308.
- Hammes, L. S.; Naud, P.; Passos, E. P.; Matos, J.; Brouwers, K.; Rivoire, W.; and Syrjanen, K. J. Value of the International Federation for Cervical Pathology and Colposcopy (IFCPC) Terminology in predicting cervical disease. *Journal of Lower Genital Tract Disease*. 2007;11(3):158-165.
- Hammou, J. C. Thin-layer cytology: identification of human papillomavirus by hybridization, capture and signal amplification assay using an alcoholic cell preservative medium. *Acta Cytologica*. 2007;51(2):193-196.
- Hancock, L.; Sanson-Fisher, R.; Perkins, J.; Corkrey, R.; Burton, R.; and Reid, S. Effect of a community action intervention on cervical cancer screening rates in rural Australian towns: the CART project. *Preventive Medicine*. 2001;32(2):109-117.
- Hans, N.; Cave, A. J.; Szafran, O.; Johnson, G.; Glass, A.; Spooner, G. R.; Klemka, P. J.; and Schipper, S. Papanicolaou smears: to swab or not to swab. *Canadian Family Physician*. 2007;53(8):1328-1329.
- Harper, D. M.; Longacre, M. R.; Noll, W. W.; Belloni, D. R.; and Cole, B. F. Factors affecting the detection rate of human papillomavirus. *Annals of Family Medicine*. 2003;1(4):221-227.
- Harper, D. M.; Noll, W. W.; Belloni, D. R.; and Cole, B. F. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed--biologic concordance and women's preferences. *American Journal of Obstetrics & Gynecology*. 2002;186(3):365-373.
- Harpole, L. H.; Mort, E. A.; Freund, K. M.; Orav, J.; and Brennan, T. A. A comparison of the preventive health care provided by women's health centers and general internal medicine practices. *Journal of General Internal Medicine*. 2000;15(1):1-7.
- Harris, T. G.; Miller, L.; Kulasingam, S. L.; Feng, Q.; Kiviat, N. B.; Schwartz, S. M.; and Koutsky, L. A. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. *American Journal of Obstetrics & Gynecology*. 2009;200(5):489-8.
- Harry, V. N.; Narayansingh, G. V.; and Parkin, D. E. Is this the end of the line for the moderate dyskaryotic smear?. *Journal of Lower Genital Tract Disease*. 2008;12(1):20-23.

- Hellsten, C.; Lindqvist, P. G.; and Sjostrom, K. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2008;115(2):205-211.
- Herbert, A. and Johnson, J. Personal view. Is it reality or an illusion that liquid-based cytology is better than conventional cervical smears?. [Review] [26 refs]. *Cytopathology*. 2001;12(6):383-389.
- Herbert, A.; Holdsworth, G.; and Kubba, A. Why young women should be screened for cervical cancer: The distinction between CIN2 and CIN3. *International Journal of Cancer*. 2010;126(9):2256-2257.
- Hermens, R. P.; Hak, E.; Hulscher, M. E.; Braspenning, J. C.; and Grol, R. P. Adherence to guidelines on cervical cancer screening in general practice: programme elements of successful implementation. *British Journal of General Practice*. 2001;51(472):897-903.
- Herzog, T. J. and Barrena Medel, N. I. Cervical Squamous Cell Carcinoma and Adenocarcinoma: Etiology and Prevention. *American Journal of Medicine*. 2009;122(8 SUPPL.):S3-S9.
- Hoerl, H. D.; Shalkham, J. E.; Cheung, K.; Hurlbert, S. D.; Inhorn, S. L.; and Kurtycz, D. F. Screening parameters for ThinPrep and conventional gynecologic cytology via automated monitoring. *Acta Cytologica*. 2000;44(4):618-624.
- Holladay, E. B. and Allen, K. A. A new era for the Pap test. *JAAPA*. 2001;14(12):53-56.
- Holladay, E. B.; Logan, S.; Arnold, J.; Knesel, B.; and Smith, G. D. A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. *Cancer*. 12-25-2006;108(6):451-461.
- Holroyd, E. A.; Taylor-Piliae, R. E.; and Twinn, S. F. Investigating Hong Kong's Filipino domestic workers' healthcare behavior, knowledge, beliefs and attitudes towards cervical cancer and cervical screening. *Women and Health*. 2003;38(1):69-82.
- Hopfl, R. Skin test for HPV: Potential for clinical application?. *Papillomavirus Report*. 2001;12(2):31-36.
- Howard, M.; Agarwal, G.; and Lytwyn, A. Accuracy of self-reports of Pap and mammography screening compared to medical record: a meta-analysis. [Review] [60 refs]. *Cancer Causes & Control*. 2009;20(1):1-13.
- Hoyo, C.; Miller, W. C.; Newman, B. M.; and Fortney, J. A. Selective screening for cervical neoplasia: an approach for resource-poor settings. *International Journal of Epidemiology*. 2000;29(5):807-812.
- Hughes, A. A.; Glazner, J.; Barton, P.; and Shlay, J. C. A cost-effectiveness analysis of four management strategies in the determination and follow-up of atypical squamous cells of undetermined significance. *Diagnostic Cytopathology*. 2005;32(2):125-132.
- Huh, W. K. Optical detection of cervical neoplasia: Results from an internally-controlled multicenter study. *Gynecologic Oncology*. 2005;99(3 SUPPL.):S53.
- Hutchinson, T. P. and Gudlaugsdottir, S. Modeling bivariate ordinal contingency tables arising in studies of interobserver variation, with application to cervical screening. *Journal of Clinical Epidemiology*. 2002;55(4):422-423.
- Insinga, R. P.; Perez, G.; Wheeler, C. M.; Koutsky, L. A.; Garland, S. M.; Leodolter, S.; Jaura, E. A.; Ferris, D. G.; Steben, M.; Brown, D. R.; Elbasha, E. H.; Paavonen, J.; Haupt, R. M.; and FUTURE, I.; I. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. *Cancer Epidemiology, Biomarkers & Prevention*. 2010;19(6):1585-1594.
- Jacobs, E. A. and Lauderdale, D. S. Receipt of cancer screening procedures among Hispanic and non-Hispanic health maintenance organization members. *Cancer*. 1-1-2001;91(1:Suppl):Suppl-61.

- Jandorf, L.; Bursac, Z.; Pulley, L.; Trevino, M.; Castillo, A.; and Erwin, D. O. Breast and cervical cancer screening among Latinas attending culturally specific educational programs. *Progress in Community Health Partnerships*. 2008;2(3):195-204.
- Jastania, R.; Geddie, W. R.; Chapman, W.; and Boerner, S. Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing. *American Journal of Clinical Pathology*. 2006;125(2):223-228.
- Jatoi, I. and Anderson, W. F. In brief. *Current Problems in Surgery*. 2005;42(9):616-618.
- Jenkins, D. Diagnosing human papillomaviruses: recent advances. [Review] [97 refs]. *Current Opinion in Infectious Diseases*. 2001;14(1):53-62.
- Jenkins, D. Histopathology and cytopathology of cervical cancer. [Review] [79 refs]. *Disease Markers*. 2007;23(4):199-212.
- Jensen, H.; Svanholm, H.; Stovring, H.; and Bro, F. A primary healthcare-based intervention to improve a Danish cervical cancer screening programme: a cluster randomised controlled trial. *Journal of Epidemiology & Community Health*. 2009;63(7):510-515.
- Jeon, J. H.; Shin, D. M.; Cho, S. Y.; Song, K. Y.; Park, N. H.; Kang, H. S.; Kim, Y. D.; and Kim, I. G. Immunocytochemical detection of HPV16 E7 in cervical smear. *Experimental & Molecular Medicine*. 10-31-2007;39(5):621-628.
- Jeong, N. H.; Woo, M. K.; Lee, N. W.; Hur, S. J.; Choi, K. S.; and Kim, H. J. Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. *Archives of Pharmacal Research*. 2009;32(7):1013-1018.
- Jeronimo, J.; Castle, P. E.; Herrero, R.; Sherman, M. E.; Bratti, M. C.; Hildesheim, A.; Alfaro, M.; Morales, J.; Hutchinson, M. L.; Burk, R. D.; Lorincz, A.; Wacholder, S.; Rodriguez, A. C.; and Schiffman, M. Right-sided ectocervical lesions may be associated with false-negative cytology among women with histologic cervical intraepithelial neoplasia 2 or 3. *Journal of Lower Genital Tract Disease*. 2003;7(3):175-183.
- Jolley, J. A. and Wing, D. A. Pregnancy management after cervical surgery. *Current Opinion in Obstetrics and Gynecology*. 2008;20(6):528-533.
- Jordan, J.; Martin-Hirsch, P.; Arbyn, M.; Schenk, U.; Baldauf, J.-J.; Da, Silva D.; Anttila, A.; Nieminen, P.; and Prendiville, W. European guidelines for clinical management of abnormal cervical cytology, Part 2. *Cytopathology*. 2009;20(1):5-16.
- Kardos, T. F. The FocalPoint System: FocalPoint slide profiler and FocalPoint GS. [Review] [21 refs]. *Cancer*. 12-25-2004;102(6):334-339.
- Karpa, K. D. First cancer vaccine approved for women. *Drug Topics*. 2006;150(14).
- Keefe, K. A.; Tadir, Y.; Tromberg, B.; Berns, M.; Osann, K.; Hashad, R.; and Monk, B. J. Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid. *Lasers in Surgery & Medicine*. 2002;31(4):289-293.
- Kennedy, A. W. What do you recommend for a patient with a Pap smear indicating atypical cells?. [Review] [6 refs]. *Cleveland Clinic Journal of Medicine*. 2000;67(9):610-611.
- Kietpeerakool, C.; Srisomboon, J.; Tiayon, J.; Ruengkachorn, I.; Cheewakriangkrai, C.; Suprasert, P.; and Pantusart, A. Appropriate interval for repeat excision in women undergoing prior loop electrosurgical excision procedure for cervical neoplasia. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2007;8(3):379-382.
- Kim, H. W. [Effects of prevention education on Human Papillomavirus linked to cervix cancer for

unmarried female university students]. [Korean]. *Journal of Korean Academy of Nursing*. 2009;39(4):490-498.

Kim, J. J.; Salomon, J. A.; Weinstein, M. C.; and Goldie, S. J. Packaging health services when resources are limited: The example of a cervical cancer screening visit. *PLoS Medicine*. 2006;3(11):2031-2038.

Kim, K. and Ryu, S.-Y. Major clinical research advances in gynecologic cancer 2009. *Journal of Gynecologic Oncology*. 2009;20(4):203-209.

Klaes, R.; Friedrich, T.; Spitkovsky, D.; Ridder, R.; Rudy, W.; Petry, U.; Dallenbach-Hellweg, G.; Schmidt, D.; and Von Knebel, Doeberitz M. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. *International Journal of Cancer*. 4-15-2001;92(2):276-284.

Kok, M. R.; Boon, M. E.; Schreiner-Kok, P. G.; Hermans, J.; Grobbee, D. E.; and Kok, L. P. Less medical intervention after sharp demarcation of Grade 1-2 cervical intraepithelial neoplasia smears by neural network screening. *Cancer*. 6-25-2001;93(3):173-178.

Kornegay, J. R.; Roger, M.; Davies, P. O.; Shepard, A. P.; Guerrero, N. A.; Lloveras, B.; Evans, D.; and Coutlee, F. International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. *Journal of Clinical Microbiology*. 2003;41(3):1080-1086.

Kotaska, A. J. and Maticic, J. P. Cervical cleaning improves Pap smear quality. *CMAJ Canadian Medical Association Journal*. 9-30-2003;169(7):666-669.

Kothari, A.; Karim, S. Z.; Gordon, A.; Raslan, F.; Abdalla, M.; and George, S. A comparative study of two devices used for cervical cell sampling raises some doubts about liquid-based cytology. *International Journal of Gynecological Cancer*. 2006;16(4):1579-1586.

Kouria, G.; Venkataraman, G.; Mehrotra, S.; Wojcik, E. M.; and Sinacore, J. Interobserver agreement in the interpretation of chromogenic in situ hybridization for detection of human papillomavirus in gynecologic cytology: an appraisal of 55 cases. *Acta Cytologica*. 2007;51(3):494-496.

Kramer, B. S. and Croswell, J. M. Cancer screening: The clash of science and intuition. *Annual Review of Medicine*. 2009;60:125-137.

Krissi, H.; Levy, T.; Ben-Rafael, Z.; and Levavi, H. Fistula formation after large loop excision of the transformation zone in patients with cervical intraepithelial neoplasia. *Acta Obstetrica et Gynecologica Scandinavica*. 2001;80(12):1137-1138.

Kubovchik, M. Abnormal pap anxiety. *Nurse Practitioner*. 2004;29(1):10.

Kuhn, L.; Wang, C.; Tsai, W.-Y.; Wright, T. C.; and Denny, L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. *AIDS*. 2010;24(16):2553-2561.

Kuitto, K.; Pickel, S.; Neumann, H.; Jahn, D.; and Metelmann, H.-R. Attitudinal and socio-structural determinants of cervical cancer screening and HPV vaccination uptake: A quantitative multivariate analysis. *Journal of Public Health*. 2010;18(2):179-188.

Kulasingam, S. L.; Kim, J. J.; Lawrence, W. F.; Mandelblatt, J. S.; Myers, E. R.; Schiffman, M.; Solomon, D.; Goldie, S. J.; and ALTS Group. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). *Journal of the National Cancer Institute*. 1-18-2006;98(2):92-100.

Kulasingam, S. L.; Pagliusi, S.; and Myers, E. Potential effects of decreased cervical cancer screening

participation after HPV vaccination: an example from the U.S. *Vaccine*. 11-23-2007;25(48):8110-8113.

Kunde, D. P. and Weekes, A. R. L. Does coital frequency influence the severity of cervical intraepithelial neoplasia?. *Journal of Obstetrics and Gynaecology*. 2004;24(5):595-596.

Kupets, R. and Covens, A. Strategies for the implementation of cervical and breast cancer screening of women by primary care physicians. [Review] [28 refs]. *Gynecologic Oncology*. 2001;83(2):186-197.

Kyrgiou, M.; Tsoumpou, I.; Vrekoussis, T.; Martin-Hirsch, P.; Arbyn, M.; Prendiville, W.; Mitrou, S.; Koliopoulos, G.; Dalkalitsis, N.; Stamatopoulos, P.; and Paraskevaidis, E. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: The cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. *Cancer Treatment Reviews*. 2006;32(7):516-523.

Lamb, R. Open disclosure: The only approach to medical error. *Quality and Safety in Health Care*. 2004;13(1):3-5.

Lawson, W.; Schlecht, N. F.; and Brandwein-Gensler, M. The role of the human papillomavirus in the pathogenesis of Schneiderian inverted papillomas: an analytic overview of the evidence. [Review]. *Head and neck pathology*. 2008;2(2):49-59.

Lazcano-Ponce, E. C.; Moss, S.; Cruz-Valdez, A.; de Ruiz, P. A.; Martinez-Leon, C. J.; Casares-Queralt, S.; and Hernandez-Avila, M. The positive experience of screening quality among users of a cervical cancer detection center. *Archives of Medical Research*. 2002;33(2):186-192.

Lazcano-Ponce, E.; Palacio-Mejia, L. S.; Allen-Leigh, B.; Yunes-Diaz, E.; Alonso, P.; Schiavon, R.; and Hernandez-Avila, M. Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology. *Cancer Epidemiology, Biomarkers & Prevention*. 2008;17(10):2808-2817.

le Riche, H. R. and Botha, M. H. Cervical conisation and reproductive outcome. *South African Journal of Obstetrics and Gynaecology*. 2006;12(3):150-154.

Lee, C.; Mancuso, V.; Contant, T.; Jackson, R.; and Smith-McCune, K. Treatment of women with low-grade squamous intraepithelial lesions on cytologic evidence or biopsy results by board-certified gynecologists.[Erratum appears in *Am J Obstet Gynecol*. 2003 Jul;189(1):227]. *American Journal of Obstetrics & Gynecology*. 2003;188(3):693-698.

Lee, E. S.; Kim, I. S.; Choi, J. S.; Yeom, B. W.; Kim, H. K.; Han, J. H.; Lee, M. S.; and Leong, A. S. Accuracy and reproducibility of telecytology diagnosis of cervical smears. A tool for quality assurance programs. *American Journal of Clinical Pathology*. 2003;119(3):356-360.

Levenback, C. F. Status of sentinel lymph node biopsy in gynecological cancers. *Annals of Surgical Oncology*. 2008;15(1):18-20.

Li, J.; Lee, J. Y.; and Yeung, E. S. Quantitative screening of single copies of human papilloma viral DNA without amplification. *Analytical Chemistry*. 9-15-2006;78(18):6490-6496.

Li, Y.; Zeng, W. J.; Ye, F.; Wang, X. Y.; Lu, W. G.; Ma, D.; Wei, L. H.; and Xie, X. Application of hTERC in thinprep samples with mild cytologic abnormality and HR-HPV positive. *Gynecologic Oncology*. 2011;120(1):73-83.

Liao, C. C.; Wang, H. Y.; Lin, R. S.; Hsieh, C. Y.; and Sung, F. C. Addressing Taiwan's high incidence of cervical cancer: factors associated with the Nation's low compliance with Papanicolaou screening in Taiwan. *Public Health*. 2006;120(12):1170-1176.

Liao, S. Y.; Rodgers, W. H.; Kauderer, J.; Bonfiglio, T. A.; Walker, J. L.; Darcy, K. M.; Carter, R.; Hatae, M.; Levine, L.; Spirtos, N. M.; and Stanbridge, E. J. Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic

diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. *International Journal of Cancer*. 11-15-2009;125(10):2434-2440.

Lin, J.-W.; Chu, P.-L.; Liou, J.-M.; and Hwang, J.-J. Applying a multiple screening program aided by a guideline-driven computerized decision support system - A pilot experience in Yun-Lin, Taiwan. *Journal of the Formosan Medical Association*. 2007;106(1):58-68.

Maksem, J. A.; Finnemore, M.; Belsheim, B. L.; Roose, E. B.; Makkapati, S. R.; Eatwell, L.; and Weidmann, J. Manual method for liquid-based cytology: a demonstration using 1,000 gynecological cytologies collected directly to vial and prepared by a smear-slide technique. *Diagnostic Cytopathology*. 2001;25(5):334-338.

Marchevsky, A. M.; Khurana, R.; Thomas, P.; Scharre, K.; Farias, P.; and Bose, S. The use of virtual microscopy for proficiency testing in gynecologic cytopathology: A feasibility study using ScanScope. *Archives of Pathology and Laboratory Medicine*. 2006;130(3):349-355.

Markovic, O. and Markovic, N. Cervical acid phosphatase: A new biomarker of cervical dysplasia. *Archive of Oncology*. 2003;11(4):243-247.

Massad, L. S.; Einstein, M.; Myers, E.; Wheeler, C. M.; Wentzensen, N.; and Solomon, D. The impact of human papillomavirus vaccination on cervical cancer prevention efforts. [Review] [42 refs]. *Gynecologic Oncology*. 2009;114(2):360-364.

Matkowski, R. and Kornafel, J. Secondary prophylaxis of cancer. *Advances in Clinical and Experimental Medicine*. 2002;11(1):81-93.

McCaffrey, P. Cervical cancer: Tailored prevention programmes fit best. *Lancet Oncology*. 2005;6(12):925.

McCoy, D. R. Defending the pap smear: a proactive approach to the litigation threat in gynecologic cytology. [Review] [10 refs]. *American Journal of Clinical Pathology*. 2000;114:Suppl-8.

McQueen, F. and Duvall, E. Using a quality control approach to define an 'adequately cellular' liquid-based cervical cytology specimen. *Cytopathology*. 2006;17(4):168-174.

Meijer, C. J. L. M.; Berkhof, J.; Heideman, D. A. M.; and Snijders, P. J. F. Cervical cancer prevention: Who should receive vaccination? Commentary. *Nature Clinical Practice Oncology*. 2008;5(1):12-13.

Meijer, C. J. L. M.; Rozendaal, R.; Verheijen, R. M.; and Walboomers, J. M. M. Clinical role of HPV testing. *CME Journal of Gynecologic Oncology*. 2000;5(1):26-29.

Meyers, J. I. The perspective of a plaintiff's attorney in disassembling the art of medicine as it relates to the interpretation and management of cervical smears. [Review] [11 refs]. *American Journal of Clinical Pathology*. 2001;116:Suppl-22.

Migliore, G.; Rossi, E.; Aldovini, A.; Mudu, P.; Alderisio, M.; Giovagnoli, M. R.; Fabiano, A.; Morosini, P. L.; and Branca, M. Variation in the assessment of adequacy in cervical smears. *Cytopathology*. 2001;12(6):377-382.

Miller, A. B. Design of cancer screening trials/randomized trials for evaluation of cancer screening. *World Journal of Surgery*. 2006;30(7):1152-1162.

Mitchell, H.; Hocking, J.; and Saville, M. Temporal characteristics of laboratory screening errors in cervical cytology. *Acta Cytologica*. 2006;50(5):492-498.

Monnier-Benoit, S.; Dalstein, V.; Riethmuller, D.; Lalaoui, N.; Mouglin, C.; and Pretet, J. L. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions.[Erratum appears in *J Clin Virol*. 2006 Oct;37(2):137]. *Journal of Clinical Virology*. 2006;35(3):270-277.

Moreno, V.; Bosch, F. X.; Munoz, N.; Meijer, C. J.; Shah, K. V.; Walboomers, J. M.; Herrero, R.;

Franceschi, S.; and International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. *Lancet*. 3-30-2002;359(9312):1085-1092.

Moriarty, A. T.; Crothers, B. A.; Bentz, J. S.; Souers, R. J.; Fatheree, L. A.; and Wilbur, D. C. Automatic failure in gynecologic cytology proficiency testing. Results from the College of American Pathologists proficiency testing program. *Archives of Pathology & Laboratory Medicine*. 2009;133(11):1757-1760.

Morrell, S.; Mamoon, H.; O'Callaghan, J.; Taylor, R.; Ross, J.; and Wain, G. Early cervical cancer rescreening. *Journal of Medical Screening*. 2002;9(1):26-32.

Morris, B. J. Cervical human papillomavirus screening by PCR: Advantages of targeting the E6/E7 region. *Clinical Chemistry and Laboratory Medicine*. 2005;43(11):1171-1177.

Moseley, R. Liquid based cytology - Potential limitations?. *CPD Bulletin Cellular Pathology*. 2003;5(1):30-34.

Mravcak, S. A. Primary care for lesbians and bisexual women. *American Family Physician*. 2006;74(2):279-288.

Mudu, P.; Migliore, G.; Alderisio, M.; Morosini, P.; Douglas, G.; Navone, R.; Montanari, G.; Di, Bonito L.; Vitali, A.; Moretti, D.; Giovagnoli, M. R.; Fulciniti, F.; Branca, M.; and National Institute of Health Coordinating Group. Papnet-assisted cytological diagnosis intensifies the already marked variability among cytological laboratories.[Erratum appears in *Eur J Gynaecol Oncol*. 2002;23(4):268. Note: Vitale, A [corrected to Vitali, A]]. *European Journal of Gynaecological Oncology*. 2002;23(3):211-215.

Mukherjee, G.; Muralidhar, B.; Bafna, U. D.; Laskey, R. A.; and Coleman, N. MCM immunocytochemistry as a first line cervical screening test in developing countries: a prospective cohort study in a regional cancer centre in India. *British Journal of Cancer*. 4-10-2007;96(7):1107-1111.

Mulkey, D. A. Interobserver agreement about cervical cytologic and histologic diagnosis. *JAMA*. 6-13-2001;285(22):2855-2856.

Mullins, R. M. Can older women be motivated to attend for their final Papanicolaou tests? The use of targeted and general personalised reminder letters. *Cancer Epidemiology*. 2009;33(3-4):306-308.

Munoz, N.; Franco, E. L.; Herrero, R.; Andrus, J. K.; de, Quadros C.; Goldie, S. J.; and Bosch, F. X. Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. *Vaccine*. 2008;26(SUPPL. 11):L96-L107.

Mutlu, D.; Kandiser, A.; Simsek, T.; Pestereli, E.; Ogunc, D.; and Gultekin, M. Detection of high risk human papilloma viruses (HR-HPV) in endocervical scrapes from women with abnormal cytology in a Turkish University Hospital. *Kuwait Medical Journal*. 2010;42(1):50-54.

Mutyaba, T.; Mirembe, F.; Sandin, S.; and Weiderpass, E. Evaluation of 'see-see and treat' strategy and role of HIV on cervical cancer prevention in Uganda. *Reproductive Health*. 2010;7(1).

Muwonge, R.; Manuel, Mda G.; Filipe, A. P.; Dumas, J. B.; Frank, M. R.; and Sankaranarayanan, R. Visual screening for early detection of cervical neoplasia in Angola. *International Journal of Gynaecology & Obstetrics*. 2010;111(1):68-72.

Muwonge, R.; Walter, S. D.; Wesley, R. S.; Basu, P.; Shastri, S. S.; Thara, S.; Mbalawa, C. G.; Sankaranarayanan, R.; and IARC Multicentre Study Group on Cervical Cancer Early Detection. Assessing the gain in diagnostic performance when two visual inspection methods are combined for cervical cancer prevention. *Journal of Medical Screening*. 2007;14(3):144-150.

Myers, E.; Huh, W. K.; Wright, J. D.; and Smith, J. S. The current and future role of screening in the era

of HPV vaccination. *Gynecologic Oncology*. 2008;109(2 SUPPL.):S31-S39.

Naik, R.; Cross, P.; Nayar, A.; Mayadevi, S.; Lopes, A.; Godfrey, K.; and Hatem, H. Conservative surgical management of small-volume stage IB1 cervical cancer. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2007;114(8):958-963.

Nannapaneni, P.; Naik, R.; De Barros, Lopes A.; and Monaghan, J. M. Intra-abdominal bleed following LLETZ. *Journal of Obstetrics & Gynaecology*. 2002;22(1):99-100.

Nasca, M. R.; Potenza, M. C.; Alessi, L.; Paravizzini, G.; and Micali, G. Absence of PCR-detectable human papilloma virus in erythroplasia of Queyrat using a comparative control group. *Sexually Transmitted Infections*. 2010;86(3):199-201.

Ng, K. Y.; Chang, C. K.; Chen, J.; Wang, P. H.; and Teng, S. W. Is direct large loop electric excision for the transformation zone reasonable in the investigation of high-grade squamous intraepithelial lesions in cervical smears?. *European Journal of Gynaecological Oncology*. 2004;25(1):61-65.

Nieminen, P.; Hakama, M.; Viikki, M.; Tarkkanen, J.; and Anttila, A. Prospective and randomised public-health trial on neural network-assisted screening for cervical cancer in Finland: results of the first year. *International Journal of Cancer*. 1-20-2003;103(3):422-426.

No authors listed. Effect of HAART on cervical growths. *Treatment Update*. 2001;13(4):3-4.

No authors listed. Most older adults do not receive preventive health services. *Drug Benefit Trends*. 2009;21(11):339.

Nunez, J. T.; Delgado, M.; Pino, G.; Giron, H.; and Bolet, B. Cyto-colpo-histological study in sexual workers. *Journal of Lower Genital Tract Disease*. 2001;5(4):208-211.

Oberg, T. N.; Kipp, B. R.; Vrana, J. A.; Bartholet, M. K.; Fales, C. J.; Garcia, R.; McDonald, A. N.; Rosas, B. L.; Henry, M. R.; and Clayton, A. C. Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens. *Diagnostic Cytopathology*. 2010;38(8):564-572.

Oettel, M. Congress Report: 2nd Meeting of the Egon & Ann Diczfalusy Foundation "Prevention in Women's Health" September 30 - October 1, 2008, Szeged, Hungary. *Journal fur Reproduktionsmedizin und Endokrinologie*. 2010;7(1):45-49.

Oevestad, I. T.; Janssen, E. A.; and Baak, J. P. The effect of different DNA isolation methods on the outcome of high-risk HPV testing. *Indian Journal of Pathology & Microbiology*. 2007;50(4):733-739.

Oh, Y. L.; Shin, K. J.; Han, J.; and Kim, D. S. Significance of high-risk human papillomavirus detection by polymerase chain reaction in primary cervical cancer screening. *Cytopathology*. 2001;12(2):75-83.

O'Malley, A. S.; Gonzalez, R. M.; Sheppard, V. B.; Huerta, E.; and Mandelblatt, J. Primary care cancer control interventions including latinos: A review. *American Journal of Preventive Medicine*. 2003;25(3):264-271.

Orbell, S.; Hagger, M.; Brown, V.; and Tidy, J. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. *British Journal of Health Psychology*. 2004;9(4):533-555.

Owusu, G. A.; Eve, S. B.; Cready, C. M.; Koelln, K.; Trevino, F.; Urrutia-Rojas, X.; and Baumer, J. Race and ethnic disparities in cervical cancer screening in a safety-net system. *Maternal & Child Health Journal*. 2005;9(3):285-295.

Pacarada, M.; Lulaj, S.; Kongjeli, G.; Kongjeli, N.; and Qavdarbasha, H. Factors associated with pathologic colposcopic and cytologic changes in 500 clinically asymptomatic women. *International Journal of Gynaecology & Obstetrics*. 2010;108(1):7-11.

Pak, S. C.; Martens, M.; Bekkers, R.; Crandon, A. J.; Land, R.; Nicklin, J. L.; Perrin, L. C.; and

- Obermair, A. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2007;47(6):504-507.
- Panos, J. C.; Jones, B. A.; and Mazzara, P. F. Usefulness of concurrent Papanicolaou smear at time of cervical biopsy. *Diagnostic Cytopathology*. 2001;25(4):270-273.
- Papastefanou, I.; Panagopoulos, P.; Samolis, S.; Karadaglis, S.; and Katsoulis, M. Minimal deviation adenocarcinoma of the cervix in a patient with a high-grade cervical squamous intraepithelial lesion: case report and review of the literature. *European Journal of Gynaecological Oncology*. 2010;31(2):227-229.
- Parker, E. M.; Foti, J. A.; and Wilbur, D. C. FocalPoint slide classification algorithms show robust performance in classification of high-grade lesions on SurePath liquid-based cervical cytology slides. *Diagnostic Cytopathology*. 2004;30(2):107-110.
- Patel, M. J.; Salahuddin, N.; Kashif, W.; Riaz, M.; Tariq, M.; Samdani, A. J.; Khan, M. S.; Ayaz, S. I.; Sorathia, A.; and Furqan, M. Preventive medicine practices by primary care providers in Karachi. *Journal of the College of Physicians and Surgeons Pakistan*. 2008;18(3):193-194.
- Peevor, R.; Bowden, S.; Jones, J.; Fiander, A. N.; and Hibbitts, S. Human Papillomavirus negative but dyskaryotic cervical cytology: re-analysis of molecular testing. *Journal of Clinical Virology*. 2009;44(4):322-324.
- Pentheroudakis, G.; Orecchia, R.; Hoekstra, H. J.; and Pavlidis, N. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2010;21(SUPPL. 5):v266-v273.
- Pentheroudakis, G. Cancer and pregnancy. *Annals of Oncology*. 2008;19(SUPPL. 5):v38-v39.
- Percac-Lima, S.; Aldrich, L. S.; Gamba, G. B.; Barse, A. M.; and Atlas, S. J. Barriers to follow-up of an abnormal Pap smear in Latina women referred for colposcopy. *Journal of General Internal Medicine*. 2010;25(11):1198-1204.
- Pereira, C. R.; Rosa, M. L.; Vasconcelos, G. A.; Faria, P. C.; Cavalcanti, S. M.; and Oliveira, L. H. Human papillomavirus prevalence and predictors for cervical cancer among high-risk women from Rio de Janeiro, Brazil. *International Journal of Gynecological Cancer*. 2007;17(3):651-660.
- Perez-Cruz, E.; Winkler, J. L.; Velasco-Mondragon, E.; Salmeron-Castro, J.; Garcia, F.; Davis-Tsu, V.; Escandon-Romero, C.; and Hernandez-Avila, M. [Screening and follow-up for cervical cancer prevention in rural Mexico using visual inspection]. [Spanish]. *Salud Publica de Mexico*. 2005;47(1):39-48.
- Perkins, R. B.; Langrish, S. M.; Stern, L. J.; Burgess, J. F.; and Simon, C. J. Impact of patient adherence and test performance on the cost-effectiveness of cervical cancer screening in developing countries: the case of Honduras. *Womens Health Issues*. 2010;20(1):35-42.
- Petignat, P. and Ahtari, C. [Gynecology]. [French]. *Revue Medicale Suisse*. 1-20-2010;6(232):105-108.
- Petignat, P.; Bouchardy, C.; and Sauthier, P. [Cervical cancer screening: current status and perspectives] [French]. *Revue Medicale Suisse*. 2006;2(66):1308-1309.
- Phelan, E. A.; Burke, W.; Deyo, R. A.; Koepsell, T. D.; and LaCroix, A. Z. Delivery of primary care to women. Do women's health centers do it better?. *Journal of General Internal Medicine*. 2000;15(1):8-15.
- Philips, Z.; Avis, M.; and Whynes, D. K. Knowledge of cervical cancer and screening among women in east-central England. *International Journal of Gynecological Cancer*. 2005;15(4):639-645.
- Pirog, E. C.; Baergen, R. N.; Soslow, R. A.; Tam, D.; DeMattia, A. E.; Chen, Y. T.; and Isacson, C. Diagnostic Accuracy of Cervical Low-Grade Squamous Intraepithelial Lesions Is Improved With MIB-1

Immunostaining. *American Journal of Surgical Pathology*. 2002;26(1):70-75.

Plummer, M. and Franceschi, S. Strategies for HPV prevention. [Review] [45 refs]. *Virus Research*. 2002;89(2):285-293.

Posner, T. N.; Boyle, F. M.; Purdie, D. M.; Dunne, M. P.; and Najman, J. M. Prevalence and risk factors for lifetime exposure to Pap smear abnormalities in the Australian community. *Sexual Health*. 2006;3(4):275-279.

Pretet, J. L.; Jacquard, A. C.; Carcopino, X.; Monnier-Benoit, S.; Averous, G.; Soubeyrand, B.; Leocmach, Y.; Mougin, C.; Riethmuller, D.; and EDITH study group. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. *International Journal of Cancer*. 1-15-2008;122(2):424-427.

Quinn, M. Screening the high risk patient for gynaecological cancer. *Yonsei Medical Journal*. 2002;43(6):717-721.

Raab, S. S. and Grzybicki, D. M. Technology and process and cervical cancer prevention. *American Journal of Clinical Pathology*. 2008;129(2):187-189.

Raab, S. S.; Jones, B. A.; Souers, R.; and Tworek, J. A. The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance. *Archives of Pathology & Laboratory Medicine*. 2008;132(1):16-22.

Raffle, A. E. Lessons from cervical screening in the UK. *Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung*. 2003;97(1):15-18.

Rambout, L.; Hopkins, L.; Hutton, B.; and Fergusson, D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. [Review] [26 refs]. *CMAJ Canadian Medical Association Journal*. 8-28-2007;177(5):469-479.

Ramirez, A. G.; Suarez, L.; Laufman, L.; Barroso, C.; and Chalela, P. Hispanic women's breast and cervical cancer knowledge, attitudes, and screening behaviors. *American Journal of Health Promotion*. 2000;14(5):292-300.

Rao, S. S.; Singh, M.; Parkar, M.; and Sugumaran, R. Health maintenance for postmenopausal women. *American Family Physician*. 2008;78(5):583-594.

Rappaport, K. M.; Forrest, C. B.; and Holtzman, N. A. Adoption of liquid-based cervical cancer screening tests by family physicians and gynecologists. *Health Services Research*. 2004;39(4:Pt 1):t-47.

Ray, P.; Thumularu, K. M.; and Kaul, V. Primary care sector versus treatment centre follow up for post-treatment cervical squamous intraepithelial neoplasia (SIL). *Archives of Gynecology & Obstetrics*. 2009;279(2):109-111.

Reesink-Peters, N.; Wisman, G. B.; Jeronimo, C.; Tokumaru, C. Y.; Cohen, Y.; Dong, S. M.; Klip, H. G.; Buikema, H. J.; Suurmeijer, A. J.; Hollema, H.; Boezen, H. M.; Sidransky, D.; and van der Zee, A. G. Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. *Molecular Cancer Research: MCR*. 2004;2(5):289-295.

Reich, O. and Ballon, M. DNA cytometry as a first-line method for diagnosis of cervical precancer with respect to clinical behaviour. *European Journal of Gynaecological Oncology*. 2010;31(4):372-374.

Reid, R. and Hyne, S. Taking better Pap smears. *Medicine Today*. 2004;5(1):59-65.

Renshaw, A. A.; Dubray-Benstein, B.; Haja, J.; Hughes, J. H.; and Cytopathology Resource Committee, College of American Pathologists. Cytologic features of low-grade squamous intraepithelial lesion in thinprep papanicolaou test slides and conventional smears: comparison of cases that performed poorly with those that performed well in the College of American Pathologists Interlaboratory Comparison Program in

Cervicovaginal Cytology. *Archives of Pathology & Laboratory Medicine*. 2005;129(1):23-25.

Renshaw, A. A.; Lezon, K. M.; and Wilbur, D. C. The human false-negative rate of rescreening pap tests: Measured in a two-arm prospective clinical trial. *Cancer*. 2001;93(2):106-110.

Renshaw, A. A.; Mody, D. R.; Wang, E.; Haja, J.; Colgan, T. J.; and Cytopathology Resource Committee, College of American Pathologists. Hyperchromatic crowded groups in cervical cytology--differing appearances and interpretations in conventional and ThinPrep preparations: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. *Archives of Pathology & Laboratory Medicine*. 2006;130(3):332-336.

Renshaw, A. A.; Schwartz, M. R.; Wang, E.; Haja, J.; and Hughes, J. H. Cytologic features of adenocarcinoma, not otherwise specified, in conventional smears: comparison of cases that performed poorly with those that performed well in the College of American Pathologists Interlaboratory Comparison Program in cervicovaginal cytology. *Archives of Pathology & Laboratory Medicine*. 2006;130(1):23-26.

Ressel, G. W. ACOG Releases Guidelines on Cervical Cytology Screening. *American Family Physician*. 2003;68(10):2081+2084.

Rha, S. H.; Dong, S. M.; Jen, J.; Nicol, T.; and Sidransky, D. Molecular detection of cervical intraepithelial neoplasia and cervical carcinoma by microsatellite analysis of Papanicolaou smears. *International Journal of Cancer*. 8-1-2001;93(3):424-429.

Rodriguez-Reyes, E. R.; Cerda-Flores, R. M.; Quinonez-Perez, J. M.; Velasco-Rodriguez, V.; and Cortes-Gutierrez, E. I. Acetic acid test: a promising screening test for early detection of cervical cancer. *Analytical & Quantitative Cytology & Histology*. 2002;24(3):134-136.

Rokyta, Z. Diagnostic reliability of prebioptic methods in the prediction of a histological basis of cervical lesions and its correlation with accuracy of colposcopically directed biopsy in patients with cervical neoplasia. *European Journal of Gynaecological Oncology*. 2000;21(5):484-486.

Rollins, G. Developments in cervical and ovarian cancer screening: Implications for current practice. *Annals of Internal Medicine*. 2000;133(12):1021-1024.

Rosen, N. O.; Knauper, B.; Di, Dio P.; Morrison, E.; Tabing, R.; Feldstain, A.; Amsel, R.; Mayrand, M. H.; Franco, E. L.; and Rosberger, Z. The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: a randomised controlled study. *Psychology & Health*. 2010;25(6):651-668.

Rossi, P. G. and Zorzi, M. Efficacy of HPV 16/18 vaccines on sexually active young women and the impact on organized cervical cancer screening. *Acta Obstetrica et Gynecologica Scandinavica*. 2010;89(6):846-847.

Rouzier, R. [Management of CIN1]. [French]. *Journal de Gynecologie, Obstetrique et Biologie de la Reproduction*. 2008;37:Suppl-20.

Rowe, L. R.; Marshall, C. J.; and Bentz, J. S. One hundred percent thorough quality control rescreening of liquid-based monolayers in cervicovaginal cytopathology. *Cancer*. 12-25-2002;96(6):325-329.

Russo, J. F. Controversies in the management of abnormal Pap smears. *Current Opinion in Obstetrics & Gynecology*. 2000;12(5):339-343.

Saad, R. S.; Kanbour-Shakir, A.; Lu, E.; Modery, J.; and Kanbour, A. Cytomorphologic analysis and histological correlation of high-grade squamous intraepithelial lesions in postmenopausal women. *Diagnostic Cytopathology*. 2006;34(7):467-471.

Safaeian, M.; Herrero, R.; Hildesheim, A.; Quint, W.; Freer, E.; van Doorn, L. J.; Porras, C.; Silva, S.; Gonzalez, P.; Bratti, M. C.; Rodriguez, A. C.; Castle, P.; and Costa Rican Vaccine Trial Group.

Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. *Journal of Clinical Microbiology*. 2007;45(5):1447-1454.

Sahebali, S.; Depuydt, C. E.; Segers, K.; Moeneclaey, L. M.; Vereecken, A. J.; Van, Marck E.; and Bogers, J. J. P16INK4a as an adjunct marker in liquid-based cervical cytology. *International Journal of Cancer*. 3-1-2004;108(6):871-876.

Sahebali, S.; Depuydt, C. E.; Segers, K.; Vereecken, A. J.; Van, Marck E.; and Bogers, J. J. Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool?. *Journal of Clinical Pathology*. 2003;56(9):681-686.

Saint, M.; Gildengorin, G.; and Sawaya, G. F. Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. *American Journal of Obstetrics & Gynecology*. 2005;192(2):414-421.

Saitz, R. Screening: Triumph of enthusiasm over evidence?. *Medicine Today*. 2005;6(2):9-10.

Salz, T.; Gottlieb, S. L.; Smith, J. S.; and Brewer, N. T. The association between cervical abnormalities and attitudes toward cervical cancer prevention. *Journal of Women's Health*. 2010;19(11):2011-2016.

Sankaranarayanan, R.; Budukh, A. M.; and Rajkumar, R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. *Bulletin of the World Health Organization*. 2001;79(10):954-962.

Sankaranarayanan, R.; Nene, B. M.; Dinshaw, K.; Rajkumar, R.; Shastri, S.; Wesley, R.; Basu, P.; Sharma, R.; Thara, S.; Budukh, A.; and Parkin, D. M. Early detection of cervical cancer with visual inspection methods: a summary of completed and on-going studies in India. *Salud Publica de Mexico*. 2003;45:Suppl-407.

Sankaranarayanan, R.; Rajkumar, R.; Theresa, R.; Esmay, P. O.; Mahe, C.; Bagyalakshmi, K. R.; Thara, S.; Frappart, L.; Lucas, E.; Muwonge, R.; Shanthakumari, S.; Jeevan, D.; Subbarao, T. M.; Parkin, D. M.; and Cherian, J. Initial results from a randomized trial of cervical visual screening in rural south India. *International Journal of Cancer*. 4-10-2004;109(3):461-467.

Sankaranarayanan, R. Royal Society of Tropical Medicine and Hygiene meeting at Manson House, London 17 January 2002. Cervical cancer in developing countries. *Transactions of the Royal Society of Tropical Medicine & Hygiene*. 2002;96(6):580-585.

Santiago, D. Chapter editor's introduction and conclusion. *CME Journal of Gynecologic Oncology*. 2007;12(2 PART 1):39-41.

Saonere, J. A. Awareness screening programme reduces the risk of cervical cancer in women. *African Journal of Pharmacy and Pharmacology*. 2010;4(6):314-323.

Sargent, A.; Bailey, A.; Almonte, M.; Turner, A.; Thomson, C.; Peto, J.; Desai, M.; Mather, J.; Moss, S.; Roberts, C.; Kitchener, H. C.; and ARTISTIC Study Group. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. *British Journal of Cancer*. 5-20-2008;98(10):1704-1709.

Sarna, L.; Tae, Y. S.; Kim, Y. H.; Brecht, M. L.; and Maxwell, A. E. Cancer screening among Korean Americans. *Cancer Practice*. 2001;9(3):134-140.

Sasco, A. J. [Screening for cancer: what's new?]. [French]. *Bulletin du Cancer*. 2000;87(3):239-243.

Sasieni, P. Cancer screening for medical oncologists: Importance of quality control and audit. *Annals of Oncology*. 2002;13(SUPPL. 4):199-204.

Sawaya, G. F.; Grady, D.; Kerlikowske, K.; Valleur, J. L.; Barnabei, V. M.; Bass, K.; Snyder, T. E.;

- Pickar, J. H.; Agarwal, S. K.; and Mandelblatt, J. The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). *Annals of Internal Medicine*. 12-19-2000;133(12):942-950.
- Sebastiao, A. P.; Noronha, L.; Pinheiro, D. L.; Collaco, L. M.; De Carvalho, N. S.; and Bleggi-Torres, L. F. Influence of specimen adequacy on the diagnosis of ASCUS. *Diagnostic Cytopathology*. 2004;31(3):155-158.
- Settakorn, J.; Rangdaeng, S.; Preechapornkul, N.; Nateewatana, S.; Pongsiralai, K.; Srisomboon, J.; and Thorner, P. S. Interobserver reproducibility with LiquiPrep liquid-based cervical cytology screening in a developing country. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2008;9(1):92-96.
- Settheetham-Ishida, W.; Yuenyao, P.; Tassaneeyakul, W.; Kanjanavirojkul, N.; Thawmor, A.; Kularbkaew, C.; Hahvajanawong, C.; Settheetham, D.; Wattanathorn, J.; Kashima, T.; and Ishida, T. Selected risk factors, human papillomavirus infection and the p53 codon 72 polymorphism in patients with squamous intraepithelial lesions in northeastern Thailand. *Asian Pacific journal of cancer prevention : APJCP*. 2006;7(1):113-118.
- Sharma, A.; Marfatia, Y. S.; and Modi, M. Reproductive tract infections in HIV positive women: A case control study. *Indian Journal of Sexually Transmitted Diseases*. 2009;30(1):16-18.
- Sherman, M. E.; Kahler, J.; Gustafson, K. S.; and Wang, S. S. "Sip volume" as a quality indicator in liquid-based cervical cytology. *Cancer*. 12-25-2006;108(6):462-467.
- Sherman, M. E.; Wang, S. S.; Tarone, R.; Rich, L.; and Schiffman, M. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. *Cancer Epidemiology, Biomarkers & Prevention*. 2003;12(4):372-379.
- Shinn, E.; Le, T.; Gallegos, J.; and Basen-Engquist, K. A pilot analysis of multispectral digital colposcopy for women with high-grade squamous intraepithelial lesion (HGSIL) Pap smear results. *Gynecologic Oncology*. 2007;107(1:Suppl 1):Suppl-5.
- Singh, V.; Sehgal, A.; Parashari, A.; Sodhani, P.; and Satyanarayana, L. Early detection of cervical cancer through acetic acid application--an aided visual inspection. *Singapore Medical Journal*. 2001;42(8):351-354.
- Sirovich, B. E.; Woloshin, S.; and Schwartz, L. M. Screening for cervical cancer: will women accept less?. *American Journal of Medicine*. 2005;118(2):151-158.
- Sizer, A. R.; Pembridge, J. M.; and O'Brien, S. C. An unusual case of uterus didelphis resulting in misdiagnosis of tubal occlusion. *Journal of Obstetrics and Gynaecology*. 2000;20(2):208-209.
- Slater, D. N. For debate--Ethical considerations of gynaecological liquid-based cytology and human papillomavirus studies. *Cytopathology*. 2001;12(4):251-256.
- Smith, T. *Colposcopy. Nursing standard (Royal College of Nursing (Great Britain))* : 1987). 2000;15(4):47-52.
- Sodhani, P.; Gupta, S.; Singh, V.; Sehgal, A.; and Mitra, A. B. Eliminating the diagnosis atypical squamous cells of undetermined significance: impact on the accuracy of the Papanicolaou test. *Acta Cytologica*. 2004;48(6):783-787.
- Sparks, R. A.; Scheid, D.; Loemker, V.; Stader, E.; Reilly, K.; Hamm, R.; and McCarthy, L. Association of cervical cryotherapy with inadequate follow-up colposcopy. *Journal of Family Practice*. 2002;51(6):526-529.
- Spence, A. R.; Goggin, P.; and Franco, E. L. Process of care failures in invasive cervical cancer:

systematic review and meta-analysis. [Review] [64 refs]. *Preventive Medicine*. 2007;45(2-3):93-106.

Stein, K.; Lewendon, G.; Jenkins, R.; and Davis, C. Improving uptake of cervical cancer screening in women with prolonged history of non-attendance for screening: a randomized trial of enhanced invitation methods. *Journal of Medical Screening*. 2005;12(4):185-189.

Stemberger-Papic, S.; Vrdoljak-Mozetic, D.; Ostojic, D. V.; Rubesa-Mihaljevic, R.; and Manestar, M. Evaluation of the HPV L1 capsid protein in prognosis of mild and moderate dysplasia of the cervix uteri. *Collegium Antropologicum*. 2010;34(2):419-423.

Streiner, D. L. and Norman, G. R. Mass screening: When does it make sense?. *Community Oncology*. 2010;7(2):93-95.

Symonds, I. M. Screening for gynaecological conditions. *Current Obstetrics and Gynaecology*. 2004;14(1):44-51.

Syrjanen, K.; Shabalova, I.; Ivanchenko, O.; Kljukina, L.; Grunberga, V.; Syrjanen, S.; and New Independent States of the Former Soviet Union Cohort Study Group. Reproducibility of classification and correction for verification bias as determinants of performance of Papanicolaou smear cytology in the screening setting: experience from the New Independent States of the former Soviet Union cohort study. *Acta Cytologica*. 2009;53(5):548-557.

Syrjanen, K. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors. *European Journal of Gynaecological Oncology*. 2008;29(3):205-221.

Tahseen, S. and Reid, P. C. Psychological distress associated with colposcopy: patients' perception. *European Journal of Obstetrics, Gynecology, & Reproductive Biology*. 2008;139(1):90-94.

Tarkkanen, J.; Geagea, A.; Nieminen, P.; and Anttila, A. Quality improvement project in cervical cancer screening: practical measures for monitoring laboratory performance. *Acta Obstetrica et Gynecologica Scandinavica*. 2003;82(1):82-88.

Tavares, S. B. N.; Alves De Sousa, N. L.; Manrique, E. J. C.; Pinheiro De Albuquerque, Z. B.; Zeferino, L. C.; and Amaral, R. G. Comparison of the performance of rapid prescreening, 10% random review, and clinical risk criteria as methods of internal quality control in cervical cytopathology. *Cancer*. 2008;114(3):165-170.

Taylor, V. M.; Jackson, J. C.; Yasui, Y.; Nguyen, T. T.; Woodall, E.; Acorda, E.; Li, L.; and Ramsey, S. Evaluation of a cervical cancer control intervention using lay health workers for Vietnamese American women. *American Journal of Public Health*. 2010;100(10):1924-1929.

Thanappapasr, D.; Wilailak, S.; Ayudhya, N. I.; Lertkhachonsuk, A. A.; Likittanasombut, P.; Chittithaworn, S.; Charakorn, C.; and Weerakiet, S. Can vaginal misoprostol effectively increase rate of a satisfactory colposcopy? A randomized double-blind placebo-controlled trial. *Japanese Journal of Clinical Oncology*. 2010;40(3):203-207.

Thomas, D. B.; Ray, R. M.; and Qin, Q. Risk factors for progression of squamous cell cervical carcinoma in-situ to invasive cervical cancer: Results of a multinational study. *Cancer Causes and Control*. 2002;13(7):683-690.

Thomas, V. Iatrogenic effects, artefacts and infections in cervical smears. *CPD Bulletin Cellular Pathology*. 2003;5(1):35-39.

Thompson, A. D.; Duggan, M. A.; Nation, J.; and Brasher, P. M. A. Investigation of laser cervical cone biopsies negative for premalignancy or malignancy. *Journal of Lower Genital Tract Disease*. 2002;6(2):84-91.

Thompson, M. and Nussbaum, R. Women's preferences for providers of and settings for Pap smears.

Journal of the American Medical Womens Association. 2001;56(1):11-14.

Tilbrook, D.; Polsky, J.; and Lofters, A. Are women with psychosis receiving adequate cervical cancer screening?. *Canadian Family Physician*. 2010;56(4):358-363.

TOMBOLA (Trial Of Management of Borderline and Other Low-grade Abnormal smears) Group, Sharp, L.; Cotton, S.; Cochran, C.; Gray, N.; Little, J.; Neal, K.; and Cruickshank, M. After-effects reported by women following colposcopy, cervical biopsies and LLETZ: results from the TOMBOLA trial. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2009;116(11):1506-1514.

Torres-Mejia, G.; Salmeron-Castro, J.; Tellez-Rojo, M. M.; Lazcano-Ponce, E. C.; Juarez-Marquez, S. A.; Torres-Torija, I.; Gil-Abadie, L.; and Buiatti, E. Call and recall for cervical cancer screening in a developing country: a randomised field trial. *International Journal of Cancer*. 9-15-2000;87(6):869-873.

Torrison, A.; Del, Mistro A.; Onnis, G. L.; Merlin, F.; Bertorelle, R.; and Minucci, D. Colposcopy, cytology and HPV-DNA testing in HIV-positive and HIV-negative women. *European Journal of Gynaecological Oncology*. 2000;21(2):168-172.

Troni, G. M.; Cipparrone, I.; Cariaggi, M. P.; Ciatto, S.; Miccinesi, G.; Zappa, M.; and Confortini, M. Detection of false-negative Pap smears using the PAPNET system. *Tumori*. 2000;86(6):455-457.

Trunk, M. J.; Dallenbach-Hellweg, G.; Ridder, R.; Petry, K. U.; Ikenberg, H.; Schneider, V.; and Von Knebel, Doeberitz M. Morphologic characteristics of p16INK4a-positive cells in cervical cytology samples. *Acta Cytologica*. 2004;48(6):771-782.

Tseng, D. S.; Cox, E.; Plane, M. B.; and Hla, K. M. Efficacy of patient letter reminders on cervical cancer screening: a meta-analysis. *Journal of General Internal Medicine*. 2001;16(8):563-568.

Twiggs, L. B. Clinical question: Ask the expert. *Journal of Lower Genital Tract Disease*. 2008;12(1):54-55.

Ubel, P. A.; Jepson, C.; Baron, J.; Hershey, J. C.; and Asch, D. A. The influence of cost-effectiveness information on physicians' cancer screening recommendations. *Social Science & Medicine*. 2003;56(8):1727-1736.

Utagawa, M. L.; Shirata, N. K.; Mattosinho de Castro Ferraz Mda, Di, Loreto C.; Dall', Agnol M.; and Longatto-Filho, A. Performance of 3 methods for quality control for gynecologic cytology diagnoses. *Acta Cytologica*. 2008;52(4):439-444.

Valanis, B. G.; Glasgow, R. E.; Mullooly, J.; Vogt, T. M.; Whitlock, E. P.; Boles, S. M.; Smith, K. S.; and Kimes, T. M. Screening HMO women overdue for both mammograms and pap tests. *Preventive Medicine*. 2002;34(1):40-50.

Valdini, A. and Esielionis, P. Measurement of colposcopy-associated distress using the psychosocial effects of having an abnormal pap smear-questionnaire in a Latina population. *Journal of Lower Genital Tract Disease*. 2004;8(1):25-32.

van Hemel, B. M.; Buikema, H. J.; Groen, H.; and Suurmeijer, A. J. Accuracy of a low priced liquid-based method for cervical cytology in 632 women referred for colposcopy after a positive Pap smear. *Diagnostic Cytopathology*. 2009;37(8):579-583.

van, Duin M.; Snijders, P. J.; Schrijnemakers, H. F.; Voorhorst, F. J.; Rozendaal, L.; Nobbenhuis, M. A.; Van Den Brule, A. J.; Verheijen, R. H.; Helmerhorst, T. J.; and Meijer, C. J. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. *International Journal of Cancer*. 4-1-2002;98(4):590-595.

Verhoeven, V.; Baay, M.; and Baay, P. People seeking health information about human papillomavirus via the internet have a very high level of anxiety. *Sexual Health*. 2009;6(3):258-259.

Virtej, P. and Vasiliu, C. Cytodiagnosis in cervical neoplasia: from the Babes/Papanicolaou smear to the actual Bethesda System. *Clinical & Experimental Obstetrics & Gynecology*. 2003;30(4):173-177.

Viswanathan, M.; Kraschnewski, J.; Nishikawa, B.; Morgan, L. C.; Thieda, P.; Honeycutt, A.; Lohr, K. N.; Jonas, D.; and RTI International-University of North Carolina Evidence-based Practice Center. Outcomes of community health worker interventions. *Evidence Report/Technology Assessment*. 2009;#volume#(181):1-1442, B1.

Von Knebel, Doeberitz M. Prognostic significance of p16INK4a expression and integrated human papillomavirus oncogen transcripts in dysplastic lesions of the uterine cervix. *CME Journal of Gynecologic Oncology*. 2003;8(3):227-232.

Voss, J. S.; Kipp, B. R.; Campion, M. B.; Sokolova, I. A.; Henry, M. R.; Halling, K. C.; and Clayton, A. C. Assessment of fluorescence in situ hybridization and hybrid capture 2 analyses of cervical cytology specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia. *Analytical & Quantitative Cytology & Histology*. 2010;32(3):121-130.

Wachtel, M. Quality control in Papanicolaou tests. *American Journal of Clinical Pathology*. 2002;118(5):804.

Wadehra, V. and Johnson, S. J. An audit of the positive predictive value of high-grade dyskaryosis in cervical smears: 2001-2002. *Cytopathology*. 2003;14(3):107-114.

Wain, G. First cancer vaccine approved for women. *Medicine Today*. 2006;7(12):55-57.

Wang, W. Z. and Tang, J. L. Medical screening: to be or not to be?. *Chinese Medical Journal*. 2010;123(14):1948-1951.

Wentzensen, N.; Wilson, L. E.; Wheeler, C. M.; Carreon, J. D.; Gravitt, P. E.; Schiffman, M.; and Castle, P. E. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. *Cancer Research*. 11-1-2010;70(21):8578-8586.

Wilbur, D. C. and Norton, M. K. The primary screening clinical trials of the TriPath AutoPap System. *Epidemiology*. 2002;13:Suppl-3.

Wilbur, D. C.; Parker, E. M.; and Foti, J. A. Location-guided screening of liquid-based cervical cytology specimens: a potential improvement in accuracy and productivity is demonstrated in a preclinical feasibility trial. *American Journal of Clinical Pathology*. 2002;118(3):399-407.

Williams, F. S.; Roure, R. M.; Till, M.; Vogler, M.; and Del Priore G. Treatment of cervical carcinoma in situ in HIV positive women. *International Journal of Gynaecology & Obstetrics*. 2000;71(2):135-139.

Wong, N. K.; Ng, F. Y.; and Leung, G. Cytological distinction between high-risk and low-risk human papillomavirus infections in SurePath liquid-based cell preparations. *Journal of Clinical Pathology*. 2008;61(12):1317-1322.

Wong, P. T.; Senterman, M. K.; Jackli, P.; Wong, R. K.; Salib, S.; Campbell, C. E.; Feigel, R.; Faight, W.; and Fung Kee, Fung M. Detailed account of confounding factors in interpretation of FTIR spectra of exfoliated cervical cells. *Biopolymers*. 2002;67(6):376-386.

Wright, T. C.; Jr. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?. [Review] [20 refs]. *Clinical Obstetrics & Gynecology*. 2007;50(2):313-323.

Yamashiro, K.; Kawamura, N.; Matsubayashi, S.; Dota, K.; Suzuki, H.; Mizushima, H.; Wakao, F.; and Azumi, N. Telecytology in Hokkaido Island, Japan: Results of primary telecytodiagnosis of routine cases. *Cytopathology*. 2004;15(4):221-227.

Yarkin, F.; Chauvin, S.; Konomi, N.; Wang, W.; Mo, R.; Bauchman, G.; Diaz, A.; Burstein, D.; Szporn, A.; Hauptman, E.; and Zhang, D. Y. Detection of HPV DNA in cervical specimens collected in

cytologic solution by ligation-dependent PCR. *Acta Cytologica*. 2003;47(3):450-456.

Yu, E. S.; Kim, K. K.; Chen, E. H.; and Brintnall, R. A. Breast and cervical cancer screening among Chinese American women. *Cancer Practice*. 2001;9(2):81-91.

Zardawi, I. M. and Rode, J. W. Clinical value of repeat Pap smear at the time of colposcopy. *Acta Cytologica*. 2002;46(3):495-498.

Zardawi, I. M.; Catterall, N.; Duncan, J.; Sullivan, J.; and Warwick, L. Effects of lubricant gel on conventional and liquid-based cervical smears [7]. *Acta Cytologica*. 2003;47(4):704-705.

Zhang, F. F.; Banks, H. W.; Langford, S. M.; and Davey, D. D. Accuracy of ThinPrep Imaging System in detecting low-grade squamous intraepithelial lesions. *Archives of Pathology & Laboratory Medicine*. 2007;131(5):773-776.

Zhang, Y.; Borders, T. F.; and Rohrer, J. E. Correlates of intent to seek unnecessary pap tests among elderly women. *Womens Health Issues*. 2007;17(6):351-359.

Zhou, J.; Tomashefski, J.; Jr.; and Khiyami, A. Diagnostic value of the thin-layer, liquid-based Pap test in endometrial cancer: a retrospective study with emphasis on cytomorphologic features. *Acta Cytologica*. 2007;51(5):735-741.

Zuna, R. E. and Dunn, S. T. Can HPV Testing Function as an Objective Quality Assurance Monitor in the Cytopathology Laboratory?. *Laboratory Medicine*. 2004;35(4):238-240.

Zuna, R. E.; Sienko, A.; Lightfoot, S.; and Gaiser, M. Cervical smear interpretations in women with a histologic diagnosis of severe dysplasia: factors associated with discrepant interpretations. *Cancer*. 8-25-2002;96(4):218-224.

Level 2: No comparison group

Cervical cytology screening. *International Journal of Gynecology and Obstetrics*. 2003;80(2):239-243.

Bofin, A. M.; Nygard, J. F.; Skare, G. B.; Dybdahl, B. M.; Westerhagen, U.; and Sauer, T. Papanicolaou smear history in women with low-grade cytology before cervical cancer diagnosis. *Cancer*. 8-25-2007;111(4):210-216.

Chivukula, M.; Saad, R. S.; Elishaev, E.; White, S.; Mauser, N.; and Dabbs, D. J. Introduction of the Thin Prep Imaging System (TIS): Experience in a high volume academic practice. *CytoJournal*. 2007;4, 2007. Article Number: 6. Date of Publication: 2007.

Crabtree, D.; Unkraut, A.; Cozens, D.; Smith, T.; Lucas, C.; Pennington, D.; Chaney, L.; Nestok, B.; Robinson-Smith, T.; and Yassin, R. Role for HPV testing in ASCUS: a cytologic-histologic correlation. *Diagnostic Cytopathology*. 2002;27(6):382-386.

Crosbie, E. J. and Kitchener, H. C. Human papillomavirus in cervical screening and vaccination. [Review] [65 refs]. *Clinical Science*. 2006;110(5):543-552.

Denton, K.; Rana, D. N.; Lynch, M. A.; and Desai, M. S. Bland dyskaryosis: a new pitfall in liquid-based cytology. *Cytopathology*. 2008;19(3):162-166.

Dobbs, S. P. and Ireland, D. H.P.V. infection and cervical screening. *CME Bulletin Gynaecology*. 2000;1(3):89-91.

Douvier, S.; Filipuzzi, L.; and Sagot, P. Management of cervical intra-epithelial neoplasm during pregnancy. [French]. *Gynecologie Obstetrique Fertilité*. 2003;31(10):851-855.

Hiatt, R. A.; Pasick, R. J.; Stewart, S.; Bloom, J.; Davis, P.; Gardiner, P.; and Luce, J. Cancer screening for underserved women: the Breast and Cervical Cancer Intervention Study. *Cancer Epidemiology*,

Biomarkers & Prevention. 2008;17(8):1945-1949.

Johnston, E. I. and Logani, S. Cytologic diagnosis of atypical squamous cells of undetermined significance in perimenopausal and postmenopausal women: lessons learned from human Papillomavirus DNA testing. *Cancer*. 6-25-2007;111(3):160-165.

Kirschner, B.; Poll, S.; Rygaard, C.; Wahlin, A.; and Junge, J. Screening history in women with cervical cancer in a Danish population-based screening program. *Gynecologic Oncology*. 2011;120(1):68-72.

Kitchener, H. C.; Almonte, M.; Wheeler, P.; Desai, M.; Gilham, C.; Bailey, A.; Sargent, A.; Peto, J.; and ARTISTIC Trial Study Group. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. *British Journal of Cancer*. 7-3-2006;95(1):56-61.

Kulasingam, S. L.; Rajan, R.; St, Pierre Y.; Atwood, C. V.; Myers, E. R.; and Franco, E. L. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. *BMC Medicine*. 2009;7:69.

Leyden, W. A.; Manos, M. M.; Geiger, A. M.; Weinmann, S.; Mouchawar, J.; Bischoff, K.; Yood, M. U.; Gilbert, J.; and Taplin, S. H. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. *Journal of the National Cancer Institute*. 5-4-2005;97(9):675-683.

Logan, J. L.; Khambaty, M. Q.; D'Souza, K. M.; and Menezes, L. J. Cervical cancer screening among HIV-infected women in a health department setting. *AIDS Patient Care & Stds*. 2010;24(8):471-475.

Massad, L. S.; Cejtin, H. E.; and Abu-Rustum, N. R. Presentation and screening history of indigent women with cervical cancer: Implications for prevention. *Journal of Lower Genital Tract Disease*. 2000;4(4):208-211.

McCaffery, K. J.; Irwig, L.; Chan, S. F.; Macaskill, P.; Barratt, A.; Lewicka, M.; Clarke, J.; and Weisberg, E. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: evaluation of a decision aid to support informed choice. *Patient Education & Counseling*. 2008;73(3):473-479.

Mohan, S. and Ind, T. Cervical screening in England and Wales: An update. *Current Opinion in Obstetrics and Gynecology*. 2004;16(6):491-496.

Moore, K. N. and Walker, J. L. The abnormal pap test: Evaluation, treatment, and monitoring. *Journal of Clinical Outcomes Management*. 2006;13(4):235-244.

Murphy, P. A.; Schwarz, E. B.; and Dyer, J. M. Cervical cancer screening practices of certified nurse-midwives in the United States. *Journal of Midwifery & Women's Health*. 2008;53(1):11-18.

Pagliusi, S. R. HPV technologies advancing public health: discussion of recent evidence. [Review] [33 refs]. *Collegium Antropologicum*. 2007;31:Suppl-60.

Strong, C. and Liang, W. Relationships between decisional balance and stage of adopting mammography and Pap testing among Chinese American women. *Cancer Epidemiology*. 2009;33(5):374-380.

Vrdoljak-Mozetic, D.; Ostojic, D. V.; Stemberger-Papic, S.; Jankovic, S.; Glibotic-Kresina, H.; Brncic-Fischer, A.; and Benic-Salamon, K. Cervical cancer screening programme in Primorsko-Goranska County, Croatia--the results of the pilot study. *Collegium Antropologicum*. 2010;34(1):225-232.

Waller, J.; Bartoszek, M.; Marlow, L.; and Wardle, J. Barriers to cervical cancer screening attendance in England: a population-based survey. *Journal of Medical Screening*. 2009;16(4):199-204.

Level 2: Excluded by Outcomes

Anttila, A.; Hakama, M.; Kotaniemi-Talonen, L.; and Nieminen, P. Alternative technologies in cervical cancer screening: a randomised evaluation trial. *BMC Public Health*. 2006;6:252.

Baleriola, C.; Millar, D.; Melki, J.; Coulston, N.; Altman, P.; Rismanto, N.; and Rawlinson, W. Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections. *Journal of Clinical Virology*. 2008;42(1):22-26.

Mishra, S. I.; Luce, P. H.; and Baquet, C. R. Increasing pap smear utilization among Samoan women: results from a community based participatory randomized trial. *Journal of Health Care for the Poor & Underserved*. 2009;20(2:Suppl):Suppl-101.

Ronco, G.; Cuzick, J.; Segnan, N.; Brezzi, S.; Carozzi, F.; Folicaldi, S.; Dalla, Palma P.; Del, Mistro A.; Gillio-Tos, A.; Giubilato, P.; Naldoni, C.; Polla, E.; Iossa, A.; Zorzi, M.; Confortini, M.; Giorgi-Rossi, P.; and NTCC Working Group. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. *European Journal of Cancer*. 2007;43(3):476-480.

Level 2: Population

Arbyn, M.; Ronco, G.; Cuzick, J.; Wentzensen, N.; and Castle, P. E. How to evaluate emerging technologies in cervical cancer screening?. [Review] [80 refs]. *International Journal of Cancer*. 12-1-2009;125(11):2489-2496.

Carozzi, F. M.; Del, Mistro A.; Confortini, M.; Sani, C.; Puliti, D.; Trevisan, R.; De, Marco L.; Tos, A. G.; Girlando, S.; Palma, P. D.; Pellegrini, A.; Schiboni, M. L.; Crucitti, P.; Pierotti, P.; Vignato, A.; and Ronco, G. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. *American Journal of Clinical Pathology*. 2005;124(5):716-721.

Confortini, M.; Bergeron, C.; Desai, M.; Negri, G.; Dalla, Palma P.; Montanari, G.; Pellegrini, A.; Ronco, G.; and New Technologies for Cervical Cancer Screening Study Cytology Group. Accuracy of liquid-based cytology: comparison of the results obtained within a randomized controlled trial (the New Technologies for Cervical Cancer Screening Study) and an external group of experts. *Cancer Cytopathology*. 8-25-2010;118(4):203-208.

McQuarrie, H. G.; Ogden, J.; and Costa, M. Understanding the financial impact of covering new screening technologies: The case of automated Pap smears. *Journal of Reproductive Medicine for the Obstetrician and Gynecologist*. 2000;45(11):898-906.

Myers, E.R.; McCrory, D.C.; Subramanian, S.; McCall, N.; Nanda, K.; Datta, S.; and Matchar, D. B. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening. *Obstetrics & Gynecology*. 2000;96(5:Pt 1):t-52.

Raab, S.S. Can glandular lesions be diagnosed pap smear cytology?. *Diagnostic Cytopathology*. 2000;23(2):127-133.

Renshaw, A. A.; Mody, D. R.; Lozano, R. L.; Volk, E. E.; Walsh, M. K.; Davey, D. D.; and Birdsong, G. G. Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions. *Archives of Pathology & Laboratory Medicine*. 2004;128(2):153-157.

Renshaw, A. A.; Young, N. A.; Birdsong, G. G.; Styer, P. E.; Davey, D.D.; Mody, D.R.; and Colgan, T.J. Comparison of performance of conventional and ThinPrep gynecologic preparations in the College

of American Pathologists Gynecologic Cytology Program. *Archives of Pathology & Laboratory Medicine*. 2004;128(1):17-22.

Vasilev, S. A. Paying for prevention: Standardizing the measurement of the value of health care interventions. *Obstetrics and Gynecology Clinics of North America*. 2002;29(4):613-643.

Level 3: Intervention

Blumenthal, P.D., Gaffikin, L., Chirenje, Z.M., McGrath, J., Womack, S., and Shah, K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. *International Journal of Gynaecology & Obstetrics*. 2001;72(1):47-53.

Castle, P.E., Cox, J.T., Schiffman, M., Wheeler, C.M., and Solomon, D. Factors influencing histologic confirmation of high-grade squamous intraepithelial lesion cytology. *Obstetrics & Gynecology*. 2008;112(3):637-645.

Claeys, P., De Vuyst H., Gonzalez, C., Garcia, A., Bello, R.E., and Temmerman, M.. Performance of the acetic acid test when used in field conditions as a screening test for cervical cancer. *Tropical Medicine & International Health*. 2003;8(8):704-709.

Davila, R.M. and Miranda, M.C.. Vaginal intraepithelial neoplasia and the pap smear. *Acta Cytologica*. 2000;44(2):137-140.

Denny, L., Kuhn, L., Pollack, A., and Wright, T.C., Jr.. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. *Cancer*. 3-15-2002;94(6):1699-1707.

Denton, K.J., Bergeron, C., Klement, P., Trunk, M.J., Keller, T., Ridder, R., and European CINtec Cytology Study Group. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. *American Journal of Clinical Pathology*. 2010;134(1):12-21.

Felix, J.C., Lonky, N.M., Tamura, K., Yu, K.J., Naidu, Y., Lai, C.R., and Lonky, S.A.. Aberrant expression of E-cadherin in cervical intraepithelial neoplasia correlates with a false-negative Papanicolaou smear. *American Journal of Obstetrics & Gynecology*. 2002;186(6):1308-1314.

Freeman-Wang, T., Walker, P., Linehan, J., Coffey, C., Glasser, B., and Sherr, L.. Anxiety levels in women attending colposcopy clinics for treatment for cervical intraepithelial neoplasia: A randomised trial of written and video information. *British Journal of Obstetrics and Gynaecology*. 2001;108(5):482-484.

Hellsten, C., Sjostrom, K., and Lindqvist, P.G.. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2008;115(2):212-218.

Kim, Y.T., Kim, J.W., Kim, S.H., Kim, Y.R., Kim, J.H., Yoon, B.S., and Park, Y.W.. Clinical usefulness of cervicogram as a primary screening test for cervical neoplasia. *Yonsei Medical Journal*. 2005;46(2):213-220.

Kobilkova, J., Pazdernik, B., and Duskova, J.. Incidence of cervical carcinoma in the Czech Republic. *Acta Cytologica*. 2001;45(4):515-518.

Kok, M.R., Boon, M.E., Schreiner-Kok, P.G., and Koss, L.G.. Cytological recognition of invasive squamous cancer of the uterine cervix: comparison of conventional light-microscopical screening and neural network-based screening. *Human Pathology*. 2000;31(1):23-28.

Lai, H.C., Lin, Y.W., Huang, R.L., Chung, M.T., Wang, H.C., Liao, Y.P., Su, P.H., Liu, Y.L., and Yu, M.H.. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and

worse. *Cancer*. 2010;116(18):4266-4274.

Lin, C. J., Lai, H.C., Wang, K.H., Hsiung, C.A., Liu, H.W., Ding, D.C., Hsieh, C.Y., and Chu, T.Y. Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. *American Journal of Obstetrics and Gynecology*. 2011;204(1):21-21.

Lonky, N.M., Felix, J., Tsadik, G.W., and Lonky, S. False-negative hybrid capture II results related to altered adhesion molecule distribution in women with atypical squamous cells Pap smear results and tissue-based human papillomavirus-positive high-grade cervical intraepithelial neoplasia. *Journal of Lower Genital Tract Disease*. 2004;8(4):285-291.

McGrath, C.M.. ASCUS in Papanicolaou smears. Problems, controversies, and potential future directions. [Review] [57 refs]. *American Journal of Clinical Pathology*. 2002;117:Suppl-75.

Negri, G., Moretto, G., Menia, E., Vittadello, F., Kasal, A., Mian, C., and Egarter-Vigl, E.. Immunocytochemistry of p16INK4a in liquid-based cervicovaginal specimens with modified Papanicolaou counterstaining. *Journal of Clinical Pathology*. 2006;59(8):827-830.

Phadnis, S.V., Doshi, J.S., Ogunnaike, O.O., Padwick, M.L., and Sanusi, F.A.. Inadequate cervical smear: what do we do?. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(5):486-488.

Pretorius, R.G., Bao, Y.P., Belinson, J.L., Burchette, R.J., Smith, J.S., and Qiao, Y.L.. Inappropriate gold standard bias in cervical cancer screening studies. *International Journal of Cancer*. 2007;121(10):2218-2224.

Raab, S.S., Andrew-Jaja, C., Grzybicki, D.M., Vrbin, C.M., Chesin, C.M., Fisch, J.M., Dabbs, D.J., Sommer, D.L., and Blaser, S.M. Dissemination of Lean methods to improve Pap testing quality and patient safety. *Journal of Lower Genital Tract Disease*. 2008;12(2):103-110.

Rebolj, M. and Lynge, E.. Incomplete follow-up of positive HPV tests: overview of randomised controlled trials on primary cervical screening. *British Journal of Cancer*. 7-27-2010;103(3):310-314.

Shin, E.K., Lee, S.R., Kim, M.K., Kang, E.J., Ju, W., Lee, S.N., Han, W.S., and Kim, S.C. Immunocytochemical staining of p16(ink4a) protein as an adjunct test in equivocal liquid-based cytology. *Diagnostic Cytopathology*. 2008;36(5):311-316.

Tong, H., Shen, R., Wang, Z., Kan, Y., Wang, Y., Li, F., Wang, F., Yang, J., Guo, X., and Mass Cervical Cancer Screening Regimen Group. DNA ploidy cytometry testing for cervical cancer screening in China (DNACIC Trial): a prospective randomized, controlled trial. *Clinical Cancer Research*. 10-15-2009;15(20):6438-6445.

Wentzensen, N., Bergeron, C., Cas, F., Vinokurova, S., and Von Knebel, Doeberitz M.. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. *Cancer*. 2-25-2007;111(1):58-66.

Zuna, R.E., Wang, S.S., Rosenthal, D.L., Jeronimo, J., Schiffman, M., Solomon, D., and ALTS Group. Determinants of human papillomavirus-negative, low-grade squamous intraepithelial lesions in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions triage study (ALTS). *Cancer*. 10-25-2005;105(5):253-262.

Level 3: Comparison – no screening, celibate or one partner

Adams, A.L., Gidley, J., Roberson, J., Wang, W., Eltoun, I., and Chhieng, D.C.. Clinical significance of unsatisfactory conventional pap smears owing to inadequate squamous cellularity defined by the Bethesda 2001 criterion. *American Journal of Clinical Pathology*. 2005;123(5):738-743.

ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. *Journal of the National Cancer Institute*. 3-1-2000;92(5):397-402.

Arbyn, M., Martin-Hirsch, P., Buntinx, F., Van, Ranst M., Paraskevaidis, E., and Dillner, J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. *Journal of Cellular & Molecular Medicine*. 2009;13(4):648-659.

Atkins, K.A., Jeronimo, J., Stoler, M.H., and ALTS Group. Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. *Cancer*. 8-25-2006;108(4):212-221.

Baer, A., Kiviat, N.B., Kulasingam, S., Mao, C., Kuypers, J., and Koutsky, L.A. Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?. *Obstetrics & Gynecology*. 2002;99(6):1053-1059.

Baldauf, J.J., Fender, M., and Baulon, E. [Screening and early diagnosis of cervical cancer] [French]. *Revue du Praticien*. 2010;60(2):213-218.

Bhaumik, J., Morris, P.G., Beer, H.R., Fielder, H., Coles, E.C., and Leeson, S. The inadequate smear: Does it matter?. *Cytopathology*. 2004;15(5):271-275.

Bishop, J.W. Cellularity of liquid-based, thin-layer cervical cytology slides. *Acta Cytologica*. 2002;46(4):633-636.

Bolanca, I.K. and Ciglar, S. Evaluation of p16INK4a in cervical lesion of premenopausal and postmenopausal women. *Collegium Antropologicum*. 2007;31:Suppl-11.

Boonlikit, S., Supakarapongkul, W., Preuksaritanond, N., Vipupinyo, C., Tuipae, S., Mangclaviras, S., Karnplumjid, S., and Chantarawiroj, P. Screening of cervical neoplasia by using pap smear with speculoscopy compared with pap smear alone. *Journal of the Medical Association of Thailand*. 2005;88(2):138-144.

Branca, M., Rossi, E., Alderisio, M., Migliore, G., Morisini, P.L., Vecchione, A., Sopracordevole, F., Mudu, P., Leoncini, L., and Syrajanen, K. Performance of cytology and colposcopy in diagnosis of cervical intraepithelial neoplasia (CIN) in HIV-positive and HIV-negative women. *Cytopathology*. 2001;12(2):84-93.

Bulk, S., Rozendaal, L., Zielinski, G. D., Berkhof, J., Daalmeijer, N.C., Snijders, P.J., van Kemenade, F.J., and Meijer, C.J. High-risk human papillomavirus is present in cytologically false-negative smears: an analysis of "normal" smears preceding CIN2/3. *Journal of Clinical Pathology*. 2008;61(3):385-389.

Callaghan, J., Karim, S., Mortlock, S., Wintert, M., and Woodward, N. Hybrid capture as a means of detecting human papillomavirus DNA from liquid-based cytology specimens: a preliminary evaluation. *British Journal of Biomedical Science*. 2001;58(3):184-189.

Cochand-Priollet, B., Le, Gales C., de, Cremoux P., Molinie, V., Sastre-Garau, X., Vacher-Lavenu, M. C., Vielh, P., Coste, J., and Monolayers French Society of Clinical Cytology Study Group. Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology. *Diagnostic Cytopathology*. 2001;24(6):412-420.

Colgan, T.J., Woodhouse, S.L., Styer, P.E., Kennedy, M., and Davey, D.D. Reparative changes and the false-positive/false-negative Papanicolaou test: a study from the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. *Archives of Pathology & Laboratory Medicine*. 2001;125(1):134-140.

- Cong, X., Cox, D.D., and Cantor, S.B. Bayesian meta-analysis of Papanicolaou smear accuracy. *Gynecologic Oncology*. 2007;107(1:Suppl 1):Suppl-7.
- Cortes-Gutierrez, E.I., Cerda-Flores, R.M., Leal-Klevezas, D.S., Hernandez-Garza, F., and Leal-Garza, C.H. Validating polymerase chain reaction for detecting HPV in cervical intraepithelial neoplasia. *Analytical & Quantitative Cytology & Histology*. 2003;25(2):115-118.
- Cotton, S., Sharp, L., Little, J., Cruickshank, M., Seth, R., Smart, L., Duncan, I., Harrild, K., Neal, K., Waugh, N., and Trial Of Management of Borderline and Other Low-grade Abnormal Smears Group. The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2010;117(6):645-659.
- Dawson, A.E. Can we change the way we screen?: the ThinPrep Imaging System. [Review] [17 refs]. *Cancer*. 2004;102(6):340-344.
- Depuydt, C.E., Boulet, G.A., Horvath, C.A., Benoy, I.H., Vereecken, A.J., and Bogers, J.J. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. *Journal of Cellular & Molecular Medicine*. 2007;11(4):881-891.
- Gray, S.H. and Walzer, T.B. New strategies for cervical cancer screening in adolescents. *Current Opinion in Pediatrics*. 2004;16(4):344-349.
- Gupta, S. and Sodhani, P. Why is high grade squamous intraepithelial neoplasia under-diagnosed on cytology in a quarter of cases? Analysis of smear characteristics in discrepant cases. *Indian Journal of Cancer*. 2004;41(3):104-108.
- Halcon, L.L., Lifson, A.R., Shew, M., Joseph, M., Hannan, P.J., and Hayman, C.R. Pap test results among low-income youth: prevalence of dysplasia and practice implications. *JOGNN - Journal of Obstetric, Gynecologic, & Neonatal Nursing*. 2002;31(3):294-304.
- Halder, K., Chachra, K.L., Sodhani, P., and Gupta, S. Utility of imprint cytology for early presumptive diagnosis in clinically suspicious cervical cancer. *Acta Cytologica*. 2008;52(3):286-293.
- Harris, P. and Carnes, M. Is there an age at which we should stop performing screening Pap smears and mammography?. *Cleveland Clinic Journal of Medicine*. 2002;69(4):272-273.
- Holcomb, K. and Runowicz, C.D. Cervical cancer screening. *Surgical Oncology Clinics of North America*. 2005;14(4):777-797.
- Hounsgaard, L., Petersen, L.K., and Pedersen, B.D. Facing possible illness detected through screening--experiences of healthy women with pathological cervical smears. *European Journal of Oncology Nursing*. 2007;11(5):417-423.
- Howard, M., Sellors, J.W., Lytwyn, A., Roth, P., and Mahony, J.B. Combining human papillomavirus testing or cervicography with cytology to detect cervical neoplasia. *Archives of Pathology & Laboratory Medicine*. 2004;128(11):1257-1262.
- Hunter, M.I., Monk, B.J., and Tewari, K.S. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. *American Journal of Obstetrics and Gynecology*. 2008;199(1):3-9.
- Insinga, R.P., Glass, A.G., and Rush, B.B. Diagnoses and outcomes in cervical cancer screening: a population-based study. *American Journal of Obstetrics & Gynecology*. 2004;191(1):105-113.
- Jeronimo, J., Khan, M.J., Schiffman, M., Solomon, D., and ALTS Group. Does the interval between papanicolaou tests influence the quality of cytology?. *Cancer*. 6-25-2005;105(3):133-138.
- Jin, X.W., Zanutti, K., and Yen-Lieberman, B. New cervical cancer screening strategy: Combined Pap and HPV testing. *Cleveland Clinic Journal of Medicine*. 2005;72(2):141-148.

- Kosel, S., Burggraf, S., Mommsen, J., Engelhardt, W., and Olgemoller, B. Type-specific detection of human papillomaviruses in a routine laboratory setting--improved sensitivity and specificity of PCR and sequence analysis compared to direct hybridisation. *Clinical Chemistry & Laboratory Medicine*. 2003;41(6):787-791.
- Krane, J.F., Granter, S.R., Trask, C.E., Hogan, C.L., and Lee, K.R. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. *Cancer*. 2-25-2001;93(1):8-15.
- Kumar, N. and Jain, S. Quality control and automation in cervical cytology. *Journal of the Indian Medical Association*. 2004;102(7):372-.
- Lie, A.K., Risberg, B., Borge, B., Sandstad, B., Delabie, J., Rimala, R., Onsrud, M., and Thoresen, S. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. *Gynecologic Oncology*. 2005;97(3):908-915.
- Macaskill, P., Walter, S.D., Irwig, L., and Franco, E.L. Assessing the gain in diagnostic performance when combining two diagnostic tests. *Statistics in Medicine*. 2002;21(17):2527-2546.
- Martin-Hirsch, P.L., Koliopoulos, G., and Paraskevaidis, E. Is it now time to evaluate the true accuracy of cervical cytology screening? A review of the literature. [Review] [15 refs]. *European Journal of Gynaecological Oncology*. 2002;23(4):363-365.
- Mubiayi, N., Bogaert, E., Boman, F., Leblanc, E., Vinatier, D., Leroy, J.L., and Querleu, D. [Cytological history of 148 women presenting with invasive cervical cancer]. [French]. *Gynecologie, Obstetrique & Fertilité*. 2002;30(3):210-217.
- Nanda, K., McCrory, D.C., Myers, E.R., Bastian, L.A., Hasselblad, V., Hickey, J.D., and Matchar, D.B. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. [Review] [125 refs]. *Annals of Internal Medicine*. 2000;132(10):810-819.
- Nguyen, D. and Church, L. Are biannual Papanicolaou (Pap) tests useful in postmenopausal women? Does hormone replacement therapy (HRT) affect the development of cervical cytology abnormalities?. *Journal of Family Practice*. 2001;50(4):368.
- Nijhuis, E.R., Reesink-Peters, N., Wisman, G.B., Nijman, H.W., van, Zanden J., Volders, H., Hollema, H., Suurmeijer, A.J., Schuurin, E., and van der Zee, A.G. An overview of innovative techniques to improve cervical cancer screening. [Review] [147 refs]. *Cellular Oncology*. 2006;28(5-6):233-246.
- Pajtler, M., Audy-Jurkovic, S., Ovanin-Rakic, A., Makarovic, Z., Milojkovic, M., and Ljubojevic, N. Diagnostic value of cytology and colposcopy for squamous and glandular cervical intraepithelial lesions. *Collegium Antropologicum*. 2003;27(1):239-246.
- Park, S., Yoo, I., and Chang, S. Relationship between the intention to repeat a papanicolaou smear test and affective response to a previous test among Korean women. *Cancer Nursing*. 2002;25(5):385-390.
- Petignat, P., de Tejada, M. B., Irion, O., and Boulvain, M. [What's new in gynecology and obstetrics?]. [French]. *Revue Medicale Suisse*. 2008;4(139):24-27.
- Petry, K.U., Menton, S., Menton, M., van Loenen-Frosch, F., de Carvalho, Gomes H., Holz, B., Schopp, B., Garbrecht-Buettner, S., Davies, P., Boehmer, G., van den Akker, E., and Iftner, T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. *British Journal of Cancer*. 2003;88(10):1570-1577.
- Pisal, N., Sindos, M., Chow, C., and Singer, A. Triage by HPV-DNA testing: is it useful in women with persistent minor smear abnormalities?. *Acta Obstetrica et Gynecologica Scandinavica*. 2003;82(6):575-577.
- Poljak, M., Kovanda, A., Kocjan, B.J., Seme, K., Jancar, N., and Vrtacnik-Bokal, E. The Abbott

RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. *Acta Dermatovenerologica Alpina, Panonica et Adriatica*. 2009;18(3):94-103.

Qureshi, M.N., Bolick, D., Ringer, P.J., Spagler, F.L., and Zimmerman, G. HPV testing in liquid cytology specimens: comparison of analytic sensitivity and specificity for in situ hybridization and chemiluminescent nucleic acid testing. *Acta Cytologica*. 2005;49(2):120-126.

Qureshi, M.N., Rudelli, R.D., Tubbs, R.R., Biscotti, C.V., and Layfield, L.J. Role of HPV DNA testing in predicting cervical intraepithelial lesions: comparison of HC HPV and ISH HPV. *Diagnostic Cytopathology*. 2003;29(3):149-155.

Ramsaroop, R., Oei, P., Ng, D., Kumar, N., and Cotter, P.D. Cervical intraepithelial neoplasia and aneusomy of TERC: assessment of liquid-based cytological preparations. *Diagnostic Cytopathology*. 2009;37(6):411-415.

Reuschenbach, M., Clad, A., Von Knebel, Doeberitz C., Wentzensen, N., Rahmsdorf, J., Schaffrath, F., Griesser, H., Freudenberg, N., and Von Knebel, Doeberitz M. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. *Gynecologic Oncology*. 2010;119(1):98-105.

Ronco, G. and Meijer, C.J.L. M. HPV screening: Available data and recommendations for clinical practice. *Current Cancer Therapy Reviews*. 2010;6(2):104-109.

Sasieni, P. and Castanon, A. Call and recall cervical screening programme: Screening interval and age limits. *Current Diagnostic Pathology*. 2006;12(2):114-126.

Schneider, V., Henry, M.R., Jimenez-Ayala, M., Turnbull, L.S., Wright, T.C., and International Consensus Conference on the Fight Against Cervical Cancer, IAC Task Force Chicago Illinois USA. Cervical cancer screening, screening errors and reporting. [Review] [32 refs]. *Acta Cytologica*. 2001;45(4):493-498.

Spayne, J., Ackerman, I., Milosevic, M., Seidenfeld, A., Covens, A., and Paszat, L. Invasive cervical cancer: a failure of screening. *European Journal of Public Health*. 2008;18(2):162-165.

Studeman, K.D., Ioffe, O.B., Puskiewicz, J., Sauvegeot, J., and Henry, M.R. Effect of cellularity on the sensitivity of detecting squamous lesions in liquid-based cervical cytology. *Acta Cytologica*. 2003;47(4):605-610.

Szarewski, A. Social and psychological aspects of cervical screening. *Expert Review of Obstetrics and Gynecology*. 2011;6(1):37-44.

Tamiolakis, D., Kalloniatiou, M., Lambropoulou, M., Kambanieris, M., Tsopelas, A., Daskalakis, G., Nikolaidou, S., Venizelos, I., and Papadopoulos, N. Contribution of combined colposcopy and cytology in cervical pathology. *Archives of Gynecology & Obstetrics*. 2005;273(1):39-42.

Twu, N.-F., Chen, Y.-J., Wang, P.-H., Yu, B.K.J., Lai, C.-R., Chao, K.-C., Yuan, C.-C., and Yen, M.-S. Improved cervical cancer screening in premenopausal women by combination of Pap smear and speculscopy. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2007;133(1):114-118.

Vrtacnik-Bokal, E., Rakar, S., Jancar, N., Mozina, A., and Poljak, M. Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions. *European Journal of Gynaecological Oncology*. 2005;26(4):427-430.

Waller, J., McCaffery, K., Kitchener, H., Nazroo, J., and Wardle, J. Women's experiences of repeated HPV testing in the context of cervical cancer screening: a qualitative study. *Psycho-Oncology*. 2007;16(3):196-204.

Wentzensen, N., Gravitt, P.E., Solomon, D., Wheeler, C.M., and Castle, P.E. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study.[Erratum appears in *Cancer Epidemiol Biomarkers Prev.* 2009 Jun;18(6):1943]. *Cancer Epidemiology, Biomarkers & Prevention.* 2009;18(5):1341-1349.

Yamazaki, H., Sasagawa, T., Basha, W., Segawa, T., and Inoue, M. Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. *International Journal of Cancer.* 2001;94(2):222-227.

Zhao, C., Florea, A., Onisko, A., and Austin, R.M. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. *Gynecologic Oncology.* 2009;114(3):383-389.

Zhao, F.H., Lin, M.J., Chen, F., Hu, S.Y., Zhang, R., Belinson, J.L., Sellors, J.W., Franceschi, S., Qiao, Y.L., Castle, P.E., and Cervical Cancer Screening Group. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. *Lancet Oncology.* 2010;11(12):1160-1171.

Level 3: Outcomes

Adams, A.L., Eltoun, I., Roberson, J., Chen, J., Connolly, K., and Chhieng, D.C. Negative colposcopic biopsy after positive human papilloma virus (HPV) DNA testing: false-positive HPV results or false-negative histologic findings?. *American Journal of Clinical Pathology.* 2006;125(3):413-418.

Agorastos, T., Sotiriadis, A., and Emmanouilides, C.J. Effect of type-specific human papillomavirus incidence on screening performance and cost. *International Journal of Gynecological Cancer.* 2010;20(2):276-282.

Alves, V.A., Bibbo, M., Schmitt, F.C., Milanezi, F., and Longatto, Filho A. Comparison of manual and automated methods of liquid-based cytology. A morphologic study. *Acta Cytologica.* 2004;48(2):187-193.

Andersson-Ellstrom, A., Seidal, T., Grannas, M., and Hagmar, B. The pap-smear history of women with invasive cervical squamous carcinoma. A case-control study from Sweden. *Acta Obstetricia et Gynecologica Scandinavica.* 2000;79(3):221-226.

Arbyn, M. and Schenck, U. Detection of false negative Pap smears by rapid reviewing. A metaanalysis. *Acta Cytologica.* 2000;44(6):949-957.

Baay, M.F., Smits, E., Tjalma, W.A., Lardon, F., Weyler, J., Van, Royen P., Van Marck, E.A., and Vermorken, J.B. Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. *International Journal of Cancer.* 1-10-2004;108(2):258-261.

Baay, M.F., Tjalma, W.A., Lambrechts, H.A., Pattyn, G.G., Lardon, F., Weyler, J., Van, Royen P., Van Marck, E.A., and Vermorken, J.B. Combined Pap and HPV testing in primary screening for cervical abnormalities: should HPV detection be delayed until age 35?. *European Journal of Cancer.* 2005;41(17):2704-2708.

Bowie, J.V., Curbow, B.A., Garza, M.A., Dreyling, E.K., Benz Scott, L.A., and McDonnell, K.A.A review of breast, cervical, and colorectal cancer screening interventions in older women. [Review] [7 refs]. *Cancer Control.* 2005;12:Suppl-69.

Castle, P.E., Bulten, J., Confortini, M., Klinkhamer, P., Pellegrini, A., Siebers, A.G., Ronco, G., and Arbyn, M. Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2010;117(9):1067-1073.

Chaplain, G., Quantin, C., Brunet-Lecomte, P., Mottot, C., Michiels-Marzais, D., and Sasco, A.J. Quality assessment of cervical screening: a population-based case-control study in the C te-D'Or region, France. *Cancer Detection & Prevention*. 2001;25(1):40-47.

Cochand-Priollet, B., Le, Gales C., de, Cremoux P., Molinie, V., Sastre-Garau, X., Vacher-Lavenu, M.C., Vielh, P., Coste, J., and Monolayers French Society of Clinical Cytology Study Group. Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: protocol of the study of the French Society of Clinical Cytology. *Diagnostic Cytopathology*. 2001;24(6):412-420.

Eltoum, I.A., Chhieng, D.C., Crowe, D.R., Roberson, J., Jin, G., and Broker, T.R. Significance and possible causes of false-negative results of reflex human Papillomavirus infection testing. *Cancer*. 6-25-2007;111(3):154-159.

Farag, R., Redline, R., and Abdul-Karim, F.W. Value of combining HPV-DNA testing with follow-up Papanicolaou smear in patients with prior atypical squamous cells of undetermined significance. *Acta Cytologica*. 2008;52(3):294-296.

French, D.P., Maissi, E., and Marteau, T.M. The psychological costs of inadequate cervical smear test results: three-month follow-up. *Psycho-Oncology*. 2006;15(6):498-508.

Gage, J.C., Schiffman, M., Solomon, D., Wheeler, C.M., and Castle, P.E. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. *Cancer Epidemiology, Biomarkers & Prevention*. 2010;19(7):1668-1674.

Giovagnoli, M.R., Cenci, M., Olla, S.V., and Vecchione, A. Cervical false negative cases detected by neural network-based technology. Critical review of cytologic errors. *Acta Cytologica*. 2002;46(6):1105-1109.

Goodman, A., Chaudhuri, P.M., Tobin-Enos, N.J., and Hutchinson, M.L. The false negative rate of cervical smears in high risk HIV seropositive and seronegative women. *International Journal of Gynecological Cancer*. 2000;10(1):27-32.

Grainge, M. J., Seth, R., Coupland, C., Guo, L., Rittman, T., Vryenhoef, P., Johnson, J., Jenkins, D., and Neal, K. R. Human papillomavirus infection in women who develop high-grade cervical intraepithelial neoplasia or cervical cancer: a case-control study in the UK. *British Journal of Cancer*. 5-9-2005;92(9):1794-1799.

Gray, N. M., Sharp, L., Cotton, S. C., Masson, L. F., Little, J., Walker, L. G., Avis, M., Philips, Z., Russell, I., Whynes, D., Cruickshank, M., Woolley, C. M., and TOMBOLA Group. Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors. *British Journal of Cancer*. 5-8-2006;94(9):1253-1262.

Hessling, J. J., Raso, D. S., Schiffer, B., Callicott, J., Jr., Husain, M., and Taylor, D. Effectiveness of thin-layer preparations vs. conventional Pap smears in a blinded, split-sample study. Extended cytologic evaluation. *Journal of Reproductive Medicine*. 2001;46(10):880-886.

Idestrom, M., Milsom, I., and Andersson-Ellstrom, A. Women's experience of coping with a positive Pap smear: A register-based study of women with two consecutive Pap smears reported as CIN I. *Acta Obstetricia et Gynecologica Scandinavica*. 2003;82(8):756-761.

Korfage, I.J., van, Ballegooijen M., Huvneers, H., and Essink-Bot, M.L. Anxiety and borderline PAP smear results. *European Journal of Cancer*. 2010;46(1):134-141.

Kruger, J., Dunton, C.J., Sewell, C., and Cardonick, E. Randomized pilot study comparing rates of endocervical cell recovery between conventional pap smears and liquid-based cytology in a pregnant population. *Journal of Lower Genital Tract Disease*. 2003;7(2):101-103.

- Luthra, U.K., Chishti, M., Dey, P., Jolly, S.V., Abdulla, M., Das, D.K., Sugathan, T.N., Ajrawi, M.T., George, J., George, S.S., Aziz, A.A., al-Juwaiser, A., Karim, F.A., Mallik, M.K., Sheikh, Z.A., and Khan, S. Performance of monolayered cervical smears in a gynecology outpatient setting in Kuwait. *Acta Cytologica*. 2002;46(2):303-310.
- Maissi, E., Marteau, T.M., Hankins, M., Moss, S., Legood, R., and Gray, A. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. *British Journal of Cancer*. 3-28-2005;92(6):990-994.
- Maissi, E., Marteau, T.M., Hankins, M., Moss, S., Legood, R., and Gray, A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. *BMJ*. 5-29-2004;328(7451):1293-.
- Mitchell, H., Hocking, J., and Saville, M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study. *Acta Cytologica*. 2004;48(5):595-600.
- Petticrew, M.P., Sowden, A.J., Lister-Sharp, D., and Wright, K. False-negative results in screening programmes: systematic review of impact and implications. [Review] [151 refs]. *Health Technology Assessment (Winchester, England)*. 2000;4(5):1-120.
- Petticrew, M., Sowden, A., and Lister-Sharp, D. False-negative results in screening programs. Medical, psychological, and other implications. [Review] [45 refs]. *International Journal of Technology Assessment in Health Care*. 2001;17(2):164-170.
- Phonrat, B., Ruengkris, T., Naksrisook, S., Intalapaporn, K., Jirakorbchaipong, P., and Pitisuttithum, P. Psychosocial burden of women with abnormal Pap smears. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2009;40(3):593-601.
- Raab, S.S., Grzybicki, D.M., Zarbo, R.J., Jensen, C., Geyer, S.J., Janosky, J.E., Meier, F.A., Vrbin, C.M., Carter, G., and Geisinger, K.R. Frequency and outcome of cervical cancer prevention failures in the United States. *American Journal of Clinical Pathology*. 2007;128(5):817-824.
- Ruba, S., Schoolland, M., Allpress, S., and Sterrett, G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. *Cancer*. 10-25-2004;102(5):280-287.
- Sherman, M.E., Carreon, J.D., and Schiffman, M. Performance of cytology and human papillomavirus testing in relation to the menstrual cycle. *British Journal of Cancer*. 6-5-2006;94(11):1690-1696.
- Siemens, F.C., van, Haaften C., Kuijpers, J.C., Helmerhorst, T.J., and Boon, M.E. Progression of abnormal MIB-1 staining patterns of reserve cells in cervical smears from women ultimately developing high grade squamous intraepithelial lesions. *Acta Cytologica*. 2006;50(6):637-642.
- Stein, S.R. ThinPrep versus the conventional Papanicolaou test: A review of specimen adequacy, sensitivity, and cost-effectiveness. *Primary Care Update for Ob/Gyns*. 2003;10(6):310-313.
- Swierczynski, S.L., Lewis-Chambers, S., Anderson, J.R., Keller, J.M., Hinkle, D.A., and Ali, S.Z. Impact of liquid-based gynecologic cytology on an HIV-positive population. *Acta Cytologica*. 2004;48(2):165-172.
- Takei, H., Ruiz, B., and Hicks, J. Cervicovaginal flora. Comparison of conventional pap smears and a liquid-based thin-layer preparation. *American Journal of Clinical Pathology*. 2006;125(6):855-859.
- Waller, J., Marlow, L.A., and Wardle, J. Anticipated shame and worry following an abnormal Pap test result: the impact of information about HPV. *Preventive Medicine*. 2009;48(5):415-419.
- Wang, K.-L., Jeng, C.-J., Yang, Y.-C., Chen, C.-A., Cheng, W.-F., Chen, T.-C., Mast, T.C., Wang, Y.-C., and Hsieh, C.-Y. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. *Journal of Psychosomatic Obstetrics and*

Gynecology. 2010;31(1):16-23.

Xiao, G.Q. and Emanuel, P.O. Cervical parakeratosis/hyperkeratosis as an important cause for false negative results of Pap smear and human papillomavirus test. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2009;49(3):302-306.

Zielinski, G.D., Snijders, P.J., Rozendaal, L., Voorhorst, F.J., van der Linden, H.C., Runsink, A.P., de Schipper, F.A., and Meijer, C.J. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. *British Journal of Cancer*. 8-3-2001;85(3):398-404.

Level 3: Study Design

Cervical cancer screening. *Prescrire International*. 2010;19(108):172-177+179.

Agnantis, N.J., Sotiriadis, A., and Paraskevaidis, E. The current status of HPV DNA testing. [Review]. *European Journal of Gynaecological Oncology*. 2003;24(5):351-356.

Agorastos, T., Sotiriadis, A., and Chatzigeorgiou, K. Can HPV testing replace the pap smear?. [Review] [39 refs]. *Annals of the New York Academy of Sciences*. 2010;1205:51-56.

Austin, R.M. Human papillomavirus reporting: minimizing patient and laboratory risk. [Review] [45 refs]. *Archives of Pathology & Laboratory Medicine*. 2003;127(8):973-977.

Baldauf, J.J., Fender, M., and Baulon, E. [Screening and early diagnosis of cervical cancer]. [French]. *Revue du Praticien*. 2-20-2010;60(2):213-218.

Bergeron, C. [The HPV test in primary cervical cancer screening]. [French]. *Annales de Pathologie*. 2008;28(1):S90-S91.

Boulanger, J.C., Fauvet, R., Urrutiaguer, S., Drean, Y., Sevestre, H., Ganry, O., Bergeron, C., and Gondry, J. [Cytological history of cases of invasive cervical cancer diagnosed in France in 2006]. [French]. *Gynecologie, Obstetrique & Fertilité*. 2007;35(9):764-771.

Brink, A.A., Zielinski, G.D., Steenbergen, R.D., Snijders, P.J., and Meijer, C.J. Clinical relevance of human papillomavirus testing in cytopathology. [Review] [50 refs]. *Cytopathology*. 2005;16(1):7-12.

Davies, P., Arbyn, M., Dillner, J., Kitchener, H.C., Meijer, C.J., Ronco, G., and Hakama, M. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. [Review] [40 refs]. *International Journal of Cancer*. 2-15-2006;118(4):791-796.

Davies, P., Bogdanovic-Guillion, A., Grce, M., and Sancho-Garnier, H. The future of cervical cancer prevention in Europe. [Review] [43 refs]. *Collegium Antropologicum*. 2007;31:Suppl-6.

Franco, E.L. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. [Review] [28 refs]. *Journal of the National Cancer Institute*. 2003;Monographs.(31):89-96.

Grce, M. and Davies, P. Human papillomavirus testing for primary cervical cancer screening. [Review] [46 refs]. *Expert Review of Molecular Diagnostics*. 2008;8(5):599-605.

Hantz, S., Caly, H., Decroisette, E., Dutrop, A., Bakeland, D., Pascal, B., Darreys, G., Dussartre, C., Renaudie, J., Rogez, S., Aubard, Y., Denis, F., and Alain, S. [Evaluation of accuracy of three assays for human papillomavirus detection and typing: Hybrid Capture 2, HPV Consensus kit and Amplicor HPV]. [French]. *Pathologie Biologie*. 2008;56(1):29-35.

Jin, X.W., Zanotti, K., and Yen-Lieberman, B. New cervical cancer screening strategy: Combined Pap and HPV testing. *Cleveland Clinic Journal of Medicine*. 2005;72(2):141-148.

Kirby, T.O. and Huh, W.K. HPV triage of patients with ASCUS cervical Pap smears. *Sexuality, Reproduction and Menopause*. 2004;2(3):146-153.

- Lorincz, A.T. Screening for cervical cancer: new alternatives and research. [Review] [53 refs]. *Salud Publica de Mexico*. 2003;45:Suppl-87.
- Lynge, E. and Rebolj, M. Primary HPV screening for cervical cancer prevention: results from European trials. [Review] [25 refs]. *Nature Reviews Clinical Oncology*. 2009;6(12):699-706.
- Martin-Hirsch, P.L., Koliopoulos, G., and Paraskevaidis, E. Is it now time to evaluate the true accuracy of cervical cytology screening? A review of the literature. [Review] [15 refs]. *European Journal of Gynaecological Oncology*. 2002;23(4):363-365.
- McCaffery, K., Waller, J., Nazroo, J., and Wardle, J. Social and psychological impact of HPV testing in cervical screening: a qualitative study. *Sexually Transmitted Infections*. 2006;82(2):169-174.
- McLachlin, C.M., Mai, V., Murphy, J., Fung-Kee-Fung, M., Chambers, A., Oliver, T.K., Cervical Screening Guidelines Development Committee of the Ontario Cervical Screening Program, and Gynecology Cancer Disease Site Group of Cancer Care Ontario. Ontario cervical cancer screening clinical practice guidelines. [Review] [45 refs]. *Journal of Obstetrics & Gynaecology Canada: JOGC*. 2007;29(4):344-353.
- Monsonogo, J. [Colposcopy: the value of HPV testing in clinical practice]. [French]. *Gynecologie, Obstetrique & Fertilité*. 2004;32(1):62-74.
- Morris, B.J. and Rose, B.R. Cervical screening in the 21st century: the case for human papillomavirus testing of self-collected specimens. [Review] [176 refs]. *Clinical Chemistry & Laboratory Medicine*. 2007;45(5):577-591.
- Petignat, P., de Tejada, M.B., Irion, O., and Boulvain, M. [What's new in gynecology and obstetrics?]. [French]. *Revue Medicale Suisse*. 1-9-2008;4(139):24-27.
- Renshaw, A.A. Measuring sensitivity in gynecologic cytology: a review. [Review] [38 refs]. *Cancer*. 8-25-2002;96(4):210-217.
- Rich, J.S. and Black, W.C. When should we stop screening?. *Effective Clinical Practice*. 2000;3(2):78-84.
- Ronco, G. and Meijer, C.J.L.M. HPV screening: Available data and recommendations for clinical practice. *Current Cancer Therapy Reviews*. 2010;6(2):104-109.
- Runowicz, C.D. and Garozzo, S. Human papillomavirus testing for primary cervical cancer screening. [Review] [26 refs]. *Current Oncology Reports*. 2008;10(6):533-537.
- Sharma, A. and Menon, U. Screening for gynaecological cancers. [Review] [76 refs]. *European Journal of Surgical Oncology*. 2006;32(8):818-824.

Cervical Cancer Screening Update Excluded Studies List

Level 2: cervical cancer screening is not focus

- Committee opinion No. 467: Human papillomavirus vaccination. *Obstetrics and Gynecology*. 2010;116(3):800-803.
- Therapeutic management of histologic lesions of the uterine cervix discovered through cervical smears. [French]. *Presse medicale (Paris, France : 1983)*. 1999;28(14):747-749.
- Use of cervical and breast cancer screening among women with and without functional limitations-- United States, 1994-1995. *MMWR*. 1998;Morbidity and mortality weekly report. 47(40):853-856.
- Abdelmutti, N. and Hoffman-Goetz, L. Risk messages about HPV, cervical cancer, and the HPV vaccine

gardasil in North American news magazines. *Journal of Cancer Education*. 2010;25(3):451-456.

Al-Jaroudi, D. and Hussain, T. Z. Prevalence of abnormal cervical cytology among subfertile Saudi women. *Annals of Saudi Medicine*. 2010;30(5):397-400.

Arbyn, M., Wallyn, S., Huet, F., and Vandenbroucke, A. Registration in the framework of organised cancer screening... Legal at last!. [French]. *Archives of Public Health*. 1999;57(3):149-153.

Ascunce, N., Salas, D., Zubizarreta, R., Almazan, R., Ibanez, J., Ederra, M., and Network of Spanish Cancer Screening Programmes (Red de Programas Espanoles de Cribado de Cancer) Cancer screening in Spain. *Annals of Oncology*. 2010;21:Suppl-51.

Bell, L. and Seale, C. The reporting of cervical cancer in the mass media: A study of UK newspapers. *European Journal of Cancer Care*. 2011;20(3):389-394.

Benmoura, D., Cravello, L., Roger, V., and Blanc, B. Management of abnormal cervical smears: management of ASCUS cervical smears. [French]. *Contraception, fertilité, sexualité* (1992). 1999;27(3):178-182.

Benmoura, D., Cravello, L., Roger, V., and Blanc, B. Management of women with abnormal cervical cytologic smear: Management of atypical smears. [French]. *Contraception Fertilité Sexualité*. 1999;27(3):178-182.

Bharti, A. C., Shukla, S., Mahata, S., Hedau, S., and Das, B. C. Human papillomavirus and control of cervical cancer in India. *Expert Review of Obstetrics and Gynecology*. 2010;5(3):329-346.

Bilgin, T., Dos, A., and Tolunay, S. Primary malignant lymphoma of the uterine cervix: Difficulties in diagnosis. *Journal of Obstetrics and Gynaecology*. 1999;19(6):671-672.

Bilhaut, J. P. Management of a high-grade cervical-vaginal smear. [French]. *Contraception, fertilité, sexualité* (1992). 1999;27(2):114-117.

Bohndiek, S. E. and Brindle, K. M. Imaging and 'omic methods for the molecular diagnosis of cancer. *Expert Review of Molecular Diagnostics*. 2010;10(4):417-434.

Cabrol, D. [Classification of the risks of premature labor. Implications for treatment]. [Review] [16 refs] [French]. *Journal de Gynecologie, Obstetrique et Biologie de la Reproduction*. 1997;26(2:Suppl):Suppl-9.

Cercato, M. C., Mariani, L., Vocaturo, A., Carrone, A., Terrenato, I., Morano, G., Benevolo, M., Rollo, F., Germelli, C., Paolini, F., and Venuti, A. Predictors of human papilloma virus (HPV) infection in Italian women. *Journal of Medical Virology*. 2010;82(11):1921-1927.

Chattopadhyay, S. K., Hall, H. I., Wolf, R. B., and Custer, W. S. Sources of health insurance in the U.S.: analysis of state-level data and implications for public health programs. *Journal of public health management and practice : JPHMP*. 1999;5(3):35-46.

Chen, L. S., Yen, A. M., Duffy, S. W., Tabar, L., Lin, W. C., and Chen, H. H. Computer-aided system of evaluation for population-based all-in-one service screening (CASE-PASS): from study design to outcome analysis with bias adjustment. *Annals of Epidemiology*. 2010;20(10):786-796.

Chin, K. J. All women with abnormal genital tract bleeding should have gynaecological examination [9]. *British Medical Journal*. 1998;316(7124):71-.

Conley, L., Bush, T., Darragh, T. M., Palefsky, J. M., Unger, E. R., Patel, P., Kojic, E. M., Cu-Uvin, S., Martin, H., Overton, E. T., Hammer, J., Henry, K., Vellozzi, C., Wood, K., Brooks, J. T., and Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN Study) Investigators Factors associated with prevalent abnormal anal cytology in a large cohort of HIV-infected adults in the United States. *Journal of Infectious Diseases*. 11-15-2010;202(10):1567-1576.

Crosbie, E. J. and Brabin, L. Cervical cancer: Problem solved? Vaccinating girls against human papillomavirus. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2010;117(2):137-142.

Diergaard, B. and Grandis, J. R. Human papillomavirus and head and neck cancer. *ONCOLOGY*. 2010;24(10):-.

DiMotto, J. Criminalizing malpractice. *Nursing Quality Connection*. 1995;5(1):1-7.

Dubbins, P. A. and Subba, B. Screening for gynecological malignancy. *Seminars in Ultrasound CT and MRI*. 1999;20(4):231-238.

Eckert, L. Screening for anal dysplasia in women with cervical, vaginal, or vulvar dysplasia: Yes, No, Maybe?. *Obstetrics and Gynecology*. 2010;116(3):566-567.

Edelman, D. A. and Van Os, W. A. A. Combined oral contraceptives and the risk of cervical cancer. *International Journal of Gynecology and Obstetrics*. 1997;56(1):57-58.

Elfgren, K., Kalantari, M., Moberger, B., Hagmar, B., and Dillner, J. A population-based five-year follow-up study of cervical human papillomavirus infection. *American Journal of Obstetrics & Gynecology*. 2000;183(3):561-567.

Errikson, K., Adolfsson, A., Forsum, U., and Larsson, P. G. Prevalence of BV on the Aland Islands. Reply to Professor Donders. *APMIS*. 2011;119(3):226-226.

Ferris, D. G. Colposcopy. *Primary Care - Clinics in Office Practice*. 1997;24(2):241-268.

Ferris, D. G. Office procedures. Colposcopy. [Review] [8 refs]. *Primary Care; Clinics in Office Practice*. 1997;24(2):241-267.

Flanagan, S. M., Wilson, S., Luesley, D., Damery, S. L., and Greenfield, S. M. Adverse outcomes after colposcopy. *BMC Women's Health*. 2011;11:2-.

Frale, W. J. ASCUS! ASCUS! down the rabbit hole. *Cancer*. 12-25-1999;87(6):319-321.

Garland, S. M. and Smith, J. S. Human papillomavirus vaccines: Current status and future prospects. *Drugs*. 2010;70(9):1079-1098.

Garrido, J. L. Twenty-five years of medical colposcopic rural tours in the Republic of Panama: commitment and integration in screening 1983-2008. *European Journal of Gynaecological Oncology*. 2010;31(4):434-436.

Gertig, D. M., Brotherton, J. M. L., and Saville, M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. *Sexual Health*. 2011;8(2):171-178.

Grulich, A. E., Jin, F., Conway, E. L., Stein, A. N., and Hocking, J. Cancers attributable to human papillomavirus infection. *Sexual Health*. 2010;7(3):244-252.

Guvenc, G., Akyuz, A., and Acikel, C. H. Health Belief Model Scale for Cervical Cancer and Pap Smear Test: psychometric testing. *Journal of Advanced Nursing*. 2011;67(2):428-437.

Hampton, K. Communicating health messages to marginalised communities - A culture sensitive approach. *International Journal of Health Promotion and Education*. 2000;38(2):40-46.

Heatley, M. K. The borderline cervical smear. *Cytopathology*. 1996;7(6):424-425.

Henning, T. R., Kissinger, P., Lacour, N., Meyaski-Schluter, M., Clark, R., and Amedee, A. M. Elevated cervical white blood cell infiltrate is associated with genital HIV detection in a longitudinal cohort of antiretroviral therapy-adherent women. *Journal of Infectious Diseases*. 11-15-2010;202(10):1543-1552.

Heraclio, Sde A., Souza, A. S., Pinto, F. R., Amorim, M. M., Oliveira, Mde L., and Souza, P. R.

- Agreement between methods for diagnosing HPV-induced anal lesions in women with cervical neoplasia. *Acta Cytologica*. 2011;55(2):218-224.
- Hilton, L. W. The Robert Tiffany Lectureship. Vital signs at the millennium: becoming more than we are. *Cancer Nursing*. 1999;22(1):6-16.
- Jewell, E., Smrtka, M., Myers, E., Samsa, G., Broadwater, G., and Havrilesky, L. Ranking women's preferences for available treatment and treatment-related complications for early-stage, high-risk cervical cancer. *Gynecologic Oncology*. 2010;Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists, SGO San Francisco, CA United States. Conference Start: 20100314 Conference End: 20100317. Conference Publication:(var.pagings):S33-.
- Johnston, C. Cervical adenocarcinoma in situ: A persistent clinical dilemma. *Lancet*. 1997;350(9088):1337-1338.
- Jorda, E. G. Telemedicine: Shortening distances. *Clinical and Translational Oncology*. 2010;12(10):650-651.
- Kocken, M., Helmerhorst, T. J. M., Berkhof, J., Louwers, J. A., Nobbenhuis, M. A. E., Bais, A. G., Hogewoning, C. J. A., Zaal, A., Verheijen, R. H. M., Snijders, P. J. F., and Meijer, C. J. L. M. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: A long-term multi-cohort study. *The Lancet Oncology*. 2011;12(5):441-450.
- Korman, J. Repeat Pap smear at the time of initial colposcopy--another view. *Gynecologic Oncology*. 1998;69(3):269-270.
- Krieger, P. and Naryshkin, S. Despite potential flaws, the false-negative proportion remains the best practical measure of the accuracy of cervical cytology screening. *Cancer*. 10-25-1997;81(5):261-263.
- Kurki, T. A survey of etiological mechanisms and therapy of preterm labor. *Acta Obstetrica et Gynecologica Scandinavica*. 1998;77(2):137-141.
- Lang, L. Pay-for-Performance Programs Show Positive Impact on Low-Performing Physicians. *Gastroenterology*. 2010;138(7):2195-2196.
- Le, Meur A., Mergui, J. L., and Napoly, V. Screening for Chlamydia trachomatis during gynecological consultation by endocervical sampling (PCR technique). [French]. *Contraception, fertilité, sexualité* (1992). 1999;27(5):345-347.
- Ledger, W. J. and Jeremias, J. Isn't it time to recognize and treat carcinoma of the cervix as an infectious disease?. *Infectious Diseases in Clinical Practice*. 1999;8(6):279-285.
- Levitt, C. A., Lupea, D., and Lewis, N. Recruiting regional primary care leads for cancer care Ontario. *Canadian Family Physician*. 2010;56(7):628-e249.
- Lin, H. W., Yu, T. C., and Ho, Y. S. A systemic review of human papillomavirus studies: Global publication comparison and research trend analyses from 1993 to 2008. *European Journal of Gynaecological Oncology*. 2011;32(2):133-140.
- Lingen, M. W. Can saliva-based HPV tests establish cancer risk and guide patient management?. *Oral Surgery Oral Medicine Oral Pathology Oral Radiology & Endodontics*. 2010;110(3):273-274.
- Matheson, C. A patient's response to recent criticisms of the findings in the report of the Cervical Cancer Inquiry 1988. *New Zealand Medical Journal*. 2010;123(1321):95-101.
- Mauad, E. C., Nicolau, S. M., Gomes, U. A., da Costa Vieira, R. A., de Castro Mattos, J. S., Longatto-Filho, A., and Baracat, E. C. Can mobile units improve the strategies for cervical cancer prevention?. *Diagnostic Cytopathology*. 2010;38(10):727-730.
- Mergui, P. Therapeutic management of histologic lesions discovered through abnormal cervical smears.

[French]. *Presse medicale* (Paris, France : 1983). 1999;28(14):749-752.

Messer, L., Steckler, A., and Dignan, M. Early detection of cervical cancer among Native American women: a qualitative supplement to a quantitative study. *Health Education & Behavior*. 1999;26(4):547-562.

Munro, M. G. Supracervical hysterectomy: ... A time for reappraisal. *Obstetrics and Gynecology*. 1997;89(1):133-139.

Narine, N., Rana, D. N., McVey, R. J., and Fitzmaurice, R. Ancillary testing in liquid based cytology to distinguish cervical glandular neoplasia from tuboendometrial metaplasia in a young woman. *Diagnostic Cytopathology*. 2010;38(11):828-832.

Newkirk, G. R. Office procedures. Electrosurgical loop excision of the cervix. [Review] [26 refs]. *Primary Care; Clinics in Office Practice*. 1997;24(2):281-302.

No authors listed Study reports vaginal gel can help improve reversion to normal pap smear. *Oncology* (Williston Park, N. 1996;Y.). 10(2):218, 221-.

Oki, A., Nishida, M., Satoh, T., Tsunoda, H., Kasahara, K., Saijo, K., Kubo, T., and Ohno, T. A novel human glassy-cell carcinoma cell line producing IL-6 and IL-8 from uterine cervix. *In Vitro Cellular and Developmental Biology - Animal*. 1998;34(4):290-297.

Pal, S. With longer survival rates, AIDS patients face elevated cancer risk. *ONCOLOGY*. 2011;25(2):-.

Pantanowitz, L. and Michelow, P. Review of human immunodeficiency virus (HIV) and squamous lesions of the uterine cervix. [Review]. *Diagnostic Cytopathology*. 2011;39(1):65-72.

Papadopoulou, M., Soucacos, P. N., and Georgoulis, A. Noulis-Lachman test (who is George Noulis?). *Sports Exercise and Injury*. 1997;3(4):157-159.

Patel, D. and Crane, L. R. Growing old with HIV. *Current Infectious Disease Reports*. 2011;13(1):75-82.

Peate, I. Cervical cancer. 2: Colposcopy, treatment and patient education. *British journal of nursing* (Mark Allen Publishing). 1999;8(12):805-809.

Rome, E. S. Sexually transmitted diseases: testing and treating. *Adolescent medicine* (Philadelphia, Pa. 1999;). 10(2):231-241, vi.

Rosen, N. O., Knauper, B., Di, Dio P., Morrison, E., Tabing, R., Feldstain, A., Amsel, R., Mayrand, M. H., Franco, E. L., and Rosberger, Z. The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: a randomised controlled study. *Psychology & Health*. 2010;25(6):651-668.

Sagot, P., Caroit, Y., Winer, N., Lopes, P., and Boog, G. Obstetrical prognosis for carbon dioxide laser conisation of the uterine cervix. *European Journal of Obstetrics, Gynecology, & Reproductive Biology*. 1995;58(1):53-58.

Sampson, A. J. Liability issues with the Papanicolaou smear: The view of a hospital administrator at Newport Hospital, Newport, Rhode Island. *Archives of Pathology and Laboratory Medicine*. 1997;121(3):241-245.

Scully, C. Oral cancer aetiopathogenesis; past, present and future aspects. *Medicina Oral, Patologia Oral y Cirugia Bucal*. 2011;16(3):306-311.

Serafini, M., Cordaro, C., Montanari, E., Falcini, F., and Bucchi, L. Diagnosis and treatment of cervical intraepithelial neoplasia grade 3: A registry-based study in the Romagna region of Italy (1986-1993). *International Journal of Epidemiology*. 1999;28(2):196-203.

Sharp, L., Cotton, S., Gray, N., Avis, M., Russell, I., Walker, L., Waugh, N., Whynes, D., Woolley, C., Thornton, A., Smart, L., Cruickshank, M., Little, J., and TOMBOLA Group Long-term psychosocial impact of alternative management policies in women with low-grade abnormal cervical cytology referred for colposcopy: a randomised controlled trial. *British Journal of Cancer*. 1-18-2011;104(2):255-264.

Sherigar, B., Dalal, A., Durdi, G., Pujar, Y., and Dhumale, H. Cervical cancer screening by visual inspection with acetic acid--interobserver variability between nurse and physician. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2010;11(3):619-622.

Sherman, M. E., Tabbara, S. O., Scott, D. R., Kurman, R. J., Glass, A. G., Manos, M. M., Burk, R. D., Rush, B. B., and Schiffman, M. "ASCUS, rule out HSIL": cytologic features, histologic correlates, and human papillomavirus detection. *Modern Pathology*. 1999;12(4):335-342.

Spitzer, M. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. [Review] [51 refs]. *Obstetrical & Gynecological Survey*. 1999;54(2):131-137.

Swan, J., Breen, N., Graubard, B. I., McNeel, T. S., Blackman, D., Tangka, F. K., and Ballard-Barbash, R. Data and trends in cancer screening in the United States: results from the 2005 National Health Interview Survey. *Cancer*. 10-15-2010;116(20):4872-4881.

Tanaka, Y., Kirihara, T., Kitamura, H., Kuriyama, M., Hori, H., and Gorai, I. Cytologic detection of recurrence in extramammary Paget's disease of the vulva: a report of two cases. *Acta Cytologica*. 2010;54(5:Suppl):Suppl-12.

Tsu, V. HPV vaccination: What practical experience tells us to date. *Annals of Oncology*. 2010;Conference: 35th ESMO Congress Milan Italy. Conference Start: 20101008 Conference End: 20101012. Conference Publication:(var.pagings):viii41-.

Wain, G. For debate: that Australia should continue using the quadrivalent vaccine. *Sexual Health*. 2010;7(3):235-237.

Wentzensen, N., Wilson, L. E., Wheeler, C. M., Carreon, J. D., Gravitt, P. E., Schiffman, M., and Castle, P. E. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. *Cancer Research*. 11-1-2010;70(21):8578-8586.

Zanotti, K. M. and Kennedy, A. W. Screening for gynecologic cancer. *Medical Clinics of North America*. 1999;83(6):1467-1487.

Zeqiri, F., Pacarada, M., Kongjeli, N., Zeqiri, V., Kongjeli, G., and Zejnullahu-Raci, P. The importance of colposcopy in the prevention of cervical malignancies. *International Journal of Gynaecology & Obstetrics*. 2010;110(2):149-150.

Level 2: Study Design

A message from Preventive Medicine and your physician. *Preventive Medicine*. 1999;28(6):543-544.

Bauch, C. T. Cervical cancer incidence can increase despite HPV vaccination - Author's reply. *The Lancet Infectious Diseases*. 2010;10(9):595-.

Burns, A., Sanghvi, H., Lu, R., Gaffikin, L., and Blumenthal, P. D. Saving women's lives from cervical cancer. *Lancet*. 4-16-2011;377(9774):1318-.

Butler, J., Barton, D., Shepherd, J., Reynolds, K., and Kehoe, S. Gynaecological examinations. Good not bad medicine. *BMJ*. 2011;342:d1760-.

Certain cancers increase in pts on long-term ART. Focus should be on screening. *AIDS Alert*. 2011;26(4):41-43.

Cheah, P. L. and Looi, L. M. Carcinoma of the uterine cervix: a review of its pathology and commentary on the problem in Malaysians. *The Malaysian journal of pathology*. 1999;21(1):1-15.

Cox, J. T. HPV DNA testing: Clinical boon or boondoggle?. *Lancet*. 1995;346(8977):717-719.

Drife, J. *European Journal of Obstetrics Gynecology and Reproductive Biology: Editor's highlights*. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2010;152(2):117-118.

Ferreira, S. E. Cervical intraepithelial neoplasia diagnosis: emotional impact and nursing implications. *Clinical excellence for nurse practitioners : the international journal of NPACE*. 1998;2(4):218-224.

Gompel, C. Pap smears: An ill-treated test. [French]. *Presse Medicale*. 1998;27(20):971-973.

Hensley, S. Improving the benchmark. Makers of a better, more costly Pap test face a tough sell. *Modern healthcare*. 1997;27(19):52-.

Higgins, C. Screening for cervical cancer. *Nursing times*. 1997;93(20):50-51.

Hillemanns, P. Response to: Demarteau N, Standaert B. Modelling the economic value of cross-and sustained-protection in vaccines against cervical cancer. *J Med Econ* 2010;13:324-38. *Journal of Medical Economics*. 2011;14(2):262-263.

Holt, H. L. Observations from the CDC: Progress report: The National Strategic Plan for the Early Detection and Control of Breast and Cervical Cancers. *Journal of Women's Health*. 1998;7(4):411-413.

Holt, H. L. Progress Report: the national strategic plan for the early detection and control of breast and cervical cancers. *Journal of women's health / the official publication of the Society for the Advancement of Women's Health Research*. 1998;7(4):411-413.

JAMA Patient Page: Pap test. *JAMA : the journal of the American Medical Association*. 1999;281(17):1666-.

Kaufman, R. H. Cancer screening in the young female. *Archives of Pathology & Laboratory Medicine*. 2011;135(3):296-297.

Kline, T. S. The Papanicolaou smear: a brief historical perspective and where we are today. *Archives of Pathology & Laboratory Medicine*. 1997;121(3):205-209.

Lambert, Ch Cervical pap smears. [French]. *Revue Medicale de Liege*. 1999;54(4):303-307.

Lantz, P. M., Stencil, D., Lippert, M. T., Beversdorf, S., Jaros, L., and Remington, P. L. Erratum: Breast and cervical cancer screening in a low-income managed care sample: The efficacy of physician letters and phone calls (*American Journal of Public Health* (1995) 85 (834-836)). *American Journal of Public Health*. 1995;85(8):1063-.

Lee, J. S. J. and Nelson, A. C. Stanley F. Patten, Jr., M.D., Ph.D., and the development of an automated papanicolaou smear screening system. *Cancer*. 1997;81(6):332-336.

Lee, S. H. Patient safety and the next generation of HPV DNA tests. *American Journal of Clinical Pathology*. 2011;135(3):481-483.

Marsan, C. [The cervico-vaginal smear. What is new with the Papanicolaou method in 1996?]. [French]. *Bulletin de l'Academie Nationale de Medecine*. 1996;180(5):1115-1119.

Martin, L. M., Parker, S. L., Wingo, P. A., and Heath, Jr Cervical cancer incidence and screening. Status report on women in the United States. *Cancer Practice*. 1996;4(3):130-134.

Melnikow, J. and Nuovo, J. Reducing mortality due to cervical cancer. PAPNET fails the test. *Archives*

of Family Medicine. 1999;8(1):56-57.

Paszkowski, T. Conference report - EUROGIN 2010 Monaco, February 17-20, 2010. [Polish, English]. *Ginekologia i Poloznictwo*. 2010;16(2):61-66.

Pelehach, L. Appraising the Pap smear. *Laboratory Medicine*. 1997;28(7):440-449.

Robles, S. C. Introduction to the special issue: timely detection of cervical cancer. *Bulletin of the Pan American Health Organization*. 1996;30(4):285-289.

Sasieni, P., Castanon, A., and Cuzick, J. ACOG guidelines on cervical screening: a step in the right direction. *Journal of Medical Screening*. 2010;17(2):55-56.

Singer, A. Cervical cancer screening: State of the art. *Bailliere's Clinical Obstetrics and Gynaecology*. 1995;9(1):39-64.

Slater, D. N. Sensitivity of primary screening by rapid review: 'To act or not to act on the results, that is the question'. *Cytopathology*. 1998;9(2):77-83.

Snyder, R. and Rini, A. G. Good intentions (Ohio's PAP smear law). *Nursing management*. 1996;27(6):59-.

Soloway, H. B. Detecting false negative smears. *Acta Cytologica*. 1997;41(6):1853-1854.

Thetard, R. C. Screening for cervical neoplasia--further lessons from Mamelodi. *South African Medical Journal*. 1996;Suid-Afrikaanse(4):378-.

Vacher-Lavenu, M. C. and Molinie, V. The monolayer technique: evolution or revolution in cervico-uterine cytology. [French]. *Annales de Pathologie*. 1998;18(3):218-220.

Vigliani, M. and Lindenmayer, J. Proposed cervical cancer screening recommendations. Rhode Island Department of Health Expert Panel on Cancer Screening. *Medicine and health, Rhode Island*. 1997;80(1):41-43.

Womack, C., Warren, A. Y., Sutton, G., Herbert, A., Slater, D., and Thornton, H. The cervical screening muddle (multiple letters) [1]. *Lancet*. 1998;351(9109):1129-1131.

Level 2: Outcomes

AbdullGaffar, B., Kamal, M. O., and Hasoub, A. The prevalence of abnormal cervical cytology in women with infertility. *Diagnostic Cytopathology*. 2010;38(11):791-794.

Alaghebandan, R., Fontaine, D., and Ratnam, S. Triage of ASC cytology using biomarkers: A comparative study of surepath and thinprep platforms. *Laboratory Investigation*. 2011;Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011 San Antonio, TX United States. Conference Start: 20110226 Conference End: 20110304. Conference Publication:(var.pagings):81A-.

Alhamany, Z., El, Mzibri M., Kharbach, A., Malihy, A., Abouqal, R., Jaddi, H., Benomar, A., Attaleb, M., Lamalmi, N., and Cherradi, N. Prevalence of human papillomavirus genotype among Moroccan women during a local screening program. *Journal of Infection in Developing Countries*. 2010;4(11):732-739.

Apgar, B. S. and Brotzman, G. HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. *American Family Physician*. 1999;59(10):2794-2800.

Aponte-Cipriani, S. L., Teplitz, C., Rorat, E., Savino, A., and Jacobs, A. J. Cervical smears prepared by an automated device versus the conventional method: A comparative analysis. *Acta Cytologica*. 1995;39(4):623-630.

- Ashfaq, R., Liang, Y., and Saboorian, M. H. Evaluation of PAPNET(TM) system for rescreening of negative cervical smears. *Diagnostic Cytopathology*. 1995;13(1):31-36.
- Autier, P., Coibion, M., De, Sutter P., and Wayemberg, M. Cytology alone versus cytology and cervicography for cervical and cervicography for cervical cancer screening: a randomized study. *European Society for Oncological Research. Obstetrics & Gynecology*. 1999;93(3):353-358.
- Autier, P., Coibion, M., De, Sutter P., and Wayemberg, M. Cytology alone versus cytology and cervicography for cervical cancer screening: A randomized study. *Obstetrics and Gynecology*. 1999;93(3):353-358.
- Barling, N. R. and Moore, S. M. Prediction of cervical cancer screening using the theory of reasoned action. *Psychological Reports*. 1996;79(1):77-78.
- Batra, P., Kuhn, L., and Denny, L. Utilisation and outcomes of cervical cancer prevention services among HIV-infected women in Cape Town. *South African Medical Journal*. 2010;100(1):39-44.
- Berger, B. M. Using the Pathfinder system to reduce missed abnormal cervical cytologic smear cases in a rescreening program. *Acta Cytologica*. 1997;41(1):173-181.
- Bergeron, C., Debaque, H., Ayivi, J., Amaizo, S., and Fagnani, F. Cervical smear histories of 585 women with biopsy-proven carcinoma in situ. *Acta Cytologica*. 1997;41(6):1676-1680.
- Bernstein, R., DeJoseph, D., and Buchanan, E. M. When to stop screening: a review of breast, gynecologic, and colorectal cancer screening in women over age 65. [Review] [37 refs]. *Care Management Journals*. 2010;11(1):48-57.
- Bertuccio, M. P., Spataro, P., Caruso, C., and Picerno, I. Detection of human papillomavirus E6/E7 mRNA in women with high-risk HPV types 16, 18, 31, 33 and 45 which are associated with the development of human cervical cancer. *European Journal of Gynaecological Oncology*. 2011;32(1):62-64.
- Bibbo, M., Hawthorne, C., and Zimmerman, B. Does use of the AutoPap assisted primary screener improve cytologic diagnosis?. *Acta Cytologica*. 1999;43(1):23-26.
- Birdsong, G. G. Automated screening of cervical cytology specimens. *Human Pathology*. 1996;27(5):468-481.
- Bishop, J. W. Comparison of the CytoRich system with conventional cervical cytology. Preliminary data on 2,032 cases from a clinical trial site. *Acta Cytologica*. 1997;41(1):15-23.
- Bollen, L. J. M., Tjong, A. Hung, Van, Der, V, Brouwer, K., Mol, B. W., Ten Kate, F. J. W., and ter, Schegget J. Human papillomavirus deoxyribonucleic acid detection in mildly or moderately dysplastic smears: A possible method for selecting patients for colposcopy. *American Journal of Obstetrics and Gynecology*. 1997;177(3):548-553.
- Boon, M. E., Ouwerkerk-Noordam, E., Meijer-Marres, E. M., and Bontekoe, T. R. Switching from neural networks (PAPNET) to the Imager (Hologic) for computer-assisted screening. *Acta Cytologica*. 2011;55(2):163-166.
- Boronow, R. C. Death of the Papanicolaou smear? A tale of three reasons. *American Journal of Obstetrics & Gynecology*. 1998;179(2):391-396.
- Bosoteanu, M., Bosoteanu, C., Deacu, M., and Aschie, M. The importance of monitoring protocols in cervical carcinoma screening. *Romanian Journal of Morphology & Embryology*. 2011;52(1:Suppl):Suppl-302.
- Botros, G., Haddad, N. G., Brooks, J., and Scalnan, J. Study of cervical screening for women under age of 25 years old, a retrospective data analysis. *Internet Journal of Gynecology and Obstetrics*.

2010;14(1):-.

Briet, M. C., Berger, T. H., van, Ballegooijen M., Boon, M. E., and Rebolj, M. Effects of streamlining cervical cancer screening the Dutch way: consequences of changes in the Dutch KOPAC-based follow-up protocol and consensus-based limitation of equivocal cytology. *Acta Cytologica*. 2010;54(6):1095-1100.

Brotzman, G. L., Kretzchmar, S., Ferguson, D., Gottlieb, M., and Stowe, C. Costs and outcomes of PAPNET secondary screening technology for cervical cytologic evaluation. A community hospital's experience. *Archives of Family Medicine*. 1999;8(1):52-55.

Broughton, S. and Thomson, K. Women with learning disabilities: risk behaviours and experiences of the cervical smear test. *Journal of Advanced Nursing*. 2000;32(4):905-912.

Brown, C. L. Screening patterns for cervical cancer: how best to reach the unscreened population. *Journal of the National Cancer Institute*. 1996;Monographs.(21):7-11.

Burger, E. A., Kornor, H., Klemp, M., Lauvrak, V., and Kristiansen, I. S. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. [Review]. *Gynecologic Oncology*. 2011;120(3):430-438.

Burks, H. R., Smith, K. M., Wentzensen, N., Tenney, M., Tuller, E., Moxley, K., Mathews, C., Dunn, S. T., Wang, S. S., and Gold, M. A. Risk of cervical intraepithelial neoplasia 2+ among women with a history of previous treatment for cervical intraepithelial neoplasia: ASCUS and LSIL Pap smears after treatment. *Journal of Lower Genital Tract Disease*. 2011;15(1):11-14.

Campian, E., Jarnagin, B., Mahadasyam, S., and Tatalovich, J. Type-specific Tem-PCR versus Hybrid-Capture II for the detection of human papillomavirus. *Gynecologic Oncology*. 2011;Conference: 42nd Annual Meeting of the Society of Gynecologic Oncologists Orlando, FL United States. Conference Start: 20110306 Conference End: 20110309. Conference Publication:(var.pagings):S114-.

Cenci, M., Nagar, C., Giovagnoli, M. R., and Vecchione, A. The PAPNET system for quality control of cervical smears: Validation and limits. *Anticancer Research*. 1997;17(6 D):4731-4734.

Chalermchockcharoenkit, A., Chayachinda, C., Thamkhantho, M., and Komoltri, C. Prevalence and cumulative incidence of abnormal cervical cytology among HIV-infected Thai women: a 5.5-year retrospective cohort study. *BMC Infectious Diseases*. 2011;11:8-.

Chankapa, Y. D., Pal, R., and Tsering, D. Correlates of cervical cancer screening among underserved women. *Indian Journal of Cancer*. 2011;48(1):40-46.

Chao, A., Becker, T. M., Jordan, S. W., Darling, R., Gilliland, F. D., and Key, C. R. Decreasing rates of cervical cancer among American Indians and Hispanics in New Mexico (United States). *Cancer Causes and Control*. 1996;7(2):205-213.

Check, W. Finding the proper fit for Pap smear devices. *CAP today / College of American Pathologists*. 1998;12(12):18-26.

Chen, H. C., You, S. L., Hsieh, C. Y., Schiffman, M., Lin, C. Y., Pan, M. H., Chou, Y. C., Liaw, K. L., Hsing, A. W., Chen, C. J., and CBCSP-HPV Study Group Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a community-based survey of 10,602 women. *International Journal of Cancer*. 3-1-2011;128(5):1192-1203.

Chua, K.-L. and Hjerpe, A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. *Cancer*. 1996;77(1):121-127.

Clarke, H. F., Joseph, R., Deschamps, M., Hislop, T. G., Band, P. R., and Atleo, R. Reducing cervical cancer among First Nations women. *The Canadian nurse*. 1998;94(3):36-41.

- Clavel, C., Masure, M., Bory, J.-P., Putaud, I., Mangeonjean, C., Lorenzato, M., Gabriel, R., Quereux, C., and Birembaut, P. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women. *British Journal of Cancer*. 1999;80(9):1306-1311.
- Coggi, G., Bulfamante, G., Romeo, M., Falleni, M., Aldovini, A., Cirillo, G., Federico, D., and Roncalli, M. Impact of the Pathfinder in a cytology laboratory. *Acta Cytologica*. 1997;41(1):166-172.
- Conway, K. Attitudes to Papanicolaou smears. *Journal of Psychosomatic Obstetrics and Gynaecology*. 1996;17(4):189-194.
- Costa, S., Sideri, M., Bucchi, L., Schettino, F., Maini, I., Spinaci, L., Bovicelli, L., and Terzano, P. Cervicography and HPV DNA testing as triage criteria for patients with abnormal Pap smear. *Gynecologic Oncology*. 1998;71(3):404-409.
- Costa, S., Venturoli, S., Mennini, F. S., Marcellusi, A., Pesaresi, M., Leo, E., Falasca, A., Marra, E., Cricca, M., Santini, D., Zerbini, M., and Pelusi, G. Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: The PATER study. *Current Medical Research and Opinion*. 2011;27(3):569-578.
- Coutlee, F., Mayrand, M. H., Provencher, D., and Franco, E. The future of HPV testing in clinical laboratories and applied virology research. [Review] [97 refs]. *Clinical & Diagnostic Virology*. 1997;8(2):123-141.
- Couzos, S., Wronski, I., Murray, R., and Cox, H. Augmentation of Pap smear screening of high risk aboriginal women. Use of a computerised process tool within the Broome Aboriginal Medical Service. *Australian Family Physician*. 1998;27(4):269-274.
- Cox, J. T. Clinical role of HPV testing. [Review] [153 refs]. *Obstetrics & Gynecology Clinics of North America*. 1996;23(4):811-851.
- Currens, H. S., Nejkauf, K. A., and Raab, S. S. Effectiveness of rapid prescreening in liquid based Pap tests. *Laboratory Investigation*. 2010;Conference: United States and Canadian Academy of Pathology Annual Meeting Washington, DC United States. Conference Start: 20100320 Conference End: 20100326. Conference Publication:(var.pagings):90A-.
- Curtis, P., Mintzer, M., Morrell, D., Resnick, J. C., Hendrix, S., and Qaqish, B. F. Characteristics and quality of Papanicolaou smears obtained by primary care clinicians using a single commercial laboratory. *Archives of Family Medicine*. 1999;8(5):407-413.
- Cuzick, J., Szarewski, A., Terry, G., Ho, L., Hanby, A., Maddox, P., Anderson, M., Kocjan, G., Steele, S. T., and Guillebaud, J. Human papillomavirus testing in primary cervical screening. *Lancet*. 6-17-1995;345(8964):1533-1536.
- Del, Priore G., Maag, T., Bhattacharya, M., Garcia, P. M., Till, M., and Lurain, J. R. The value of cervical cytology in HIV-infected women. *Gynecologic Oncology*. 1995;56(3):395-398.
- Diaz, M., de, Sanjose S., Ortendahl, J., O'Shea, M., Goldie, S. J., Bosch, F. X., and Kim, J. J. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. *European Journal of Cancer*. 2010;46(16):2973-2985.
- Dillner, J. Can cervical cancer screening programs be improved by incorporating screening for human papillomavirus infection?. *Cancer Journal*. 1998;11(6):272-276.
- Dodson, M., Belnap, T., Sause, W., Webb, J., and Soisson, A. Inappropriate use of human papillomavirus testing at the time of routine Pap. *Gynecologic Oncology*. 2010;Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists, SGO San Francisco, CA United States. Conference Start: 20100314 Conference End: 20100317. Conference Publication:(var.pagings):S59-.

Doornewaard, H., van de Seijp, H., Woudt, J. M., van der Graaf, Y., and van den Tweel, J. G. Negative cervical smears before CIN 3/carcinoma. Reevaluation with the PAPNET Testing System. *Acta Cytologica*. 1997;41(1):74-78.

Doornewaard, H., van der Schouw, Y. T., van der Graaf, Y., Bos, A. B., and van den Tweel, J. G. Observer variation in cytologic grading for cervical dysplasia of Papanicolaou smears with the PAPNET Testing System. *Cancer*. 1999;87(4):178-183.

Doornewaard, H., Woudt, J. M., Strubbe, P., van de Seijp, H., and van den Tweel, J. G. Evaluation of PAPNET-assisted cervical rescreening. *Cytopathology*. 1997;8(5):313-321.

Doran, A. E., LaFond, J., Fine, S., Al-Bawardy, B., Jencks, D., Uradomo, L. T., and Borum, M. L. Sub-optimal Pap smear performance and increased risk of cervical dysplasia in women with IBD: A potentially dangerous combination. *Gastroenterology*. 2011;Conference: Digestive Disease Week, DDW 2011 Chicago, IL United States. Conference Start: 20110507 Conference End: 20110510. Conference Publication:(var.pagings):S432-.

Dudding, N. Rapid rescreening of cervical smears: an improved method of quality control. *Cytopathology*. 1995;6(2):95-99.

Dudding, N., Renshaw, A. A., and Ellis, K. Rapid pre-screening is more sensitive in liquid-based cytology than in conventional smears. *Acta Cytologica*. 2011;55(1):54-56.

Dufresne, S., Sauthier, P., Mayrand, M. H., Petignat, P., Provencher, D., Drouin, P., Gauthier, P., Dupuis, M. J., Michon, B., Ouellet, S., Hadjeres, R., Ferenczy, A., Franco, E. L., and Coutlee, F. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with AmpliCor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix. *Journal of Clinical Microbiology*. 2011;49(1):48-53.

Dupree, W. B., Suprun, H. Z., Beckwith, D. G., Shane, J. J., and Lucente, V. The promise and risk of a new technology: The Lehigh Valley Hospital's experience with liquid-based cervical cytology. *Cancer*. 1998;84(4):202-207.

Edelman, M., Fox, A. S., Alderman, E. M., Neal, W., Shapiro, A., Silver, E. J., Spigland, I., and Suhrland, M. Cervical Papanicolaou smear abnormalities in inner city Bronx adolescents: prevalence, progression, and immune modifiers. *Cancer*. 8-25-1999;87(4):184-189.

Eltabbakh, G. H. and Eltabbakh, G. D. Papanicolaou smear: can we make a good test better? Technical and interpretive challenges for the practitioner. [Review] [37 refs]. *Journal of Womens Health & Gender-Based Medicine*. 1999;8(4):469-476.

Ermel, A., Qadadri, B., Morishita, A., Miyagawa, I., Yamazaki, G., Weaver, B., Tu, W., Tong, Y., Randolph, M., Cramer, H., and Brown, D. Human papillomavirus detection and typing in thin prep cervical cytologic specimens comparing the Digene Hybrid Capture II Assay, the Roche Linear Array HPV Genotyping Assay, and the Kurabo GeneSquare Microarray Assay. *Journal of Virological Methods*. 2010;169(1):154-161.

Etherington, I. J., Dunn, J., Shafi, M. I., Smith, T., and Luesley, D. M. Video colpography: a new technique for secondary cervical screening. *British Journal of Obstetrics & Gynaecology*. 1997;104(2):150-153.

False-negative Pap test rate high. *Newsline (People with AIDS Coalition of New York)*. 1999;#volume#:31-May.

Ferenczy, A., Robitaille, J., Franco, E., Arseneau, J., Richart, R. M., and Wright, T. C. Conventional cervical cytologic smears vs. ThinPrep smears: A paired comparison study on cervical cytology. *Acta Cytologica*. 1996;40(6):1136-1142.

- Fernandez, M. E., DeBor, M., Candreia, M. J., Wagner, A. K., and Stewart, K. R. Evaluation of ENCOREplus. A community-based breast and cervical cancer screening program. *American Journal of Preventive Medicine*. 1999;16(3 Suppl):35-49.
- Fiscella, K. and Franks, P. The adequacy of Papanicolaou smears as performed by family physicians and obstetrician-gynecologists. *The Journal of family practice*. 1999;48(4):294-298.
- Fitch, M. I., Greenberg, M., Cava, M., Spaner, D., and Taylor, K. Exploring the barriers to cervical screening in an urban Canadian setting. *Cancer Nursing*. 1998;21(6):441-449.
- Fletcher, A. H., Barklow, T. A., Murphy, N. J., Culbertson, L. H., Davis, A. V., and Hunter, L. ProExC triage of atypical glandular cells on liquid-based cervical cytology specimens. *Journal of Lower Genital Tract Disease*. 2011;15(1):6-10.
- Fox, J., Remington, P., Layde, P., and Klein, G. The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. *American Journal of Obstetrics & Gynecology*. 1999;180(5):1104-1109.
- Frale, W. J. Does a zero error standard exist for the Papanicolaou smear? A pathologist's perspective. [Review] [42 refs]. *Archives of Pathology & Laboratory Medicine*. 1997;121(3):301-310.
- Franco, E. L. and Ferenczy, A. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to papanicolaou smear in the triage of women with cervical cytologic abnormalities. [Review] [10 refs]. *American Journal of Obstetrics & Gynecology*. 1999;181(2):382-386.
- Galliano, G. E., Moatamed, N. A., Lee, S., Salami, N., and Apple, S. K. Reflex high risk HPV testing in atypical squamous cells, cannot exclude high grade intraepithelial lesion: a large institution's experience with the significance of this often ordered test. *Acta Cytologica*. 2011;55(2):167-172.
- Galliano, G. E., Moatamed, N. A., Lee, S., Salami, N., and Apple, S. K. Reflex high risk HPV testing (HR HPV) is not useful in women with atypical squamous cells - Can not exclude high grade squamous intraepithelial lesion (ASC-H). *Laboratory Investigation*. 2010;Conference: United States and Canadian Academy of Pathology Annual Meeting Washington, DC United States. Conference Start: 20100320 Conference End: 20100326. Conference Publication:(var.pagings):92A-.
- Gilles, M. T., Crewe, S., Granites, I. N., and Coppola, A. A community-based cervical screening program in a remote Aboriginal community in the Northern Territory. *Australian Journal of Public Health*. 1995;19(5):477-481.
- Gjoen, K., Sauer, T., Olsen, A. O., and Orstavik, I. Correlation between polymerase chain reaction and cervical cytology for detection of human papillomavirus infection in women with and without dysplasia. *APMIS*. 1997;105(1):71-75.
- Gjoen, K., Olsen, A. O., Magnus, P., Grinde, B., Sauer, T., and Orstavik, I. Prevalence of human papillomavirus in cervical scrapes, as analyzed by PCR, in a population-based sample of women with and without cervical dysplasia. *APMIS*. 1996;104(1):68-74.
- Goldie, S. J., Weinstein, M. C., Kuntz, K. M., and Freedberg, K. A. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. *Annals of Internal Medicine*. 1999;130(2):97-107.
- Gravitt, P. E., Paul, P., Katki, H. A., Vendantham, H., Ramakrishna, G., Sudula, M., Kalpana, B., Ronnett, B. M., Vijayaraghavan, K., Shah, K. V., and CATCH Study Team Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. *PLoS ONE [Electronic Resource]*. 2010;5(10):e13711-.
- Guidos, B. J. and Selvaggi, S. M. Use of the Thin Prep Pap Test in clinical practice. *Diagnostic Cytopathology*. 1999;20(2):70-73.

Guidozzi, F. Screening for cervical cancer. *Obstetrical and Gynecological Survey*. 1996;51(4):247-252.

Gullotta, G., Margariti, P. A., Rabitti, C., Balsamo, G., Valle, D., Capelli, A., and Mancuso, S. Cytology, histology, and colposcopy in the diagnosis of neoplastic non-invasive epithelial lesions of the cervix. *European Journal of Gynaecological Oncology*. 1997;18(1):36-38.

Gyrd-Hansen, D., Holund, B., and Andersen, P. A cost-effectiveness analysis of cervical cancer screening: Health policy implications. *Health Policy*. 1995;34(1):35-51.

Hall, S., Lorincz, A., Shah, F., Sherman, M. E., Abbas, F., Paull, G., Kurman, R. J., and Shah, K. V. Human papillomavirus DNA detection in cervical specimens by hybrid capture: Correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix. *Gynecologic Oncology*. 1996;62(3):353-359.

Hancock, L., Sanson-Fisher, R., and Kentish, L. Cervical cancer screening in rural NSW: Health Insurance Commission data compared to self-report. *Australian and New Zealand Journal of Public Health*. 1998;22(3):307-312.

Hanselaar, A. G. J. M., Boss, E. A., Massuger, L. F. A. G., and Bernheim, J. L. Cytologic examination to detect clear cell adenocarcinoma of the vagina or cervix. *Gynecologic Oncology*. 1999;75(3):338-344.

Haran, D., Maingon, R., Sandiford, P., and Cassel, J. The potential of hydrolysed DNA assay to improve cervical screening programmes; Evidence from a developing country setting. *Medical Science Research*. 1999;27(8):557-559.

Harris, J. M., Jr. Papanicolaou smear recommendations, patient complaints, and patient satisfaction in managed-care medical organizations. *Medical Care*. 1995;33(3):272-279.

Herrington, C. S., Evans, M. F., Charnock, F. M., Gray, W., and O'D, McGee J. HPV testing in patients with low grade cervical cytological abnormalities: a follow up study. *Journal of Clinical Pathology*. 1996;49(6):493-496.

Hislop, T. G., Clarke, H. F., Deschamps, M., Joseph, R., Band, P. R., Smith, J., Le, N., and Atleo, R. Cervical cytology screening. How can we improve rates among First Nations women in urban British Columbia?. *Canadian family physician Medecin de famille canadien*. 1996;42:1701-1708.

Hodge, F. S., Fredericks, L., and Rodriguez, B. American Indian women's talking circle. A cervical cancer screening and prevention project. *Cancer*. 10-1-1996;78(7:Suppl):Suppl-7.

Howell, L. P., Davis, R. L., Belk, T. I., Agdigos, R., and Lowe, J. The AutoCyte preparation system for gynecologic cytology. *Acta Cytologica*. 1998;42(1):171-177.

Huang, S., Erickson, B., Salituro, J., Engel, H., Gurok, U., Neuscheler, P., Mak, W., and Abravaya, K. Performance Of abbot cervi-collect specimen collection kit For detection Of HPV using abbot realTime high risk HPV assay. *Journal of Molecular Diagnostics*. 2010;Conference: Association for Molecular Pathology Annual Meeting San Jose, CA United States. Conference Start: 20101118 Conference End: 20101120. Conference Publication:(var.pagings):916-.

Huang, T. W., Lin, T. S. M., and Lee, J. S. J. Sensitivity studies of AutoPap system location-guided screening of cervical-vaginal cytologic smears. *Acta Cytologica*. 1999;43(3):363-368.

Hyndman, J. C., Straton, J. A., Pritchard, D. A., and Le, Sueur H. Cost-effectiveness of interventions to promote cervical screening in general practice. *Australian & New Zealand Journal of Public Health*. 1996;20(3):272-277.

Iftner, T., Eberle, S., Iftner, A., Holz, B., Banik, N., Quint, W., and Straube, A. N. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study.

Journal of Medical Virology. 2010;82(11):1928-1939.

Jenny, J., Isenegger, I., Boon, M. E., and Husain, O. A. Consistency of a double PAPNET scan of cervical smears. *Acta Cytologica*. 1997;41(1):82-87.

Ji, H., Sako, J., and Ewaskow, S. P. Clinical performance of the cervista HPV test in detection of high-risk human papillomavirus. *Journal of Molecular Diagnostics*. 2010;Conference: Association for Molecular Pathology Annual Meeting San Jose, CA United States. Conference Start: 20101118 Conference End: 20101120. Conference Publication:(var.pagings):899-900.

Kaminsky, F. C., Burke, R. J., Haberle, K. R., and Mullins, D. L. An economic model for comparing alternative policies for cervical cytologic smear screening. *Acta Cytologica*. 1995;39(2):232-238.

Kaufman, R. H. and Adam, E. Is human papillomavirus testing of value in clinical practice?. *American Journal of Obstetrics and Gynecology*. 1999;180(5):1049-1053.

Kavak, Z. N., Eren, F., Pekin, S., and Kullu, S. A randomized comparison of the 3 Papanicolaou smear collection methods. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 1995;35(4):446-449.

Kavanagh, A. M., Santow, G., and Mitchell, H. Consequences of current patterns of Pap smear and colposcopy use. *Journal of Medical Screening*. 1996;3(1):29-34.

Kawakami, Y., Takehara, K., Kumagai, M., Nakamura, H., Samura, O., Saito, A., Kuraoka, K., Mizunoe, T., Nishiwaki, M., and Taniyama, K. Liquid-based cytology and human papillomavirus genotyping of uterine cervical lesions. *Gynecologic Oncology*. 2010;Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists, SGO San Francisco, CA United States. Conference Start: 20100314 Conference End: 20100317. Conference Publication:(var.pagings):S31-S32.

Keegan, H. E., Pilkington, L., Mc, Inerney J., Szenthe, B., Benczik, M., Kaltenecker, B., Mozes, J., Kovacs, A., Solt, A., Bolger, N., Jeney, C., O'Leary, J. J., and Martin, C. M. Comparison of HPV detection technologies; hybrid capture 2 (Qiagen), full-spectrum HPV (Genoid), genoid molecular beacon real-time HPV assay with genotyping by linear array (Roche) and genoid HPV ELISA genotyping assay in an Irish colposcopy population. *Laboratory Investigation*. 2011;Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011 San Antonio, TX United States. Conference Start: 20110226 Conference End: 20110304. Conference Publication:(var.pagings):95A-

Keegan, H., Pilkington, L., Jamison, J., Wilson, R., and Carson, J. Comparison of HPV DNA detection technologies; Hybrid Capture II (QIAGEN), Cervista HPV HR (Hologic UK Ltd) in a northern Irish screening population. *Laboratory Investigation*. 2010;Conference: United States and Canadian Academy of Pathology Annual Meeting Washington, DC United States. Conference Start: 20100320 Conference End: 20100326. Conference Publication:(var.pagings):97A-

Keyhani-Rofagha, S., Palma, T., and O'Toole, R. V. Automated screening for quality control using PAPNET: a study of 638 negative Pap smears. *Diagnostic Cytopathology*. 1996;14(4):316-320.

Khaengkhor, P., Mairaing, K., Suwannarurk, K., Thaweekul, Y., Poomtavorn, Y., Pattaraarchachai, J., and Bhamarapravata, K. Prevalence of abnormal cervical cytology by liquid based cytology in the antenatal care clinic, Thammasat University Hospital. *Journal of the Medical Association of Thailand*. 2011;94(2):152-158.

Kinney, W., Fetterman, B., Cox, J. T., Lorey, T., Flanagan, T., and Castle, P. E. Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. *Gynecologic Oncology*. 2011;121(2):309-313.

Kitchener, H. C., Blanks, R., Dunn, G., Gunn, L., Desai, M., Albrow, R., Mather, J., Rana, D. N., Cubie, H., Moore, C., Legood, R., Gray, A., and Moss, S. Automation-assisted versus manual reading of

cervical cytology (MAVARIC): a randomised controlled trial. *Lancet Oncology*. 2011;12(1):56-64.

Kjaer, S. K., van den Brule, A. J., Bock, J. E., Poll, P. A., Engholm, G., Sherman, M. E., Walboomers, J. M., and Meijer, C. J. Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. *International Journal of Cancer*. 3-1-1996;65(5):601-606.

Koczka, C. P., Lukolic, I., Lee, D. S., and Gress, F. G. Cervical cancer screening in African Americans with inflammatory bowel disease. *Gastroenterology*. 2011;Conference: Digestive Disease Week, DDW 2011 Chicago, IL United States. Conference Start: 20110507 Conference End: 20110510. Conference Publication:(var.pagings):S722-.

Konno, R., Sagae, S., Yoshikawa, H., Basu, P. S., Hanley, S. J., Tan, J. H., and Shin, H. R. Cervical Cancer Working Group report. *Japanese Journal of Clinical Oncology*. 2010;40:Suppl-50.

Kotloff, K. L., Wasserman, S. S., Russ, K., Shapiro, S., Daniel, R., Brown, W., Frost, A., Tabara, S. O., and Shah, K. Detection of genital human papillomavirus and associated cytological abnormalities among college women. *Sexually Transmitted Diseases*. 1998;25(5):243-250.

Kreuger, F. A., Beerman, H., Nijs, H. G., and van, Ballegooijen M. Positive diagnostic values and histological detection ratios from the Rotterdam cervical cancer screening programme. *International Journal of Epidemiology*. 1998;27(3):377-381.

Kuhn, L., Wang, C., Tsai, W. Y., Wright, T. C., and Denny, L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. *AIDS*. 10-23-2010;24(16):2553-2561.

Kuramoto, H., Sugimoto, N., and Iida, M. Screening for cancer of the cervix with simultaneous pap smear and colposcopy. The efficacy of pap smear and colposcopy. *European Journal of Gynaecological Oncology*. 2011;32(1):73-76.

Labbe, S. and Petitjean, A. False negative rate in quality assessment of Pap smears: Rescreening from 522 histologically proven lesions. [French]. *Annales de Pathologie*. 1999;19(5):457-462.

Lancaster, E. J., Banach, L., Lekalakala, T., and Mandiwana, I. Carcinoma of the uterine cervix: Results of Ka-Ngwane screening programme and comparison between the results obtained from urban and other unscreened rural communities. *East African Medical Journal*. 1999;76(2):101-104.

Laverty, C. R., Farnsworth, A., Thurloe, J. K., Grieves, A., and Bowditch, R. Evaluation of the CytoRich slide preparation process. *Analytical & Quantitative Cytology & Histology*. 1997;19(3):239-245.

Lazcano-Ponce, E. C., Alonso de, Ruiz P., Lopez-Carrillo, L., Najera-Aguilar, P., Avila-Ceniceros, R., Escandon-Romero, C., Cisneros, M. T., and Hernandez-Avila, M. Validity and reproducibility of cytologic diagnosis in a sample of cervical cancer screening centers in Mexico. *Acta Cytologica*. 1997;41(2):277-284.

Lee, K. R., Ashfaq, R., Birdsong, G. G., Corkill, M. E., McIntosh, K. M., and Inhorn, S. L. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. *Obstetrics & Gynecology*. 1997;90(2):278-284.

Leece, P., Kendall, C., Touchie, C., Pottie, K., Angel, J. B., and Jaffey, J. Cervical cancer screening among HIV-positive women: Retrospective cohort study from a tertiary care HIV clinic. *Canadian Family Physician*. 2010;56(12):e425-e431.

Lerma, E., Colomo, L., Carreras, A., Esteva, E., Quilez, M., and Prat, J. Rescreening of atypical cervicovaginal smears using PAPNET. *Cancer*. 1998;84(6):361-365.

Lim, E. J., Morgan, J., and Fielding, R. Cervical screening uptake in immunocompromised women in

Waikato, New Zealand. *International Journal of STD & AIDS*. 2010;21(12):835-836.

Lin, C. T., Tseng, C. J., Chou, H. H., Huang, K. G., Chang, T. C., Lai, H. H., and Soong, Y. K. High-risk human papillomavirus deoxyribonucleic acid as an adjunct marker in cervical cytology. *Changgeng yi xue za zhi / Changgeng ji nian yi yuan = Chang Gung medical journal / Chang Gung Memorial Hospital*. 1999;22(3):409-415.

Lindebaum, K., Horlitz, M., Kupfer, C., Papadopoulos, C., Giles, J., and Sprenger-Haussels, M. Evaluation of an automated DNA extraction method for use with cervical SurePath specimens. *Journal of Molecular Diagnostics*. 2010;Conference: Association for Molecular Pathology Annual Meeting San Jose, CA United States. Conference Start: 20101118 Conference End: 20101120. Conference Publication:(var.pagings):891-.

Linder, J. and Zahniser, D. ThinPrep Papanicolaou testing to reduce false-negative cervical cytology. *Archives of Pathology and Laboratory Medicine*. 1998;122(2):139-144.

Linder, J. Recent advances in thin-layer cytology. *Diagnostic Cytopathology*. 1998;18(1):24-32.

Liu, S. S., Leung, R. C., Chan, K. K., Cheung, A. N., and Ngan, H. Y. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche Linear Array HPV genotyping assay. *Journal of Clinical Microbiology*. 2010;48(3):758-764.

Liu, S., Ramachandran, S., and Eder, P. Performance of the digene HPV eHC test with cervical specimens in PreservCyt medium. *Journal of Molecular Diagnostics*. 2010;Conference: Association for Molecular Pathology Annual Meeting San Jose, CA United States. Conference Start: 20101118 Conference End: 20101120. Conference Publication:(var.pagings):891-.

Lorincz, A. T. Hybrid Capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. *The journal of obstetrics and gynaecology research*. 1996;22(6):629-636.

Mango, L. J. Reducing false negatives in clinical practice: The role of neural network technology. *American Journal of Obstetrics and Gynecology*. 1996;175(4 II SUPPL.):1114-1119.

Mannino, J. R. Natural history of false-negative papanicolaou smears: a prospective study using screening colposcopy in addition to cytology. *Journal of the American Osteopathic Association*. 1998;98(10):542-546.

Marcus, A. C. and Crane, L. A. A review of cervical cancer screening intervention research: Implications for public health programs and future research. *Preventive Medicine*. 1998;27(1):13-31.

Masood, S. Why women still die from cervical cancer. *The Journal of the Florida Medical Association*. 1997;84(6):379-383.

Masood, S., Cajulis, R. S., Cibas, E. S., Wilbur, D. C., and Bedrossian, C. W. M. Automation in cytology: A survey conducted by the New Technology Task Force, Papanicolaou Society of Cytopathology. *Diagnostic Cytopathology*. 1998;18(1):47-55.

Mateos Burguillo, J. F., Rodriguez, Zarauz R., Uguet de, Resayre C., and Bajo Arenas, J. M. Diagnosis, treatment and follow-up of H.P.V.-C.I.N. *European Journal of Gynaecological Oncology*. 1995;16(1):48-53.

Matsunaga, G., Tsuji, I., Sato, S., Fukao, A., Hisamichi, S., and Yajima, A. Cost-effective analysis of mass screening for cervical cancer in Japan. *Journal of Epidemiology*. 1997;7(3):135-141.

Mayeaux, E. J., Jr., Harper, M. B., Abreo, F., Pope, J. B., and Phillips, G. S. A comparison of the reliability of repeat cervical smears and colposcopy in patients with abnormal cervical cytology. *Journal of Family Practice*. 1995;40(1):57-62.

- McGoogan, E. and Reith, A. Would monolayers provide more representative samples and improved preparations for cervical screening? Overview and evaluation of systems available. *Acta Cytologica*. 1996;40(1):107-119.
- McNeil, C. New Pap test technologies hit heavy seas but sales keep flying. *Journal of the National Cancer Institute*. 1998;90(18):1327-1329.
- Meeuwis, K. A., van Rossum, M. M., Hoitsma, A. J., and de Hullu, J. A. (Pre)malignancies of the female anogenital tract in renal transplant recipients. [Review]. *Transplantation*. 1-15-2011;91(1):8-10.
- Michelow, P. M., Hlongwane, N. F., and Leiman, G. Simulation of primary cervical cancer screening by the PAPNET system in an unscreened, high-risk community. *Acta Cytologica*. 1997;41(1):88-92.
- Mignotte, H., Perol, D., Fontaniere, B., Nachury, L.-P., Blanc-Jouvand, A., Fouillat, V., Chauvin, F., and Lasset, C. Cervical cancer screening for high risk women: Is it possible? Results of a cervical cancer screening program in three suburban districts of Lyon. [French]. *Bulletin du Cancer*. 1999;86(6):573-579.
- Miller, K. S., Yunger, J., Single, N., and Kunz, J. Prevalence of abnormal Pap smears in rural family practice. *Journal of Rural Health*. 1996;12(1):33-38.
- Mintzer, M., Curtis, P., Resnick, J. C., and Morrell, D. The effect of the quality of Papanicolaou smears on the detection of cytologic abnormalities. *Cancer*. 1999;87(3):113-117.
- Misra, J. S., Das, K., and Chandrawati Results of clinically downstaging cervical cancer in a cytological screening programme. *Diagnostic Cytopathology*. 1998;19(5):344-348.
- Mitchell, C. M., Bradford, C. M., Wadhvani, N. R., Mehrotra, S., Barkan, G. A., and Kapur, U. Reflex HPV testing in vaginal smears. *Laboratory Investigation*. 2010;Conference: United States and Canadian Academy of Pathology Annual Meeting Washington, DC United States. Conference Start: 20100320 Conference End: 20100326. Conference Publication:(var.pagings):101A-.
- Mitchell, H. and Medley, G. Detection of laboratory false negative smears by the PAPNET cytologic screening system. *Acta Cytologica*. 1998;42(1):265-270.
- Mitchell, H. and Medley, G. Detection of unsuspected abnormalities by PAPNET-assisted review. *Acta Cytologica*. 1998;42(1):260-264.
- Mitchell, H. and Medley, G. Differences between false-negative and true-positive Papanicolaou smears on Papnet-assisted review. *Diagnostic Cytopathology*. 1998;19(2):138-140.
- Mitchell, H. and Medley, G. Differences between Papanicolaou smears with correct and incorrect diagnoses. *Cytopathology*. 1995;6(6):368-375.
- Mitchell, H. Outcome after a Pap smear report of low-grade abnormality: a longitudinal comparative study. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 1999;39(3):345-348.
- Monnet, E., Carbillet, J. P., Meslans, Y., Petitjean, A., and Gautier, C. P. Participation of women in cervical cancer screening. Results of the first 5 years of a pilot program in the province of Doubs. [French]. *Presse medicale (Paris, France : 1983)*. 1999;28(38):2093-2097.
- Moscicki, A.-B., Widdice, L., Ma, Y., Farhat, S., Miller-Benningfield, S., Jonte, J., Jay, J., Godwin de, Medina C., Hanson, E., Clayton, L., and Shiboski, S. Comparison of natural histories of human papillomavirus detected by clinician-and self-sampling. *International Journal of Cancer*. 2010;127(8):1882-1892.
- Moss, E. L., Moran, A., Douce, G., Parkes, J., Todd, R. W., and Redman, C. W. Cervical cytology/histology discrepancy: a 4-year review of patient outcome. *Cytopathology*. 2010;21(6):389-394.

Murphy, K. M., Hosler, G. A., Henry, T., Cavagnolo, R. Z., Washington, P. J., and Jenevein, E. P. Clinical performance characteristics of the cervista HPV HR assay: Correlation of cytology and HPV from 56,501 specimens. *Journal of Molecular Diagnostics*. 2010;Conference: Association for Molecular Pathology Annual Meeting San Jose, CA United States. Conference Start: 20101118 Conference End: 20101120. Conference Publication:(var.pagings):891-

Nasioutziki, M., Daniilidis, A., Dinas, K., Kyrgiou, M., Valasoulis, G., Loufopoulos, P. D., Paraskevaidis, E., Loufopoulos, A., and Karakitsos, P. The evaluation of p16ink4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. *International Journal of Gynecological Cancer*. 2011;21(1):79-85.

Neilson, A. and Jones, R. K. Women's lay knowledge of cervical cancer/cervical screening: accounting for non-attendance at cervical screening clinics. *Journal of Advanced Nursing*. 1998;28(3):571-575.

Nieves-Arriba, L., Belinson, S., Booth, C., Brainard, J., Chiesa-Vottero, A., Enerson, C., Perez, A., Sun, Z., and Belinson, J. MECCS II: Primary screening for cervical cancer with an mRNA human papillomavirus assay. *Gynecologic Oncology*. 2011;Conference: 42nd Annual Meeting of the Society of Gynecologic Oncologists Orlando, FL United States. Conference Start: 20110306 Conference End: 20110309. Conference Publication:(var.pagings):S115-

Nieves-Arriba, L., Enerson, C., Belinson, S., Booth, C., Brainard, J., Chiesa-Vottero, A., Perez, A., Sun, Z., Novick, L., and Belinson, J. Mexican cervical cancer screening study II: Acceptability of a new self-sampling device. *Gynecologic Oncology*. 2010;Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists, SGO San Francisco, CA United States. Conference Start: 20100314 Conference End: 20100317. Conference Publication:(var.pagings):S18-S19.

Nijhawan, R., Mittal, N., Suri, V., and Rajwanshi, A. Enhancing the scope of conventional cervical cytology for detecting HPV infection. *Diagnostic Cytopathology*. 2010;38(9):645-651.

Nobbenhuis, M. A., Walboomers, J. M., Helmerhorst, T. J., Rozendaal, L., Remmink, A. J., Risse, E. K., van der Linden, H. C., Voorhorst, F. J., Kenemans, P., and Meijer, C. J. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. *Lancet*. 7-3-1999;354(9172):20-25.

Nuovo, G. J. Detection of human papillomavirus in Papanicolaou smears: correlation with pathologic findings and clinical outcome. *Diagnostic Molecular Pathology*. 1998;7(3):158-163.

O'Leary, T. J., Tellado, M., Buckner, S. B., Ali, I. S., Stevens, A., and Ollayos, C. W. PAPNET-assisted rescreening of cervical smears: cost and accuracy compared with a 100% manual rescreening strategy. *JAMA*. 1-21-1998;279(3):235-237.

O'Sullivan, J. P. Observer variation in gynaecological cytopathology. *Cytopathology*. 1998;9(1):6-14.

Oteng, B., Marra, F., Lynd, L. D., Ogilvie, G., Patrick, D., and Marra, C. A. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme. *Sexually Transmitted Infections*. 2011;87(1):52-57.

Papillo, J. L., Zarka, M. A., and St John, T. L. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16,314-case experience in northern Vermont. *Acta Cytologica*. 1998;42(1):203-208.

Park, H. J., Choi, Y. M., Chung, C. K., Lee, S. H., Yim, G. W., Kim, S. W., Nam, E. J., and Kim, Y. T. Pap smear screening for small cell carcinoma of the uterine cervix: A case series and review of the literature. *Journal of Gynecologic Oncology*. 2011;22(1):39-43.

Patten, S. F., Jr., Lee, J. S., Wilbur, D. C., Bonfiglio, T. A., Colgan, T. J., Richart, R. M., Cramer, H., and Moinuddin, S. The AutoPap 300 QC System multicenter clinical trials for use in quality control rescreening of cervical smears: II. Prospective and archival sensitivity studies. *Cancer*. 12-25-

1997;81(6):343-347.

Pearce, K. F., Haefner, H. K., Sarwar, S. F., and Nolan, T. E. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. *New England Journal of Medicine*. 11-21-1996;335(21):1559-1562.

Perlman, S. E. Pap smears: screening, interpretation, treatment. *Adolescent Medicine State of the Art Reviews*. 1999;10(2):243-254.

Petry, K. U., Schmidt, D., Scherbring, S., Luyten, A., Reinecke-Luthge, A., Bergeron, C., Kommos, F., Loning, T., Ordi, J., Regauer, S., and Ridder, R. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. *Gynecologic Oncology*. 2011;121(3):505-509.

Peyton, C. L., Schiffman, M., Lorincz, A. T., Hunt, W. C., Mielzynska, I., Bratti, C., Eaton, S., Hildesheim, A., Morera, L. A., Rodriguez, A. C., Herrero, R., Sherman, M. E., and Wheeler, C. M. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies.[Erratum appears in *J Clin Microbiol* 1999 Feb;37(2):478]. *Journal of Clinical Microbiology*. 1998;36(11):3248-3254.

Plotkin, A., Khalifa, M. A., Ismiil, N., Dube, V., Saad, R. S., Ghorab, Z., Wong, J., Desai, G., and Nofech-Mozes, S. Comparative analysis of HPV DNA test utilization in community and colposcopy clinics. *Laboratory Investigation*. 2010;Conference: United States and Canadian Academy of Pathology Annual Meeting Washington, DC United States. Conference Start: 20100320 Conference End: 20100326. Conference Publication:(var.pagings):259A-260A.

Poljak, M., Brencic, A., Seme, K., Vince, A., and Marin, I. J. Comparative evaluation of first- and second-generation Digene Hybrid Capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. *Journal of Clinical Microbiology*. 1999;37(3):796-797.

Polyzos, N. P., Valachis, A., Mauri, D., and Ioannidis, J. P. A. Industry involvement and baseline assumptions of cost-effectiveness analyses: Diagnostic accuracy of the Papanicolaou test. *CMAJ*. 2011;183(6):E337-E343.

Pretet, J.-L., Vidal, C., Le Bail, Carval K., Ramanah, R., Carcopino, X., Cartier, I., Labouyrie, E., Kantelip, B., Coumes-Marquet, S., Riethmuller, D., and Mougin, C. Novaprep Vial Test is a suitable liquid-based cytology medium for high risk human papillomavirus testing by Hybrid Capture 2. *Journal of Clinical Virology*. 2010;49(4):286-289.

Raab, S. S. The cost-effectiveness of cervical-vaginal rescreening. *American Journal of Clinical Pathology*. 1997;108(5):525-536.

Raab, S. S. The utility and cost-effectiveness of Pap test rescreening. *Clinical laboratory management review : official publication of the Clinical Laboratory Management Association / CLMA*. 1998;12(2):91-96.

Raab, S. S., Bishop, N. S., and Zaleski, M. S. Cost effectiveness of rescreening cervicovaginal smears. *American Journal of Clinical Pathology*. 1999;111(5):601-609.

Raab, S. S., Zaleski, M. S., and Silverman, J. F. The cost-effectiveness of the cytology laboratory and new cytology technologies in cervical cancer prevention. *American Journal of Clinical Pathology*. 1999;111(2):259-266.

Rankow, E. J. and Tessaro, I. Cervical cancer risk and papanicolaou screening in a sample of lesbian and bisexual women. *Journal of Family Practice*. 1998;47(2):139-143.

Ravolamanana, Ralisata L., Randrianjafisamindrakotroka, N. S., Rakoto, E. B., and Ranaivozanany, A.

[Value and limits of cytology in the diagnosis of cervico-vaginal lesions at the Mahajanga University Hospital Center: 465 cases]. [French]. *Archives de l'Institut Pasteur de Madagascar*. 1999;65(1-2):120-123.

Richard, K., Dziura, B., and Hornish, A. Cell block preparation as a diagnostic technique complementary to fluid-based monolayer cervicovaginal specimens. *Acta Cytologica*. 1999;43(1):69-73.

Rimel, B., Ferda, A., Erwin, J., Dewdney, S., Seamon, L., DeSimone, C., Gao, F., Huh, W., and Massad, L. Liquid-based cervical cytology in the detection of recurrence after treatment for cervical cancer. *Gynecologic Oncology*. 2011;Conference: 42nd Annual Meeting of the Society of Gynecologic Oncologists Orlando, FL United States. Conference Start: 20110306 Conference End: 20110309. Conference Publication:(var.pagings):S109-S110.

Roberts, J. M., Thurloe, J. K., Bowditch, R. C., Humcevic, J., and Laverty, C. R. A. Comparison of ThinPrep and Pap smear in relation to prediction of adenocarcinoma in situ. *Acta Cytologica*. 1999;43(1):74-80.

Rodriguez, E. F., Reynolds, J. P., Jenkins, S., Henry, M. R., and Nassar, A. Atypical squamous cells of undetermined significance in patients with HPV positive DNA testing and correlation with disease progression by age group: An institutional experience. *Laboratory Investigation*. 2011;Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011 San Antonio, TX United States. Conference Start: 20110226 Conference End: 20110304. Conference Publication:(var.pagings):102A-103A.

Ronco, G., Iossa, A., Naldoni, C., Pilutti, S., Anghinoni, E., Zappa, M., Palma, P. D., Ciatto, S., and Segnan, N. A first survey of organized cervical cancer screening programs in Italy. *Tumori*. 1998;84(6):624-630.

Rosenthal, D. L., Acosta, D., and Peters, R. K. Computer-assisted rescreening of clinically important false negative cervical smears using the PAPNET Testing System. *Acta Cytologica*. 1996;40(1):120-126.

Sato, S., Matunaga, G., Tsuji, I., Yajima, A., and Sasaki, H. Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models. *Acta Cytologica*. 1999;43(6):1006-1014.

Saurel, J., Rabreau, M., Landi, M., Bondu, C., Montoya, G., Morance, C., Auber, M., Percheron, N., Santa-Maria, M., Bec, M., Berteau, M. J., Muller, E., Gominet, C., Besserves, S., and Thomas, E. Cytological screening of uterine cervical cancer by samples in liquid medium (CytoRich). Preliminary study of a series of 111 292 patients. [French]. *Contraception, fertilité, sexualité* (1992). 1999;27(12):853-857.

Saurel, J., Rabreau, M., Landi, M., Bondu, C., Montoya, G., Morance, C., Auber, M., Percheron, N., Santa-Maria, M., Bec, M., Berteau, M. J., Muller, E., Gominet, C., Besserves, S., and Thomas, E. Cytological cervical screening by liquid medium sample. [French]. *Contraception Fertilité Sexualité*. 1999;27(12):853-857.

Sawaya, G. F. and Grimes, D. A. New technologies in cervical cytology screening: A word of caution. *Obstetrics and Gynecology*. 1999;94(2):307-310.

Schneider, A. and Zahm, D.-M. New adjunctive methods for cervical cancer screening. *Obstetrics and Gynecology Clinics of North America*. 1996;23(3):657-673.

Schneider, A., Zahm, D. M., Kirchmayr, R., and Schneider, V. L. Screening for cervical intraepithelial neoplasia grade 2/3: Validity of cytologic study, cervicography, and human papillomavirus detection. *American Journal of Obstetrics and Gynecology*. 1996;174(5):1534-1541.

Schwartz, P. E., Hadjimichael, O., Lowell, D. M., Merino, M. J., and Janerich, D. Rapidly progressive

cervical cancer: the Connecticut experience. *American Journal of Obstetrics & Gynecology*. 1996;175(4:Pt 2):t-9.

Scoggins, J. F., Ramsey, S. D., Jackson, J. C., and Taylor, V. M. Cost effectiveness of a program to promote screening for cervical cancer in the Vietnamese-American population. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2010;11(3):717-722.

Sengupta, S., Chaudhuri, S. K., Das, P., Raichaudhuri, B., and Pramanik, R. Integrated approach to prediction of cervical intra-epithelial neoplasia status through a case-control study. *International Journal of Cancer*. 2-19-1999;84(1):69-73.

Shah, K. V., Solomon, L., Daniel, R., Cohn, S., and Vlahov, D. Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. *Journal of Clinical Microbiology*. 1997;35(2):517-519.

Shamsuddin, L., Chowdhury, T. A., Azim, A., and Rahman, A. J. Clinical down staging of cancer cervix with cytology. *Bangladesh Medical Research Council Bulletin*. 1995;21(3):108-114.

Sherman, M. E., Schiffman, M. H., Lorincz, A. T., Herrero, R., Hutchinson, M. L., Bratti, C., Zahniser, D., Morales, J., Hildesheim, A., Helgesen, K., Kelly, D., Alfaro, M., Mena, F., Balmaceda, I., Mango, L., and Greenberg, M. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. *Cancer*. 1997;81(2):89-97.

Shield, P. W. and Cox, N. C. The sensitivity of rapid (partial) review of cervical smears. *Cytopathology*. 1998;9(2):84-92.

Shim, H. S., Noh, S., Park, A. R., Lee, Y. N., Kim, J. K., Chung, H. J., Kang, K. S., and Cho, N. H. Detection of sexually transmitted infection and human papillomavirus in negative cytology by multiplex-PCR. *BMC Infectious Diseases*. 2010;10:284-.

Shipitsyna, E., Zolotoverkhaya, E., Kuevda, D., Nasonova, V., Romanyuk, T., Khachatryan, A., Orlova, O., Abashova, E., Kostyuchek, I., Shipulina, O., Anttila, A., and Savicheva, A. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia. *Cancer Epidemiology*. 2011;35(2):160-164.

Shlay, J. C., McGill, W. L., Masloboeva, H. A., and Douglas, J. M., Jr. Pap smear screening in an urban STD clinic. Yield of screening and predictors of abnormalities. *Sexually Transmitted Diseases*. 1998;25(9):468-475.

Sigurdsson, K., Arnadottir, T., Snorraddottir, M., Benediktsdottir, K., and Saemundsson, H. Human papillomavirus (HPV) in an Icelandic population: The role of HPV DNA testing based on hybrid capture and PCR assays among women with screen-detected abnormal PAP smears. *International Journal of Cancer*. 1997;72(3):446-452.

Slater, D. N. False-negative cervical smears: Medico-legal fallacies and suggested remedies. *Cytopathology*. 1998;9(3):145-154.

Smith, B. L., Lee, M., Leader, S., and Wertlake, P. Economic impact of automated primary cancer screening for cervical. *Journal of Reproductive Medicine for the Obstetrician and Gynecologist*. 1999;44(6):518-528.

Songveeratham, S., Kietpeerakool, C., Khunamornpong, S., Sribanditmongkol, N., and Srisomboon, J. Preceding cervical cytology in women with high-grade squamous intraepithelial lesion. *Archives of Gynecology and Obstetrics*. 2011;283(6):1381-1384.

Sorbye, S. W., Fismen, S., Gutteberg, T. J., and Mortensen, E. S. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. *Journal of Virological Methods*. 2010;169(1):219-222.

Sprenger, E., Schwarzmann, P., Kirkpatrick, M., Fox, W., Heinzerling, R. H., Geyer, J. W., and Knesel, E. A. The false negative rate in cervical cytology: Comparison of monolayers to conventional smears. *Acta Cytologica*. 1996;40(1):81-89.

Stevens, M. W., Milne, A. J., James, K. A., Brancheau, D., Ellison, D., and Kuan, L. Effectiveness of automated cervical cytology rescreening using the AutoPap 300 QC System. *Diagnostic Cytopathology*. 1997;16(6):505-512.

Stevens, M. W., Nespolon, W. W., Milne, A. J., and Rowland, R. Evaluation of the CytoRich technique for cervical smears. *Diagnostic Cytopathology*. 1998;18(3):236-242.

Stillson, T., Knight, A. L., and Elswick, R. K., Jr. The effectiveness and safety of two cervical cytologic techniques during pregnancy. *Journal of Family Practice*. 1997;45(2):159-163.

Stoler, M. H., Wright, T. C., Jr., Sharma, A., Apple, R., Gutekunst, K., Wright, T. L., and ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. *American Journal of Clinical Pathology*. 2011;135(3):468-475.

Stoll, L. M., Johnson, M. W., Yean, S.-L., Levin, M., and Rao, J. A novel liquid based clearprep technique: Comparison to surepath methodology for cervical pap smear. *Laboratory Investigation*. 2011;Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011 San Antonio, TX United States. Conference Start: 20110226 Conference End: 20110304. Conference Publication:(var.pagings):107A-

Strategies for providing follow-up and treatment services in the National Breast and Cervical Cancer Early Detection Program--United States, 1997. *MMWR*. 1998;Morbidity and mortality weekly report. 47(11):215-218.

Tabrizi, S. N., Taylor, N., McCullough, M. J., Phillips, G., Wark, J., Gertig, D., Petersen, R. W., Saville, M., Garland, S. M., and CeCaGeEnStudy Group Human papillomavirus genotype detection from archival papanicolaou-stained cervical tests. *Cancer Cytopathology*. 12-25-2010;118(6):482-489.

Takahashi, M. and Naito, M. Application of the CytoRich monolayer preparation system for cervical cytology: A prelude to automated primary screening. *Acta Cytologica*. 1997;41(6):1785-1789.

Taoka, H., Yamamoto, Y., Sakurai, N., Fukuda, M., Asakawa, Y., Kurasaki, A., Oharaseki, T., and Kubushiro, K. Comparison of conventional and liquid-based cytology, and human papillomavirus testing using SurePath preparation in Japan. *Human Cell*. 2010;23(4):126-133.

Tasso, D., Kjeldahl, K., Pambuccian, S. E., Thyagarajan, B., and Gulbahce, H. E. Outcomes in high-risk HPV-positive and HPV18/18-positive women with ASC-US differ based on the women's age group. *Laboratory Investigation*. 2010;Conference: United States and Canadian Academy of Pathology Annual Meeting Washington, DC United States. Conference Start: 20100320 Conference End: 20100326. Conference Publication:(var.pagings):106A-

Taube, J. M., Kamira, B., Motevalli, M., Nakabiito, C., Lukande, R., Kelly, D. P., Erozan, Y. S., Gravitt, P. E., Buresh, M. E., Mmiro, F., Bagenda, D., Guay, L. A., and Jackson, J. B. Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation. *Diagnostic Cytopathology*. 2010;38(8):555-563.

Tawfik, O., Davis, M., Dillon, S., Friesen, D., O'Neil, M., Fan, F., and Madan, R. Telepapology vs liquid-based thin-layer cervical cytology: A Comparative study evaluating specimen adequacy and non-neoplastic findings. *Laboratory Investigation*. 2011;Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011 San Antonio, TX United States. Conference Start: 20110226 Conference End: 20110304. Conference Publication:(var.pagings):107A-

- Taylor, R. N., Gagnon, M., Lange, J., Lee, T., Draut, R., and Kujawski, E. CytoView. A prototype computer image-based Papanicolaou smear proficiency test. *Acta Cytologica*. 1999;43(6):1045-1051.
- Tezuka, F., Oikawa, H., Shuki, H., and Higashiiwai, H. Diagnostic efficacy and validity of the ThinPrep method in cervical cytology. *Acta Cytologica*. 1996;40(3):513-518.
- The cost-effectiveness of three new technologies to enhance Pap testing. *Tecnologica*. 1998;MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel.:40-41.
- Thommasen, H., Lenci, P., Brake, I., and Anderson, G. Cervical cancer screening performed by a nurse. Evaluation in family practice. *Canadian Family Physician*. 1996;42:2179-2183.
- Thrall, M. J. and Mody, D. R. Clinical human papillomavirus testing modalities: Established techniques and new directions. *Pathology Case Reviews*. 2011;16(2):55-61.
- Tsompou, I., Valasoulis, G., Founta, C., Kyrgiou, M., Nasioutziki, M., Daponte, A., Koliopoulos, G., Malamou-Mitsi, V., Karakitsos, P., and Paraskevaidis, E. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study. *Gynecologic Oncology*. 2011;121(1):49-53.
- Ueki, M., Ueda, M., Kumagai, K., Okamoto, Y., Noda, S., and Matsuoka, M. Cervical cytology and conservative management of cervical neoplasias during pregnancy. *International Journal of Gynecological Pathology*. 1995;14(1):63-69.
- Usman, F. and Hammond, R. Cervical screening: management of patients referred for colposcopy with smear abnormalities less severe than dyskaryosis. *Cytopathology*. 1998;9(2):100-106.
- Vallejos-Sologuren, C. The health minister's response to managing cervical cancer in low-income countries. *Annals of Oncology*. 2010;Conference: 35th ESMO Congress Milan Italy. Conference Start: 20101008 Conference End: 20101012. Conference Publication:(var.pagings):viii41-.
- van, Ballegooijen M., Beck, S., Boon, M. E., Boer, R., and Habbema, J. D. F. Rescreen effect in conventional and PAPNET screening: Observed in a study using material enriched with positive smears. *Acta Cytologica*. 1998;42(5):1133-1138.
- Vassilakos, P., Cossali, D., Albe, X., Alonso, L., Hohener, R., and Puget, E. Efficacy of monolayer preparations for cervical cytology: Emphasis on suboptimal specimens. *Acta Cytologica*. 1996;40(3):496-500.
- Vassilakos, P., DeMarval, F., Munoz, M., Broquet, G., and Campana, A. Human papillomavirus (HPV) DNA assay as an adjunct to liquid-based Pap test in the diagnostic triage of women with an abnormal Pap smear. *International Journal of Gynecology and Obstetrics*. 1998;61(1):45-50.
- Vassilakos, P., Griffin, S., Megevand, E., and Campana, A. CytoRich liquid-based cervical cytologic test. Screening results in a routine cytopathology service. *Acta Cytologica*. 1998;42(1):198-202.
- Walboomers, J. M., de Roda Husman, A. M., Snijders, P. J., Stel, H. V., Risse, E. K., Helmerhorst, T. J., Voorhorst, F. J., and Meijer, C. J. Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer. *Journal of Clinical Pathology*. 1995;48(8):728-732.
- Wang, S. E., Ritchie, M. J., and Atkinson, B. F. Cervical cytologic smear false negative fraction. Reduction in a small community hospital. *Acta Cytologica*. 1997;41(6):1690-1696.
- Weintraub, J. The coming revolution in cervical cytology: A pathologist's guide for the clinician. [French]. *References en Gynecologie Obstetrique*. 1997;5(2):169-175.
- Welner, S. L. Screening issues in gynecologic malignancies for women with disabilities: Critical considerations. *Journal of Women's Health*. 1998;7(3):281-285.

Wertlake, P. T., Francus, K., Newkirk, G. R., and Parham, G. P. Effectiveness of the Papanicolaou smear and speculscopy as compared with the Papanicolaou smear alone: a community-based clinical trial. *Obstetrics & Gynecology*. 1997;90(3):421-427.

Wilbur, D. C., Dubeshter, B., Angel, C., and Atkison, K. M. Use of thin-layer preparations for gynecologic smears with emphasis on the cytomorphology of high-grade intraepithelial lesions and carcinomas. *Diagnostic Cytopathology*. 1996;14(3):201-211.

Woo, J. S., Sutton, B. J., and Laudadio, J. Type-specific HPV testing on liquid-based cytology samples in routine clinical practice reveals 46% type-specific persistence. *Journal of Molecular Diagnostics*. 2010;Conference: Association for Molecular Pathology Annual Meeting San Jose, CA United States. Conference Start: 20101118 Conference End: 20101120. Conference Publication:(var.pagings):890-.

Wright, T. C., Sun, X. W., and Koulos, J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. *Obstetrics & Gynecology*. 1995;85(2):202-210.

Yeoh, G. P. S. and Chan, K. W. Cell block preparation on residual ThinPrep sample. *Diagnostic Cytopathology*. 1999;21(6):427-431.

Yoshida, T., Sano, T., Takada, N., Kanuma, T., Inoue, H., Itoh, T., Yazaki, C., Obara, M., and Fukuda, T. Comparison of self-collected and clinician-collected materials for cervical cytology and human papillomavirus genotyping: analysis by linear array assay. *Acta Cytologica*. 2011;55(1):106-112.

Youens, K. E., Hosler, G. A., Washington, P. J., Jenevein, E. P., and Murphy, K. M. Clinical experience with the cervista HPV HR assay: Correlation of cytology and HPV status from 56,501 specimens. *Journal of Molecular Diagnostics*. 2011;13(2):160-166.

Young, J., Badman, B., Lazenby, G., Nyanga'nyi, A., Stoler, M., and Taylor, P. Rapid high-risk human papillomavirus test shows excellent agreement with standard Hybrid Capture 2 when used onsite in rural northern Tanzania. *Gynecologic Oncology*. 2011;Conference: 42nd Annual Meeting of the Society of Gynecologic Oncologists Orlando, FL United States. Conference Start: 20110306 Conference End: 20110309. Conference Publication:(var.pagings):S123-.

Zarcone, R., Bellini, P., and Cardone, G. Role of HPV-DNA typing in women with cytological diagnosis of squamous atypia. *Panminerva medica*. 1995;37(1):8-10.

Zehbe, I., Rylander, E., Edlund, K., Wadell, G., and Wilander, E. Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques. *Virchows Archiv*. 1996;428(3):151-157.

Level 3: Population

Abulafia, O. and Sherer, D. M. Automated cervical cytology: Meta-analyses of the performance of the PAPNET system. *Obstetrical and Gynecological Survey*. 1999;54(4):253-264.

Barnett, D. B. Cervical cancer screening programs: Technical cooperation in the Caribbean. *Bulletin of the Pan American Health Organization*. 1996;30(4):409-412.

Bell, J. and Ward, J. Cervical screening: Linking practice, policy and research in women's health. *Cancer Forum*. 1998;22(1):6-11.

Bennetts, A., Irwig, L., Oldenburg, B., Simpson, J. M., Mock, P., Boyes, A., Adams, K., Weisberg, E., and Shelley, J. PEAPS-Q: a questionnaire to measure the psychosocial effects of having an abnormal pap smear. *Psychosocial Effects of Abnormal Pap Smears Questionnaire*. *Journal of Clinical Epidemiology*. 1995;48(10):1235-1243.

Bonfiglio, T. A. Diagnostic cytology of the uterine cervix: A major contribution and classic reference in

gynecologic cytopathology. *Cancer*. 1997;81(6):324-327.

Braly, P. Preventing cervical cancer. *Nature Medicine*. 1996;2(7):749-751.

Carney, X. C., Aguilar, P. N., and Ponce, E. C. L. Community promotion and dissemination of programs to prevent cervical cancer. *Bulletin of the Pan American Health Organization*. 1996;30(4):394-396.

Casper, M. J. and Clarke, A. E. Making the Pap smear into the "right tool" for the job. *Social studies of science*. 1998;28(2):255-290.

Davisson, L. Rational care or rationing care? Updates and controversies in women's prevention. *The West Virginia medical journal*. 2011;107(1):26-32.

Faraker, C. A. Rapid review. [Review] [13 refs]. *Cytopathology*. 1998;9(2):71-76.

Foulks, M. J. The Papanicolaou smear: its impact on the promotion of women's health. *Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG*. 1998;27(4):367-373.

Frame, P. S. and Frame, J. S. Determinants of cancer screening frequency: the example of screening for cervical cancer. *The Journal of the American Board of Family Practice / American Board of Family Practice*. 1998;11(2):87-95.

Franco, E., Syrjanen, K., De, Wolf C., Patnick, J., Ferenczy, A., McGoogan, E., Bosch, X., Singer, A., Munoz, N., Meheus, A., and Monsonego, J. New developments in cervical cancer screening and prevention. *Cancer Epidemiology Biomarkers and Prevention*. 1996;5(10):853-856.

Grapsa, D., Ioakim-Liossi, A., Stergiou, E., Petrakakou, E., Nicolopoulou-Stamati, P., Patsouris, E., and Athanassiadou, P. Repeat processing of residual ThinPrep Pap tests: sampling of the vial may not be invariably homogeneous. *Acta Cytologica*. 2011;55(2):213-217.

Grohs, D. H., Gombrich, P. P., and Domanik, R. A. AccuMed International, Inc.: Meeting the challenges in cervical cancer screening: The AcCell Series 2000 automated slide handling and data management system. *Acta Cytologica*. 1996;40(1):26-30.

Herbert, A., Johnson, J., Patnick, J., Burtenshaw, A., Codling, B. W., Day, N. E., Duncan, I. D., Lancucki, L., Luke, K., McGoogan, E., Rodway, A., Silcocks, P. B., Slater, D. N., and Williams, D. R. Achievable standards, benchmarks for reporting, criteria for evaluating cervical cytopathology. *Cytopathology*. 1995;6(SUPPL. 2):1-32.

Hillard, P. Adolescent pap smear screening: yes or no. *Journal of Pediatric and Adolescent Gynecology*. 1996;9(2):93-97.

Hristova, L. and Hakama, M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. *Acta Oncologica*. 1997;36:Suppl-60.

Katz, A. Cervical cancer screening. [Review] [29 refs]. *Canadian Family Physician*. 1998;44:1661-1665.

Knesel, Jr Roche Image Analysis Systems, Inc.. *Acta Cytologica*. 1996;40(1):60-66.

Ku, N. N. K. Automated Papanicolaou smear analysis as a screening tool for female lower genital tract malignancies. *Current Opinion in Obstetrics and Gynecology*. 1999;11(1):41-43.

Lee, J. S., Wilhelm, P., Kuan, L., Ellison, D. G., Lei, X., Oh, S., and Patten, S. F., Jr. AutoPap system performance in screening for low prevalence and small cell abnormalities. *Acta Cytologica*. 1997;41(1):56-64.

Lengerich, E. J., Conlisk, E. A., Pisano, E., Harris, L., and Holliday, J. A program to control breast and cervical cancer in North Carolina. *North Carolina medical journal*. 1998;59(2):110-114.

Linder, J. Automation of the Papanicolaou smear: a technology assessment perspective. [Review] [30

refs]. Archives of Pathology & Laboratory Medicine. 1997;121(3):282-286.

McIntyre-Seltman, K. The abnormal papanicolaou smear. Medical Clinics of North America. 1995;79(6):1427-1442.

McNeil, C. Novel technologies for cervical cancer screening seen on the horizon. Journal of the National Cancer Institute. 1995;87(11):789-790.

Merviel, P., Mergui, J. L., Gaudet, R., Sananes, S., Cortez, A., and Uzan, S. Are cervicovaginal smears feasible in women over 65 years under hormone replacement therapy?. [French]. Contraception, fertilité, sexualité (1992). 1999;27(12):826-832.

Monsonogo, J. Screening for cancer of the cervix. [French]. Presse Medicale. 1997;26(14):668-669.

Patten, S. F., Jr., Lee, J. S., and Nelson, A. C. NeoPath, Inc. NeoPath AutoPap 300 Automatic Pap Screener System. [Review] [12 refs]. Acta Cytologica. 1996;40(1):45-52.

Perlman, S. E., Kahn, J. A., and Emans, S. J. Should pelvic examinations and papanicolaou cervical screening be part of preventive health care for sexually active adolescent girls?. Journal of Adolescent Health. 1998;23(2):62-67.

Sasieni, P. D. Statistical analysis of the performance of diagnostic tests. Cytopathology. 1999;10(2):73-78.

Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., Shah, M., and Brawley, O. W. Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer Journal for Clinicians. 2011;61(1):8-30.

Smith, W. J. The cost-effectiveness of cervical screening. Current Opinion in Obstetrics and Gynecology. 1999;11(1):83-85.

Stewart, C. J. R. Is the proficiency test in cervical cytology proficient?. Journal of Clinical Pathology. 1997;50(6):450-453.

Takahashi, M., Kimura, M., Akagi, A., and Naitoh, M. AutoCyte SCREEN interactive automated primary cytology screening system. A preliminary evaluation. Acta Cytologica. 1998;42(1):185-188.

Level 3: Intervention

From the Centers for Disease Control and Prevention. Strategies for providing follow-up and treatment services in the National Breast and Cervical Cancer Early Detection Program--United States, 1997. JAMA : the journal of the American Medical Association. 1998;279(24):1941-1942.

Test detects HPV. AIDS Patient Care and STDs. 1999;13(6):377-.

Batar, I. Screening for breast and cervical cancer in Europe. Hungary. Entre nous (Copenhagen, Denmark). 1996;#volume#(34-35):9-.

Belinson, S. E., Wulan, N., Li, R., Zhang, W., Rong, X., Zhu, Y., Wu, R., and Belinson, J. L. SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China. International Journal of Gynecological Cancer. 2010;20(6):1006-1010.

Ceccaldi, P. F., Ferreira, C., Coussy, F., Mechler, C., Meier, F., Crenn-Hebert, C., and Mandelbrot, L. [Cervical disease in postmenopausal HIV-1-infected women]. [French]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction. 2010;39(6):466-470.

Delaloye, J. F. and De, Grandi P. Cervical cancer screening. [French]. Revue Medicale de la Suisse Romande. 1997;117(8):589-591.

- Edlin, M. Pharms expand focus on women's health. *Drug Topics*. 2010;154(2):26-.
- Fauci, J. M., Schneider, K. E., Whitworth, J. M., Subramaniam, A., Erickson, B. K., Kim, K., and Huh, W. K. Referral patterns and incidence of cervical intraepithelial neoplasia in adolescent and pregnant patients: The impact of the 2006 guidelines. *Journal of Lower Genital Tract Disease*. 2011;15(2):124-127.
- Jondet, M. 1989-1999: Ten years of screening for cancer of the uterine cervix. [French]. *Reproduction Humaine et Hormones*. 1999;12(8):753-757.
- Kottke, T. E. and Trapp, M. A. The quality of Pap test specimens collected by nurses in a breast and cervical cancer screening clinic. *American Journal of Preventive Medicine*. 1998;14(3):196-200.
- Kvale, K. M., Davis, K. D., Paul, K. S., Schell, W. L., and Remington, P. L. A breast and cervical cancer screening intervention at public health influenza clinics, Dane County, Wis. *Wisconsin Medical Journal*. 1995;94(9):515-516.
- Lazcano-Ponce, E. C., Rascon-Pacheco, R. A., Lozano-Ascencio, R., and Mondragon, H. E. Mortality from cervical carcinoma in Mexico: Impact of screening, 1980- 1990. *Acta Cytologica*. 1996;40(3):506-512.
- Maiman, M., Fruchter, R. G., Sedlis, A., Feldman, J., Chen, P., Burk, R. D., and Minkoff, H. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. *Gynecologic Oncology*. 1998;68(3):233-239.
- Martin, C. K., Richardson, L. C., Berkman, N. D., Kuo, T. M., Yuen, A. N., and Benard, V. B. Impact of the 2002 American society for Colposcopy and Cervical Pathology guidelines on cervical cancer diagnosis in a geographically diverse population of commercially insured women, 1999-2004. *Journal of Lower Genital Tract Disease*. 2011;15(1):25-32.
- Meissner, H. I., Breen, N., Coyne, C., Legler, J. M., Green, D. T., and Edwards, B. K. Breast and cervical cancer screening interventions: An assessment of the literature. *Cancer Epidemiology Biomarkers and Prevention*. 1998;7(10):951-961.
- Miladinov-Mikov, M., Popovic, Petrovic S., Burany, B., and Tesic, M. Invasive and in situ cervical carcinoma in Vojvodina, 1985-1996. *Archive of Oncology*. 1999;7(1):29-.
- Mitchell, H. and Medley, G. Detection of unsuspected abnormalities by PAPNET-assisted review. *Acta Cytologica*. 1998;42(1):260-264.
- Moran, T. and Woodman, C. B. J. Screening for gynaecological cancers. *Current Obstetrics and Gynaecology*. 1997;7(4):224-231.
- Naud, P., Buseti, M., Becker, E., Camozzato, A., Siegler, R., Cavagnoli, J., Machado, E., Lima, G. B., and Timm, A. R. Screening for cervical cancer in Brazil. *Bulletin of the Pan American Health Organization*. 1996;30(4):391-394.
- Nyante, S. J., Black, A., Kreimer, A. R., Duggan, M. A., Carreon, J. D., Kessel, B., Buys, S. S., Ragard, L. R., Johnson, K. A., Dunn, B. K., Lamerato, L., Commins, J. M., Berg, C. D., and Sherman, M. E. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. *Gynecologic Oncology*. 2011;120(3):474-479.
- Orazi, G., Bogaert, E., Vinatier, D., Querleu, D., and Leroy, J. L. Should cytological screening for cervical cancer be interrupted after the menopause?. [French]. *Contraception Fertilite Sexualite*. 1999;27(12):833-836.
- Pallatrone, L. The new technology for cervical cancer screening: costs versus reimbursement. *MLO: medical laboratory observer*. 1999;31(3):44-46, 48, 50.

Rosenfeld, J. A. The natural history of Pap test screening in a rural population. *Tennessee Medicine*. 1998;91(5):179-182.

Rubin, M. M. Cytologic concerns in adolescents. Entering the transformation zone. *Advance for nurse practitioners*. 1999;7(9):53-54, 56.

Saurel, J. [Adenocarcinoma in situ of the cervix uteri. Cytologic and histologic aspects]. [French]. *Annales de Pathologie*. 1996;16(5):374-380.

Level 3: Comparison

A simpler test for cervical cancer. *Environmental health perspectives*. 1999;107(10):A498-.

Cervical cancer. Summary of the National Institutes of Health (NIH) consensus. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 1997;37(3):339-341.

Recommendations for cervical screening 1997. Members of the Working Party on Cervical Screening. *The New Zealand medical journal*. 1998;111(1062):94-98.

Recommendations for the screening of the uterine cervix cancer in France (July, 2010). [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2011;40(3):279-282.

Routine cancer screening. *International Journal of Gynecology and Obstetrics*. 1997;59(2):157-161.

Agarwal, S. S., Murthy, N. S., Sharma, S., Sharma, K. C., and Das, D. K. Evaluation of a hospital based cytology screening programme for reduction in life time risk of cervical cancer. *Neoplasma*. 1995;42(2):93-96.

Alexandraki, I. The United States-Mexico border: An area in need of cancer screening interventions. *Journal of Women's Health*. 2011;20(5):653-655.

Anderson, G., MacAulay, C., Maticic, J., Garner, D., and Palcic, B. The use of an automated image cytometer for screening and quantitative assessment of cervical lesions in the British Columbia Cervical Smear Screening Programme. *Cytopathology*. 1997;8(5):298-312.

Anderson, M. B. and Jones, B. A. False positive cervicovaginal cytology. A follow-up study. *Acta Cytologica*. 1997;41(6):1697-1700.

Anschau, F. and Guimaraes Goncalves, M. A. Discordance between cytology and biopsy histology of the cervix: what to consider and what to do. *Acta Cytologica*. 2011;55(2):158-162.

Anttila, A., Pukkala, E., Soderman, B., Kallio, M., Nieminen, P., and Hakama, M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: Recent increase in cervical cancer incidence. *International Journal of Cancer*. 1999;83(1):59-65.

Apgar, B. S. and Brotzman, G. HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. [Review] [29 refs]. *American Family Physician*. 5-15-1999;59(10):2794-2801.

Apgar, B. S. and Brotzman, G. HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. *American Family Physician*. 1999;59(10):2794-2800.

Arbyn, M., Van, Nieuwenhuysse A., Bogers, J., De, Jonge E., De Beeck, L. O., Mathei, C., and Buntinx, F. Cytological screening for cervical cancer in the province of Limburg, Belgium. *European Journal of Cancer Prevention*. 2011;20(1):18-24.

Armstrong, C. ACOG updates guidelines on cervical cytology screening. *American Family Physician*. 2010;81(11):1380-1385.

Arveux, P. Exclusion of low-risk women from screening programs for cervix uteri cancers: based on

mathematical modeling. [French]. *Revue d'Epidemiologie et de Sante Publique*. 1999;47(4):389-390.

Barrasso, R. and Monsonogo, J. Is cervical screening justified among adolescents?. [French]. *Contraception Fertilite Sexualite*. 1996;24(2):101-103.

Bergstrom, R., Sparen, P., and Adami, H. O. Trends in cancer of the cervix uteri in Sweden following cytological screening. *British Journal of Cancer*. 1999;81(1):159-166.

Castle, P. E., Fetterman, B., Poitras, N., Lorey, T., Shaber, R., Schiffman, M., Demuth, F., and Kinney, W. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. *Obstetrics & Gynecology*. 2011;117(3):650-656.

Castle, P. E., Fetterman, B., Thomas, Cox J., Shaber, R., Poitras, N., Lorey, T., and Kinney, W. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer.[Erratum appears in *Obstet Gynecol*. 2010 Sep;116(3):775-7]. *Obstetrics & Gynecology*. 2010;116(1):76-84.

Chappell, C. A., West, A. M., Kabbani, W., and Werner, C. L. Off-label high-risk HPV DNA testing of vaginal ASC-US and LSIL cytologic abnormalities at Parkland hospital. *Journal of Lower Genital Tract Disease*. 2010;14(4):352-355.

Ciatto, S., Cecchini, S., Iossa, A., Grazzini, G., Bonardi, R., Zappa, M., Carli, S., and Barchielli, A. Trends in cervical cancer incidence in the district of Florence. *European Journal of Cancer*. 1995;31A(3):354-355.

Cope, J. U., Hildesheim, A., Schiffman, M. H., Manos, M. M., Lorincz, A. T., Burk, R. D., Glass, A. G., Greer, C., Buckland, J., Helgesen, K., Scott, D. R., Sherman, M. E., Kurman, R. J., and Liaw, K. L. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. *Journal of Clinical Microbiology*. 1997;35(9):2262-2265.

Creighton, P., Lew, J. B., Clements, M., Smith, M., Howard, K., Dyer, S., Lord, S., and Canfell, K. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. *BMC Public Health*. 2010;10:734-.

Cruickshank, M. E., Angus, V., Kelly, M., McPhee, S., and Kitchener, H. C. The case for stopping cervical screening at age 50. *British Journal of Obstetrics & Gynaecology*. 1997;104(5):586-589.

Curtis, P., Mintzer, M., Resnick, J., Morrell, D., and Hendrix, S. The quality of cervical cancer screening: a primary care perspective. *American journal of medical quality : the official journal of the American College of Medical Quality*. 1996;11(1):11-17.

De Vries, C. E., Shen, R., and Suarez, A. A. Is high grade cervical intraepithelial neoplasia ever found on follow up of equivocal and low positive hybrid capture 2 results in women 50 years and older?. *Laboratory Investigation*. 2011;Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011 San Antonio, TX United States. Conference Start: 20110226 Conference End: 20110304. Conference Publication:(var.pagings):87A-88A.

Delaloye, J.-F. and De, Grandi P. For and against 3-yearly Papanicolaou smear for cervical cancer screening. [French]. *Schweizerische Medizinische Wochenschrift*. 1998;128(23):909-913.

Denenberg, R. Cervical cancer and women with HIV. *GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies*. 1997;11(7-8):10-18.

Denny, L., Kuhn, L., Hu, C. C., Tsai, W. Y., and Wright, T. C., Jr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. *Journal of the National Cancer Institute*. 10-20-2010;102(20):1557-1567.

Dinkelspiel, H., Poitras, N., Fetterman, B., Kinney, W., Cox, T., Lorey, T., and Castle, P. Cervical cancer rates in clinical practice with co-testing, interval extension and current evaluation of women with

pap-negative, human papillomavirus-positive screening tests. *Gynecologic Oncology*. 2011;Conference: 42nd Annual Meeting of the Society of Gynecologic Oncologists Orlando, FL United States. Conference Start: 20110306 Conference End: 20110309. Conference Publication:(var.pagings):S19-.

Duggan, M. A. and Brasher, P. M. Accuracy of Pap tests reported as CIN I. *Diagnostic Cytopathology*. 1999;21(2):129-136.

Fahs, M. C., Plichta, S. B., and Mandelblatt, J. S. Cost-effective policies for cervical cancer screening: An international review. *PharmacoEconomics*. 1996;9(3):211-230.

Fletcher, H. Screening for cervical cancer in Jamaica. *Caribbean health*. 1999;2(1):9-11.

Gallagher, F. and Gallagher, J. A closer look at cervical smear uptake and results pre- and post-introduction of the national screening programme. *Irish Medical Journal*. 1-20-2010;103(7):199-200.

Garnier, A., Exbrayat, C., Bolla, M., Marron, J., Winckel, P., and Billette, de, V Campaign for cervical cancer screening with vaginal smears in women aged 50-69 years in Isere (France). Results of the first round (January 1991-June 1993). [French]. *Bulletin du Cancer*. 1997;84(8):791-795.

Gok, M., Rozendaal, L., Berkhof, J., Visser, O., Meijer, C. J., and van Kemenade, F. J. Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases. *British Journal of Cancer*. 2-15-2011;104(4):685-692.

Grant, C. M. Cervical screening interval: Costing the options in one health authority. *Journal of Public Health Medicine*. 1999;21(2):140-144.

Gustafsson, L., Sparen, P., Gustafsson, M., Wilander, E., Bergstrom, R., and Adami, H. O. Efficiency of organised and opportunistic cytological screening for cancer in situ of the cervix. *British Journal of Cancer*. 1995;72(2):498-505.

Gyrd-Hansen, D. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer. *Critical Reviews in Oncology/Hematology*. 1999;32(2):133-144.

Hailey, D. M. and Lea, R. Prospects for newer technologies in cervical cancer screening programmes. *Journal of Quality in Clinical Practice*. 1995;15(3):139-145.

Hall, J. M., Han, J. J., and Fadare, O. The value of repeated cytology at the time of first colposcopy: a retrospective analysis of 1,087 cases. *American Journal of Clinical Pathology*. 2011;135(4):628-636.

Hang, Lee S. From human papillomavirus to cervical cancer. *Obstetrics and Gynecology*. 2010;116(5):1221-.

Harry, C. Cervical cancer screening in the Bahamas. *Bulletin of the Pan American Health Organization*. 1996;30(4):414-.

Hatcher, J., Studts, C. R., Dignan, M. B., Turner, L. M., and Schoenberg, N. E. Predictors of cervical cancer screening for rarely or never screened rural Appalachian women. *Journal of Health Care for the Poor & Underserved*. 2011;22(1):176-193.

Herbert, A. and Smith, J. A. E. Cervical intraepithelial neoplasia grade III (CIN III) and invasive cervical carcinoma: The yawning gap revisited and the treatment of risk. *Cytopathology*. 1999;10(3):161-170.

Herbert, A., Breen, C., Bryant, T. N., Hitchcock, A., Macdonald, H., Millward-Sadler, G. H., and Smith, J. Invasive cervical cancer in Southampton and South West Hampshire: effect of introducing a comprehensive screening programme. *Journal of Medical Screening*. 1996;3(1):23-28.

Hernandez-Avila, M., Lazcano-Ponce, E. C., Berumen-Campos, J., Cruz-Valdez, A., Alonso de Ruiz, P. P., and Gonzalez-Lira, G. Human papilloma virus 16-18 infection and cervical cancer in Mexico: a case-

control study. *Archives of Medical Research*. 1997;28(2):265-271.

Hoffman, M. S. and Cavanagh, D. Cervical cancer: Screening and prevention of invasive disease. *Cancer Control*. 1995;2(6):503-509.

HooKim, K., Smola, B., Newton, D., Lieberman, R., and Knoepp, S. The significance of ASCUS-equivocal high risk HPV DNA tests in thinprep specimens: A cytologic/histologic review of 315 cases. *Laboratory Investigation*. 2011;Conference: United States and Canadian Academy of Pathology Annual Meeting, USCAP 2011 San Antonio, TX United States. Conference Start: 20110226 Conference End: 20110304. Conference Publication:(var.pagings):249A-.

Horwitz, L. A. Cervical cancer screening among low-income women: results of a national screening program, 1991-1995. *Journal of Nurse-Midwifery*. 1999;44(2):165-166.

Huynh, J., Howard, M., and Lytwyn, A. Self-collection for vaginal human papillomavirus testing: systematic review of studies asking women their perceptions. [Review]. *Journal of Lower Genital Tract Disease*. 2010;14(4):356-362.

Ince, U., Aydin, O., and Peker, O. Clinical importance of "low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion (LSIL-H)" terminology for cervical smears 5-year analysis of the positive predictive value of LSIL-H compared with ASC-H, LSIL, and HSIL in the detection of high-grade cervical lesions with a review of the literature. [Review]. *Gynecologic Oncology*. 2011;121(1):152-156.

Janerich, D. T., Hadjimichael, O., Schwartz, P. E., Lowell, D. M., Meigs, J. W., Merino, M. J., Flannery, J. T., and Polednak, A. P. The screening histories of women with invasive cervical cancer, Connecticut. *American Journal of Public Health*. 1995;85(6):791-762.

Jones, M. H., Singer, A., and Jenkins, D. The mildly abnormal cervical smear: patient anxiety and choice of management. *Journal of the Royal Society of Medicine*. 1996;89(5):257-260.

Jungmann, E. M. A., Smith, N. A., Bradbeer, C., and De, Ruiter A. An audit of cervical cytological screening amongst HIV-positive women. *International Journal of STD and AIDS*. 1998;9(5):301-302.

Kim, S. J. Screening and epidemiological trends in cervical cancer. *Journal of Obstetrics and Gynaecology Research*. 1996;22(6):621-627.

Kostova, P. and Zlatkov, V. Is cervical cancer screening necessary or the "Paradox" example of Bulgaria. *Journal of B*. 2010;15(3):556-560.

Kotaniemi-Talonen, L., Malila, N., Anttila, A., Nieminen, P., and Hakama, M. Intensified screening among high risk women within the organised screening programme for cervical cancer in Finland. *Acta Oncologica*. 2011;50(1):106-111.

Kumarasinghe, M. P. An effective and affordable cervical carcinoma screening programme for Sri Lanka. *The Ceylon medical journal*. 1999;44(4):156-158.

Kuyumcuoglu, U., Hocaoglu, S., Guzel, A. I., and Celik, Y. The clinical significance of HPV screening in premalignant cervical lesions. *European Journal of Gynaecological Oncology*. 2010;31(5):596-597.

Lauver, D. R., Kruse, K., and Baggot, A. Women's uncertainties, coping, and moods regarding abnormal papanicolaou results. *Journal of Womens Health & Gender-Based Medicine*. 1999;8(8):1103-1112.

Lazaar, H. B., Aounallah-Skhiri, H., Oueslati, F., Frikha, H., Achour, N., and Hsairi, M. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia]. [French]. *Eastern Mediterranean Health Journal*. 2010;16(6):602-608.

Lazcano-Ponce, E., Lorincz, A. T., Salmeron, J., Fernandez, I., Cruz, A., Hernandez, P., Mejia, I., and Hernandez-Avila, M. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine

Mexican Social Security Program. *Cancer Causes & Control*. 2010;21(10):1693-1700.

Lieu, D. The Papanicolaou smear: Its value and limitations. *Journal of Family Practice*. 1996;42(4):391-399.

Littell, R. D., Kinney, W., Fetterman, B., Cox, J. T., Shaber, R., Poitras, N., Lorey, T., and Castle, P. E. Risk of cervical precancer and cancer in women aged 30 years and older with an HPV-negative low-grade squamous intraepithelial lesion screening result. *Journal of Lower Genital Tract Disease*. 2011;15(1):54-59.

Lonky, N. M., Sadeghi, M., Tsadik, G. W., and Petitti, D. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. *American Journal of Obstetrics & Gynecology*. 1999;181(3):560-566.

Mandelblatt, J. S. and Phillips, R. N. Cervical cancer: How often - And why - To screen older women. *Geriatrics*. 1996;51(6):45-48.

Midzuaray, A. Program for the control of cervical cancer in Peru. *Bulletin of the Pan American Health Organization*. 1996;30(4):413-.

Miller, A. B. An epidemiological perspective on cancer screening. [Review] [55 refs]. *Clinical Biochemistry*. 1995;28(1):41-48.

Mitchell, H. S. and Giles, G. G. Cancer diagnosis after a report of negative cervical cytology. *Medical Journal of Australia*. 3-4-1996;164(5):270-273.

Morrison, B. J., Coldman, A. J., Boyes, D. A., and Anderson, G. H. Forty years of repeated screening: the significance of carcinoma in situ. *British Journal of Cancer*. 1996;74(5):814-819.

Moss, E. L., Pearmain, P., Askew, S., Owen, G., Reynolds, T. M., Prabakar, I. M., Douce, G., Parkes, J., Menon, V., Todd, R. W., and Redman, C. W. Implementing the national invasive cervical cancer audit: a local perspective. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2010;117(11):1411-1416.

Murthy, N. S. and Mathew, A. Screening for cancer of uterine cervix and approaches adopted in India. *Indian Journal of Cancer*. 1999;36(2-4):154-162.

Naper, J. Cervical cancer: new technologies target treatment strategies. *Hospital technology series*. 1995;14(8):1-2.

Nieminen, P., Kallio, M., and Hakama, M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. *Obstetrics and Gynecology*. 1995;85(6):1017-1021.

No authors listed Cervical cancer screening. Pap smears. *Institute for Clinical Systems Integration. Postgraduate medicine*. 1997;102(3):185-194.

Parboosingh, J. Screening for cervical cancer. Canadian programmatic guidelines. *Canadian family physician Medecin de famille canadien*. 1999;45:383-393.

Peate, I. Cervical cancer. 1: Role of nurses in the primary healthcare setting. *British journal of nursing (Mark Allen Publishing)*. 1999;8(11):730-734.

Perez-Gomez, B., Martinez, C., Navarro, C., Franch, P., Galceran, J., Marcos-Gragera, R., and Cervical Cancer Working Group The moderate decrease in invasive cervical cancer incidence rates in Spain (1980-2004): limited success of opportunistic screening?. *Annals of Oncology*. 2010;21:Suppl-68.

Powell, N. Single HPV test not useful for predicting CIN2 or worse or for guiding choice of further investigations for women aged 20-59 presenting to NHS cervical screening programme with borderline abnormalities or mild dyskaryosis. *Evidence-Based Medicine*. 2010;15(6):182-183.

- Printz, C. Reaching out to undeserved populations. *Cancer*. 2011;117(1):1-3.
- Quinn, M. A. Adenocarcinoma of the cervix. [Review] [37 refs]. *Annals of the Academy of Medicine, Singapore*. 1998;27(5):662-665.
- Quinn, M., Babb, P., Jones, J., and Allen, E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. *BMJ*. 4-3-1999;318(7188):904-908.
- Raffle, A. E., Alden, B., and Mackenzie, E. F. Detection rates for abnormal cervical smears: what are we screening for?. *Lancet*. 6-10-1995;345(8963):1469-1473.
- Repse-Fokter, A. Accuracy of the Papanicolaou test in the detection of high-grade cervical lesions. *International Journal of Gynaecology & Obstetrics*. 2011;112(1):65-66.
- Rinas, A. C. The gynecological Pap test. *Clinical laboratory science : journal of the American Society for Medical Technology*. 1999;12(4):239-245.
- Ronco, G., Segnan, N., Giordano, L., Pilutti, S., Senore, C., Ponti, A., and Volante, R. Interaction of spontaneous and organised screening for cervical cancer in Turin, Italy. *European Journal of Cancer*. 1997;33(8):1262-1267.
- Rosenfeld, J. A. The natural history of Pap test screening in a rural population. *Tennessee Medicine*. 1998;91(5):179-182.
- Sankar, K. N. and Tayal, S. C. Cervical smear: Is screening of teenagers justified?. *International Journal of STD and AIDS*. 1998;9(5):303-.
- Sasieni, P. and Adams, J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. *BMJ*. 5-8-1999;318(7193):1244-1245.
- Sato, S., Matunaga, G., Tsuji, I., Yajima, A., and Sasaki, H. Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models. *Acta Cytologica*. 1999;43(6):1006-1014.
- Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J. C., and Castle, P. E. Human papillomavirus testing in the prevention of cervical cancer. [Review]. *Journal of the National Cancer Institute*. 3-2-2011;103(5):368-383.
- Schmeink, C. E., Bekkers, R. L. M., Massuger, L. F. A. G., and Melchers, W. J. G. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. *Reviews in Medical Virology*. 2011;21(3):139-153.
- Shafer, M.-A. Annual pelvic examination in the sexually active adolescent female: What are we doing and why are we doing it?. *Journal of Adolescent Health*. 1998;23(2):68-73.
- Shingleton, H. M., Patrick, R. L., Johnston, W. W., and Smith, R. A. The current status of the Papanicolaou smear. [Review] [51 refs]. *CA: a Cancer Journal for Clinicians*. 1995;45(5):305-320.
- Sigurdsson, K. Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines. [Review]. *Cytopathology*. 2010;21(4):213-222.
- Sigurdsson, K. The Icelandic and Nordic cervical screening programs: Trends in incidence and mortality rates through 1995. *Acta Obstetrica et Gynecologica Scandinavica*. 1999;78(6):478-485.
- Sorbye, S. W., Fismen, S., Gutteberg, T., and Mortensen, E. S. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. *PLoS ONE [Electronic Resource]*. 2010;5(9):e12724-.
- Spitzer, M. Cervical screening adjuncts: recent advances. [Review] [107 refs]. *American Journal of Obstetrics & Gynecology*. 1998;179(2):544-556.

Stevermer, J. J. and Chambliss, M. L. Pap smear of the vaginal cuff. *Journal of Family Practice*. 1997;44(3):250-252.

Syrjanen, K., Di, Bonito L., Goncalves, L., Murjal, L., Santamaria, M., Mahovlic, V., Karakitsos, P., Onal, B., and Schmitt, F. C. Cervical cancer screening in Mediterranean countries: implications for the future. [Review]. *Cytopathology*. 2010;21(6):359-367.

Szarewski, A. Social and psychological aspects of cervical screening. *Expert Review of Obstetrics and Gynecology*. 2011;6(1):37-44.

Szarewski, A., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Edwards, R., Lyons, D., Walker, J., Christison, J., Frater, A., and Waller, J. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. *British Journal of Cancer*. 3-15-2011;104(6):915-920.

Thiryayi, S. A., Marshall, J., and Rana, D. N. An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia. *Cytopathology*. 2010;21(4):223-228.

Tota, J., Mahmud, S. M., Ferenczy, A., Coutlee, F., and Franco, E. L. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. [Review]. *Sexual Health*. 2010;7(3):376-382.

Vacher-Lavenu, M. C. [Cervix uteri cancer screening: update 2010]. [French]. *Annales de Pathologie*. 2010;30(5:Suppl 1):Suppl-31.

van Oortmarssen, G. J. and Habbema, J. D. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. *International Journal of Epidemiology*. 1995;24(2):300-307.

Level 3: Outcomes

Abulafia, O. and Sherer, D. M. Automated cervical cytology: meta-analyses of the performance of the AutoPap 300 QC System. *Obstetrical & Gynecological Survey*. 1999;54(7):469-476.

Anschau, F. and Guimaraes Goncalves, M. A. Discordance between cytology and biopsy histology of the cervix: what to consider and what to do. *Acta Cytologica*. 2011;55(2):158-162.

Baldauf, J.-J., Dreyfus, M., Ritter, J., Meyer, P., and Philippe, E. Cervicography: Does it improve cervical cancer screening?. *Acta Cytologica*. 1997;41(2):295-301.

Bell, S., Porter, M., Kitchener, H., Fraser, C., Fisher, P., and Mann, E. Psychological response to cervical screening. *Preventive Medicine*. 1995;24(6):610-616.

Bishop, J. W., Bigner, S. H., Colgan, T. J., Husain, M., Howell, L. P., McIntosh, K. M., Taylor, D. A., and Sadeghi, M. H. Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears. Including initial biopsy results. *Acta Cytologica*. 1998;42(1):189-197.

Bolanca, I. K. and Vrane, J. Diagnostic methods and techniques in preventing cervical carcinoma Part I: Conventional cytology and new cytological methods. *Medicinski Glasnik*. 2010;7(1):12-17.

Bosanquet, N., Coleman, D. V., Dore, C. J., Douglas, G., Magee, L. J., Baker, R., Amerasinghe, C., Falcon, C., McKee, G., Sayer, B., Morse, A., Padel, A., Symonds, M., Kocjan, G., McGloin, J., Havelock, C., and Hudson, E. Assessment of automated primary screening on PAPNET of cervical smears in the PRISMATIC trial. *Lancet*. 1999;353(9162):1381-1385.

Carpenter, A. B. and Davey, D. D. ThinPrep Pap Test: performance and biopsy follow-up in a university hospital. *Cancer*. 6-25-1999;87(3):105-112.

- Cecchini, S., Ciatto, S., Zappa, M., and Biggeri, A. Trends in the prevalence of cervical intraepithelial neoplasia grade 3 in the district of Florence, Italy. *Tumori*. 1995;81(5):330-333.
- Chebib, I. and Wilbur, D. C. Automation in gynecologic cytology. *Pathology Case Reviews*. 2011;16(2):62-66.
- Confortini, M., Giorgi, Rossi P., Barbarino, P., Passarelli, A. M., Orzella, L., and Tufi, M. C. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. *Journal of Medical Screening*. 2010;17(2):79-86.
- Cullimore, J. E. and Waddell, C. Cervical cytology and glandular neoplasia. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2010;117(9):1047-1050.
- Cuzick, J., Sasieni, P., Davies, P., Adams, J., Normand, C., Frater, A., van, Ballegooijen M., and Van den Akker, E. A systematic review of the role of human papillomavirus testing within a cervical screening programme. *Health Technology Assessment*. 1999;3(14):iii-130.
- Davion, S., Lucas, E., Kemp, A., and Nayar, R. HPV DNA testing: Is it used appropriately?. *Laboratory Investigation*. 2010;Conference: United States and Canadian Academy of Pathology Annual Meeting Washington, DC United States. Conference Start: 20100320 Conference End: 20100326. Conference Publication:(var.pagings):239A-
- Dubois, G. Cytologic screening for cervix cancer: each year or each 3 years?. [Review] [14 refs]. *European Journal of Obstetrics, Gynecology, & Reproductive Biology*. 1996;65(1):57-59.
- Duggan, M. A. and Brasher, P. Paired comparison of manual and automated Pap test screening using the PAPNET system. *Diagnostic Cytopathology*. 1997;17(4):248-254.
- Fait, G., Daniel, Y., Kupferminc, M. J., Lessing, J. B., Niv, J., and Bar-Am, A. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?. *Gynecologic Oncology*. 1998;70(3):319-322.
- Farnsworth, A., Chambers, F. M., and Goldschmidt, C. S. Evaluation of the PAPNET system in a general pathology service. *Medical Journal of Australia*. 10-21-1996;165(8):429-431.
- Forsmo, S., Jacobsen, B. K., and Stalsberg, H. Cervical neoplasia in pap smears: risk of cervical intra-epithelial neoplasia (CIN) after negative or no prior smears in a population without a mass screening programme. *International Journal of Epidemiology*. 1996;25(1):53-58.
- Fouquet, R. and Gage, H. Role of screening in reducing invasive cervical cancer registrations in England. *Journal of Medical Screening*. 1996;3(2):90-96.
- Garrote, L. F., Anta, J. J. L., Cruz, E. C., Romero, T., and Camacho, R. Evaluation of the cervical cancer control program in Cuba. *Bulletin of the Pan American Health Organization*. 1996;30(4):387-391.
- Giorgi, Rossi P., Marsili, L. M., Camilloni, L., Iossa, A., Lattanzi, A., Sani, C., Di, Pierro C., Grazzini, G., Angeloni, C., Capparucci, P., Pellegrini, A., Schiboni, M. L., Sperati, A., Confortini, M., Bellanova, C., D'Addetta, A., Mania, E., Visioli, C. B., Sereno, E., Carozzi, F., and Self-Sampling Study Working Group The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). *British Journal of Cancer*. 1-18-2011;104(2):248-254.
- Gustafsson, L., Ponten, J., Zack, M., and Adami, H.-O. International incidence rates of invasive cervical cancer after introduction of cytological screening. *Cancer Causes and Control*. 1997;8(5):755-763.
- Gustafsson, L., Sparen, P., Gustafsson, M., Wilander, E., Bergstrom, R., and Adami, H. O. Efficiency of organised and opportunistic cytological screening for cancer in situ of the cervix. *British Journal of Cancer*. 1995;72(2):498-505.
- Hatch, K. D., Schneider, A., and Abdel-Nour, M. W. An evaluation of human papillomavirus testing for

intermediate- and high-risk types as triage before colposcopy. *American Journal of Obstetrics & Gynecology*. 1995;172(4:Pt 1):t-5.

Heider, A., Austin, R. M., and Zhao, C. HPV test results stratify risk for histopathologic follow-up findings of high-grade cervical intra-epithelial neoplasia in women with low-grade squamous intra-epithelial lesion pap results. *Acta Cytologica*. 2010;55(1):48-53.

Herbert, A., Breen, C., Bryant, T. N., Hitchcock, A., Macdonald, H., Millward-Sadler, G. H., and Smith, J. Invasive cervical cancer in Southampton and South West Hampshire: effect of introducing a comprehensive screening programme. *Journal of Medical Screening*. 1996;3(1):23-28.

Hutchinson, M. L., Zahniser, D. J., Sherman, M. E., Herrero, R., Alfaro, M., Bratti, M. C., Hildesheim, A., Lorincz, A. T., Greenberg, M. D., Morales, J., and Schiffman, M. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. *Cancer*. 4-25-1999;87(2):48-55.

Kitchener, H. C., Gilham, C., Sargent, A., Bailey, A., Albrow, R., Roberts, C., Desai, M., Mather, J., Turner, A., Moss, S., and Peto, J. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. *European Journal of Cancer*. 2011;47(6):864-871.

Kjaer, S. K., Frederiksen, K., Munk, C., and Iftner, T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. *Journal of the National Cancer Institute*. 10-6-2010;102(19):1478-1488.

Kok, M. R. and Boon, M. E. Consequences of neural network technology for cervical screening: increase in diagnostic consistency and positive scores. *Cancer*. 7-1-1996;78(1):112-117.

Koss, L. G., Sherman, M. E., Cohen, M. B., Anes, A. R., Darragh, T. M., Lemos, L. B., McClellan, B. J., Rosenthal, D. L., Keyhani-Rofagha, S., Schreiber, K., and Valente, P. T. Significant reduction in the rate of false-negative cervical smears with neural network-based technology (PAPNET Testing System). *Human Pathology*. 1997;28(10):1196-1203.

Laverty, C. R. A. Evaluation of the ThinPrep Pap test as an adjunct to the conventional Pap smear. *Medical Journal of Australia*. 1997;167(9):466-469.

Linder, J. and Zahniser, D. The ThinPrep Pap test. A review of clinical studies. [Review] [22 refs]. *Acta Cytologica*. 1997;41(1):30-38.

Mango, L. J. and Valente, P. T. Neural-network-assisted analysis and microscopic rescreening in presumed negative cervical cytologic smears. A comparison. *Acta Cytologica*. 1998;42(1):227-232.

Mango, L. J. Clinical validation of interactive cytologic screening. Automating the search, not the interpretation. [Review] [15 refs]. *Acta Cytologica*. 1997;41(1):93-97.

Mango, L. J. Reducing false negatives in clinical practice: the role of neural network technology. [Review] [31 refs]. *American Journal of Obstetrics & Gynecology*. 1996;175(4:Pt 2):t-9.

Manos, M. M., Kinney, W. K., Hurley, L. B., Sherman, M. E., Shieh-Ngai, J., Kurman, R. J., Ransley, J. E., Fetterman, B. J., Hartinger, J. S., McIntosh, K. M., Pawlick, G. F., and Hiatt, R. A. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. *JAMA*. 5-5-1999;281(17):1605-1610.

McCrorry, D. C., Matchar, D. B., Bastian, L., Datta, S., Hasselblad, V., Hickey, J., Myers, E., and Nanda, K. Evaluation of cervical cytology. [Review] [0 refs]. *Evidence Report: Technology Assessment (Summary)*. 1999;#volume#(5):1-6.

McKenzie, C. A. and Duncan, I. D. The value of cervical screening in women over 50 years of age -

Time for a multicentre audit. *Scottish Medical Journal*. 1998;43(1):19-20.

Mitchell, H. S. and Giles, G. G. Cancer diagnosis after a report of negative cervical cytology. *Medical Journal of Australia*. 3-4-1996;164(5):270-273.

Mitchell, H., Medley, G., Gordon, I., and Giles, G. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. *British Journal of Cancer*. 1995;71(4):894-897.

Monsonogo, J. Cervical cancer screening and management, new challenges. *European Journal of Gynaecological Oncology*. 1999;20(5-6):352-354.

Musa, J., Taiwo, B., Goldsmith, S., Sutton, S., Berzins, B., and Murphy, R. L. Predictors of atypical squamous cell of undetermined significance cervical cytology with high-risk human papilloma virus genotypes. *Archives of Gynecology & Obstetrics*. 2011;283(2):343-348.

Ogilvie, G. S., van Niekerk, D. J., Kraiden, M., Martin, R. E., Ehlen, T. G., Ceballos, K., Peacock, S. J., Smith, L. W., Kan, L., Cook, D. A., Mei, W., Stuart, G. C., Franco, E. L., and Coldman, A. J. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). *BMC Cancer*. 2010;Vol10, pp111, 2010:111-.

Olaitan, A. and Johnson, M. A. Cervical intraepithelial neoplasia in women with HIV. *Journal of the International Association of Physicians in AIDS Care*. 1997;3(5):15-17.

Park, J. S. The role of HPV DNA testing in cervical neoplasia. *Journal of Obstetrics and Gynaecology Research*. 1996;22(6):611-620.

Paskett, E. D. and Rimer, B. K. Psychosocial effects of abnormal Pap tests and mammograms: A review. *Journal of Women's Health*. 1995;4(1):73-82.

Petry, K. U., Bohmer, G., Iftner, T., Flemming, P., Stoll, M., and Schmidt, R. E. Human papillomavirus testing in primary screening for cervical cancer of human immunodeficiency virus-infected women, 1990-1998. *Gynecologic Oncology*. 1999;75(3):427-431.

Quinn, M., Babb, P., Jones, J., and Allen, E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. *BMJ*. 4-3-1999;318(7188):904-908.

Ratnam, S., Coutlee, F., Fontaine, D., Bentley, J., Escott, N., Ghatage, P., Gadag, V., Holloway, G., Bartellas, E., Kum, N., Giede, C., and Lear, A. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. *Journal of Clinical Microbiology*. 2011;49(2):557-564.

Recommendations for the screening of the uterine cervix cancer in France (July, 2010). [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2011;40(3):279-282.

Richart, R. M., Patten, S. F., Jr., and Lee, J. S. Prospects for automated cytology. *Obstetrics & Gynecology Clinics of North America*. 1996;23(4):853-859.

Rijkaart, D. C., Coupe, V. M., van Kemenade, F. J., Heideman, D. A., Hesselink, A. T., Verweij, W., Rozendaal, L., Verheijen, R. H., Snijders, P. J., Berkhof, J., and Meijer, C. J. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. *British Journal of Cancer*. 9-28-2010;103(7):939-946.

Rosenthal, D. L. Computerized scanning devices for pap smear screening: Current status and critical review. *Clinics in Laboratory Medicine*. 1997;17(2):263-284.

Rozendaal, L., Walboomers, J. M., van der Linden, J. C., Voorhorst, F. J., Kenemans, P., Helmerhorst, T. J., van, Ballegooijen M., and Meijer, C. J. PCR-based high-risk HPV test in cervical cancer screening

gives objective risk assessment of women with cytomorphologically normal cervical smears. *International Journal of Cancer*. 12-11-1996;68(6):766-769.

Sherman, M. E., Mendoza, M., Lee, K. R., Ashfaq, R., Birdsong, G. G., Corkill, M. E., McIntosh, K. M., Inhorn, S. L., Zahniser, D. J., Baber, G., Barber, C., and Stoler, M. H. Performance of liquid-based, thin-layer cervical cytology: correlation with reference diagnoses and human papillomavirus testing. *Modern Pathology*. 1998;11(9):837-843.

Sherman, M. E., Schiffman, M., Herrero, R., Kelly, D., Bratti, C., Mango, L. J., Alfaro, M., Hutchinson, M. L., Mena, F., Hildesheim, A., Morales, J., Greenberg, M. D., Balmaceda, I., and Lorincz, A. T. Performance of a semiautomated Papanicolaou smear screening system: results of a population-based study conducted in Guanacaste, Costa Rica. *Cancer*. 10-25-1998;84(5):273-280.

Sidawy, M. K. and Solomon, D. Pitfalls in diagnostic cervicovaginal cytology. [Review] [45 refs]. *Monographs in pathology*. 1997;#volume#(39):1-15.

Sigurdsson, K. Cervical cancer, Pap smear and HPV testing: An update of the role of organized Pap smear screening and HPV testing. *Acta Obstetrica et Gynecologica Scandinavica*. 1999;78(6):467-477.

Sigurdsson, K. Trends in cervical intra-epithelial neoplasia in Iceland through 1995: Evaluation of targeted age groups and screening intervals. *Acta Obstetrica et Gynecologica Scandinavica*. 1999;78(6):486-492.

Sireci, A. N., Crapanzano, J. P., Mansukhani, M., Wright, T., Babiac, A., Erroll, M., Vazquez, M., and Saqi, A. Atypical glandular cells (AGC): ThinPrep Imaging System (TIS), manual screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. *Diagnostic Cytopathology*. 2010;38(10):705-709.

Solomon, H. M. and Frist, S. PAPNET testing for HSILs. The few cell/small cell challenge. [Review] [41 refs]. *Acta Cytologica*. 1998;42(1):253-259.

Stuart, G. C. E., Elizabeth, McGregor S., Duggan, M. A., and Nation, J. G. Review of the screening history of Alberta women with invasive cervical cancer. *Canadian Medical Association Journal*. 1997;157(5):513-519.

Sturgis, C. D., Isoe, C., McNeal, N. E., Yu, G. H., and DeFrias, D. V. PAPNET computer-aided rescreening for detection of benign and malignant glandular elements in cervicovaginal smears: a review of 61 cases. *Diagnostic Cytopathology*. 1998;18(4):307-311.

Subramaniam, A., Fauci, J. M., Schneider, K. E., Whitworth, J. M., Erickson, B. K., Kim, K., and Huh, W. K. Invasive cervical cancer and screening: What are the rates of unscreened and underscreened women in the modern era?. *Journal of Lower Genital Tract Disease*. 2011;15(2):110-113.

Syrjanen, K. J. and Syrjanen, S. M. Human papillomavirus (HPV) typing as an adjunct to cervical cancer screening. *Cytopathology*. 1999;10(1):8-15.

van, Ballegooijen M., van den Akker-van Marle ME, Warmerdam, P. G., Meijer, C. J., Walboomers, J. M., and Habbema, J. D. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. *British Journal of Cancer*. 1997;76(5):651-657.

Vassilakos, P., Saurel, J., and Rondez, R. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. *Acta Cytologica*. 1999;43(1):65-68.

Veneti, S., Papaefthimiou, M., Symiakaki, H., and Ioannidou-Mouzaka, L. PAPNET for cervical cytology screening. Experience in Greece. *Acta Cytologica*. 1999;43(1):30-33.

Walsh, J. M. E. Cervical cancer: Developments in screening and evaluation of the abnormal Pap smear.

Western Journal of Medicine. 1998;169(5):304-310.

Weintraub, J. Experience with new technologies within the context of Swiss practice and conclusions. [French]. *Annales de Pathologie*. 1999;19(5 Suppl):S96-S98.

Weissbrod, D., Torres, M., Rodriguez, A., Urena, I., Estrada, J., Reyes, M. E., and Carreto, A. J. Comparison of the cervical cytology test using the PAPNET method and conventional microscopy. *Bulletin of the Pan American Health Organization*. 1996;30(4):339-347.

Wertlake, P. Results of AutoPap system-assisted and manual cytologic screening. A comparison. *Journal of Reproductive Medicine*. 1999;44(1):11-17.

Wilbur, D. C., Bonfiglio, T. A., Rutkowski, M. A., Atkison, K. M., Richart, R. M., Lee, J. S., and Patten, S. F., Jr. Sensitivity of the AutoPap 300 QC System for cervical cytologic abnormalities. Biopsy data confirmation. *Acta Cytologica*. 1996;40(1):127-132.

Wilbur, D. C., Facik, M. S., Rutkowski, M. A., Mulford, D. K., and Atkison, K. M. Clinical trials of the CytoRich specimen-preparation device for cervical cytology: Preliminary results. *Acta Cytologica*. 1997;41(1):24-29.

Wilbur, D. C., Prey, M. U., Miller, W. M., Pawlick, G. F., and Colgan, T. J. The AutoPap system for primary screening in cervical cytology. Comparing the results of a prospective, intended-use study with routine manual practice. *Acta Cytologica*. 1998;42(1):214-220.

Wilbur, D. C., Prey, M. U., Miller, W. M., Pawlick, G. F., Colgan, T. J., and Dax, Taylor D. Detection of high grade squamous intraepithelial lesions and tumors using the AutoPap System: results of a primary screening clinical trial. *Cancer*. 12-25-1999;87(6):354-358.

Wilson, S. and Woodman, C. Assessing the effectiveness of cervical screening. [Review] [36 refs]. *Clinical Obstetrics & Gynecology*. 1995;38(3):577-584.

Yu, K. K., Forstner, R., and Hricak, H. Cervical carcinoma: Role of imaging. *Abdominal Imaging*. 1997;22(2):208-215.

Level 3: Study Design

Accetta, G., Biggeri, A., Carreras, G., Lippi, G., Carozzi, F. M., Confortini, M., Zappa, M., and Paci, E. Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. *Journal of Medical Screening*. 2010;17(4):181-189.

Berkhof, J., Coupe, V. M., Bogaards, J. A., van Kemenade, F. J., Helmerhorst, T. J., Snijders, P. J., and Meijer, C. J. The health and economic effects of HPV DNA screening in the Netherlands. *International Journal of Cancer*. 2010;127(9):2147-2158.

Castronovo, V., Foidart, J. M., and Boniver, J. Cervical cancer: Cost-benefit and efficacy of opportunistic versus organized screening. [French]. *Revue Medicale de Liege*. 1998;53(5):305-307.

Chow, I. H., Tang, C. H., You, S. L., Liao, C. H., Chu, T. Y., Chen, C. J., Chen, C. A., and Pwu, R. F. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. *British Journal of Cancer*. 12-7-2010;103(12):1773-1782.

DeMay, R. M. Common problems in Papanicolaou smear interpretation. [Review] [173 refs]. *Archives of Pathology & Laboratory Medicine*. 1997;121(3):229-238.

Flores, Y. N., Bishai, D. M., Lorincz, A., Shah, K. V., Lazcano-Ponce, E., Hernandez, M., Granados-Garcia, V., Perez, R., and Salmeron, J. HPV testing for cervical cancer screening appears more cost-effective than Papanicolaou cytology in Mexico. *Cancer Causes & Control*. 2011;22(2):261-272.

Inoue, M., Okamura, M., Hashimoto, S., Tango, M., and Ukita, T. Adoption of HPV testing as an adjunct to conventional cytology in cervical cancer screening in Japan. *International Journal of Gynaecology & Obstetrics*. 2010;111(2):110-114.

Kirschner, B., Poll, S., Rygaard, C., Wahlin, A., and Junge, J. Screening history in women with cervical cancer in a Danish population-based screening program. *Gynecologic Oncology*. 2011;120(1):68-72.

Monsonogo, J. The HPV test in clinical practice. [French]. *Contraception Fertilite Sexualite*. 1999;27(12):811-815.

No authors listed Cervical cancer screening. Organised screening to avoid unnecessary conisation. [Review]. *Prescrire International*. 2010;19(108):172-177.

Vassilakos, P., De, Marval F., and Munoz, M. [Cervical cancer screening. False negative smears]. [Review] [7 refs] [French]. *Revue Medicale de la Suisse Romande*. 1997;117(8):597-601.

Vijayaraghavan, A., Efrusy, M. B., Goodman, K. A., Santas, C. C., and Huh, W. K. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. *Gynecologic Oncology*. 2010;119(2):237-242.

Zucchetto, A., Franceschi, S., Clagnan, E., Serraino, D., Zanier, L., Franzo, A., and Friuli Venezia Giulia Cancer Registry Working Group Screening history of women with invasive cervical cancer in north-east Italy. *European Journal of Obstetrics, Gynecology, & Reproductive Biology*. 2010;152(2):200-204.

Level 4: Key Question

Baldauf, J.-J., Dreyfus, M., Ritter, J., Meyer, P., and Philippe, E. Screening histories of incidence cases of cervical cancer and high grade SIL: A comparison. *Acta Cytologica*. 1997;41(5):1431-1438.

Choconta-Piraquive, L. A., Alvis-Guzman, N., and Hoz-Restrepo, F. How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case. *BMC Health Services Research*. 2010;10:270-.

Cuzick, J., Beverley, E., Ho, L., Terry, G., Sapper, H., Mielzynska, I., Lorincz, A., Chan, W. K., Krausz, T., and Soutter, P. HPV testing in primary screening of older women. *British Journal of Cancer*. 1999;81(3):554-558.

Edmondson, R. J., Errington, C. A., and Mansour, D. J. Liquid based cytology improves the positive predictive value of glandular smears compared to conventional cytology. *European Journal of Gynaecological Oncology*. 2010;31(3):288-290.

Gram, I. T., Macaluso, M., and Stalsberg, H. Incidence of cervical intraepithelial neoplasia grade III, and cancer of the cervix uteri following a negative Pap-smear in an opportunistic screening. *Acta Obstetrica et Gynecologica Scandinavica*. 1998;77(2):228-232.

Jansson, A., Gustafsson, M., and Wilander, E. Efficiency of cytological screening for detection of cervical squamous carcinoma. A study in the county of Uppsala 1991-1994. *Uppsala Journal of Medical Sciences*. 1998;103(2):147-154.

Juneja, A., Murthy, N. S., Tuteja, R. K., Sardana, S., and Das, D. K. Reduction in the cumulative incidence rate of cervical cancer by one life time selective screening. *Neoplasma*. 1997;44(4):272-274.

Kenter, G. G., Schoonderwald, E. M., Koelma, I. A., Arentz, N., Hermans, J., and Fleuren, G. J. The cytological screening history of 469 patients with squamous cell carcinoma of the cervix uteri; does interval carcinoma exist?. *Acta Obstetrica et Gynecologica Scandinavica*. 1996;75(4):400-403.

Milne, D. S., Wadehra, V., Mennim, D., and Wagstaff, T. I. A prospective follow up study of women

with colposcopically unconfirmed positive cervical smears. *British Journal of Obstetrics & Gynaecology*. 1999;106(1):38-41.

Mittra, I., Mishra, G. A., Singh, S., Aranke, S., Notani, P., Badwe, R., Miller, A. B., Daniel, E. E., Gupta, S., Uplap, P., Thakur, M. H., Ramani, S., Kerkar, R., Ganesh, B., and Shastri, S. S. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. *International journal of cancer Journal international du cancer*. 2010;126(4):976-984.

Nenning, H., Horn, L.-C., Kuhndel, K., and Bilek, K. False positive cervical smears: A cytometric and histological study. *Analytical Cellular Pathology*. 1995;9(1):61-68.

Rebolj, M., Pribac, I., and Lynge, E. False-positive Human Papillomavirus DNA tests in cervical screening: it is all in a definition. *European Journal of Cancer*. 2011;47(2):255-261.

Summers, A. Mental, health consequences of cervical screening. *Psychology, Health and Medicine*. 1998;3(1):113-126.

van Wijngaarden, W. J., Duncan, I. D., and Hussain, K. A. Screening for cervical neoplasia in Dundee and Angus: 10 years on. *British Journal of Obstetrics & Gynaecology*. 1995;102(2):137-142.

Observational Excluded Studies List

Level 2: Cervical Cancer Screening as the Focus

Gynecologic Oncology. 2009;Conference: 40th Annual Meeting of the Society of Gynecologic Oncologists San Antonio, TX United States. Conference Start: 20090205 Conference End: 20090208.

Journal of Cancer Education. 2009; Conference: Joint Annual Meeting for AACE, CPEN, and EACE 2009 International Cancer Education Conference Houston, TX United States. Conference Start: 20091015 Conference End: 20091017.

ACOG Committee Opinion. Evaluation and management of abnormal cervical cytology and histology in the adolescent. Number 330, April 2006. *Obstetrics and Gynecology*. 2006;107(4):963-968.

ACOG Practice Bulletin #66: Management of abnormal cervical cytology and histology. *Obstetrics and Gynecology*. 2005;106(3):645-663.

ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). *Obstetrics and Gynecology*. 2003;102(2):417-427.

Are we there yet?. *Laboratory Medicine*. 2005;36(11):694-732.

Cervical cancer - Clinical management guidelines. *Oncology Forum*. 2003;6(2):14-15.

Cervical cancer prevention in low-resource settings. *International Journal of Gynecology and Obstetrics*. 2005;90(1):86-87.

Challenges ahead for cervical cancer screening. *European journal of cancer (Oxford, England : 1990)*. 2007;43(6):969-970.

Committee opinion no. 467: human papillomavirus vaccination. *Obstetrics and Gynecology*. 2010;116(3):800-803.

Erratum: Cost-effectiveness of cervical-cancer screening in developing countries (New England Journal of Medicine (April 6, 2006) 354 (1535-1536)). New England Journal of Medicine. 2006;355(7):745.

Every encounter is an opportunity for recommending breast and cervical cancer screening in women. Alaska Breast & Cervical Cancer Early Detection Program. Alaska medicine. 2000;42(2):46-47.

Expanded use of HPV test. FDA consumer. 2003;37(3):4-Jun.

Gatekeepers provide positive influence on mammography, Pap screening rates. Capitation rates & data. 2006;11(1):5-7.

Human papillomavirus. A major cause of cervical cancer. Mayo Clinic women's healthsource. 2006;10(5):6.

Human papillomavirus. Obstetrics and Gynecology. 2005;105(4):905-918.

JAMA Patient Page: cervical cancer. JAMA : the journal of the American Medical Association. 2000;283(8):1094.

Management of abnormal pap smear--consensus guidelines of the National Cervical Cancer Screening Programme in Poland Coordinating Centre, the Polish Gynaecological Society, the Polish Society of Pathologists, and Polish Society of Colposcopy and Uterine Cervix Pathology. Ginekologia polska. 2009;80(2):129-138.

Management of abnormal uterine cervix smears (2). [French]. Medecine et Hygiene. 2003;61(2446):1526.

Most older adults do not receive preventive health services. Drug Benefit Trends. 2009;21(11):339.

New way to detect cervical cancer. The Canadian nurse. 2001;97(5):10.

Now that I'm 65, can I stop getting Pap tests?. Mayo Clinic women's healthsource. 2006;10(6):10.

Prevention of cervical cancer. Guidelines. [French]. Journal de gynecologie, obstetrique et biologie de la reproduction. 2008;37 Suppl 1:S167-S172.

Recommendations for Client- and Provider-Directed Interventions to Increase Breast, Cervical, and Colorectal Cancer Screening. American Journal of Preventive Medicine. 2008;35(1 SUPPL.):S21-S25.

Screening based on papillomavirus detection: too many false alarms. Prescrire international. 2010;19(108):178-179.

Summaries for patients. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Annals of internal medicine. 2009;151(8):I36.

Summaries for patients. Results of Pap smears and human papillomavirus tests during cervical cancer screening. Annals of internal medicine. 2008;148(7):I32.

Testing for human papillomavirus during a Pap test. Mayo Clinic women's healthsource. 2003;7(10):3.

The cervical cancer vaccine. A new vaccine promises to save lives, but won't replace the Pap test. *Harvard health letter / from Harvard Medical School*. 2006;31(11):1-2.

Timely breast, cervical cancer screening improves with managed care penetration. *Capitation rates & data*. 2006;11(2):21-24.

Two techniques for cervical smear sampling. *Prescrire international*. 2010;19(108):176.

Vaccination against human papillomavirus. *Drug and Therapeutics Bulletin*. 2008;46(12):89-93.

What is the HPV test?. [French]. *La Revue du praticien*. 2006;56(17):1920.

AbdullGaffar, B., Kamal, M. O., Khalid, M., Samuel, R., and AlGhufli, R.. Atypical bare nuclei in liquid-based cervical cytology and their significance. *Acta Cytologica*. 2009;53(6):637-643.

Acosta-Mesa, H. G., Cruz-Ramirez, N., and Hernandez-Jimenez, R.. Aceto-white temporal pattern classification using k-NN to identify precancerous cervical lesion in colposcopic images. *Computers in Biology and Medicine*. 2009;39(9):778-784.

Aerssens, A., Claeys, P., Beerens, E., Garcia, A., Weyers, S., Van, Renterghem L., Praet, M., Temmerman, M., Velasquez, R., and Cuvelier, C. A.. Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia. *Cytopathology*. 2009;20(1):27-35.

Agorastos, T., Dinas, K., Lloveras, B., Font, R., Kornegay, J. R., Bontis, J., and De, Sanjose S.. Self-sampling versus physician-sampling for human papillomavirus testing. *International Journal of STD and AIDS*. 2005;16(11):727-729.

Ahmidat, A. and Tailor, A.. Unusual presentation of vaginal foreign body. *Journal of Obstetrics and Gynaecology*. 2010;30(8):873-875.

Akers, A. Y., Newmann, S. J., and Smith, J. S.. Factors Underlying Disparities in Cervical Cancer Incidence, Screening, and Treatment in the United States. *Current Problems in Cancer*. 2007;31(3):157-181.

Alibhai, S. M. H.. Cancer screening: The importance of outcome measures. *Critical Reviews in Oncology/Hematology*. 2006;57(3):215-224.

Alonzo, T. A.. Comparing accuracy in an unpaired post-market device study with incomplete disease assessment. *Biometrical Journal*. 2009;51(3):491-503.

Alsharif, M., Kjeldahl, K., Curran, C., Miller, S., Gulbahce, H. E., and Pambuccian, S. E.. Clinical significance of the diagnosis of low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion. *Cancer cytopathology*. 2009;117(2):92-100.

Ananth, R.. Downstaging of cervical cancer. *Journal of the Indian Medical Association*. 2000;98(2):41-44.

Anderson, S. M.. Human papillomavirus and cervical cancer. *Clinical Microbiology Newsletter*. 2002;24(15):113-118.

Antonishyn, N. A., Horsman, G. B., Kelln, R. A., and Severini, A.. Human papillomavirus typing and viral gene expression analysis for the triage of women with abnormal results from papanicolaou test smears to colposcopy. *Archives of Pathology and Laboratory Medicine*. 2009;133(10):1577-1586.

Anttila, A. and Ronco, G.. Description of the national situation of cervical cancer screening in

the member states of the European Union. *European Journal of Cancer*. 2009;45(15):2685-2708.

Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., Wiener, H., Herbert, A., and von, Karsa L.. European guidelines for quality assurance in cervical cancer screening. Second edition-summary document. *Annals of Oncology*. 2010;21(3):448-458.

Armstrong, C.. Practice guidelines: ACIP releases recommendations on quadrivalent human papillomavirus vaccine. *American Family Physician*. 2007;75(9):1391-1394.

Armstrong, E. P.. Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic HPV types. *Journal of Managed Care Pharmacy*. 2010;16(3):217-230.

Atahan, S., Ekinci, C., Icli, F., and Erdogan, N.. Cytology of clear cell carcinoma of the female genital tract in fine needle aspirates and ascites. *Acta Cytologica*. 2000;44(6):1005-1009.

Aubin, F.. Human papillomavirus infection. Screening, treatment and vaccination. [French]. *Revue du Praticien*. 2006;56(17):1875-1876.

Austin, R. and Zhao, C.. Test group biases and ethical concerns mar New England Journal of Medicine articles promoting HPV screening for cervical cancer in rural India. *CytoJournal*. 2009;6 , 2009. Article Number: 12. Date of Publication: 2009.

Austin, R. M., Onisko, A., and Druzdzel, M. J.. The pittsburgh cervical cancer screening model a risk assessment tool. *Archives of Pathology and Laboratory Medicine*. 2010;134(5):744-750.

Avgeris, M., Mavridis, K., and Scorilas, A.. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. *Biological Chemistry*. 2010;391(5):505-511.

Azaiza, F. and Cohen, M.. Between traditional and modern perceptions of breast and cervical cancer screenings: A qualitative study of Arab women in Israel. *Psycho-Oncology*. 2008;17(1):34-41.

Balasubramani, L., Orbell, S., Hagger, M., Brown, V., and Tidy, J.. Do women with high-grade cervical intraepithelial neoplasia prefer a see and treat option in colposcopy?. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2007;114(1):39-45.

Baldauf, J.-J., Baulon, E., and Fender, M.. Screening of cervical lesions in 2007: Defense of the smears. [French]. *Revue du Praticien - Gynecologie et Obstetrique*. 2007;#volume#(113):24-25.

Balducci, L.. Prevention of cancer in the older person. *Cancer Journal*. 2005;11(6):442-448.

Barbee, L., Kobetz, E., Menard, J., Cook, N., Blanco, J., Barton, B., Auguste, P., and McKenzie, N.. Assessing the acceptability of self-sampling for HPV among haitian immigrant women: CBPR in action. *Cancer Causes and Control*. 2010;21(3):421-431.

Baron, R. C., Rimer, B. K., Breslow, R. A., Coates, R. J., Kerner, J., Melillo, S., Habarta, N., Kalra, G. P., Chattopadhyay, S., Wilson, K. M., Lee, N. C., Mullen, P. D., Coughlin, S. S., and Briss, P. A.. Client-Directed Interventions to Increase Community Demand for Breast, Cervical, and Colorectal Cancer Screening. A Systematic Review. *American Journal of Preventive Medicine*. 2008;35(1 SUPPL.):S34-S55.

Baron, R. C., Rimer, B. K., Coates, R. J., Kerner, J., Mullen, P. D., Chattopadhyay, S., and Briss, P. A.. Methods for Conducting Systematic Reviews of Evidence on Effectiveness and

Economic Efficiency of Interventions to Increase Screening for Breast, Cervical, and Colorectal Cancers. *American Journal of Preventive Medicine*. 2008;35(1 SUPPL.):S26-S33.

Bartholomew, D. A.. Human papillomavirus infection in adolescents: A rational approach. *Adolescent Medicine Clinics*. 2004;15(3):569-595.

Basen-Engquist, K., Fouladi, R. T., Cantor, S. B., Shinn, E., Sui, D., Sharman, M., and Follen, M.. Patient assessment of tests to detect cervical cancer. *International Journal of Technology Assessment in Health Care*. 2007;23(2):240-247.

Bastos, J., Peleteiro, B., Gouveia, J., Coleman, M. P., and Lunet, N.. The state of the art of cancer control in 30 European countries in 2008. *International Journal of Cancer*. 2010;126(11):2700-2715.

Basu, P., Roychowdhury, S., Bafna, U. D., Chaudhury, S., Kothari, S., Sekhon, R., Saranath, D., Biswas, S., Gronn, P., Silva, I., Siddiqi, M., and Ratnam, S.. Human papillomavirus genotype distribution in cervical cancer in India: Results from a multi-center study. *Asian Pacific Journal of Cancer Prevention*. 2009;10(1):27-34.

Baudier, F., Schapman, S., and Giordanella, J. P.. The recommendations of experimental sites to implement the organized screening for cervical cancer in France. [French]. *Sante Publique*. 2000;12(SPEC. ISS.):71-88.

Bayas, J.-M., Costas, L., and Munoz, A.. Cervical cancer vaccination indications, efficacy, and side effects. *Gynecologic Oncology*. 2008;110(3 SUPPL.2):S11-S14.

Bedford, S.. Cervical cancer: physiology, risk factors, vaccination and treatment. *British journal of nursing (Mark Allen Publishing)*. 2009;18(2):80-84.

Bekova, A. and Kobilkova, J.. Cytopathology in the Czech Republic. *Cytopathology*. 2005;16(3):147-149.

Belinson, S. E. and Belinson, J. L.. Human papillomavirus DNA testing for cervical cancer screening: Practical aspects in developing countries. *Molecular Diagnosis and Therapy*. 2010;14(4):215-222.

Ben, Gobrane H., Aounallah-Skhiri, H., Oueslati, F., Frikha, H., Achour, N., and Hsairi, M.. Estimated cost of managing invasive cervical cancer in Tunisia. [French]. *Sante publique (Vandoeuvre-les-Nancy, France)*. 2009;21(6):561-569.

Berek, J. S.. Cervical cancer: an opportunity to prevent and cure. *Cancer journal (Sudbury, Mass.* 2003;). 9(5):325-326.

Bergeron, C.. How are the recommendations on cervical cancer screening in 2007 followed?. [French]. *Revue du Praticien - Gynecologie et Obstetrique*. 2007;#volume#(113):29-31.

Berman, M. L.. Advances in cervical cancer management from North American Cooperative Group Clinical Trials. *Yonsei Medical Journal*. 2002;43(6):729-736.

Berman, N. R.. Cervical cancer screening today. The role of HPV DNA testing. *Advance for nurse practitioners*. 2006;14(4):24-29.

Birdsong, G. G.. Pap smear adequacy: Is our understanding satisfactory... or limited?. *Diagnostic Cytopathology*. 2001;24(2):79-81.

Biswas, A.. Human papillomavirus (HPV) and cervical cancer. *Journal of the Indian Medical*

Association. 2000;98(2):53-55.

Black, M. E., Frisina, A., Hack, T., and Carpio, B.. Improving early detection of breast and cervical cancer in Chinese and Vietnamese immigrant women. *Oncology nursing forum*. 2006;33(5):873-876.

Blair, A. R. and Casas, C. M.. *Gynecologic Cancers. Primary Care - Clinics in Office Practice*. 2009;36(1):115-130.

Bleyer, A. and Barr, R.. *Cancer in Young Adults 20 to 39 Years of Age: Overview. Seminars in Oncology*. 2009;36(3):194-206.

Boardman, L. A. and Fuchs, K.. *Young woman with HPV? Different risks. Sexuality, Reproduction and Menopause*. 2008;6(1):11-15.

Bomfim, S., Santana-Franco, E., and Bahamondes, L.. *Visual inspection with acetic acid for cervical cancer detection. International Journal of Gynecology and Obstetrics*. 2005;88(1):65-66.

Bond, S.. *When Compared With Other Medically-Related Television News, HPV Vaccination Receives a Modest Amount of Coverage. Journal of Midwifery and Women's Health*. 2010;55(1):81-82.

Bonfiglio, T. A.. *Atypical squamous cells of undetermined significance: A continuing controversy. Cancer*. 2002;96(3):125-127.

Bonnez, W.. *Immunization against genital human papillomaviruses. Pediatric Infectious Disease Journal*. 2005;24(11):1005-1006.

Borlado, L. R. and Mendez, J.. *CDC6: From DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis*. 2008;29(2):237-243.

Bosch, F. X., Castellsague, X., and De, Sanjose S.. *HPV and cervical cancer: Screening or vaccination?. British Journal of Cancer*. 2008;98(1):15-21.

Bosch, X. and Harper, D.. *Prevention strategies of cervical cancer in the HPV vaccine era. Gynecologic Oncology*. 2006;103(1):21-24.

Botha, M. H.. *Human Papilloma Virus and cervical cancer: The link is now clear. Obstetrics and Gynaecology Forum*. 2008;18(1):25-28.

Boulangier, J.-C., Sevestre, H., Bauville, E., Ghighi, C., Harlicot, J.-P., and Gondry, J.. *Epidemiology of HPV infection. [French]. Gynecologie Obstetrique Fertilité*. 2004;32(3):218-223.

Boulangier, J.-C.. *Organization of cervical cancer screening: What is needed to change?. [French]. Revue du Praticien - Gynecologie et Obstetrique*. 2006;(104):27-34.

Boulangier, J.-C.. *Should cervical cancer screening undergo some changes?. [French]. Gynecologie Obstetrique Fertilité*. 2009;37(7-8):669-670.

Bowen, S. A., Heidari, K., Byrd, M. D., Swayampakala, K., Young, V. M., and Gibson, J. J.. *The epidemiological profile of South Carolina women who do not receive regular pap test: improving access to care. Journal of the South Carolina Medical Association (1975)*. 2009;105(7):246-253.

- Boyle, P., Leon, M. E., Maisonneuve, P., and Autier, P.. Cancer control in women. Update 2003. *International Journal of Gynecology and Obstetrics*. 2003;83(SUPPL 1):179-202.
- Bradley, J., Barone, M., Mahe, C., Lewis, R., and Luciani, S.. Delivering cervical cancer prevention services in low-resource settings. *International Journal of Gynecology and Obstetrics*. 2005;89(SUPPL. 2):S21-S29.
- Breitkopf, C. R. and Pearson, H. C.. A theory-based approach to understanding follow-up of abnormal pap tests. *Journal of health psychology*. 2009;14(3):361-371.
- Breslow, R. A., Rimer, B. K., Baron, R. C., Coates, R. J., Kerner, J., Wilson, K. M., Lee, N. C., Mullen, P. D., Coughlin, S. S., and Briss, P. A.. Introducing the Community Guide's Reviews of Evidence on Interventions to Increase Screening for Breast, Cervical, and Colorectal Cancers. *American Journal of Preventive Medicine*. 2008;35(1 SUPPL.):S14-S20.
- Brinkman, J. A., Caffrey, A. S., Muderspach, L. I., Roman, L. D., and Kast, W. M.. The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: Consequences for clinical management. *European Journal of Gynaecological Oncology*. 2005;26(2):129-142.
- Brinkmann, D., Gladman, M. A., Norman, S., and Lawton, F. G.. Why do women still develop cancer of the cervix despite the existence of a national screening programme?. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2005;119(1):123-124.
- Brismar-Wendel, S., Froberg, M., Hjerpe, A., Andersson, S., and Johansson, B.. Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. *British Journal of Cancer*. 2009;101(3):511-517.
- Bruno, Zappacosta J., Romano, L., Guerriero, M., Graziano, M., Vitrani, A., De, Ninno M., and Carbone, A.. Detection of 14 human papillomavirus genotypes in cervical samples in women from a central-southern area of Italy showing different Pap test results. *New Microbiologica*. 2009;32(4):351-358.
- Bryder, L.. Debates about cervical screening: An historical overview. *Journal of Epidemiology and Community Health*. 2008;62(4):284-287.
- Burnett, A. F.. A typical glandular cells of undetermined significance Pap smears: Appropriate evaluation and management. *Current Opinion in Obstetrics and Gynecology*. 2000;12(1):33-37.
- Burnett, A. F.. Atypical glandular cells of undetermined significance Pap smears: appropriate evaluation and management. *Current opinion in obstetrics & gynecology*. 2000;12(1):33-37.
- Buster, J. E. and Heard, M. J.. Current issues in medical management of ectopic pregnancy. *Current Opinion in Obstetrics and Gynecology*. 2000;12(6):525-527.
- Bynum, S. A., Wright, M. S., Brandt, H. M., Burgis, J. T., and Bacon, J. L.. Knowledge, beliefs, and attitudes related to human papillomavirus infection and vaccination, pap tests, and cervical intraepithelial neoplasia among adolescent girls and young women. *Journal of the South Carolina Medical Association (1975)*. 2009;105(7):267-272.
- Cain, J. M. and Howett, M. K.. Preventing cervical cancer. *Science*. 2000;288(5472):1753-1754.
- Campos-Outcalt, D.. The case for HPV immunization. *Journal of Family Practice*.

2009;58(12):660-664.

Cardenas-Turanzas, M., Follen, M., Benedet, J.-L., and Cantor, S. B.. See-and-treat strategy for diagnosis and management of cervical squamous intraepithelial lesions. *Lancet Oncology*. 2005;6(1):43-50.

Carter, J.. An experience with transvaginal sonography in gynaecologic tumour surveillance. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. 2000;40(4):438-441.

Castellsague, X.. Natural history and epidemiology of HPV infection and cervical cancer. *Gynecologic Oncology*. 2008;110(3 SUPPL.2):S4-S7.

Castle, P. E., Solomon, D., Saslow, D., and Schiffman, M.. Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. *Cancer*. 2008;113(10 SUPPL.):3031-3035.

Chaturvedi, S., Radhakrishnan, G., Singh, R. A., Desai, N. G., Bhatia, A., and Thakur, R.. Higher rate of benign cellular changes of uterine cervix in women with chronic mental illness. *Tropical Doctor*. 2004;34(3):186-187.

Chen, L.-M., Rubin, M., and Smith-McCune, K.. Screening and treatment of HPV-related diseases in gynecologic practice. *Seminars in Colon and Rectal Surgery*. 2005;15(4 SPEC. ISS.):201-209.

Cheng, W.-F.. Human papillomavirus vaccine for cervical cancer: Where are we now?. *Taiwanese Journal of Obstetrics and Gynecology*. 2005;44(3):232-241.

Chin-Hong, P. V. and Klausner, J. D.. New diagnostic tests for HPV in the developed and the developing world. *MLO: medical laboratory observer*. 2008;40(11):48, 50, 52-48, 50, 53.

Chumworathayi, B. and Tomuen, C.. Can pap smear exclude the need for colposcopy in referred VIA-positive cases?. *International Journal of Cancer Prevention*. 2008;2(5):357-361.

Church, J. M.. Colon cancer screening update and management of the malignant polyp. *Clinics in Colon and Rectal Surgery*. 2005;18(3):141-149.

Chute, D. J., Lim, H., and Kong, C. S.. BD focalpoint slide profiler performance with atypical glandular cells on SurePath Papanicolaou smears. *Cancer cytopathology*. 2010;118(2):68-74.

Cid-Arregui, A.. Prophylactic HPV vaccines. *Open Vaccine Journal*. 2009;2:123-133.

Coleman, N. and Laskey, R. A.. Minichromosome maintenance proteins in cancer screening. *European Journal of Cancer*. 2009;45(SUPPL. 1):416-417.

Cornuz, J., Gervasoni, J.-P., Hengstler, P., Battegay, M., and Battegay, E.. Preventive health services in adults: Clinical recommendations in 2002. [French]. *Medecine et Hygiene*. 2002;60(2411):2008-2016.

Coughlin, L.. American Cancer Society releases annual guidelines for the early detection of cancer. *American Family Physician*. 2005;71(11):2202-2205.

Coupe, V. M., Berkhof, J., Verheijen, R. H., and Meijer, C. J.. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2007;114(4):416-424.

- Coutlee, F., Rouleau, D., Ferenczy, A., and Franco, E.. The laboratory diagnosis of genital human papillomavirus infections. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2005;16(2):83-91.
- Creasman, W. T.. Vaginal cancers. *Current Opinion in Obstetrics and Gynecology*. 2005;17(1):71-76.
- Croll, E., Rana, D. N., and Walton, L. J.. Hyperchromatic crowded cell groups in gynaecological liquid-based cytology samples. *British Journal of Biomedical Science*. 2010;67(3):154-163.
- Crum, C. P., Abbott, D. W., and Quade, B. J.. Cervical cancer screening: from the Papanicolaou smear to the vaccine era. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2003;21(10 Suppl):224s-230s.
- Cullati, S., Charvet-Berard, A. I., and Perneger, T. V.. Cancer screening in a middle-aged general population: factors associated with practices and attitudes. *BMC Public Health*. 2009;9:118.
- Cuzick, J.. Long-term cervical cancer prevention strategies across the globe. *Gynecologic Oncology*. 2010;117(2 SUPPL.):S11-S14.
- Cuzick, J.. Routine audit of large-scale cervical cancer screening programs. *Journal of the National Cancer Institute*. 5-7-2008;100(9):605-606.
- Dakubo, G. D., Jakupciak, J. P., Birch-Machin, M. A., and Parr, R. L.. Clinical implications and utility of field cancerization. *Cancer Cell International*. 2007;7 , 2007. Article Number: 2. Date of Publication: 15 Mar 2007.
- Dal, Maso L., Polesel, J., Serraino, D., Lise, M., Piselli, P., Falcini, F., Russo, A., Intriери, T., Vercelli, M., Zambon, P., Tagliabue, G., Zanetti, R., Federico, M., Limina, R. M., Mangone, L., De, Lisi, V., Stracci, F., Ferretti, S., Piffer, S., Budroni, M., Donato, A., Giacomini, A., Bellu, F., Fusco, M., Madeddu, A., Vitarelli, S., Tessandori, R., Tumino, R., Suligoj, B., and Franceschi, S.. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. *British Journal of Cancer*. 2009;100(5):840-847.
- Daley, E. M., Perrin, K. M., McDermott, R. J., Vamos, C. A., Rayko, H. L., Packing-Ebuen, J. L., Webb, C., and McFarlane, M.. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV+ women. *Journal of health psychology*. 2010;15(2):279-290.
- Dallred, C.. Cervical cancer screening in older women. *Clinical journal of oncology nursing*. 2006;10(1):31-33.
- D'Alo, D., Stracci, F., Cassetti, T., Scheibel, M., Pascucci, C., and La, Rosa F.. Recent trends in incidence, mortality and survival after cancer of the female breast and reproductive organs. Umbria, Italy: 1978-2005. *European Journal of Gynaecological Oncology*. 2010;31(2):174-180.
- Dalton, S. O., Laursen, T. M., Ross, L., Mortensen, P. B., and Johansen, C.. Risk for hospitalization with depression after a cancer diagnosis: A nationwide, population-based study of cancer patients in Denmark from 1973 to 2003. *Journal of Clinical Oncology*. 2009;27(9):1440-1445.
- Das, I. P., Messias, D. K., Parra-Medina, D., Luchok, K., and Richter, D. L.. Making it happen: low-income African American women's follow-up to abnormal pap tests. *Journal of the South*

- Carolina Medical Association (1975). 2009;105(7):254-259.
- Das, N., Sutton, V., Bevan, J., Brinkmann, D., and Woolas, R.. Cytological follow-up of women older than 50 years with high-grade cervical smear treated by large loop excision. *Journal of Lower Genital Tract Disease*. 2009;13(3):165-168.
- Dasari, P., Rajathi, S., and Kumar, S.. Colposcopic evaluation of cervix with persistent inflammatory Pap smear: A prospective analytical study. *CytoJournal*. 2010;7 , 2010. Article Number: 16. Date of Publication: 2010.
- Datta, P., Bhatla, N., Dar, L., Patro, A. R., Gulati, A., Kriplani, A., and Singh, N.. Prevalence of human papillomavirus infection among young women in North India. *Cancer Epidemiology*. 2010;34(2):157-161.
- Davey, E., Irwig, L., Macaskill, P., Clarke, J., Thurloe, J., Hyne, S., and Biro, C.. Does providing previous results change the accuracy of cervical cytology?. *Acta Cytologica*. 2009;53(6):644-652.
- Davies, P., Kornegay, J., and Iftner, T.. Current methods of testing for human papillomavirus. *Best Practice and Research in Clinical Obstetrics and Gynaecology*. 2001;15(5):677-700.
- Davy, M.. Where we have travelled in cervical cancer protection. *Cancer Forum*. 2008;32(2):105-107.
- Dawar, M., Deeks, S., and Dobson, S.. Human papillomavirus vaccines launch a new era in cervical cancer prevention. *Canadian Medical Association Journal*. 2007;177(5):456-461.
- De, Alba, I, Anton-Culver, H., Hubbell, F. A., Ziogas, A., Hess, J. R., Bracho, A., Arias, C., and Manetta, A.. Self-sampling for human papillomavirus in a community setting: Feasibility in Hispanic women. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(8):2163-2168.
- De, Palo G.. Cervical precancer and cancer, past, present and future. *European Journal of Gynaecological Oncology*. 2004;25(3):269-278.
- Denny, L. and Ngan, H. Y. S.. Section B: Malignant manifestations of HPV infection
Carcinoma of the cervix, vulva, vagina, anus, and penis. *International Journal of Gynecology and Obstetrics*. 2006;94(SUPPL. 1):S50-S55.
- Denny, L.. The prevention of cervical cancer in developing countries. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2005;112(9):1204-1212.
- Dewilde, S. and Anderson, R.. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: A comparison using a model of cervical cancer. *Medical Decision Making*. 2004;24(5):486-492.
- di Paola, G. R.. History of the International Federation of Cervical Pathology and Colposcopy (IFCPC). *European Journal of Gynaecological Oncology*. 2009;30(2):117-123.
- Diem, K., Spitzer, M., Twiggs, L. B., Cox, J. T., Kaufman, R. H., Moscicki, A. B., and Rubin, M.. A 23-year-old woman has her first Pap smear, thin prep smear interpreted as "high grade squamous intraepithelial lesion". *Journal of Lower Genital Tract Disease*. 2008;12(1):54-58.
- Dillner, J.. Primary screening for human papillomavirus infection. *Best Practice and Research in Clinical Obstetrics and Gynaecology*. 2001;15(5):743-757.

- Ding, L., Zou, X.-J., Ao, J.-E., Yao, A.-X., and Cai, L.. ELISA test to detect CDKN2A (p16INK4a) expression in exfoliative cells: A new screening tool for cervical cancer. *Molecular Diagnosis and Therapy*. 2008;12(6):395-400.
- Dixon, E. P., Lenz, K. L., Doobay, H., Brown, C. A., Malinowski, D. P., and Fischer, T. J.. Recovery of DNA from BD SurePath cytology specimens and compatibility with the Roche AMPLICOR Human Papillomavirus (HPV) Test. *Journal of Clinical Virology*. 2010;48(1):31-35.
- Dreyer, G., Snyman, L. C., Mouton, A., and Lindeque, B. G.. Management of recurrent cervical cancer. *Best Practice and Research in Clinical Obstetrics and Gynaecology*. 2005;19(4 SPEC. ISS.):631-644.
- Drijkoningen, M., Bogers, J.-P., Bourgain, C., Cuvelier, C., Delvenne, P., Gompel, C., Saerens, L., Thienpont, L., Van, Damme B., Van, Eycken L., Verhest, A., and Weynand, B.. Cytopathology in Belgium. *Cytopathology*. 2005;16(2):100-104.
- Duncan, P. M., Duncan, E. D., and Swanson, J.. Bright futures: The screening table recommendations. *Pediatric Annals*. 2008;37(3):152-158.
- Dunleavey, R.. Incidence, pathophysiology and treatment of cervical cancer. *Nursing times*. 2004;100(44):38-41.
- Dunne, E. F. and Markowitz, L. E.. Genital human papillomavirus infection. *Clinical Infectious Diseases*. 2006;43(5):624-629.
- Dzuba, I. G., Calderon, R., Bliesner, S., Luciani, S., Amado, F., and Jacob, M.. A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia. *Revista Panamericana de Salud Publica/Pan American Journal of Public Health*. 2005;18(1):53-63.
- Ellis, P., Ciliska, D., Sussman, J., Robinson, P., Armour, T., Brouwers, M., O'Brien, M. A., and Raina, P.. A systematic review of studies evaluating diffusion and dissemination of selected cancer control interventions. *Health Psychology*. 2005;24(5):488-500.
- Ersahin, C., Yong, S., and Wojcik, E. M.. *Alternaria* spp. in the pap test of a 25 year-old woman. *Diagnostic Cytopathology*. 2006;34(5):349.
- Evans, M. I., Galen, R. S., and Britt, D. W.. Principles of screening. *Seminars in Perinatology*. 2005;29(6):364-366.
- Eversole, G. M., Moriarty, A. T., Schwartz, M. R., Clayton, A. C., Souers, R., Fatheree, L. A., Chmara, B. A., Tench, W. D., Henry, M. R., and Wilbur, D. C.. Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. *Archives of Pathology and Laboratory Medicine*. 2010;134(3):331-335.
- Ezat, W. P. and Aljunid, S.. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2010;11(1):79-90.
- Farrer, F.. Cancer screening in primary care. *SA Pharmaceutical Journal*. 2010;77(9):41-45.
- Feeley, C.. Advances in cervical cancer screening and human papillomavirus vaccines. *Journal of the British Menopause Society*. 2006;12(1):19-23.
- Fernandez, M. E., Gonzales, A., Tortolero-Luna, G., Partida, S., and Bartholomew, L. K.. Using

intervention mapping to develop a breast and cervical cancer screening program for Hispanic farmworkers: *Cultivando La Salud. Health promotion practice.* 2005;6(4):394-404.

Fisher, J. W. and Brundage, S. I.. The challenge of eliminating cervical cancer in the United States: a story of politics, prudishness, and prevention. *Women & health.* 2009;49(2-3):246-261.

Flanagan, M.. HPV testing in cervical cancer screening: A pathologist's perspective. *Community Oncology.* 2009;6(6):253-254.

Flores, K. and Bencomo, C.. Preventing cervical cancer in the Latina population. *Journal of women's health (2002).* 2009;18(12):1935-1943.

Forbes, K. A.. Memoirs inspire effort to eradicate human papillomavirus. *Clinical journal of oncology nursing.* 2009;13(6):615-616.

Fortenberry, J. D.. Sexually transmitted infections. *Pediatric Annals.* 2005;34(10):803-810.

Fowler, C.. Smears reported as code 6-glandular abnormality--are associated with a high probability of a clinically significant lesion. *Cytopathology.* 2007;18(1):64.

Franco, E. L. and Ferenczy, A.. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. *Future Oncology.* 2007;3(3):319-327.

Franco, E. L., Coutlee, F., and Ferenczy, A.. Integrating human papillomavirus vaccination in cervical cancer control programmes. *Public Health Genomics.* 2009;12(5-6):352-361.

Franco, E. L., Mahmud, S. M., Tota, J., Ferenczy, A., and Coutlee, F.. The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change. *Archives of Medical Research.* 2009;40(6):478-485.

Frisch, L. L., Allen, G. D., Padonu, G., Dontje, K. J., and Burhansstipanov, L.. Social influences on Pap smear screening frequency. *Alaska medicine.* 2000;42(2):41-45, 47.

Gakidou, E., Nordhagen, S., and Obermeyer, Z.. Coverage of cervical cancer screening in 57 countries: Low average levels and large inequalities. *PLoS Medicine.* 2008;5(6):0863-0868.

Gallwas, J., Ditsch, N., Hillemanns, P., Friese, K., Thaler, C., and Dannecker, C.. The significance of HPV in the follow-up period after treatment for CIN. *European Journal of Gynaecological Oncology.* 2010;31(1):27-30.

Gander, S., Scholten, V., Osswald, I., Sutton, M., and van, Wylick R.. Cervical Dysplasia and Associated Risk Factors in a Juvenile Detainee Population. *Journal of Pediatric and Adolescent Gynecology.* 2009;22(6):351-355.

Garland, S. M.. Human papillomavirus vaccines: Challenges to implementation. *Sexual Health.* 2006;3(2):63-65.

Giuliano, A. R., Papenfuss, M. R., Denman, C. A., Guernsey De, Zapien J., Abrahamsen, M., and Hunter, J. B.. Human papillomavirus prevalence at the USA-Mexico border among women 40 years of age and older. *International Journal of STD and AIDS.* 2005;16(3):247-251.

Glass, R. M.. Human papillomavirus infection. *Journal of the American Medical Association.* 2007;297(8):912.

Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Xavier, Bosch F., and

- Franco, E.. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. *Journal of the National Cancer Institute*. 2004;96(8):604-615.
- Goldie, S. J.. Chapter 15: Public health policy and cost-effectiveness analysis. *Journal of the National Cancer Institute*. 2003;Monographs.(31):102-110.
- Grabe, N., Lahrmann, B., Pommerencke, T., Von Knebel, Doeberitz M., Reuschenbach, M., and Wentzensen, N.. A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides. *Cellular Oncology*. 2010;32(1-2):109-119.
- Gravitt, P. E., Coutlee, F., Iftner, T., Sellors, J. W., Quint, W. G. V., and Wheeler, C. M.. *New Technologies in Cervical Cancer Screening. Vaccine*. 2008;26(SUPPL. 10):K42-K52.
- Gray, W., Bayer-Pietsch, E., Chieco, P., Cochand, Priollet B., Desai, M., Drijkoningen, M., Griffin, M., Hagmar, B., Kapila, K., Kloboves-Prevodnik, V., Kobayashi, T., Krogerus, L., Majak, B., Mihailovici, M., Olszewski, W., Schenck, U., Schmitt, F., Shabalova, I., Shapiro, N., Smith, J., Tani, E., Totsch, M., Vass, L., Wiener, H., and Herbert, A.. The future of cytopathology in Europe. Will the wider use of HPV testing have an impact on the provision of cervical screening?. *Cytopathology*. 2007;18(5):278-282.
- Grce, M.. Cervical cancer and human papillomavirus. *Balkan Journal of Medical Genetics*. 2005;8(1-2):19-25.
- Gupta, S., Chachra, K. L., Bhadola, P., and Sodhani, P.. Modified Papanicolaou staining protocol with minimum alcohol use: A cost-cutting measure for resource-limited settings. *Cytopathology*. 2010;21(4):229-233.
- Hager, W. D.. Human Papilloma Virus Infection and Prevention in the Adolescent Population. *Journal of Pediatric and Adolescent Gynecology*. 2009;22(4):197-204.
- Halder, K., Chachra, K. L., Sodhani, P., and Gupta, S.. Utility of imprint cytology for early presumptive diagnosis in clinically suspicious cervical cancer. *Acta Cytologica*. 2008;52(3):286-293.
- Hantz, S., Goudard, M., Marczuk, V., Renaudie, J., Dussartre, C., Bakeland, D., Denis, F., and Alain, S.. HPV detection and typing by INNO-LiPA assay on liquid cytology media Easyfix Labonord after extraction QIAamp DNA Blood Mini Kit Qiagen and Nuclisens easyMAG Biomerieux. [French]. *Pathologie Biologie*. 2010;58(2):179-183.
- Hardie, A., Moore, C., Patnick, J., Cuschieri, K., Graham, C., Beadling, C., Ellis, K., Frew, V., and Cubie, H. A.. High-risk HPV detection in specimens collected in SurePath preservative fluid: Comparison of ambient and refrigerated storage. *Cytopathology*. 2009;20(4):235-241.
- Hariharan, I. and Radhakrishna, Pillai M.. Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine. *Indian Journal of Medical Research*. 2009;130(3):247-260.
- Harper, D. M.. Are we closer to the prevention of HPV-related diseases?. *Journal of Family Practice*. 2005;54(SPEC. ISS.):s10-s16.
- Harper, D. M.. Current prophylactic HPV vaccines and gynecologic premalignancies. *Current opinion in obstetrics & gynecology*. 2009;21(6):457-464.
- Harry, V. N., Narayansingh, G. V., and Parkin, D. E.. Is this the end of the line for the moderate dyskaryotic smear?. *Journal of Lower Genital Tract Disease*. 2008;12(1):20-23.

- Hatch, K. D.. A3. Vaginal intraepithelial neoplasia (VAIN). *International Journal of Gynecology and Obstetrics*. 2006;94(SUPPL. 1):S40-S43.
- Head, S. K., Crosby, R. A., and Moore, G. R.. Pap Smear Knowledge Among Young Women Following the Introduction of the HPV Vaccine. *Journal of Pediatric and Adolescent Gynecology*. 2009;22(4):251-256.
- Heard, I.. Ano-genital lesions due to human papillomavirus infection in women. [French]. *Medecine et Maladies Infectieuses*. 2005;35(5 SPEC. ISS.):302-305.
- Heavey, E.. Start early to prevent genital HPV infection-and cervical cancer. *Nursing*. 2008;38(5):62-63.
- Heinan, M. L. and Clinical and Scientific Affairs Council of the AAPA. Cancer screening: Guidelines for cervical cytology. *JAAPA : official journal of the American Academy of Physician Assistants*. 2010;23(7):16, 18.
- Heise, A.. The clinical significance of HPV. *The Nurse practitioner*. 2003;28(10):8-19.
- Heley, S. and Brotherton, J.. Abnormal Pap tests after the HPV vaccine. *Australian family physician*. 2009;38(12):977-979.
- Henderson, H. J.. Why lesbians should be encouraged to have regular cervical screening. *Journal of Family Planning and Reproductive Health Care*. 2009;35(1):49-52.
- Henderson, J. W.. Cost-effectiveness of cervical cancer screening strategies. *Expert Review of Pharmacoeconomics and Outcomes Research*. 2004;4(3):287-296.
- Herbert, R.. What's new in nicotine & tobacco research?. *Nicotine and Tobacco Research*. 2005;7(6):817-820.
- Herod, J. J. O., Decruze, S. B., and Patel, R. D.. A report of two cases of the management of cervical cancer in pregnancy by cone biopsy and laparoscopic pelvic node dissection. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2010;117(12):1558-1561.
- Herzog, T. J. and Wright, J. D.. The impact of cervical cancer on quality of life-The components and means for management. *Gynecologic Oncology*. 2007;107(3):572-577.
- Hessel, L.. Introduction of vaccination against human papillomavirus in developing countries: update and perspectives. [French]. *Medecine tropicale : revue du Corps de sante colonial*. 2009;69(4):323-326.
- Hicks, M. L., Yap, O. W., Matthews, R., and Parham, G.. Disparities in cervical cancer screening, treatment and outcomes. *Ethnicity & disease*. 2006;16(2 Suppl 3):S3-S6.
- Hoda, R. S.. Non-gynecologic cytology on liquid-based preparations: A morphologic review of facts and artifacts. *Diagnostic Cytopathology*. 2007;35(10):621-634.
- Hong, J. H., Song, S. H., Kim, J. K., Han, J. H., and Lee, J. K.. Comparison of the novel human papillomavirus 4 auto-capillary electrophoresis test with the hybrid capture 2 assay and with the PCR HPV typing set test in the detection of high-risk HPV including HPV 16 and 18 genotypes in cervical specimens. *Journal of Korean medical science*. 2009;24(4):579-584.
- Horvath, C., Boulet, G., Sahebali, S., Bogers, J., Depuydt, C., Vereecken, A., Vermeulen, T., and Vanden Broeck, D.. Effects of fixation on RNA integrity in a liquid-based cervical cytology

setting. *Journal of clinical pathology*. 2008;61(1):132-137.

Howard, M., Sellors, J., and Lytwyn, A.. Cervical intraepithelial neoplasia in women presenting with external genital warts. *CMAJ Canadian Medical Association Journal*. 3-5-2002;166(5):598-599.

Howell-Jones, R., Bailey, A., Beddows, S., Sargent, A., De, Silva N., Wilson, G., Anton, J., Nichols, T., Soldan, K., and Kitchener, H.. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. *British Journal of Cancer*. 2010;103(2):209-216.

Hughes, C.. Cervical cancer: prevention, diagnosis, treatment and nursing care. *Nursing standard (Royal College of Nursing (Great Britain) : 1987)*. 2009;23(27):48-56.

Huh, W., Einstein, M. H., Herzog, T. J., and Franco, E. L.. What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?. *Gynecologic Oncology*. 2010;117(3):481-485.

Huijssoon, A., Sastrowijoto, P., and Ter, Harmsel B.. Papillary adenocarcinoma of the ovary presenting in a PAP-smear. *Acta Obstetricia et Gynecologica Scandinavica*. 2001;80(7):659-660.

Hunter, J. L.. Better late than never: Reflections on the delayed prioritization of cervical cancer in international health. *Health Care for Women International*. 2006;27(1):2-17.

Idotta, R., Fiorino, M. T., Surace, P., Arena, F., and Scopelliti, I.. Gynecological screening for HPV infection. *Clinical and Experimental Obstetrics and Gynecology*. 2007;34(4):242-243.

Iftner, T. and Villa, L. L.. Chapter 12: Human papillomavirus technologies. *Journal of the National Cancer Institute*. 2003;Monographs.(31):80-88.

Ikeda, R., Suga, K., and Suzuki, K.. MRI appearance of a leiomyoma of the female urethra. *Clinical Radiology*. 2001;56(1):76-79.

Ioffe, O. B.. Update on the diagnosis of noninvasive endocervical glandular neoplasia. *Pathology Case Reviews*. 2006;11(3):112-116.

Ioka, A., Tsukuma, H., Ajiki, W., and Oshima, A.. Influence of age on cervical cancer survival in Japan. *Japanese journal of clinical oncology*. 2005;35(8):464-469.

Ivanov, L. L., Hu, J., and Leak, A.. Immigrant women's cancer screening behaviors. *Journal of Community Health Nursing*. 2010;27(1):32-45.

Jalali, G. R., Herzog, T. J., Dziura, B., Walat, R., and Kilpatrick, M. W.. Amplification of the chromosome 3q26 region shows high negative predictive value for nonmalignant transformation of LSIL cytologic finding. *American Journal of Obstetrics and Gynecology*. 2010;202(6):581-581.

Jamison, J., Wilson, R. T., and Carson, J.. The evaluation of human papillomavirus genotyping in cervical liquid-based cytology specimens; Using the Roche Linear Array HPV genotyping assay. *Cytopathology*. 2009;20(4):242-248.

Jefferies, H.. Cervical cancer 1: an overview of screening and diagnosis. *Nursing times*. 2008;104(44):26-27.

Jefferies, H.. Cervical cancer 2: treatment options and side-effects. *Nursing times*. 2008;104(45):26-27.

Jhala, D. and Eltoum, I. Barriers to adoption of recent technology in cervical screening. *CytoJournal*. 2007;4 , 2007. Article Number: 16. Date of Publication: 2007.

Jones, H. E., Wiegerinck, M. A., Nieboer, T. E., Mol, B. W., and Westhoff, C. L.. Women in the Netherlands prefer self-sampling with a novel lavaging device to clinician collection of specimens for cervical cancer screening. *Sexually Transmitted Diseases*. 2008;35(11):916-917.

Jones, R. W., Best, D. V., Cox, B., Fitzgerald, N. W., Hill, M., Jennings, P., Peddie, D., and Sage, M. J.. Guidelines for the management of women with abnormal cervical smears 1998. *The New Zealand medical journal*. 2000;113(1109):168-171.

Jorda, E. G.. Interview with Dr. Ramon Colomer Bosch, president of the Spanish Society of Medical Oncology (SEOM). *Clinical and Translational Oncology*. 2008;10(6):310-312.

Joste, N.. Overview of the Cytology Laboratory: Specimen Processing Through Diagnosis. *Obstetrics and Gynecology Clinics of North America*. 2008;35(4):549-563.

Julian, T. M., Dexeus, S., Kitchener, H. C., and Shier, R. M.. Clinical question: ask the experts. A 45-year-old woman seeks treatment at your clinic with atypical squamous cells from Pap smear results. *Journal of Lower Genital Tract Disease*. 2006;10(1):64-65.

Kajbaf, S., Nichol, G., and Zimmerman, D.. Cancer screening and life expectancy of Canadian patients with kidney failure. *Nephrology Dialysis Transplantation*. 2002;17(10):1786-1789.

Kalmar, L., Deak, J., Thurzo, L., Pal, A., Bernad, E., and Nyari, T. A.. Epidemiological modelling of risk factors of human papilloma virus in women with positive cytology in the county of Csongrad. *European Journal of Gynaecological Oncology*. 2010;31(2):185-186.

Karlan, B. Y.. Testimony before the subcommittee on criminal justice, drug policy and human resources: committee on government reform United States house of representatives. *Gynecologic Oncology*. 2005;99(2):257-260.

Katori, H., Nozawa, A., and Tsukuda, M.. Relationship between p21 and p53 Expression, Human Papilloma Virus Infection and Malignant Transformation in Sinonasal-inverted Papilloma. *Clinical Oncology*. 2006;18(4):300-305.

Kavathkar, A., Nagwanshi, C., and Dabak, S.. Study of a manual method of liquid-based cervical cytology. *Indian Journal of Pathology and Microbiology*. 2008;51(2):190-194.

Kavoussi, S. K., Smith, Y. R., Ernst, S. D., and Quint, E. H.. Cervical cancer screening with liquid cytology in women with developmental disabilities. *Journal of Women's Health*. 2009;18(1):115-118.

Kelloff, G. J., Sullivan, D. C., Baker, H., Clarke, L. P., Nordstrom, R., Tatum, J. L., Dorfman, G. S., Jacobs, P., Berg, C. D., Pomper, M. G., Birrer, M. J., Tempero, M., Higley, H. R., Petty, B. G., Sigman, C. C., Maley, C., Sharma, P., Wax, A., Ginsberg, G. G., Dannenberg, A. J., Hawk, E. T., Messing, E. M., Grossman, H. B., Harisinghani, M., Bigio, I. J., Griebel, D., Henson, D. E., Fabian, C. J., Ferrara, K., Fantini, S., Schnall, M. D., Zujewski, J. A., Hayes, W., Klein, E. A., DeMarzo, A., Ocak, I., Ketterling, J. A., Tempany, C., Shtern, F., Parnes, H. L., Gomez, J., Srivastava, S., Szabo, E., Lam, S., Seibel, E. J., Massion, P., McLennan, G., Cleary, K., Suh, R., Burt, R. W., Pfeiffer, R. M., Hoffman, J. M., Roy, H. K., Wang, T.,

Limburg, P. J., El-Deiry, W. S., Papadimitrakopoulou, V., Hittelman, W. N., MacAulay, C., Veltri, R. W., Solomon, D., Jeronimo, J., Richards-Kortum, R., Johnson, K. A., Viner, J. L., Stratton, S. P., Rajadhyaksha, M., and Dhawan, A.. Workshop on imaging science development for cancer prevention and preemption. *Cancer Biomarkers*. 2007;3(1):1-33.

Kendall, C., Isabelle, M., Bazant-Hegemark, F., Hutchings, J., Orr, L., Babrah, J., Baker, R., and Stone, N.. Vibrational spectroscopy: A clinical tool for cancer diagnostics. *Analyst*. 2009;134(6):1029-1045.

Kim, J. J., Leung, G. M., Woo, P. P. S., and Goldie, S. J.. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. *Journal of Public Health*. 2004;26(2):130-137.

Kim, J. J., Wright, T. C., and Goldie, S. J.. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. *Journal of the American Medical Association*. 2002;287(18):2382-2390.

King, M. E.. From preparation to reporting - Optimizing PAP testing. *Laboratory Medicine*. 2009;40(3):144-145.

Kirwan, J. M. J. and Herrington, C. S.. Human papillomavirus and cervical cancer: Where are we now?. *British Journal of Obstetrics and Gynaecology*. 2001;108(12):1204-1213.

Kisseljov, F., Sakharova, O., and Kondratjeva, T.. Chapter 2 Cellular and Molecular Biological Aspects of Cervical Intraepithelial Neoplasia. *International Review of Cell and Molecular Biology*. 2008;271(C):35-95.

Kldiashvili, E. and Schrader, T.. Implementation of telepathology in the republic of Georgia. *Telemedicine and e-Health*. 2009;15(5):479-483.

Klungsoyr, O., Nygard, M., Skare, G., Eriksen, T., and Nygrd, J. F.. Validity of self-reported Pap smear history in Norwegian women. *Journal of medical screening*. 2009;16(2):91-97.

Kobilkova, J., Pazdernik, B., and Duskova, J.. Incidence of cervical carcinoma in the Czech Republic. *Acta Cytologica*. 2001;45(4):515-518.

Kolomainen, D. F., Herod, J. J. O., Holland, N., and Shepherd, J. H.. Actinomyces on a papanicolaou smear following a radical trachelectomy. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2003;110(11):1036-1037.

Koutsky, L.. The Epidemiology behind the HPV Vaccine Discovery. *Annals of Epidemiology*. 2009;19(4):239-244.

Krech, T., Castriciano, S., Jang, D., Smieja, M., Enders, G., and Chernesky, M.. Detection of high risk HPV and Chlamydia trachomatis in vaginal and cervical samples collected with flocced nylon and wrapped rayon dual swabs transported in dry tubes. *Journal of Virological Methods*. 2009;162(1-2):291-293.

Kreuter, A., Wieland, U., Brockmeyer, N. H., and German Network of Competence HIV/AIDS. Genital human papillomavirus-associated (pre-) malignant skin diseases drastically increase in the era of highly active antiretroviral therapy for HIV infection. *Journal of the American Academy of Dermatology*. 2006;55(6):1116-1117.

- Kuemper, C., Burges, A., Hillemanns, P., Mueller-Egloff, S., Lenhard, M., Ditsch, N., and Strauss, A.. Supraclavicular lymph node metastases of unknown origin: HPV-typing identifies the primary tumour. *European Journal of Cancer Care*. 2009;18(6):606-611.
- Kurshumliu, F., Thorns, C., and Gashi-Luci, L.. p16INK4A in routine practice as a marker of cervical epithelial neoplasia. *Gynecologic Oncology*. 2009;115(1):127-131.
- Lavoue, V. and Leveque, J.. Cervical cancer screening: A new tool to do one's best or doing one's best with a new tool?. [French]. *Gynecologie Obstetrique Fertilité*. 2009;37(7-8):680-682.
- Lazaroiu, A. M., Comanescu, M., Moldovan, V., Secara, D., Cirstoiu, M., Sajin, M., Stoian, M., and Anton, G.. Past experience of SUUB's pathology department in classic based cervico-vaginal cytology. *Romanian Journal of Morphology and Embryology*. 2009;50(4):619-623.
- Learmonth, G., Willemse, S., Pillay, K., Venter, F., and Gopolang, F.. Cytomorphology of cells on conventional cervical smears from HIV-infected women. *Acta Cytologica*. 2007;51(3):488-489.
- Ledger, W. J.. Human papillomavirus infection in women: An update. *Infectious Diseases in Clinical Practice*. 2005;13(4):154-157.
- Lee, H. P., Chew, C. T., Consigliere, D. T., Heng, D., Huang, D. T., Khoo, J., Khoo, K. S., Low, J., Lui, S., Ooi, L. L., Puvanendran, R., Siow, A., Tan, A., and Yeoh, K. G.. Ministry of health clinical practice guidelines: Cancer screening. *Singapore Medical Journal*. 2010;51(2):170-175.
- Lenselink, C. H., De Bie, R. P., Van, Hamont D., Bakkers, J. M. J. E., Quint, W. G. V., Massuger, L. F. A. G., Bekkers, R. L. M., and Melchers, W. J. G.. Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: New possibilities for cervical cancer screening. *Journal of Clinical Microbiology*. 2009;47(8):2564-2570.
- Leveque, J., Classe, J.-M., Marret, H., and Audrain, O.. Contribution of viral typing in cytological anomalies of the cervix. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2005;34(5):427-439.
- Lin, M. K., Moskowitz, J. M., Kazinets, G., Ivey, S. L., Kim, Y. B., and McDonnell, D. D.. Adherence to Pap test guidelines: variation among Asians in California. *Ethnicity & disease*. 2009;19(4):425-432.
- Lin, Y.-J., Chen, C.-S., Liu, T.-C., and Lin, H.-C.. Taiwan's national health insurance system and the application of preventive care: the case of Pap smear testing. *Public Health*. 2008;122(9):857-861.
- Lindholm, K.. Cytopathology in Sweden. *Diagnostic Cytopathology*. 2000;23(1):70-72.
- Lippman, S. M. and Hawk, E. T.. Cancer prevention: From 1727 to milestones of the past 100 years. *Cancer Research*. 2009;69(13):5269-5284.
- Lippman, S. M.. Cancer Prevention Research: Back to the future. *Cancer Prevention Research*. 2009;2(6):503-513.
- Lomnytska, M. I., Becker, S., Hellman, K., Hellstrom, A.-C., Souchelnytskyi, S., Mints, M., Hellman, U., Andersson, S., and Auer, G.. Diagnostic protein marker patterns in squamous

cervical cancer. *Proteomics - Clinical Applications*. 2010;4(1):17-31.

Love, R. R.. Global cancer research initiative. *Cancer Management and Research*. 2010;2(1):105-109.

Lowy, D. R., Solomon, D., Hildesheim, A., Schiller, J. T., and Schiffman, M.. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. *Cancer*. 2008;113(7):1980-1993.

Lu, D. and Yeh, I.-T.. Nonneoplastic glandular lesions of the cervix. *Pathology Case Reviews*. 2006;11(3):105-111.

Lyons, F., Prendiville, W., and Mulcahy, F.. Cervical disease in HIV-1-positive women: A review. *International Journal of STD and AIDS*. 2004;15(2):89-93.

Lyons, F., Walsh, T., Hayden, C., Boyd, W., and Coughlan, B. M.. Cervical cytology history in Irish doctors and midwives. *Irish medical journal*. 2000;93(6):176-178.

Makhija, S.. Risk-based strategy for vaccination of the 19-26-year-old female population. *Community Oncology*. 2009;6(6):251-252.

Maki, C., Groen, J., Delgado, B., and Piura, B.. Cervical metastasis as the first manifestation of ovarian papillary serous carcinoma. *Journal of Obstetrics and Gynaecology*. 2010;30(3):325-326.

Makwela, M. R.. Should a smear result of H-SIL always be followed by a biopsy?. *Obstetrics and Gynaecology Forum*. 2009;19(2):47-49.

Mandelblatt, J. S. and Yabroff, K. R.. Breast and cervical cancer screening for older women: recommendations and challenges for the 21st century. *Journal of the American Medical Women's Association (1972)*. 2000;55(4):210-215.

Mariani, L.. HPV-vaccine and screening programs: The new era of global prevention. *Journal of Preventive Medicine and Hygiene*. 2009;50(2):90-95.

Marsan, C.. Why do we go on screening?. *Polish Journal of Pathology*. 2005;56(4):167-169.

Martinez-Donate, A. P.. Using lay health advisors to promote breast and cervical cancer screening among Latinas: a review. *WMJ : official publication of the State Medical Society of Wisconsin*. 2009;108(5):259-262.

Martinez-Giron, R. and Fernandez-Garcia, C.. *Aspergillus/Penicillium* sp. spores as a contaminant on conventional Pap smear. *Diagnostic Cytopathology*. 2009;37(12):899-900.

Martin-Lopez, R., Hernandez-Barrera, V., De Andres, A. L., Garrido, P. C., De Miguel, A. G., and Garcia, R. J.. Breast and cervical cancer screening in Spain and predictors of adherence. *European Journal of Cancer Prevention*. 2010;19(3):239-245.

Massad, L. S., Seaberg, E. C., Watts, D. H., Minkoff, H., Levine, A. M., Henry, D., Colie, C., Darragh, T. M., and Hessol, N. A.. Long-term incidence of cervical cancer in women with human immunodeficiency virus. *Cancer*. 2009;115(3):524-530.

Mathieu-D'Argent, E.. Screening strategy of MAP (threat of premature birth): Selective use of fetal fibronectin detection. [French]. *Revue du Praticien - Gynecologie et Obstetrique*. 2006;#volume#(102):8.

Mayo, R., Scott, D. B., and Williams, D. G.. The Upstate Witness Project: addressing breast

and cervical cancer disparities in African American churches. *Journal of the South Carolina Medical Association* (1975). 2009;105(7):290-296.

Mbizvo, E. M., Msuya, S. E., Stray-Pedersen, B., Chirenje, M. Z., and Hussain, A.. Cervical dyskaryosis among women with and without HIV: Prevalence and risk factors. *International Journal of STD and AIDS*. 2005;16(12):789-793.

McCaffery, K. and Irwig, L.. Australian women's needs and preferences for information about human papillomavirus in cervical screening. *Journal of medical screening*. 2005;12(3):134-141.

McCartney, M.. Smear fears. *BMJ*. 2010;341(7763):74-75.

McFadden, S. E. and Schumann, L.. The role of human papillomavirus in screening for cervical cancer. *Journal of the American Academy of Nurse Practitioners*. 2001;13(3):116-125.

McGoogan, E.. Liquid-based cytology: The new screening test for cervical cancer control. *Journal of Family Planning and Reproductive Health Care*. 2004;30(2):123-125.

McLelland, J.. Neoplastic and pre-neoplastic diseases of the vulva. *CME Bulletin Dermatology*. 2000;2(3):92-95.

Meijer, C. J., Heideman, D. A., Berkhof, H., and Snijders, P. J.. Prevention of cervical cancer: where immunology meets diagnostics. *Immunology letters*. 2009;122(2):126-127.

Meissner, H. I., Tiro, J. A., Yabroff, K. R., Haggstrom, D. A., and Coughlin, S. S.. Too much of a good thing? Physician practices and patient willingness for less frequent pap test screening intervals. *Medical Care*. 2010;48(3):249-259.

Melnikow, J., Kulasingam, S., Slee, C., Helms, L. J., Kuppermann, M., Birch, S., McGahan, C. E., Coldman, A., Chan, B. K., and Sawaya, G. F.. Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. *Obstetrics & Gynecology*. 2010;116(5):1158-1170.

Mendoza, Torres L., Paez, M., Insaurralde, A., Rodriguez, M. I., Castro, A., and Kasamatsu, E.. Detection of high risk human papillomavirus cervical infections by the hybrid capture in Asuncion, Paraguay. *Brazilian Journal of Infectious Diseases*. 2009;13(3):203-206.

Mennini, F. S., Giorgi, Rossi P., Palazzo, F., and Largeron, N.. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. *Gynecologic Oncology*. 2009;112(2):370-376.

Mergui, J.-L. and Leveque, J.. What kind of follow-up after surgical treatment for high-grade cervix lesion?. [French]. *Gynecologie Obstetrique Fertilité*. 2008;36(4):441-447.

Mergui, J.-L.. Evaluation of professional practices: Number 1. The HPV test. [French]. *Revue du Praticien - Gynecologie et Obstetrique*. 2006;#volume#(101):21-22.

Michelow, P., McKee, G., and Hlongwane, F.. Rapid rescreening of cervical smears as a quality control method in a high-risk population. *Cytopathology*. 2006;17(3):110-115.

Michels, K. B. and zur, Hausen H.. HPV vaccine for all. *The Lancet*. 2009;374(9686):268-270.

Miller, A. B.. Natural history of cervical human papillomavirus infections. *Lancet*. 6-9-2001;357(9271):1816.

Milliez, J.. HPV vaccination and screening to eliminate cervical cancer. FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. *International Journal of*

Gynecology and Obstetrics. 2008;101(2):216-217.

Mirzendehtdel, S., Nadji, S. A., Tabarsi, P., Baghaei, P., Javanmard, P., Sigarroodi, A., and Fekrat, M.. Prevalence of HPV and HIV among female drug addicts attending a drop-in center in Tehran, Iran. *International Journal of Gynecology and Obstetrics*. 2010;108(3):254-255.

Miser, W. F.. Cancer Screening in the Primary Care Setting. The Role of the Primary Care Physician in Screening for Breast, Cervical, Colorectal, Lung, Ovarian, and Prostate Cancers. *Primary Care - Clinics in Office Practice*. 2007;34(1):137-167.

Mitchell, S. and Hall, V. P.. Women's initial experience of abnormal papanicolaou smear. *Journal of holistic nursing : official journal of the American Holistic Nurses' Association*. 2009;27(2):93-102.

Monif, G. R. G.. Continued cytological monitoring for cervical cancer despite prior vaccination. *Infections in Medicine*. 2009;26(5):157.

Monk, B. J. and Wiley, D. J.. Human Papillomavirus Infections: Truth or Consequences. *Cancer*. 2004;100(2):225-227.

Monsonogo, J., Bosch, F. X., Coursaget, P., Cox, J. T., Franco, E., Frazer, I., Sankaranarayanan, R., Schiller, J., Singer, A., Wright, T., Kinney, W., Meijer, C., and Linder, J.. Cervical cancer control, priorities and new directions. *International Journal of Cancer*. 2004;108(3):329-333.

Monsonogo, J.. Cervical cancer prevention: Vaccination and screening protect more than smear test alone. [French]. *Reproduction Humaine et Hormones*. 2009;22(2):34-38.

Monsonogo, J.. Cervical cancer: Prevention's stakes. [French]. *Gynecologie Obstetrique Fertilité*. 2000;28(11):847-854.

Montz, F. J., Farber, F. L., Bristow, R. E., and Cornelison, T.. Impact of increasing Papanicolaou test sensitivity and compliance: a modeled cost and outcomes analysis. *Obstetrics & Gynecology*. 2001;97(5:Pt 1):t-8.

Moore, D. H.. Cervical cancer. *Obstetrics and Gynecology*. 2006;107(5):1152-1161.

Morantz, C.. ACS Guidelines for Early Detection of Cancer. *American Family Physician*. 2004;69(8):2013.

Morasse, L., Davidov, A., and Castellanos, M. R.. The role of human papillomavirus testing in cervical cancer screening. *JAAPA : official journal of the American Academy of Physician Assistants*. 2009;22(11):20-23.

Moriarty, A. T., Clayton, A. C., Zaleski, S., Henry, M. R., Schwartz, M. R., Eversole, G. M., Tench, W. D., Fatheree, L. A., Souers, R. J., and Wilbur, D. C.. Unsatisfactory reporting rates: 2006 practices of participants in the college of american pathologists interlaboratory comparison program in gynecologic cytology. *Archives of pathology & laboratory medicine*. 2009;133(12):1912-1916.

Moscicki, A.-B.. Genital human papillomavirus infections in children and adolescents. *Current Problems in Dermatology*. 2000;12(3):134-140.

Moss, E. L., Pearmain, P., Askew, S., Owen, G., Reynolds, T. M., Prabakar, I. M., Douce, G., Parkes, J., Menon, V., Todd, R. W., and Redman, C. W.. Implementing the national invasive cervical cancer audit: a local perspective. *BJOG: An International Journal of Obstetrics &*

Gynaecology. 2010;117(11):1411-1416.

Mourouga, P. and Mahe, C.. Screening of cervical lesions: To improve the situation in France. [French]. *Revue du Praticien - Gynecologie et Obstetrique*. 2007;#volume#(113):26-28.

Naik, R., Abang-Mohammed, K., Tjalma, W. A., Nordin, A., De Barros, Lopes A., Cross, P. A., Hemming, J. D., and Monaghan, J. M.. The feasibility of a one-stop colposcopy clinic in the management of women with low grade smear abnormalities: a prospective study. *European journal of obstetrics, gynecology, and reproductive biology*. 2001;98(2):205-208.

Nakagawa, M., Gupta, S. K., Coleman, H. N., Sellers, M. A., Banken, J. A., and Greenfield, W. W.. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 E6 antigens in women being studied for abnormal pap smear results. *Journal of Lower Genital Tract Disease*. 2010;14(2):124-129.

Nam, K. H., Kim, Y. T., Kim, S. R., Kim, S. W., Kim, J. W., Lee, M. K., Nam, E. J., and Jung, Y. W.. Association between bacterial vaginosis and cervical intraepithelial neoplasia. *Journal of Gynecologic Oncology*. 2009;20(1):39-43.

Narine, N. and Young, W.. Transformation zone sampling rate is a useful performance indicator for practitioners collecting cervical samples using SurePath liquid-based cytology system. *Cytopathology*. 2007;18(4):220-224.

Ndlovu, N. and Kambarami, R.. Factors associated with tumour stage at presentation in invasive cervical cancer. *Central African Journal of Medicine*. 2003;49(9-10):107-111.

Ngan, H. Y. S. and Trimble, C. L.. A4. Preinvasive lesions of the cervix. *International Journal of Gynecology and Obstetrics*. 2006;94(SUPPL. 1):S44-S49.

Ngoma, T. A.. World Health Organization cancer priorities in developing countries. *Annals of Oncology*. 2006;17(SUPPL. 8):viii9-viii14.

Nicol, A. F., Nuovo, G. J., and Dillner, J.. A summary of the 25th International Papillomavirus Conference 2009: Vaccines, screening, epidemiology and therapeutics. *Journal of Clinical Virology*. 2010;47(3):208-215.

Nicoletti, A.. Pelvics, Paps, and HPV. *Journal of Pediatric and Adolescent Gynecology*. 2003;16(6):389-390.

no authors listed. The risk of cervical dysplasia. *Treatment Update*. 2000;12(2):6-7.

Nonogaki, S., Wakamatsu, A., Longatto, Filho A., Roteli-Martins, C., Di, Loreto C., Sakamoto Maeda, M. Y., Utagawa, M. L., Pereira, S. M. M., Polli, S., Alves, V. A. F., and Syrjanen, K.. Molecular strategies for identifying human papillomavirus infection in routinely processed samples: Focus on paraffin sections. *Journal of Lower Genital Tract Disease*. 2005;9(4):219-224.

Nyitray, A. G., Smith, D., Villa, L., Lazcano-Ponce, E., Abrahamsen, M., Papenfuss, M., and Giuliano, A. R.. Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross-national study. *The Journal of infectious diseases*. 2010;201(10):1498-1508.

Obiechina, N. J. and Mbamara, S. U.. Knowledge attitude and practice of cervical cancer screening among sexually active women in Onitsha, southeast Nigeria. *Nigerian journal of*

medicine : journal of the National Association of Resident Doctors of Nigeria. 2009;18(4):384-387.

O'Mahony, C.. Genital warts: Current and future management options. *American Journal of Clinical Dermatology*. 2005;6(4):239-243.

Onah, H. E. and Iyoke, C. A.. Abnormal Pap smears: A comparison of total abdominal hysterectomy and cone biopsy in management. *Journal of Obstetrics and Gynaecology*. 2006;26(1):48-51.

Ornelas-Aguirre, J. M., Gomez-Meda, B. C., Zamora-Perez, A. L., Ramos-Ibarra, M. L., Batista-Gonzalez, C. M., and Zuniga-Gonzalez, G. M.. Micronucleus induction by metronidazole in rat vaginal mucosa. *Environmental and Molecular Mutagenesis*. 2006;47(5):352-356.

Osborne, N. G.. Human papilloma virus infection and cervical disease. *Journal of Gynecologic Surgery*. 2002;18(3):117-119.

Ostojic, D. V., Vrdoljak-Mozetic, D., Stemberger-Papic, S., Finderle, A., and Eminovic, S.. Cervical cytology and HPV test in follow-up after conisation or LLETZ. *Collegium antropologicum*. 2010;34(1):219-224.

Othman, N. H. and Rebolj, M.. Challenges to cervical screening in a developing country: The case of Malaysia. *Asian Pacific journal of cancer prevention : APJCP*. 2009;10(5):747-752.

Paczos, T. A., Ackers, S., Odunsi, K., Lele, S., and Mhaweche-Fauceglia, P.. Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy. *International Journal of Gynecological Pathology*. 2010;29(2):193-196.

Pai, M., Pai, N., Bilal, S., Ashok, M., and Radhika, P.. Cervical cancer screening: is it a priority among nurses?.[Erratum appears in *Natl Med J India* 2001 Mar-Apr;14(2):89]. *National Medical Journal of India*. 2001;14(1):59-60.

Pajtler, M., Audy-Jurkovic, S., Skopljanac-Macina, L., Antulov, J., Barisic, A., and Milicic-Juhas, V.. Rapid cervicovaginal smear screening: Method of quality control and assessing individual cytotechnologist performance. *Cytopathology*. 2006;17(3):121-126.

Panagiotis, C., Efthimios, D., Konstantinos, P., and George, C.. Human papilloma virus: diagnostic, treatment and preventive issues. *Akusherstvo i ginekologija*. 2008;47(1):35-38.

Papastefanou, I., Panagopoulos, P., Samolis, S., Karadaglis, S., and Katsoulis, M.. Minimal deviation adenocarcinoma of the cervix in a patient with a high-grade cervical squamous intraepithelial lesion: Case report and review of the literature. *European Journal of Gynaecological Oncology*. 2010;31(2):227-229.

Parra-Medina, D., Messias, D. K., Fore, E., Rachel, M., Petry, D., and Das, I. P.. The partnership for cancer prevention: addressing access to cervical cancer screening among Latinas in South Carolina. *Journal of the South Carolina Medical Association (1975)*. 2009;105(7):297-305.

Partridge, E. E., Abu-Rustum, N., Campos, S., Fahey, P. J., Greer, B. E., Lele, S. M., Lieberman, R. W., Lipscomb, G. H., Morgan, M., Nava, M. E. R., Reynolds, R. K., Singh, D. K., Smith-McCune, K., Teng, N., Trimble, C. L., Valea, F., and Wilczynski, S.. Cervical cancer screening. *JNCCN Journal of the National Comprehensive Cancer Network*. 2008;6(1):58-82.

- Pecorelli, S., Favalli, G., Zigliani, L., and Odicino, F.. Cancer in women. *International Journal of Gynecology and Obstetrics*. 2003;82(3):369-379.
- Peavor, R. and Fiander, A. N.. Human papillomavirus (including vaccination). *Obstetrics, Gynaecology and Reproductive Medicine*. 2010;20(10):295-299.
- Peltecu, G., Bari, M., Lancu, G., and Popa, F.. Human papilloma virus and cervical preinvasive disease. *Journal of medicine and life*. 2009;2(4):373-377.
- Petignat, P. and Roy, M.. Diagnosis and management of cervical cancer. *British Medical Journal*. 2007;335(7623):765-768.
- Philips, Z. and Whynes, D. K.. Early withdrawal from cervical cancer screening: The question of cost-effectiveness. *European Journal of Cancer*. 2001;37(14):1775-1780.
- Pichichero, M. E.. Who should get the HPV vaccine?. *Journal of Family Practice*. 2007;56(3):197-202.
- Pinkowish, M. D.. Human papillomavirus genotype distributions inform screening and vaccination policy. *CA Cancer Journal for Clinicians*. 2009;59(5):280-281.
- Polednak, A. P.. Later-stage cancer in relation to medically underserved areas in Connecticut. *Journal of Health Care for the Poor and Underserved*. 2000;11(3):301-309.
- Pollack, A. E., Balkin, M. S., and Denny, L.. Cervical cancer: A call for political will. *International Journal of Gynecology and Obstetrics*. 2006;94(3):333-342.
- Power, J., McNair, R., and Carr, S.. Absent sexual scripts: Lesbian and bisexual women's knowledge, attitudes and action regarding safer sex and sexual health information. *Culture, Health and Sexuality*. 2009;11(1):67-81.
- Prasad, S. R.. Management strategies and cost effectiveness in the prevention of cervical cancer. *ClinicoEconomics and Outcomes Research*. 2009;1(1):17-23.
- Prendiville, W.. Recent innovations in colposcopy practice. *Best Practice and Research in Clinical Obstetrics and Gynaecology*. 2005;19(5):779-792.
- Pretet, J.-L., Vidal, C., Le Bail, Carval K., Ramanah, R., Carcopino, X., Cartier, I., Labouyrie, E., Kantelip, B., Coumes-Marquet, S., Riethmuller, D., and Mouglin, C.. Novaprep Vial Test is a suitable liquid-based cytology medium for high risk human papillomavirus testing by Hybrid Capture 2. *Journal of Clinical Virology*. 2010;49(4):286-289.
- Priest, P., Sadler, L., Sykes, P., Marshall, R., Peters, J., and Crengle, S.. Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand. *Cancer Causes and Control*. 2010;21(2):209-214.
- Quilliam, S.. Positive smear and on: The partner's story. *Journal of Family Planning and Reproductive Health Care*. 2009;35(1):63-64.
- Rajab, K. E., Ali, Issa A., and Jamsheer, H.. Cervical cancer prevention in Bahrain: Review. *Bahrain Medical Bulletin*. 2009;31(1).
- Ramphul, M., Dimitriou, E., and Byrne, B.. An unusual reproductive consequence of needle excision of the transformation zone. *Journal of Obstetrics and Gynaecology*. 2010;30(3):311-312.
- Ramsey, S. D., Cheadle, A. D., Neighbor, W. E., Gore, E., Temple, P., Staiger, T., and

Goldberg, H. I.. Relative impact of patient and clinic factors on adherence to primary care preventive service guidelines: an exploratory study. *Medical Care*. 2001;39(9):979-989.

Rastogi, T., Devesa, S., Mangtani, P., Mathew, A., Cooper, N., Kao, R., and Sinha, R.. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. *International Journal of Epidemiology*. 2008;37(1):147-160.

Read, C. M. and Bateson, D. J.. Marrying research, clinical practice and cervical screening in Australian Aboriginal women in western New South Wales, Australia. *Rural and remote health*. 2009;9(2):1117-1Jun.

Reed, G.. Targeting cancer with the resource at hand: Rolando Camacho, MD chair, National Oncology Group. *MEDICC Review*. 2009;11(3):13-15.

Renshaw, A. A.. Qualification of ASCUS. *American journal of clinical pathology*. 2002;117(2):333-336.

Reshmi, G. and Pillai, M. R.. In silico screening of novel inhibitors for HPV: A rational structure based approach (docking versus pharmacophore model generation). *Letters in Drug Design and Discovery*. 2009;6(7):494-501.

Reust, C. E.. Does the increased sensitivity of the new Papanicolaou (Pap) tests improve the cost-effectiveness of screening for cervical cancer?. *The Journal of family practice*. 2001;50(2):175.

Reynales-Shigematsu, L. M., Rodrigues, E. R., and Lazcano-Ponce, E.. Cost-Effectiveness Analysis of a Quadrivalent Human Papilloma Virus Vaccine in Mexico. *Archives of Medical Research*. 2009;40(6):503-513.

Rezvani, M. and Shaaban, A.. Imaging of cervical pathology. *Clinical Obstetrics and Gynecology*. 2009;52(1):94-111.

Ribeiro, A. A., Dos Santos, S. D. C. D., De Souza E Silva, Do Nascimento, M. A., Fonsechi-Carvasan, G. A., Carneiro, M. A. S., Rabelo-Santos, M., and Rabelo-Santos, S. H.. Endocervical component in conventional cervical smears: Influence on detection of squamous cytologic abnormalities. *Diagnostic Cytopathology*. 2007;35(4):209-212.

Ricciardi, A., Largeron, N., Rossi, P. G., Raffaele, M., Cohet, C., FedericF, A., and Palazzo, F.. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. *Tumori*. 2009;95(2):146-152.

Riethmuller, D.. Cervical cancer screening: Restoration or reconstruction?. [French]. *Gynecologie Obstetrique Fertilité*. 2009;37(7-8):671-679.

Rijkaart, D. C., Berkhof, J., Van Kemenade, F. J., Rozendaal, L., Verheijen, R. H. M., Bulk, S., Herreilers, M. E., Verweij, W., Snijders, P. J. F., and Meijer, C. J. L. M.. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). *International Journal of Cancer*. 2010;126(9):2175-2181.

Rimiene, J., Petronyte, J., Gudleviciene, Z., Smailyte, G., Krasauskaite, I., and Laurinavicius, A.. A Shandon PapSpin liquid-based gynecological test: A split-sample and direct-to-vial test with histology follow-up study. *CytoJournal*. 2010;7 , 2010. Article Number: 2. Date of Publication: 2010.

Ripabelli, G., Grasso, G. M., Del, Riccio, I, Tamburro, M., and Sammarco, M. L.. Prevalence and genotype identification of human papillomavirus in women undergoing voluntary cervical cancer screening in Molise, Central Italy. *Cancer Epidemiology*. 2010;34(2):162-167.

Robb-Nicholson, C.. By the way, doctor. I recently read that a test for the virus linked to cervical cancer may be better than a Pap smear. Does this mean I can avoid a regular pelvic exam and Pap smear? Should I ask my doctor for this test?. *Harvard women's health watch*. 2000;7(7):8.

Robb-Nicholson, C.. By the way, doctor. Is there an age when a woman no longer needs a Pap smear?. *Harvard women's health watch*. 2008;16(4):8.

Rodnick, J.. Physicians who do not follow screening guidelines. *American Family Physician*. 2006;73(1):161-163.

Rogers, N. M. and Cantu, A. G.. The nurse's role in the prevention of cervical cancer among underserved and minority populations. *Journal of Community Health*. 2009;34(2):135-143.

Rojas-Espaillet, L. A. and Rose, P. G.. Management of locally advanced cervical cancer. *Current Opinion in Oncology*. 2005;17(5):485-492.

Roland, K. B., Benard, V. B., Saraiya, M., Hawkins, N. A., Brandt, H., and Friedman, A. L.. Assessing cervical cancer screening guidelines in patient education materials. *Journal of Women's Health*. 2009;18(1):5-12.

Roland, K. B., Larkins, T. L., Benard, V. B., Berkowitz, Z., and Saraiya, M.. Content analysis of continuing medical education for cervical cancer screening. *Journal of Women's Health*. 2010;19(4):651-657.

Ronco, G. and Anttila, A.. Cervical cancer screening in Europe - Changes over the last 9 years. *European Journal of Cancer*. 2009;45(15):2629-2631.

Ronco, G. and Rossi, P. G.. New paradigms in cervical cancer prevention: Opportunities and risks. *BMC women's health*. 2008;8 , 2008. Article Number: 23. Date of Publication: 17 Dec 2008.

Ronco, G., Ballegooijen, M., Becker, N., Chil, A., Fender, M., Giubilato, P., Kurtinaitis, J., Lancucki, L., Lynge, E., Morais, A., O'Reilly, M., Sparen, P., Suteu, O., Rebolj, M., Veerus, P., Zakelj, M. P., and Anttila, A.. Process performance of cervical screening programmes in Europe. *European Journal of Cancer*. 2009;45(15):2659-2670.

Rosen, N. O., Knauper, B., Page, G., Dio, P. D., Morrison, E., Mayrand, M.-H., Franco, E. L., and Rosberger, Z.. Brief research report: Uncertainty-inducing and reassuring facts about HVP: A descriptive study of French Canadian women. *Health Care for Women International*. 2009;30(10):892-902.

Rubin, M. M. and Tripsas, C. K.. Perceived uncertainty, coping strategies, and adaptation in women with human papillomavirus on pap smear. *Journal of Lower Genital Tract Disease*. 2010;14(2):81-89.

Rubin, S. C.. Cervical cancer: Successes and failures. *Ca-A Cancer Journal for Clinicians*. 2001;51(2):89-91.

Ruhl, C.. The future of the Pap: where is cervical cancer screening headed?. *Nursing for*

women's health. 2008;12(5):427-431.

Ruskamp-Hatz, J. and Oliver, L.. Preventing cervical cancer. NCSL legisbrief. 2006;14(44):1-2.

Sabatino, S. A., Habarta, N., Baron, R. C., Coates, R. J., Rimer, B. K., Kerner, J., Coughlin, S. S., Kalra, G. P., and Chattopadhyay, S.. Interventions to Increase Recommendation and Delivery of Screening for Breast, Cervical, and Colorectal Cancers by Healthcare Providers. Systematic Reviews of Provider Assessment and Feedback and Provider Incentives. American Journal of Preventive Medicine. 2008;35(1 SUPPL.):S67-S74.

Sahasrabudde, V. V., Bhosale, R. A., Joshi, S. N., Kavatkar, A. N., Nagwanshi, C. A., Kelkar, R. S., Jenkins, C. A., Shepherd, B. E., Sahay, S., Risbud, A. R., Vermund, S. H., and Mehendale, S. M.. Prevalence and predictors of colposcopic-histopathologically confirmed cervical intraepithelial neoplasia in HIV-infected women in India. PloS one. 2010;5(1):e8634.

Sakauchi, F. and Japan Collaborative Cohort Study for Evaluation of Cancer. Reproductive history and health screening for women and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). Asian Pacific Journal of Cancer Prevention: Apjcp. 2007;8:Suppl-34.

Samson, K. J.. Painless cervical cancer probe uses fiberoptics. Biomedical Instrumentation and Technology. 2000;34(6):409-411.

Sanfilippo, J. S., Cox, J. T., and Wright, T. C.. What you need to know about cervical cancer, genital warts, and HPV. Journal of Family Practice. 2007;56(7):S1-S2.

Savoy, J. E., Hurley, D. M., Brandt, H. M., Bolick-Aldrich, S. W., and Ehlers, M. E.. Cervical cancer in South Carolina: epidemiologic profile. Journal of the South Carolina Medical Association (1975). 2009;105(7):227-230.

Scarinci, I. C., Garcia, F. A. R., Kobetz, E., Partridge, E. E., Brandt, H. M., Bell, M. C., Dignan, M., Ma, G. X., Daye, J. L., and Castle, P. E.. Cervical cancer prevention: New tools and old barriers. Cancer. 2010;116(11):2531-2542.

Scheiden, R., Wagener, C., Knolle, U., Wehenkel, A., Dippel, W., and Capesius, C.. Cervical screening in Luxembourg: 1990-1999. Cytopathology. 2003;14(5):235-240.

Schiffman, M.. Evidence-Based Screening and Management Guidelines Address the Realistic Concerns of Practicing Clinicians and Pathologists. Journal of Lower Genital Tract Disease. 2004;8(2):150-154.

Schmitt, M., Dalstein, V., Waterboer, T., Clavel, C., Gissmann, L., and Pawlita, M.. Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Research. 2010;70(1):249-256.

Schmitz, M., Scheungraber, C., Herrmann, J., Teller, K., Gajda, M., Runnebaum, I. B., and Durst, M.. Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types. Journal of Clinical Virology. 2009;44(4):302-307.

Schorn, M.. What are the current Pap test guidelines?. Nursing. 2004;34(12):26.

Schwartz, L. A.. Cervical cancer: disease prevention and informational support. Canadian oncology nursing journal = Revue canadienne de nursing oncologique. 2009;19(1):6-9.

Shafer, M.-A.. No: Recommending annual exams is not evidence based. Western Journal of

Medicine. 2000;173(5):293.

Shanta, V., Krishnamurthi, S., Gajalakshmi, C. K., Swaminathan, R., and Ravichandran, K.. Epidemiology of cancer of the cervix: global and national perspective. *Journal of the Indian Medical Association*. 2000;98(2):49-52.

Sherman, M. E.. Chapter 11: Future directions in cervical pathology. *Journal of the National Cancer Institute*. 2003;Monographs.(31):72-79.

Shimada, T., Yamaguchi, N., Nishida, N., Yamasaki, K., Miura, K., Katamine, S., and Masuzaki, H.. Human papillomavirus DNA in plasma of patients with HPV16 DNA-positive uterine cervical cancer. *Japanese journal of clinical oncology*. 2010;40(5):420-424.

Shimano, S., Kawamura, M., Sonoda, T., and Minakami, H.. Possible association between screening BV at the prenatal visit and reduced cervical cerclage: Multi-center questionnaire in Hokkaido, Japan. *Journal of Obstetrics and Gynaecology Research*. 2009;35(2):262-270.

Siebers, A. G., Massuger, L. F. A. G., and Bulten, J.. Referral compliance, outcome and predictors of CIN after repeated borderline cervical smears in the Netherlands. *Cytopathology*. 2007;18(2):96-104.

Signore, M. and Villani, C.. Prevention of cervical cancer. *Giornale Italiano di Ostetricia e Ginecologia*. 2005;27(3):81-83.

Sigurdsson, K.. Cervical cancer: Cytological cervical screening in Iceland and implications of HPV vaccines. *Cytopathology*. 2010;21(4):213-222.

Sikora, K.. Cancer screening. *Medicine*. 2008;36(1):45-49.

Silva, K. C., Rosa, M. L. G., Moyses, N., Afonso, L. A., Oliveira, L. H. S., and Cavalcanti, S. M. B.. Risk factors associated with human papillomavirus infection in two populations from Rio de Janeiro, Brazil. *Memorias do Instituto Oswaldo Cruz*. 2009;104(6):885-891.

Simmons, S.. Regular, routine screening key to keeping cervical cancer rates on the decline. *The Nurse practitioner*. 2010;35(7):18-19.

Sitaras, N. M.. Women versus Men: Dear God, help me find if we are equal. *Journal of B*. 2009;U.ON.. 14(2):345-346.

Sivalingam, N. and Mak, F. K.. Delayed diagnosis of cervical pregnancy: Management options. *Singapore Medical Journal*. 2000;41(12):599-601.

Slomski, A.. Expert panel offers advice to improve screening rates for colorectal cancer. *JAMA - Journal of the American Medical Association*. 2010;303(14):1356-1357.

Smedts, F.. Efficacy of Ki-67 antigen staining in Papanicolaou (pap) smears in postmenopausal women with atypia--an audit. *Cytopathology*. 2001;12(2):130-132.

Smeltzer, S. C.. Preventive health screening for breast and cervical cancer and osteoporosis in women with physical disabilities. *Family & community health*. 2006;29(1 Suppl):35S-43S.

Smith, R. A., Cokkinides, V., and Eyre, H. J.. American Cancer Society guidelines for the early detection of cancer, 2005. *Ca-A Cancer Journal for Clinicians*. 2005;55(1):31-44.

Smith, R. A., Cokkinides, V., and Eyre, H. J.. American Cancer Society guidelines for the early detection of cancer, 2006. *Ca-A Cancer Journal for Clinicians*. 2006;56(1):11-25.

Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., and Brawley, O. W.. Cancer screening in the United States, 2010: A review of current American Cancer Society guidelines and issues in cancer screening. *CA Cancer Journal for Clinicians*. 2010;60(2):99-119.

Smith, R. A., Mellin, C. J., Davis, K. J., and Eyre, H.. American cancer society guidelines for the early detection of cancer. *Ca-A Cancer Journal for Clinicians*. 2000;50(1):34-49.

Smith, T.. Cervical carcinoma clinical update. *Journal of the South Carolina Medical Association (1975)*. 2003;99(4):82-84.

Smrkolj, S., Rakar, S., Mozina, A., and Erzen, M.. Evaluation of causes of increased incidence of cervical cancer in Slovenia. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2004;117(2):213-221.

Snijders, P. J. F., Heideman, D. A. M., and Meijer, C. J. L. M.. Methods for HPV detection in exfoliated cell and tissue specimens. *APMIS*. 2010;118(6-7):520-528.

Soler, M. E. and Blumenthal, P. D.. New technologies in cervical cancer precursor detection. *Current Opinion in Oncology*. 2000;12(5):460-465.

Spitzer, M.. Screening and management of women and girls with human papillomavirus infection. *Gynecologic Oncology*. 2007;107(2 SUPPL.):S14-S18.

Sridhar, N.. New initiatives to combat cervical cancer in India. *The Lancet Infectious Diseases*. 2001;1(5):292.

Stanimirovic, B.. National program of early detection and treatment of uterine cervical cancer. *Archive of Oncology*. 2000;8(2):61-64.

Stanley, M. and Villa, L. L.. Monitoring HPV vaccination. *Vaccine*. 2008;26(SUPPL. 1):A24-A27.

Stanley, M.. Pathology and epidemiology of HPV infection in females. *Gynecologic Oncology*. 2010;117(2 SUPPL.):S5-S10.

Steben, M., Lippman, A., Boscoe, M., and Scurfield, C.. Rebuttal: Do you approve of spending 0 million on HPV vaccination? YES. [French, English]. *Canadian Family Physician*. 2008;54(3):342-345.

Steinau, M., Swan, D. C., and Unger, E. R.. Type-specific reproducibility of the Roche linear array HPV genotyping test. *Journal of Clinical Virology*. 2008;42(4):412-414.

Stillman, M. J., Day, S. P., and Schutzbank, T. E.. A comparative review of laboratory-developed tests utilizing Invader HPV analyte-specific reagents for the detection of high-risk human papillomavirus. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S73-S77.

Suarez, E. and PRIETO, M.. Cervical Cancer: The Chilean Perspective. *International Journal of Gynecology and Obstetrics*. 2006;95(SUPPL. 1):S235-S238.

Suhatno. Palliative care in cervical cancer. *Gan to kagaku ryoho*. 2000;Cancer & chemotherapy. 27 Suppl 2:440-448.

Symonds, R. P.. Audit of treatment by radiotherapy of carcinoma of the cervix in the UK in 1993: worse than expected results. *Clinical Oncology (Royal College of Radiologists)*. 2000;12(6):343-344.

- Syrjanen, K. J.. Histology, classification and natural history of cervical intraepithelial neoplasia (CIN). *CME Journal of Gynecologic Oncology*. 2009;14(1):4-21.
- Syrjanen, S., Naud, P., Sarian, L., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Hammes, L. S., Costa, S., and Syrjanen, K.. Up-regulation of 14-3-3 (stratifin) is associated with high-grade CIN and high-risk human papillomavirus (HPV) at baseline but does not predict outcomes of HR-HPV infections or incident CIN in the LAMS* study. *American journal of clinical pathology*. 2010;133(2):232-240.
- Szarewski, A.. Social and psychological aspects of cervical screening. *Expert Review of Obstetrics and Gynecology*. 2011;6(1):37-44.
- Taylor, R.. Halving deaths from cervical cancer. *New South Wales public health bulletin*. 2003;14(3):55-56.
- Taylor, V. M., Yasui, Y., Nguyen, T. T., Woodall, E., Do, H. H., Acorda, E., Li, L., Choe, J., and Jackson, J. C.. Pap smear receipt among Vietnamese immigrants: The importance of health care factors. *Ethnicity and Health*. 2009;14(6):575-589.
- Teitelman, A. M., Stringer, M., Averbuch, T., and Witkoski, A.. Human papillomavirus, current vaccines, and cervical cancer prevention. *JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing*. 2009;38(1):69-80.
- Thaker, P., Kizer, N. T., Nguyen, T., Zigelboim, I., and Allsworth, J.. Discussion: 'Value of HPV testing in follow-up of treated high-risk CIN1' by Alonso et al. *American Journal of Obstetrics and Gynecology*. 2007;197(4):e1-e4.
- Thekkekk, N. and Richards-Kortum, R.. Optical imaging for cervical cancer detection: Solutions for a continuing global problem. *Nature Reviews Cancer*. 2008;8(9):725-731.
- Tiffen, J. and Mahon, S. M.. Cervical cancer: what should we tell women about screening?. *Clinical journal of oncology nursing*. 2006;10(4):527-531.
- Todd, R. W. and Shafi, M.. Invasive cervical cancer. *Current Obstetrics and Gynaecology*. 2004;14(3):200-206.
- Toivonen, T., Nieminen, P., Tarkkanen, J., Timonen, T., Krogerus, L., and Klemi, P.. Cytopathology in Finland. *Cytopathology*. 2005;16(4):210-214.
- Tota, J., Mahmud, S. M., Ferenczy, A., Coutle, F., and Franco, E. L.. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. *Sexual Health*. 2010;7(3):376-382.
- Tribe, K. L., Knight, V., and Pell, C.. A prospective descriptive study of women attending a colposcopy clinic. *Contemporary Nurse*. 2008;31(1):80-85.
- Tsang, N. and Osmun, W. E.. Smear tactics: A more comfortable Papanicolaou test. *Canadian Family Physician*. 2007;53(5):835.
- Tsu, V. D. and Pollack, A. E.. Preventing cervical cancer in low-resource settings: How far have we come and what does the future hold?. *International Journal of Gynecology and Obstetrics*. 2005;89(SUPPL. 2):S55-S59.
- Tubiana, M. and Hill, C.. Progress in the fight against cancer in France and in the European Union. [French]. *Oncologie*. 2004;6(4):229-244.

Twiggs, L. B., Kaufman, R. H., Noller, K., and Ferris, D. G.. A 14-year-old female with LSIL. *Journal of Lower Genital Tract Disease*. 2002;6(4):244-246.

Ulene, V.. Cervical cancer. A message from preventive medicine and your physician. *Preventive Medicine*. 2000;31(5):465-466.

Underwood, S. M., Ramsay-Johnson, E., Dean, A., Russ, J., and Ivalis, R.. Expanding the scope of nursing research in low resource and middle resource countries, regions, and states focused on cervical cancer prevention, early detection, and control. *Journal of National Black Nurses' Association : JNBNA*. 2009;20(2):42-54.

Valkov, I., Zlatkov, V., and Kostova, P.. Cytopathology in Bulgaria. *Cytopathology*. 2004;15(4):228-232.

VALLIKAD, E.. Cervical Cancer: The Indian Perspective. *International Journal of Gynecology and Obstetrics*. 2006;95(SUPPL. 1):S215-S233.

Van, Le L.. Current Problems in Obstetrics, Gynecology and Fertility: Foreword. *Current Problems in Obstetrics, Gynecology and Fertility*. 2001;24(1):5.

Van, Zyl T., Wooltorton, E., and MacDonald, N.. Patient information about HPV and the HPV vaccine. *Canadian Medical Association Journal*. 2007;177(5):462.

Vladareanu, R. and Andrei, C.. Modern screening in cervical cancer. Perspectives of HPV prophylactic vaccines. *Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi*. 2007;111(1):144-154.

Vollmer, R. T.. Endocervical cells, pathology of the cervix, and time. *American journal of clinical pathology*. 2002;117(1):166-167.

Waddell, C.. Detecting and interpreting glandular lesions in cervical cytology. *Diagnostic Histopathology*. 2009;15(7):335-343.

Wafo, E., Ivorra-Deleuze, D., Thuillier, C., and Rouzier, R.. Evolution of the awareness of Human Papillomavirus (HPV) in the French population: Results of a telephonic inquiry. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2010;39(4):305-309.

Wain, G.. The human papillomavirus (HPV) vaccine, HPV related diseases and cervical cancer in the post-reproductive years. *Maturitas*. 2010;65(3):205-209.

Waller, J., McCaffery, K., Kitchener, H., Nazroo, J., and Wardle, J.. Women's experiences of repeated HPV testing in the context of cervical cancer screening: A qualitative study. *Psycho-Oncology*. 2007;16(3):196-204.

Walsh, C. A., Allen, W., and Moore, K. H.. 'Urinary incontinence' post-radiotherapy: A diagnostic conundrum. *Journal of Obstetrics and Gynaecology*. 2010;30(4):424-425.

Walton, A., Calvo, Y., Flores, M., Navarrete, L., and Ruiz, L.. Promotoras: observations and implications for increasing cervical cancer prevention and screening in the Hispanic community. *Journal of the South Carolina Medical Association (1975)*. 2009;105(7):306-308.

Wang, P. E., Wang, T. T., Chiu, Y. H., Yen, A. M., and Chen, T. H.. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions?. *Journal of medical screening*. 2006;13 Suppl 1:S54-S58.

- Wang, S. and Pisharodi, L.. Advances in cytopathology. *Medicine and health, Rhode Island*. 2005;88(7):232-235.
- Wang, X., Fang, C., Tan, Y., Liu, A., and Ma, G. X.. Evidence-based intervention to reduce access barriers to cervical cancer screening among underserved Chinese American women. *Journal of Women's Health*. 2010;19(3):463-469.
- Wasserman, M., Bender, D., and Lee, S.-Y.. Use of preventive maternal and child health services by Latina women: A review of published intervention studies. *Medical Care Research and Review*. 2007;64(1):4-45.
- Waxman, A. G. and Zsemlye, M. M.. Preventing Cervical Cancer: The Pap Test and the HPV Vaccine. *Medical Clinics of North America*. 2008;92(5):1059-1082.
- Waxman, A. G.. Cervical Cancer Screening in the Early Postvaccine Era. *Obstetrics and Gynecology Clinics of North America*. 2008;35(4):537-548.
- Weigl, G., Pokieser, W., Schuller, B., Weigert, M., Ulrich, W., Sevelde, P., and Breiteneker, G.. Investigation of 208 consecutive cases of cervical cone biopsies with regard to indication, negative samples and quality control. *Acta Cytologica*. 2006;50(2):185-190.
- Weisenberg, E., Froula, E., and Tan, B.. Chlamydia trachomatis in a Thin-Prep papanicolaou test. *Archives of Pathology and Laboratory Medicine*. 2001;125(7):981.
- Wensveen, C. W. M., Beerman, H., and Trimbos, J. B. M. Z.. Viral load of human papillomavirus and high-grade cervical intraepithelial neoplasia. *International Journal of Gynecology and Obstetrics*. 2006;95(1):56-57.
- Westhoff, C.. IUDs and colonization or infection with *Actinomyces*. *Contraception*. 2007;75(6 SUPPL.):S48-S50.
- Wheeler, C. M. and Franceschi, S.. EUROGIN 2007 roadmap-Conclusion. *Vaccine*. 2008;26(SUPPL. 1):A28-A31.
- Whitcomb, B. P.. Gynecologic Malignancies. *Surgical Clinics of North America*. 2008;88(2):301-317.
- Widdice, L. E. and Moscicki, A.-B.. Updated Guidelines for Papanicolaou Tests, Colposcopy, and Human Papillomavirus Testing in Adolescents. *Journal of Adolescent Health*. 2008;43(4 SUPPL.):S41-S51.
- Wigfall, L., Duffus, W. A., Annang, L., Richter, D. L., Torres, M. E., Williams, E. M., and Glover, S. H.. Pap test and HIV testing behaviors of South Carolina women 18-64 years old. *Journal of the South Carolina Medical Association (1975)*. 2009;105(7):274-280.
- Wiley, D. and Masongsong, E.. Human papillomavirus: The burden of infection. *Obstetrical and Gynecological Survey*. 2006;61(6 SUPPL. 1):S3-S14.
- Wise, J.. UK pilot scheme for HPV testing announced. *BMJ (Clinical research ed)*. 2000;320(7235):600.
- Wong, C., Berkowitz, Z., Saraiya, M., Wideroff, L., and Benard, V. B.. US physicians intentions regarding impact of human papillomavirus vaccine on cervical cancer screening. *Sexual Health*. 2010;7(3):338-345.

- Wright, J. D. and Herzog, T. J.. Human papillomavirus: emerging trends in detection and management. *Current women's health reports*. 2002;2(4):259-265.
- Wright, Jr and Bosch, F. X.. Is viral status needed before vaccination?. *Vaccine*. 2008;26(SUPPL. 1):A12-A15.
- Wright, Jr, Massad, L. S., Dunton, C. J., Spitzer, M., Wilkinson, E. J., and Solomon, D.. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. *American Journal of Obstetrics and Gynecology*. 2007;197(4):346-355.
- Wright, Jr. Natural history of HPV infections. *Journal of Family Practice*. 2009;58(9):S3-S7.
- Xiong, H., Murphy, M., Mathews, M., Gadag, V., and Wang, P. P.. Cervical cancer screening among Asian Canadian immigrant and nonimmigrant women. *American journal of health behavior*. 2010;34(2):131-143.
- Yabroff, K. R., Saraiya, M., Meissner, H. I., Haggstrom, D. A., Wideroff, L., Yuan, G., Berkowitz, Z., Davis, W. W., Benard, V. B., and Coughlin, S. S.. Specialty differences in primary care physician reports of Papanicolaou test screening practices: A national survey, 2006 to 2007. *Annals of internal medicine*. 2009;151(9):602-611.
- Yakoushina, T. V., Medina, I. M., and Hoda, R. S.. "String of pearls" appearance of blue blobs in postmenopausal atrophy on thinprep pap test. *Diagnostic Cytopathology*. 2009;37(10):738-739.
- Yamazaki, T., Inaba, F., Takeda, N., Furuno, M., Kamemori, T., Kosaka, N., Ohta, Y., Fukasawa, I., and Inaba, N.. A study of abnormal cervical cytology in pregnant women. *Archives of Gynecology and Obstetrics*. 2006;273(6):355-359.
- Young, T. K., Lee, J. M., Hur, S.-Y., Cho, C.-H., Kim, Y. T., Seung, C. K., and Kang, S. B.. Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. *International Journal of Cancer*. 2010;126(8):1903-1909.
- Zandi, K., Eghbali, S. S., Hamkar, R., Ahmadi, S., Ramedani, E., Deilami, I., Nejad, H. A., Farshadpour, F., and Rastian, Z.. Prevalence of various Human Papillomavirus (HPV) genotypes among women who subjected to routine Pap smear test in Bushehr city (South west of Iran)2008-2009. *Virology Journal*. 2010;7.
- Zhang, P. J., Deng, X. X., Bai, G. R., Jiang, S. F., Lu, C. L., Zhang, X. J., Tong, H. L., Du, Y. N., Fu, H. Y., Huang, P., Ma, Y., and Tian, Y. P.. A new method of screening human papillomavirus genotypes and clinical validation. *Frontiers in bioscience (Elite edition)*. 2010;2:1015-1027.
- Zhang, P., Tao, G., and Irwin, K. L.. Utilization of preventive medical services in the United States: A comparison between rural and urban populations. *Journal of Rural Health*. 2000;16(4):349-356.
- Zhao, P., Dai, M., Chen, W., and Li, N.. Cancer trends in China. *Japanese journal of clinical oncology*. 2010;40(4):281-285.
- Zuna, R. E. and Dunn, S. T.. Can HPV Testing Function as an Objective Quality Assurance Monitor in the Cytopathology Laboratory?. *Laboratory Medicine*. 2004;35(4):238-240.

Level 2: Comparison

AbdullGaffar, B. and Kamal, M. O.. Not all unsatisfactory ThinPrep cervical Pap tests are unsatisfactory: Reprocessing improves the satisfactory and detection rates of ThinPrep cervical cytology. *Diagnostic Cytopathology*. 2010;38(9):699-701.

Akinola, O. I., Fabamwo, A. O., Oshodi, Y. A., Banjo, A. A., Odusanya, O., Gbadegesin, A., and Tayo, A.. Efficacy of visual inspection of the cervix using acetic acid in cervical cancer screening: A comparison with cervical cytology. *Journal of Obstetrics and Gynaecology*. 2007;27(7):703-705.

Alsharif, M., McKeon, D. M., Gulbahce, H. E., Savik, K., and Pambuccian, S. E.. Unsatisfactory SurePath liquid-based Papanicolaou tests: causes and significance. *Cancer cytopathology*. 2009;117(1):15-26.

Bansal, M., Austin, R. M., and Zhao, C.. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older. *Gynecologic Oncology*. 2009;115(2):257-261.

Bentz, J. S.. Liquid-based cytology for cervical cancer screening. *Expert Review of Molecular Diagnostics*. 2005;5(6):857-871.

Bhatla, N., Dar, L., Patro, A. R., Kumar, P., Kriplani, A., Gulati, A., Iyer, V. K., Mathur, S. R., Sreenivas, V., Shah, K. V., and Gravitt, P. E.. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?. *Cancer Epidemiology*. 2009;33(6):446-450.

Boon, M. E., Rijkaart, D. C., Ouwerkerk-Noordam, E., and Korporaal, H.. Dutch solutions for liquid-based cytology: Analysis of unsatisfactory slides and HPV testing of equivocal cytology. *Diagnostic Cytopathology*. 2006;34(9):644-648.

Brewer, N., Pearce, N., Jeffreys, M., Borman, B., and Ellison-Loschmann, L.. Does screening history explain the ethnic differences in stage at diagnosis of cervical cancer in New Zealand?. *International Journal of Epidemiology*. 2010;39(1):156-165.

Buechler, E. J.. Pap tests and HPV infection. *Advances in screening and interpretation. Postgraduate medicine*. 2005;118(2):37-46.

Christe, D. M., Mohanambal, M., Ramamurthy, V., and Sneha, N. B.. A study of cervical cancer screening for prevention of carcinoma cervix. *Journal of the Indian Medical Association*. 2008;106(12):779-782.

Cuzick, J., Szarewski, A., Cubie, H., Castle, P. E., and Schiffman, M.. Women with a positive HPV test can safely have yearly surveillance rather than immediate colposcopy. *Evidence-based Obstetrics and Gynecology*. 2004;6(3):150-151.

Gray, S. H. and Walzer, T. B.. New strategies for cervical cancer screening in adolescents. *Current Opinion in Pediatrics*. 2004;16(4):344-349.

Harkness, C. B., Theofrastous, J. P., Ibrahim, S. N., Galvin, S. L., and Lawrence, H. C.. Papanicolaou and thin-layer cervical cytology with colposcopic biopsy control: A comparison. *Journal of Reproductive Medicine for the Obstetrician and Gynecologist*. 2003;48(9):681-686.

Harrison, W. N., Teale, A. M., Jones, S. P., and Mohammed, M. A.. The impact of the introduction of liquid based cytology on the variation in the proportion of inadequate samples between GP practices. *BMC Public Health*. 2007;7:191.

Hodgson, W., Kaplan, K. J., Rodriguez, M., McHale, M. T., Rose, G. S., and Elkas, J. C.. The impact of

- converting to liquid-based cervical cytology in a military population. *Gynecologic Oncology*. 2005;99(2):422-426.
- Lee, H. P. and Seo, S. S.. The application of human papillomavirus testing to cervical cancer screening. *Yonsei Medical Journal*. 2002;43(6):763-768.
- Lee, S. H., Vigliotti, V. S., and Pappu, S.. Molecular tests for human papillomavirus (HPV), Chlamydia trachomatis and Neisseria gonorrhoeae in liquid-based cytology specimen. *BMC women's health*. 2009;9:8.
- Leyden, W. A., Manos, M. M., Geiger, A. M., Weinmann, S., Mouchawar, J., Bischoff, K., Yood, M. U., Gilbert, J., and Taplin, S. H.. Cervical cancer in women with comprehensive health care access: Attributable factors in the screening process. *Journal of the National Cancer Institute*. 2005;97(9):675-683.
- Liu, H., Shi, J., Wilkerson, M., Huang, Y., Meschter, S., Dupree, W., and Lin, F.. Immunohistochemical detection of p16INK4a in liquid-based cytology specimens on cell block sections. *Cancer*. 2007;111(2):74-82.
- Manavi, M., Hudelist, G., Fink-Retter, A., Gschwandtler-Kaulich, D., Pischinger, K., and Czerwenka, K.. Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. *Gynecologic Oncology*. 2007;105(2):418-426.
- Masumoto, N., Fujii, T., Ishikawa, M., Mukai, M., Saito, M., Iwata, T., Fukuchi, T., Kubushiro, K., Tsukazaki, K., and Nozawa, S.. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. *British Journal of Cancer*. 2003;88(12):1883-1888.
- Mohan, S. and Ind, T.. Cervical screening in England and Wales: An update. *Current Opinion in Obstetrics and Gynecology*. 2004;16(6):491-496.
- Monsonogo, J., Autillo-Touati, A., Bergeron, C., Dachez, R., Liaras, J., Saurel, J., Zerat, L., Chatelain, P., and Mottot, C.. Liquid-based cytology for primary cervical cancer screening: A multi-centre study. [French]. *Gynecologie Obstetrique Fertilité*. 2001;29(11):799-807.
- Oberg, T. N., Kipp, B. R., Vrana, J. A., Bartholet, M. K., Fales, C. J., Garcia, R., McDonald, A. N., Rosas, B. L., Henry, M. R., and Clayton, A. C.. Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens. *Diagnostic Cytopathology*. 2010;38(8):564-572.
- Omar, H., Callahan, P., Aggarwal, S., Perkins, K., and Young, K.. Cervical pathology in West Virginia adolescents. *The West Virginia medical journal*. 2000;96(2):408-409.
- Pinto, A. P., Maia, H. F., Di, Loretto C., Krunn, P., Tulio, S., and Collaco, L. M.. Repeating cytological preparations on liquid-based cytology samples: A methodological advantage?. *Diagnostic Cytopathology*. 2007;35(10):663-669.
- Sandri, M. T., Lentati, P., Benini, E., Dell'Orto, P., Zorzino, L., Carozzi, F. M., Maisonneuve, P., Passerini, R., Salvatici, M., Casadio, C., Boveri, S., and Sideri, M.. Comparison of the digene HC2 assay and the roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. *Journal of Clinical Microbiology*. 2006;44(6):2141-2146.
- Sanner, K., Wikstrom, I., Strand, A., Lindell, M., and Wilander, E.. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. *British Journal of Cancer*. 2009;101(5):871-874.
- Schalasta, G., Rosenthal, T., and Grothe, M.. Roche AMPLICOR human papilloma virus (HPV) and LINEAR ARRAY HPV tests will profit from automated DNA extraction. *Clinical Laboratory*. 2007;53(3-4):131-133.
- Stark, A.. Rejected and unsatisfactory specimens: A comparative study of liquid-based (SurePath) preparations and conventional pap smears for cervicovaginal screening. *Laboratory Medicine*.

2007;38(12):729-733.

Stevens, M. P., Garland, S. M., and Tabrizi, S. N.. Validation of an automated detection platform for use with the Roche Linear Array human papillomavirus genotyping test. *Journal of Clinical Microbiology*. 2008;46(11):3813-3816.

Wilson, F.. HPV testing bests papanicolaou in 2 studies. *Laboratory Medicine*. 2000;31(3):126-.

Wright, Jr, Schiffman, M., Solomon, D., Cox, J. T., Garcia, F., Goldie, S., Hatch, K., Noller, K. L., Roach, N., Runowicz, C., and Saslow, D.. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. *Obstetrics and Gynecology*. 2004;103(2):304-309.

Wright, Jr. CHAPTER 3 Pathology of HPV infection at the cytologic and histologic levels: Basis for a 2-tiered morphologic classification system. *International Journal of Gynecology and Obstetrics*. 2006;94(SUPPL. 1):S22-S31.

Level 2: Outcomes

Committee opinion no. 356: Routine cancer screening. *Obstetrics and Gynecology*. 2006;108(6):1611-1613.

Erratum: Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness (*Journal of the American Medical Association* (June 27, 2001) 285 (3107-3115)). *Journal of the American Medical Association*. 2001;286(9):1026.

Everything you know about cervical cancer screening in Alberta just changed. *Alberta RN / Alberta Association of Registered Nurses*. 2009;65(9):10-11.

HPV genotyping clinical update. *Journal of Family Practice*. 2009;58(9):S8-S10.

In South Africa, having one pap smear lowers women's chances of cervical cancer. *International family planning perspectives*. 2003;29(4):196.

Is liquid-based cytology better than Pap tests for CIN 2?. *Journal of Family Practice*. 2008;57(4):218.

Liquid-based not better than conventional Pap. *Journal of Family Practice*. 2006;55(4):284.

Pap test update. New guidelines reflect new evidence. *Mayo Clinic women's healthsource*. 2003;7(5):1-2.

Update: cervical cancer screening. *AWHONN lifelines / Association of Women's Health, Obstetric and Neonatal Nurses*. 2003;7(2):116-117.

Abulafia, O., Pezzullo, J. C., and Sherer, D. M.. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: A quantitative survey. *Gynecologic Oncology*. 2003;90(1):137-144.

Agorastos, T., Dinas, K., Lloveras, B., De, Sanjose S., Kornegay, J. R., Bonti, H., Bosch, F. X., Constantinidis, T., and Bontis, J.. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. *Gynecologic Oncology*. 2005;96(3):714-720.

Agorastos, T., Sotiriadis, A., and Emmanouilides, C. J.. Effect of type-specific human papillomavirus incidence on screening performance and cost. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010;20(2):276-282.

Anderson, R., Haas, M., and Shanahan, M.. The cost-effectiveness of cervical screening in Australia: What is the impact of screening at different intervals or over a different age range?. *Australian and New Zealand Journal of Public Health*. 2008;32(1):43-52.

Andersson, S., Dillner, L., Elfgrén, K., Mints, M., Persson, M., and Rylander, E.. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(10):996-1000.

Andy, C. and Turner, L. F.. Is the ThinPrep better than conventional Pap smear at detecting cervical cancer?. *Journal of Family Practice*. 2004;53(4):313-316.

Anttila, A., Ronco, G., Clifford, G., Bray, F., Hakama, M., Arbyn, M., and Weiderpass, E.. Cervical cancer screening programmes and policies in 18 European countries. *British Journal of Cancer*. 2004;91(5):935-941.

Arbyn, M., Simoons, C., Buntinx, F., Martin-Hirsch, P. P. L., Paraskevaidis, E., and Prendiville, W. J. P.. Triage with human papillomavirus (HPV) testing versus repeat cytology for underlying high-grade cervical intraepithelial neoplasia in women with minor cytological lesions. *Cochrane Database of Systematic Reviews*. 2009;#volume#(4):.

Arias, Y. R., Carrillo, E. F., and Aristizabal, F. A.. Human papillomavirus (HPV) detected in restored plasma DNA from women diagnosed with pre-invasive lesions and invasive cervical cancer. *Colombia Medica*. 2010;41(2):148-154.

Bach, P. B.. Gardasil: from bench, to bedside, to blunder. *The Lancet*. 2010;375(9719):963-964.

Baileff, A.. Cervical screening: patients' negative attitudes and experiences. *Nursing standard (Royal College of Nursing (Great Britain))* : 1987). 2000;14(44):35-37.

Balasubramanian, A., Kulasingam, S. L., Baer, A., Hughes, J. P., Myers, E. R., Mao, C., Kiviat, N. B., and Koutsky, L. A.. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. *Journal of Lower Genital Tract Disease*. 2010;14(3):185-195.

Bandyopadhyay, S., Austin, R. M., Dabbs, D., and Zhao, C.. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. *Archives of Pathology and Laboratory Medicine*. 2008;132(12):1874-1881.

Bano, F., Kolhe, S., Zamblera, D., Jolaoso, A., Folayan, O., Page, L., and Norton, J.. Cervical screening in under 25s: A high-risk young population. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2008;139(1):86-89.

Baseman, J. G., Kulasingam, S. L., Harris, T. G., Hughes, J. P., Kiviat, N. B., Mao, C., and Koutsky, L. A.. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. *American Journal of Obstetrics and Gynecology*. 2008;199(1):26-26.

Basu, P. and Chowdhury, D.. Cervical cancer screening & HPV vaccination: A comprehensive approach to cervical cancer control. *Indian Journal of Medical Research*. 2009;130(3):241-246.

Becker, N.. Epidemiological aspects of cancer screening in Germany. *Journal of cancer research and clinical oncology*. 2003;129(12):691-702.

Beerman, H., van Dorst, E. B. L., Kuenen-Boumeester, V., and Hogendoorn, P. C. W.. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. *Gynecologic Oncology*. 2009;112(3):572-576.

Benevolo, M., Vocaturo, A., Mottolese, M., Mariani, L., Vocaturo, G., Marandino, F., Sperduti, I., Rollo, F., Antoniani, B., and Donnorso, R. P.. Clinical role of p16INK4a expression in liquid-based cervical cytology: correlation with HPV testing and histologic diagnosis. *American journal of clinical pathology*. 2008;129(4):606-612.

Bergeron, C., Cas, F., Fagnani, F., Contrepas, A., Wadier, R., and Poveda, J. D.. Assessment of human papillomavirus testing on liquid-based Cyto-screen system for women with atypical squamous cells of undetermined significance. Effect of age. [French]. *Gynecologie, obstetrique & fertilité*. 2006;34(4):312-316.

Bergeron, C., Cas, F., Fagnani, F., Didaieller-Lambert, F., and Poveda, J. D.. Human papillomavirus testing with a liquid-based system: Feasibility and comparison with reference diagnoses. *Acta Cytologica*. 2006;50(1):16-22.

Bergeron, C., Clavel, C., Crott, M. R., Hill, C., Jaury, P., Lehr-Drylewicz, A.-M., Leroy, J.-L., Lunel, F., Monsonogo, J., Mougin, C., Orth, G., Petitjean, A., De, Reilhac P., Riethmuller, D., Sancho-Garnier, H., Sevestre, H., D'Alche-Gautier, M.-J., Agius, G., Arbyn, M., Birembaut, P., Baldauf, J.-J., Bonnier, P., Boulanger, J.-C., Boman, F., Cayrol, M.-H., Charpentier, J.-M., Cochand-Priollet, B., Dalstein, V., Duport, N., Fournier, A., Guyot, H., Halfon, P., Mergui, J.-L., Morice, P., Mousteou, F., Querleu, D., Sastre-Garau, X., Sauthier, P., and Vacher-Lavenu, M.-C.. Usefulness of searching for human papillomavirus (HPV): Evaluation of screening practices for precancerous lesions of the uterine cervix. [French]. *Annales de pathologie*. 2005;25(2):173-177.

Bergeron, C., Jeannel, D., Poveda, J., Cassonnet, P., and Orth, G.. Human papillomavirus testing in women with mild cytologic atypia. *Obstetrics and Gynecology*. 2000;95(6 Pt 1):821-827.

Berkhof, J., De Bruijne, M. C., Zielinski, G. D., and Meijer, C. J. L. M.. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. *International Journal of Cancer*. 2005;115(2):268-275.

Bhatla, N. and Moda, N.. The clinical utility of HPV DNA testing in cervical cancer screening strategies. *Indian Journal of Medical Research*. 2009;130(3):261-265.

Bhatla, N., Gulati, A., Mathur, S. R., Rani, S., Anand, K., Muwonge, R., and Sankaranarayanan, R.. Evaluation of cervical screening in rural North India. *International Journal of Gynaecology & Obstetrics*. 2009;105(2):145-149.

Blanks, R. G. and Kelly, R. S.. Comparison of cytology and histology results in English cervical screening laboratories before and after liquid-based cytology conversion: Do the data provide evidence for a single category of high-grade dyskaryosis?. *Cytopathology*. 2010;21(6):368-373.

Boardman, L. A., Weitzen, S., and Stanko, C.. Atypical squamous cells of undetermined significance, human papillomavirus, and cervical intraepithelial neoplasia 2 or 3 in adolescents: ASC-US, age, and high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2006;10(3):140-145.

Bolanca, I. K. and Vranes, J.. Diagnostic methods and techniques in preventing cervical carcinoma. Part I: Conventional cytology and new cytological methods. *Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina*. 2010;7(1):12-17.

Bollmann, R., Bankfalvi, A., Griefingholt, H., Trosic, A., Speich, N., Schmitt, C., and Bollmann, M.. Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: results from 31031 women from the Bonn-region in West Germany. *Oncology Reports*. 2005;13(5):915-922.

Bond, S.. Conventional Glass Slide Pap Smears are as Accurate as Liquid-Based Tests in Detecting Cervical Disease. *Journal of Midwifery and Women's Health*. 2008;53(4):395-396.

Boschert, S.. ACOG changes cervical Ca recommendations. *Oncology Report*. 2010;#volume#(JANUARY-FEBRUARY):23.

Braganca, J. F., Derchain, S. F., Sarian, L. O., Messias Da Silva, S. M., Labatte, S., and Zeferino, L. C.. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions. *Clinical and Experimental Obstetrics and Gynecology*.

2005;32(4):225-229.

Brink, A. A. T. P., Snijders, P. J. F., and Meijer, C. J. L. M.. HPV detection methods. *Disease Markers*. 2007;23(4):273-281.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, A. J. P., Verheijen, R. H. M., Snijders, P. J. F., and Meijer, C. J. L. M.. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. *International Journal of Cancer*. 2007;121(2):361-367.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, J. P., and Verheijen, R. H. M.. Erratum: Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing and at 6-month (International Journal Cancer (2007) 121, (361-367)). *International Journal of Cancer*. 2007;121(8):1873.

Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H. M., and Meijer, C. J. L. M.. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. *British Journal of Cancer*. 2003;89(5):834-839.

Bulkman, N. W. J., Rozendaal, L., Voorhorst, F. J., Snijders, P. J. F., and Meijer, C. J. L. M.. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. *British Journal of Cancer*. 2005;92(9):1800-1802.

Bull, S. L. and Schorge, J. O.. A study of the impact of adding HPV types to cervical cancer screening and triage tests. *Women's Oncology Review*. 2005;5(2):99-100.

Bulten, J., De Wilde, P. C. M., Boonstra, H., Gemmink, J. H., and Hanselaar, A. G. J. M.. Proliferation in 'atypical' atrophic Pap smears. *Gynecologic Oncology*. 2000;79(2):225-229.

Camilleri, G. and Blundell, R.. Pre-invasive cervical disease and cervical carcinoma. *Research Journal of Medical Sciences*. 2009;3(1):4-11.

Cardenas-Turanzas, M., Follen, M., Nogueras-Gonzalez, G. M., Benedet, J. L., Beck, J. R., and Cantor, S. B.. The accuracy of the papanicolaou smear in the screening and diagnostic settings. *Journal of Lower Genital Tract Disease*. 2008;12(4):269-275.

Cardenas-Turanzas, M., Nogueras-Gonzalez, G. M., Scheurer, M. E., Adler-Storthz, K., Benedet, J. L., Beck, J. R., Follen, M., and Cantor, S. B.. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(10):2865-2871.

Carozzi, F., Bisanzi, S., Sani, C., Zappa, M., Cecchini, S., Ciatto, S., and Confortini, M.. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. *Journal of Clinical Microbiology*. 2007;45(2):364-369.

Carozzi, F., Cecchini, S., Confortini, M., Becattini, V., Cariaggi, M. P., Pontenani, G., Sani, C., and Ciatto, S.. Role of P16(INK4A) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. *Cancer*. 2006;108(2):119-123.

Carreon, J. D., Sherman, M. E., Guillen, D., Solomon, D., Herrero, R., Jeronimo, J., Wacholder, S., Rodriguez, A. C., Morales, J., Hutchinson, M., Burk, R. D., and Schiffman, M.. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. *International Journal of Gynecological Pathology*. 2007;26(4):441-446.

Casamitjana, M., Sala, M., Ochoa, D., Fuste, P., Castells, X., and Alameda, F.. Results of a cervical cancer screening programme from an area of Barcelona (Spain) with a large immigrant population. *European Journal of Public Health*. 2009;19(5):499-503.

- Castle, P. E., Lorincz, A. T., Scott, D. R., Sherman, M. E., Glass, A. G., Rush, B. B., Wacholder, S., Burk, R. D., Manos, M. M., Schussler, J. E., Macomber, P., and Schiffman, M.. Comparison between prototype Hybrid Capture 3 and Hybrid Capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. *Journal of Clinical Microbiology*. 2003;41(9):4022-4030.
- Castle, P. E., Solomon, D., Schiffman, M., and Wheeler, C. M.. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. *Journal of the National Cancer Institute*. 2005;97(14):1066-1071.
- Castle, P. E., Wacholder, S., Sherman, M. E., Lorincz, A. T., Glass, A. G., Scott, D. R., Rush, B. B., Demuth, F., and Schiffman, M.. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. *Cancer*. 2002;95(10):2145-2151.
- Castle, P. E.. Screening: HPV testing for cervical cancer: The good, the bad, and the ugly. *Nature Reviews Clinical Oncology*. 2010;7(7):364-365.
- Castle, P. E.. The evolving definition of carcinogenic human papillomavirus. *Infectious Agents and Cancer*. 2009;4(1).
- Cattani, P., Zannoni, G. F., Ricci, C., D'Onghia, S., Trivellizzi, I. N., Di, Franco A., Vellone, V. G., Durante, M., Fadda, G., Scambia, G., Capelli, G., and De, Vincenzo R.. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. *Journal of Clinical Microbiology*. 2009;47(12):3895-3901.
- Celik, C., Gezginc, K., Toy, H., Findik, S., and Yilmaz, O.. A comparison of liquid-based cytology with conventional cytology. *International Journal of Gynecology and Obstetrics*. 2008;100(2):163-166.
- Cenci, M. and Vecchione, A.. Usefulness of cervical collection by the Exact Touch, the Saccomanno single sampler, combined with automated primary screening. *Diagnostic Cytopathology*. 2000;23(4):242-244.
- Cenci, M., Nagar, C., and Vecchione, A.. PAPNET-assisted primary screening of conventional cervical smears. *Anticancer Research*. 2000;20(5 C):3887-3889.
- Chacho, M. S., Mattie, M. E., and Schwartz, P. E.. Cytohistologic correlation rates between conventional Papanicolaou smears and ThinPrep cervical cytology: A comparison. *Cancer*. 2003;99(3):135-140.
- Chao, A., Chang, C.-J., Lai, C.-H., Chao, F.-Y., Hsu, Y.-H., Chou, H.-H., Huang, H.-J., Jung, S.-M., Lin, C.-T., Cheng, H.-H., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology - A population-based cohort study from Taiwan. *International Journal of Cancer*. 2010;126(1):191-198.
- Chao, A., Hsu, K.-H., Lai, C.-H., Huang, H.-J., Hsueh, S., Lin, S.-R., Jung, S.-M., Chao, F.-Y., Huang, S.-L., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study. *International Journal of Cancer*. 2008;122(12):2835-2841.
- Chao, F.-Y., Chao, A., Huang, C.-C., Hsueh, S., Yang, J.-E., Huang, H.-J., Wang, L.-C., Lin, C.-T., Chou, H.-H., and Lai, C.-H.. Defining detection threshold and improving analytical proficiency of HPV testing in clinical specimens. *Gynecologic Oncology*. 2010;117(2):302-307.
- Chen, H.-S., Yang, Y.-C., Su, T.-H., Wang, T.-Y., and Huang, Y.-W.. Human papillomavirus testing (Hybrid Capture II) to detect high-grade cervical intraepithelial neoplasia in women with mildly abnormal Papanicolaou results. *Taiwanese Journal of Obstetrics and Gynecology*. 2005;44(3):252-257.
- Chen, L. and Yang, B.. Assessment of reflex human papillomavirus DNA testing in patients with

atypical endocervical cells on cervical cytology. *Cancer*. 8-25-2008;114(4):236-241.

Cheung, A. N. Y., Szeto, E. F., Leung, B. S. Y., Khoo, U.-S., and Ng, A. W. Y.. Liquid-Based Cytology and Conventional Cervical Smears: A Comparison Study in an Asian Screening Population. *Cancer*. 2003;99(6):331-335.

Chin-Hong, P. V. and Klausner, J. D.. Diagnostic tests for HPV infection. *MLO: medical laboratory observer*. 2004;36(10):10-16.

Chivukula, M., Saad, R. S., Elishaev, E., White, S., Mauser, N., and Dabbs, D. J.. Introduction of the Thin Prep Imaging System (TIS): Experience in a high volume academic practice. *CytoJournal*. 2007;4 , 2007. Article Number: 6. Date of Publication: 2007.

Cibas, E. S., Alonzo, T. A., Austin, R. M., Bolick, D. R., Glant, M. D., Henry, M. R., Moriarty, A. T., Molina, J. T., Rushing, L., Slowman, S. D., Torno, R., and Eisenhut, C. C.. The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. *American journal of clinical pathology*. 2008;129(2):193-201.

Cirpan, T., Guliyeva, A., Onder, G., Terek, M. C., Ozsaran, A., Kabasakal, Y., Zekioglu, O., and Yucebilgin, S.. Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren's syndrome. *European Journal of Gynaecological Oncology*. 2007;28(4):302-306.

Cohen, D., Shorie, J., and Biscotti, C.. Glacial acetic acid treatment and atypical endocervical glandular cells: An Analysis of 92 Cases. *American journal of clinical pathology*. 2010;133(5):799-801.

Cohn, J. A., Gagnon, S., Spence, M. R., Harrison, D. D., Kluzak, T. R., Langenberg, P., Brinson, C., Stein, A., and Hellinger, J.. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. *American Journal of Obstetrics and Gynecology*. 2001;184(3):322-330.

Colgan, T. J., Woodhouse, S. L., Styer, P. E., Kennedy, M., and Davey, D. D.. Reparative changes and the false-positive/false-negative papanicolaou test: A study from the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. *Archives of Pathology and Laboratory Medicine*. 2001;125(1):134-140.

Confortini, M., Giorgi, Rossi P., Barbarino, P., Passarelli, A. M., Orzella, L., and Tufi, M. C.. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. *Journal of medical screening*. 2010;17(2):79-86.

Coquillard, G., Palao, B., and Patterson, B. K.. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. *Gynecologic Oncology*. 2011;120(1):89-93.

Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women. *Obstetrics & Gynecology*. 2002;100(1):79-86.

Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women1. *Obstetrics and Gynecology*. 2002;100(1):79-86.

Corusic, A., Skrgatic, L., Mahovlic, V., Mandic, V., Planinic, P., and Karadza, M.. Cervical cancer as a public health issue--what next?. *Collegium antropologicum*. 2010;34(1):301-307.

Coste, J., Cochand-Priollet, B., de, Cremoux P., Buntinx, F., and Arbyn, M.. Conventional cervical smears were better than monolayer cytology or human papillomavirus testing for detecting cervical

intraepithelial neoplasia. *Evidence-Based Medicine*. 2003;8(6):187.

Coutlee, F., Rouleau, D., Petignat, P., Ghattas, G., Kornegay, J. R., Schlag, P., Boyle, S., Hankins, C., Vezina, S., Cote, P., Macleod, J., Voyer, H., Forest, P., Walmsley, S., Franco, E., Conners, J., Grimshaw, R., Haase, D., Johnston, L., Schlech, W., Yuzicappi-Fayant, A., Landis, S., Smaill, F., Austin, T., Hammerberg, O., Ralph, T., Falutz, J., Ferenczy, A., Klein, M., Labrecque, L., Lalonde, R., Noel, G., Perron, C., Routy, J.-P., Toma, E., Touchie, C., Victor, G., Cote, L., Senay, H., Trottier, S., Williams, K., Piche, A., Sandre, R., Binder, L., Keystone, D., Phillips, A., Rachlis, A., Salit, I., Wagner, C., Braitstein, P., Burdge, D., Harris, M., Money, D., and Montaner, J.. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. *Journal of Clinical Microbiology*. 2006;44(6):1998-2006.

Cox, J. T.. Corrigendum to "History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results" [*J. Clin. Virol.* 45 (1) (2009) S3-S12] (PII:S1386-6532(09)X0008-9). *Journal of Clinical Virology*. 2010;47(3):299.

Cox, J. T.. Human papillomavirus testing in primary cervical screening and abnormal papanicolaou management. *Obstetrical and Gynecological Survey*. 2006;61(6 SUPPL. 1):S15-S25.

Cox, J. T.. Liquid-based cytology: evaluation of effectiveness, cost-effectiveness, and application to present practice. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2004;2(6):597-611.

Curran, D. R. and Stigleman, S.. Should we discontinue Pap smear screening in women aged >65 years?. *Journal of Family Practice*. 2004;53(4):308-310.

Cuzick, J., Arbyn, M., Sankaranarayanan, R., Tsu, V., Ronco, G., Mayrand, M.-H., Dillner, J., and Meijer, C. J. L. M.. Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. *Vaccine*. 2008;26(SUPPL. 10):K29-K41.

Cuzick, J., Clavel, C., Petry, K.-U., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., and Iftner, T.. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006;119(5):1095-1101.

Cuzick, J., Szarewski, A., Mesher, D., Cadman, L., Austin, J., Perryman, K., Ho, L., Terry, G., Sasieni, P., Dina, R., and Soutter, W. P.. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - Results from the Hammersmith study. *International Journal of Cancer*. 2008;122(10):2294-2300.

Cuzick, J.. Time to consider HPV testing in cervical screening. *Annals of Oncology*. 2001;12(11):1511-1514.

Datta, S. D., Koutsky, L. A., Ratelle, S., Unger, E. R., Shlay, J., McClain, T., Weaver, B., Kerndt, P., Zenilman, J., Hagensee, M., Suhr, C. J., and Weinstock, H.. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. *Annals of internal medicine*. 2008;148(7):493-500.

Davey, E., D'Assuncao, J., Irwig, L., Macaskill, P., Chan, S. F., Richards, A., and Farnsworth, A.. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: Prospective study. *British Medical Journal*. 2007;335(7609):31-35.

De Francesco, M. A., Gargiulo, F., Schreiber, C., Ciravolo, G., Salinaro, F., and Manca, N.. Comparison of the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. *Journal of Virological Methods*. 2008;147(1):10-17.

- De, Lang A. and Wilander, E.. Sensitivity of HPV tests on stained vs. unstained cervical smears. *Acta Cytologica*. 2005;49(6):595-599.
- De, Lang A., Wikstrom, I., and Wilander, E.. Significance of HPV tests on women with cervical smears showing ASCUS. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(10):1001-1005.
- Denton, K. J., Bergeron, C., Klement, P., Trunk, M. J., Keller, T., and Ridder, R.. The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. *American journal of clinical pathology*. 2010;134(1):12-21.
- Derchain, S. F., Sarian, L. O., Naud, P., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Serpa-Hammes, L., Matos, J., Gontijo, R. C., Braganca, J. F., Lima, T. P., Maeda, M. Y., Lorincz, A., Dores, G. B., Costa, S., Syrjanen, S., and Syrjanen, K.. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study. *Journal of medical screening*. 2008;15(2):97-104.
- Desai, M.. Role of automation in cervical cytology. *Diagnostic Histopathology*. 2009;15(7):323-329.
- Diaz-Montes, T. P., Farinola, M. A., Zahurak, M. L., Bristow, R. E., and Rosenthal, D. L.. Clinical utility of atypical glandular cells (AGC) classification: Cytohistologic comparison and relationship to HPV results. *Gynecologic Oncology*. 2007;104(2):366-371.
- Difurio, M. J., Mailhiot, T., Sundborg, M. J., and Nauschuetz, K. K.. Comparison of the clinical significance of the papanicolaou test interpretations LSIL cannot rule out HSIL and ASC-H. *Diagnostic Cytopathology*. 2010;38(5):313-317.
- Dockter, J., Schroder, A., Hill, C., Guzinski, L., Monsonogo, J., and Giachetti, C.. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S55-S61.
- Duby, J. M. and Difurio, M. J.. Implementation of the ThinPrep Imaging System in a tertiary military medical center. *Cancer cytopathology*. 2009;117(4):264-270.
- Duggan, M. A., Khalil, M., Brasher, P. M. A., and Nation, J. G.. Comparative study of the ThinPrep Pap test and conventional cytology results in a Canadian cohort. *Cytopathology*. 2006;17(2):73-81.
- Dziura, B., Quinn, S., and Richard, K.. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the uterine cervix. *Acta Cytologica*. 2006;50(3):309-311.
- Eilstein, D., Hedelin, G., and Schaffer, P.. Cervical cancer in Bas-Rhin: Trend and prediction of the incidence in 2014. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2002;31(1):28-33.
- Einstein, M. H., Studentsov, Y. Y., Ho, G. Y. F., Fazzari, M., Marks, M., Kadish, A. S., Goldberg, G. L., Runowicz, C. D., and Burk, R. D.. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. *International Journal of Cancer*. 2007;120(1):55-59.
- Elfgren, K., Kalantari, M., Moberger, B., Hagmar, B., and Dillner, J.. A population-based five-year follow-up study of cervical human papillomavirus infection. *American Journal of Obstetrics and Gynecology*. 2000;183(3):561-567.
- Elsheikh, T. M., Kirkpatrick, J. L., and Wu, H. H.. The significance of "low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion" as a distinct squamous abnormality category in Papanicolaou tests. *Cancer*. 2006;108(5):277-281.
- Eltoum, I. A. and Roberson, J.. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national pap test volume: Projections from the National Health Interview Survey

(NHIS). *Cancer*. 2007;111(1):34-40.

Eltoum, I. A., Chhieng, D. C., Roberson, J., McMillon, D., and Partridge, E. E.. Reflex human papilloma virus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2-3 in young versus elderly women. *Cancer*. 2005;105(4):194-198.

Fait, G., Kupferminc, M. J., Daniel, Y., Geva, E., Ron, I. G., Lessing, J. B., and Bar-Am, A.. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal Pap smears before colposcopy referral. *Gynecologic Oncology*. 2000;79(2):177-180.

Farag, R., Redline, R., and Abdul-Karim, F. W.. Value of combining HPV-DNA testing with follow-up papanicolaou smear in patients with prior atypical squamous cells of undetermined significance. *Acta Cytologica*. 2008;52(3):294-296.

Federico, C., Alleyn, J., Dola, C., Tafti, S., Galandak, J., Jacob, C., Bhuiyan, A., and Cheng, J.. Relationship among age, race, medical funding, and cervical cancer survival. *Journal of the National Medical Association*. 2010;102(3):199-205.

Feng, J., Al-Abadi, M. A., Bandyopadhyay, S., Salimnia, H., and Husain, M.. Significance of high-risk human papillomavirus DNA-positive atypical squamous cells of undetermined significance pap smears in perimenopausal and postmenopausal women. *Acta Cytologica*. 2008;52(4):434-438.

Ferreccio, C., Bratti, M. C., Sherman, M. E., Herrero, R., Wacholder, S., Hildesheim, A., Burk, R. D., Hutchinson, M., Alfaro, M., Greenberg, M. D., Morales, J., Rodriguez, A. C., Schussler, J., Eklund, C., Marshall, G., and Schiffman, M.. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. *Cancer Epidemiology Biomarkers and Prevention*. 2003;12(9):815-823.

Ferris, D. G., Gilman, P. A., Leyva Lopez, A. G., Litaker, M. S., Miller, J. A., and Macfee, M. S.. Psychological effects women experience before and after a colposcopic examination and primary care appointment. *Journal of Lower Genital Tract Disease*. 2003;7(2):89-94.

Ferris, D. G., Heidemann, N. L., Litaker, M. S., Crosby, J. H., and Macfee, M. S.. The efficacy of liquid-based cervical cytology using direct-to-vial sample collection. *Journal of Family Practice*. 2000;49(11):1005-1011.

Fink, J. L.. Beyond the shock of an abnormal Pap. *RN*. 2003;66(6):56-61.

Freeman-Wang, T. and Walker, P.. Psychological aspects of colposcopy. *CME Journal of Gynecologic Oncology*. 2005;10(2):123-126.

Frega, A., Biamonti, A., Maranghi, L., Vetrano, G., Palazzo, A., Iacovelli, R., Corosu, R., French, D., Moscarini, M., and Vecchione, A.. Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. Analysis of risk factors. *Anticancer Research*. 2006;26(4 B):3167-3170.

Freitas, R. A. P., Carvasan, G. A. F., Morais, S. S., and Zeferino, L. C.. Excessive pap smears due to opportunistic cervical cancer screening. *European Journal of Gynaecological Oncology*. 2008;29(5):479-482.

Fremont-Smith, M., Marino, J., Griffin, B., Spencer, L., and Bolick, D.. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. *Cancer*. 2004;102(5):269-279.

Froberg, M., Johansson, B., Hjerpe, A., and Andersson, S.. Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities. *British Journal of Cancer*. 2008;99(4):563-568.

Gage, J. C., Schiffman, M., Solomon, D., Wheeler, C. M., and Castle, P. E.. Comparison of

measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. *Cancer Epidemiology Biomarkers and Prevention*. 2010;19(7):1668-1674.

Garcia-Garcia, J. A., Perez-Valles, A., Martorell, M., Gomez, B., Gomez-Cabrero, D., Soler, F., and Calabuig, C.. Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. *Acta Cytologica*. 2010;54(2):159-164.

Garcia-Sierra, N., Martro, E., Castella, E., Llatjos, M., Tarrats, A., Bascunana, E., Diaz, R., Carrasco, M., Sirera, G., Matas, L., and Ausina, V.. Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening. *Journal of Clinical Microbiology*. 2009;47(7):2165-2169.

Gazzaz, F. S. B.. Molecular testing of human papillomavirus in cervical specimens. *Saudi Medical Journal*. 2007;28(12):1810-1818.

Ge, Y., Smith, D., Schwartz, M. R., and Mody, D. R.. Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population. *Cancer cytopathology*. 2009;117(5):326-332.

Geldenhuis, L. and Murray, M. L.. Sensitivity and specificity of the pap smear for glandular lesions of the cervix and endometrium. *Acta Cytologica*. 2007;51(1):47-50.

Ginsberg, G. M., Edejer, T. T. T., Lauer, J. A., and Sepulveda, C.. Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis. *Vaccine*. 2009;27(43):6060-6079.

Giordano, G., Gnetti, L., Pilato, F. P., Viviano, L., and Silini, E. M.. The role of cervical smear in the diagnosis and management of extrauterine malignancies metastatic to the cervix: Three case reports. *Diagnostic Cytopathology*. 2010;38(1):41-46.

Girianelli, V. R. and Thuler, L. C. S.. Evaluation of agreement between conventional and liquid-based cytology in cervical cancer early detection based on analysis of 2,091 smears: Experience at the Brazilian National Cancer Institute. *Diagnostic Cytopathology*. 2007;35(9):545-549.

Gontijo, R. C., Derchain, S. F. M., Roteli-Martins, C., Braganca, J. F., Sarian, L. O., Morais, S. S., Maeda, M. Y. S., Longatto-Filho, A., and Syrjanen, K. J.. Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2007;133(2):239-246.

Grace, A., McBrearty, P., Troost, S., Thornhill, M., Kay, E., and Leader, M.. Comparative study: Conventional cervical and ThinPrep Pap tests in a routine clinical setting. *Cytopathology*. 2002;13(4):200-205.

Grainge, M. J., Seth, R., Guo, L., Neal, K. R., Coupland, C., Vryenhoef, P., Johnson, J., and Jenkins, D.. Cervical human papillomavirus screening among older women. *Emerging Infectious Diseases*. 2005;11(11):1680-1685.

Greydanus, D. E., Omar, H., and Patel, D. R.. Cervical cancer screening in adolescents. *Pediatrics in Review*. 2009;30(1):23-25.

Greydanus, D. E., Omar, H., and Patel, D. R.. What's new: Cervical cancer screening in adolescents. *Pediatrics in review / American Academy of Pediatrics*. 2009;30(1):23-25.

Guido, R.. Guidelines for screening and treatment of cervical disease in the adolescent. *Journal of Pediatric and Adolescent Gynecology*. 2004;17(5):303-311.

Guidos, B. J. and Selvaggi, S. M.. Detection of endometrial adenocarcinoma with the ThinPrep Pap

Test(TM). *Diagnostic Cytopathology*. 2000;23(4):260-265.

Guillaud, M., Benedet, J. L., Cantor, S. B., Staerckel, G., Follen, M., and MacAulay, C.. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. *Cancer*. 2006;107(2):309-318.

Guo, M., Hu, L., Martin, L., Liu, S., Baliga, M., and Hughson, M. D.. Accuracy of liquid-based pap tests: Comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal pap smears. *Acta Cytologica*. 2005;49(2):132-138.

Guo, M., Patel, S. J., Chovanec, M., Yee, J. J., Tarco, E., Bevers, T. B., Anderson, K., and Sneige, N.. A human papillomavirus testing system in women with abnormal pap results: A comparison study with follow-up biopsies. *Acta Cytologica*. 2007;51(5):749-754.

Halfon, P., Benmoura, D., Agostini, A., Khiri, H., Martineau, A., Penaranda, G., and Blanc, B.. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. *Journal of Clinical Virology*. 2010;47(2):177-181.

Halfon, P., Benmoura, D., Khiri, H., Penaranda, G., Blanc, B., Riggio, D., and Sandri, M. T.. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. *Journal of Clinical Virology*. 2010;47(1):38-42.

Halford, J. A., Batty, T., Boost, T., Duhig, J., Hall, J., Lee, C., and Walker, K.. Comparison of the sensitivity of conventional cytology and the ThinPrep imaging system for 1,083 biopsy confirmed high-grade squamous lesions. *Diagnostic Cytopathology*. 2010;38(5):318-326.

Hall, J. and Kendall, B.. High risk human papillomavirus DNA detection in pap tests with both atypical squamous cells of undetermined significance and candida. *Acta Cytologica*. 2009;53(2):150-152.

Hamashima, C., Aoki, D., Miyagi, E., Saito, E., Nakayama, T., Sagawa, M., Saito, H., Sobue, T., and Japanese Research Group for Development of Cervical Cancer Screening Guidelines. The Japanese guideline for cervical cancer screening. *Japanese journal of clinical oncology*. 2010;40(6):485-502.

Hantz, S., Caly, H., Decroisette, E., Dutrop, A., Bakeland, D., Pascal, B., Darreys, G., Dussartre, C., Renaudie, J., Rogez, S., Aubard, Y., Denis, F., and Alain, S.. Evaluation of accuracy of three assays for human papillomavirus detection and typing: Hybrid Capture 2, HPV Consensus kit and AmpliCor HPV. [French]. *Pathologie Biologie*. 2008;56(1):29-35.

Hartmann, K. E., Nanda, K., Hall, S., and Myers, E.. Technologic advances for evaluation of cervical cytology: Is newer better?. *Obstetrical and Gynecological Survey*. 2001;56(12):765-774.

Harvey, M., Stout, S., Starkey, C. R., Hendren, R., Holt, S., and Miller, G. C.. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S79-S83.

Hatch, K. D., Sheets, E., Kennedy, A., Ferris, D. G., Darragh, T., and Twiggs, L.. Multicenter direct to vial evaluation of a liquid-based Pap test. *Journal of Lower Genital Tract Disease*. 2004;8(4):308-312.

Healey, S. M., Aronson, K., Mao, Y., and Franco, E. L.. Human papillomavirus and cervical dysplasia in Nunavut: prelude to a screening strategy. *International Journal of Circumpolar Health*. 2004;63 Suppl 2:199-201.

Hellsten, C., Lindqvist, P. G., and Sjostrom, K.. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2008;115(2):205-211.

Hellsten, C., Sjostrom, K., and Lindqvist, P. G.. A prospective Swedish cohort study on psychosocial factors influencing anxiety in women referred for colposcopy. *BJOG: An International Journal of*

Obstetrics & Gynaecology. 2007;114(1):32-38.

Herbert, A.. Cervical screening in England and Wales: Its effect has been underestimated. *Cytopathology*. 2000;11(6):471-479.

Hesselink, A. T., Berkhof, J., Heideman, D. A., Bulkman, N. W., van Tellingen, J. E., Meijer, C. J., and Snijders, P. J.. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. *International Journal of Cancer*. 2009;Journal international du cancer. 124(2):381-386.

Hoekstra, A. V., Kosinski, A., and Huh, W. K.. Hormonal contraception and false-positive cervical cytology: Is there an association?. *Journal of Lower Genital Tract Disease*. 2006;10(2):102-106.

Holmquist, N. D.. Revisiting the effect of the pap test on cervical cancer. *American journal of public health*. 2000;90(4):620-623.

Hong, D. G., Seong, W. J., Kim, S. Y., Lee, Y. S., and Cho, Y. L.. Prediction of high-grade squamous intraepithelial lesions using the modified Reid index. *International Journal of Clinical Oncology*. 2010;15(1):65-69.

Howard, K., Salkeld, G., McCaffery, K., and Irwig, L.. HPV triage testing or repeat pap smear for the management of a typical squamous cells (ASCUS) on pap smear: Is there evidence of process utility?. *Health Economics*. 2008;17(5):593-605.

Huang, S., Erickson, B., Tang, N., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S19-S23.

Hunter, C., Duggan, M. A., Duan, Q., Power, P., Gregoire, J., and Nation, J.. Cytology and outcome of LSIL: Cannot exclude HSIL compared to ASC-H. *Cytopathology*. 2009;20(1):17-26.

Hussein, T., Desai, M., Tomlinson, A., and Kitchener, H. C.. The comparative diagnostic accuracy of conventional and liquid-based cytology in a colposcopic setting. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2005;112(11):1542-1546.

Illades-Aguiar, B., Alarcon-Romero, L., Antonio-Vejar, V., Zamudio-Lopez, N., Sales-Linares, N., Flores-Alfaro, E., Fernandez-Tilapa, G., Vences-Velazquez, A., Munoz-Valle, J. F., and Leyva-Vazquez, M.-A.. Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico. *Gynecologic Oncology*. 2010;117(2):291-296.

Inoue, M., Sakaguchi, J., Sasagawa, T., and Tango, M.. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. *International Journal of Gynecological Cancer*. 2006;16(3):1007-1013.

Jacot-Guillarmod, M., Hohlfeld, P., and Renteria, S.-C.. Role of the PAP smear in adolescence. [French]. *Revue Medicale Suisse*. 2009;5(222):2078-2084.

Jeng, C.-J., Ko, M.-L., Ling, Q.-D., Shen, J., Lin, H.-W., Tzeng, C.-R., Ho, C.-M., Chien, T.-Y., and Chen, S.-C.. Prevalence of cervical human papillomavirus in Taiwanese women. *Clinical and Investigative Medicine*. 2005;28(5):261-266.

Jiang, J., Wei, L.-H., Li, Y.-L., Wu, R.-F., Xie, X., Feng, Y.-J., Zhang, G., Zhao, C., Zhao, Y., and Chen, Z.. Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer: A multicenter study in China. *Journal of Molecular Diagnostics*. 2010;12(6):808-817.

Julian, T. M.. Erratum: Type-specific HPV testing as a predictor of high-grade squamous intraepithelial lesion outcome after cytologic abnormalities (*Journal of Lower Genital Tract Disease* (2005) 9, (3),

(154-159)). *Journal of Lower Genital Tract Disease*. 2006;10(1):63.

Juric, D., Mahovlic, V., Rajhvajn, S., Ovanin-Rakic, A., Skopljanac-Macina, L., Barisic, A., Projic, I. S., Babic, D., Susa, M., Corusic, A., and Oreskovic, S.. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions. *Collegium antropologicum*. 2010;34(1):19-24.

Kang, W. D., Kim, C. H., Cho, M. K., Kim, J. W., Kim, Y. H., Choi, H. S., and Kim, S. M.. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. *International Journal of Gynecological Cancer*. 2009;19(5):924-928.

Karabulut, A., Alan, T., Ali, Ekiz M., Iritas, A., Kesen, Z., and Yahsi, S.. Evaluation of cervical screening results in a population at normal risk. *International Journal of Gynecology and Obstetrics*. 2010;110(1):40-42.

Karam, W. G., Bedran, F., Tohme, R. A., Moukarbel, N., Abdallah, I., Jurjus, A. R., Jurjus, R. A., Khairallah, S., and Aftimos, G.. Human papillomavirus testing as an adjunct to cytology evaluation in cervical specimens of selected and consecutively screened Lebanese women: A prospective clinical study. *Journal Medical Libanais*. 2005;53(3):132-138.

Karasz, A., McKee, M. D., and Roybal, K.. Women's experiences of abnormal cervical cytology: illness representations, care processes, and outcomes. *Annals of family medicine*. 2003;1(4):196-202.

Kent, A.. Screening and logical cytology - A review. *Obstetrics and Gynaecology Forum*. 2009;19(4):141-143.

Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M. S., Scott, D. R., Rush, B. R., Glass, A. G., and Schiffman, M.. The elevated 10-Year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *Journal of the National Cancer Institute*. 2005;97(14):1072-1079.

Kiatpongsan, S., Niruthisard, S., Mutirangura, A., Trivijitsilp, P., Vasuratna, A., Chaithongwongwatthana, S., and Lertkhachonsuk, R.. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. *International Journal of Gynecological Cancer*. 2006;16(1):262-265.

Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., and Choi, C.. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Gynecologic Oncology*. 2010;116(1):99-104.

Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., Choi, C., Kweon, S.-S., Fackler, M. J., and Sukumar, S.. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Virchows Archiv*. 2010;457(1):35-42.

Kinney, W., Castle, P. E., Fetterman, B., Poitras, N., Lorey, T., and Shaber, R.. Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. *Obstetrics and Gynecology*. 2009;113(3):595-600.

Kirschner, B., Simonsen, K., and Junge, J.. Comparison of conventional Papanicolaou smear and SurePath liquid-based cytology in the Copenhagen population screening programme for cervical cancer. *Cytopathology*. 2006;17(4):187-194.

Kjaer, S., Hogdall, E., Frederiksen, K., Munk, C., Van Den Brule, A., Svare, E., Meijer, C., Lorincz, A., and Iftner, T.. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. *Cancer Research*. 2006;66(21):10630-10636.

Klinkhamer, P. J. J. M., Meerding, W. J., Rosier, P. F. W. M., and Hanselaar, A. G. J. M.. Liquid-based cervical cytology: A review of the literature with methods of evidence-based medicine. *Cancer*. 2003;99(5):263-271.

- Knoepp, S. M., Kuebler, D. L., and Wilbur, D. C.. Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: a cytologic/histologic review of 367 cases. *Cancer cytopathology*. 2010;118(4):209-217.
- Knoepp, S. M., Kuebler, D. L., and Wilbur, D. C.. Resolution of equivocal results with the hybrid capture II high-risk HPV DNA Test: A cytologic/histologic review of 191 cases. *Diagnostic Molecular Pathology*. 2007;16(3):125-129.
- Ko, V., Nanji, S., Tambouret, R. H., and Wilbur, D. C.. Testing for HPV as an objective measure for quality assurance in gynecologic cytology: Positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio. *Cancer*. 2007;111(2):67-73.
- Ko, V., Tambouret, R. H., Kuebler, D. L., Black-Schaffer, W. S., and Wilbur, D. C.. Human papillomavirus testing using Hybrid Capture II with SurePath collection: Initial evaluation and longitudinal data provide clinical validation for this method. *Cancer*. 2006;108(6):468-474.
- Koliopoulos, G., Valasoulis, G., and Zilakou, E.. An update review on HPV testing methods for cervical neoplasia. *Expert Opinion on Medical Diagnostics*. 2009;3(2):123-131.
- Koong, S. L., Yen, A. M., and Chen, T. H.. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. *Journal of medical screening*. 2006;13 Suppl 1:S44-S47.
- Kotaniemi-Talonen, L., Nieminen, P., Hakama, M., Seppanen, J., Ikkala, J., Martikainen, J., Tarkkanen, J., Toivonen, T., and Anttila, A.. Significant variation in performance does not reflect the effectiveness of the cervical cancer screening programme in Finland. *European Journal of Cancer*. 2007;43(1):169-174.
- Kulasingam, S. L. and Myers, E. R.. Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs. *Journal of the American Medical Association*. 2003;290(6):781-789.
- Kulmala, S.-M., Syrjanen, S., Shabalova, I., Petrovichev, N., Kozachenko, V., Podistov, J., Ivanchenko, O., Zakharenko, S., Nerovjna, R., Kljukina, L., Branovskaja, M., Grunberga, V., Juschenko, A., Tosi, P., Santopietro, R., and Syrjanen, K.. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. *Journal of Clinical Microbiology*. 2004;42(6):2470-2475.
- Kumar, N., Bongiovanni, M., Molliet, M.-J., Pelte, M.-F., Egger, J.-F., and Pache, J.-C.. Reclassification and analysis of clinical significance of atypical glandular cells on ThinPrep using the Bethesda 2001: Geneva experience. *Swiss Medical Weekly*. 2007;137(45-46):635-641.
- Kurtycz, D. F. I., Smith, M., He, R., Miyazaki, K., and Shalkham, J.. Comparison of methods trial for high-risk HPV. *Diagnostic Cytopathology*. 2010;38(2):104-108.
- Kyrgiou, M., Tsoumpou, I., Vrekoussis, T., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Mitrou, S., Koliopoulos, G., Dalkalitsis, N., Stamatopoulos, P., and Paraskevaidis, E.. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: The cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. *Cancer Treatment Reviews*. 2006;32(7):516-523.
- Lam, C. L. K.. The price of cancer screening. *Hong Kong Practitioner*. 2004;26(3):142-145.
- Lavoue, V., Bergeron, C., Riethmuller, D., Darai, E., Mergui, J.-L., Baldauf, J.-J., Gondry, J., Douvier, S., Lopes, P., De, Reilhac P., Quereux, C., Letombe, B., Marchetta, J., Boulanger, J.-C., and Leveque, J.. Cervical screening: Toward a new paradigm?. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2010;39(2):102-115.
- Lazcano-Ponce, E., Lorincz, A. T., Salmeron, J., Fernandez, I., Cruz, A., Hernandez, P., Mejia, I., and

- Hernandez-Avila, M.. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican social security program. *Cancer Causes and Control*. 2010;21(10):1693-1700.
- Lee, C. Y. K. and Ng, W.-K.. A follow-up study off atypical squamous cells in gynecologic cytology using conventional papanicolaou smears and liquid-based preparations: The impact of the Bethesda system 2001. *American journal of clinical pathology*. 2007;127(4):548-555.
- Lee, S. H., Vigliotti, V. S., and Pappu, S.. HPV infection among women in a representative rural and suburban population of the USA. *International Journal of Gynecology and Obstetrics*. 2009;105(3):210-214.
- Lerma, E., Quintana, M. J., Quilez, M., Esteva, E., Carreras, A., Bonfill, X., Prat, J., and Calaf, J.. Effectiveness of liquid-based cytology and Papanicolaou tests in a low risk population. *Acta Cytologica*. 2007;51(3):399-406.
- Li, N., Shi, J.-F., Franceschi, S., Zhang, W.-H., Dai, M., Liu, B., Zhang, Y.-Z., Li, L.-K., Wu, R.-F., De Vuyst H., Plummer, M., Qiao, Y.-L., and Clifford, G.. Different cervical cancer screening approaches in a Chinese multicentre study. *British Journal of Cancer*. 2009;100(3):532-537.
- Liang, J., Mittal, K. R., Wei, J. J., Yee, H., Chiriboga, L., and Shukla, P.. Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with silverberg scoring system for endocervical glandular lesions. *International Journal of Gynecological Pathology*. 2007;26(1):71-75.
- Lie, A. K., Risberg, B., Borge, B., Sandstad, B., Delabie, J., Rimala, R., Onsrud, M., and Thoresen, S.. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. *Gynecologic Oncology*. 2005;97(3):908-915.
- Liman, A. K., Giampoli, E. J., and Bonfiglio, T. A.. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?. *Cancer*. 2005;105(6):457-460.
- Liu, S. S., Leung, R. C. Y., Chan, K. K. L., Cheung, A. N. Y., and Ngan, H. Y. S.. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche linear array HPV genotyping assay. *Journal of Clinical Microbiology*. 2010;48(3):758-764.
- Longatto, Filho A., Miranda Pereira, S. M., Di, Loreto C., Utagawa, M. L., Makabe, S., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., and Castelo, A.. DCS liquid-based system is more effective than conventional smears to diagnosis of cervical lesions: Study in high-risk population with biopsy-based confirmation. *Gynecologic Oncology*. 2005;97(2):497-500.
- Longatto-Filho, A., Erzen, M., Branca, M., Roteli-Martins, C., Naud, P., Derchain, S. F. M., Hammes, L., Sarian, L. O., Braganca, J. F., Matos, J., Gontijo, R., Lima, T., Maeda, M. Y. S., Tatti, S., Syrjanen, S., Dores, G., Lorincz, A., and Syrjanen, K.. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: Experience from the Latin American screening study. *International Journal of Gynecological Cancer*. 2006;16(3):955-962.
- Lonky, N. M., Mahdavi, A., Wolde-Tsadik, G., Bajamundi, K., and Felix, J. C.. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: A retrospective review of the southern california permanente medical group experience. *Journal of Lower Genital Tract Disease*. 2010;14(3):200-205.
- Lorenzato, M., Caudroy, S., Bronner, C., Evrard, G., Simon, M., Durlach, A., Birembaut, P., and Clavel, C.. Cell cycle and/or proliferation markers: What is the best method to discriminate cervical high-grade lesions?. *Human Pathology*. 2005;36(10):1101-1107.
- Lozano, R.. Comparison of computer-assisted and manual screening of cervical cytology. *Gynecologic Oncology*. 2007;104(1):134-138.

- Luque, A. E., Jabeen, M., Messing, S., Lane, C. A., Demeter, L. M., Rose, R. C., and Reichman, R. C.. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. *Journal of Infectious Diseases*. 2006;194(4):428-434.
- Ma, L., Bian, M.-L., Cheng, J.-Y., Xiao, W., Hao, M., Zhu, J., Chen, Y., and Liu, J.. Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study. *Experimental and Therapeutic Medicine*. 2010;1(1):193-198.
- Maehama, T.. Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterine cervix. *Infectious diseases in obstetrics and gynecology*. 2005;13(2):77-80.
- Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. *BMJ*. 5-29-2004;328(7451):1293.
- Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-Month follow-up. *British Journal of Cancer*. 2005;92(6):990-994.
- Mao, C., Balasubramanian, A., Yu, M., Kiviat, N., Ridder, R., Reichert, A., Herkert, M., Von Knebel, Doeberitz M., and Koutsky, L. A.. Evaluation of a new p16INK4a ELISA test and a high-risk HPV DNA test for cervical cancer screening: Results from proof-of-concept study. *International Journal of Cancer*. 2007;120(11):2435-2438.
- Marchetti, I., Zavaglia, K., Bertacca, G., Aretini, P., Matteoli, B., Viacava, P., Prato, B., De, Punzio C., Genazzani, A. R., Bevilacqua, G., and Di, Coscio G.. HPV testing and Pap test: Role for a combined approach in a non-screened population. *International Journal of Biological Markers*. 2006;21(3):149-156.
- Massad, S. L., Markwell, S., Cejtin, H. E., and Collins, Y.. Risk of high-grade cervical intraepithelial neoplasia among young women with abnormal screening cytology. *Journal of Lower Genital Tract Disease*. 2005;9(4):225-229.
- Mathur, S. P., Mathur, R. S., Creasman, W. T., Underwood, P. B., and Kohler, M.. Early non-invasive diagnosis of cervical cancer: beyond Pap smears and human papilloma virus (HPV) testing. *Cancer biomarkers : section A of Disease markers*. 2005;1(2-3):183-191.
- Matthews-Greer, J., Rivette, D., Reyes, R., Vanderloos, C. F., and Turbat-Herrera, E. A.. Human papillomavirus detection: verification with cervical cytology. *Clinical laboratory science : journal of the American Society for Medical Technology*. 2004;17(1):8-11.
- Mattimoe, T.. No more annual pap tests: reviewing the consensus of experts. *Advance for nurse practitioners*. 2010;18(5):18.
- McBride, D.. New DNA test for cervical cancer outperforms Pap test. *ONS connect*. 2009;24(7):23.
- McCaffery, K. J., Irwig, L., Chan, S. F., Macaskill, P., Barratt, A., Lewicka, M., Clarke, J., and Weisberg, E.. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: Evaluation of a decision aid to support informed choice. *Patient Education and Counseling*. 2008;73(3):473-481.
- McCaffery, K., Waller, J., Forrest, S., Cadman, L., Szarewski, A., and Wardle, J.. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact.[Erratum appears in *BJOG*. 2004 Dec;111(12):1489]. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2004;111(12):1437-1443.
- McGrath, C. M., Kurtis, J. D., and Yu, G. H.. Evaluation of mild-to-moderate dysplasia on cervical-endocervical (Pap) smear: A subgroup of patients who bridge LSIL and HSIL. *Diagnostic*

Cytopathology. 2000;23(4):245-248.

Meijer, C. J. L. M., Berkhof, H., Heideman, D. A. M., Hesselink, A. T., and Snijders, P. J. F.. Validation of high-risk HPV tests for primary cervical screening. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S1-S4.

Meijer, C. J., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., Heideman, D. A., and Snijders, P. J.. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *International Journal of Cancer*. 2009;Journal international du cancer. 124(3):516-520.

Meissner, H. I., Tiro, J. A., Haggstrom, D., Lu-Yao, G., and Breen, N.. Does patient health and hysterectomy status influence cervical cancer screening in older women?. *Journal of General Internal Medicine*. 2008;23(11):1822-1828.

Meshner, D., Szarewski, A., Cadman, L., Cubie, H., Kitchener, H., Luesley, D., Menon, U., Hulman, G., Desai, M., Ho, L., Terry, G., Williams, A., Sasieni, P., and Cuzick, J.. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: Results from the HART study. *British Journal of Cancer*. 2010;102(9):1405-1410.

Meyer, J. L., Hanlon, D. W., Andersen, B. T., Rasmussen, O. F., and Bisgaard, K.. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: Correlation with biopsy follow-up results. *Cancer*. 2007;111(2):83-92.

Milanova, E., Naumov, J., Nikolovska, E., and Damcevski, N.. Correlation of conventional and liquid-based cytology and their meaning in management of precancerous cervical lesions. *Akusherstvo i ginekologija*. 2005;44(1):60-62.

Miranda Pereira, S. M., Castelo, A., Makabe, S., Utagawa, M. L., Di Loreto C., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., Filho, A. L., and Das Dores, G. B.. Screening for cervical cancer in high-risk populations: DNA Pap test or hybrid capture II test alone?. *International Journal of Gynecological Pathology*. 2006;25(1):38-41.

Mo, L. Z., Monnier-Benoit, S., Kantelip, B., Petitjean, A., Riethmuller, D., Pretet, J. L., and Mouglin, C.. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2008;41(2):104-110.

Monsonogo, J., Bohbot, J. M., Pollini, G., Krawec, C., Vincent, C., Merignargues, I., Haroun, F., Sednaoui, P., Monfort, L., Dachez, R., and Syrjanen, K.. Performance of the Roche AMPLICOR Human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. *Gynecologic Oncology*. 2005;99(1):160-168.

Monsonogo, J., Pintos, J., Semaille, C., Beumont, M., Dachez, R., Zerat, L., Bianchi, A., and Franco, E.. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. *International Journal of Gynecological Cancer*. 2006;16(2):591-598.

Montemor, E. B. L., Roteli-Martins, C. M., Zeferino, L. C., Amaral, R. G., Fonseca-Carvasan, G. A., Shirata, N. K., Utagawa, M. L., Longatto-Filho, A., and Syrjanen, K. J.. Whole, turret and step methods of rapid rescreening: Is there any difference in performance?. *Diagnostic Cytopathology*. 2007;35(1):57-60.

Moore, K. N. and Walker, J. L.. The abnormal pap test: Evaluation, treatment, and monitoring. *Journal of Clinical Outcomes Management*. 2006;13(4):235-244.

Moore, M. A. and Tajima, K.. Cervical cancer in the asian pacific-epidemiology, screening and

treatment. *Asian Pacific journal of cancer prevention* : APJCP. 2004;5(4):349-361.

Moscicki, A.-B.. Cervical cytology screening in teens. *Current women's health reports*. 2003;3(6):433-437.

Moss, S., Gray, A., Legood, R., Vessey, M., Patnick, J., and Kitchener, H.. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: Observational before and after study. *British Medical Journal*. 2006;332(7533):83-85.

Moy, L. M., Zhao, F.-H., Li, L.-Y., Ma, J.-F., Zhang, Q.-M., Chen, F., Song, Y., Hu, S.-Y., Balasubramanian, A., Pan, Q.-J., Koutsky, L., Zhang, W.-H., Lim, J. M., Qiao, Y.-L., and Sellors, J. W.. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral. *International Journal of Cancer*. 2010;127(3):646-656.

Nam, J.-H., Kim, H.-S., Lee, J.-S., Choi, H.-S., Min, K.-W., and Park, C.-S.. A comparison of modified MonoPrep2 of liquid-based cytology with ThinPrep Pap test. *Gynecologic Oncology*. 2004;94(3):693-698.

Nassar, A., O'Reilly, K., Cohen, C., and Siddiqui, M. T.. Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations. *Diagnostic Cytopathology*. 2008;36(3):142-148.

Negri, G., Menia, E., Egarter-Vigl, E., Vittadello, F., and Mian, C.. ThinPrep versus Conventional Papanicolaou Smear in the Cytologic Follow-Up of Women with Equivocal Cervical Smears. *Cancer*. 2003;99(6):342-345.

Negri, G., Rigo, B., Vittadello, F., Mian, C., and Egarter-Vigl, E.. Abnormal cervicovaginal cytology with negative human papillomavirus testing. *Cancer*. 2007;111(5):280-284.

no authors listed. Many unnecessary Pap smears are performed after hysterectomy. *Journal of Family Practice*. 2004;53(9):682.

Nofech-Mozes, S., Khalifa, M. M., Ismiil, N., Dube, V., Saad, R. S., Sun, P., Seth, A., and Ghorab, Z.. Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. *Applied Immunohistochemistry and Molecular Morphology*. 2010;18(1):80-85.

Nygard, J. F., Nygard, M., Skare, G. B., and Thoresen, S. O.. Pap smear screening in women under 30 in the Norwegian coordinated-cervical cancer screening program, with a comparison of immediate biopsy vs. pap smear triage of moderate dysplasia. *Acta Cytologica*. 2006;50(3):295-302.

Oliveira, E. R. Z. M., Derchain, S. F. M., Rabelo-Santos, S. H., Westin, M. C. A., Zeferino, L. C., Campos, E. A., and Syrjanen, K. J.. Detection of high-risk human papillomavirus (HPV) DNA by hybrid capture II in women referred due to atypical glandular cells in the primary screening. *Diagnostic Cytopathology*. 2004;31(1):19-22.

Onuma, K., Saad, R. S., Kanbour-Shakir, A., Kanbour, A. I., and Dabbs, D. J.. Clinical implications of the diagnosis "Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" in pregnant women. *Cancer*. 2006;108(5):282-287.

Orbell, S., Hagger, M., Brown, V., and Tidy, J.. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. *British Journal of Health Psychology*. 2004;9(4):533-555.

Ovanin-Rakic, A., Mahovlic, V., Audy-Jurkovic, I., Barisic, A., Skopljanac-Macina, L., Juric, D., Rajhvajn, S., Ilic-Forko, J., Babic, D., Folnovic, D., and Kani, D.. Cytology of cervical intraepithelial glandular lesions. *Collegium antropologicum*. 2010;34(2):401-406.

Pajtler, M., Milicic-Juhas, V., Milojkovic, M., Topolovec, Z., Curzik, D., and Mihaljevic, I.. Assessment

of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2. *Collegium antropologicum*. 2010;34(1):81-86.

Papathanasiou, K., Daniilidis, A., Koutsos, I., Sardeli, C., Giannoulis, C., and Tzafettas, J.. Verification of the accuracy of cervical cytology reports in women referred for colposcopy. *European Journal of Gynaecological Oncology*. 2010;31(2):187-190.

Papillo, J. L., St.John, T. L., and Leiman, G.. Effectiveness of the ThinPrep Imaging System: Clinical experience in a low risk screening population. *Diagnostic Cytopathology*. 2008;36(3):155-160.

Park, J., Jung, E.-H., Kim, C., and Young, H. C.. Direct-to-vial comparison of a new liquid-based cytology system, Liqui-PREP versus the conventional Pap smear. *Diagnostic Cytopathology*. 2007;35(8):488-492.

Peng, Y. and Wang, H. H.. Impact of reflex HPV testing on interpretation and management of ThinPrep pap tests. *Diagnostic Cytopathology*. 2006;34(8):585-588.

Perovic, S.. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia. *Journal of B*. 2009;U.ON.. 14(1):93-96.

Pickett, K. E.. HPV triage was more sensitive than cytological monitoring for management of women with an ASCUS cervical screening result. *Evidence-based Obstetrics and Gynecology*. 2004;6(3):147-149.

Polednak, A. P.. Trends in late-stage breast and cervical cancer incidence rates in Connecticut (United States). *Cancer Causes and Control*. 2003;14(4):361-365.

Poljak, M., Kovanda, A., Kocjan, B. J., Seme, K., Jancar, N., and Vrtacnik-Bokal, E.. The Abbott RealTime High Risk HPV test: Comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. *Acta Dermatovenerologica Alpina, Pannonica et Adriatica*. 2009;18(3):94-103.

Power, P., Gregoire, J., Duggan, M., and Nation, J.. Low-grade pap smears containing occasional high-grade cells as a predictor of high-grade dysplasia. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC*. 2006;28(10):884-887.

Prandi, S., Beccati, D., De, Aloysio G., Fulgenzi, P., Gabrielli, M., Ghirardini, C., Rivasi, F., Saragoni, L., de Bianchi, P. S., and Bucchi, L.. Applicability of the Bethesda System 2001 to a public health setting. *Cancer*. 2006;108(5):271-276.

Proca, D. M., Williams, J. D., Rofagha, S., Tranovich, V. L., and Keyhani-Rofagha, S.. Improved rate of high-grade cervical intraepithelial neoplasia detection in human papillomavirus DNA hybrid capture testing. *Analytical and Quantitative Cytology and Histology*. 2007;29(4):264-270.

Puig-Tintore, L. M., Torne, A., and Alonso, I.. Current techniques in screening for cervical cancer in Spain: Updated recommendations. *Gynecologic Oncology*. 2008;110(3 SUPPL.2):S8-S10.

Quddus, M., Neves, T., Reilly, M., Steinhoff, M., and Sung, C.. Does the ThinPrep Imaging System increase the detection of high-risk HPV-positive ASC-US and AGUS the Women and Infants Hospital experience with over 200,000 cervical cytology cases. *CytoJournal*. 2009;6 , 2009. Article Number: 15. Date of Publication: 2009.

Raab, S. S., Jones, B. A., Souers, R., and Tworek, J. A.. The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance. *Archives of Pathology and Laboratory Medicine*. 2008;132(1):16-22.

Rabelo-Santos, S. H., Derchain, S. F. M., Do Amaral Westin, M. C., Angelo-Andrade, L. A. L., Sarian, L. O. Z., Oliveira, E. R. Z. M., Morais, S. S., and Zeferino, L. C.. Endocervical glandular cell

abnormalities in conventional cervical smears: Evaluation of the performance of cytomorphological criteria and HPV testing in predicting neoplasia. *Cytopathology*. 2008;19(1):34-43.

Ramsaroop, R. and Chu, I. Accuracy of diagnosis of atypical glandular cells - Conventional and ThinPrep. *Diagnostic Cytopathology*. 2006;34(9):614-619.

Reuschenbach, M., Clad, A., von Knebel, Doeberitz C., Wentzensen, N., Rahmsdorf, J., Schaffrath, F., Griesser, H., Freudenberg, N., and Von Knebel, Doeberitz M.. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. *Gynecologic Oncology*. 2010;119(1):98-105.

Rieck, G. C., Bhaumik, J., Beer, H. R., and Leeson, S. C.. Repeating cytology at initial colposcopy does not improve detection of high-grade abnormalities: A retrospective cohort study of 6595 women. *Gynecologic Oncology*. 2006;101(2):228-233.

Riethmuller, D., Gabelle, C., Ramanah, R., Sautiere, J.-L., Pretet, J.-L., Schaal, J.-P., Kantelip, B., Mouglin, C., and Maillat, R.. Importance of human papillomavirus (HPV) screening in the follow-up after CIN2-3 treatment. A study of 386 cases. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2008;37(4):329-337.

Rijkaart, D. C., Coupe, V. M. H., Van Kemenade, F. J., Heideman, D. A. M., Hesselink, A. T., Verweij, W., Rozendaal, L., Verheijen, R. H., Snijders, P. J., Berkhof, J., and Meijer, C. J. L. M.. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. *British Journal of Cancer*. 2010;103(7):939-946.

Roberts, J. M. and Thurloe, J. K.. Comparative sensitivities of ThinPrep and papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): Comparison with HSIL. *Cancer*. 2007;111(6):482-486.

Roberts, J. M., Thurloe, J. K., Bowditch, R. C., Hyne, S. G., Greenberg, M., Clarke, J. M., and Biro, C.. A three-armed trial of the thinprep imaging system. *Diagnostic Cytopathology*. 2007;35(2):96-102.

Roghaei, M. A., Afshar, Moghaddam N., Pooladkhan, Sh, and Roghaie, Sh. Adequacy criteria and cytomorphological changes in liqui-prep TM versus conventional cervical cytology. *Shiraz E Medical Journal*. 2010;11(4):173-182.

Rogoza, R. M., Ferko, N., Bentley, J., Meijer, C. J. L. M., Berkhof, J., Wang, K.-L., Downs, L., Smith, J. S., and Franco, E. L.. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. *Vaccine*. 2008;26(SUPPL.5):F46-F58.

Rooney, C. M., Hopkins, M. P., Oza, R., Nelson, K., and Alford, W.. The Efficacy of the ThinPrep Pap Preparation Versus Conventional Means of Cervical Cancer Screening. *Journal of Pelvic Medicine and Surgery*. 2004;10(1):31-35.

Rosenthal, D. L., Geddes, S., Trimble, C. L., Carson, K. A., and Alli, P. M.. The PapSpin: A reasonable alternative to other, more expensive liquid-based Papanicolaou tests. *Cancer*. 2006;108(3):137-143.

Rossetti, D., Gerli, S., Saab, J.-C., and Di Renzo, G. C.. Atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) and histology. *Journal Medical Libanais*. 2000;48(3):127-130.

Rossi, P. G., Baiocchi, D., Ciatto, S., Cariaggi, P., Gustinucci, D., Camilli, I., Mancini, E., Montanari, G., Caprioglio, A., Parisio, F., Angeloni, C., Di, Gabriele G., Carantoni, A., Tinacci, G., Matteucci, M., Pontani, G., Collina, G., Carmelo, M., Biavati, P., Schincaglia, P., Serafini, M., Palma, P. D., Polla, E., Scarfantonio, A. A., Schiboni, M. L., and Anghinoni, E.. Risk of CIN2 in women with a Pap test without

endocervical cells vs. those with a negative Pap test with endocervical cells: A cohort study with 4.5 years of follow-up. *Acta Cytologica*. 2010;54(3):265-271.

Rughooputh, S., Parmar, K., and Greenwell, P.. Detection of human papillomavirus from liquid-based cytology specimens by in-house PCR: A pilot study. *British Journal of Biomedical Science*. 2004;61(1):22-25.

Rugpao, S., Koonlertkit, S., Ruengkrist, T., Lamlerkittikul, S., Pinjaroen, S., Limtrakul, A., Werawatakul, Y., and Sinchai, W.. ThinPrep Pap-smear and cervical intraepithelial neoplasia in reproductive-aged Thai women. *Journal of Obstetrics and Gynaecology Research*. 2009;35(3):551-554.

Sabath, A. P. and Kiviat, N. B.. Detection and classification of cervical Neoplasia in the era of HPV. *Pathology Case Reviews*. 2010;15(4):135-140.

Safaeian, M., Kiddugavu, M., Gravitt, P. E., Ssekasanvu, J., Murokora, D., Sklar, M., Serwadda, D., Wawer, M. J., Shah, K. V., and Gray, R.. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. *Sexually Transmitted Diseases*. 2007;34(7):429-436.

Sancho-Garnier, H.. Screening for breast and cervical cancers. [French]. *Oncologie*. 2002;4(8):493-498.

Saraiya, M., Berkowitz, Z., Yabroff, K. R., Wideroff, L., Kobrin, S., and Benard, V.. Cervical cancer screening with both human papillomavirus and papanicolaou testing vs papanicolaou testing alone: What screening intervals are physicians recommending?. *Archives of Internal Medicine*. 2010;170(11):977-986.

Saraiya, M., Martinez, G., Glaser, K., and Kulasingam, S.. Pap testing and sexual activity among young women in the united states. *Obstetrics and Gynecology*. 2009;114(6):1213-1219.

Sargent, A., Bailey, A., Turner, A., Almonte, M., Gilham, C., Baysson, H., Peto, J., Roberts, C., Thomson, C., Desai, M., Mather, J., and Kitchener, H.. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: Data from the ARTISTIC trial. *Journal of Clinical Microbiology*. 2010;48(2):554-558.

Sarode, V. R., Werner, C., Gander, R., Foster, B., Fulmer, A., Saboorian, M. H., and Ashfaq, R.. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: Focus on age-stratified clinical performance. *Cancer*. 2003;99(3):149-155.

Sass, M. A.. Use of A Liquid-Based, Thin-Layer Pap Test in A Community Hospital: Impact on Cytology Performance and Productivity. *Acta Cytologica*. 2004;48(1):17-22.

Sayed, K., Korourian, S., Ellison, D. A., Kozlowski, K., Talley, L., Horn, H. V., Simpson, P., and Parham, D. M.. Diagnosing cervical biopsies in adolescents: The use of p16 immunohistochemistry to improve reliability and reproducibility. *Journal of Lower Genital Tract Disease*. 2007;11(3):141-146.

Scheiden, R., Knolle, U., Wagener, C., Wehenkel, A. M., and Capesius, C.. Cervical cancer screening in Luxembourg. *European Journal of Cancer*. 2000;36(17):2240-2243.

Schenck, U. and von, Karsa L.. Cervical cancer screening in Germany. *European Journal of Cancer*. 2000;36(17):2221-2226.

Schiffman, M., Khan, M. J., Solomon, D., Herrero, R., Wacholder, S., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Wheeler, C. M., and Burk, R. D.. A study of the impact of adding HPV types to cervical cancer screening and triage test. *Journal of the National Cancer Institute*. 2005;97(2):147-150.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Improvement of diagnostic accuracy and screening conditions with liquid-based cytology. *Diagnostic Cytopathology*. 2006;34(11):780-785.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Significance of atypia in conventional Papanicolaou

smears and liquid-based cytology: A follow-up study. *Cytopathology*. 2004;15(3):148-153.

Schneede, P., Hillemanns, P., Ziller, F., Hofstetter, A., Stockfleth, E., Arndt, R., and Meyer, T.. Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening. *Acta Obstetrica et Gynecologica Scandinavica*. 2001;80(8):750-752.

Schneider, A., Gleizes, O., Nieminen, P., Erdemoglu, E., Boselli, F., and Jenkins, D.. Implications of varied patterns of cervical cancer screening for introduction of human papillomavirus vaccines in Europe. *Journal of the Turkish German Gynecology Association Artemis*. 2009;10(2):61-67.

Schneider, A., Hoyer, H., Lotz, B., Leistritz, S., Kuhne-Heid, R., Nindl, I., Muller, B., Haerting, J., and Durst, M.. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. *International Journal of Cancer*. 2000;89(6):529-534.

Schopp, B., Holz, B., Zago, M., Stubenrauch, F., Petry, K.-U., Kjaer, S. K., and Iftner, T.. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. *Journal of Medical Virology*. 2010;82(4):605-615.

Segnan, N., Ronco, G., and Ciatto, S.. Cervical cancer screening in Italy. *European Journal of Cancer*. 2000;36(17):2235-2239.

Sehgal, A. and Singh, V.. Human papillomavirus infection (hpv) & screening strategies for cervical cancer. *Indian Journal of Medical Research*. 2009;130(3):234-240.

Sharp, L. K., Zurawski, J. M., Roland, P. Y., O'Toole, C., and Hines, J.. Health literacy, cervical cancer risk factors, and distress in low-income African-American women seeking colposcopy. *Ethnicity & disease*. 2002;12(4):541-546.

Sharpless, K. E., O'Sullivan, D. M., and Schnatz, P. F.. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. *Journal of Lower Genital Tract Disease*. 2009;13(2):72-78.

Shastri, S. S., Dinshaw, K., Amin, G., Goswami, S., Patil, S., Chinoy, R., Kane, S., Kelkar, R., Muwonge, R., Mahe, C., Ajit, D., and Sankaranarayanan, R.. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. *Bulletin of the World Health Organization*. 2005;83(3):186-194.

Shastri, S. S.. Cervical cancer screening and vaccination in India. *Indian journal of medical ethics*. 2010;7(1):41-43.

Sheriff, S. K., Petry, K. U., Ikenberg, H., Crouse, G., Mazonson, P. D., and Santas, C. C.. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany. *European Journal of Health Economics*. 2007;8(2):153-160.

Sherlaw-Johnson, C. and Philips, Z.. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. *British Journal of Cancer*. 2004;91(1):84-91.

Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., Schiffman, M., and Helmerhorst, T.. Pap smear and HPV testing in combination were more accurate than either test alone for predicting the future development of CIN3 or cervical cancer. *Evidence-based Obstetrics and Gynecology*. 2003;5(3):137-138.

Shinn, E., Basen-Engquist, K., Le, T., Hansis-Diarte, A., Bostic, D., Martinez-Cross, J., Santos, A., and Follen, M.. Distress after an abnormal Pap smear result: Scale development and psychometric validation. *Preventive Medicine*. 2004;39(2):404-412.

Siddiqi, A., Spataro, M., McIntire, H., Akhtar, I., Baliga, M., Flowers, R., Lin, E., and Guo, M.. Hybrid

capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance Papanicolaou results in SurePath and ThinPrep specimens. *Cancer cytopathology*. 2009;117(5):318-325.

Siddiqui, M. T., Cohen, C., and Nassar, A.. Detecting high-grade cervical disease on ASC-H cytology: Role of BD ProEx C and digene hybrid capture II HPV DNA testing. *American journal of clinical pathology*. 2008;130(5):765-770.

Siebert, U., Sroczynski, G., Hillemanns, P., Engel, J., Stabenow, R., Stegmaier, C., Voigt, K., Gibis, B., Holzel, D., and Goldie, S. J.. The German Cervical Cancer Screening Model: Development and validation of a decision-analytic model for cervical cancer screening in Germany. *European Journal of Public Health*. 2006;16(2):185-192.

Silverloo, I., Andrae, B., and Wilander, E.. Value of high-risk HPV-DNA testing in the triage of ASCUS. *Acta Obstetrica et Gynecologica Scandinavica*. 2009;88(9):1006-1010.

Sireci, A. N., Crapanzano, J. P., Mansukhani, M., Wright, T., Babiac, A., Erroll, M., Vazquez, M., and Saqi, A.. Atypical Glandular Cells (AGC): ThinPrep Imaging System (TIS), Manual Screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. *Diagnostic Cytopathology*. 2010;38(10):705-709.

Sirovich, B. E. and Welch, H. G.. The frequency of Pap smear screening in the United States. *Journal of General Internal Medicine*. 2004;19(3):243-250.

Sirovich, B. E., Gottlieb, D. J., and Fisher, E. S.. The burden of prevention: Downstream consequences of Pap smear testing in the elderly. *Journal of medical screening*. 2003;10(4):189-195.

Smith, J. H. F.. The future of cervical screening in the UK. *Diagnostic Histopathology*. 2009;15(7):330-334.

Sodhani, P., Gupta, S., Singh, V., Sehgal, A., Halder, K., and Parashari, A.. Sensitivity of the pap test in detecting high grade lesions: What should be the acceptable cytologic threshold for colposcopic referral?. *Acta Cytologica*. 2006;50(2):181-184.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Acta Cytologica*. 2009;53(3):247-248.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *American journal of clinical pathology*. 2009;131(6):768-769.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Diagnostic Cytopathology*. 2009;37(7):542-543.

Solomon, D., Papillo, J., and Davis, Davey D.. Statement on HPV DNA test utilization. *Journal of Lower Genital Tract Disease*. 2009;13(3):135-136.

Solomon, D.. Chapter 14: Role of triage testing in cervical cancer screening. *Journal of the National Cancer Institute*. 2003;Monographs.(31):97-101.

Son, S., Noh, H. T., and An, S.. Human papillomavirus status in cervical scrapes and biopsy specimens using the HPV genotyping DNA microarray. *International Journal of Gynecology and Obstetrics*. 2006;93(3):258-259.

Soutter, W. P., Butler, J. S., and Tipples, M.. The role of colposcopy in the follow up of women treated for cervical intraepithelial neoplasia. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2006;113(5):511-514.

Sowjanya, A. P., Paul, P., Vedantham, H., Ramakrishna, G., Vidyadhari, D., Vijayaraghavan, K., Lakshmi, S., Sudula, M., Ronnett, B. M., Das, M., Shah, K. V., and Gravitt, P. E.. Suitability of self-

collected vaginal samples for cervical cancer screening in Periurban Villages in Andhra Pradesh, India. *Cancer Epidemiology Biomarkers and Prevention*. 2009;18(5):1373-1378.

Spiryda, L. B., Brown, M., Creek, K. E., and Pirisi-Creek, L.. HSIL pap test and risk factors predicting acquisition of CIN 2/3 on colposcopy-directed biopsies. *Journal of the South Carolina Medical Association* (1975). 2009;105(7):281-286.

Srodon, M., Parry, Dilworth H., and Ronnett, B. M.. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results. *Cancer*. 2006;108(1):32-38.

Stamataki, P., Papazafiropoulou, A., Elefsiniotis, I., Giannakopoulou, M., Brokalaki, H., Apostolopoulou, E., Sarafis, P., and Saroglou, G.. Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. *BMC infectious diseases*. 2010;10:27.

Stein, S. R.. ThinPrep versus the conventional Papanicolaou test: A review of specimen adequacy, sensitivity, and cost-effectiveness. *Primary Care Update for Ob/Gyns*. 2003;10(6):310-313.

Stensson, E., Frberg, M., Hjerpe, A., Zethraeus, N., and Andersson, S.. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. *Acta Obstetricia et Gynecologica Scandinavica*. 2010;89(10):1316-1325.

Stinnett, B. A.. Use of Psychosocial Effects of Abnormal Pap Smears Questionnaire (PEAPS-Q) in a community hospital colposcopy clinic. *Journal of Lower Genital Tract Disease*. 2000;4(1):34-39.

Streiner, D. L. and Norman, G. R.. Mass screening: When does it make sense?. *Community Oncology*. 2010;7(2):93-95.

Symonds, I. M.. Screening for gynaecological conditions. *Foundation Years*. 2007;3(6):263-267.

Syrjanen, K., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Hammes, L. S., Sarian, L., Naud, P., Tatti, S., Branca, M., Erzen, M., Matos, J., Gontijo, R., Braganca, J., Arlindo, F., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among Latin American Women < 35 and >= 35 years of age: Experience from the Latin American Screening Study. *Acta Cytologica*. 2008;52(6):641-653.

Syrjanen, K., Naud, P., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Hammes, L. S., Matos, J., Gontijo, R., Sarian, L., Braganca, J., Arlindo, F. C., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. *Anticancer Research*. 2005;25(5):3469-3480.

Szarewski, A., Ambroisine, L., Cadman, L., Austin, J., Ho, L., Terry, G., Liddle, S., Dina, R., McCarthy, J., Buckley, H., Bergeron, C., Soutter, P., Lyons, D., and Cuzick, J.. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(11):3033-3042.

Szarewski, A.. Cervical screening by visual inspection with acetic acid. *Lancet*. 2007;370(9585):365-366.

Tang, N., Huang, S., Erickson, B., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S25-S28.

Taoka, H., Yamamoto, Y., Sakurai, N., Fukuda, M., Asakawa, Y., Kurasaki, A., Oharaseki, T., and Kubushiro, K.. Comparison of conventional and liquid-based cytology, and human papillomavirus testing using SurePath preparation in Japan. *Human Cell*. 2010;23(4):126-133.

Terret, C., Castel-Kremer, E., Albrand, G., and Droz, J. P.. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. *The Lancet Oncology*. 2009;10(1):80-87.

Thiryayi, S. A., Marshall, J., and Rana, D. N.. An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia. *Cytopathology*. 2010;21(4):223-228.

Thiryayi, S. A., Marshall, J., and Rana, D. N.. Differentiating between endocervical glandular neoplasia and high grade squamous intraepithelial lesions in endocervical crypts: Cytological features in ThinPrep and SurePath cervical cytology samples. *Diagnostic Cytopathology*. 2009;37(5):315-319.

Thrall, M. J., Pambuccian, S. E., Stelow, E. B., McKeon, D. M., Miller, L., Savik, K., and Gulbahce, H. E.. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda system on the sensitivity and specificity of the papanicolaou test: A 5-year follow-up study of papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria. *Cancer*. 2008;114(3):171-179.

Thrall, M. J., Russell, D. K., Facik, M. S., Yao, J. L., Warner, J. N., Bonfiglio, T. A., and Giampoli, E. J.. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. *American journal of clinical pathology*. 2010;133(6):894-898.

Thrall, M. J., Smith, D. A., and Mody, D. R.. Women ≥ 30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: Should we reconsider HPV triage for LSIL in older women?. *Diagnostic Cytopathology*. 2010;38(6):407-412.

Thrall, M., Kjeldahl, K., Gulbahce, H. E., and Pambuccian, S. E.. Liquid-based papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: Study of 272 cases classified by the 2001 Bethesda system. *Cancer*. 2007;111(4):217-223.

Tiews, S., Steinberg, W., Schneider, W., and Hanrath, C.. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: Preliminary data. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S11-S15.

Tinelli, A., Leo, G., Pisano, M., Storelli, F., Leo, S., Vergara, D., and Malvasi, A.. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. *Current Pharmaceutical Biotechnology*. 2009;10(8):767-771.

Treacy, A., Reynolds, J., Kay, E. W., Leader, M., and Grace, A.. Has the ThinPrep Method of Cervical Screening Maintained Its Improvement Over Conventional Smears in terms of Specimen Adequacy?. *Diagnostic Cytopathology*. 2009;37(4):239-240.

Troni, G. M., Cipparrone, I., Cariaggi, M. P., Ciatto, S., Miccinesi, G., Zappa, M., and Confortini, M.. Detection of false-negative pap smears using the PAPNET system. *Tumori*. 2000;86(6):455-457.

Tsai, H.-T., Tsai, Y.-M., Yang, S.-F., Lee, C.-H., Lin, L.-Y., Lee, S., and Wu, M.-T.. A notable accessory screening program for detection of cervical intraepithelial neoplasia. *Pathologie Biologie*. 2009;57(6):477-482.

Tuncer, Z. S., Basaran, M., Sezgin, Y., Firat, P., and Kuzey, G. M.. Clinical results of a split sample liquid-based cytology (ThinPrep) study of 4,322 patients in a Turkish institution. *European Journal of Gynaecological Oncology*. 2005;26(6):646-648.

Uyar, D. S., Eltabbakh, G. H., and Mount, S. L.. Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant. *Gynecologic Oncology*.

2003;89(2):227-232.

Valdini, A. and Esielionis, P.. Measurement of colposcopy-associated distress using the psychosocial effects of having an abnormal pap smear-questionnaire in a Latina population. *Journal of Lower Genital Tract Disease*. 2004;8(1):25-32.

Varnai, A. D., Bollmann, M., Bankfalvi, A., Speich, N., Schmitt, C., Griefingholt, H., Kovacs, K., Klozoris, C., and Bollmann, R.. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: Diagnostic and prognostic implications. *Oncology Reports*. 2008;19(2):457-465.

Vijayaraghavan, A., Efrusy, M. B., Mayrand, M. H., Santas, C. C., and Goggin, P.. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. *Canadian Journal of Public Health*. 2010;Revue canadienne de sante publique. 101(3):220-225.

Vijayaraghavan, A., Efrusy, M., Lindeque, G., Dreyer, G., and Santas, C.. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. *Gynecologic Oncology*. 2009;112(2):377-383.

Vollmer, R. T.. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. *Cancer*. 10-25-2002;96(5):316-318.

Voskanyan, M. A.. Precancerous cervical lesions: Diagnosis and treatment. *New Armenian Medical Journal*. 2009;3(3):49-56.

Voss, J. S., Kipp, B. R., Campion, M. B., Sokolova, I. A., Henry, M. R., Halling, K. C., and Clayton, A. C.. Assessment of fluorescence in situ hybridization and hybrid capture 2 analyses of cervical cytology specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia. *Analytical and Quantitative Cytology and Histology*. 2010;32(3):121-130.

Vrtacnik-Bokal, E., Rakar, S., Jancar, N., Mozina, A., and Poljak, M.. Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions. *European Journal of Gynaecological Oncology*. 2005;26(4):427-430.

Walter, L. C., Lewis, C. L., and Barton, M. B.. Screening for colorectal, breast, and cervical cancer in the elderly: A review of the evidence. *American Journal of Medicine*. 2005;118(10):1078-1086.

Wang, K. L., Jeng, C. J., Yang, Y. C., Chen, C. A., Cheng, W. F., Chen, T. C., Mast, T. C., Wang, Y. C., and Hsieh, C. Y.. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. *Journal of Psychosomatic Obstetrics & Gynecology*. 2010;31(1):16-23.

Wang, X., Zheng, B., Li, S., Zhang, R., Mulvihill, J. J., Chen, W. R., and Liu, H.. Automated detection and analysis of fluorescent in situ hybridization spots depicted in digital microscopic images of Pap-smear specimens. *Journal of biomedical optics*. 2009;14(2):021002-021Apr.

Warman, J.. Cervical cancer screening in young women: saving lives with prevention and detection. *Oncology nursing forum*. 2010;37(1):33-38.

Warren, J. B., Gullett, H., and King, V. J.. Cervical Cancer Screening and Updated Pap Guidelines. *Primary Care - Clinics in Office Practice*. 2009;36(1):131-149.

Wells, S. F.. Cervical cancer: an overview with suggested practice and policy goals. *Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses*. 2008;17(1):43-50.

Wentzensen, N., Bergeron, C., Cas, F., Vinokurova, S., and Von Knebel, Doeberitz M.. Triage of

women with ASCUS and LSIL cytology: Use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. *Cancer*. 2007;111(1):58-66.

Wentzensen, N., Hampl, M., Herkert, M., Reichert, A., Trunk, M. J., Poremba, C., Ridder, R., and Von Knebel, Doeberitz M.. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. *Cancer*. 2006;107(9):2307-2313.

Werner, C. L., Griffith III, W. F., Ashfaq, R., Gossett, D., Wilkinson, E., Raab, S., Bambot, S., Mongin, D., and Faupel, M.. Comparison of human papilloma virus testing and spectroscopy combined with cervical cytology for the detection of high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2007;11(2):73-79.

Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., Markman, M., Mayer, R., Pfister, D., Raghavan, D., Ramsey, S., Reaman, G., Sandler, H., Sawaya, R., Schuchter, L., Sweetenham, J., Vahdat, L., Schilsky, R. L., and Sweet, D.. Clinical cancer advances 2008: Major research advances in cancer treatment, prevention, and screening-a report from the american society of clinical oncology. *Journal of Clinical Oncology*. 2009;27(5):812-826.

Witt, A., Hudelist, G., Gregor, H., Kucera, E., Walchetseder, C., and Czerwenka, K.. The detection of HPV DNA improves the recognition of cervical intraepithelial lesions. *Archives of Gynecology and Obstetrics*. 2003;268(1):29-34.

Wong, A. K., Chan, R. C., Nichols, W. S., and Bose, S.. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance. *Cancer*. 2009;115(4):823-832.

Wongworapat, K., Keawvichit, R., Sirirojn, B., Dokuta, S., Ruangyuttikarn, C., Sriplienchan, S., Sontirat, A., Kla, K. T., Gravitt, P. E., and Celentano, D. D.. Detection of human papillomavirus from self-collected vaginal samples of women in Chiang Mai, Thailand. *Sexually Transmitted Diseases*. 2008;35(2):172-173.

Wood, M. D., Horst, J. A., and Bibbo, M.. Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based pap tests: A review. *Diagnostic Cytopathology*. 2007;35(1):12-17.

Wright, P. K., Marshall, J., and Desai, M.. Comparison of SurePath and ThinPrep liquid-based cervical cytology using positive predictive value, atypical predictive value and total predictive value as performance indicators. *Cytopathology*. 2010;21(6):374-378.

Wu, S. F., Meng, L., Wang, S. X., and Ma, D.. A comparison of four screening methods for cervical neoplasia. *International Journal of Gynecology and Obstetrics*. 2005;91(2):189-193.

Yang, B., Pretorius, R. G., Belinson, J. L., Zhang, X., Burchette, R., and Qiao, Y.-L.. False negative colposcopy is associated with thinner cervical intraepithelial neoplasia 2 and 3. *Gynecologic Oncology*. 2008;110(1):32-36.

Yapikakis, C., Adamopoulou, M., Antonopoulos, G., Koufaliotis, N., and Vairaktaris, E.. Prevalence of HPV types in a cohort of greeks with clinical indication of infection. *Anticancer Research*. 2008;28(4 B):2233-2237.

Yeoh, G. P. S., Tse, M. P. Y., Chan, K. W., and Lord, L.. Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and follow-up patient group. *Acta Cytologica*. 2006;50(6):627-631.

Yoon, J. H., Yoo, S. C., Kim, W. Y., Chang, S. J., Chang, K. H., and Ryu, H. S.. Role of HPV DNA testing for detection of high-grade cervical lesions in women with atypical squamous cells of undetermined significance: A prospective study in a Korean population. *European Journal of Gynaecological Oncology*. 2009;30(3):271-274.

Yuan, Q. and Wilbur, D. C.. Original cervical cytology and follow-up biopsy results in positive high risk

human papillomavirus DNA tests with high-level results. *Acta Cytologica*. 2008;52(5):557-562.

Zhao, C. and Austin, R. M.. High-risk human papillomavirus DNA test results are useful for disease risk stratification in women with unsatisfactory liquid-based cytology pap test results. *Journal of Lower Genital Tract Disease*. 2009;13(2):79-84.

Zhao, C., Florea, A., and Austin, R. M.. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. *Archives of pathology & laboratory medicine*. 2010;134(1):103-108.

Zhao, C., Florea, A., Onisko, A., and Austin, R. M.. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: Results from a large academic womens hospital laboratory employing sensitive screening methods. *Gynecologic Oncology*. 2009;114(3):383-389.

Zhu, J., Norman, I., Elfgrén, K., Gaberi, V., Hagmar, B., Hjerpe, A., and Andersson, S.. A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. *Oncology Reports*. 2007;18(1):157-160.

Level 2: Answered No

. Committee opinion no. 356: Routine cancer screening. *Obstetrics and Gynecology*. 2006;108(6):1611-1613.

. Erratum: Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness (*Journal of the American Medical Association* (June 27, 2001) 285 (3107-3115)). *Journal of the American Medical Association*. 2001;286(9):1026-.

. Everything you know about cervical cancer screening in Alberta just changed. *Alberta RN / Alberta Association of Registered Nurses*. 2009;65(9):10-11.

. HPV genotyping clinical update. *Journal of Family Practice*. 2009;58(9):S8-S10.

. In South Africa, having one pap smear lowers women's chances of cervical cancer. *International family planning perspectives*. 2003;29(4):196-.

. Is liquid-based cytology better than Pap tests for CIN 2?. *Journal of Family Practice*. 2008;57(4):218-.

. Liquid-based not better than conventional Pap. *Journal of Family Practice*. 2006;55(4):284-.

. Pap test update. New guidelines reflect new evidence. *Mayo Clinic women's healthsource*. 2003;7(5):1-2.

. Update: cervical cancer screening. *AWHONN lifelines / Association of Women's Health, Obstetric and Neonatal Nurses*. 2003;7(2):116-117.

Abulafia, O., Pezzullo, J. C., and Sherer, D. M.. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: A quantitative survey. *Gynecologic Oncology*. 2003;90(1):137-144.

Adab, P., McGhee, S. M., Yanova, J., Wong, C. M., and Hedley, A. J.. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. *Medical Care*. 2004;42(6):600-609.

Agorastos, T., Dinas, K., Lloveras, B., De, Sanjose S., Kornegay, J. R., Bonti, H., Bosch, F. X., Constantinidis, T., and Bontis, J.. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. *Gynecologic Oncology*. 2005;96(3):714-720.

Agorastos, T., Sotiriadis, A., and Emmanouilides, C. J.. Effect of type-specific human papillomavirus incidence on screening performance and cost. *International journal of gynecological cancer : official*

journal of the International Gynecological Cancer Society. 2010;20(2):276-282.

Aklimunnessa, K., Mori, M., Khan, M. M. H., Sakauchi, F., Kubo, T., Fujino, Y., Suzuki, S., Tokudome, S., and Tamakoshi, A.. Effectiveness of cervical cancer screening over cervical cancer mortality among Japanese women. *Japanese journal of clinical oncology*. 2006;36(8):511-518.

Almonte, M., Ferreccio, C., Winkler, J. L., Cuzick, J., Tsu, V., Robles, S., Takahashi, R., and Sasieni, P.. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. *International Journal of Cancer*. 2007;121(4):796-802.

Anderson, R., Haas, M., and Shanahan, M.. The cost-effectiveness of cervical screening in Australia: What is the impact of screening at different intervals or over a different age range?. *Australian and New Zealand Journal of Public Health*. 2008;32(1):43-52.

Andersson, S., Dillner, L., Elfgrén, K., Mints, M., Persson, M., and Rylander, E.. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(10):996-1000.

Andrae, B., Kemetli, L., Sparen, P., Silfverdal, L., Strander, B., Ryd, W., Dillner, J., and Tornberg, S.. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *Journal of the National Cancer Institute*. 2008;100(9):622-629.

Andy, C. and Turner, L. F.. Is the ThinPrep better than conventional Pap smear at detecting cervical cancer?. *Journal of Family Practice*. 2004;53(4):313-316.

Anttila, A., Ronco, G., Clifford, G., Bray, F., Hakama, M., Arbyn, M., and Weiderpass, E.. Cervical cancer screening programmes and policies in 18 European countries. *British Journal of Cancer*. 2004;91(5):935-941.

Arbyn, M., Simoons, C., Buntinx, F., Martin-Hirsch, P. P. L., Paraskevaidis, E., and Prendiville, W. J. P.. Triage with human papillomavirus (HPV) testing versus repeat cytology for underlying high-grade cervical intraepithelial neoplasia in women with minor cytological lesions. *Cochrane Database of Systematic Reviews*. 2009;#volume#(4):-.

Arias, Y. R., Carrillo, E. F., and Aristizabal, F. A.. Human papillomavirus (HPV) detected in restored plasma DNA from women diagnosed with pre-invasive lesions and invasive cervical cancer. *Colombia Medica*. 2010;41(2):148-154.

Baay, M. F. D., Tjalma, W. A. A., Lambrechts, H. A. J., Pattyn, G. G. O., Lardon, F., Weyler, J., Van Royen, P., Van Marck, E. A. E., and Vermorken, J. B.. Combined Pap and HPV testing in primary screening for cervical abnormalities: Should HPV detection be delayed until age 35?. *European Journal of Cancer*. 2005;41(17):2704-2708.

Bach, P. B.. Gardasil: from bench, to bedside, to blunder. *The Lancet*. 2010;375(9719):963-964.

Baileff, A.. Cervical screening: patients' negative attitudes and experiences. *Nursing standard (Royal College of Nursing (Great Britain))* : 1987). 2000;14(44):35-37.

Balasubramanian, A., Kulasingam, S. L., Baer, A., Hughes, J. P., Myers, E. R., Mao, C., Kiviat, N. B., and Koutsky, L. A.. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. *Journal of Lower Genital Tract Disease*. 2010;14(3):185-195.

Bandyopadhyay, S., Austin, R. M., Dabbs, D., and Zhao, C.. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. *Archives of Pathology and Laboratory Medicine*. 2008;132(12):1874-1881.

Bano, F., Kolhe, S., Zamblera, D., Jolaoso, A., Folayan, O., Page, L., and Norton, J.. Cervical screening

in under 25s: A high-risk young population. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2008;139(1):86-89.

Baseman, J. G., Kulasingam, S. L., Harris, T. G., Hughes, J. P., Kiviat, N. B., Mao, C., and Koutsky, L. A.. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. *American Journal of Obstetrics and Gynecology*. 2008;199(1):26-26.

Basu, P. and Chowdhury, D.. Cervical cancer screening & HPV vaccination: A comprehensive approach to cervical cancer control. *Indian Journal of Medical Research*. 2009;130(3):241-246.

Becker, N.. Epidemiological aspects of cancer screening in Germany. *Journal of cancer research and clinical oncology*. 2003;129(12):691-702.

Beerman, H., van Dorst, E. B. L., Kuenen-Boumeester, V., and Hogendoorn, P. C. W.. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. *Gynecologic Oncology*. 2009;112(3):572-576.

Benevolo, M., Vocaturo, A., Mottolese, M., Mariani, L., Vocaturo, G., Marandino, F., Sperduti, I., Rollo, F., Antoniani, B., and Donnorso, R. P.. Clinical role of p16INK4a expression in liquid-based cervical cytology: correlation with HPV testing and histologic diagnosis. *American journal of clinical pathology*. 2008;129(4):606-612.

Bergeron, C., Cas, F., Fagnani, F., Contrepas, A., Wadier, R., and Poveda, J. D.. Assessment of human papillomavirus testing on liquid-based Cyto-screen system for women with atypical squamous cells of undetermined significance. Effect of age. [French]. *Gynecologie, obstetrique & fertilité*. 2006;34(4):312-316.

Bergeron, C., Cas, F., Fagnani, F., Didaiiller-Lambert, F., and Poveda, J. D.. Human papillomavirus testing with a liquid-based system: Feasibility and comparison with reference diagnoses. *Acta Cytologica*. 2006;50(1):16-22.

Bergeron, C., Clavel, C., Crott, M. R., Hill, C., Jaury, P., Lehr-Drylewicz, A.-M., Leroy, J.-L., Lunel, F., Monsonego, J., Mouglin, C., Orth, G., Petitjean, A., De, Reilhac P., Riethmuller, D., Sancho-Garnier, H., Sevestre, H., D'Alche-Gautier, M.-J., Agius, G., Arbyn, M., Birembaut, P., Baldauf, J.-J., Bonnier, P., Boulanger, J.-C., Boman, F., Cayrol, M.-H., Charpentier, J.-M., Cochand-Priollet, B., Dalstein, V., Duport, N., Fournier, A., Guyot, H., Halfon, P., Mergui, J.-L., Morice, P., Mousteou, F., Querleu, D., Sastre-Garau, X., Sauthier, P., and Vacher-Lavenu, M.-C.. Usefulness of searching for human papillomavirus (HPV): Evaluation of screening practices for precancerous lesions of the uterine cervix. [French]. *Annales de pathologie*. 2005;25(2):173-177.

Bergeron, C., Jeannel, D., Poveda, J., Cassonnet, P., and Orth, G.. Human papillomavirus testing in women with mild cytologic atypia. *Obstetrics and Gynecology*. 2000;95(6 Pt 1):821-827.

Bergeron, C.. Screening and early diagnosis of cervical cancer in a context of HPV vaccination. [French]. *Revue du Praticien*. 2010;60(2):214-215.

Berkhof, J., De Bruijne, M. C., Zielinski, G. D., and Meijer, C. J. L. M.. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. *International Journal of Cancer*. 2005;115(2):268-275.

Bhatla, N. and Moda, N.. The clinical utility of HPV DNA testing in cervical cancer screening strategies. *Indian Journal of Medical Research*. 2009;130(3):261-265.

Bhatla, N., Gulati, A., Mathur, S. R., Rani, S., Anand, K., Muwonge, R., and Sankaranarayanan, R.. Evaluation of cervical screening in rural North India. *International Journal of Gynaecology & Obstetrics*. 2009;105(2):145-149.

Bibliograph

Blake, G., Hanchard, B., Gibson, T., Wolff, C., Samuels, E., Waugh, N., and Simpson, D.. Gynaecologic cancer incidence, Kingston and St Andrew, Jamaica, 1973-1997, and gynaecologic cancer mortality, Jamaica, 1999. *West Indian Medical Journal*. 2003;52(4):273-277.

Blanks, R. G. and Kelly, R. S.. Comparison of cytology and histology results in English cervical screening laboratories before and after liquid-based cytology conversion: Do the data provide evidence for a single category of high-grade dyskaryosis?. *Cytopathology*. 2010;21(6):368-373.

Blanks, R. G., Moss, S. M., Addou, S., Coleman, D. A., and Swerdlow, A. J.. Risk of cervical abnormality after age 50 in women with previously negative smears. *British Journal of Cancer*. 2009;100(11):1832-1836.

Boardman, L. A., Weitzen, S., and Stanko, C.. Atypical squamous cells of undetermined significance, human papillomavirus, and cervical intraepithelial neoplasia 2 or 3 in adolescents: ASC-US, age, and high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2006;10(3):140-145.

Bolanca, I. K. and Vranes, J.. Diagnostic methods and techniques in preventing cervical carcinoma. Part I: Conventional cytology and new cytological methods. *Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina*. 2010;7(1):12-17.

Bollmann, R., Bankfalvi, A., Griefingholt, H., Trosic, A., Speich, N., Schmitt, C., and Bollmann, M.. Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: results from 31031 women from the Bonn-region in West Germany. *Oncology Reports*. 2005;13(5):915-922.

Bond, S.. Conventional Glass Slide Pap Smears are as Accurate as Liquid-Based Tests in Detecting Cervical Disease. *Journal of Midwifery and Women's Health*. 2008;53(4):395-396.

Boschert, S.. ACOG changes cervical Ca recommendations. *Oncology Report*. 2010;#volume#(JANUARY-FEBRUARY):23-.

Braganca, J. F., Derchain, S. F., Sarian, L. O., Messias Da Silva, S. M., Labatte, S., and Zeferino, L. C.. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions. *Clinical and Experimental Obstetrics and Gynecology*. 2005;32(4):225-229.

Bray, F., Loos, A. H., McCarron, P., Weiderpass, E., Arbyn, M., Moller, H., Hakama, M., and Parkin, D. M.. Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. *Cancer Epidemiology Biomarkers and Prevention*. 2005;14(3):677-686.

Brink, A. A. T. P., Snijders, P. J. F., and Meijer, C. J. L. M.. HPV detection methods. *Disease Markers*. 2007;23(4):273-281.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, A. J. P., Verheijen, R. H. M., Snijders, P. J. F., and Meijer, C. J. L. M.. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. *International Journal of Cancer*. 2007;121(2):361-367.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, J. P., and Verheijen, R. H. M.. Erratum: Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing and at 6-month (International Journal Cancer (2007) 121, (361-367)). *International Journal of Cancer*. 2007;121(8):1873-.

Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H. M., and Meijer, C. J. L. M.. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. *International Journal of Cancer*. 2005;113(6):1005-1009.

Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H. M., and Meijer, C. J. L. M.. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. *British Journal of Cancer*. 2003;89(5):834-839.

Bulkmans, N. W. J., Rozendaal, L., Voorhorst, F. J., Snijders, P. J. F., and Meijer, C. J. L. M.. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. *British Journal of Cancer*. 2005;92(9):1800-1802.

Bull, S. L. and Schorge, J. O.. A study of the impact of adding HPV types to cervical cancer screening and triage tests. *Women's Oncology Review*. 2005;5(2):99-100.

Bulten, J., De Wilde, P. C. M., Boonstra, H., Gemmink, J. H., and Hanselaar, A. G. J. M.. Proliferation in 'atypical' atrophic Pap smears. *Gynecologic Oncology*. 2000;79(2):225-229.

Camilleri, G. and Blundell, R.. Pre-invasive cervical disease and cervical carcinoma. *Research Journal of Medical Sciences*. 2009;3(1):4-11.

Canfell, K., Barnabas, R., Patnick, J., and Beral, V.. The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study. *British Journal of Cancer*. 2004;91(3):530-536.

Cardenas-Turanzas, M., Follen, M., Nogueras-Gonzalez, G. M., Benedet, J. L., Beck, J. R., and Cantor, S. B.. The accuracy of the papanicolaou smear in the screening and diagnostic settings. *Journal of Lower Genital Tract Disease*. 2008;12(4):269-275.

Cardenas-Turanzas, M., Nogueras-Gonzalez, G. M., Scheurer, M. E., Adler-Storthz, K., Benedet, J. L., Beck, J. R., Follen, M., and Cantor, S. B.. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(10):2865-2871.

Carozzi, F., Bisanzi, S., Sani, C., Zappa, M., Cecchini, S., Ciatto, S., and Confortini, M.. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. *Journal of Clinical Microbiology*. 2007;45(2):364-369.

Carozzi, F., Cecchini, S., Confortini, M., Becattini, V., Cariaggi, M. P., Pontenani, G., Sani, C., and Ciatto, S.. Role of P16(INK4A) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. *Cancer*. 2006;108(2):119-123.

Carreon, J. D., Sherman, M. E., Guillen, D., Solomon, D., Herrero, R., Jeronimo, J., Wacholder, S., Rodriguez, A. C., Morales, J., Hutchinson, M., Burk, R. D., and Schiffman, M.. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. *International Journal of Gynecological Pathology*. 2007;26(4):441-446.

Casamitjana, M., Sala, M., Ochoa, D., Fuste, P., Castells, X., and Alameda, F.. Results of a cervical cancer screening programme from an area of Barcelona (Spain) with a large immigrant population. *European Journal of Public Health*. 2009;19(5):499-503.

Castle, P. E., Fetterman, B., Thomas, Cox J., Shaber, R., Poitras, N., Lorey, T., and Kinney, W.. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. *Obstetrics and Gynecology*. 2010;116(1):76-84.

Castle, P. E., Lorincz, A. T., Scott, D. R., Sherman, M. E., Glass, A. G., Rush, B. B., Wacholder, S., Burk, R. D., Manos, M. M., Schussler, J. E., Macomber, P., and Schiffman, M.. Comparison between prototype Hybrid Capture 3 and Hybrid Capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. *Journal of Clinical Microbiology*. 2003;41(9):4022-4030.

Castle, P. E., Rodriguez, A. C., Burk, R. D., Herrero, R., Hildesheim, A., Solomon, D., Sherman, M. E., Jeronimo, J., Alfaro, M., Morales, J., Guillen, D., Hutchinson, M. L., Wacholder, S., and Schiffman, M.. Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. *International Journal of Cancer*. 2009;125(7):1649-1656.

Castle, P. E., Solomon, D., Schiffman, M., and Wheeler, C. M.. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. *Journal of the National Cancer Institute*. 2005;97(14):1066-1071.

Castle, P. E., Wacholder, S., Sherman, M. E., Lorincz, A. T., Glass, A. G., Scott, D. R., Rush, B. B., Demuth, F., and Schiffman, M.. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. *Cancer*. 2002;95(10):2145-2151.

Castle, P. E.. Screening: HPV testing for cervical cancer: The good, the bad, and the ugly. *Nature Reviews Clinical Oncology*. 2010;7(7):364-365.

Castle, P. E.. The evolving definition of carcinogenic human papillomavirus. *Infectious Agents and Cancer*. 2009;4(1):-.

Cattani, P., Zannoni, G. F., Ricci, C., D'Onghia, S., Trivellizzi, I. N., Di, Franco A., Vellone, V. G., Durante, M., Fadda, G., Scambia, G., Capelli, G., and De, Vincenzo R.. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. *Journal of Clinical Microbiology*. 2009;47(12):3895-3901.

Celik, C., Gezgin, K., Toy, H., Findik, S., and Yilmaz, O.. A comparison of liquid-based cytology with conventional cytology. *International Journal of Gynecology and Obstetrics*. 2008;100(2):163-166.

Cenci, M. and Vecchione, A.. Usefulness of cervical collection by the Exact Touch, the Saccomanno single sampler, combined with automated primary screening. *Diagnostic Cytopathology*. 2000;23(4):242-244.

Cenci, M., Nagar, C., and Vecchione, A.. PAPNET-assisted primary screening of conventional cervical smears. *Anticancer Research*. 2000;20(5 C):3887-3889.

Chacho, M. S., Mattie, M. E., and Schwartz, P. E.. Cytohistologic correlation rates between conventional Papanicolaou smears and ThinPrep cervical cytology: A comparison. *Cancer*. 2003;99(3):135-140.

Chan, P. G., Sung, H.-Y., and Sawaya, G. F.. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. *Obstetrics and Gynecology*. 2003;102(4):765-773.

Chan, P. K. S., Chang, A. R., Yu, M. Y., Li, W.-H., Chan, M. Y. M., Yeung, A. C. M., Cheung, T.-H., Yau, T.-N., Wong, S.-M., Yau, C.-W., and Ng, H.-K.. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal of Cancer*. 2010;126(1):297-301.

Chao, A., Chang, C.-J., Lai, C.-H., Chao, F.-Y., Hsu, Y.-H., Chou, H.-H., Huang, H.-J., Jung, S.-M., Lin, C.-T., Cheng, H.-H., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology - A population-based cohort study from Taiwan. *International Journal of Cancer*. 2010;126(1):191-198.

Chao, A., Hsu, K.-H., Lai, C.-H., Huang, H.-J., Hsueh, S., Lin, S.-R., Jung, S.-M., Chao, F.-Y., Huang, S.-L., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study. *International Journal of Cancer*. 2008;122(12):2835-2841.

Chao, F.-Y., Chao, A., Huang, C.-C., Hsueh, S., Yang, J.-E., Huang, H.-J., Wang, L.-C., Lin, C.-T., Chou, H.-H., and Lai, C.-H.. Defining detection threshold and improving analytical proficiency of HPV

testing in clinical specimens. *Gynecologic Oncology*. 2010;117(2):302-307.

Chen, H.-S., Yang, Y.-C., Su, T.-H., Wang, T.-Y., and Huang, Y.-W.. Human papillomavirus testing (Hybrid Capture II) to detect high-grade cervical intraepithelial neoplasia in women with mildly abnormal Papanicolaou results. *Taiwanese Journal of Obstetrics and Gynecology*. 2005;44(3):252-257.

Chen, L. and Yang, B.. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. *Cancer*. 8-25-2008;114(4):236-241.

Chen, Y.-Y., You, S.-L., Chen, C.-A., Shih, L.-Y., Koong, S.-L., Chao, K.-Y., Hsiao, M.-L., Hsieh, C.-Y., and Chen, C.-J.. Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences. *British Journal of Cancer*. 2009;101(1):174-177.

Cheung, A. N. Y., Szeto, E. F., Leung, B. S. Y., Khoo, U.-S., and Ng, A. W. Y.. Liquid-Based Cytology and Conventional Cervical Smears: A Comparison Study in an Asian Screening Population. *Cancer*. 2003;99(6):331-335.

Chin-Hong, P. V. and Klausner, J. D.. Diagnostic tests for HPV infection. *MLO: medical laboratory observer*. 2004;36(10):10-16.

Chivukula, M., Saad, R. S., Elishaev, E., White, S., Mauser, N., and Dabbs, D. J.. Introduction of the Thin Prep Imaging System (TIS): Experience in a high volume academic practice. *CytoJournal*. 2007;4, 2007. Article Number: 6. Date of Publication: 2007.-.

Christe, D. M., Mohanambal, M., Ramamurthy, V., and Sneha, N. B.. A study of cervical cancer screening for prevention of carcinoma cervix. *Journal of the Indian Medical Association*. 2008;106(12):779-782.

Cibas, E. S., Alonzo, T. A., Austin, R. M., Bolick, D. R., Glant, M. D., Henry, M. R., Moriarty, A. T., Molina, J. T., Rushing, L., Slowman, S. D., Torno, R., and Eisenhut, C. C.. The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. *American journal of clinical pathology*. 2008;129(2):193-201.

Cirpan, T., Guliyeva, A., Onder, G., Terek, M. C., Ozsaran, A., Kabasakal, Y., Zekioglu, O., and Yucebilgin, S.. Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren's syndrome. *European Journal of Gynaecological Oncology*. 2007;28(4):302-306.

Cohen, D., Shorie, J., and Biscotti, C.. Glacial acetic acid treatment and atypical endocervical glandular cells: An Analysis of 92 Cases. *American journal of clinical pathology*. 2010;133(5):799-801.

Cohn, J. A., Gagnon, S., Spence, M. R., Harrison, D. D., Kluzak, T. R., Langenberg, P., Brinson, C., Stein, A., and Hellinger, J.. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. *American Journal of Obstetrics and Gynecology*. 2001;184(3):322-330.

Coldman, A., Phillips, N., Kan, L., Maticic, J., Benedet, L., and Towers, L.. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives. *Journal of medical screening*. 2005;12(1):7-11.

Coldman, A., Phillips, N., Kan, L., Maticic, J., Benedet, L., and Towers, L.. Risk of invasive cervical cancer after three consecutive negative Pap smears. *Journal of medical screening*. 2003;10(4):196-200.

Colgan, T. J., Woodhouse, S. L., Styer, P. E., Kennedy, M., and Davey, D. D.. Reparative changes and the false-positive/false-negative papanicolaou test: A study from the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. *Archives of Pathology and Laboratory Medicine*. 2001;125(1):134-140.

Comber, H. and Gavin, A.. Recent trends in cervical cancer mortality in Britain and Ireland: The case for population-based cervical cancer screening. *British Journal of Cancer*. 2004;91(11):1902-1904.

Confortini, M., Giorgi, Rossi P., Barbarino, P., Passarelli, A. M., Orzella, L., and Tufi, M. C.. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. *Journal of medical screening*. 2010;17(2):79-86.

Coquillard, G., Palao, B., and Patterson, B. K.. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. *Gynecologic Oncology*. 2011;120(1):89-93.

Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women. *Obstetrics & Gynecology*. 2002;100(1):79-86.

Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women¹. *Obstetrics and Gynecology*. 2002;100(1):79-86.

Corusic, A., Skrgatic, L., Mahovlic, V., Mandic, V., Planinic, P., and Karadza, M.. Cervical cancer as a public health issue--what next?. *Collegium antropologicum*. 2010;34(1):301-307.

Coste, J., Cochand-Priollet, B., de, Cremoux P., Buntinx, F., and Arbyn, M.. Conventional cervical smears were better than monolayer cytology or human papillomavirus testing for detecting cervical intraepithelial neoplasia. *Evidence-Based Medicine*. 2003;8(6):187-.

Coutlee, F., Rouleau, D., Petignat, P., Ghattas, G., Kornegay, J. R., Schlag, P., Boyle, S., Hankins, C., Vezina, S., Cote, P., Macleod, J., Voyer, H., Forest, P., Walmsley, S., Franco, E., Connors, J., Grimshaw, R., Haase, D., Johnston, L., Schlech, W., Yuzicappi-Fayant, A., Landis, S., Smaill, F., Austin, T., Hammerberg, O., Ralph, T., Falutz, J., Ferenczy, A., Klein, M., Labrecque, L., Lalonde, R., Noel, G., Perron, C., Routy, J.-P., Toma, E., Touchie, C., Victor, G., Cote, L., Senay, H., Trottier, S., Williams, K., Piche, A., Sandre, R., Binder, L., Keystone, D., Phillips, A., Rachlis, A., Salit, I., Wagner, C., Braitstein, P., Burdge, D., Harris, M., Money, D., and Montaner, J.. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGM1 primers and the linear array HPV genotyping test. *Journal of Clinical Microbiology*. 2006;44(6):1998-2006.

Cox, J. T.. Corrigendum to "History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results" [*J. Clin. Virol.* 45 (1) (2009) S3-S12] (PII:S1386-6532(09)X0008-9). *Journal of Clinical Virology*. 2010;47(3):299-.

Cox, J. T.. Human papillomavirus testing in primary cervical screening and abnormal papanicolaou management. *Obstetrical and Gynecological Survey*. 2006;61(6 SUPPL. 1):S15-S25.

Cox, J. T.. Liquid-based cytology: evaluation of effectiveness, cost-effectiveness, and application to present practice. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2004;2(6):597-611.

Curran, D. R. and Stigleman, S.. Should we discontinue Pap smear screening in women aged >65 years?. *Journal of Family Practice*. 2004;53(4):308-310.

Cuzick, J., Arbyn, M., Sankaranarayanan, R., Tsu, V., Ronco, G., Mayrand, M.-H., Dillner, J., and Meijer, C. J. L. M.. Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. *Vaccine*. 2008;26(SUPPL. 10):K29-K41.

Cuzick, J., Clavel, C., Petry, K.-U., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., and Iftner, T.. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006;119(5):1095-1101.

Cuzick, J., Szarewski, A., Mesher, D., Cadman, L., Austin, J., Perryman, K., Ho, L., Terry, G., Sasieni, P., Dina, R., and Soutter, W. P.. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - Results from the Hammersmith study. *International Journal of Cancer*. 2008;122(10):2294-2300.

Cuzick, J.. Time to consider HPV testing in cervical screening. *Annals of Oncology*. 2001;12(11):1511-1514.

Datta, S. D., Koutsky, L. A., Ratelle, S., Unger, E. R., Shlay, J., McClain, T., Weaver, B., Kerndt, P., Zenilman, J., Hagensee, M., Suhr, C. J., and Weinstock, H.. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. *Annals of internal medicine*. 2008;148(7):493-500.

Davey, E., D'Assuncao, J., Irwig, L., Macaskill, P., Chan, S. F., Richards, A., and Farnsworth, A.. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: Prospective study. *British Medical Journal*. 2007;335(7609):31-35.

Day, G. E., Lanier, A. P., Bulkow, L., Kelly, J. J., and Murphy, N.. Cancers of the breast, uterus, ovary and cervix among Alaska native women, 1974-2003. *International Journal of Circumpolar Health*. 2010;69(1):72-86.

De Francesco, M. A., Gargiulo, F., Schreiber, C., Ciravolo, G., Salinaro, F., and Manca, N.. Comparison of the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. *Journal of Virological Methods*. 2008;147(1):10-17.

De, Lang A. and Wilander, E.. Sensitivity of HPV tests on stained vs. unstained cervical smears. *Acta Cytologica*. 2005;49(6):595-599.

De, Lang A., Wikstrom, I., and Wilander, E.. Significance of HPV tests on women with cervical smears showing ASCUS. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(10):1001-1005.

Deerasamee, S., Srivatanakul, P., Sriplung, H., Nilvachararung, S., Tansuwan, U., Pitakpraiwan, P., Kaewkungwal, J., Singhasivanon, P., Nimnakorn, P., and Sankaranarayanan, R.. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand. *Asian Pacific journal of cancer prevention : APJCP*. 2007;8(4):547-556.

Denton, K. J., Bergeron, C., Klement, P., Trunk, M. J., Keller, T., and Ridder, R.. The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. *American journal of clinical pathology*. 2010;134(1):12-21.

Derchain, S. F., Sarian, L. O., Naud, P., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Serpa-Hammes, L., Matos, J., Gontijo, R. C., Braganca, J. F., Lima, T. P., Maeda, M. Y., Lorincz, A., Dores, G. B., Costa, S., Syrjanen, S., and Syrjanen, K.. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study. *Journal of medical screening*. 2008;15(2):97-104.

Desai, M.. Role of automation in cervical cytology. *Diagnostic Histopathology*. 2009;15(7):323-329.

Diaz-Montes, T. P., Farinola, M. A., Zahurak, M. L., Bristow, R. E., and Rosenthal, D. L.. Clinical utility of atypical glandular cells (AGC) classification: Cytohistologic comparison and relationship to HPV results. *Gynecologic Oncology*. 2007;104(2):366-371.

Difurio, M. J., Mailhiot, T., Sundborg, M. J., and Nauschuetz, K. K.. Comparison of the clinical significance of the papanicolaou test interpretations LSIL cannot rule out HSIL and ASC-H. *Diagnostic Cytopathology*. 2010;38(5):313-317.

Dockter, J., Schroder, A., Hill, C., Guzinski, L., Monsonego, J., and Giachetti, C.. Clinical performance

of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S55-S61.

Duby, J. M. and Difurio, M. J.. Implementation of the ThinPrep Imaging System in a tertiary military medical center. *Cancer cytopathology*. 2009;117(4):264-270.

Duggan, M. A., Khalil, M., Brasher, P. M. A., and Nation, J. G.. Comparative study of the ThinPrep Pap test and conventional cytology results in a Canadian cohort. *Cytopathology*. 2006;17(2):73-81.

Dunton, C. J., Dooley, M., and Holtz, D. O.. Early detection of cervical cancer by human papillomavirus DNA testing: Case reports. *Journal of Lower Genital Tract Disease*. 2006;10(4):256-257.

Dziura, B., Quinn, S., and Richard, K.. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the uterine cervix. *Acta Cytologica*. 2006;50(3):309-311.

Eilstein, D., Hedelin, G., and Schaffer, P.. Cervical cancer in Bas-Rhin: Trend and prediction of the incidence in 2014. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2002;31(1):28-33.

Einstein, M. H., Studentsov, Y. Y., Ho, G. Y. F., Fazzari, M., Marks, M., Kadish, A. S., Goldberg, G. L., Runowicz, C. D., and Burk, R. D.. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. *International Journal of Cancer*. 2007;120(1):55-59.

El, Gnaoui N., Saile, R., and Benomar, H.. Pap smear an inevitable test in the screening of the lesions of the cervix. [French]. *Journal Africain du Cancer*. 2010;2(1):9-13.

Elfgren, K., Kalantari, M., Moberger, B., Hagmar, B., and Dillner, J.. A population-based five-year follow-up study of cervical human papillomavirus infection. *American Journal of Obstetrics and Gynecology*. 2000;183(3):561-567.

Elsheikh, T. M., Kirkpatrick, J. L., and Wu, H. H.. The significance of "low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion" as a distinct squamous abnormality category in Papanicolaou tests. *Cancer*. 2006;108(5):277-281.

Eltoum, I. A. and Roberson, J.. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national pap test volume: Projections from the National Health Interview Survey (NHIS). *Cancer*. 2007;111(1):34-40.

Eltoum, I. A., Chhieng, D. C., Roberson, J., McMillon, D., and Partridge, E. E.. Reflex human papilloma virus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2-3 in young versus elderly women. *Cancer*. 2005;105(4):194-198.

Escobedo, L. G., Zhong, Z., and Key, C.. Breast and cervical cancer screening and disease incidence and stage in New Mexico. *Cancer Causes and Control*. 2002;13(2):137-145.

Fait, G., Kupferminc, M. J., Daniel, Y., Geva, E., Ron, I. G., Lessing, J. B., and Bar-Am, A.. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal Pap smears before colposcopy referral. *Gynecologic Oncology*. 2000;79(2):177-180.

Farag, R., Redline, R., and Abdul-Karim, F. W.. Value of combining HPV-DNA testing with follow-up papanicolaou smear in patients with prior atypical squamous cells of undetermined significance. *Acta Cytologica*. 2008;52(3):294-296.

Federico, C., Alleyn, J., Dola, C., Tafti, S., Galandak, J., Jacob, C., Bhuiyan, A., and Cheng, J.. Relationship among age, race, medical funding, and cervical cancer survival. *Journal of the National Medical Association*. 2010;102(3):199-205.

Feng, J., Al-Abbadi, M. A., Bandyopadhyay, S., Salimnia, H., and Husain, M.. Significance of high-risk

human papillomavirus DNA-positive atypical squamous cells of undetermined significance pap smears in perimenopausal and postmenopausal women. *Acta Cytologica*. 2008;52(4):434-438.

Ferreccio, C., Bratti, M. C., Sherman, M. E., Herrero, R., Wacholder, S., Hildesheim, A., Burk, R. D., Hutchinson, M., Alfaro, M., Greenberg, M. D., Morales, J., Rodriguez, A. C., Schussler, J., Eklund, C., Marshall, G., and Schiffman, M.. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. *Cancer Epidemiology Biomarkers and Prevention*. 2003;12(9):815-823.

Ferris, D. G., Gilman, P. A., Leyva Lopez, A. G., Litaker, M. S., Miller, J. A., and Macfee, M. S.. Psychological effects women experience before and after a colposcopic examination and primary care appointment. *Journal of Lower Genital Tract Disease*. 2003;7(2):89-94.

Ferris, D. G., Heidemann, N. L., Litaker, M. S., Crosby, J. H., and Macfee, M. S.. The efficacy of liquid-based cervical cytology using direct-to-vial sample collection. *Journal of Family Practice*. 2000;49(11):1005-1011.

Fink, J. L.. Beyond the shock of an abnormal Pap. *RN*. 2003;66(6):56-61.

Flori, M., Dupraz, C., Erpeldinger, S., and Le, Goaziou M. F.. Cervical smears among women after 65 years. One-year retrospective descriptive study. [French]. *Revue du Praticien*. 2009;59(10 SUPPL. 1):29-32.

Freeman-Wang, T. and Walker, P.. Psychological aspects of colposcopy. *CME Journal of Gynecologic Oncology*. 2005;10(2):123-126.

Frega, A., Biamonti, A., Maranghi, L., Vetrano, G., Palazzo, A., Iacovelli, R., Corosu, R., French, D., Moscarini, M., and Vecchione, A.. Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. Analysis of risk factors. *Anticancer Research*. 2006;26(4 B):3167-3170.

Freitas, R. A. P., Carvasan, G. A. F., Morais, S. S., and Zeferino, L. C.. Excessive pap smears due to opportunistic cervical cancer screening. *European Journal of Gynaecological Oncology*. 2008;29(5):479-482.

Fremont-Smith, M., Marino, J., Griffin, B., Spencer, L., and Bolick, D.. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. *Cancer*. 2004;102(5):269-279.

Froberg, M., Johansson, B., Hjerpe, A., and Andersson, S.. Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities. *British Journal of Cancer*. 2008;99(4):563-568.

Gage, J. C., Schiffman, M., Solomon, D., Wheeler, C. M., and Castle, P. E.. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. *Cancer Epidemiology Biomarkers and Prevention*. 2010;19(7):1668-1674.

Garcia-Garcia, J. A., Perez-Valles, A., Martorell, M., Gomez, B., Gomez-Cabrero, D., Soler, F., and Calabuig, C.. Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. *Acta Cytologica*. 2010;54(2):159-164.

Garcia-Sierra, N., Martro, E., Castella, E., Llatjos, M., Tarrats, A., Bascunana, E., Diaz, R., Carrasco, M., Sirera, G., Matas, L., and Ausina, V.. Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening. *Journal of Clinical Microbiology*. 2009;47(7):2165-2169.

Gazzaz, F. S. B.. Molecular testing of human papillomavirus in cervical specimens. *Saudi Medical Journal*. 2007;28(12):1810-1818.

Ge, Y., Smith, D., Schwartz, M. R., and Mody, D. R.. Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population. *Cancer cytopathology*. 2009;117(5):326-332.

Geldenhuis, L. and Murray, M. L.. Sensitivity and specificity of the pap smear for glandular lesions of the cervix and endometrium. *Acta Cytologica*. 2007;51(1):47-50.

Ginsberg, G. M., Edejer, T. T. T., Lauer, J. A., and Sepulveda, C.. Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis. *Vaccine*. 2009;27(43):6060-6079.

Giordano, G., Gnetti, L., Pilato, F. P., Viviano, L., and Silini, E. M.. The role of cervical smear in the diagnosis and management of extruterine malignancies metastatic to the cervix: Three case reports. *Diagnostic Cytopathology*. 2010;38(1):41-46.

Girianelli, V. R. and Thuler, L. C. S.. Evaluation of agreement between conventional and liquid-based cytology in cervical cancer early detection based on analysis of 2,091 smears: Experience at the Brazilian National Cancer Institute. *Diagnostic Cytopathology*. 2007;35(9):545-549.

Goldie, S. J., Kim, J. J., and Wright, T. C.. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. *Obstetrics and Gynecology*. 2004;103(4):619-631.

Gontijo, R. C., Derchain, S. F. M., Roteli-Martins, C., Braganca, J. F., Sarian, L. O., Morais, S. S., Maeda, M. Y. S., Longatto-Filho, A., and Syrjanen, K. J.. Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2007;133(2):239-246.

Grace, A., McBrearty, P., Troost, S., Thornhill, M., Kay, E., and Leader, M.. Comparative study: Conventional cervical and ThinPrep Pap tests in a routine clinical setting. *Cytopathology*. 2002;13(4):200-205.

Grainge, M. J., Seth, R., Guo, L., Neal, K. R., Coupland, C., Vryenhoef, P., Johnson, J., and Jenkins, D.. Cervical human papillomavirus screening among older women. *Emerging Infectious Diseases*. 2005;11(11):1680-1685.

Greydanus, D. E., Omar, H., and Patel, D. R.. Cervical cancer screening in adolescents. *Pediatrics in Review*. 2009;30(1):23-25.

Greydanus, D. E., Omar, H., and Patel, D. R.. What's new: Cervical cancer screening in adolescents. *Pediatrics in review / American Academy of Pediatrics*. 2009;30(1):23-25.

Guido, R.. Guidelines for screening and treatment of cervical disease in the adolescent. *Journal of Pediatric and Adolescent Gynecology*. 2004;17(5):303-311.

Guidos, B. J. and Selvaggi, S. M.. Detection of endometrial adenocarcinoma with the ThinPrep Pap Test(TM). *Diagnostic Cytopathology*. 2000;23(4):260-265.

Guillaud, M., Benedet, J. L., Cantor, S. B., Staerke, G., Follen, M., and MacAulay, C.. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. *Cancer*. 2006;107(2):309-318.

Gunnell, A. S., Ylitalo, N., Sandin, S., Sparen, P., Adami, H.-O., and Ripatti, S.. A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: Evidence of effectiveness and overtreatment. *Cancer Epidemiology Biomarkers and Prevention*. 2007;16(12):2641-2648.

- Guo, M., Hu, L., Martin, L., Liu, S., Baliga, M., and Hughson, M. D.. Accuracy of liquid-based pap tests: Comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal pap smears. *Acta Cytologica*. 2005;49(2):132-138.
- Guo, M., Patel, S. J., Chovanec, M., Yee, J. J., Tarco, E., Bevers, T. B., Anderson, K., and Sneige, N.. A human papillomavirus testing system in women with abnormal pap results: A comparison study with follow-up biopsies. *Acta Cytologica*. 2007;51(5):749-754.
- Gupta, S., Sodhani, P., Halder, K., Chachra, K. L., Singh, V., and Sehgal, A.. Age trends in pre-cancerous and cancerous lesions of the uterine cervix in a cytology screening programme: What should be the target age group for a major thrust of screening in resource-limited settings?. *Cytopathology*. 2008;19(2):106-110.
- Halfon, P., Benmoura, D., Agostini, A., Khiri, H., Martineau, A., Penaranda, G., and Blanc, B.. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. *Journal of Clinical Virology*. 2010;47(2):177-181.
- Halfon, P., Benmoura, D., Khiri, H., Penaranda, G., Blanc, B., Riggio, D., and Sandri, M. T.. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. *Journal of Clinical Virology*. 2010;47(1):38-42.
- Halford, J. A., Batty, T., Boost, T., Duhig, J., Hall, J., Lee, C., and Walker, K.. Comparison of the sensitivity of conventional cytology and the ThinPrep imaging system for 1,083 biopsy confirmed high-grade squamous lesions. *Diagnostic Cytopathology*. 2010;38(5):318-326.
- Hall, J. and Kendall, B.. High risk human papillomavirus DNA detection in pap tests with both atypical squamous cells of undetermined significance and candida. *Acta Cytologica*. 2009;53(2):150-152.
- Hamashima, C., Aoki, D., Miyagi, E., Saito, E., Nakayama, T., Sagawa, M., Saito, H., Sobue, T., and Japanese Research Group for Development of Cervical Cancer Screening Guidelines. The Japanese guideline for cervical cancer screening. *Japanese journal of clinical oncology*. 2010;40(6):485-502.
- Hantz, S., Caly, H., Decroisette, E., Dutrop, A., Bakeland, D., Pascal, B., Darreye, G., Dussartre, C., Renaudie, J., Rogez, S., Aubard, Y., Denis, F., and Alain, S.. Evaluation of accuracy of three assays for human papillomavirus detection and typing: Hybrid Capture 2, HPV Consensus kit and AmpliCor HPV. [French]. *Pathologie Biologie*. 2008;56(1):29-35.
- Hartmann, K. E., Nanda, K., Hall, S., and Myers, E.. Technologic advances for evaluation of cervical cytology: Is newer better?. *Obstetrical and Gynecological Survey*. 2001;56(12):765-774.
- Harvey, M., Stout, S., Starkey, C. R., Hendren, R., Holt, S., and Miller, G. C.. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S79-S83.
- Hatch, K. D., Sheets, E., Kennedy, A., Ferris, D. G., Darragh, T., and Twiggs, L.. Multicenter direct to vial evaluation of a liquid-based Pap test. *Journal of Lower Genital Tract Disease*. 2004;8(4):308-312.
- Healey, S. M., Aronson, K., Mao, Y., and Franco, E. L.. Human papillomavirus and cervical dysplasia in Nunavut: prelude to a screening strategy. *International Journal of Circumpolar Health*. 2004;63 Suppl 2:199-201.
- Hellsten, C., Lindqvist, P. G., and Sjostrom, K.. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2008;115(2):205-211.
- Hellsten, C., Sjostrom, K., and Lindqvist, P. G.. A prospective Swedish cohort study on psychosocial factors influencing anxiety in women referred for colposcopy. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2007;114(1):32-38.

- Hemminki, K., Li, X., and Mutanen, P.. Age-incidence relationships and time trends in cervical cancer in Sweden. *European Journal of Epidemiology*. 2001;17(4):323-328.
- Herbert, A., Gregory, M., Gupta, S. S., and Singh, N.. Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2009;116(6):854-859.
- Herbert, A., Holdsworth, G., and Kubba, A. A.. Cervical screening: Why young women should be encouraged to be screened. *Journal of Family Planning and Reproductive Health Care*. 2008;34(1):21-25.
- Herbert, A.. Cervical screening in England and Wales: Its effect has been underestimated. *Cytopathology*. 2000;11(6):471-479.
- Hesselink, A. T., Berkhof, J., Heideman, D. A., Bulkmand, N. W., van Telling, J. E., Meijer, C. J., and Snijders, P. J.. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. *International Journal of Cancer*. 2009;Journal international du cancer. 124(2):381-386.
- Hoekstra, A. V., Kosinski, A., and Huh, W. K.. Hormonal contraception and false-positive cervical cytology: Is there an association?. *Journal of Lower Genital Tract Disease*. 2006;10(2):102-106.
- Holmquist, N. D.. Revisiting the effect of the pap test on cervical cancer. *American journal of public health*. 2000;90(4):620-623.
- Hong, D. G., Seong, W. J., Kim, S. Y., Lee, Y. S., and Cho, Y. L.. Prediction of high-grade squamous intraepithelial lesions using the modified Reid index. *International Journal of Clinical Oncology*. 2010;15(1):65-69.
- Hoonhorst, F. and Hamon, A.. Cervical cancer and HPV screening. [French]. *IRBM News*. 2008;29(3-4):19-21.
- Howard, K., Salkeld, G., McCaffery, K., and Irwig, L.. HPV triage testing or repeat pap smear for the management of a typical squamous cells (ASCUS) on pap smear: Is there evidence of process utility?. *Health Economics*. 2008;17(5):593-605.
- Huang, S., Erickson, B., Tang, N., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S19-S23.
- Hunter, C., Duggan, M. A., Duan, Q., Power, P., Gregoire, J., and Nation, J.. Cytology and outcome of LSIL: Cannot exclude HSIL compared to ASC-H. *Cytopathology*. 2009;20(1):17-26.
- Hussein, T., Desai, M., Tomlinson, A., and Kitchener, H. C.. The comparative diagnostic accuracy of conventional and liquid-based cytology in a colposcopic setting. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2005;112(11):1542-1546.
- Igdbashian, S., Maggioni, A., Casadio, C., Boveri, S., Cristoforoni, P., and Sideri, M.. Sentinel Pap smears in 261 invasive cervical cancer patients in Italy. *Vaccine*. 2009;27(SUPPL. 1):A34-A38.
- Illades-Aguar, B., Alarcon-Romero, L., Antonio-Vejar, V., Zamudio-Lopez, N., Sales-Linares, N., Flores-Alfaro, E., Fernandez-Tilapa, G., Vences-Velazquez, A., Munoz-Valle, J. F., and Leyva-Vazquez, M.-A.. Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico. *Gynecologic Oncology*. 2010;117(2):291-296.
- Ingemann-Hansen, O., Lidang, M., Niemann, I., Dinesen, J., Baandrup, U., Svanholm, H., and Petersen, L. K.. Screening history of women with cervical cancer: A 6-year study in Aarhus, Denmark. *British*

Journal of Cancer. 2008;98(7):1292-1294.

Inoue, M., Sakaguchi, J., Sasagawa, T., and Tango, M.. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. *International Journal of Gynecological Cancer*. 2006;16(3):1007-1013.

Jacot-Guillarmod, M., Hohlfeld, P., and Renteria, S.-C.. Role of the PAP smear in adolescence. [French]. *Revue Medicale Suisse*. 2009;5(222):2078-2084.

Jeng, C.-J., Ko, M.-L., Ling, Q.-D., Shen, J., Lin, H.-W., Tzeng, C.-R., Ho, C.-M., Chien, T.-Y., and Chen, S.-C.. Prevalence of cervical human papillomavirus in Taiwanese women. *Clinical and Investigative Medicine*. 2005;28(5):261-266.

Jiang, J., Wei, L.-H., Li, Y.-L., Wu, R.-F., Xie, X., Feng, Y.-J., Zhang, G., Zhao, C., Zhao, Y., and Chen, Z.. Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer: A multicenter study in China. *Journal of Molecular Diagnostics*. 2010;12(6):808-817.

Jones, H. E., Wiegerinck, M. A., Nieboer, T. E., Mol, B. W., and Westhoff, C. L.. Women in the Netherlands prefer self-sampling with a novel lavaging device to clinician collection of specimens for cervical cancer screening. *Sexually Transmitted Diseases*. 2008;35(11):916-917.

Julian, T. M.. Erratum: Type-specific HPV testing as a predictor of high-grade squamous intraepithelial lesion outcome after cytologic abnormalities (*Journal of Lower Genital Tract Disease* (2005) 9, (3), (154-159)). *Journal of Lower Genital Tract Disease*. 2006;10(1):63-.

Juric, D., Mahovlic, V., Rajhvajn, S., Ovanin-Rakic, A., Skopljanac-Macina, L., Barisic, A., Projic, I. S., Babic, D., Susa, M., Corusic, A., and Oreskovic, S.. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions. *Collegium antropologicum*. 2010;34(1):19-24.

Kahn, J. A., Slap, G. B., Bernstein, D. I., Kollar, L. M., Tissot, A. M., Hillard, P. A., and Rosenthal, S. L.. Psychological, behavioral, and interpersonal impact of human papillomavirus and pap test results. *Journal of Women's Health*. 2005;14(7):650-659.

Kang, W. D., Kim, C. H., Cho, M. K., Kim, J. W., Kim, Y. H., Choi, H. S., and Kim, S. M.. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. *International Journal of Gynecological Cancer*. 2009;19(5):924-928.

Karabulut, A., Alan, T., Ali, Ekiz M., Iritas, A., Kesen, Z., and Yahsi, S.. Evaluation of cervical screening results in a population at normal risk. *International Journal of Gynecology and Obstetrics*. 2010;110(1):40-42.

Karam, W. G., Bedran, F., Tohme, R. A., Moukarbel, N., Abdallah, I., Jurjus, A. R., Jurjus, R. A., Khairallah, S., and Aftimos, G.. Human papillomavirus testing as an adjunct to cytology evaluation in cervical specimens of selected and consecutively screened Lebanese women: A prospective clinical study. *Journal Medical Libanais*. 2005;53(3):132-138.

Karasz, A., McKee, M. D., and Roybal, K.. Women's experiences of abnormal cervical cytology: illness representations, care processes, and outcomes. *Annals of family medicine*. 2003;1(4):196-202.

Kent, A.. Screening and logical cytology - A review. *Obstetrics and Gynaecology Forum*. 2009;19(4):141-143.

Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M. S., Scott, D. R., Rush, B. R., Glass, A. G., and Schiffman, M.. The elevated 10-Year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *Journal of the National Cancer Institute*. 2005;97(14):1072-1079.

Khuakoonratt, N., Tangjitgamol, S., Manusirivithaya, S., Khunnarong, J., Pataradule, K., Thavaramara,

T., and Suekwattana, P.. Prevalence of high grade squamous intraepithelial lesion (HSIL) and invasive cervical cancer in patients with low grade squamous intraepithelial lesion (LSIL) at cervical pap smear. *Asian Pacific journal of cancer prevention : APJCP*. 2008;9(2):253-257.

Kiatpongsan, S., Niruthisard, S., Mutirangura, A., Trivijitsilp, P., Vasuratna, A., Chaithongwongwatthana, S., and Lertkhachonsuk, R.. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. *International Journal of Gynecological Cancer*. 2006;16(1):262-265.

Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., and Choi, C.. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Gynecologic Oncology*. 2010;116(1):99-104.

Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., Choi, C., Kweon, S.-S., Fackler, M. J., and Sukumar, S.. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Virchows Archiv*. 2010;457(1):35-42.

Kinney, W., Castle, P. E., Fetterman, B., Poitras, N., Lorey, T., and Shaber, R.. Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. *Obstetrics and Gynecology*. 2009;113(3):595-600.

Kinney, W., Sawaya, G. F., Sung, H. Y., Kearney, K. A., Miller, M., and Hiatt, R. A.. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. [Review] [27 refs]. *Acta Cytologica*. 2003;47(2):167-171.

Kirschner, B., Simonsen, K., and Junge, J.. Comparison of conventional Papanicolaou smear and SurePath liquid-based cytology in the Copenhagen population screening programme for cervical cancer. *Cytopathology*. 2006;17(4):187-194.

Kjaer, S., Hogdall, E., Frederiksen, K., Munk, C., Van Den Brule, A., Svare, E., Meijer, C., Lorincz, A., and Iftner, T.. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. *Cancer Research*. 2006;66(21):10630-10636.

Klinkhamer, P. J. J. M., Meerding, W. J., Rosier, P. F. W. M., and Hanselaar, A. G. J. M.. Liquid-based cervical cytology: A review of the literature with methods of evidence-based medicine. *Cancer*. 2003;99(5):263-271.

Knoepf, S. M., Kuebler, D. L., and Wilbur, D. C.. Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: a cytologic/histologic review of 367 cases. *Cancer cytopathology*. 2010;118(4):209-217.

Knoepf, S. M., Kuebler, D. L., and Wilbur, D. C.. Resolution of equivocal results with the hybrid capture II high-risk HPV DNA Test: A cytologic/histologic review of 191 cases. *Diagnostic Molecular Pathology*. 2007;16(3):125-129.

Ko, V., Nanji, S., Tambouret, R. H., and Wilbur, D. C.. Testing for HPV as an objective measure for quality assurance in gynecologic cytology: Positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio. *Cancer*. 2007;111(2):67-73.

Ko, V., Tambouret, R. H., Kuebler, D. L., Black-Schaffer, W. S., and Wilbur, D. C.. Human papillomavirus testing using Hybrid Capture II with SurePath collection: Initial evaluation and longitudinal data provide clinical validation for this method. *Cancer*. 2006;108(6):468-474.

Koliopoulos, G., Valasoulis, G., and Zilakou, E.. An update review on HPV testing methods for cervical neoplasia. *Expert Opinion on Medical Diagnostics*. 2009;3(2):123-131.

- Koong, S. L., Yen, A. M., and Chen, T. H.. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. *Journal of medical screening*. 2006;13 Suppl 1:S44-S47.
- Kotaniemi-Talonen, L., Nieminen, P., Hakama, M., Seppanen, J., Ikkala, J., Martikainen, J., Tarkkanen, J., Toivonen, T., and Anttila, A.. Significant variation in performance does not reflect the effectiveness of the cervical cancer screening programme in Finland. *European Journal of Cancer*. 2007;43(1):169-174.
- Kulasingam, S. L. and Myers, E. R.. Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs. *Journal of the American Medical Association*. 2003;290(6):781-789.
- Kulmala, S.-M., Syrjanen, S., Shabalova, I., Petrovichev, N., Kozachenko, V., Podistov, J., Ivanchenko, O., Zakharenko, S., Nerovjna, R., Kljukina, L., Branovskaja, M., Grunberga, V., Juschenko, A., Tosi, P., Santopietro, R., and Syrjanen, K.. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. *Journal of Clinical Microbiology*. 2004;42(6):2470-2475.
- Kumar, N., Bongiovanni, M., Molliet, M.-J., Pelte, M.-F., Egger, J.-F., and Pache, J.-C.. Reclassification and analysis of clinical significance of atypical glandular cells on ThinPrep using the Bethesda 2001: Geneva experience. *Swiss Medical Weekly*. 2007;137(45-46):635-641.
- Kurtycz, D. F. I., Smith, M., He, R., Miyazaki, K., and Shalkham, J.. Comparison of methods trial for high-risk HPV. *Diagnostic Cytopathology*. 2010;38(2):104-108.
- Kyrgiou, M., Tsoumpou, I., Vrekoussis, T., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Mitrou, S., Koliopoulos, G., Dalkalitsis, N., Stamatopoulos, P., and Paraskevaidis, E.. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: The cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. *Cancer Treatment Reviews*. 2006;32(7):516-523.
- Lam, C. L. K.. The price of cancer screening. *Hong Kong Practitioner*. 2004;26(3):142-145.
- Lavoue, V., Bergeron, C., Riethmuller, D., Darai, E., Mergui, J.-L., Baldauf, J.-J., Gondry, J., Douvier, S., Lopes, P., De, Reilhac P., Quereux, C., Letombe, B., Marchetta, J., Boulanger, J.-C., and Leveque, J.. Cervical screening: Toward a new paradigm?. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2010;39(2):102-115.
- Lazcano-Ponce, E., Lorincz, A. T., Salmeron, J., Fernandez, I., Cruz, A., Hernandez, P., Mejia, I., and Hernandez-Avila, M.. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican social security program. *Cancer Causes and Control*. 2010;21(10):1693-1700.
- Lee, C. Y. K. and Ng, W.-K.. A follow-up study off atypical squamous cells in gynecologic cytology using conventional papanicolaou smears and liquid-based preparations: The impact of the Bethesda system 2001. *American journal of clinical pathology*. 2007;127(4):548-555.
- Lee, S. H., Vigliotti, V. S., and Pappu, S.. HPV infection among women in a representative rural and suburban population of the USA. *International Journal of Gynecology and Obstetrics*. 2009;105(3):210-214.
- Lerma, E., Quintana, M. J., Quilez, M., Esteva, E., Carreras, A., Bonfill, X., Prat, J., and Calaf, J.. Effectiveness of liquid-based cytology and Papanicolaou tests in a low risk population. *Acta Cytologica*. 2007;51(3):399-406.
- Levi, F., Lucchini, F., Negri, E., Franceschi, S., and La, Vecchia C.. Cervical cancer mortality in young women in Europe patterns and trends. *European Journal of Cancer*. 2000;36(17):2266-2271.
- Li, N., Shi, J.-F., Franceschi, S., Zhang, W.-H., Dai, M., Liu, B., Zhang, Y.-Z., Li, L.-K., Wu, R.-F., De, Vuyst H., Plummer, M., Qiao, Y.-L., and Clifford, G.. Different cervical cancer screening approaches in

- a Chinese multicentre study. *British Journal of Cancer*. 2009;100(3):532-537.
- Liang, J., Mittal, K. R., Wei, J. J., Yee, H., Chiriboga, L., and Shukla, P.. Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with silverberg scoring system for endocervical glandular lesions. *International Journal of Gynecological Pathology*. 2007;26(1):71-75.
- Lie, A. K., Risberg, B., Borge, B., Sandstad, B., Delabie, J., Rimala, R., Onsrud, M., and Thoresen, S.. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. *Gynecologic Oncology*. 2005;97(3):908-915.
- Liman, A. K., Giampoli, E. J., and Bonfiglio, T. A.. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?. *Cancer*. 2005;105(6):457-460.
- Liu, S. S., Leung, R. C. Y., Chan, K. K. L., Cheung, A. N. Y., and Ngan, H. Y. S.. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche linear array HPV genotyping assay. *Journal of Clinical Microbiology*. 2010;48(3):758-764.
- Liu, S., Semenciw, R., Probert, A., and Mao, Y.. Cervical cancer in Canada: Changing patterns in incidence and mortality. *International Journal of Gynecological Cancer*. 2001;11(1):24-31.
- Longatto, Filho A., Miranda Pereira, S. M., Di, Loreto C., Utagawa, M. L., Makabe, S., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., and Castelo, A.. DCS liquid-based system is more effective than conventional smears to diagnosis of cervical lesions: Study in high-risk population with biopsy-based confirmation. *Gynecologic Oncology*. 2005;97(2):497-500.
- Longatto-Filho, A., Erzen, M., Branca, M., Roteli-Martins, C., Naud, P., Derchain, S. F. M., Hammes, L., Sarian, L. O., Braganca, J. F., Matos, J., Gontijo, R., Lima, T., Maeda, M. Y. S., Tatti, S., Syrjanen, S., Dores, G., Lorincz, A., and Syrjanen, K.. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: Experience from the Latin American screening study. *International Journal of Gynecological Cancer*. 2006;16(3):955-962.
- Lonky, N. M., Mahdavi, A., Wolde-Tsadik, G., Bajamundi, K., and Felix, J. C.. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: A retrospective review of the southern california permanente medical group experience. *Journal of Lower Genital Tract Disease*. 2010;14(3):200-205.
- Lorenzato, M., Caudroy, S., Bronner, C., Evrard, G., Simon, M., Durlach, A., Birembaut, P., and Clavel, C.. Cell cycle and/or proliferation markers: What is the best method to discriminate cervical high-grade lesions?. *Human Pathology*. 2005;36(10):1101-1107.
- Lozano, R.. Comparison of computer-assisted and manual screening of cervical cytology. *Gynecologic Oncology*. 2007;104(1):134-138.
- Luque, A. E., Jabeen, M., Messing, S., Lane, C. A., Demeter, L. M., Rose, R. C., and Reichman, R. C.. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. *Journal of Infectious Diseases*. 2006;194(4):428-434.
- Luyten, A., Scherbring, S., Reinecke-Luthge, A., Braun, B. E., Pietralla, M., Theiler, K., and Petry, K. U.. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany - Experience over 3 years. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S5-S10.
- Ma, L., Bian, M.-L., Cheng, J.-Y., Xiao, W., Hao, M., Zhu, J., Chen, Y., and Liu, J.. Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study. *Experimental and Therapeutic Medicine*. 2010;1(1):193-198.

- Maehama, T.. Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterine cervix. *Infectious diseases in obstetrics and gynecology*. 2005;13(2):77-80.
- Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. *BMJ*. 5-29-2004;328(7451):1293-.
- Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-Month follow-up. *British Journal of Cancer*. 2005;92(6):990-994.
- Mao, C., Balasubramanian, A., Yu, M., Kiviat, N., Ridder, R., Reichert, A., Herkert, M., Von Knebel, Doeberitz M., and Koutsky, L. A.. Evaluation of a new p16INK4a ELISA test and a high-risk HPV DNA test for cervical cancer screening: Results from proof-of-concept study. *International Journal of Cancer*. 2007;120(11):2435-2438.
- Marchetti, I., Zavaglia, K., Bertacca, G., Aretini, P., Matteoli, B., Viacava, P., Prato, B., De, Punzio C., Genazzani, A. R., Bevilacqua, G., and Di, Coscio G.. HPV testing and Pap test: Role for a combined approach in a non-screened population. *International Journal of Biological Markers*. 2006;21(3):149-156.
- Massad, S. L., Markwell, S., Cejtin, H. E., and Collins, Y.. Risk of high-grade cervical intraepithelial neoplasia among young women with abnormal screening cytology. *Journal of Lower Genital Tract Disease*. 2005;9(4):225-229.
- Mathur, S. P., Mathur, R. S., Creasman, W. T., Underwood, P. B., and Kohler, M.. Early non-invasive diagnosis of cervical cancer: beyond Pap smears and human papilloma virus (HPV) testing. *Cancer biomarkers : section A of Disease markers*. 2005;1(2-3):183-191.
- Matthews-Greer, J., Rivette, D., Reyes, R., Vanderloos, C. F., and Turbat-Herrera, E. A.. Human papillomavirus detection: verification with cervical cytology. *Clinical laboratory science : journal of the American Society for Medical Technology*. 2004;17(1):8-11.
- Mattimoe, T.. No more annual pap tests: reviewing the consensus of experts. *Advance for nurse practitioners*. 2010;18(5):18-.
- McBride, D.. New DNA test for cervical cancer outperforms Pap test. *ONS connect*. 2009;24(7):23-.
- McCaffery, K. J., Irwig, L., Chan, S. F., Macaskill, P., Barratt, A., Lewicka, M., Clarke, J., and Weisberg, E.. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: Evaluation of a decision aid to support informed choice. *Patient Education and Counseling*. 2008;73(3):473-481.
- McCaffery, K., Waller, J., Forrest, S., Cadman, L., Szarewski, A., and Wardle, J.. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact.[Erratum appears in *BJOG*. 2004 Dec;111(12):1489]. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2004;111(12):1437-1443.
- McGrath, C. M., Kurtis, J. D., and Yu, G. H.. Evaluation of mild-to-moderate dysplasia on cervical-endocervical (Pap) smear: A subgroup of patients who bridge LSIL and HSIL. *Diagnostic Cytopathology*. 2000;23(4):245-248.
- Meijer, C. J. L. M., Berkhof, H., Heideman, D. A. M., Hesselink, A. T., and Snijders, P. J. F.. Validation of high-risk HPV tests for primary cervical screening. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S1-S4.
- Meijer, C. J., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., Heideman, D. A., and Snijders, P. J.. Guidelines for human papillomavirus

DNA test requirements for primary cervical cancer screening in women 30 years and older. *International Journal of Cancer*. 2009; *Journal international du cancer*. 124(3):516-520.

Meissner, H. I., Tiro, J. A., Haggstrom, D., Lu-Yao, G., and Breen, N.. Does patient health and hysterectomy status influence cervical cancer screening in older women?. *Journal of General Internal Medicine*. 2008;23(11):1822-1828.

Meshner, D., Szarewski, A., Cadman, L., Cubie, H., Kitchener, H., Luesley, D., Menon, U., Hulman, G., Desai, M., Ho, L., Terry, G., Williams, A., Sasieni, P., and Cuzick, J.. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: Results from the HART study. *British Journal of Cancer*. 2010;102(9):1405-1410.

Meyer, J. L., Hanlon, D. W., Andersen, B. T., Rasmussen, O. F., and Bisgaard, K.. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: Correlation with biopsy follow-up results. *Cancer*. 2007;111(2):83-92.

Milanova, E., Naumov, J., Nikolovska, E., and Damcevski, N.. Correlation of conventional and liquid-based cytology and their meaning in management of precancerous cervical lesions. *Akusherstvo i ginekologija*. 2005;44(1):60-62.

Miller, M. G., Sung, H. Y., Sawaya, G. F., Kearney, K. A., Kinney, W., and Hiatt, R. A.. Screening interval and risk of invasive squamous cell cervical cancer. *Obstetrics & Gynecology*. 2003;101(1):29-37.

Minelli, L., Stracci, F., Prandini, S., Moffa, I. F., and La, Rosa F.. Gynaecological cancers in Umbria (Italy): Trends of incidence, mortality and survival, 1978-1998. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2004;115(1):59-65.

Miranda Pereira, S. M., Castelo, A., Makabe, S., Utogawa, M. L., Di, Loreto C., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., Filho, A. L., and Das Dores, G. B.. Screening for cervical cancer in high-risk populations: DNA Pap test or hybrid capture II test alone?. *International Journal of Gynecological Pathology*. 2006;25(1):38-41.

Misra, J. S., Gupta, H. P., and Das, V.. Assessing the feasibility of single lifetime PAP smear evaluation between 41-50 years of age as strategy for cervical cancer control in developing countries from our 32 years of experience of hospital-based routine cytological screening. *Diagnostic Cytopathology*. 2004;31(6):376-379.

Mo, L. Z., Monnier-Benoit, S., Kantelip, B., Petitjean, A., Riethmuller, D., Pretet, J. L., and Mougin, C.. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2008;41(2):104-110.

Monsonogo, J., Bohbot, J. M., Pollini, G., Krawec, C., Vincent, C., Merignargues, I., Haroun, F., Sednaoui, P., Monfort, L., Dachez, R., and Syrjanen, K.. Performance of the Roche AMPLICOR Human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. *Gynecologic Oncology*. 2005;99(1):160-168.

Monsonogo, J., Pintos, J., Semaille, C., Beumont, M., Dachez, R., Zerat, L., Bianchi, A., and Franco, E.. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. *International Journal of Gynecological Cancer*. 2006;16(2):591-598.

Montemor, E. B. L., Roteli-Martins, C. M., Zeferino, L. C., Amaral, R. G., Fonseca-Carvasan, G. A., Shirata, N. K., Utogawa, M. L., Longatto-Filho, A., and Syrjanen, K. J.. Whole, turret and step methods of rapid rescreening: Is there any difference in performance?. *Diagnostic Cytopathology*. 2007;35(1):57-60.

Moore, G., Fetterman, B., Cox, J. T., Poitras, N., Lorey, T., Kinney, W., and Castle, P. E.. Lessons from practice: Risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24. *Journal of Lower Genital Tract Disease*. 2010;14(2):97-102.

Moore, K. N. and Walker, J. L.. The abnormal pap test: Evaluation, treatment, and monitoring. *Journal of Clinical Outcomes Management*. 2006;13(4):235-244.

Moore, M. A. and Tajima, K.. Cervical cancer in the asian pacific-epidemiology, screening and treatment. *Asian Pacific journal of cancer prevention : APJCP*. 2004;5(4):349-361.

Moreira, M. A. R., Longato-Filho, A., Taromaru, E., Queiroz, G., Jube, L. F., Pinto, S. A., and Schmitt, F. C.. Investigation of human papillomavirus by hybrid capture II in cervical carcinomas including 113 adenocarcinomas and related lesions. *International Journal of Gynecological Cancer*. 2006;16(2):586-590.

Moscicki, A.-B.. Cervical cytology screening in teens. *Current women's health reports*. 2003;3(6):433-437.

Moss, S., Gray, A., Legood, R., Vessey, M., Patnick, J., and Kitchener, H.. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: Observational before and after study. *British Medical Journal*. 2006;332(7533):83-85.

Moy, L. M., Zhao, F.-H., Li, L.-Y., Ma, J.-F., Zhang, Q.-M., Chen, F., Song, Y., Hu, S.-Y., Balasubramanian, A., Pan, Q.-J., Koutsky, L., Zhang, W.-H., Lim, J. M., Qiao, Y.-L., and Sellors, J. W.. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral. *International Journal of Cancer*. 2010;127(3):646-656.

Nam, J.-H., Kim, H.-S., Lee, J.-S., Choi, H.-S., Min, K.-W., and Park, C.-S.. A comparison of modified MonoPrep2 of liquid-based cytology with ThinPrep Pap test. *Gynecologic Oncology*. 2004;94(3):693-698.

Nassar, A., O'Reilly, K., Cohen, C., and Siddiqui, M. T.. Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations. *Diagnostic Cytopathology*. 2008;36(3):142-148.

Negri, G., Menia, E., Egarter-Vigl, E., Vittadello, F., and Mian, C.. ThinPrep versus Conventional Papanicolaou Smear in the Cytologic Follow-Up of Women with Equivocal Cervical Smears. *Cancer*. 2003;99(6):342-345.

Negri, G., Rigo, B., Vittadello, F., Mian, C., and Egarter-Vigl, E.. Abnormal cervicovaginal cytology with negative human papillomavirus testing. *Cancer*. 2007;111(5):280-284.

Nincic, D., Mandic, A., Dugandzija, T., Zivaljevic, M., Rajovic, J., and Vojinovic, D.. Linear trend analysis of patients with cervical cancer treated at the Institute of Oncology Vojvodina in 2001-2007. *Journal of B*. 2009;U.ON.. 14(4):669-672.

no authors listed. Many unnecessary Pap smears are performed after hysterectomy. *Journal of Family Practice*. 2004;53(9):682-.

Nofech-Mozes, S., Khalifa, M. M., Ismiil, N., Dube, V., Saad, R. S., Sun, P., Seth, A., and Ghorab, Z.. Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. *Applied Immunohistochemistry and Molecular Morphology*. 2010;18(1):80-85.

Nygaard, J. F., Nygaard, M., Skare, G. B., and Thoresen, S. O.. Pap smear screening in women under 30 in the Norwegian coordinated-cervical cancer screening program, with a comparison of immediate biopsy vs. pap smear triage of moderate dysplasia. *Acta Cytologica*. 2006;50(3):295-302.

- Nygard, J. F., Skare, G. B., and Thoresen, S. O.. The cervical cancer screening programme in Norway, 1992-2000: Changes in Pap smear coverage and incidence of cervical cancer. *Journal of medical screening*. 2002;9(2):86-91.
- Ogilvie, D.. Early discharge of low-risk women from cervical screening. *Journal of Public Health Medicine*. 2001;23(4):272-277.
- Ohl, M. and Kane, K. Y.. 3-Year interval between Pap smears adequate for women with prior negative results. *Journal of Family Practice*. 2004;53(3):172+175-.
- Okewole, I. A., Fawole, A. O., Omigbodun, A. O., and Adewole, I. F.. Does screening for cervical intra-epithelial neoplasm in developing countries prevent invasive cervical cancer?. *African Journal of Medicine & Medical Sciences*. 2003;32(3):283-285.
- Oliveira, E. R. Z. M., Derchain, S. F. M., Rabelo-Santos, S. H., Westin, M. C. A., Zeferino, L. C., Campos, E. A., and Syrjanen, K. J.. Detection of high-risk human papillomavirus (HPV) DNA by hybrid capture II in women referred due to atypical glandular cells in the primary screening. *Diagnostic Cytopathology*. 2004;31(1):19-22.
- Onuma, K., Saad, R. S., Kanbour-Shakir, A., Kanbour, A. I., and Dabbs, D. J.. Clinical implications of the diagnosis "Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" in pregnant women. *Cancer*. 2006;108(5):282-287.
- Orbell, S., Hagger, M., Brown, V., and Tidy, J.. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. *British Journal of Health Psychology*. 2004;9(4):533-555.
- Ovanin-Rakic, A., Mahovlic, V., Audy-Jurkovic, I., Barisic, A., Skopljanac-Macina, L., Juric, D., Rajhvajn, S., Ilic-Forko, J., Babic, D., Folnovic, D., and Kani, D.. Cytology of cervical intraepithelial glandular lesions. *Collegium antropologicum*. 2010;34(2):401-406.
- Paci, E., Quaglia, A., Pannelli, F., and Budroni, M.. The impact of screening and early diagnosis on survival--results from the Italian cancer registries. *Epidemiologia e prevenzione*. 2001;25(3 Suppl):9-14.
- Pajtler, M., Milicic-Juhas, V., Milojkovic, M., Topolovec, Z., Curzik, D., and Mihaljevic, I.. Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2. *Collegium antropologicum*. 2010;34(1):81-86.
- Papathanasiou, K., Daniilidis, A., Koutsos, I., Sardeli, C., Giannoulis, C., and Tzafettas, J.. Verification of the accuracy of cervical cytology reports in women referred for colposcopy. *European Journal of Gynaecological Oncology*. 2010;31(2):187-190.
- Papillo, J. L., St.John, T. L., and Leiman, G.. Effectiveness of the ThinPrep Imaging System: Clinical experience in a low risk screening population. *Diagnostic Cytopathology*. 2008;36(3):155-160.
- Park, J., Jung, E.-H., Kim, C., and Young, H. C.. Direct-to-vial comparison of a new liquid-based cytology system, Liqui-PREP versus the conventional Pap smear. *Diagnostic Cytopathology*. 2007;35(8):488-492.
- Partridge, E. E., Abu-Rustum, N. R., Campos, S., Edelson, M., Fahey, P. J., Fiorica, J., Greer, B. E., Lieberman, R. W., Likes, W., Molpus, K. L., Nava, M. E., Reynolds, R. K., Singh, D. K., Smith-McCune, K., Soper, J., Teng, N., Trimble, C. L., and Wilczynski, S.. Cervical cancer screening clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2004;2(6):570-587.
- Patro, B. K. and Nongkynrih, B.. Review of screening and preventive strategies for cervical cancer in India. *Indian journal of public health*. 2007;51(4):216-221.

- Peng, Y. and Wang, H. H.. Impact of reflex HPV testing on interpretation and management of ThinPrep pap tests. *Diagnostic Cytopathology*. 2006;34(8):585-588.
- Perovic, S.. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia. *Journal of B*. 2009;U.ON.. 14(1):93-96.
- Petignat, P., Faltin, D., Coffin, F., Billieux, M.-H., Stucki, D., Sporri, S., and Vassilakos, P.. Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma. *Cancer*. 2005;105(3):126-132.
- Peto, P. J., Gilham, P. C., Fletcher, O., and Matthews, F. E.. The cervical cancer epidemic that screening has prevented in the UK. *Lancet*. 2004;364(9430):249-256.
- Pickett, K. E.. HPV triage was more sensitive than cytological monitoring for management of women with an ASCUS cervical screening result. *Evidence-based Obstetrics and Gynecology*. 2004;6(3):147-149.
- Pirotta, M., Ung, L., Stein, A., Conway, E. L., Mast, T. C., Fairley, C. K., and Garland, S.. The psychosocial burden of human papillomavirus related disease and screening interventions. *Sexually Transmitted Infections*. 2009;85(7):508-513.
- Polednak, A. P.. Trends in late-stage breast and cervical cancer incidence rates in Connecticut (United States). *Cancer Causes and Control*. 2003;14(4):361-365.
- Poljak, M., Kovanda, A., Kocjan, B. J., Seme, K., Jancar, N., and Vrtacnik-Bokal, E.. The Abbott RealTime High Risk HPV test: Comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. *Acta Dermatovenerologica Alpina, Pannonica et Adriatica*. 2009;18(3):94-103.
- Powell, N., Boyde, A., Tristram, A., Hibbitts, S., and Fiander, A.. The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: An observational retrospective analysis of invasive cervical cancers. *International Journal of Cancer*. 2009;125(10):2425-2427.
- Power, P., Gregoire, J., Duggan, M., and Nation, J.. Low-grade pap smears containing occasional high-grade cells as a predictor of high-grade dysplasia. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC*. 2006;28(10):884-887.
- Prandi, S., Beccati, D., De, Aloysio G., Fulgenzi, P., Gabrielli, M., Ghirardini, C., Rivasi, F., Saragoni, L., de Bianchi, P. S., and Bucci, L.. Applicability of the Bethesda System 2001 to a public health setting. *Cancer*. 2006;108(5):271-276.
- Priest, P., Sadler, L., Sykes, P., Marshall, R., Peters, J., and Crengle, S.. Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand. *Cancer Causes and Control*. 2010;21(2):209-214.
- Proca, D. M., Williams, J. D., Rofagha, S., Tranovich, V. L., and Keyhani-Rofagha, S.. Improved rate of high-grade cervical intraepithelial neoplasia detection in human papillomavirus DNA hybrid capture testing. *Analytical and Quantitative Cytology and Histology*. 2007;29(4):264-270.
- Puig-Tintore, L. M., Torne, A., and Alonso, I.. Current techniques in screening for cervical cancer in Spain: Updated recommendations. *Gynecologic Oncology*. 2008;110(3 SUPPL.2):S8-S10.
- Qiao, Y., Sellors, J. W., Eder, P. S., Bao, Y., Lim, J. M., Zhao, F., Weigl, B., Zhang, W., Peck, R. B., Li, L., Chen, F., Pan, Q., and Lorincz, A. T.. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. *The Lancet Oncology*. 2008;9(10):929-936.

Quddus, M., Neves, T., Reilly, M., Steinhoff, M., and Sung, C.. Does the ThinPrep Imaging System increase the detection of high-risk HPV-positive ASC-US and AGUS the Women and Infants Hospital experience with over 200,000 cervical cytology cases. *CytoJournal*. 2009;6 , 2009. Article Number: 15. Date of Publication: 2009.:-

Raab, S. S., Jones, B. A., Souers, R., and Tworek, J. A.. The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance. *Archives of Pathology and Laboratory Medicine*. 2008;132(1):16-22.

Rabelo-Santos, S. H., Derchain, S. F. M., Do Amaral Westin, M. C., Angelo-Andrade, L. A. L., Sarian, L. O. Z., Oliveira, E. R. Z. M., Morais, S. S., and Zeferino, L. C.. Endocervical glandular cell abnormalities in conventional cervical smears: Evaluation of the performance of cytomorphological criteria and HPV testing in predicting neoplasia. *Cytopathology*. 2008;19(1):34-43.

Raffle, A. E., Alden, B., Quinn, M., Babb, P. J., and Brett, M. T.. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented.[Erratum appears in *BMJ*. 2003 Aug 9;327(7410):325]. *BMJ*. 4-26-2003;326(7395):901-.

Ramsaroop, R. and Chu, I.. Accuracy of diagnosis of atypical glandular cells - Conventional and ThinPrep. *Diagnostic Cytopathology*. 2006;34(9):614-619.

Rebolj, M., van, Ballegooijen M., Lynge, E., Looman, C., Essink-Bot, M.-L., Boer, R., and Habbema, D.. Incidence of cervical cancer after several negative smear results by age 50: Prospective observational study. *BMJ*. 2009;338(7702):1058-1060.

Reuschenbach, M., Clad, A., von Knebel, Doeberitz C., Wentzensen, N., Rahmsdorf, J., Schaffrath, F., Griesser, H., Freudenberg, N., and Von Knebel, Doeberitz M.. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. *Gynecologic Oncology*. 2010;119(1):98-105.

Rieck, G. C., Bhaumik, J., Beer, H. R., and Leeson, S. C.. Repeating cytology at initial colposcopy does not improve detection of high-grade abnormalities: A retrospective cohort study of 6595 women. *Gynecologic Oncology*. 2006;101(2):228-233.

Riethmuller, D., Gabelle, C., Ramanah, R., Sautiere, J.-L., Pretet, J.-L., Schaal, J.-P., Kantelip, B., Mouglin, C., and Maillet, R.. Importance of human papillomavirus (HPV) screening in the follow-up after CIN2-3 treatment. A study of 386 cases. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2008;37(4):329-337.

Rijkaart, D. C., Berkhof, J., Van Kemenade, F. J., Rozendaal, L., Verheijen, R. H. M., Bulk, S., Herreilers, M. E., Verweij, W., Snijders, P. J. F., and Meijer, C. J. L. M.. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). *International Journal of Cancer*. 2010;126(9):2175-2181.

Rijkaart, D. C., Coupe, V. M. H., Van Kemenade, F. J., Heideman, D. A. M., Hesselink, A. T., Verweij, W., Rozendaal, L., Verheijen, R. H., Snijders, P. J., Berkhof, J., and Meijer, C. J. L. M.. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. *British Journal of Cancer*. 2010;103(7):939-946.

Roberts, J. M. and Thurloe, J. K.. Comparative sensitivities of ThinPrep and papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): Comparison with HSIL. *Cancer*. 2007;111(6):482-486.

Roberts, J. M., Thurloe, J. K., Bowditch, R. C., Hyne, S. G., Greenberg, M., Clarke, J. M., and Biro, C.. A three-armed trial of the thinprep imaging system. *Diagnostic Cytopathology*. 2007;35(2):96-102.

Roghaei, M. A., Afshar, Moghaddam N., Pooladkhan, Sh, and Roghaie, Sh. Adequacy criteria and

cytomorphological changes in liqui-prep TM versus conventional cervical cytology. *Shiraz E Medical Journal*. 2010;11(4):173-182.

Rogoza, R. M., Ferko, N., Bentley, J., Meijer, C. J. L. M., Berkhof, J., Wang, K.-L., Downs, L., Smith, J. S., and Franco, E. L.. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. *Vaccine*. 2008;26(SUPPL.5):F46-F58.

Rooney, C. M., Hopkins, M. P., Oza, R., Nelson, K., and Alford, W.. The Efficacy of the ThinPrep Pap Preparation Versus Conventional Means of Cervical Cancer Screening. *Journal of Pelvic Medicine and Surgery*. 2004;10(1):31-35.

Rosenthal, D. L., Geddes, S., Trimble, C. L., Carson, K. A., and Alli, P. M.. The PapSpin: A reasonable alternative to other, more expensive liquid-based Papanicolaou tests. *Cancer*. 2006;108(3):137-143.

Rossetti, D., Gerli, S., Saab, J.-C., and Di Renzo, G. C.. Atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) and histology. *Journal Medical Libanais*. 2000;48(3):127-130.

Rossi, P. G., Baiocchi, D., Ciatto, S., Cariaggi, P., Gustinucci, D., Camilli, I., Mancini, E., Montanari, G., Caprioglio, A., Parisio, F., Angeloni, C., Di, Gabriele G., Carantoni, A., Tinacci, G., Matteucci, M., Pontani, G., Collina, G., Carmelo, M., Biavati, P., Schincaglia, P., Serafini, M., Palma, P. D., Polla, E., Scarfanti, A. A., Schiboni, M. L., and Anghinoni, E.. Risk of CIN2 in women with a Pap test without endocervical cells vs. those with a negative Pap test with endocervical cells: A cohort study with 4.5 years of follow-up. *Acta Cytologica*. 2010;54(3):265-271.

Rughooputh, S., Parmar, K., and Greenwell, P.. Detection of human papillomavirus from liquid-based cytology specimens by in-house PCR: A pilot study. *British Journal of Biomedical Science*. 2004;61(1):22-25.

Rugpao, S., Koonlertkit, S., Ruengkrist, T., Lamlertkittikul, S., Pinjaroen, S., Limtrakul, A., Werawatakul, Y., and Sinchai, W.. ThinPrep Pap-smear and cervical intraepithelial neoplasia in reproductive-aged Thai women. *Journal of Obstetrics and Gynaecology Research*. 2009;35(3):551-554.

Sabath, A. P. and Kiviat, N. B.. Detection and classification of cervical Neoplasia in the era of HPV. *Pathology Case Reviews*. 2010;15(4):135-140.

Safaeian, M., Kiddugavu, M., Gravitt, P. E., Ssekanvu, J., Murokora, D., Sklar, M., Serwadda, D., Wawer, M. J., Shah, K. V., and Gray, R.. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. *Sexually Transmitted Diseases*. 2007;34(7):429-436.

Sancho-Garnier, H.. Screening for breast and cervical cancers. [French]. *Oncologie*. 2002;4(8):493-498.

Saraiya, M., Berkowitz, Z., Yabroff, K. R., Wideroff, L., Kobrin, S., and Benard, V.. Cervical cancer screening with both human papillomavirus and papanicolaou testing vs papanicolaou testing alone: What screening intervals are physicians recommending?. *Archives of Internal Medicine*. 2010;170(11):977-986.

Saraiya, M., Martinez, G., Glaser, K., and Kulasingam, S.. Pap testing and sexual activity among young women in the united states. *Obstetrics and Gynecology*. 2009;114(6):1213-1219.

Sargent, A., Bailey, A., Turner, A., Almonte, M., Gilham, C., Baysson, H., Peto, J., Roberts, C., Thomson, C., Desai, M., Mather, J., and Kitchener, H.. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: Data from the ARTISTIC trial. *Journal of Clinical Microbiology*. 2010;48(2):554-558.

Sarode, V. R., Werner, C., Gander, R., Foster, B., Fulmer, A., Saboorian, M. H., and Ashfaq, R.. Reflex

human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: Focus on age-stratified clinical performance. *Cancer*. 2003;99(3):149-155.

Sasieni, P. and Adams, J.. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. *Lancet*. 2001;357(9267):1490-1493.

Sasieni, P., Adams, J., and Cuzick, J.. Benefit of cervical screening at different ages: Evidence from the UK audit of screening histories. *British Journal of Cancer*. 2003;89(1):88-93.

Sasieni, P., Castanon, A., and Cuzick, J.. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data.[Erratum appears in *BMJ*. 2009;339:b3115]. *BMJ*. 2009;339:b2968-.

Sass, M. A.. Use of A Liquid-Based, Thin-Layer Pap Test in A Community Hospital: Impact on Cytology Performance and Productivity. *Acta Cytologica*. 2004;48(1):17-22.

Sawaya, G. F., McConnell, K. J., Kulasingam, S. L., Lawson, H. W., Kerlikowske, K., Melnikow, J., Lee, N. C., Gildengorin, G., Myers, E. R., and Washington, A. E.. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. *New England Journal of Medicine*. 2003;349(16):1501-1509.

Sawaya, G. F., Sung, H.-Y., Kearney, K. A., Miller, M., Kinney, W., Hiatt, R. A., and Mandelblatt, J.. Advancing age and cervical cancer screening and prognosis. *Journal of the American Geriatrics Society*. 2001;49(11):1499-1504.

Sayed, K., Korourian, S., Ellison, D. A., Kozlowski, K., Talley, L., Horn, H. V., Simpson, P., and Parham, D. M.. Diagnosing cervical biopsies in adolescents: The use of p16 immunohistochemistry to improve reliability and reproducibility. *Journal of Lower Genital Tract Disease*. 2007;11(3):141-146.

Scheiden, R., Knolle, U., Wagener, C., Wehenkel, A. M., and Capesius, C.. Cervical cancer screening in Luxembourg. *European Journal of Cancer*. 2000;36(17):2240-2243.

Schenck, U. and von, Karsa L.. Cervical cancer screening in Germany. *European Journal of Cancer*. 2000;36(17):2221-2226.

Schiffman, M., Khan, M. J., Solomon, D., Herrero, R., Wacholder, S., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Wheeler, C. M., and Burk, R. D.. A study of the impact of adding HPV types to cervical cancer screening and triage test. *Journal of the National Cancer Institute*. 2005;97(2):147-150.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Improvement of diagnostic accuracy and screening conditions with liquid-based cytology. *Diagnostic Cytopathology*. 2006;34(11):780-785.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Significance of atypia in conventional Papanicolaou smears and liquid-based cytology: A follow-up study. *Cytopathology*. 2004;15(3):148-153.

Schneede, P., Hillemanns, P., Ziller, F., Hofstetter, A., Stockfleth, E., Arndt, R., and Meyer, T.. Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening. *Acta Obstetrica et Gynecologica Scandinavica*. 2001;80(8):750-752.

Schneider, A., Gleizes, O., Nieminen, P., Erdemoglu, E., Boselli, F., and Jenkins, D.. Implications of varied patterns of cervical cancer screening for introduction of human papillomavirus vaccines in Europe. *Journal of the Turkish German Gynecology Association Artemis*. 2009;10(2):61-67.

Schneider, A., Hoyer, H., Lotz, B., Leistritz, S., Kuhne-Heid, R., Nindl, I., Muller, B., Haerting, J., and Durst, M.. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. *International Journal of Cancer*. 2000;89(6):529-534.

Schopp, B., Holz, B., Zago, M., Stubenrauch, F., Petry, K.-U., Kjaer, S. K., and Iftner, T.. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other

genotyping systems and the HC2 test. *Journal of Medical Virology*. 2010;82(4):605-615.

Segnan, N., Ronco, G., and Ciatto, S.. Cervical cancer screening in Italy. *European Journal of Cancer*. 2000;36(17):2235-2239.

Sehgal, A. and Singh, V.. Human papillomavirus infection (hpv) & screening strategies for cervical cancer. *Indian Journal of Medical Research*. 2009;130(3):234-240.

Sharp, L. K., Zurawski, J. M., Roland, P. Y., O'Toole, C., and Hines, J.. Health literacy, cervical cancer risk factors, and distress in low-income African-American women seeking colposcopy. *Ethnicity & disease*. 2002;12(4):541-546.

Sharpless, K. E., O'Sullivan, D. M., and Schnatz, P. F.. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. *Journal of Lower Genital Tract Disease*. 2009;13(2):72-78.

Shastri, S. S., Dinshaw, K., Amin, G., Goswami, S., Patil, S., Chinoy, R., Kane, S., Kelkar, R., Muwonge, R., Mahe, C., Ajit, D., and Sankaranarayanan, R.. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. *Bulletin of the World Health Organization*. 2005;83(3):186-194.

Shastri, S. S.. Cervical cancer screening and vaccination in India. *Indian journal of medical ethics*. 2010;7(1):41-43.

Sheriff, S. K., Petry, K. U., Ikenberg, H., Crouse, G., Mazonson, P. D., and Santas, C. C.. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany. *European Journal of Health Economics*. 2007;8(2):153-160.

Sherlaw-Johnson, C. and Philips, Z.. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. *British Journal of Cancer*. 2004;91(1):84-91.

Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., and Schiffman, M.. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. *Journal of the National Cancer Institute*. 2003;95(1):46-52.

Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., Schiffman, M., and Helmerhorst, T.. Pap smear and HPV testing in combination were more accurate than either test alone for predicting the future development of CIN3 or cervical cancer. *Evidence-based Obstetrics and Gynecology*. 2003;5(3):137-138.

Shinn, E., Basen-Engquist, K., Le, T., Hansis-Diarte, A., Bostic, D., Martinez-Cross, J., Santos, A., and Follen, M.. Distress after an abnormal Pap smear result: Scale development and psychometric validation. *Preventive Medicine*. 2004;39(2):404-412.

Siddiqi, A., Spataro, M., McIntire, H., Akhtar, I., Baliga, M., Flowers, R., Lin, E., and Guo, M.. Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance Papanicolaou results in SurePath and ThinPrep specimens. *Cancer cytopathology*. 2009;117(5):318-325.

Siddiqui, M. T., Cohen, C., and Nassar, A.. Detecting high-grade cervical disease on ASC-H cytology: Role of BD ProEx C and digene hybrid capture II HPV DNA testing. *American journal of clinical pathology*. 2008;130(5):765-770.

Siebert, U., Sroczynski, G., Hillemanns, P., Engel, J., Stabenow, R., Stegmaier, C., Voigt, K., Gibis, B., Holzel, D., and Goldie, S. J.. The German Cervical Cancer Screening Model: Development and validation of a decision-analytic model for cervical cancer screening in Germany. *European Journal of*

Public Health. 2006;16(2):185-192.

Siemens, F. C., Boon, M. E., Kuypers, J. C., and Kok, L. P.. Population-based cervical screening with a 5-year interval in the Netherlands: Stabilization of the incidence of squamous cell carcinoma and its precursor lesions in the screened population. *Acta Cytologica*. 2004;48(3):348-354.

Sigurdsson, K. and Sigvaldason, H.. Effectiveness of cervical cancer screening in Iceland, 1964-2002: A study on trends in incidence and mortality and the effect of risk factors. *Acta Obstetricia et Gynecologica Scandinavica*. 2006;85(3):343-349.

Sigurdsson, K. and Sigvaldason, H.. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. *European Journal of Cancer*. 2007;43(4):769-774.

Silverloo, I., Andrae, B., and Wilander, E.. Value of high-risk HPV-DNA testing in the triage of ASCUS. *Acta Obstetricia et Gynecologica Scandinavica*. 2009;88(9):1006-1010.

Simcock, B., Sykes, P., and Laney, M.. The impact of the National Cervical Screening Programme on the presentation of cancer of the cervix in Canterbury. *New Zealand Medical Journal*. 8-24-2001;114(1138):378-380.

Sireci, A. N., Crapanzano, J. P., Mansukhani, M., Wright, T., Babiak, A., Erroll, M., Vazquez, M., and Saqi, A.. Atypical Glandular Cells (AGC): ThinPrep Imaging System (TIS), Manual Screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. *Diagnostic Cytopathology*. 2010;38(10):705-709.

Sirovich, B. E. and Welch, H. G.. The frequency of Pap smear screening in the United States. *Journal of General Internal Medicine*. 2004;19(3):243-250.

Sirovich, B. E., Gottlieb, D. J., and Fisher, E. S.. The burden of prevention: Downstream consequences of Pap smear testing in the elderly. *Journal of medical screening*. 2003;10(4):189-195.

Smith, J. H. F.. The future of cervical screening in the UK. *Diagnostic Histopathology*. 2009;15(7):330-334.

Sodhani, P., Gupta, S., Singh, V., Sehgal, A., Halder, K., and Parashari, A.. Sensitivity of the pap test in detecting high grade lesions: What should be the acceptable cytologic threshold for colposcopic referral?. *Acta Cytologica*. 2006;50(2):181-184.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Acta Cytologica*. 2009;53(3):247-248.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *American journal of clinical pathology*. 2009;131(6):768-769.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Diagnostic Cytopathology*. 2009;37(7):542-543.

Solomon, D., Papillo, J., and Davis, Davey D.. Statement on HPV DNA test utilization. *Journal of Lower Genital Tract Disease*. 2009;13(3):135-136.

Solomon, D.. Chapter 14: Role of triage testing in cervical cancer screening. *Journal of the National Cancer Institute*. 2003;Monographs.(31):97-101.

Son, S., Noh, H. T., and An, S.. Human papillomavirus status in cervical scrapes and biopsy specimens using the HPV genotyping DNA microarray. *International Journal of Gynecology and Obstetrics*. 2006;93(3):258-259.

Soutter, W. P., Butler, J. S., and Tipples, M.. The role of colposcopy in the follow up of women treated for cervical intraepithelial neoplasia. *BJOG: An International Journal of Obstetrics & Gynaecology*.

2006;113(5):511-514.

Sowjanya, A. P., Paul, P., Vedantham, H., Ramakrishna, G., Vidyadhari, D., Vijayaraghavan, K., Lakshmi, S., Sudula, M., Ronnett, B. M., Das, M., Shah, K. V., and Gravitt, P. E.. Suitability of self-collected vaginal samples for cervical cancer screening in Periurban Villages in Andhra Pradesh, India. *Cancer Epidemiology Biomarkers and Prevention*. 2009;18(5):1373-1378.

Spiryda, L. B., Brown, M., Creek, K. E., and Pirisi-Creek, L.. HSIL pap test and risk factors predicting acquisition of CIN 2/3 on colposcopy-directed biopsies. *Journal of the South Carolina Medical Association* (1975). 2009;105(7):281-286.

Srodon, M., Parry, Dilworth H., and Ronnett, B. M.. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results. *Cancer*. 2006;108(1):32-38.

Stamataki, P., Papazafiropoulou, A., Elefsiniotis, I., Giannakopoulou, M., Brokalaki, H., Apostolopoulou, E., Sarafis, P., and Saroglou, G.. Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. *BMC infectious diseases*. 2010;10:27-.

Stein, S. R.. ThinPrep versus the conventional Papanicolaou test: A review of specimen adequacy, sensitivity, and cost-effectiveness. *Primary Care Update for Ob/Gyns*. 2003;10(6):310-313.

Stensson, E., Frberg, M., Hjerpe, A., Zethraeus, N., and Andersson, S.. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. *Acta Obstetrica et Gynecologica Scandinavica*. 2010;89(10):1316-1325.

Stinnett, B. A.. Use of Psychosocial Effects of Abnormal Pap Smears Questionnaire (PEAPS-Q) in a community hospital colposcopy clinic. *Journal of Lower Genital Tract Disease*. 2000;4(1):34-39.

Streiner, D. L. and Norman, G. R.. Mass screening: When does it make sense?. *Community Oncology*. 2010;7(2):93-95.

Sudha, S. and Muthumani, V.. Standardization of human papilloma virus DNA test correlation with pathology of cervical cancer. *Journal of Pure and Applied Microbiology*. 2010;4(1):243-246.

Symonds, I. M.. Screening for gynaecological conditions. *Foundation Years*. 2007;3(6):263-267.

Syrjanen, K., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Hammes, L. S., Sarian, L., Naud, P., Tatti, S., Branca, M., Erzen, M., Matos, J., Gontijo, R., Braganca, J., Arlindo, F., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among Latin American Women < 35 and >= 35 years of age: Experience from the Latin American Screening Study. *Acta Cytologica*. 2008;52(6):641-653.

Syrjanen, K., Naud, P., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Hammes, L. S., Matos, J., Gontijo, R., Sarian, L., Braganca, J., Arlindo, F. C., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. *Anticancer Research*. 2005;25(5):3469-3480.

Szarewski, A., Ambroisine, L., Cadman, L., Austin, J., Ho, L., Terry, G., Liddle, S., Dina, R., McCarthy, J., Buckley, H., Bergeron, C., Soutter, P., Lyons, D., and Cuzick, J.. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(11):3033-3042.

Szarewski, A.. Cervical screening by visual inspection with acetic acid. *Lancet*. 2007;370(9585):365-

Tang, N., Huang, S., Erickson, B., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S25-S28.

Taoka, H., Yamamoto, Y., Sakurai, N., Fukuda, M., Asakawa, Y., Kurasaki, A., Oharaseki, T., and Kubushiro, K.. Comparison of conventional and liquid-based cytology, and human papillomavirus testing using SurePath preparation in Japan. *Human Cell*. 2010;23(4):126-133.

Taylor, R. J., Morrell, S. L., Mamoon, H. A., and Wain, G. V.. Effects of screening on cervical cancer incidence and mortality in New South Wales implied by influences of period of diagnosis and birth cohort. *Journal of Epidemiology & Community Health*. 2001;55(11):782-788.

Terret, C., Castel-Kremer, E., Albrand, G., and Droz, J. P.. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. *The Lancet Oncology*. 2009;10(1):80-87.

Thiryayi, S. A., Marshall, J., and Rana, D. N.. An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia. *Cytopathology*. 2010;21(4):223-228.

Thiryayi, S. A., Marshall, J., and Rana, D. N.. Differentiating between endocervical glandular neoplasia and high grade squamous intraepithelial lesions in endocervical crypts: Cytological features in ThinPrep and SurePath cervical cytology samples. *Diagnostic Cytopathology*. 2009;37(5):315-319.

Thrall, M. J., Pambuccian, S. E., Stelow, E. B., McKeon, D. M., Miller, L., Savik, K., and Gulbahce, H. E.. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda system on the sensitivity and specificity of the papanicolaou test: A 5-year follow-up study of papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria. *Cancer*. 2008;114(3):171-179.

Thrall, M. J., Russell, D. K., Facik, M. S., Yao, J. L., Warner, J. N., Bonfiglio, T. A., and Giampoli, E. J.. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. *American journal of clinical pathology*. 2010;133(6):894-898.

Thrall, M. J., Smith, D. A., and Mody, D. R.. Women ≥ 30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: Should we reconsider HPV triage for LSIL in older women?. *Diagnostic Cytopathology*. 2010;38(6):407-412.

Thrall, M., Kjeldahl, K., Gulbahce, H. E., and Pambuccian, S. E.. Liquid-based papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: Study of 272 cases classified by the 2001 Bethesda system. *Cancer*. 2007;111(4):217-223.

Tiews, S., Steinberg, W., Schneider, W., and Hanrath, C.. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: Preliminary data. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S11-S15.

Tinelli, A., Leo, G., Pisano, M., Storelli, F., Leo, S., Vergara, D., and Malvasi, A.. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. *Current Pharmaceutical Biotechnology*. 2009;10(8):767-771.

Treacy, A., Reynolds, J., Kay, E. W., Leader, M., and Grace, A.. Has the ThinPrep Method of Cervical Screening Maintained Its Improvement Over Conventional Smears in terms of Specimen Adequacy?. *Diagnostic Cytopathology*. 2009;37(4):239-240.

Trivers, K. F., Benard, V. B., Ehemann, C. R., Royalty, J. E., Ekwueme, D. U., and Lawson, H. W.. Repeat pap testing and colposcopic biopsies in the underserved. *Obstetrics and Gynecology*. 2009;114(5):1049-1056.

- Troni, G. M., Cipparrone, I., Cariaggi, M. P., Ciatto, S., Miccinesi, G., Zappa, M., and Confortini, M.. Detection of false-negative pap smears using the PAPNET system. *Tumori*. 2000;86(6):455-457.
- Tsai, H.-T., Tsai, Y.-M., Yang, S.-F., Lee, C.-H., Lin, L.-Y., Lee, S., and Wu, M.-T.. A notable accessory screening program for detection of cervical intraepithelial neoplasia. *Pathologie Biologie*. 2009;57(6):477-482.
- Tsiodras, S., Georgoulakis, J., Chranioti, A., Voulgaris, Z., Psyrris, A., Tsvilika, A., Panayiotides, J., and Karakitsos, P.. Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. *BMC Cancer*. 2010;10, 2010. Article Number: 53. Date of Publication: 22 Feb 2010.:-.
- Tuncer, Z. S., Basaran, M., Sezgin, Y., Firat, P., and Kuzey, G. M.. Clinical results of a split sample liquid-based cytology (ThinPrep) study of 4,322 patients in a Turkish institution. *European Journal of Gynaecological Oncology*. 2005;26(6):646-648.
- Uyar, D. S., Eltabbakh, G. H., and Mount, S. L.. Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant. *Gynecologic Oncology*. 2003;89(2):227-232.
- Valdini, A. and Esielionis, P.. Measurement of colposcopy-associated distress using the psychosocial effects of having an abnormal pap smear-questionnaire in a Latina population. *Journal of Lower Genital Tract Disease*. 2004;8(1):25-32.
- Van Den Akker-Van Marle, van, Ballegooijen M., and Habbema, J. D. F.. Low risk of cervical cancer during a long period after negative screening in the Netherlands. *British Journal of Cancer*. 2003;88(7):1054-1057.
- van der Aa, M. A., De Kok, I. M. C. M., Siesling, S., van, Ballegooijen M., and Coebergh, J. W. W.. Does lowering the screening age for cervical cancer in the Netherlands make sense?. *International Journal of Cancer*. 2008;123(6):1403-1406.
- van der Aa, M. A., Schutter, E. M., Looijen-Salamon, M., Martens, J. E., and Siesling, S.. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of The Netherlands, 1992-2001. *European Journal of Obstetrics, Gynecology, & Reproductive Biology*. 2008;139(2):204-209.
- Varnai, A. D., Bollmann, M., Bankfalvi, A., Speich, N., Schmitt, C., Griefingholt, H., Kovacs, K., Klozoris, C., and Bollmann, R.. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: Diagnostic and prognostic implications. *Oncology Reports*. 2008;19(2):457-465.
- Vijayaraghavan, A., Efrusy, M. B., Mayrand, M. H., Santas, C. C., and Goggin, P.. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. *Canadian Journal of Public Health*. 2010;Revue canadienne de sante publique. 101(3):220-225.
- Vijayaraghavan, A., Efrusy, M., Lindeque, G., Dreyer, G., and Santas, C.. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. *Gynecologic Oncology*. 2009;112(2):377-383.
- Vollmer, R. T.. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. *Cancer*. 10-25-2002;96(5):316-318.
- Voskanyan, M. A.. Precancerous cervical lesions: Diagnosis and treatment. *New Armenian Medical Journal*. 2009;3(3):49-56.
- Voss, J. S., Kipp, B. R., Campion, M. B., Sokolova, I. A., Henry, M. R., Halling, K. C., and Clayton, A. C.. Assessment of fluorescence in situ hybridization and hybrid capture 2 analyses of cervical cytology

specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia. *Analytical and Quantitative Cytology and Histology*. 2010;32(3):121-130.

Vrtacnik-Bokal, E., Rakar, S., Jancar, N., Mozina, A., and Poljak, M.. Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions. *European Journal of Gynaecological Oncology*. 2005;26(4):427-430.

Walter, L. C., Lewis, C. L., and Barton, M. B.. Screening for colorectal, breast, and cervical cancer in the elderly: A review of the evidence. *American Journal of Medicine*. 2005;118(10):1078-1086.

Wang, K. L., Jeng, C. J., Yang, Y. C., Chen, C. A., Cheng, W. F., Chen, T. C., Mast, T. C., Wang, Y. C., and Hsieh, C. Y.. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. *Journal of Psychosomatic Obstetrics & Gynecology*. 2010;31(1):16-23.

Wang, X., Zheng, B., Li, S., Zhang, R., Mulvihill, J. J., Chen, W. R., and Liu, H.. Automated detection and analysis of fluorescent in situ hybridization spots depicted in digital microscopic images of Pap-smear specimens. *Journal of biomedical optics*. 2009;14(2):021002-021Apr.

Warman, J.. Cervical cancer screening in young women: saving lives with prevention and detection. *Oncology nursing forum*. 2010;37(1):33-38.

Warren, J. B., Gullett, H., and King, V. J.. Cervical Cancer Screening and Updated Pap Guidelines. *Primary Care - Clinics in Office Practice*. 2009;36(1):131-149.

Wells, S. F.. Cervical cancer: an overview with suggested practice and policy goals. *Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses*. 2008;17(1):43-50.

Wentzensen, N., Bergeron, C., Cas, F., Vinokurova, S., and Von Knebel, Doeberitz M.. Triage of women with ASCUS and LSIL cytology: Use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. *Cancer*. 2007;111(1):58-66.

Wentzensen, N., Hampl, M., Herkert, M., Reichert, A., Trunk, M. J., Poremba, C., Ridder, R., and Von Knebel, Doeberitz M.. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. *Cancer*. 2006;107(9):2307-2313.

Werner, C. L., Griffith III, W. F., Ashfaq, R., Gossett, D., Wilkinson, E., Raab, S., Bambot, S., Mongin, D., and Faupel, M.. Comparison of human papilloma virus testing and spectroscopy combined with cervical cytology for the detection of high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2007;11(2):73-79.

Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., Markman, M., Mayer, R., Pfister, D., Raghavan, D., Ramsey, S., Reaman, G., Sandler, H., Sawaya, R., Schuchter, L., Sweetenham, J., Vahdat, L., Schilsky, R. L., and Sweet, D.. Clinical cancer advances 2008: Major research advances in cancer treatment, prevention, and screening-a report from the american society of clinical oncology. *Journal of Clinical Oncology*. 2009;27(5):812-826.

Witt, A., Hudelist, G., Gregor, H., Kucera, E., Walchetseder, C., and Czerwenka, K.. The detection of HPV DNA improves the recognition of cervical intraepithelial lesions. *Archives of Gynecology and Obstetrics*. 2003;268(1):29-34.

Wong, A. K., Chan, R. C., Nichols, W. S., and Bose, S.. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance. *Cancer*. 2009;115(4):823-832.

Wongworapat, K., Keawvichit, R., Sirojorn, B., Dokuta, S., Ruangyuttikarn, C., Sriplienchan, S., Sontirat, A., Kla, K. T., Gravitt, P. E., and Celentano, D. D.. Detection of human papillomavirus from

- self-collected vaginal samples of women in Chiang Mai, Thailand. *Sexually Transmitted Diseases*. 2008;35(2):172-173.
- Woo, P. P. S., Thach, T. Q., Choy, S. T. B., McGhee, S. M., and Leung, G. M.. Modelling the impact of population-based cytologic screening on cervical cancer incidence and mortality in Hong Kong: An age-period-cohort approach. *British Journal of Cancer*. 2005;93(9):1077-1083.
- Wood, M. D., Horst, J. A., and Bibbo, M.. Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based pap tests: A review. *Diagnostic Cytopathology*. 2007;35(1):12-17.
- Wright, P. K., Marshall, J., and Desai, M.. Comparison of SurePath and ThinPrep liquid-based cervical cytology using positive predictive value, atypical predictive value and total predictive value as performance indicators. *Cytopathology*. 2010;21(6):374-378.
- Wu, S. F., Meng, L., Wang, S. X., and Ma, D.. A comparison of four screening methods for cervical neoplasia. *International Journal of Gynecology and Obstetrics*. 2005;91(2):189-193.
- Yang, B., Morrell, S., Zuo, Y., Roder, D., Tracey, E., and Jelfs, P.. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women. *Cancer Causes Control*. 2008;19(6):569-576.
- Yang, B., Pretorius, R. G., Belinson, J. L., Zhang, X., Burchette, R., and Qiao, Y.-L.. False negative colposcopy is associated with thinner cervical intraepithelial neoplasia 2 and 3. *Gynecologic Oncology*. 2008;110(1):32-36.
- Yapjakis, C., Adamopoulou, M., Antonopoulos, G., Koufaliotis, N., and Vairaktaris, E.. Prevalence of HPV types in a cohort of greeks with clinical indication of infection. *Anticancer Research*. 2008;28(4 B):2233-2237.
- Yeoh, G. P. S., Tse, M. P. Y., Chan, K. W., and Lord, L.. Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and follow-up patient group. *Acta Cytologica*. 2006;50(6):627-631.
- Yoon, J. H., Yoo, S. C., Kim, W. Y., Chang, S. J., Chang, K. H., and Ryu, H. S.. Role of HPV DNA testing for detection of high-grade cervical lesions in women with atypical squamous cells of undetermined significance: A prospective study in a Korean population. *European Journal of Gynaecological Oncology*. 2009;30(3):271-274.
- Young, T. K., Lee, J. M., Hur, S.-Y., Cho, C.-H., Kim, Y. T., Seung, C. K., and Kang, S. B.. Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. *International Journal of Cancer*. 2010;126(8):1903-1909.
- Yuan, Q. and Wilbur, D. C.. Original cervical cytology and follow-up biopsy results in positive high risk human papillomavirus DNA tests with high-level results. *Acta Cytologica*. 2008;52(5):557-562.
- Zhao, C. and Austin, R. M.. High-risk human papillomavirus DNA test results are useful for disease risk stratification in women with unsatisfactory liquid-based cytology pap test results. *Journal of Lower Genital Tract Disease*. 2009;13(2):79-84.
- Zhao, C., Florea, A., and Austin, R. M.. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. *Archives of pathology & laboratory medicine*. 2010;134(1):103-108.
- Zhao, C., Florea, A., Onisko, A., and Austin, R. M.. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: Results from a large academic womens hospital laboratory employing sensitive screening methods. *Gynecologic Oncology*. 2009;114(3):383-389.
- Zhu, J., Norman, I., Elfgrén, K., Gaberi, V., Hagmar, B., Hjerpe, A., and Andersson, S.. A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. *Oncology Reports*.

2007;18(1):157-160.

Committee opinion no. 356: Routine cancer screening. *Obstetrics and Gynecology*. 2006;108(6):1611-1613.

Erratum: Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness (*Journal of the American Medical Association* (June 27, 2001) 285 (3107-3115)). *Journal of the American Medical Association*. 2001;286(9):1026.

Everything you know about cervical cancer screening in Alberta just changed. *Alberta RN / Alberta Association of Registered Nurses*. 2009;65(9):10-11.

HPV genotyping clinical update. *Journal of Family Practice*. 2009;58(9):S8-S10.

In South Africa, having one pap smear lowers women's chances of cervical cancer. *International family planning perspectives*. 2003;29(4):196.

Is liquid-based cytology better than Pap tests for CIN ?? *Journal of Family Practice*. 2008;57(4):218.

Liquid-based not better than conventional Pap. *Journal of Family Practice*. 2006;55(4):284.

Pap test update. New guidelines reflect new evidence. *Mayo Clinic women's healthsource*. 2003;7(5):1-2.

Update: cervical cancer screening. *AWHONN lifelines / Association of Women's Health, Obstetric and Neonatal Nurses*. 2003;7(2):116-117.

Abulafia, O., Pezzullo, J. C., and Sherer, D. M.. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: A quantitative survey. *Gynecologic Oncology*. 2003;90(1):137-144.

Agorastos, T., Dinas, K., Lloveras, B., De, Sanjose S., Kornegay, J. R., Bonti, H., Bosch, F. X., Constantinidis, T., and Bontis, J.. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. *Gynecologic Oncology*. 2005;96(3):714-720.

Agorastos, T., Sotiriadis, A., and Emmanouilides, C. J.. Effect of type-specific human papillomavirus incidence on screening performance and cost. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010;20(2):276-282.

Anderson, R., Haas, M., and Shanahan, M.. The cost-effectiveness of cervical screening in Australia: What is the impact of screening at different intervals or over a different age range?. *Australian and New Zealand Journal of Public Health*. 2008;32(1):43-52.

Andersson, S., Dillner, L., Elfgrén, K., Mints, M., Persson, M., and Rylander, E.. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(10):996-1000.

Andy, C. and Turner, L. F.. Is the ThinPrep better than conventional Pap smear at detecting cervical cancer?. *Journal of Family Practice*. 2004;53(4):313-316.

Anttila, A., Ronco, G., Clifford, G., Bray, F., Hakama, M., Arbyn, M., and Weiderpass, E.. Cervical cancer screening programmes and policies in 18 European countries. *British Journal of Cancer*. 2004;91(5):935-941.

Arbyn, M., Simoons, C., Buntinx, F., Martin-Hirsch, P. P. L., Paraskevaidis, E., and Prendiville, W. J. P.. Triage with human papillomavirus (HPV) testing versus repeat cytology for underlying high-grade cervical intraepithelial neoplasia in women with minor cytological lesions. *Cochrane Database of Systematic Reviews*. 2009;#volume#(4):.

Arias, Y. R., Carrillo, E. F., and Aristizabal, F. A.. Human papillomavirus (HPV) detected in restored

plasma DNA from women diagnosed with pre-invasive lesions and invasive cervical cancer. *Colombia Medica*. 2010;41(2):148-154.

Bach, P. B.. Gardasil: from bench, to bedside, to blunder. *The Lancet*. 2010;375(9719):963-964.

Baileff, A.. Cervical screening: patients' negative attitudes and experiences. *Nursing standard (Royal College of Nursing (Great Britain))* : 1987). 2000;14(44):35-37.

Balasubramanian, A., Kulasingam, S. L., Baer, A., Hughes, J. P., Myers, E. R., Mao, C., Kiviat, N. B., and Koutsky, L. A.. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. *Journal of Lower Genital Tract Disease*. 2010;14(3):185-195.

Bandyopadhyay, S., Austin, R. M., Dabbs, D., and Zhao, C.. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. *Archives of Pathology and Laboratory Medicine*. 2008;132(12):1874-1881.

Bano, F., Kolhe, S., Zamblera, D., Jolaoso, A., Folayan, O., Page, L., and Norton, J.. Cervical screening in under 25s: A high-risk young population. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2008;139(1):86-89.

Baseman, J. G., Kulasingam, S. L., Harris, T. G., Hughes, J. P., Kiviat, N. B., Mao, C., and Koutsky, L. A.. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. *American Journal of Obstetrics and Gynecology*. 2008;199(1):26-26.

Basu, P. and Chowdhury, D.. Cervical cancer screening & HPV vaccination: A comprehensive approach to cervical cancer control. *Indian Journal of Medical Research*. 2009;130(3):241-246.

Becker, N.. Epidemiological aspects of cancer screening in Germany. *Journal of cancer research and clinical oncology*. 2003;129(12):691-702.

Beerman, H., van Dorst, E. B. L., Kuenen-Boumeester, V., and Hogendoorn, P. C. W.. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. *Gynecologic Oncology*. 2009;112(3):572-576.

Benevolo, M., Vocaturo, A., Mottolese, M., Mariani, L., Vocaturo, G., Marandino, F., Sperduti, I., Rollo, F., Antoniani, B., and Donnorso, R. P.. Clinical role of p16INK4a expression in liquid-based cervical cytology: correlation with HPV testing and histologic diagnosis. *American journal of clinical pathology*. 2008;129(4):606-612.

Bergeron, C., Cas, F., Fagnani, F., Contrepas, A., Wadier, R., and Poveda, J. D.. Assessment of human papillomavirus testing on liquid-based Cyto-screen system for women with atypical squamous cells of undetermined significance. Effect of age. [French]. *Gynecologie, obstetrique & fertilité*. 2006;34(4):312-316.

Bergeron, C., Cas, F., Fagnani, F., Didaiiller-Lambert, F., and Poveda, J. D.. Human papillomavirus testing with a liquid-based system: Feasibility and comparison with reference diagnoses. *Acta Cytologica*. 2006;50(1):16-22.

Bergeron, C., Clavel, C., Crott, M. R., Hill, C., Jaury, P., Lehr-Drylewicz, A.-M., Leroy, J.-L., Lunel, F., Monsonogo, J., Mougin, C., Orth, G., Petitjean, A., De, Reilhac P., Riethmuller, D., Sancho-Garnier, H., Sevestre, H., D'Alche-Gautier, M.-J., Agius, G., Arbyn, M., Birembaut, P., Baldauf, J.-J., Bonnier, P., Boulanger, J.-C., Boman, F., Cayrol, M.-H., Charpentier, J.-M., Cochand-Priollet, B., Dalstein, V., Dupont, N., Fournier, A., Guyot, H., Halfon, P., Mergui, J.-L., Morice, P., Mousteou, F., Querleu, D., Sastre-Garau, X., Sauthier, P., and Vacher-Lavenu, M.-C.. Usefulness of searching for human papillomavirus (HPV): Evaluation of screening practices for precancerous lesions of the uterine cervix.

[French]. *Annales de pathologie*. 2005;25(2):173-177.

Bergeron, C., Jeannel, D., Poveda, J., Cassonnet, P., and Orth, G.. Human papillomavirus testing in women with mild cytologic atypia. *Obstetrics and Gynecology*. 2000;95(6 Pt 1):821-827.

Berkhof, J., De Bruijne, M. C., Zielinski, G. D., and Meijer, C. J. L. M.. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. *International Journal of Cancer*. 2005;115(2):268-275.

Bhatla, N. and Moda, N.. The clinical utility of HPV DNA testing in cervical cancer screening strategies. *Indian Journal of Medical Research*. 2009;130(3):261-265.

Bhatla, N., Gulati, A., Mathur, S. R., Rani, S., Anand, K., Muwonge, R., and Sankaranarayanan, R.. Evaluation of cervical screening in rural North India. *International Journal of Gynaecology & Obstetrics*. 2009;105(2):145-149.

Blanks, R. G. and Kelly, R. S.. Comparison of cytology and histology results in English cervical screening laboratories before and after liquid-based cytology conversion: Do the data provide evidence for a single category of high-grade dyskaryosis?. *Cytopathology*. 2010;21(6):368-373.

Boardman, L. A., Weitzen, S., and Stanko, C.. Atypical squamous cells of undetermined significance, human papillomavirus, and cervical intraepithelial neoplasia 2 or 3 in adolescents: ASC-US, age, and high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2006;10(3):140-145.

Bolanca, I. K. and Vranes, J.. Diagnostic methods and techniques in preventing cervical carcinoma. Part I: Conventional cytology and new cytological methods. *Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina*. 2010;7(1):12-17.

Bollmann, R., Bankfalvi, A., Griefingholt, H., Trosic, A., Speich, N., Schmitt, C., and Bollmann, M.. Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: results from 31031 women from the Bonn-region in West Germany. *Oncology Reports*. 2005;13(5):915-922.

Bond, S.. Conventional Glass Slide Pap Smears are as Accurate as Liquid-Based Tests in Detecting Cervical Disease. *Journal of Midwifery and Women's Health*. 2008;53(4):395-396.

Boschert, S.. ACOG changes cervical Ca recommendations. *Oncology Report*. 2010;#volume#(JANUARY-FEBRUARY):23.

Braganca, J. F., Derchain, S. F., Sarian, L. O., Messias Da Silva, S. M., Labatte, S., and Zeferino, L. C.. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions. *Clinical and Experimental Obstetrics and Gynecology*. 2005;32(4):225-229.

Brink, A. A. T. P., Snijders, P. J. F., and Meijer, C. J. L. M.. HPV detection methods. *Disease Markers*. 2007;23(4):273-281.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, A. J. P., Verheijen, R. H. M., Snijders, P. J. F., and Meijer, C. J. L. M.. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. *International Journal of Cancer*. 2007;121(2):361-367.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, J. P., and Verheijen, R. H. M.. Erratum: Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing and at 6-month (International Journal Cancer (2007) 121, (361-367)). *International Journal of Cancer*. 2007;121(8):1873.

Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H. M., and Meijer, C. J. L. M.. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. *British Journal of Cancer*.

2003;89(5):834-839.

Bulkmans, N. W. J., Rozendaal, L., Voorhorst, F. J., Snijders, P. J. F., and Meijer, C. J. L. M.. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. *British Journal of Cancer*. 2005;92(9):1800-1802.

Bull, S. L. and Schorge, J. O.. A study of the impact of adding HPV types to cervical cancer screening and triage tests. *Women's Oncology Review*. 2005;5(2):99-100.

Bulten, J., De Wilde, P. C. M., Boonstra, H., Gemmink, J. H., and Hanselaar, A. G. J. M.. Proliferation in 'atypical' atrophic Pap smears. *Gynecologic Oncology*. 2000;79(2):225-229.

Camilleri, G. and Blundell, R.. Pre-invasive cervical disease and cervical carcinoma. *Research Journal of Medical Sciences*. 2009;3(1):4-11.

Cardenas-Turanzas, M., Follen, M., Nogueras-Gonzalez, G. M., Benedet, J. L., Beck, J. R., and Cantor, S. B.. The accuracy of the papanicolaou smear in the screening and diagnostic settings. *Journal of Lower Genital Tract Disease*. 2008;12(4):269-275.

Cardenas-Turanzas, M., Nogueras-Gonzalez, G. M., Scheurer, M. E., Adler-Storthz, K., Benedet, J. L., Beck, J. R., Follen, M., and Cantor, S. B.. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(10):2865-2871.

Carozzi, F., Bisanzi, S., Sani, C., Zappa, M., Cecchini, S., Ciatto, S., and Confortini, M.. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. *Journal of Clinical Microbiology*. 2007;45(2):364-369.

Carozzi, F., Cecchini, S., Confortini, M., Becattini, V., Cariaggi, M. P., Pontenani, G., Sani, C., and Ciatto, S.. Role of P16(INK4A) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. *Cancer*. 2006;108(2):119-123.

Carreon, J. D., Sherman, M. E., Guillen, D., Solomon, D., Herrero, R., Jeronimo, J., Wacholder, S., Rodriguez, A. C., Morales, J., Hutchinson, M., Burk, R. D., and Schiffman, M.. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. *International Journal of Gynecological Pathology*. 2007;26(4):441-446.

Casamitjana, M., Sala, M., Ochoa, D., Fuste, P., Castells, X., and Alameda, F.. Results of a cervical cancer screening programme from an area of Barcelona (Spain) with a large immigrant population. *European Journal of Public Health*. 2009;19(5):499-503.

Castle, P. E., Lorincz, A. T., Scott, D. R., Sherman, M. E., Glass, A. G., Rush, B. B., Wacholder, S., Burk, R. D., Manos, M. M., Schussler, J. E., Macomber, P., and Schiffman, M.. Comparison between prototype Hybrid Capture 3 and Hybrid Capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. *Journal of Clinical Microbiology*. 2003;41(9):4022-4030.

Castle, P. E., Solomon, D., Schiffman, M., and Wheeler, C. M.. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. *Journal of the National Cancer Institute*. 2005;97(14):1066-1071.

Castle, P. E., Wacholder, S., Sherman, M. E., Lorincz, A. T., Glass, A. G., Scott, D. R., Rush, B. B., Demuth, F., and Schiffman, M.. Absolute risk of a subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. *Cancer*. 2002;95(10):2145-2151.

Castle, P. E.. Screening: HPV testing for cervical cancer: The good, the bad, and the ugly. *Nature Reviews Clinical Oncology*. 2010;7(7):364-365.

Castle, P. E.. The evolving definition of carcinogenic human papillomavirus. *Infectious Agents and Cancer*. 2009;4(1).

Cattani, P., Zannoni, G. F., Ricci, C., D'Onghia, S., Trivellizzi, I. N., Di, Franco A., Vellone, V. G., Durante, M., Fadda, G., Scambia, G., Capelli, G., and De, Vincenzo R.. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. *Journal of Clinical Microbiology*. 2009;47(12):3895-3901.

Celik, C., Gezginc, K., Toy, H., Findik, S., and Yilmaz, O.. A comparison of liquid-based cytology with conventional cytology. *International Journal of Gynecology and Obstetrics*. 2008;100(2):163-166.

Cenci, M. and Vecchione, A.. Usefulness of cervical collection by the Exact Touch, the Saccomanno single sampler, combined with automated primary screening. *Diagnostic Cytopathology*. 2000;23(4):242-244.

Cenci, M., Nagar, C., and Vecchione, A.. PAPNET-assisted primary screening of conventional cervical smears. *Anticancer Research*. 2000;20(5 C):3887-3889.

Chacho, M. S., Mattie, M. E., and Schwartz, P. E.. Cytohistologic correlation rates between conventional Papanicolaou smears and ThinPrep cervical cytology: A comparison. *Cancer*. 2003;99(3):135-140.

Chao, A., Chang, C.-J., Lai, C.-H., Chao, F.-Y., Hsu, Y.-H., Chou, H.-H., Huang, H.-J., Jung, S.-M., Lin, C.-T., Cheng, H.-H., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology - A population-based cohort study from Taiwan. *International Journal of Cancer*. 2010;126(1):191-198.

Chao, A., Hsu, K.-H., Lai, C.-H., Huang, H.-J., Hsueh, S., Lin, S.-R., Jung, S.-M., Chao, F.-Y., Huang, S.-L., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study. *International Journal of Cancer*. 2008;122(12):2835-2841.

Chao, F.-Y., Chao, A., Huang, C.-C., Hsueh, S., Yang, J.-E., Huang, H.-J., Wang, L.-C., Lin, C.-T., Chou, H.-H., and Lai, C.-H.. Defining detection threshold and improving analytical proficiency of HPV testing in clinical specimens. *Gynecologic Oncology*. 2010;117(2):302-307.

Chen, H.-S., Yang, Y.-C., Su, T.-H., Wang, T.-Y., and Huang, Y.-W.. Human papillomavirus testing (Hybrid Capture II) to detect high-grade cervical intraepithelial neoplasia in women with mildly abnormal Papanicolaou results. *Taiwanese Journal of Obstetrics and Gynecology*. 2005;44(3):252-257.

Chen, L. and Yang, B.. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. *Cancer*. 8-25-2008;114(4):236-241.

Cheung, A. N. Y., Szeto, E. F., Leung, B. S. Y., Khoo, U.-S., and Ng, A. W. Y.. Liquid-Based Cytology and Conventional Cervical Smears: A Comparison Study in an Asian Screening Population. *Cancer*. 2003;99(6):331-335.

Chin-Hong, P. V. and Klausner, J. D.. Diagnostic tests for HPV infection. *MLO: medical laboratory observer*. 2004;36(10):10-16.

Chivukula, M., Saad, R. S., Elishaev, E., White, S., Mauser, N., and Dabbs, D. J.. Introduction of the Thin Prep Imaging System (TIS): Experience in a high volume academic practice. *CytoJournal*. 2007;4, 2007. Article Number: 6. Date of Publication: 2007.

Cibas, E. S., Alonzo, T. A., Austin, R. M., Bolick, D. R., Glant, M. D., Henry, M. R., Moriarty, A. T., Molina, J. T., Rushing, L., Slowman, S. D., Torno, R., and Eisenhut, C. C.. The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. *American journal of clinical pathology*. 2008;129(2):193-201.

Cirpan, T., Guliyeva, A., Onder, G., Terek, M. C., Ozsaran, A., Kabasakal, Y., Zekioglu, O., and Yucebilgin, S.. Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren's syndrome. *European Journal of Gynaecological Oncology*. 2007;28(4):302-306.

Cohen, D., Shorie, J., and Biscotti, C.. Glacial acetic acid treatment and atypical endocervical glandular cells: An Analysis of 92 Cases. *American journal of clinical pathology*. 2010;133(5):799-801.

Cohn, J. A., Gagnon, S., Spence, M. R., Harrison, D. D., Kluzak, T. R., Langenberg, P., Brinson, C., Stein, A., and Hellinger, J.. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. *American Journal of Obstetrics and Gynecology*. 2001;184(3):322-330.

Colgan, T. J., Woodhouse, S. L., Styer, P. E., Kennedy, M., and Davey, D. D.. Reparative changes and the false-positive/false-negative papanicolaou test: A study from the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. *Archives of Pathology and Laboratory Medicine*. 2001;125(1):134-140.

Confortini, M., Giorgi, Rossi P., Barbarino, P., Passarelli, A. M., Orzella, L., and Tufi, M. C.. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. *Journal of medical screening*. 2010;17(2):79-86.

Coquillard, G., Palao, B., and Patterson, B. K.. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. *Gynecologic Oncology*. 2011;120(1):89-93.

Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women. *Obstetrics & Gynecology*. 2002;100(1):79-86.

Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women1. *Obstetrics and Gynecology*. 2002;100(1):79-86.

Corusic, A., Skrgatic, L., Mahovlic, V., Mandic, V., Planinic, P., and Karadza, M.. Cervical cancer as a public health issue--what next?. *Collegium antropologicum*. 2010;34(1):301-307.

Coste, J., Cochand-Priollet, B., de, Cremoux P., Buntinx, F., and Arbyn, M.. Conventional cervical smears were better than monolayer cytology or human papillomavirus testing for detecting cervical intraepithelial neoplasia. *Evidence-Based Medicine*. 2003;8(6):187.

Coutlee, F., Rouleau, D., Petignat, P., Ghattas, G., Kornegay, J. R., Schlag, P., Boyle, S., Hankins, C., Vezina, S., Cote, P., Macleod, J., Voyer, H., Forest, P., Walmsley, S., Franco, E., Connors, J., Grimshaw, R., Haase, D., Johnston, L., Schlech, W., Yuzicappi-Fayant, A., Landis, S., Smaill, F., Austin, T., Hammerberg, O., Ralph, T., Falutz, J., Ferenczy, A., Klein, M., Labrecque, L., Lalonde, R., Noel, G., Perron, C., Routy, J.-P., Toma, E., Touchie, C., Victor, G., Cote, L., Senay, H., Trottier, S., Williams, K., Piche, A., Sandre, R., Binder, L., Keystone, D., Phillips, A., Rachlis, A., Salit, I., Wagner, C., Braitstein, P., Burdge, D., Harris, M., Money, D., and Montaner, J.. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGM1 primers and the linear array HPV genotyping test. *Journal of Clinical Microbiology*. 2006;44(6):1998-2006.

Cox, J. T.. Corrigendum to "History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results" [*J. Clin. Virol.* 45 (1) (2009) S3-S12] (PII:S1386-6532(09)X0008-9). *Journal of Clinical Virology*. 2010;47(3):299.

- Cox, J. T.. Human papillomavirus testing in primary cervical screening and abnormal papanicolaou management. *Obstetrical and Gynecological Survey*. 2006;61(6 SUPPL. 1):S15-S25.
- Cox, J. T.. Liquid-based cytology: evaluation of effectiveness, cost-effectiveness, and application to present practice. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2004;2(6):597-611.
- Curran, D. R. and Stigleman, S.. Should we discontinue Pap smear screening in women aged >65 years?. *Journal of Family Practice*. 2004;53(4):308-310.
- Cuzick, J., Arbyn, M., Sankaranarayanan, R., Tsu, V., Ronco, G., Mayrand, M.-H., Dillner, J., and Meijer, C. J. L. M.. Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. *Vaccine*. 2008;26(SUPPL. 10):K29-K41.
- Cuzick, J., Clavel, C., Petry, K.-U., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., and Iftner, T.. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006;119(5):1095-1101.
- Cuzick, J., Szarewski, A., Mesher, D., Cadman, L., Austin, J., Perryman, K., Ho, L., Terry, G., Sasieni, P., Dina, R., and Soutter, W. P.. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - Results from the Hammersmith study. *International Journal of Cancer*. 2008;122(10):2294-2300.
- Cuzick, J.. Time to consider HPV testing in cervical screening. *Annals of Oncology*. 2001;12(11):1511-1514.
- Datta, S. D., Koutsky, L. A., Ratelle, S., Unger, E. R., Shlay, J., McClain, T., Weaver, B., Kerndt, P., Zenilman, J., Hagensee, M., Suhr, C. J., and Weinstock, H.. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. *Annals of internal medicine*. 2008;148(7):493-500.
- Davey, E., D'Assuncao, J., Irwig, L., Macaskill, P., Chan, S. F., Richards, A., and Farnsworth, A.. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: Prospective study. *British Medical Journal*. 2007;335(7609):31-35.
- De Francesco, M. A., Gargiulo, F., Schreiber, C., Ciravolo, G., Salinaro, F., and Manca, N.. Comparison of the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. *Journal of Virological Methods*. 2008;147(1):10-17.
- De, Lang A. and Wilander, E.. Sensitivity of HPV tests on stained vs. unstained cervical smears. *Acta Cytologica*. 2005;49(6):595-599.
- De, Lang A., Wikstrom, I., and Wilander, E.. Significance of HPV tests on women with cervical smears showing ASCUS. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(10):1001-1005.
- Denton, K. J., Bergeron, C., Klement, P., Trunk, M. J., Keller, T., and Ridder, R.. The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. *American journal of clinical pathology*. 2010;134(1):12-21.
- Derchain, S. F., Sarian, L. O., Naud, P., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Serpa-Hammes, L., Matos, J., Gontijo, R. C., Braganca, J. F., Lima, T. P., Maeda, M. Y., Lorincz, A., Dores, G. B., Costa, S., Syrjanen, S., and Syrjanen, K.. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study. *Journal of medical screening*. 2008;15(2):97-104.
- Desai, M.. Role of automation in cervical cytology. *Diagnostic Histopathology*. 2009;15(7):323-329.

Diaz-Montes, T. P., Farinola, M. A., Zahurak, M. L., Bristow, R. E., and Rosenthal, D. L.. Clinical utility of atypical glandular cells (AGC) classification: Cytohistologic comparison and relationship to HPV results. *Gynecologic Oncology*. 2007;104(2):366-371.

Difurio, M. J., Mailhot, T., Sundborg, M. J., and Nauschuetz, K. K.. Comparison of the clinical significance of the papanicolaou test interpretations LSIL cannot rule out HSIL and ASC-H. *Diagnostic Cytopathology*. 2010;38(5):313-317.

Dockter, J., Schroder, A., Hill, C., Guzinski, L., Monsonogo, J., and Giachetti, C.. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S55-S61.

Duby, J. M. and Difurio, M. J.. Implementation of the ThinPrep Imaging System in a tertiary military medical center. *Cancer cytopathology*. 2009;117(4):264-270.

Duggan, M. A., Khalil, M., Brasher, P. M. A., and Nation, J. G.. Comparative study of the ThinPrep Pap test and conventional cytology results in a Canadian cohort. *Cytopathology*. 2006;17(2):73-81.

Dziura, B., Quinn, S., and Richard, K.. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the uterine cervix. *Acta Cytologica*. 2006;50(3):309-311.

Eilstein, D., Hedelin, G., and Schaffer, P.. Cervical cancer in Bas-Rhin: Trend and prediction of the incidence in 2014. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2002;31(1):28-33.

Einstein, M. H., Studentsov, Y. Y., Ho, G. Y. F., Fazzari, M., Marks, M., Kadish, A. S., Goldberg, G. L., Runowicz, C. D., and Burk, R. D.. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. *International Journal of Cancer*. 2007;120(1):55-59.

Elfgren, K., Kalantari, M., Moberger, B., Hagmar, B., and Dillner, J.. A population-based five-year follow-up study of cervical human papillomavirus infection. *American Journal of Obstetrics and Gynecology*. 2000;183(3):561-567.

Elsheikh, T. M., Kirkpatrick, J. L., and Wu, H. H.. The significance of "low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion" as a distinct squamous abnormality category in Papanicolaou tests. *Cancer*. 2006;108(5):277-281.

Eltoum, I. A. and Roberson, J.. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national pap test volume: Projections from the National Health Interview Survey (NHIS). *Cancer*. 2007;111(1):34-40.

Eltoum, I. A., Chhieng, D. C., Roberson, J., McMillon, D., and Partridge, E. E.. Reflex human papilloma virus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2-3 in young versus elderly women. *Cancer*. 2005;105(4):194-198.

Fait, G., Kupferminc, M. J., Daniel, Y., Geva, E., Ron, I. G., Lessing, J. B., and Bar-Am, A.. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal Pap smears before colposcopy referral. *Gynecologic Oncology*. 2000;79(2):177-180.

Farag, R., Redline, R., and Abdul-Karim, F. W.. Value of combining HPV-DNA testing with follow-up papanicolaou smear in patients with prior atypical squamous cells of undetermined significance. *Acta Cytologica*. 2008;52(3):294-296.

Federico, C., Alleyn, J., Dola, C., Tafti, S., Galandak, J., Jacob, C., Bhuiyan, A., and Cheng, J.. Relationship among age, race, medical funding, and cervical cancer survival. *Journal of the National Medical Association*. 2010;102(3):199-205.

- Feng, J., Al-Abbadi, M. A., Bandyopadhyay, S., Salimnia, H., and Husain, M.. Significance of high-risk human papillomavirus DNA-positive atypical squamous cells of undetermined significance pap smears in perimenopausal and postmenopausal women. *Acta Cytologica*. 2008;52(4):434-438.
- Ferreccio, C., Bratti, M. C., Sherman, M. E., Herrero, R., Wacholder, S., Hildesheim, A., Burk, R. D., Hutchinson, M., Alfaro, M., Greenberg, M. D., Morales, J., Rodriguez, A. C., Schussler, J., Eklund, C., Marshall, G., and Schiffman, M.. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. *Cancer Epidemiology Biomarkers and Prevention*. 2003;12(9):815-823.
- Ferris, D. G., Gilman, P. A., Leyva Lopez, A. G., Litaker, M. S., Miller, J. A., and Macfee, M. S.. Psychological effects women experience before and after a colposcopic examination and primary care appointment. *Journal of Lower Genital Tract Disease*. 2003;7(2):89-94.
- Ferris, D. G., Heidemann, N. L., Litaker, M. S., Crosby, J. H., and Macfee, M. S.. The efficacy of liquid-based cervical cytology using direct-to-vial sample collection. *Journal of Family Practice*. 2000;49(11):1005-1011.
- Fink, J. L.. Beyond the shock of an abnormal Pap. *RN*. 2003;66(6):56-61.
- Freeman-Wang, T. and Walker, P.. Psychological aspects of colposcopy. *CME Journal of Gynecologic Oncology*. 2005;10(2):123-126.
- Frega, A., Biamonti, A., Maranghi, L., Vetrano, G., Palazzo, A., Iacovelli, R., Corosu, R., French, D., Moscarini, M., and Vecchione, A.. Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. Analysis of risk factors. *Anticancer Research*. 2006;26(4 B):3167-3170.
- Freitas, R. A. P., Carvasan, G. A. F., Morais, S. S., and Zeferino, L. C.. Excessive pap smears due to opportunistic cervical cancer screening. *European Journal of Gynaecological Oncology*. 2008;29(5):479-482.
- Fremont-Smith, M., Marino, J., Griffin, B., Spencer, L., and Bolick, D.. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. *Cancer*. 2004;102(5):269-279.
- Froberg, M., Johansson, B., Hjerpe, A., and Andersson, S.. Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities. *British Journal of Cancer*. 2008;99(4):563-568.
- Gage, J. C., Schiffman, M., Solomon, D., Wheeler, C. M., and Castle, P. E.. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. *Cancer Epidemiology Biomarkers and Prevention*. 2010;19(7):1668-1674.
- Garcia-Garcia, J. A., Perez-Valles, A., Martorell, M., Gomez, B., Gomez-Cabrero, D., Soler, F., and Calabuig, C.. Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. *Acta Cytologica*. 2010;54(2):159-164.
- Garcia-Sierra, N., Martro, E., Castella, E., Llatjos, M., Tarrats, A., Bascunana, E., Diaz, R., Carrasco, M., Sirera, G., Matas, L., and Ausina, V.. Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening. *Journal of Clinical Microbiology*. 2009;47(7):2165-2169.
- Gazzaz, F. S. B.. Molecular testing of human papillomavirus in cervical specimens. *Saudi Medical Journal*. 2007;28(12):1810-1818.
- Ge, Y., Smith, D., Schwartz, M. R., and Mody, D. R.. Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private

practice population. *Cancer cytopathology*. 2009;117(5):326-332.

Geldenhuis, L. and Murray, M. L.. Sensitivity and specificity of the pap smear for glandular lesions of the cervix and endometrium. *Acta Cytologica*. 2007;51(1):47-50.

Ginsberg, G. M., Edejer, T. T. T., Lauer, J. A., and Sepulveda, C.. Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis. *Vaccine*. 2009;27(43):6060-6079.

Giordano, G., Gnetti, L., Pilato, F. P., Viviano, L., and Silini, E. M.. The role of cervical smear in the diagnosis and management of extrauterine malignancies metastatic to the cervix: Three case reports. *Diagnostic Cytopathology*. 2010;38(1):41-46.

Girianelli, V. R. and Thuler, L. C. S.. Evaluation of agreement between conventional and liquid-based cytology in cervical cancer early detection based on analysis of 2,091 smears: Experience at the Brazilian National Cancer Institute. *Diagnostic Cytopathology*. 2007;35(9):545-549.

Gontijo, R. C., Derchain, S. F. M., Roteli-Martins, C., Braganca, J. F., Sarian, L. O., Morais, S. S., Maeda, M. Y. S., Longatto-Filho, A., and Syrjanen, K. J.. Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2007;133(2):239-246.

Grace, A., McBrearty, P., Troost, S., Thornhill, M., Kay, E., and Leader, M.. Comparative study: Conventional cervical and ThinPrep Pap tests in a routine clinical setting. *Cytopathology*. 2002;13(4):200-205.

Grainge, M. J., Seth, R., Guo, L., Neal, K. R., Coupland, C., Vryenhoef, P., Johnson, J., and Jenkins, D.. Cervical human papillomavirus screening among older women. *Emerging Infectious Diseases*. 2005;11(11):1680-1685.

Greydanus, D. E., Omar, H., and Patel, D. R.. Cervical cancer screening in adolescents. *Pediatrics in Review*. 2009;30(1):23-25.

Greydanus, D. E., Omar, H., and Patel, D. R.. What's new: Cervical cancer screening in adolescents. *Pediatrics in review / American Academy of Pediatrics*. 2009;30(1):23-25.

Guido, R.. Guidelines for screening and treatment of cervical disease in the adolescent. *Journal of Pediatric and Adolescent Gynecology*. 2004;17(5):303-311.

Guidos, B. J. and Selvaggi, S. M.. Detection of endometrial adenocarcinoma with the ThinPrep Pap Test(TM). *Diagnostic Cytopathology*. 2000;23(4):260-265.

Guillaud, M., Benedet, J. L., Cantor, S. B., Staerckel, G., Follen, M., and MacAulay, C.. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. *Cancer*. 2006;107(2):309-318.

Guo, M., Hu, L., Martin, L., Liu, S., Baliga, M., and Hughson, M. D.. Accuracy of liquid-based pap tests: Comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal pap smears. *Acta Cytologica*. 2005;49(2):132-138.

Guo, M., Patel, S. J., Chovanec, M., Yee, J. J., Tarco, E., Bevers, T. B., Anderson, K., and Sneige, N.. A human papillomavirus testing system in women with abnormal pap results: A comparison study with follow-up biopsies. *Acta Cytologica*. 2007;51(5):749-754.

Halfon, P., Benmoura, D., Agostini, A., Khiri, H., Martineau, A., Penaranda, G., and Blanc, B.. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS

- EasyQ HPV assay. *Journal of Clinical Virology*. 2010;47(2):177-181.
- Halfon, P., Benmoura, D., Khiri, H., Penaranda, G., Blanc, B., Riggio, D., and Sandri, M. T.. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. *Journal of Clinical Virology*. 2010;47(1):38-42.
- Halford, J. A., Batty, T., Boost, T., Duhig, J., Hall, J., Lee, C., and Walker, K.. Comparison of the sensitivity of conventional cytology and the ThinPrep imaging system for 1,083 biopsy confirmed high-grade squamous lesions. *Diagnostic Cytopathology*. 2010;38(5):318-326.
- Hall, J. and Kendall, B.. High risk human papillomavirus DNA detection in pap tests with both atypical squamous cells of undetermined significance and candida. *Acta Cytologica*. 2009;53(2):150-152.
- Hamashima, C., Aoki, D., Miyagi, E., Saito, E., Nakayama, T., Sagawa, M., Saito, H., Sobue, T., and Japanese Research Group for Development of Cervical Cancer Screening Guidelines. The Japanese guideline for cervical cancer screening. *Japanese journal of clinical oncology*. 2010;40(6):485-502.
- Hantz, S., Caly, H., Decroisette, E., Dutrop, A., Bakeland, D., Pascal, B., Darreys, G., Dussartre, C., Renaudie, J., Rogez, S., Aubard, Y., Denis, F., and Alain, S.. Evaluation of accuracy of three assays for human papillomavirus detection and typing: Hybrid Capture 2, HPV Consensus kit and Amplikor HPV. [French]. *Pathologie Biologie*. 2008;56(1):29-35.
- Hartmann, K. E., Nanda, K., Hall, S., and Myers, E.. Technologic advances for evaluation of cervical cytology: Is newer better?. *Obstetrical and Gynecological Survey*. 2001;56(12):765-774.
- Harvey, M., Stout, S., Starkey, C. R., Hendren, R., Holt, S., and Miller, G. C.. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S79-S83.
- Hatch, K. D., Sheets, E., Kennedy, A., Ferris, D. G., Darragh, T., and Twiggs, L.. Multicenter direct to vial evaluation of a liquid-based Pap test. *Journal of Lower Genital Tract Disease*. 2004;8(4):308-312.
- Healey, S. M., Aronson, K., Mao, Y., and Franco, E. L.. Human papillomavirus and cervical dysplasia in Nunavut: prelude to a screening strategy. *International Journal of Circumpolar Health*. 2004;63 Suppl 2:199-201.
- Hellsten, C., Lindqvist, P. G., and Sjostrom, K.. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2008;115(2):205-211.
- Hellsten, C., Sjostrom, K., and Lindqvist, P. G.. A prospective Swedish cohort study on psychosocial factors influencing anxiety in women referred for colposcopy. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2007;114(1):32-38.
- Herbert, A.. Cervical screening in England and Wales: Its effect has been underestimated. *Cytopathology*. 2000;11(6):471-479.
- Hesselink, A. T., Berkhof, J., Heideman, D. A., Bulkman, N. W., van Telling, J. E., Meijer, C. J., and Snijders, P. J.. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. *International Journal of Cancer*. 2009;Journal international du cancer. 124(2):381-386.
- Hoekstra, A. V., Kosinski, A., and Huh, W. K.. Hormonal contraception and false-positive cervical cytology: Is there an association?. *Journal of Lower Genital Tract Disease*. 2006;10(2):102-106.
- Holmquist, N. D.. Revisiting the effect of the pap test on cervical cancer. *American journal of public health*. 2000;90(4):620-623.
- Hong, D. G., Seong, W. J., Kim, S. Y., Lee, Y. S., and Cho, Y. L.. Prediction of high-grade squamous

intraepithelial lesions using the modified Reid index. *International Journal of Clinical Oncology*. 2010;15(1):65-69.

Howard, K., Salkeld, G., McCaffery, K., and Irwig, L.. HPV triage testing or repeat pap smear for the management of a typical squamous cells (ASCUS) on pap smear: Is there evidence of process utility?. *Health Economics*. 2008;17(5):593-605.

Huang, S., Erickson, B., Tang, N., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S19-S23.

Hunter, C., Duggan, M. A., Duan, Q., Power, P., Gregoire, J., and Nation, J.. Cytology and outcome of LSIL: Cannot exclude HSIL compared to ASC-H. *Cytopathology*. 2009;20(1):17-26.

Hussein, T., Desai, M., Tomlinson, A., and Kitchener, H. C.. The comparative diagnostic accuracy of conventional and liquid-based cytology in a colposcopic setting. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2005;112(11):1542-1546.

Illades-Aguilar, B., Alarcon-Romero, L., Antonio-Vejar, V., Zamudio-Lopez, N., Sales-Linares, N., Flores-Alfaro, E., Fernandez-Tilapa, G., Vences-Velazquez, A., Munoz-Valle, J. F., and Leyva-Vazquez, M.-A.. Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico. *Gynecologic Oncology*. 2010;117(2):291-296.

Inoue, M., Sakaguchi, J., Sasagawa, T., and Tango, M.. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. *International Journal of Gynecological Cancer*. 2006;16(3):1007-1013.

Jacot-Guillarmod, M., Hohlfeld, P., and Renteria, S.-C.. Role of the PAP smear in adolescence. [French]. *Revue Medicale Suisse*. 2009;5(222):2078-2084.

Jeng, C.-J., Ko, M.-L., Ling, Q.-D., Shen, J., Lin, H.-W., Tzeng, C.-R., Ho, C.-M., Chien, T.-Y., and Chen, S.-C.. Prevalence of cervical human papillomavirus in Taiwanese women. *Clinical and Investigative Medicine*. 2005;28(5):261-266.

Jiang, J., Wei, L.-H., Li, Y.-L., Wu, R.-F., Xie, X., Feng, Y.-J., Zhang, G., Zhao, C., Zhao, Y., and Chen, Z.. Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer: A multicenter study in China. *Journal of Molecular Diagnostics*. 2010;12(6):808-817.

Julian, T. M.. Erratum: Type-specific HPV testing as a predictor of high-grade squamous intraepithelial lesion outcome after cytologic abnormalities (*Journal of Lower Genital Tract Disease* (2005) 9, (3), (154-159)). *Journal of Lower Genital Tract Disease*. 2006;10(1):63.

Juric, D., Mahovlic, V., Rajhvajn, S., Ovanin-Rakic, A., Skopljanac-Macina, L., Barisic, A., Projic, I. S., Babic, D., Susa, M., Corusic, A., and Oreskovic, S.. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions. *Collegium antropologicum*. 2010;34(1):19-24.

Kang, W. D., Kim, C. H., Cho, M. K., Kim, J. W., Kim, Y. H., Choi, H. S., and Kim, S. M.. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. *International Journal of Gynecological Cancer*. 2009;19(5):924-928.

Karabulut, A., Alan, T., Ali, Ekiz M., Iritas, A., Kesen, Z., and Yahsi, S.. Evaluation of cervical screening results in a population at normal risk. *International Journal of Gynecology and Obstetrics*. 2010;110(1):40-42.

Karam, W. G., Bedran, F., Tohme, R. A., Moukarbel, N., Abdallah, I., Jurjus, A. R., Jurjus, R. A., Khairallah, S., and Aftimos, G.. Human papillomavirus testing as an adjunct to cytology evaluation in

- cervical specimens of selected and consecutively screened Lebanese women: A prospective clinical study. *Journal Medical Libanais*. 2005;53(3):132-138.
- Karasz, A., McKee, M. D., and Roybal, K.. Women's experiences of abnormal cervical cytology: illness representations, care processes, and outcomes. *Annals of family medicine*. 2003;1(4):196-202.
- Kent, A.. Screening and logical cytology - A review. *Obstetrics and Gynaecology Forum*. 2009;19(4):141-143.
- Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M. S., Scott, D. R., Rush, B. R., Glass, A. G., and Schiffman, M.. The elevated 10-Year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *Journal of the National Cancer Institute*. 2005;97(14):1072-1079.
- Kiatpongsan, S., Niruthisard, S., Mutirangura, A., Trivijitsilp, P., Vasuratna, A., Chaithongwongwatthana, S., and Lertkhachonsuk, R.. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. *International Journal of Gynecological Cancer*. 2006;16(1):262-265.
- Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., and Choi, C.. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Gynecologic Oncology*. 2010;116(1):99-104.
- Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., Choi, C., Kweon, S.-S., Fackler, M. J., and Sukumar, S.. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Virchows Archiv*. 2010;457(1):35-42.
- Kinney, W., Castle, P. E., Fetterman, B., Poitras, N., Lorey, T., and Shaber, R.. Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. *Obstetrics and Gynecology*. 2009;113(3):595-600.
- Kirschner, B., Simonsen, K., and Junge, J.. Comparison of conventional Papanicolaou smear and SurePath liquid-based cytology in the Copenhagen population screening programme for cervical cancer. *Cytopathology*. 2006;17(4):187-194.
- Kjaer, S., Hogdall, E., Frederiksen, K., Munk, C., Van Den Brule, A., Svare, E., Meijer, C., Lorincz, A., and Iftner, T.. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. *Cancer Research*. 2006;66(21):10630-10636.
- Klinkhamer, P. J. J. M., Meerding, W. J., Rosier, P. F. W. M., and Hanselaar, A. G. J. M.. Liquid-based cervical cytology: A review of the literature with methods of evidence-based medicine. *Cancer*. 2003;99(5):263-271.
- Knoepp, S. M., Kuebler, D. L., and Wilbur, D. C.. Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: a cytologic/histologic review of 367 cases. *Cancer cytopathology*. 2010;118(4):209-217.
- Knoepp, S. M., Kuebler, D. L., and Wilbur, D. C.. Resolution of equivocal results with the hybrid capture II high-risk HPV DNA Test: A cytologic/histologic review of 191 cases. *Diagnostic Molecular Pathology*. 2007;16(3):125-129.
- Ko, V., Nanji, S., Tambouret, R. H., and Wilbur, D. C.. Testing for HPV as an objective measure for quality assurance in gynecologic cytology: Positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio. *Cancer*. 2007;111(2):67-73.
- Ko, V., Tambouret, R. H., Kuebler, D. L., Black-Schaffer, W. S., and Wilbur, D. C.. Human papillomavirus testing using Hybrid Capture II with SurePath collection: Initial evaluation and

longitudinal data provide clinical validation for this method. *Cancer*. 2006;108(6):468-474.

Koliopoulos, G., Valasoulis, G., and Zilakou, E.. An update review on HPV testing methods for cervical neoplasia. *Expert Opinion on Medical Diagnostics*. 2009;3(2):123-131.

Koong, S. L., Yen, A. M., and Chen, T. H.. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. *Journal of medical screening*. 2006;13 Suppl 1:S44-S47.

Kotaniemi-Talonen, L., Nieminen, P., Hakama, M., Seppanen, J., Ikkala, J., Martikainen, J., Tarkkanen, J., Toivonen, T., and Anttila, A.. Significant variation in performance does not reflect the effectiveness of the cervical cancer screening programme in Finland. *European Journal of Cancer*. 2007;43(1):169-174.

Kulasingam, S. L. and Myers, E. R.. Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs. *Journal of the American Medical Association*. 2003;290(6):781-789.

Kulmala, S.-M., Syrjanen, S., Shabalova, I., Petrovichev, N., Kozachenko, V., Podistov, J., Ivanchenko, O., Zakharenko, S., Nerovjna, R., Kljukina, L., Branovskaja, M., Grunberga, V., Juschenko, A., Tosi, P., Santopietro, R., and Syrjanen, K.. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. *Journal of Clinical Microbiology*. 2004;42(6):2470-2475.

Kumar, N., Bongiovanni, M., Molliet, M.-J., Pelte, M.-F., Egger, J.-F., and Pache, J.-C.. Reclassification and analysis of clinical significance of atypical glandular cells on ThinPrep using the Bethesda 2001: Geneva experience. *Swiss Medical Weekly*. 2007;137(45-46):635-641.

Kurtycz, D. F. I., Smith, M., He, R., Miyazaki, K., and Shalkham, J.. Comparison of methods trial for high-risk HPV. *Diagnostic Cytopathology*. 2010;38(2):104-108.

Kyrgiou, M., Tsoumpou, I., Vrekoussis, T., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Mitrou, S., Koliopoulos, G., Dalkalitsis, N., Stamatopoulos, P., and Paraskevaidis, E.. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: The cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. *Cancer Treatment Reviews*. 2006;32(7):516-523.

Lam, C. L. K.. The price of cancer screening. *Hong Kong Practitioner*. 2004;26(3):142-145.

Lavoue, V., Bergeron, C., Riethmuller, D., Darai, E., Mergui, J.-L., Baldauf, J.-J., Gondry, J., Douvier, S., Lopes, P., De, Reilhac P., Quereux, C., Letombe, B., Marchetta, J., Boulanger, J.-C., and Leveque, J.. Cervical screening: Toward a new paradigm?. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2010;39(2):102-115.

Lazcano-Ponce, E., Lorincz, A. T., Salmeron, J., Fernandez, I., Cruz, A., Hernandez, P., Mejia, I., and Hernandez-Avila, M.. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican social security program. *Cancer Causes and Control*. 2010;21(10):1693-1700.

Lee, C. Y. K. and Ng, W.-K.. A follow-up study off atypical squamous cells in gynecologic cytology using conventional papanicolaou smears and liquid-based preparations: The impact of the Bethesda system 2001. *American journal of clinical pathology*. 2007;127(4):548-555.

Lee, S. H., Vigliotti, V. S., and Pappu, S.. HPV infection among women in a representative rural and suburban population of the USA. *International Journal of Gynecology and Obstetrics*. 2009;105(3):210-214.

Lerma, E., Quintana, M. J., Quilez, M., Esteva, E., Carreras, A., Bonfill, X., Prat, J., and Calaf, J.. Effectiveness of liquid-based cytology and Papanicolaou tests in a low risk population. *Acta Cytologica*. 2007;51(3):399-406.

Li, N., Shi, J.-F., Franceschi, S., Zhang, W.-H., Dai, M., Liu, B., Zhang, Y.-Z., Li, L.-K., Wu, R.-F., De,

Vuyst H., Plummer, M., Qiao, Y.-L., and Clifford, G.. Different cervical cancer screening approaches in a Chinese multicentre study. *British Journal of Cancer*. 2009;100(3):532-537.

Liang, J., Mittal, K. R., Wei, J. J., Yee, H., Chiriboga, L., and Shukla, P.. Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with silverberg scoring system for endocervical glandular lesions. *International Journal of Gynecological Pathology*. 2007;26(1):71-75.

Lie, A. K., Risberg, B., Borge, B., Sandstad, B., Delabie, J., Rimala, R., Onsrud, M., and Thoresen, S.. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. *Gynecologic Oncology*. 2005;97(3):908-915.

Liman, A. K., Giampoli, E. J., and Bonfiglio, T. A.. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?. *Cancer*. 2005;105(6):457-460.

Liu, S. S., Leung, R. C. Y., Chan, K. K. L., Cheung, A. N. Y., and Ngan, H. Y. S.. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche linear array HPV genotyping assay. *Journal of Clinical Microbiology*. 2010;48(3):758-764.

Longatto, Filho A., Miranda Pereira, S. M., Di, Loreto C., Utagawa, M. L., Makabe, S., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., and Castelo, A.. DCS liquid-based system is more effective than conventional smears to diagnosis of cervical lesions: Study in high-risk population with biopsy-based confirmation. *Gynecologic Oncology*. 2005;97(2):497-500.

Longatto-Filho, A., Erzen, M., Branca, M., Roteli-Martins, C., Naud, P., Derchain, S. F. M., Hammes, L., Sarian, L. O., Braganca, J. F., Matos, J., Gontijo, R., Lima, T., Maeda, M. Y. S., Tatti, S., Syrjanen, S., Dores, G., Lorincz, A., and Syrjanen, K.. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: Experience from the Latin American screening study. *International Journal of Gynecological Cancer*. 2006;16(3):955-962.

Lonky, N. M., Mahdavi, A., Wolde-Tsadik, G., Bajamundi, K., and Felix, J. C.. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: A retrospective review of the southern california permanente medical group experience. *Journal of Lower Genital Tract Disease*. 2010;14(3):200-205.

Lorenzato, M., Caudroy, S., Bronner, C., Evrard, G., Simon, M., Durlach, A., Birembaut, P., and Clavel, C.. Cell cycle and/or proliferation markers: What is the best method to discriminate cervical high-grade lesions?. *Human Pathology*. 2005;36(10):1101-1107.

Lozano, R.. Comparison of computer-assisted and manual screening of cervical cytology. *Gynecologic Oncology*. 2007;104(1):134-138.

Luque, A. E., Jabeen, M., Messing, S., Lane, C. A., Demeter, L. M., Rose, R. C., and Reichman, R. C.. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. *Journal of Infectious Diseases*. 2006;194(4):428-434.

Ma, L., Bian, M.-L., Cheng, J.-Y., Xiao, W., Hao, M., Zhu, J., Chen, Y., and Liu, J.. Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study. *Experimental and Therapeutic Medicine*. 2010;1(1):193-198.

Maehama, T.. Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterine cervix. *Infectious diseases in obstetrics and gynecology*. 2005;13(2):77-80.

Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test

results: cross sectional questionnaire study. *BMJ*. 5-29-2004;328(7451):1293.

Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-Month follow-up. *British Journal of Cancer*. 2005;92(6):990-994.

Mao, C., Balasubramanian, A., Yu, M., Kiviat, N., Ridder, R., Reichert, A., Herkert, M., Von Knebel, Doeberitz M., and Koutsky, L. A.. Evaluation of a new p16INK4a ELISA test and a high-risk HPV DNA test for cervical cancer screening: Results from proof-of-concept study. *International Journal of Cancer*. 2007;120(11):2435-2438.

Marchetti, I., Zavaglia, K., Bertacca, G., Aretini, P., Matteoli, B., Viacava, P., Prato, B., De, Punzio C., Genazzani, A. R., Bevilacqua, G., and Di, Coscio G.. HPV testing and Pap test: Role for a combined approach in a non-screened population. *International Journal of Biological Markers*. 2006;21(3):149-156.

Massad, S. L., Markwell, S., Cejtin, H. E., and Collins, Y.. Risk of high-grade cervical intraepithelial neoplasia among young women with abnormal screening cytology. *Journal of Lower Genital Tract Disease*. 2005;9(4):225-229.

Mathur, S. P., Mathur, R. S., Creasman, W. T., Underwood, P. B., and Kohler, M.. Early non-invasive diagnosis of cervical cancer: beyond Pap smears and human papilloma virus (HPV) testing. *Cancer biomarkers : section A of Disease markers*. 2005;1(2-3):183-191.

Matthews-Greer, J., Rivette, D., Reyes, R., Vanderloos, C. F., and Turbat-Herrera, E. A.. Human papillomavirus detection: verification with cervical cytology. *Clinical laboratory science : journal of the American Society for Medical Technology*. 2004;17(1):8-11.

Mattimoe, T.. No more annual pap tests: reviewing the consensus of experts. *Advance for nurse practitioners*. 2010;18(5):18.

McBride, D.. New DNA test for cervical cancer outperforms Pap test. *ONS connect*. 2009;24(7):23.

McCaffery, K. J., Irwig, L., Chan, S. F., Macaskill, P., Barratt, A., Lewicka, M., Clarke, J., and Weisberg, E.. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: Evaluation of a decision aid to support informed choice. *Patient Education and Counseling*. 2008;73(3):473-481.

McCaffery, K., Waller, J., Forrest, S., Cadman, L., Szarewski, A., and Wardle, J.. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact.[Erratum appears in *BJOG*. 2004 Dec;111(12):1489]. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2004;111(12):1437-1443.

McGrath, C. M., Kurtis, J. D., and Yu, G. H.. Evaluation of mild-to-moderate dysplasia on cervical-endocervical (Pap) smear: A subgroup of patients who bridge LSIL and HSIL. *Diagnostic Cytopathology*. 2000;23(4):245-248.

Meijer, C. J. L. M., Berkhof, H., Heideman, D. A. M., Hesselink, A. T., and Snijders, P. J. F.. Validation of high-risk HPV tests for primary cervical screening. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S1-S4.

Meijer, C. J., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., Heideman, D. A., and Snijders, P. J.. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *International Journal of Cancer*. 2009;Journal international du cancer. 124(3):516-520.

Meissner, H. I., Tiro, J. A., Haggstrom, D., Lu-Yao, G., and Breen, N.. Does patient health and hysterectomy status influence cervical cancer screening in older women?. *Journal of General Internal*

Medicine. 2008;23(11):1822-1828.

Mesher, D., Szarewski, A., Cadman, L., Cubie, H., Kitchener, H., Luesley, D., Menon, U., Hulman, G., Desai, M., Ho, L., Terry, G., Williams, A., Sasieni, P., and Cuzick, J.. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: Results from the HART study. *British Journal of Cancer*. 2010;102(9):1405-1410.

Meyer, J. L., Hanlon, D. W., Andersen, B. T., Rasmussen, O. F., and Bisgaard, K.. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: Correlation with biopsy follow-up results. *Cancer*. 2007;111(2):83-92.

Milanova, E., Naumov, J., Nikolovska, E., and Damcevski, N.. Correlation of conventional and liquid-based cytology and their meaning in management of precancerous cervical lesions. *Akusherstvo i ginekologija*. 2005;44(1):60-62.

Miranda Pereira, S. M., Castelo, A., Makabe, S., Utagawa, M. L., Di Loreto C., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., Filho, A. L., and Das Dores, G. B.. Screening for cervical cancer in high-risk populations: DNA Pap test or hybrid capture II test alone?. *International Journal of Gynecological Pathology*. 2006;25(1):38-41.

Mo, L. Z., Monnier-Benoit, S., Kantelip, B., Petitjean, A., Riethmuller, D., Pretet, J. L., and Mouglin, C.. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2008;41(2):104-110.

Monsonogo, J., Bohbot, J. M., Pollini, G., Krawec, C., Vincent, C., Merignargues, I., Haroun, F., Sednaoui, P., Monfort, L., Dachez, R., and Syrjanen, K.. Performance of the Roche AMPLICOR Human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. *Gynecologic Oncology*. 2005;99(1):160-168.

Monsonogo, J., Pintos, J., Semaille, C., Beumont, M., Dachez, R., Zerat, L., Bianchi, A., and Franco, E.. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. *International Journal of Gynecological Cancer*. 2006;16(2):591-598.

Montemor, E. B. L., Roteli-Martins, C. M., Zeferino, L. C., Amaral, R. G., Fonseca-Carvasan, G. A., Shirata, N. K., Utagawa, M. L., Longatto-Filho, A., and Syrjanen, K. J.. Whole, turret and step methods of rapid rescreeing: Is there any difference in performance?. *Diagnostic Cytopathology*. 2007;35(1):57-60.

Moore, K. N. and Walker, J. L.. The abnormal pap test: Evaluation, treatment, and monitoring. *Journal of Clinical Outcomes Management*. 2006;13(4):235-244.

Moore, M. A. and Tajima, K.. Cervical cancer in the asian pacific-epidemiology, screening and treatment. *Asian Pacific journal of cancer prevention : APJCP*. 2004;5(4):349-361.

Moscicki, A.-B.. Cervical cytology screening in teens. *Current women's health reports*. 2003;3(6):433-437.

Moss, S., Gray, A., Legood, R., Vessey, M., Patnick, J., and Kitchener, H.. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: Observational before and after study. *British Medical Journal*. 2006;332(7533):83-85.

Moy, L. M., Zhao, F.-H., Li, L.-Y., Ma, J.-F., Zhang, Q.-M., Chen, F., Song, Y., Hu, S.-Y., Balasubramanian, A., Pan, Q.-J., Koutsky, L., Zhang, W.-H., Lim, J. M., Qiao, Y.-L., and Sellors, J. W.. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral. *International*

Journal of Cancer. 2010;127(3):646-656.

Nam, J.-H., Kim, H.-S., Lee, J.-S., Choi, H.-S., Min, K.-W., and Park, C.-S.. A comparison of modified MonoPrep2 of liquid-based cytology with ThinPrep Pap test. *Gynecologic Oncology*. 2004;94(3):693-698.

Nassar, A., O'Reilly, K., Cohen, C., and Siddiqui, M. T.. Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations. *Diagnostic Cytopathology*. 2008;36(3):142-148.

Negri, G., Menia, E., Egarter-Vigl, E., Vittadello, F., and Mian, C.. ThinPrep versus Conventional Papanicolaou Smear in the Cytologic Follow-Up of Women with Equivocal Cervical Smears. *Cancer*. 2003;99(6):342-345.

Negri, G., Rigo, B., Vittadello, F., Mian, C., and Egarter-Vigl, E.. Abnormal cervicovaginal cytology with negative human papillomavirus testing. *Cancer*. 2007;111(5):280-284.

no authors listed. Many unnecessary Pap smears are performed after hysterectomy. *Journal of Family Practice*. 2004;53(9):682.

Nofech-Mozes, S., Khalifa, M. M., Ismiil, N., Dube, V., Saad, R. S., Sun, P., Seth, A., and Ghorab, Z.. Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. *Applied Immunohistochemistry and Molecular Morphology*. 2010;18(1):80-85.

Nygard, J. F., Nygard, M., Skare, G. B., and Thoresen, S. O.. Pap smear screening in women under 30 in the Norwegian coordinated-cervical cancer screening program, with a comparison of immediate biopsy vs. pap smear triage of moderate dysplasia. *Acta Cytologica*. 2006;50(3):295-302.

Oliveira, E. R. Z. M., Derchain, S. F. M., Rabelo-Santos, S. H., Westin, M. C. A., Zeferino, L. C., Campos, E. A., and Syrjanen, K. J.. Detection of high-risk human papillomavirus (HPV) DNA by hybrid capture II in women referred due to atypical glandular cells in the primary screening. *Diagnostic Cytopathology*. 2004;31(1):19-22.

Onuma, K., Saad, R. S., Kanbour-Shakir, A., Kanbour, A. I., and Dabbs, D. J.. Clinical implications of the diagnosis "Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" in pregnant women. *Cancer*. 2006;108(5):282-287.

Orbell, S., Hagger, M., Brown, V., and Tidy, J.. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. *British Journal of Health Psychology*. 2004;9(4):533-555.

Ovanin-Rakic, A., Mahovlic, V., Audy-Jurkovic, I., Barisic, A., Skopljanac-Macina, L., Juric, D., Rajhvajn, S., Ilic-Forko, J., Babic, D., Folnovic, D., and Kani, D.. Cytology of cervical intraepithelial glandular lesions. *Collegium antropologicum*. 2010;34(2):401-406.

Pajtler, M., Milicic-Juhas, V., Milojkovic, M., Topolovec, Z., Curzik, D., and Mihaljevic, I.. Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2. *Collegium antropologicum*. 2010;34(1):81-86.

Papathanasiou, K., Daniilidis, A., Koutsos, I., Sardeli, C., Giannoulis, C., and Tzafettas, J.. Verification of the accuracy of cervical cytology reports in women referred for colposcopy. *European Journal of Gynaecological Oncology*. 2010;31(2):187-190.

Papillo, J. L., St.John, T. L., and Leiman, G.. Effectiveness of the ThinPrep Imaging System: Clinical experience in a low risk screening population. *Diagnostic Cytopathology*. 2008;36(3):155-160.

Park, J., Jung, E.-H., Kim, C., and Young, H. C.. Direct-to-vial comparison of a new liquid-based cytology system, Liqui-PREP versus the conventional Pap smear. *Diagnostic Cytopathology*.

2007;35(8):488-492.

Peng, Y. and Wang, H. H.. Impact of reflex HPV testing on interpretation and management of ThinPrep pap tests. *Diagnostic Cytopathology*. 2006;34(8):585-588.

Perovic, S.. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia. *Journal of B*. 2009;U.ON.. 14(1):93-96.

Pickett, K. E.. HPV triage was more sensitive than cytological monitoring for management of women with an ASCUS cervical screening result. *Evidence-based Obstetrics and Gynecology*. 2004;6(3):147-149.

Polednak, A. P.. Trends in late-stage breast and cervical cancer incidence rates in Connecticut (United States). *Cancer Causes and Control*. 2003;14(4):361-365.

Poljak, M., Kovanda, A., Kocjan, B. J., Seme, K., Jancar, N., and Vrtacnik-Bokal, E.. The Abbott RealTime High Risk HPV test: Comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. *Acta Dermatovenerologica Alpina, Pannonica et Adriatica*. 2009;18(3):94-103.

Power, P., Gregoire, J., Duggan, M., and Nation, J.. Low-grade pap smears containing occasional high-grade cells as a predictor of high-grade dysplasia. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC*. 2006;28(10):884-887.

Prandi, S., Beccati, D., De, Aloysio G., Fulgenzi, P., Gabrielli, M., Ghirardini, C., Rivasi, F., Saragoni, L., de Bianchi, P. S., and Bucchini, L.. Applicability of the Bethesda System 2001 to a public health setting. *Cancer*. 2006;108(5):271-276.

Proca, D. M., Williams, J. D., Rofagha, S., Tranovich, V. L., and Keyhani-Rofagha, S.. Improved rate of high-grade cervical intraepithelial neoplasia detection in human papillomavirus DNA hybrid capture testing. *Analytical and Quantitative Cytology and Histology*. 2007;29(4):264-270.

Puig-Tintore, L. M., Torne, A., and Alonso, I.. Current techniques in screening for cervical cancer in Spain: Updated recommendations. *Gynecologic Oncology*. 2008;110(3 SUPPL.2):S8-S10.

Quddus, M., Neves, T., Reilly, M., Steinhoff, M., and Sung, C.. Does the ThinPrep Imaging System increase the detection of high-risk HPV-positive ASC-US and AGUS the Women and Infants Hospital experience with over 200,000 cervical cytology cases. *CytoJournal*. 2009;6 , 2009. Article Number: 15. Date of Publication: 2009.

Raab, S. S., Jones, B. A., Souers, R., and Tworek, J. A.. The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance. *Archives of Pathology and Laboratory Medicine*. 2008;132(1):16-22.

Rabelo-Santos, S. H., Derchain, S. F. M., Do Amaral Westin, M. C., Angelo-Andrade, L. A. L., Sarian, L. O. Z., Oliveira, E. R. Z. M., Morais, S. S., and Zeferino, L. C.. Endocervical glandular cell abnormalities in conventional cervical smears: Evaluation of the performance of cytomorphological criteria and HPV testing in predicting neoplasia. *Cytopathology*. 2008;19(1):34-43.

Ramsaroop, R. and Chu, I.. Accuracy of diagnosis of atypical glandular cells - Conventional and ThinPrep. *Diagnostic Cytopathology*. 2006;34(9):614-619.

Reuschenbach, M., Clad, A., von Knebel, Doeberitz C., Wentzensen, N., Rahmsdorf, J., Schaffrath, F., Griesser, H., Freudenberg, N., and Von Knebel, Doeberitz M.. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. *Gynecologic Oncology*. 2010;119(1):98-105.

Rieck, G. C., Bhaumik, J., Beer, H. R., and Leeson, S. C.. Repeating cytology at initial colposcopy does

- not improve detection of high-grade abnormalities: A retrospective cohort study of 6595 women. *Gynecologic Oncology*. 2006;101(2):228-233.
- Riethmuller, D., Gabelle, C., Ramanah, R., Sautiere, J.-L., Pretet, J.-L., Schaal, J.-P., Kantelip, B., Mouglin, C., and Maillet, R.. Importance of human papillomavirus (HPV) screening in the follow-up after CIN2-3 treatment. A study of 386 cases. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2008;37(4):329-337.
- Rijkaart, D. C., Coupe, V. M. H., Van Kemenade, F. J., Heideman, D. A. M., Hesselink, A. T., Verweij, W., Rozendaal, L., Verheijen, R. H., Snijders, P. J., Berkhof, J., and Meijer, C. J. L. M.. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. *British Journal of Cancer*. 2010;103(7):939-946.
- Roberts, J. M. and Thurloe, J. K.. Comparative sensitivities of ThinPrep and papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): Comparison with HSIL. *Cancer*. 2007;111(6):482-486.
- Roberts, J. M., Thurloe, J. K., Bowditch, R. C., Hyne, S. G., Greenberg, M., Clarke, J. M., and Biro, C.. A three-armed trial of the thinprep imaging system. *Diagnostic Cytopathology*. 2007;35(2):96-102.
- Roghaei, M. A., Afshar, Moghaddam N., Pooladkhan, Sh, and Roghaie, Sh. Adequacy criteria and cytomorphological changes in liqui-prep TM versus conventional cervical cytology. *Shiraz E Medical Journal*. 2010;11(4):173-182.
- Rogoza, R. M., Ferko, N., Bentley, J., Meijer, C. J. L. M., Berkhof, J., Wang, K.-L., Downs, L., Smith, J. S., and Franco, E. L.. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. *Vaccine*. 2008;26(SUPPL.5):F46-F58.
- Rooney, C. M., Hopkins, M. P., Oza, R., Nelson, K., and Alford, W.. The Efficacy of the ThinPrep Pap Preparation Versus Conventional Means of Cervical Cancer Screening. *Journal of Pelvic Medicine and Surgery*. 2004;10(1):31-35.
- Rosenthal, D. L., Geddes, S., Trimble, C. L., Carson, K. A., and Alli, P. M.. The PapSpin: A reasonable alternative to other, more expensive liquid-based Papanicolaou tests. *Cancer*. 2006;108(3):137-143.
- Rossetti, D., Gerli, S., Saab, J.-C., and Di Renzo, G. C.. Atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) and histology. *Journal Medical Libanais*. 2000;48(3):127-130.
- Rossi, P. G., Baiocchi, D., Ciatto, S., Cariaggi, P., Gustinucci, D., Camilli, I., Mancini, E., Montanari, G., Caprioglio, A., Parisio, F., Angeloni, C., Di, Gabriele G., Carantoni, A., Tinacci, G., Matteucci, M., Pontani, G., Collina, G., Carmelo, M., Biavati, P., Schincaglia, P., Serafini, M., Palma, P. D., Polla, E., Scarfantonio, A. A., Schiboni, M. L., and Anghinoni, E.. Risk of CIN2 in women with a Pap test without endocervical cells vs. those with a negative Pap test with endocervical cells: A cohort study with 4.5 years of follow-up. *Acta Cytologica*. 2010;54(3):265-271.
- Rughooputh, S., Parmar, K., and Greenwell, P.. Detection of human papillomavirus from liquid-based cytology specimens by in-house PCR: A pilot study. *British Journal of Biomedical Science*. 2004;61(1):22-25.
- Rugpao, S., Koonlertkit, S., Ruengkrist, T., Lamlertkittikul, S., Pinjaroen, S., Limtrakul, A., Werawatakul, Y., and Sinchai, W.. ThinPrep Pap-smear and cervical intraepithelial neoplasia in reproductive-aged Thai women. *Journal of Obstetrics and Gynaecology Research*. 2009;35(3):551-554.
- Sabath, A. P. and Kiviat, N. B.. Detection and classification of cervical Neoplasia in the era of HPV.

Pathology Case Reviews. 2010;15(4):135-140.

Safaeian, M., Kiddugavu, M., Gravitt, P. E., Ssekasanvu, J., Murokora, D., Sklar, M., Serwadda, D., Wawer, M. J., Shah, K. V., and Gray, R.. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. *Sexually Transmitted Diseases*. 2007;34(7):429-436.

Sancho-Garnier, H.. Screening for breast and cervical cancers. [French]. *Oncologie*. 2002;4(8):493-498.

Saraiya, M., Berkowitz, Z., Yabroff, K. R., Wideroff, L., Kobrin, S., and Benard, V.. Cervical cancer screening with both human papillomavirus and papanicolaou testing vs papanicolaou testing alone: What screening intervals are physicians recommending?. *Archives of Internal Medicine*. 2010;170(11):977-986.

Saraiya, M., Martinez, G., Glaser, K., and Kulasingam, S.. Pap testing and sexual activity among young women in the united states. *Obstetrics and Gynecology*. 2009;114(6):1213-1219.

Sargent, A., Bailey, A., Turner, A., Almonte, M., Gilham, C., Baysson, H., Peto, J., Roberts, C., Thomson, C., Desai, M., Mather, J., and Kitchener, H.. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: Data from the ARTISTIC trial. *Journal of Clinical Microbiology*. 2010;48(2):554-558.

Sarode, V. R., Werner, C., Gander, R., Foster, B., Fulmer, A., Saboorian, M. H., and Ashfaq, R.. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: Focus on age-stratified clinical performance. *Cancer*. 2003;99(3):149-155.

Sass, M. A.. Use of A Liquid-Based, Thin-Layer Pap Test in A Community Hospital: Impact on Cytology Performance and Productivity. *Acta Cytologica*. 2004;48(1):17-22.

Sayed, K., Korourian, S., Ellison, D. A., Kozlowski, K., Talley, L., Horn, H. V., Simpson, P., and Parham, D. M.. Diagnosing cervical biopsies in adolescents: The use of p16 immunohistochemistry to improve reliability and reproducibility. *Journal of Lower Genital Tract Disease*. 2007;11(3):141-146.

Scheiden, R., Knolle, U., Wagener, C., Wehenkel, A. M., and Capesius, C.. Cervical cancer screening in Luxembourg. *European Journal of Cancer*. 2000;36(17):2240-2243.

Schenck, U. and von, Karsa L.. Cervical cancer screening in Germany. *European Journal of Cancer*. 2000;36(17):2221-2226.

Schiffman, M., Khan, M. J., Solomon, D., Herrero, R., Wacholder, S., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Wheeler, C. M., and Burk, R. D.. A study of the impact of adding HPV types to cervical cancer screening and triage test. *Journal of the National Cancer Institute*. 2005;97(2):147-150.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Improvement of diagnostic accuracy and screening conditions with liquid-based cytology. *Diagnostic Cytopathology*. 2006;34(11):780-785.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Significance of atypia in conventional Papanicolaou smears and liquid-based cytology: A follow-up study. *Cytopathology*. 2004;15(3):148-153.

Schneede, P., Hillemanns, P., Ziller, F., Hofstetter, A., Stockfleth, E., Arndt, R., and Meyer, T.. Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening. *Acta Obstetrica et Gynecologica Scandinavica*. 2001;80(8):750-752.

Schneider, A., Gleizes, O., Nieminen, P., Erdemoglu, E., Boselli, F., and Jenkins, D.. Implications of varied patterns of cervical cancer screening for introduction of human papillomavirus vaccines in Europe. *Journal of the Turkish German Gynecology Association Artemis*. 2009;10(2):61-67.

Schneider, A., Hoyer, H., Lotz, B., Leistritz, S., Kuhne-Heid, R., Nindl, I., Muller, B., Haerting, J., and Durst, M.. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk

HPV, routine cytology or colposcopy. *International Journal of Cancer*. 2000;89(6):529-534.

Schopp, B., Holz, B., Zago, M., Stubenrauch, F., Petry, K.-U., Kjaer, S. K., and Iftner, T.. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. *Journal of Medical Virology*. 2010;82(4):605-615.

Segnan, N., Ronco, G., and Ciatto, S.. Cervical cancer screening in Italy. *European Journal of Cancer*. 2000;36(17):2235-2239.

Sehgal, A. and Singh, V.. Human papillomavirus infection (hpv) & screening strategies for cervical cancer. *Indian Journal of Medical Research*. 2009;130(3):234-240.

Sharp, L. K., Zurawski, J. M., Roland, P. Y., O'Toole, C., and Hines, J.. Health literacy, cervical cancer risk factors, and distress in low-income African-American women seeking colposcopy. *Ethnicity & disease*. 2002;12(4):541-546.

Sharpless, K. E., O'Sullivan, D. M., and Schnatz, P. F.. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. *Journal of Lower Genital Tract Disease*. 2009;13(2):72-78.

Shastri, S. S., Dinshaw, K., Amin, G., Goswami, S., Patil, S., Chinoy, R., Kane, S., Kelkar, R., Muwonge, R., Mahe, C., Ajit, D., and Sankaranarayanan, R.. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. *Bulletin of the World Health Organization*. 2005;83(3):186-194.

Shastri, S. S.. Cervical cancer screening and vaccination in India. *Indian journal of medical ethics*. 2010;7(1):41-43.

Sheriff, S. K., Petry, K. U., Ikenberg, H., Crouse, G., Mazonson, P. D., and Santas, C. C.. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany. *European Journal of Health Economics*. 2007;8(2):153-160.

Sherlaw-Johnson, C. and Philips, Z.. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. *British Journal of Cancer*. 2004;91(1):84-91.

Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., Schiffman, M., and Helmerhorst, T.. Pap smear and HPV testing in combination were more accurate than either test alone for predicting the future development of CIN3 or cervical cancer. *Evidence-based Obstetrics and Gynecology*. 2003;5(3):137-138.

Shinn, E., Basen-Engquist, K., Le, T., Hansis-Diarte, A., Bostic, D., Martinez-Cross, J., Santos, A., and Follen, M.. Distress after an abnormal Pap smear result: Scale development and psychometric validation. *Preventive Medicine*. 2004;39(2):404-412.

Siddiqi, A., Spataro, M., McIntire, H., Akhtar, I., Baliga, M., Flowers, R., Lin, E., and Guo, M.. Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance Papanicolaou results in SurePath and ThinPrep specimens. *Cancer cytopathology*. 2009;117(5):318-325.

Siddiqui, M. T., Cohen, C., and Nassar, A.. Detecting high-grade cervical disease on ASC-H cytology: Role of BD ProEx C and digene hybrid capture II HPV DNA testing. *American journal of clinical pathology*. 2008;130(5):765-770.

Siebert, U., Sroczynski, G., Hillemanns, P., Engel, J., Stabenow, R., Stegmaier, C., Voigt, K., Gibis, B., Holzel, D., and Goldie, S. J.. The German Cervical Cancer Screening Model: Development and validation of a decision-analytic model for cervical cancer screening in Germany. *European Journal of*

Public Health. 2006;16(2):185-192.

Silverloo, I., Andrae, B., and Wilander, E.. Value of high-risk HPV-DNA testing in the triage of ASCUS. *Acta Obstetrica et Gynecologica Scandinavica*. 2009;88(9):1006-1010.

Sireci, A. N., Crapanzano, J. P., Mansukhani, M., Wright, T., Babiac, A., Erroll, M., Vazquez, M., and Saqi, A.. Atypical Glandular Cells (AGC): ThinPrep Imaging System (TIS), Manual Screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. *Diagnostic Cytopathology*. 2010;38(10):705-709.

Sirovich, B. E. and Welch, H. G.. The frequency of Pap smear screening in the United States. *Journal of General Internal Medicine*. 2004;19(3):243-250.

Sirovich, B. E., Gottlieb, D. J., and Fisher, E. S.. The burden of prevention: Downstream consequences of Pap smear testing in the elderly. *Journal of medical screening*. 2003;10(4):189-195.

Smith, J. H. F.. The future of cervical screening in the UK. *Diagnostic Histopathology*. 2009;15(7):330-334.

Sodhani, P., Gupta, S., Singh, V., Sehgal, A., Halder, K., and Parashari, A.. Sensitivity of the pap test in detecting high grade lesions: What should be the acceptable cytologic threshold for colposcopic referral?. *Acta Cytologica*. 2006;50(2):181-184.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Acta Cytologica*. 2009;53(3):247-248.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *American journal of clinical pathology*. 2009;131(6):768-769.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Diagnostic Cytopathology*. 2009;37(7):542-543.

Solomon, D., Papillo, J., and Davis, Davey D.. Statement on HPV DNA test utilization. *Journal of Lower Genital Tract Disease*. 2009;13(3):135-136.

Solomon, D.. Chapter 14: Role of triage testing in cervical cancer screening. *Journal of the National Cancer Institute*. 2003;Monographs.(31):97-101.

Son, S., Noh, H. T., and An, S.. Human papillomavirus status in cervical scrapes and biopsy specimens using the HPV genotyping DNA microarray. *International Journal of Gynecology and Obstetrics*. 2006;93(3):258-259.

Soutter, W. P., Butler, J. S., and Tipples, M.. The role of colposcopy in the follow up of women treated for cervical intraepithelial neoplasia. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2006;113(5):511-514.

Sowjanya, A. P., Paul, P., Vedantham, H., Ramakrishna, G., Vidyadhari, D., Vijayaraghavan, K., Lakshmi, S., Sudula, M., Ronnett, B. M., Das, M., Shah, K. V., and Gravitt, P. E.. Suitability of self-collected vaginal samples for cervical cancer screening in Periurban Villages in Andhra Pradesh, India. *Cancer Epidemiology Biomarkers and Prevention*. 2009;18(5):1373-1378.

Spiryda, L. B., Brown, M., Creek, K. E., and Pirisi-Creek, L.. HSIL pap test and risk factors predicting acquisition of CIN 2/3 on colposcopy-directed biopsies. *Journal of the South Carolina Medical Association (1975)*. 2009;105(7):281-286.

Srodon, M., Parry, Dilworth H., and Ronnett, B. M.. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results. *Cancer*. 2006;108(1):32-38.

Stamataki, P., Papazafiropoulou, A., Elefsiniotis, I., Giannakopoulou, M., Brokalaki, H.,

- Apostolopoulou, E., Sarafis, P., and Saroglou, G.. Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. *BMC infectious diseases*. 2010;10:27.
- Stein, S. R.. ThinPrep versus the conventional Papanicolaou test: A review of specimen adequacy, sensitivity, and cost-effectiveness. *Primary Care Update for Ob/Gyns*. 2003;10(6):310-313.
- Stensson, E., Frberg, M., Hjerpe, A., Zethraeus, N., and Andersson, S.. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. *Acta Obstetrica et Gynecologica Scandinavica*. 2010;89(10):1316-1325.
- Stinnett, B. A.. Use of Psychosocial Effects of Abnormal Pap Smears Questionnaire (PEAPS-Q) in a community hospital colposcopy clinic. *Journal of Lower Genital Tract Disease*. 2000;4(1):34-39.
- Streiner, D. L. and Norman, G. R.. Mass screening: When does it make sense?. *Community Oncology*. 2010;7(2):93-95.
- Symonds, I. M.. Screening for gynaecological conditions. *Foundation Years*. 2007;3(6):263-267.
- Syrjanen, K., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Hammes, L. S., Sarian, L., Naud, P., Tatti, S., Branca, M., Erzen, M., Matos, J., Gontijo, R., Braganca, J., Arlindo, F., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among Latin American Women < 35 and >= 35 years of age: Experience from the Latin American Screening Study. *Acta Cytologica*. 2008;52(6):641-653.
- Syrjanen, K., Naud, P., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Hammes, L. S., Matos, J., Gontijo, R., Sarian, L., Braganca, J., Arlindo, F. C., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. *Anticancer Research*. 2005;25(5):3469-3480.
- Szarewski, A., Ambroisine, L., Cadman, L., Austin, J., Ho, L., Terry, G., Liddle, S., Dina, R., McCarthy, J., Buckley, H., Bergeron, C., Soutter, P., Lyons, D., and Cuzick, J.. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(11):3033-3042.
- Szarewski, A.. Cervical screening by visual inspection with acetic acid. *Lancet*. 2007;370(9585):365-366.
- Tang, N., Huang, S., Erickson, B., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S25-S28.
- Taoka, H., Yamamoto, Y., Sakurai, N., Fukuda, M., Asakawa, Y., Kurasaki, A., Oharaseki, T., and Kubushiro, K.. Comparison of conventional and liquid-based cytology, and human papillomavirus testing using SurePath preparation in Japan. *Human Cell*. 2010;23(4):126-133.
- Terret, C., Castel-Kremer, E., Albrand, G., and Droz, J. P.. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. *The Lancet Oncology*. 2009;10(1):80-87.
- Thiryayi, S. A., Marshall, J., and Rana, D. N.. An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia. *Cytopathology*. 2010;21(4):223-228.
- Thiryayi, S. A., Marshall, J., and Rana, D. N.. Differentiating between endocervical glandular neoplasia and high grade squamous intraepithelial lesions in endocervical crypts: Cytological features in ThinPrep

and SurePath cervical cytology samples. *Diagnostic Cytopathology*. 2009;37(5):315-319.

Thrall, M. J., Pambuccian, S. E., Stelow, E. B., McKeon, D. M., Miller, L., Savik, K., and Gulbahce, H. E.. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda system on the sensitivity and specificity of the papanicolaou test: A 5-year follow-up study of papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria. *Cancer*. 2008;114(3):171-179.

Thrall, M. J., Russell, D. K., Facik, M. S., Yao, J. L., Warner, J. N., Bonfiglio, T. A., and Giampoli, E. J.. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. *American journal of clinical pathology*. 2010;133(6):894-898.

Thrall, M. J., Smith, D. A., and Mody, D. R.. Women ≥ 30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: Should we reconsider HPV triage for LSIL in older women?. *Diagnostic Cytopathology*. 2010;38(6):407-412.

Thrall, M., Kjeldahl, K., Gulbahce, H. E., and Pambuccian, S. E.. Liquid-based papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: Study of 272 cases classified by the 2001 Bethesda system. *Cancer*. 2007;111(4):217-223.

Tiews, S., Steinberg, W., Schneider, W., and Hanrath, C.. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: Preliminary data. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S11-S15.

Tinelli, A., Leo, G., Pisano, M., Storelli, F., Leo, S., Vergara, D., and Malvasi, A.. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. *Current Pharmaceutical Biotechnology*. 2009;10(8):767-771.

Treacy, A., Reynolds, J., Kay, E. W., Leader, M., and Grace, A.. Has the ThinPrep Method of Cervical Screening Maintained Its Improvement Over Conventional Smears in terms of Specimen Adequacy?. *Diagnostic Cytopathology*. 2009;37(4):239-240.

Troni, G. M., Cipparrone, I., Cariaggi, M. P., Ciatto, S., Miccinesi, G., Zappa, M., and Confortini, M.. Detection of false-negative pap smears using the PAPNET system. *Tumori*. 2000;86(6):455-457.

Tsai, H.-T., Tsai, Y.-M., Yang, S.-F., Lee, C.-H., Lin, L.-Y., Lee, S., and Wu, M.-T.. A notable accessory screening program for detection of cervical intraepithelial neoplasia. *Pathologie Biologie*. 2009;57(6):477-482.

Tuncer, Z. S., Basaran, M., Sezgin, Y., Firat, P., and Kuzey, G. M.. Clinical results of a split sample liquid-based cytology (ThinPrep) study of 4,322 patients in a Turkish institution. *European Journal of Gynaecological Oncology*. 2005;26(6):646-648.

Uyar, D. S., Eltabbakh, G. H., and Mount, S. L.. Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant. *Gynecologic Oncology*. 2003;89(2):227-232.

Valdini, A. and Esielionis, P.. Measurement of colposcopy-associated distress using the psychosocial effects of having an abnormal pap smear-questionnaire in a Latina population. *Journal of Lower Genital Tract Disease*. 2004;8(1):25-32.

Varnai, A. D., Bollmann, M., Bankfalvi, A., Speich, N., Schmitt, C., Griefingholt, H., Kovacs, K., Klozoris, C., and Bollmann, R.. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: Diagnostic and prognostic implications. *Oncology Reports*. 2008;19(2):457-465.

Vijayaraghavan, A., Efrusy, M. B., Mayrand, M. H., Santas, C. C., and Goggin, P.. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. *Canadian Journal of Public Health*. 2010;Revue canadienne de sante publique. 101(3):220-225.

Vijayaraghavan, A., Efrusy, M., Lindeque, G., Dreyer, G., and Santas, C.. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. *Gynecologic Oncology*. 2009;112(2):377-383.

Vollmer, R. T.. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. *Cancer*. 10-25-2002;96(5):316-318.

Voskanyan, M. A.. Precancerous cervical lesions: Diagnosis and treatment. *New Armenian Medical Journal*. 2009;3(3):49-56.

Voss, J. S., Kipp, B. R., Campion, M. B., Sokolova, I. A., Henry, M. R., Halling, K. C., and Clayton, A. C.. Assessment of fluorescence in situ hybridization and hybrid capture 2 analyses of cervical cytology specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia. *Analytical and Quantitative Cytology and Histology*. 2010;32(3):121-130.

Vrtacnik-Bokal, E., Rakar, S., Jancar, N., Mozina, A., and Poljak, M.. Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions. *European Journal of Gynaecological Oncology*. 2005;26(4):427-430.

Walter, L. C., Lewis, C. L., and Barton, M. B.. Screening for colorectal, breast, and cervical cancer in the elderly: A review of the evidence. *American Journal of Medicine*. 2005;118(10):1078-1086.

Wang, K. L., Jeng, C. J., Yang, Y. C., Chen, C. A., Cheng, W. F., Chen, T. C., Mast, T. C., Wang, Y. C., and Hsieh, C. Y.. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. *Journal of Psychosomatic Obstetrics & Gynecology*. 2010;31(1):16-23.

Wang, X., Zheng, B., Li, S., Zhang, R., Mulvihill, J. J., Chen, W. R., and Liu, H.. Automated detection and analysis of fluorescent in situ hybridization spots depicted in digital microscopic images of Pap-smear specimens. *Journal of biomedical optics*. 2009;14(2):021002-021Apr.

Warman, J.. Cervical cancer screening in young women: saving lives with prevention and detection. *Oncology nursing forum*. 2010;37(1):33-38.

Warren, J. B., Gullett, H., and King, V. J.. Cervical Cancer Screening and Updated Pap Guidelines. *Primary Care - Clinics in Office Practice*. 2009;36(1):131-149.

Wells, S. F.. Cervical cancer: an overview with suggested practice and policy goals. *Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses*. 2008;17(1):43-50.

Wentzensen, N., Bergeron, C., Cas, F., Vinokurova, S., and Von Knebel, Doeberitz M.. Triage of women with ASCUS and LSIL cytology: Use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. *Cancer*. 2007;111(1):58-66.

Wentzensen, N., Hampl, M., Herkert, M., Reichert, A., Trunk, M. J., Poremba, C., Ridder, R., and Von Knebel, Doeberitz M.. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. *Cancer*. 2006;107(9):2307-2313.

Werner, C. L., Griffith III, W. F., Ashfaq, R., Gossett, D., Wilkinson, E., Raab, S., Bambot, S., Mongin, D., and Faupel, M.. Comparison of human papilloma virus testing and spectroscopy combined with cervical cytology for the detection of high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2007;11(2):73-79.

- Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., Markman, M., Mayer, R., Pfister, D., Raghavan, D., Ramsey, S., Reaman, G., Sandler, H., Sawaya, R., Schuchter, L., Sweetenham, J., Vahdat, L., Schilsky, R. L., and Sweet, D.. Clinical cancer advances 2008: Major research advances in cancer treatment, prevention, and screening-a report from the american society of clinical oncology. *Journal of Clinical Oncology*. 2009;27(5):812-826.
- Witt, A., Hudelist, G., Gregor, H., Kucera, E., Walchetseder, C., and Czerwenka, K.. The detection of HPV DNA improves the recognition of cervical intraepithelial lesions. *Archives of Gynecology and Obstetrics*. 2003;268(1):29-34.
- Wong, A. K., Chan, R. C., Nichols, W. S., and Bose, S.. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance. *Cancer*. 2009;115(4):823-832.
- Wongworapat, K., Keawvichit, R., Sirojorn, B., Dokuta, S., Ruangyuttikarn, C., Sriplienchan, S., Sontirat, A., Kla, K. T., Gravitt, P. E., and Celentano, D. D.. Detection of human papillomavirus from self-collected vaginal samples of women in Chiang Mai, Thailand. *Sexually Transmitted Diseases*. 2008;35(2):172-173.
- Wood, M. D., Horst, J. A., and Bibbo, M.. Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based pap tests: A review. *Diagnostic Cytopathology*. 2007;35(1):12-17.
- Wright, P. K., Marshall, J., and Desai, M.. Comparison of SurePath and ThinPrep liquid-based cervical cytology using positive predictive value, atypical predictive value and total predictive value as performance indicators. *Cytopathology*. 2010;21(6):374-378.
- Wu, S. F., Meng, L., Wang, S. X., and Ma, D.. A comparison of four screening methods for cervical neoplasia. *International Journal of Gynecology and Obstetrics*. 2005;91(2):189-193.
- Yang, B., Pretorius, R. G., Belinson, J. L., Zhang, X., Burchette, R., and Qiao, Y.-L.. False negative colposcopy is associated with thinner cervical intraepithelial neoplasia 2 and 3. *Gynecologic Oncology*. 2008;110(1):32-36.
- Yapijakis, C., Adamopoulou, M., Antonopoulos, G., Koufaliotis, N., and Vairaktaris, E.. Prevalence of HPV types in a cohort of greeks with clinical indication of infection. *Anticancer Research*. 2008;28(4 B):2233-2237.
- Yeoh, G. P. S., Tse, M. P. Y., Chan, K. W., and Lord, L.. Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and follow-up patient group. *Acta Cytologica*. 2006;50(6):627-631.
- Yoon, J. H., Yoo, S. C., Kim, W. Y., Chang, S. J., Chang, K. H., and Ryu, H. S.. Role of HPV DNA testing for detection of high-grade cervical lesions in women with atypical squamous cells of undetermined significance: A prospective study in a Korean population. *European Journal of Gynaecological Oncology*. 2009;30(3):271-274.
- Yuan, Q. and Wilbur, D. C.. Original cervical cytology and follow-up biopsy results in positive high risk human papillomavirus DNA tests with high-level results. *Acta Cytologica*. 2008;52(5):557-562.
- Zhao, C. and Austin, R. M.. High-risk human papillomavirus DNA test results are useful for disease risk stratification in women with unsatisfactory liquid-based cytology pap test results. *Journal of Lower Genital Tract Disease*. 2009;13(2):79-84.
- Zhao, C., Florea, A., and Austin, R. M.. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. *Archives of pathology & laboratory medicine*. 2010;134(1):103-108.
- Zhao, C., Florea, A., Onisko, A., and Austin, R. M.. Histologic follow-up results in 662 patients with

Pap test findings of atypical glandular cells: Results from a large academic womens hospital laboratory employing sensitive screening methods. *Gynecologic Oncology*. 2009;114(3):383-389.

Zhu, J., Norman, I., Elfgrén, K., Gaberi, V., Hagmar, B., Hjerpe, A., and Andersson, S.. A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. *Oncology Reports*. 2007;18(1):157-160.

Level 2: Answered No

. Committee opinion no. 356: Routine cancer screening. *Obstetrics and Gynecology*. 2006;108(6):1611-1613.

. Erratum: Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness (*Journal of the American Medical Association* (June 27, 2001) 285 (3107-3115)). *Journal of the American Medical Association*. 2001;286(9):1026-.

. Everything you know about cervical cancer screening in Alberta just changed. *Alberta RN / Alberta Association of Registered Nurses*. 2009;65(9):10-11.

. HPV genotyping clinical update. *Journal of Family Practice*. 2009;58(9):S8-S10.

. In South Africa, having one pap smear lowers women's chances of cervical cancer. *International family planning perspectives*. 2003;29(4):196-.

. Is liquid-based cytology better than Pap tests for CIN 2?. *Journal of Family Practice*. 2008;57(4):218-.

. Liquid-based not better than conventional Pap. *Journal of Family Practice*. 2006;55(4):284-.

. Pap test update. New guidelines reflect new evidence. *Mayo Clinic women's healthsource*. 2003;7(5):1-2.

. Update: cervical cancer screening. *AWHONN lifelines / Association of Women's Health, Obstetric and Neonatal Nurses*. 2003;7(2):116-117.

Abulafia, O., Pezzullo, J. C., and Sherer, D. M.. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: A quantitative survey. *Gynecologic Oncology*. 2003;90(1):137-144.

Adab, P., McGhee, S. M., Yanova, J., Wong, C. M., and Hedley, A. J.. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. *Medical Care*. 2004;42(6):600-609.

Agorastos, T., Dinas, K., Lloveras, B., De, Sanjose S., Kornegay, J. R., Bonti, H., Bosch, F. X., Constantinidis, T., and Bontis, J.. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. *Gynecologic Oncology*. 2005;96(3):714-720.

Agorastos, T., Sotiriadis, A., and Emmanouilides, C. J.. Effect of type-specific human papillomavirus incidence on screening performance and cost. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010;20(2):276-282.

Aklimunnessa, K., Mori, M., Khan, M. M. H., Sakauchi, F., Kubo, T., Fujino, Y., Suzuki, S., Tokudome, S., and Tamakoshi, A.. Effectiveness of cervical cancer screening over cervical cancer mortality among Japanese women. *Japanese journal of clinical oncology*. 2006;36(8):511-518.

Almonte, M., Ferreccio, C., Winkler, J. L., Cuzick, J., Tsu, V., Robles, S., Takahashi, R., and Sasieni, P.. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. *International Journal of Cancer*. 2007;121(4):796-802.

Anderson, R., Haas, M., and Shanahan, M.. The cost-effectiveness of cervical screening in Australia: What is the impact of screening at different intervals or over a different age range?. *Australian and New*

Zealand Journal of Public Health. 2008;32(1):43-52.

Andersson, S., Dillner, L., Elfgrén, K., Mints, M., Persson, M., and Rylander, E.. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. *Acta Obstetrica et Gynecologica Scandinavica*. 2005;84(10):996-1000.

Andrae, B., Kemetli, L., Sparen, P., Silfverdal, L., Strander, B., Ryd, W., Dillner, J., and Tornberg, S.. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. *Journal of the National Cancer Institute*. 2008;100(9):622-629.

Andy, C. and Turner, L. F.. Is the ThinPrep better than conventional Pap smear at detecting cervical cancer?. *Journal of Family Practice*. 2004;53(4):313-316.

Anttila, A., Ronco, G., Clifford, G., Bray, F., Hakama, M., Arbyn, M., and Weiderpass, E.. Cervical cancer screening programmes and policies in 18 European countries. *British Journal of Cancer*. 2004;91(5):935-941.

Arbyn, M., Simoons, C., Buntinx, F., Martin-Hirsch, P. P. L., Paraskevaidis, E., and Prendiville, W. J. P.. Triage with human papillomavirus (HPV) testing versus repeat cytology for underlying high-grade cervical intraepithelial neoplasia in women with minor cytological lesions. *Cochrane Database of Systematic Reviews*. 2009;#volume#(4):-.

Arias, Y. R., Carrillo, E. F., and Aristizabal, F. A.. Human papillomavirus (HPV) detected in restored plasma DNA from women diagnosed with pre-invasive lesions and invasive cervical cancer. *Colombia Medica*. 2010;41(2):148-154.

Baay, M. F. D., Tjalma, W. A. A., Lambrechts, H. A. J., Pattyn, G. G. O., Lardon, F., Weyler, J., Van Royen P., Van Marck, E. A. E., and Vermorken, J. B.. Combined Pap and HPV testing in primary screening for cervical abnormalities: Should HPV detection be delayed until age 35?. *European Journal of Cancer*. 2005;41(17):2704-2708.

Bach, P. B.. Gardasil: from bench, to bedside, to blunder. *The Lancet*. 2010;375(9719):963-964.

Baileff, A.. Cervical screening: patients' negative attitudes and experiences. *Nursing standard (Royal College of Nursing (Great Britain))* : 1987). 2000;14(44):35-37.

Balasubramanian, A., Kulasingam, S. L., Baer, A., Hughes, J. P., Myers, E. R., Mao, C., Kiviat, N. B., and Koutsky, L. A.. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. *Journal of Lower Genital Tract Disease*. 2010;14(3):185-195.

Bandyopadhyay, S., Austin, R. M., Dabbs, D., and Zhao, C.. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. *Archives of Pathology and Laboratory Medicine*. 2008;132(12):1874-1881.

Bano, F., Kolhe, S., Zamblera, D., Jolaoso, A., Folayan, O., Page, L., and Norton, J.. Cervical screening in under 25s: A high-risk young population. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2008;139(1):86-89.

Baseman, J. G., Kulasingam, S. L., Harris, T. G., Hughes, J. P., Kiviat, N. B., Mao, C., and Koutsky, L. A.. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. *American Journal of Obstetrics and Gynecology*. 2008;199(1):26-26.

Basu, P. and Chowdhury, D.. Cervical cancer screening & HPV vaccination: A comprehensive approach to cervical cancer control. *Indian Journal of Medical Research*. 2009;130(3):241-246.

Becker, N.. Epidemiological aspects of cancer screening in Germany. *Journal of cancer research and*

clinical oncology. 2003;129(12):691-702.

Beerman, H., van Dorst, E. B. L., Kuenen-Boumeester, V., and Hogendoorn, P. C. W.. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. *Gynecologic Oncology*. 2009;112(3):572-576.

Benevolo, M., Vocaturo, A., Mottolese, M., Mariani, L., Vocaturo, G., Marandino, F., Sperduti, I., Rollo, F., Antoniani, B., and Donnorso, R. P.. Clinical role of p16INK4a expression in liquid-based cervical cytology: correlation with HPV testing and histologic diagnosis. *American journal of clinical pathology*. 2008;129(4):606-612.

Bergeron, C., Cas, F., Fagnani, F., Contrepas, A., Wadier, R., and Poveda, J. D.. Assessment of human papillomavirus testing on liquid-based Cyto-screen system for women with atypical squamous cells of undetermined significance. Effect of age. [French]. *Gynecologie, obstetrique & fertilité*. 2006;34(4):312-316.

Bergeron, C., Cas, F., Fagnani, F., Didaiiller-Lambert, F., and Poveda, J. D.. Human papillomavirus testing with a liquid-based system: Feasibility and comparison with reference diagnoses. *Acta Cytologica*. 2006;50(1):16-22.

Bergeron, C., Clavel, C., Crott, M. R., Hill, C., Jaury, P., Lehr-Drylewicz, A.-M., Leroy, J.-L., Lunel, F., Monsonogo, J., Mouglin, C., Orth, G., Petitjean, A., De, Reilhac P., Riethmuller, D., Sancho-Garnier, H., Sevestre, H., D'Alche-Gautier, M.-J., Agius, G., Arbyn, M., Birembaut, P., Baldauf, J.-J., Bonnier, P., Boulanger, J.-C., Boman, F., Cayrol, M.-H., Charpentier, J.-M., Cochand-Priollet, B., Dalstein, V., Duport, N., Fournier, A., Guyot, H., Halfon, P., Mergui, J.-L., Morice, P., Mousteou, F., Querleu, D., Sastre-Garau, X., Sauthier, P., and Vacher-Lavenu, M.-C.. Usefulness of searching for human papillomavirus (HPV): Evaluation of screening practices for precancerous lesions of the uterine cervix. [French]. *Annales de pathologie*. 2005;25(2):173-177.

Bergeron, C., Jeannel, D., Poveda, J., Cassonnet, P., and Orth, G.. Human papillomavirus testing in women with mild cytologic atypia. *Obstetrics and Gynecology*. 2000;95(6 Pt 1):821-827.

Bergeron, C.. Screening and early diagnosis of cervical cancer in a context of HPV vaccination. [French]. *Revue du Praticien*. 2010;60(2):214-215.

Berkhof, J., De Bruijne, M. C., Zielinski, G. D., and Meijer, C. J. L. M.. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. *International Journal of Cancer*. 2005;115(2):268-275.

Bhatla, N. and Moda, N.. The clinical utility of HPV DNA testing in cervical cancer screening strategies. *Indian Journal of Medical Research*. 2009;130(3):261-265.

Bhatla, N., Gulati, A., Mathur, S. R., Rani, S., Anand, K., Muwonge, R., and Sankaranarayanan, R.. Evaluation of cervical screening in rural North India. *International Journal of Gynaecology & Obstetrics*. 2009;105(2):145-149.

Bibliograph

Blake, G., Hanchard, B., Gibson, T., Wolff, C., Samuels, E., Waugh, N., and Simpson, D.. Gynaecologic cancer incidence, Kingston and St Andrew, Jamaica, 1973-1997, and gynaecologic cancer mortality, Jamaica, 1999. *West Indian Medical Journal*. 2003;52(4):273-277.

Blanks, R. G. and Kelly, R. S.. Comparison of cytology and histology results in English cervical screening laboratories before and after liquid-based cytology conversion: Do the data provide evidence for a single category of high-grade dyskaryosis?. *Cytopathology*. 2010;21(6):368-373.

Blanks, R. G., Moss, S. M., Addou, S., Coleman, D. A., and Swerdlow, A. J.. Risk of cervical abnormality after age 50 in women with previously negative smears. *British Journal of Cancer*.

2009;100(11):1832-1836.

Boardman, L. A., Weitzen, S., and Stanko, C.. Atypical squamous cells of undetermined significance, human papillomavirus, and cervical intraepithelial neoplasia 2 or 3 in adolescents: ASC-US, age, and high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2006;10(3):140-145.

Bolanca, I. K. and Vranes, J.. Diagnostic methods and techniques in preventing cervical carcinoma. Part I: Conventional cytology and new cytological methods. *Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina*. 2010;7(1):12-17.

Bollmann, R., Bankfalvi, A., Griefingholt, H., Trosic, A., Speich, N., Schmitt, C., and Bollmann, M.. Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: results from 31031 women from the Bonn-region in West Germany. *Oncology Reports*. 2005;13(5):915-922.

Bond, S.. Conventional Glass Slide Pap Smears are as Accurate as Liquid-Based Tests in Detecting Cervical Disease. *Journal of Midwifery and Women's Health*. 2008;53(4):395-396.

Boschert, S.. ACOG changes cervical Ca recommendations. *Oncology Report*. 2010;#volume#(JANUARY-FEBRUARY):23-.

Braganca, J. F., Derchain, S. F., Sarian, L. O., Messias Da Silva, S. M., Labatte, S., and Zeferino, L. C.. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions. *Clinical and Experimental Obstetrics and Gynecology*. 2005;32(4):225-229.

Bray, F., Loos, A. H., McCarron, P., Weiderpass, E., Arbyn, M., Moller, H., Hakama, M., and Parkin, D. M.. Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. *Cancer Epidemiology Biomarkers and Prevention*. 2005;14(3):677-686.

Brink, A. A. T. P., Snijders, P. J. F., and Meijer, C. J. L. M.. HPV detection methods. *Disease Markers*. 2007;23(4):273-281.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, A. J. P., Verheijen, R. H. M., Snijders, P. J. F., and Meijer, C. J. L. M.. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. *International Journal of Cancer*. 2007;121(2):361-367.

Bulk, S., Bulkman, N. W. J., Berkhof, J., Rozendaal, L., Boeke, J. P., and Verheijen, R. H. M.. Erratum: Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing and at 6-month (International Journal Cancer (2007) 121, (361-367)). *International Journal of Cancer*. 2007;121(8):1873-.

Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H. M., and Meijer, C. J. L. M.. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. *International Journal of Cancer*. 2005;113(6):1005-1009.

Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H. M., and Meijer, C. J. L. M.. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. *British Journal of Cancer*. 2003;89(5):834-839.

Bulkman, N. W. J., Rozendaal, L., Voorhorst, F. J., Snijders, P. J. F., and Meijer, C. J. L. M.. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. *British Journal of Cancer*. 2005;92(9):1800-1802.

Bull, S. L. and Schorge, J. O.. A study of the impact of adding HPV types to cervical cancer screening and triage tests. *Women's Oncology Review*. 2005;5(2):99-100.

Bulten, J., De Wilde, P. C. M., Boonstra, H., Gemmink, J. H., and Hanselaar, A. G. J. M.. Proliferation

in 'atypical' atrophic Pap smears. *Gynecologic Oncology*. 2000;79(2):225-229.

Camilleri, G. and Blundell, R.. Pre-invasive cervical disease and cervical carcinoma. *Research Journal of Medical Sciences*. 2009;3(1):4-11.

Canfell, K., Barnabas, R., Patnick, J., and Beral, V.. The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study. *British Journal of Cancer*. 2004;91(3):530-536.

Cardenas-Turanzas, M., Follen, M., Nogueras-Gonzalez, G. M., Benedet, J. L., Beck, J. R., and Cantor, S. B.. The accuracy of the papanicolaou smear in the screening and diagnostic settings. *Journal of Lower Genital Tract Disease*. 2008;12(4):269-275.

Cardenas-Turanzas, M., Nogueras-Gonzalez, G. M., Scheurer, M. E., Adler-Storthz, K., Benedet, J. L., Beck, J. R., Follen, M., and Cantor, S. B.. The performance of human papillomavirus high-risk DNA testing in the screening and diagnostic settings. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(10):2865-2871.

Carozzi, F., Bisanzi, S., Sani, C., Zappa, M., Cecchini, S., Ciatto, S., and Confortini, M.. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. *Journal of Clinical Microbiology*. 2007;45(2):364-369.

Carozzi, F., Cecchini, S., Confortini, M., Becattini, V., Cariaggi, M. P., Pontenani, G., Sani, C., and Ciatto, S.. Role of P16(INK4A) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology. *Cancer*. 2006;108(2):119-123.

Carreon, J. D., Sherman, M. E., Guillen, D., Solomon, D., Herrero, R., Jeronimo, J., Wacholder, S., Rodriguez, A. C., Morales, J., Hutchinson, M., Burk, R. D., and Schiffman, M.. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. *International Journal of Gynecological Pathology*. 2007;26(4):441-446.

Casamitjana, M., Sala, M., Ochoa, D., Fuste, P., Castells, X., and Alameda, F.. Results of a cervical cancer screening programme from an area of Barcelona (Spain) with a large immigrant population. *European Journal of Public Health*. 2009;19(5):499-503.

Castle, P. E., Fetterman, B., Thomas, Cox J., Shaber, R., Poitras, N., Lorey, T., and Kinney, W.. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. *Obstetrics and Gynecology*. 2010;116(1):76-84.

Castle, P. E., Lorincz, A. T., Scott, D. R., Sherman, M. E., Glass, A. G., Rush, B. B., Wacholder, S., Burk, R. D., Manos, M. M., Schussler, J. E., Macomber, P., and Schiffman, M.. Comparison between prototype Hybrid Capture 3 and Hybrid Capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. *Journal of Clinical Microbiology*. 2003;41(9):4022-4030.

Castle, P. E., Rodriguez, A. C., Burk, R. D., Herrero, R., Hildesheim, A., Solomon, D., Sherman, M. E., Jeronimo, J., Alfaro, M., Morales, J., Guillen, D., Hutchinson, M. L., Wacholder, S., and Schiffman, M.. Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. *International Journal of Cancer*. 2009;125(7):1649-1656.

Castle, P. E., Solomon, D., Schiffman, M., and Wheeler, C. M.. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. *Journal of the National Cancer Institute*. 2005;97(14):1066-1071.

Castle, P. E., Wacholder, S., Sherman, M. E., Lorincz, A. T., Glass, A. G., Scott, D. R., Rush, B. B., Demuth, F., and Schiffman, M.. Absolute risk of a subsequent abnormal Pap among oncogenic human

papillomavirus DNA-positive, cytologically negative women. *Cancer*. 2002;95(10):2145-2151.

Castle, P. E.. Screening: HPV testing for cervical cancer: The good, the bad, and the ugly. *Nature Reviews Clinical Oncology*. 2010;7(7):364-365.

Castle, P. E.. The evolving definition of carcinogenic human papillomavirus. *Infectious Agents and Cancer*. 2009;4(1):-.

Cattani, P., Zannoni, G. F., Ricci, C., D'Onghia, S., Trivellizzi, I. N., Di, Franco A., Vellone, V. G., Durante, M., Fadda, G., Scambia, G., Capelli, G., and De, Vincenzo R.. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. *Journal of Clinical Microbiology*. 2009;47(12):3895-3901.

Celik, C., Gezginc, K., Toy, H., Findik, S., and Yilmaz, O.. A comparison of liquid-based cytology with conventional cytology. *International Journal of Gynecology and Obstetrics*. 2008;100(2):163-166.

Cenci, M. and Vecchione, A.. Usefulness of cervical collection by the Exact Touch, the Saccomanno single sampler, combined with automated primary screening. *Diagnostic Cytopathology*. 2000;23(4):242-244.

Cenci, M., Nagar, C., and Vecchione, A.. PAPNET-assisted primary screening of conventional cervical smears. *Anticancer Research*. 2000;20(5 C):3887-3889.

Chacho, M. S., Mattie, M. E., and Schwartz, P. E.. Cytohistologic correlation rates between conventional Papanicolaou smears and ThinPrep cervical cytology: A comparison. *Cancer*. 2003;99(3):135-140.

Chan, P. G., Sung, H.-Y., and Sawaya, G. F.. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. *Obstetrics and Gynecology*. 2003;102(4):765-773.

Chan, P. K. S., Chang, A. R., Yu, M. Y., Li, W.-H., Chan, M. Y. M., Yeung, A. C. M., Cheung, T.-H., Yau, T.-N., Wong, S.-M., Yau, C.-W., and Ng, H.-K.. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal of Cancer*. 2010;126(1):297-301.

Chao, A., Chang, C.-J., Lai, C.-H., Chao, F.-Y., Hsu, Y.-H., Chou, H.-H., Huang, H.-J., Jung, S.-M., Lin, C.-T., Cheng, H.-H., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology - A population-based cohort study from Taiwan. *International Journal of Cancer*. 2010;126(1):191-198.

Chao, A., Hsu, K.-H., Lai, C.-H., Huang, H.-J., Hsueh, S., Lin, S.-R., Jung, S.-M., Chao, F.-Y., Huang, S.-L., Huang, C.-C., Yang, J.-E., and Chang, T.-C.. Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study. *International Journal of Cancer*. 2008;122(12):2835-2841.

Chao, F.-Y., Chao, A., Huang, C.-C., Hsueh, S., Yang, J.-E., Huang, H.-J., Wang, L.-C., Lin, C.-T., Chou, H.-H., and Lai, C.-H.. Defining detection threshold and improving analytical proficiency of HPV testing in clinical specimens. *Gynecologic Oncology*. 2010;117(2):302-307.

Chen, H.-S., Yang, Y.-C., Su, T.-H., Wang, T.-Y., and Huang, Y.-W.. Human papillomavirus testing (Hybrid Capture II) to detect high-grade cervical intraepithelial neoplasia in women with mildly abnormal Papanicolaou results. *Taiwanese Journal of Obstetrics and Gynecology*. 2005;44(3):252-257.

Chen, L. and Yang, B.. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. *Cancer*. 8-25-2008;114(4):236-241.

Chen, Y.-Y., You, S.-L., Chen, C.-A., Shih, L.-Y., Koong, S.-L., Chao, K.-Y., Hsiao, M.-L., Hsieh, C.-Y., and Chen, C.-J.. Effectiveness of national cervical cancer screening programme in Taiwan: 12-year

experiences. *British Journal of Cancer*. 2009;101(1):174-177.

Cheung, A. N. Y., Szeto, E. F., Leung, B. S. Y., Khoo, U.-S., and Ng, A. W. Y.. Liquid-Based Cytology and Conventional Cervical Smears: A Comparison Study in an Asian Screening Population. *Cancer*. 2003;99(6):331-335.

Chin-Hong, P. V. and Klausner, J. D.. Diagnostic tests for HPV infection. *MLO: medical laboratory observer*. 2004;36(10):10-16.

Chivukula, M., Saad, R. S., Elishaev, E., White, S., Mauser, N., and Dabbs, D. J.. Introduction of the Thin Prep Imaging System (TIS): Experience in a high volume academic practice. *CytoJournal*. 2007;4 , 2007. Article Number: 6. Date of Publication: 2007.-.

Christe, D. M., Mohanambal, M., Ramamurthy, V., and Snehaa, N. B.. A study of cervical cancer screening for prevention of carcinoma cervix. *Journal of the Indian Medical Association*. 2008;106(12):779-782.

Cibas, E. S., Alonzo, T. A., Austin, R. M., Bolick, D. R., Glant, M. D., Henry, M. R., Moriarty, A. T., Molina, J. T., Rushing, L., Slowman, S. D., Torno, R., and Eisenhut, C. C.. The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: results of a multicenter clinical trial. *American journal of clinical pathology*. 2008;129(2):193-201.

Cirpan, T., Guliyeva, A., Onder, G., Terek, M. C., Ozsaran, A., Kabasakal, Y., Zekioglu, O., and Yucebilgin, S.. Comparison of human papillomavirus testing and cervical cytology with colposcopic examination and biopsy in cervical cancer screening in a cohort of patients with Sjogren's syndrome. *European Journal of Gynaecological Oncology*. 2007;28(4):302-306.

Cohen, D., Shorie, J., and Biscotti, C.. Glacial acetic acid treatment and atypical endocervical glandular cells: An Analysis of 92 Cases. *American journal of clinical pathology*. 2010;133(5):799-801.

Cohn, J. A., Gagnon, S., Spence, M. R., Harrison, D. D., Kluzak, T. R., Langenberg, P., Brinson, C., Stein, A., and Hellinger, J.. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. *American Journal of Obstetrics and Gynecology*. 2001;184(3):322-330.

Coldman, A., Phillips, N., Kan, L., Maticic, J., Benedet, L., and Towers, L.. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives. *Journal of medical screening*. 2005;12(1):7-11.

Coldman, A., Phillips, N., Kan, L., Maticic, J., Benedet, L., and Towers, L.. Risk of invasive cervical cancer after three consecutive negative Pap smears. *Journal of medical screening*. 2003;10(4):196-200.

Colgan, T. J., Woodhouse, S. L., Styer, P. E., Kennedy, M., and Davey, D. D.. Reparative changes and the false-positive/false-negative papanicolaou test: A study from the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. *Archives of Pathology and Laboratory Medicine*. 2001;125(1):134-140.

Comber, H. and Gavin, A.. Recent trends in cervical cancer mortality in Britain and Ireland: The case for population-based cervical cancer screening. *British Journal of Cancer*. 2004;91(11):1902-1904.

Confortini, M., Giorgi, Rossi P., Barbarino, P., Passarelli, A. M., Orzella, L., and Tufi, M. C.. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. *Journal of medical screening*. 2010;17(2):79-86.

Coquillard, G., Palao, B., and Patterson, B. K.. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. *Gynecologic Oncology*. 2011;120(1):89-93.

- Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women. *Obstetrics & Gynecology*. 2002;100(1):79-86.
- Cornelison, T. L., Montz, F. J., Bristow, R. E., Chou, B., Bovicelli, A., and Zeger, S. L.. Decreased incidence of cervical cancer in medicare-eligible California women¹. *Obstetrics and Gynecology*. 2002;100(1):79-86.
- Corusic, A., Skrgatic, L., Mahovlic, V., Mandic, V., Planinic, P., and Karadza, M.. Cervical cancer as a public health issue--what next?. *Collegium antropologicum*. 2010;34(1):301-307.
- Coste, J., Cochand-Priollet, B., de, Cremoux P., Buntinx, F., and Arbyn, M.. Conventional cervical smears were better than monolayer cytology or human papillomavirus testing for detecting cervical intraepithelial neoplasia. *Evidence-Based Medicine*. 2003;8(6):187-.
- Coutlee, F., Rouleau, D., Petignat, P., Ghattas, G., Kornegay, J. R., Schlag, P., Boyle, S., Hankins, C., Vezina, S., Cote, P., Macleod, J., Voyer, H., Forest, P., Walmsley, S., Franco, E., Connors, J., Grimshaw, R., Haase, D., Johnston, L., Schlech, W., Yuzicappi-Fayant, A., Landis, S., Smaill, F., Austin, T., Hammerberg, O., Ralph, T., Falutz, J., Ferenczy, A., Klein, M., Labrecque, L., Lalonde, R., Noel, G., Perron, C., Routy, J.-P., Toma, E., Touchie, C., Victor, G., Cote, L., Senay, H., Trottier, S., Williams, K., Piche, A., Sandre, R., Binder, L., Keystone, D., Phillips, A., Rachlis, A., Salit, I., Wagner, C., Braitstein, P., Burdge, D., Harris, M., Money, D., and Montaner, J.. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGM1 primers and the linear array HPV genotyping test. *Journal of Clinical Microbiology*. 2006;44(6):1998-2006.
- Cox, J. T.. Corrigendum to "History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results" [*J. Clin. Virol.* 45 (1) (2009) S3-S12] (PII:S1386-6532(09)X0008-9). *Journal of Clinical Virology*. 2010;47(3):299-.
- Cox, J. T.. Human papillomavirus testing in primary cervical screening and abnormal papanicolaou management. *Obstetrical and Gynecological Survey*. 2006;61(6 SUPPL. 1):S15-S25.
- Cox, J. T.. Liquid-based cytology: evaluation of effectiveness, cost-effectiveness, and application to present practice. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2004;2(6):597-611.
- Curran, D. R. and Stigleman, S.. Should we discontinue Pap smear screening in women aged >65 years?. *Journal of Family Practice*. 2004;53(4):308-310.
- Cuzick, J., Arbyn, M., Sankaranarayanan, R., Tsu, V., Ronco, G., Mayrand, M.-H., Dillner, J., and Meijer, C. J. L. M.. Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries. *Vaccine*. 2008;26(SUPPL. 10):K29-K41.
- Cuzick, J., Clavel, C., Petry, K.-U., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., and Iftner, T.. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *International Journal of Cancer*. 2006;119(5):1095-1101.
- Cuzick, J., Szarewski, A., Mesher, D., Cadman, L., Austin, J., Perryman, K., Ho, L., Terry, G., Sasieni, P., Dina, R., and Soutter, W. P.. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - Results from the Hammersmith study. *International Journal of Cancer*. 2008;122(10):2294-2300.
- Cuzick, J.. Time to consider HPV testing in cervical screening. *Annals of Oncology*. 2001;12(11):1511-1514.
- Datta, S. D., Koutsky, L. A., Ratelle, S., Unger, E. R., Shlay, J., McClain, T., Weaver, B., Kerndt, P., Zenilman, J., Hagensee, M., Suhr, C. J., and Weinstock, H.. Human papillomavirus infection and

cervical cytology in women screened for cervical cancer in the United States, 2003-2005. *Annals of internal medicine*. 2008;148(7):493-500.

Davey, E., D'Assuncao, J., Irwig, L., Macaskill, P., Chan, S. F., Richards, A., and Farnsworth, A.. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: Prospective study. *British Medical Journal*. 2007;335(7609):31-35.

Day, G. E., Lanier, A. P., Bulkow, L., Kelly, J. J., and Murphy, N.. Cancers of the breast, uterus, ovary and cervix among Alaska native women, 1974-2003. *International Journal of Circumpolar Health*. 2010;69(1):72-86.

De Francesco, M. A., Gargiulo, F., Schreiber, C., Ciravolo, G., Salinaro, F., and Manca, N.. Comparison of the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear. *Journal of Virological Methods*. 2008;147(1):10-17.

De, Lang A. and Wilander, E.. Sensitivity of HPV tests on stained vs. unstained cervical smears. *Acta Cytologica*. 2005;49(6):595-599.

De, Lang A., Wikstrom, I., and Wilander, E.. Significance of HPV tests on women with cervical smears showing ASCUS. *Acta Obstetricia et Gynecologica Scandinavica*. 2005;84(10):1001-1005.

Deerasamee, S., Srivatanakul, P., Sriplung, H., Nilvachararung, S., Tansuwan, U., Pitakpraiwan, P., Kaewkungwal, J., Singhasivanon, P., Nimnakorn, P., and Sankaranarayanan, R.. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand. *Asian Pacific journal of cancer prevention : APJCP*. 2007;8(4):547-556.

Denton, K. J., Bergeron, C., Klement, P., Trunk, M. J., Keller, T., and Ridder, R.. The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL Pap cytology results. *American journal of clinical pathology*. 2010;134(1):12-21.

Derchain, S. F., Sarian, L. O., Naud, P., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Serpa-Hammes, L., Matos, J., Gontijo, R. C., Braganca, J. F., Lima, T. P., Maeda, M. Y., Lorincz, A., Dores, G. B., Costa, S., Syrjanen, S., and Syrjanen, K.. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study. *Journal of medical screening*. 2008;15(2):97-104.

Desai, M.. Role of automation in cervical cytology. *Diagnostic Histopathology*. 2009;15(7):323-329.

Diaz-Montes, T. P., Farinola, M. A., Zahurak, M. L., Bristow, R. E., and Rosenthal, D. L.. Clinical utility of atypical glandular cells (AGC) classification: Cytohistologic comparison and relationship to HPV results. *Gynecologic Oncology*. 2007;104(2):366-371.

Difurio, M. J., Mailhiot, T., Sundborg, M. J., and Nauschuetz, K. K.. Comparison of the clinical significance of the papanicolaou test interpretations LSIL cannot rule out HSIL and ASC-H. *Diagnostic Cytopathology*. 2010;38(5):313-317.

Dockter, J., Schroder, A., Hill, C., Guzanski, L., Monsonego, J., and Giachetti, C.. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S55-S61.

Duby, J. M. and Difurio, M. J.. Implementation of the ThinPrep Imaging System in a tertiary military medical center. *Cancer cytopathology*. 2009;117(4):264-270.

Duggan, M. A., Khalil, M., Brasher, P. M. A., and Nation, J. G.. Comparative study of the ThinPrep Pap test and conventional cytology results in a Canadian cohort. *Cytopathology*. 2006;17(2):73-81.

Dunton, C. J., Dooley, M., and Holtz, D. O.. Early detection of cervical cancer by human papillomavirus

DNA testing: Case reports. *Journal of Lower Genital Tract Disease*. 2006;10(4):256-257.

Dziura, B., Quinn, S., and Richard, K.. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the uterine cervix. *Acta Cytologica*. 2006;50(3):309-311.

Eilstein, D., Hedelin, G., and Schaffer, P.. Cervical cancer in Bas-Rhin: Trend and prediction of the incidence in 2014. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2002;31(1):28-33.

Einstein, M. H., Studentsov, Y. Y., Ho, G. Y. F., Fazzari, M., Marks, M., Kadish, A. S., Goldberg, G. L., Runowicz, C. D., and Burk, R. D.. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. *International Journal of Cancer*. 2007;120(1):55-59.

El, Gnaoui N., Saile, R., and Benomar, H.. Pap smear an inevitable test in the screening of the lesions of the cervix. [French]. *Journal Africain du Cancer*. 2010;2(1):9-13.

Elfgren, K., Kalantari, M., Moberger, B., Hagmar, B., and Dillner, J.. A population-based five-year follow-up study of cervical human papillomavirus infection. *American Journal of Obstetrics and Gynecology*. 2000;183(3):561-567.

Elsheikh, T. M., Kirkpatrick, J. L., and Wu, H. H.. The significance of "low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion" as a distinct squamous abnormality category in Papanicolaou tests. *Cancer*. 2006;108(5):277-281.

Eltoum, I. A. and Roberson, J.. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national pap test volume: Projections from the National Health Interview Survey (NHIS). *Cancer*. 2007;111(1):34-40.

Eltoum, I. A., Chhieng, D. C., Roberson, J., McMillon, D., and Partridge, E. E.. Reflex human papilloma virus infection testing detects the same proportion of cervical intraepithelial neoplasia grade 2-3 in young versus elderly women. *Cancer*. 2005;105(4):194-198.

Escobedo, L. G., Zhong, Z., and Key, C.. Breast and cervical cancer screening and disease incidence and stage in New Mexico. *Cancer Causes and Control*. 2002;13(2):137-145.

Fait, G., Kupferminc, M. J., Daniel, Y., Geva, E., Ron, I. G., Lessing, J. B., and Bar-Am, A.. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal Pap smears before colposcopy referral. *Gynecologic Oncology*. 2000;79(2):177-180.

Farag, R., Redline, R., and Abdul-Karim, F. W.. Value of combining HPV-DNA testing with follow-up papanicolaou smear in patients with prior atypical squamous cells of undetermined significance. *Acta Cytologica*. 2008;52(3):294-296.

Federico, C., Alleyn, J., Dola, C., Tafti, S., Galandak, J., Jacob, C., Bhuiyan, A., and Cheng, J.. Relationship among age, race, medical funding, and cervical cancer survival. *Journal of the National Medical Association*. 2010;102(3):199-205.

Feng, J., Al-Abbadi, M. A., Bandyopadhyay, S., Salimnia, H., and Husain, M.. Significance of high-risk human papillomavirus DNA-positive atypical squamous cells of undetermined significance pap smears in perimenopausal and postmenopausal women. *Acta Cytologica*. 2008;52(4):434-438.

Ferreccio, C., Bratti, M. C., Sherman, M. E., Herrero, R., Wacholder, S., Hildesheim, A., Burk, R. D., Hutchinson, M., Alfaro, M., Greenberg, M. D., Morales, J., Rodriguez, A. C., Schussler, J., Eklund, C., Marshall, G., and Schiffman, M.. A comparison of single and combined visual, cytologic, and virologic tests as screening strategies in a region at high risk of cervical cancer. *Cancer Epidemiology Biomarkers and Prevention*. 2003;12(9):815-823.

Ferris, D. G., Gilman, P. A., Leyva Lopez, A. G., Litaker, M. S., Miller, J. A., and Macfee, M. S..

Psychological effects women experience before and after a colposcopic examination and primary care appointment. *Journal of Lower Genital Tract Disease*. 2003;7(2):89-94.

Ferris, D. G., Heidemann, N. L., Litaker, M. S., Crosby, J. H., and Macfee, M. S.. The efficacy of liquid-based cervical cytology using direct-to-vial sample collection. *Journal of Family Practice*. 2000;49(11):1005-1011.

Fink, J. L.. Beyond the shock of an abnormal Pap. *RN*. 2003;66(6):56-61.

Flori, M., Dupraz, C., Erpeldinger, S., and Le, Goaziou M. F.. Cervical smears among women after 65 years. One-year retrospective descriptive study. [French]. *Revue du Praticien*. 2009;59(10 SUPPL. 1):29-32.

Freeman-Wang, T. and Walker, P.. Psychological aspects of colposcopy. *CME Journal of Gynecologic Oncology*. 2005;10(2):123-126.

Frega, A., Biamonti, A., Maranghi, L., Vetrano, G., Palazzo, A., Iacovelli, R., Corosu, R., French, D., Moscarini, M., and Vecchione, A.. Follow-up of high-grade squamous intra-epithelial lesions (H-SILs) in human immunodeficiency virus (HIV)-positive and human papillomavirus (HPV)-positive women. Analysis of risk factors. *Anticancer Research*. 2006;26(4 B):3167-3170.

Freitas, R. A. P., Carvasan, G. A. F., Morais, S. S., and Zeferino, L. C.. Excessive pap smears due to opportunistic cervical cancer screening. *European Journal of Gynaecological Oncology*. 2008;29(5):479-482.

Fremont-Smith, M., Marino, J., Griffin, B., Spencer, L., and Bolick, D.. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a multisite direct-to-vial study. *Cancer*. 2004;102(5):269-279.

Froberg, M., Johansson, B., Hjerpe, A., and Andersson, S.. Human papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities. *British Journal of Cancer*. 2008;99(4):563-568.

Gage, J. C., Schiffman, M., Solomon, D., Wheeler, C. M., and Castle, P. E.. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. *Cancer Epidemiology Biomarkers and Prevention*. 2010;19(7):1668-1674.

Garcia-Garcia, J. A., Perez-Valles, A., Martorell, M., Gomez, B., Gomez-Cabrero, D., Soler, F., and Calabuig, C.. Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology. *Acta Cytologica*. 2010;54(2):159-164.

Garcia-Sierra, N., Martro, E., Castella, E., Llatjos, M., Tarrats, A., Bascunana, E., Diaz, R., Carrasco, M., Sirera, G., Matas, L., and Ausina, V.. Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening. *Journal of Clinical Microbiology*. 2009;47(7):2165-2169.

Gazzaz, F. S. B.. Molecular testing of human papillomavirus in cervical specimens. *Saudi Medical Journal*. 2007;28(12):1810-1818.

Ge, Y., Smith, D., Schwartz, M. R., and Mody, D. R.. Image-guided ThinPrep Papanicolaou tests and cotesting with high-risk human papillomavirus in women aged 30 years and older in a low-risk private practice population. *Cancer cytopathology*. 2009;117(5):326-332.

Geldenhuis, L. and Murray, M. L.. Sensitivity and specificity of the pap smear for glandular lesions of the cervix and endometrium. *Acta Cytologica*. 2007;51(1):47-50.

Ginsberg, G. M., Edejer, T. T. T., Lauer, J. A., and Sepulveda, C.. Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis. *Vaccine*.

2009;27(43):6060-6079.

Giordano, G., Gnetti, L., Pilato, F. P., Viviano, L., and Silini, E. M.. The role of cervical smear in the diagnosis and management of extrauterine malignancies metastatic to the cervix: Three case reports. *Diagnostic Cytopathology*. 2010;38(1):41-46.

Girianelli, V. R. and Thuler, L. C. S.. Evaluation of agreement between conventional and liquid-based cytology in cervical cancer early detection based on analysis of 2,091 smears: Experience at the Brazilian National Cancer Institute. *Diagnostic Cytopathology*. 2007;35(9):545-549.

Goldie, S. J., Kim, J. J., and Wright, T. C.. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. *Obstetrics and Gynecology*. 2004;103(4):619-631.

Gontijo, R. C., Derchain, S. F. M., Roteli-Martins, C., Braganca, J. F., Sarian, L. O., Morais, S. S., Maeda, M. Y. S., Longatto-Filho, A., and Syrjanen, K. J.. Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2007;133(2):239-246.

Grace, A., McBrearty, P., Troost, S., Thornhill, M., Kay, E., and Leader, M.. Comparative study: Conventional cervical and ThinPrep Pap tests in a routine clinical setting. *Cytopathology*. 2002;13(4):200-205.

Grainge, M. J., Seth, R., Guo, L., Neal, K. R., Coupland, C., Vryenhoef, P., Johnson, J., and Jenkins, D.. Cervical human papillomavirus screening among older women. *Emerging Infectious Diseases*. 2005;11(11):1680-1685.

Greydanus, D. E., Omar, H., and Patel, D. R.. Cervical cancer screening in adolescents. *Pediatrics in Review*. 2009;30(1):23-25.

Greydanus, D. E., Omar, H., and Patel, D. R.. What's new: Cervical cancer screening in adolescents. *Pediatrics in review / American Academy of Pediatrics*. 2009;30(1):23-25.

Guido, R.. Guidelines for screening and treatment of cervical disease in the adolescent. *Journal of Pediatric and Adolescent Gynecology*. 2004;17(5):303-311.

Guidos, B. J. and Selvaggi, S. M.. Detection of endometrial adenocarcinoma with the ThinPrep Pap Test(TM). *Diagnostic Cytopathology*. 2000;23(4):260-265.

Guillaud, M., Benedet, J. L., Cantor, S. B., Staerckel, G., Follen, M., and MacAulay, C.. DNA ploidy compared with human papilloma virus testing (Hybrid Capture II) and conventional cervical cytology as a primary screening test for cervical high-grade lesions and cancer in 1555 patients with biopsy confirmation. *Cancer*. 2006;107(2):309-318.

Gunnell, A. S., Ylitalo, N., Sandin, S., Sparen, P., Adami, H.-O., and Ripatti, S.. A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: Evidence of effectiveness and overtreatment. *Cancer Epidemiology Biomarkers and Prevention*. 2007;16(12):2641-2648.

Guo, M., Hu, L., Martin, L., Liu, S., Baliga, M., and Hughson, M. D.. Accuracy of liquid-based pap tests: Comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal pap smears. *Acta Cytologica*. 2005;49(2):132-138.

Guo, M., Patel, S. J., Chovanec, M., Yee, J. J., Tarco, E., Bevers, T. B., Anderson, K., and Sneige, N.. A human papillomavirus testing system in women with abnormal pap results: A comparison study with follow-up biopsies. *Acta Cytologica*. 2007;51(5):749-754.

Gupta, S., Sodhani, P., Halder, K., Chachra, K. L., Singh, V., and Sehgal, A.. Age trends in pre-cancerous and cancerous lesions of the uterine cervix in a cytology screening programme: What should

be the target age group for a major thrust of screening in resource-limited settings?. *Cytopathology*. 2008;19(2):106-110.

Halfon, P., Benmoura, D., Agostini, A., Khiri, H., Martineau, A., Penaranda, G., and Blanc, B.. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. *Journal of Clinical Virology*. 2010;47(2):177-181.

Halfon, P., Benmoura, D., Khiri, H., Penaranda, G., Blanc, B., Riggio, D., and Sandri, M. T.. Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck HPV-screening assay. *Journal of Clinical Virology*. 2010;47(1):38-42.

Halford, J. A., Batty, T., Boost, T., Duhig, J., Hall, J., Lee, C., and Walker, K.. Comparison of the sensitivity of conventional cytology and the ThinPrep imaging system for 1,083 biopsy confirmed high-grade squamous lesions. *Diagnostic Cytopathology*. 2010;38(5):318-326.

Hall, J. and Kendall, B.. High risk human papillomavirus DNA detection in pap tests with both atypical squamous cells of undetermined significance and candida. *Acta Cytologica*. 2009;53(2):150-152.

Hamashima, C., Aoki, D., Miyagi, E., Saito, E., Nakayama, T., Sagawa, M., Saito, H., Sobue, T., and Japanese Research Group for Development of Cervical Cancer Screening Guidelines. The Japanese guideline for cervical cancer screening. *Japanese journal of clinical oncology*. 2010;40(6):485-502.

Hantz, S., Caly, H., Decroisette, E., Dutrop, A., Bakeland, D., Pascal, B., Darreys, G., Dussartre, C., Renaudie, J., Rogez, S., Aubard, Y., Denis, F., and Alain, S.. Evaluation of accuracy of three assays for human papillomavirus detection and typing: Hybrid Capture 2, HPV Consensus kit and AmpliCor HPV. [French]. *Pathologie Biologie*. 2008;56(1):29-35.

Hartmann, K. E., Nanda, K., Hall, S., and Myers, E.. Technologic advances for evaluation of cervical cytology: Is newer better?. *Obstetrical and Gynecological Survey*. 2001;56(12):765-774.

Harvey, M., Stout, S., Starkey, C. R., Hendren, R., Holt, S., and Miller, G. C.. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S79-S83.

Hatch, K. D., Sheets, E., Kennedy, A., Ferris, D. G., Darragh, T., and Twigg, L.. Multicenter direct to vial evaluation of a liquid-based Pap test. *Journal of Lower Genital Tract Disease*. 2004;8(4):308-312.

Healey, S. M., Aronson, K., Mao, Y., and Franco, E. L.. Human papillomavirus and cervical dysplasia in Nunavut: prelude to a screening strategy. *International Journal of Circumpolar Health*. 2004;63 Suppl 2:199-201.

Hellsten, C., Lindqvist, P. G., and Sjostrom, K.. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2008;115(2):205-211.

Hellsten, C., Sjostrom, K., and Lindqvist, P. G.. A prospective Swedish cohort study on psychosocial factors influencing anxiety in women referred for colposcopy. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2007;114(1):32-38.

Hemminki, K., Li, X., and Mutanen, P.. Age-incidence relationships and time trends in cervical cancer in Sweden. *European Journal of Epidemiology*. 2001;17(4):323-328.

Herbert, A., Gregory, M., Gupta, S. S., and Singh, N.. Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2009;116(6):854-859.

Herbert, A., Holdsworth, G., and Kubba, A. A.. Cervical screening: Why young women should be encouraged to be screened. *Journal of Family Planning and Reproductive Health Care*. 2008;34(1):21-

25.

Herbert, A.. Cervical screening in England and Wales: Its effect has been underestimated. *Cytopathology*. 2000;11(6):471-479.

Hesselink, A. T., Berkhof, J., Heideman, D. A., Bulkman, N. W., van Tellingen, J. E., Meijer, C. J., and Snijders, P. J.. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. *International Journal of Cancer*. 2009;Journal international du cancer. 124(2):381-386.

Hoekstra, A. V., Kosinski, A., and Huh, W. K.. Hormonal contraception and false-positive cervical cytology: Is there an association?. *Journal of Lower Genital Tract Disease*. 2006;10(2):102-106.

Holmquist, N. D.. Revisiting the effect of the pap test on cervical cancer. *American journal of public health*. 2000;90(4):620-623.

Hong, D. G., Seong, W. J., Kim, S. Y., Lee, Y. S., and Cho, Y. L.. Prediction of high-grade squamous intraepithelial lesions using the modified Reid index. *International Journal of Clinical Oncology*. 2010;15(1):65-69.

Hoonhorst, F. and Hamon, A.. Cervical cancer and HPV screening. [French]. *IRBM News*. 2008;29(3-4):19-21.

Howard, K., Salkeld, G., McCaffery, K., and Irwig, L.. HPV triage testing or repeat pap smear for the management of a typical squamous cells (ASCUS) on pap smear: Is there evidence of process utility?. *Health Economics*. 2008;17(5):593-605.

Huang, S., Erickson, B., Tang, N., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S19-S23.

Hunter, C., Duggan, M. A., Duan, Q., Power, P., Gregoire, J., and Nation, J.. Cytology and outcome of LSIL: Cannot exclude HSIL compared to ASC-H. *Cytopathology*. 2009;20(1):17-26.

Hussein, T., Desai, M., Tomlinson, A., and Kitchener, H. C.. The comparative diagnostic accuracy of conventional and liquid-based cytology in a colposcopic setting. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2005;112(11):1542-1546.

Igdbashian, S., Maggioni, A., Casadio, C., Boveri, S., Cristoforoni, P., and Sideri, M.. Sentinel Pap smears in 261 invasive cervical cancer patients in Italy. *Vaccine*. 2009;27(SUPPL. 1):A34-A38.

Illades-Aguilar, B., Alarcon-Romero, L., Antonio-Vejar, V., Zamudio-Lopez, N., Sales-Linares, N., Flores-Alfaro, E., Fernandez-Tilapa, G., Vences-Velazquez, A., Munoz-Valle, J. F., and Leyva-Vazquez, M.-A.. Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico. *Gynecologic Oncology*. 2010;117(2):291-296.

Ingemann-Hansen, O., Lidang, M., Niemann, I., Dinesen, J., Baandrup, U., Svanholm, H., and Petersen, L. K.. Screening history of women with cervical cancer: A 6-year study in Aarhus, Denmark. *British Journal of Cancer*. 2008;98(7):1292-1294.

Inoue, M., Sakaguchi, J., Sasagawa, T., and Tango, M.. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. *International Journal of Gynecological Cancer*. 2006;16(3):1007-1013.

Jacot-Guillarmod, M., Hohlfeld, P., and Renteria, S.-C.. Role of the PAP smear in adolescence. [French]. *Revue Medicale Suisse*. 2009;5(222):2078-2084.

Jeng, C.-J., Ko, M.-L., Ling, Q.-D., Shen, J., Lin, H.-W., Tzeng, C.-R., Ho, C.-M., Chien, T.-Y., and

- Chen, S.-C.. Prevalence of cervical human papillomavirus in Taiwanese women. *Clinical and Investigative Medicine*. 2005;28(5):261-266.
- Jiang, J., Wei, L.-H., Li, Y.-L., Wu, R.-F., Xie, X., Feng, Y.-J., Zhang, G., Zhao, C., Zhao, Y., and Chen, Z.. Detection of TERC amplification in cervical epithelial cells for the diagnosis of high-grade cervical lesions and invasive cancer: A multicenter study in China. *Journal of Molecular Diagnostics*. 2010;12(6):808-817.
- Jones, H. E., Wiegerinck, M. A., Nieboer, T. E., Mol, B. W., and Westhoff, C. L.. Women in the Netherlands prefer self-sampling with a novel lavaging device to clinician collection of specimens for cervical cancer screening. *Sexually Transmitted Diseases*. 2008;35(11):916-917.
- Julian, T. M.. Erratum: Type-specific HPV testing as a predictor of high-grade squamous intraepithelial lesion outcome after cytologic abnormalities (*Journal of Lower Genital Tract Disease* (2005) 9, (3), (154-159)). *Journal of Lower Genital Tract Disease*. 2006;10(1):63-.
- Juric, D., Mahovlic, V., Rajhvajn, S., Ovanin-Rakic, A., Skopljanac-Macina, L., Barisic, A., Projic, I. S., Babic, D., Susa, M., Corusic, A., and Oreskovic, S.. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions. *Collegium antropologicum*. 2010;34(1):19-24.
- Kahn, J. A., Slap, G. B., Bernstein, D. I., Kollar, L. M., Tissot, A. M., Hillard, P. A., and Rosenthal, S. L.. Psychological, behavioral, and interpersonal impact of human papillomavirus and pap test results. *Journal of Women's Health*. 2005;14(7):650-659.
- Kang, W. D., Kim, C. H., Cho, M. K., Kim, J. W., Kim, Y. H., Choi, H. S., and Kim, S. M.. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. *International Journal of Gynecological Cancer*. 2009;19(5):924-928.
- Karabulut, A., Alan, T., Ali, Ekiz M., Iritas, A., Kesen, Z., and Yahsi, S.. Evaluation of cervical screening results in a population at normal risk. *International Journal of Gynecology and Obstetrics*. 2010;110(1):40-42.
- Karam, W. G., Bedran, F., Tohme, R. A., Moukarbel, N., Abdallah, I., Jurjus, A. R., Jurjus, R. A., Khairallah, S., and Aftimos, G.. Human papillomavirus testing as an adjunct to cytology evaluation in cervical specimens of selected and consecutively screened Lebanese women: A prospective clinical study. *Journal Medical Libanais*. 2005;53(3):132-138.
- Karasz, A., McKee, M. D., and Roybal, K.. Women's experiences of abnormal cervical cytology: illness representations, care processes, and outcomes. *Annals of family medicine*. 2003;1(4):196-202.
- Kent, A.. Screening and logical cytology - A review. *Obstetrics and Gynaecology Forum*. 2009;19(4):141-143.
- Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M. S., Scott, D. R., Rush, B. R., Glass, A. G., and Schiffman, M.. The elevated 10-Year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *Journal of the National Cancer Institute*. 2005;97(14):1072-1079.
- Khuakoonratt, N., Tangjitgamol, S., Manusirivithaya, S., Khunnarong, J., Pataradule, K., Thavaramara, T., and Suekwattana, P.. Prevalence of high grade squamous intraepithelial lesion (HSIL) and invasive cervical cancer in patients with low grade squamous intraepithelial lesion (LSIL) at cervical pap smear. *Asian Pacific journal of cancer prevention : APJCP*. 2008;9(2):253-257.
- Kiatpongsan, S., Niruthisard, S., Mutirangura, A., Trivijitsilp, P., Vasuratna, A., Chaithongwongwatthana, S., and Lertkhachonsuk, R.. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. *International Journal of Gynecological Cancer*. 2006;16(1):262-265.

- Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., and Choi, C.. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Gynecologic Oncology*. 2010;116(1):99-104.
- Kim, J.-H., Choi, Y. D., Lee, J. S., Lee, J. H., Nam, J. H., Choi, C., Kweon, S.-S., Fackler, M. J., and Sukumar, S.. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. *Virchows Archiv*. 2010;457(1):35-42.
- Kinney, W., Castle, P. E., Fetterman, B., Poitras, N., Lorey, T., and Shaber, R.. Five-year experience of human papillomavirus DNA and papanicolaou test cotesting. *Obstetrics and Gynecology*. 2009;113(3):595-600.
- Kinney, W., Sawaya, G. F., Sung, H. Y., Kearney, K. A., Miller, M., and Hiatt, R. A.. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. [Review] [27 refs]. *Acta Cytologica*. 2003;47(2):167-171.
- Kirschner, B., Simonsen, K., and Junge, J.. Comparison of conventional Papanicolaou smear and SurePath liquid-based cytology in the Copenhagen population screening programme for cervical cancer. *Cytopathology*. 2006;17(4):187-194.
- Kjaer, S., Hogdall, E., Frederiksen, K., Munk, C., Van Den Brule, A., Svare, E., Meijer, C., Lorincz, A., and Iftner, T.. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. *Cancer Research*. 2006;66(21):10630-10636.
- Klinkhamer, P. J. J. M., Meerding, W. J., Rosier, P. F. W. M., and Hanselaar, A. G. J. M.. Liquid-based cervical cytology: A review of the literature with methods of evidence-based medicine. *Cancer*. 2003;99(5):263-271.
- Knoepf, S. M., Kuebler, D. L., and Wilbur, D. C.. Correlation between hybrid capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: a cytologic/histologic review of 367 cases. *Cancer cytopathology*. 2010;118(4):209-217.
- Knoepf, S. M., Kuebler, D. L., and Wilbur, D. C.. Resolution of equivocal results with the hybrid capture II high-risk HPV DNA Test: A cytologic/histologic review of 191 cases. *Diagnostic Molecular Pathology*. 2007;16(3):125-129.
- Ko, V., Nanji, S., Tambouret, R. H., and Wilbur, D. C.. Testing for HPV as an objective measure for quality assurance in gynecologic cytology: Positive rates in equivocal and abnormal specimens and comparison with the ASCUS to SIL ratio. *Cancer*. 2007;111(2):67-73.
- Ko, V., Tambouret, R. H., Kuebler, D. L., Black-Schaffer, W. S., and Wilbur, D. C.. Human papillomavirus testing using Hybrid Capture II with SurePath collection: Initial evaluation and longitudinal data provide clinical validation for this method. *Cancer*. 2006;108(6):468-474.
- Koliopoulos, G., Valasoulis, G., and Zilakou, E.. An update review on HPV testing methods for cervical neoplasia. *Expert Opinion on Medical Diagnostics*. 2009;3(2):123-131.
- Koong, S. L., Yen, A. M., and Chen, T. H.. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. *Journal of medical screening*. 2006;13 Suppl 1:S44-S47.
- Kotaniemi-Talonen, L., Nieminen, P., Hakama, M., Seppanen, J., Ikkala, J., Martikainen, J., Tarkkanen, J., Toivonen, T., and Anttila, A.. Significant variation in performance does not reflect the effectiveness of the cervical cancer screening programme in Finland. *European Journal of Cancer*. 2007;43(1):169-174.
- Kulasingam, S. L. and Myers, E. R.. Potential Health and Economic Impact of Adding a Human

Papillomavirus Vaccine to Screening Programs. *Journal of the American Medical Association*. 2003;290(6):781-789.

Kulmala, S.-M., Syrjanen, S., Shabalova, I., Petrovichev, N., Kozachenko, V., Podistov, J., Ivanchenko, O., Zakharenko, S., Nerovjna, R., Kljukina, L., Branovskaja, M., Grunberga, V., Juschenko, A., Tosi, P., Santopietro, R., and Syrjanen, K.. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. *Journal of Clinical Microbiology*. 2004;42(6):2470-2475.

Kumar, N., Bongiovanni, M., Molliet, M.-J., Pelte, M.-F., Egger, J.-F., and Pache, J.-C.. Reclassification and analysis of clinical significance of atypical glandular cells on ThinPrep using the Bethesda 2001: Geneva experience. *Swiss Medical Weekly*. 2007;137(45-46):635-641.

Kurtycz, D. F. I., Smith, M., He, R., Miyazaki, K., and Shalkham, J.. Comparison of methods trial for high-risk HPV. *Diagnostic Cytopathology*. 2010;38(2):104-108.

Kyrgiou, M., Tsoumpou, I., Vrekoussis, T., Martin-Hirsch, P., Arbyn, M., Prendiville, W., Mitrou, S., Koliopoulos, G., Dalkalitsis, N., Stamatopoulos, P., and Paraskevaidis, E.. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: The cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. *Cancer Treatment Reviews*. 2006;32(7):516-523.

Lam, C. L. K.. The price of cancer screening. *Hong Kong Practitioner*. 2004;26(3):142-145.

Lavoue, V., Bergeron, C., Riethmuller, D., Darai, E., Mergui, J.-L., Baldauf, J.-J., Gondry, J., Douvier, S., Lopes, P., De, Reilhac P., Quereux, C., Letombe, B., Marchetta, J., Boulanger, J.-C., and Leveque, J.. Cervical screening: Toward a new paradigm?. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2010;39(2):102-115.

Lazcano-Ponce, E., Lorincz, A. T., Salmeron, J., Fernandez, I., Cruz, A., Hernandez, P., Mejia, I., and Hernandez-Avila, M.. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican social security program. *Cancer Causes and Control*. 2010;21(10):1693-1700.

Lee, C. Y. K. and Ng, W.-K.. A follow-up study off atypical squamous cells in gynecologic cytology using conventional papanicolaou smears and liquid-based preparations: The impact of the Bethesda system 2001. *American journal of clinical pathology*. 2007;127(4):548-555.

Lee, S. H., Vigliotti, V. S., and Pappu, S.. HPV infection among women in a representative rural and suburban population of the USA. *International Journal of Gynecology and Obstetrics*. 2009;105(3):210-214.

Lerma, E., Quintana, M. J., Quilez, M., Esteva, E., Carreras, A., Bonfill, X., Prat, J., and Calaf, J.. Effectiveness of liquid-based cytology and Papanicolaou tests in a low risk population. *Acta Cytologica*. 2007;51(3):399-406.

Levi, F., Lucchini, F., Negri, E., Franceschi, S., and La, Vecchia C.. Cervical cancer mortality in young women in Europe patterns and trends. *European Journal of Cancer*. 2000;36(17):2266-2271.

Li, N., Shi, J.-F., Franceschi, S., Zhang, W.-H., Dai, M., Liu, B., Zhang, Y.-Z., Li, L.-K., Wu, R.-F., De, Vuyst H., Plummer, M., Qiao, Y.-L., and Clifford, G.. Different cervical cancer screening approaches in a Chinese multicentre study. *British Journal of Cancer*. 2009;100(3):532-537.

Liang, J., Mittal, K. R., Wei, J. J., Yee, H., Chiriboga, L., and Shukla, P.. Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with silverberg scoring system for endocervical glandular lesions. *International Journal of Gynecological Pathology*. 2007;26(1):71-75.

Lie, A. K., Risberg, B., Borge, B., Sandstad, B., Delabie, J., Rimala, R., Onsrud, M., and Thoresen, S.. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia.

Gynecologic Oncology. 2005;97(3):908-915.

Liman, A. K., Giampoli, E. J., and Bonfiglio, T. A.. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?. *Cancer*. 2005;105(6):457-460.

Liu, S. S., Leung, R. C. Y., Chan, K. K. L., Cheung, A. N. Y., and Ngan, H. Y. S.. Evaluation of a newly developed GenoArray human papillomavirus (HPV) genotyping assay and comparison with the Roche linear array HPV genotyping assay. *Journal of Clinical Microbiology*. 2010;48(3):758-764.

Liu, S., Semenciw, R., Probert, A., and Mao, Y.. Cervical cancer in Canada: Changing patterns in incidence and mortality. *International Journal of Gynecological Cancer*. 2001;11(1):24-31.

Longatto, Filho A., Miranda Pereira, S. M., Di, Loreto C., Utagawa, M. L., Makabe, S., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., and Castelo, A.. DCS liquid-based system is more effective than conventional smears to diagnosis of cervical lesions: Study in high-risk population with biopsy-based confirmation. *Gynecologic Oncology*. 2005;97(2):497-500.

Longatto-Filho, A., Erzen, M., Branca, M., Roteli-Martins, C., Naud, P., Derchain, S. F. M., Hammes, L., Sarian, L. O., Braganca, J. F., Matos, J., Gontijo, R., Lima, T., Maeda, M. Y. S., Tatti, S., Syrjanen, S., Dores, G., Lorincz, A., and Syrjanen, K.. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: Experience from the Latin American screening study. *International Journal of Gynecological Cancer*. 2006;16(3):955-962.

Lonky, N. M., Mahdavi, A., Wolde-Tsadik, G., Bajamundi, K., and Felix, J. C.. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: A retrospective review of the southern california permanente medical group experience. *Journal of Lower Genital Tract Disease*. 2010;14(3):200-205.

Lorenzato, M., Caudroy, S., Bronner, C., Evrard, G., Simon, M., Durlach, A., Birembaut, P., and Clavel, C.. Cell cycle and/or proliferation markers: What is the best method to discriminate cervical high-grade lesions?. *Human Pathology*. 2005;36(10):1101-1107.

Lozano, R.. Comparison of computer-assisted and manual screening of cervical cytology. *Gynecologic Oncology*. 2007;104(1):134-138.

Luque, A. E., Jabeen, M., Messing, S., Lane, C. A., Demeter, L. M., Rose, R. C., and Reichman, R. C.. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. *Journal of Infectious Diseases*. 2006;194(4):428-434.

Luyten, A., Scherbring, S., Reinecke-Luthge, A., Braun, B. E., Pietralla, M., Theiler, K., and Petry, K. U.. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany - Experience over 3 years. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S5-S10.

Ma, L., Bian, M.-L., Cheng, J.-Y., Xiao, W., Hao, M., Zhu, J., Chen, Y., and Liu, J.. Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study. *Experimental and Therapeutic Medicine*. 2010;1(1):193-198.

Maehama, T.. Epidemiological study in Okinawa, Japan, of human papillomavirus infection of the uterine cervix. *Infectious diseases in obstetrics and gynecology*. 2005;13(2):77-80.

Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. *BMJ*. 5-29-2004;328(7451):1293-.

Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., and Gray, A.. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test

results: 6-Month follow-up. *British Journal of Cancer*. 2005;92(6):990-994.

Mao, C., Balasubramanian, A., Yu, M., Kiviat, N., Ridder, R., Reichert, A., Herkert, M., Von Knebel, Doeberitz M., and Koutsky, L. A.. Evaluation of a new p16INK4a ELISA test and a high-risk HPV DNA test for cervical cancer screening: Results from proof-of-concept study. *International Journal of Cancer*. 2007;120(11):2435-2438.

Marchetti, I., Zavaglia, K., Bertacca, G., Aretini, P., Matteoli, B., Viacava, P., Prato, B., De, Punzio C., Genazzani, A. R., Bevilacqua, G., and Di, Coscio G.. HPV testing and Pap test: Role for a combined approach in a non-screened population. *International Journal of Biological Markers*. 2006;21(3):149-156.

Massad, S. L., Markwell, S., Cejtin, H. E., and Collins, Y.. Risk of high-grade cervical intraepithelial neoplasia among young women with abnormal screening cytology. *Journal of Lower Genital Tract Disease*. 2005;9(4):225-229.

Mathur, S. P., Mathur, R. S., Creasman, W. T., Underwood, P. B., and Kohler, M.. Early non-invasive diagnosis of cervical cancer: beyond Pap smears and human papilloma virus (HPV) testing. *Cancer biomarkers : section A of Disease markers*. 2005;1(2-3):183-191.

Matthews-Greer, J., Rivette, D., Reyes, R., Vanderloos, C. F., and Turbat-Herrera, E. A.. Human papillomavirus detection: verification with cervical cytology. *Clinical laboratory science : journal of the American Society for Medical Technology*. 2004;17(1):8-11.

Mattimoe, T.. No more annual pap tests: reviewing the consensus of experts. *Advance for nurse practitioners*. 2010;18(5):18-.

McBride, D.. New DNA test for cervical cancer outperforms Pap test. *ONS connect*. 2009;24(7):23-.

McCaffery, K. J., Irwig, L., Chan, S. F., Macaskill, P., Barratt, A., Lewicka, M., Clarke, J., and Weisberg, E.. HPV testing versus repeat Pap testing for the management of a minor abnormal Pap smear: Evaluation of a decision aid to support informed choice. *Patient Education and Counseling*. 2008;73(3):473-481.

McCaffery, K., Waller, J., Forrest, S., Cadman, L., Szarewski, A., and Wardle, J.. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact.[Erratum appears in *BJOG*. 2004 Dec;111(12):1489]. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2004;111(12):1437-1443.

McGrath, C. M., Kurtis, J. D., and Yu, G. H.. Evaluation of mild-to-moderate dysplasia on cervical-endocervical (Pap) smear: A subgroup of patients who bridge LSIL and HSIL. *Diagnostic Cytopathology*. 2000;23(4):245-248.

Meijer, C. J. L. M., Berkhof, H., Heideman, D. A. M., Hesselink, A. T., and Snijders, P. J. F.. Validation of high-risk HPV tests for primary cervical screening. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S1-S4.

Meijer, C. J., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., Heideman, D. A., and Snijders, P. J.. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *International Journal of Cancer*. 2009;Journal international du cancer. 124(3):516-520.

Meissner, H. I., Tiro, J. A., Haggstrom, D., Lu-Yao, G., and Breen, N.. Does patient health and hysterectomy status influence cervical cancer screening in older women?. *Journal of General Internal Medicine*. 2008;23(11):1822-1828.

Meshor, D., Szarewski, A., Cadman, L., Cubie, H., Kitchener, H., Luesley, D., Menon, U., Hulman, G., Desai, M., Ho, L., Terry, G., Williams, A., Sasieni, P., and Cuzick, J.. Long-term follow-up of cervical

disease in women screened by cytology and HPV testing: Results from the HART study. *British Journal of Cancer*. 2010;102(9):1405-1410.

Meyer, J. L., Hanlon, D. W., Andersen, B. T., Rasmussen, O. F., and Bisgaard, K.. Evaluation of p16INK4a expression in ThinPrep cervical specimens with the CINtec p16INK4a assay: Correlation with biopsy follow-up results. *Cancer*. 2007;111(2):83-92.

Milanova, E., Naumov, J., Nikolovska, E., and Damcevski, N.. Correlation of conventional and liquid-based cytology and their meaning in management of precancerous cervical lesions. *Akusherstvo i ginekologija*. 2005;44(1):60-62.

Miller, M. G., Sung, H. Y., Sawaya, G. F., Kearney, K. A., Kinney, W., and Hiatt, R. A.. Screening interval and risk of invasive squamous cell cervical cancer. *Obstetrics & Gynecology*. 2003;101(1):29-37.

Minelli, L., Stracci, F., Prandini, S., Moffa, I. F., and La, Rosa F.. Gynaecological cancers in Umbria (Italy): Trends of incidence, mortality and survival, 1978-1998. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2004;115(1):59-65.

Miranda Pereira, S. M., Castelo, A., Makabe, S., Utagawa, M. L., Di, Loreto C., Sakamoto Maeda, M. Y., Marques, J. A., Santoro, C. L. F., Filho, A. L., and Das Dores, G. B.. Screening for cervical cancer in high-risk populations: DNA Pap test or hybrid capture II test alone?. *International Journal of Gynecological Pathology*. 2006;25(1):38-41.

Misra, J. S., Gupta, H. P., and Das, V.. Assessing the feasibility of single lifetime PAP smear evaluation between 41-50 years of age as strategy for cervical cancer control in developing countries from our 32 years of experience of hospital-based routine cytological screening. *Diagnostic Cytopathology*. 2004;31(6):376-379.

Mo, L. Z., Monnier-Benoit, S., Kantelip, B., Petitjean, A., Riethmuller, D., Pretet, J. L., and Mouglin, C.. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2008;41(2):104-110.

Monsonogo, J., Bohbot, J. M., Pollini, G., Krawec, C., Vincent, C., Merignargues, I., Haroun, F., Sednaoui, P., Monfort, L., Dachez, R., and Syrjanen, K.. Performance of the Roche AMPLICOR Human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. *Gynecologic Oncology*. 2005;99(1):160-168.

Monsonogo, J., Pintos, J., Semaille, C., Beumont, M., Dachez, R., Zerat, L., Bianchi, A., and Franco, E.. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia. *International Journal of Gynecological Cancer*. 2006;16(2):591-598.

Montemor, E. B. L., Roteli-Martins, C. M., Zeferino, L. C., Amaral, R. G., Fonseca-Carvasan, G. A., Shirata, N. K., Utagawa, M. L., Longatto-Filho, A., and Syrjanen, K. J.. Whole, turret and step methods of rapid rescreening: Is there any difference in performance?. *Diagnostic Cytopathology*. 2007;35(1):57-60.

Moore, G., Fetterman, B., Cox, J. T., Poitras, N., Lorey, T., Kinney, W., and Castle, P. E.. Lessons from practice: Risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24. *Journal of Lower Genital Tract Disease*. 2010;14(2):97-102.

Moore, K. N. and Walker, J. L.. The abnormal pap test: Evaluation, treatment, and monitoring. *Journal of Clinical Outcomes Management*. 2006;13(4):235-244.

Moore, M. A. and Tajima, K.. Cervical cancer in the asian pacific-epidemiology, screening and

treatment. *Asian Pacific journal of cancer prevention* : APJCP. 2004;5(4):349-361.

Moreira, M. A. R., Longato-Filho, A., Taromaru, E., Queiroz, G., Jube, L. F., Pinto, S. A., and Schmitt, F. C.. Investigation of human papillomavirus by hybrid capture II in cervical carcinomas including 113 adenocarcinomas and related lesions. *International Journal of Gynecological Cancer*. 2006;16(2):586-590.

Moscicki, A.-B.. Cervical cytology screening in teens. *Current women's health reports*. 2003;3(6):433-437.

Moss, S., Gray, A., Legood, R., Vessey, M., Patnick, J., and Kitchener, H.. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: Observational before and after study. *British Medical Journal*. 2006;332(7533):83-85.

Moy, L. M., Zhao, F.-H., Li, L.-Y., Ma, J.-F., Zhang, Q.-M., Chen, F., Song, Y., Hu, S.-Y., Balasubramanian, A., Pan, Q.-J., Koutsky, L., Zhang, W.-H., Lim, J. M., Qiao, Y.-L., and Sellors, J. W.. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral. *International Journal of Cancer*. 2010;127(3):646-656.

Nam, J.-H., Kim, H.-S., Lee, J.-S., Choi, H.-S., Min, K.-W., and Park, C.-S.. A comparison of modified MonoPrep2 of liquid-based cytology with ThinPrep Pap test. *Gynecologic Oncology*. 2004;94(3):693-698.

Nassar, A., O'Reilly, K., Cohen, C., and Siddiqui, M. T.. Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations. *Diagnostic Cytopathology*. 2008;36(3):142-148.

Negri, G., Menia, E., Egarter-Vigl, E., Vittadello, F., and Mian, C.. ThinPrep versus Conventional Papanicolaou Smear in the Cytologic Follow-Up of Women with Equivocal Cervical Smears. *Cancer*. 2003;99(6):342-345.

Negri, G., Rigo, B., Vittadello, F., Mian, C., and Egarter-Vigl, E.. Abnormal cervicovaginal cytology with negative human papillomavirus testing. *Cancer*. 2007;111(5):280-284.

Nincic, D., Mandic, A., Dugandzija, T., Zivaljevic, M., Rajovic, J., and Vojinovic, D.. Linear trend analysis of patients with cervical cancer treated at the Institute of Oncology Vojvodina in 2001-2007. *Journal of B*. 2009;U.ON.. 14(4):669-672.

no authors listed. Many unnecessary Pap smears are performed after hysterectomy. *Journal of Family Practice*. 2004;53(9):682-.

Nofech-Mozes, S., Khalifa, M. M., Ismiil, N., Dube, V., Saad, R. S., Sun, P., Seth, A., and Ghorab, Z.. Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. *Applied Immunohistochemistry and Molecular Morphology*. 2010;18(1):80-85.

Nygaard, J. F., Nygaard, M., Skare, G. B., and Thoresen, S. O.. Pap smear screening in women under 30 in the Norwegian coordinated-cervical cancer screening program, with a comparison of immediate biopsy vs. pap smear triage of moderate dysplasia. *Acta Cytologica*. 2006;50(3):295-302.

Nygaard, J. F., Skare, G. B., and Thoresen, S. O.. The cervical cancer screening programme in Norway, 1992-2000: Changes in Pap smear coverage and incidence of cervical cancer. *Journal of medical screening*. 2002;9(2):86-91.

Ogilvie, D.. Early discharge of low-risk women from cervical screening. *Journal of Public Health Medicine*. 2001;23(4):272-277.

Ohl, M. and Kane, K. Y.. 3-Year interval between Pap smears adequate for women with prior negative

results. *Journal of Family Practice*. 2004;53(3):172+175-.

Okewole, I. A., Fawole, A. O., Omigbodun, A. O., and Adewole, I. F.. Does screening for cervical intra-epithelial neoplasm in developing countries prevent invasive cervical cancer?. *African Journal of Medicine & Medical Sciences*. 2003;32(3):283-285.

Oliveira, E. R. Z. M., Derchain, S. F. M., Rabelo-Santos, S. H., Westin, M. C. A., Zeferino, L. C., Campos, E. A., and Syrjanen, K. J.. Detection of high-risk human papillomavirus (HPV) DNA by hybrid capture II in women referred due to atypical glandular cells in the primary screening. *Diagnostic Cytopathology*. 2004;31(1):19-22.

Onuma, K., Saad, R. S., Kanbour-Shakir, A., Kanbour, A. I., and Dabbs, D. J.. Clinical implications of the diagnosis "Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" in pregnant women. *Cancer*. 2006;108(5):282-287.

Orbell, S., Hagger, M., Brown, V., and Tidy, J.. Appraisal theory and emotional sequelae of first visit to colposcopy following an abnormal cervical screening result. *British Journal of Health Psychology*. 2004;9(4):533-555.

Ovanin-Rakic, A., Mahovlic, V., Audy-Jurkovic, I., Barisic, A., Skopljanac-Macina, L., Juric, D., Rajhvajn, S., Ilic-Forko, J., Babic, D., Folvovic, D., and Kani, D.. Cytology of cervical intraepithelial glandular lesions. *Collegium antropologicum*. 2010;34(2):401-406.

Paci, E., Quaglia, A., Pannelli, F., and Budroni, M.. The impact of screening and early diagnosis on survival--results from the Italian cancer registries. *Epidemiologia e prevenzione*. 2001;25(3 Suppl):9-14.

Pajtler, M., Milicic-Juhas, V., Milojkovic, M., Topolovec, Z., Curzik, D., and Mihaljevic, I.. Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2. *Collegium antropologicum*. 2010;34(1):81-86.

Papathanasiou, K., Daniilidis, A., Koutsos, I., Sardeli, C., Giannoulis, C., and Tzafettas, J.. Verification of the accuracy of cervical cytology reports in women referred for colposcopy. *European Journal of Gynaecological Oncology*. 2010;31(2):187-190.

Papillo, J. L., St.John, T. L., and Leiman, G.. Effectiveness of the ThinPrep Imaging System: Clinical experience in a low risk screening population. *Diagnostic Cytopathology*. 2008;36(3):155-160.

Park, J., Jung, E.-H., Kim, C., and Young, H. C.. Direct-to-vial comparison of a new liquid-based cytology system, Liqui-PREP versus the conventional Pap smear. *Diagnostic Cytopathology*. 2007;35(8):488-492.

Partridge, E. E., Abu-Rustum, N. R., Campos, S., Edelson, M., Fahey, P. J., Fiorica, J., Greer, B. E., Lieberman, R. W., Likes, W., Molpus, K. L., Nava, M. E., Reynolds, R. K., Singh, D. K., Smith-McCune, K., Soper, J., Teng, N., Trimble, C. L., and Wilczynski, S.. Cervical cancer screening clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2004;2(6):570-587.

Patro, B. K. and Nongkynrih, B.. Review of screening and preventive strategies for cervical cancer in India. *Indian journal of public health*. 2007;51(4):216-221.

Peng, Y. and Wang, H. H.. Impact of reflex HPV testing on interpretation and management of ThinPrep pap tests. *Diagnostic Cytopathology*. 2006;34(8):585-588.

Perovic, S.. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia. *Journal of B*. 2009;U.ON.. 14(1):93-96.

Petignat, P., Faltin, D., Coffin, F., Billieux, M.-H., Stucki, D., Sporri, S., and Vassilakos, P.. Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma

screening in a population with a low incidence of cervical carcinoma. *Cancer*. 2005;105(3):126-132.

Peto, P. J., Gilham, P. C., Fletcher, O., and Matthews, F. E.. The cervical cancer epidemic that screening has prevented in the UK. *Lancet*. 2004;364(9430):249-256.

Pickett, K. E.. HPV triage was more sensitive than cytological monitoring for management of women with an ASCUS cervical screening result. *Evidence-based Obstetrics and Gynecology*. 2004;6(3):147-149.

Pirotta, M., Ung, L., Stein, A., Conway, E. L., Mast, T. C., Fairley, C. K., and Garland, S.. The psychosocial burden of human papillomavirus related disease and screening interventions. *Sexually Transmitted Infections*. 2009;85(7):508-513.

Polednak, A. P.. Trends in late-stage breast and cervical cancer incidence rates in Connecticut (United States). *Cancer Causes and Control*. 2003;14(4):361-365.

Poljak, M., Kovanda, A., Kocjan, B. J., Seme, K., Jancar, N., and Vrtacnik-Bokal, E.. The Abbott RealTime High Risk HPV test: Comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test. *Acta Dermatovenerologica Alpina, Pannonica et Adriatica*. 2009;18(3):94-103.

Powell, N., Boyde, A., Tristram, A., Hibbitts, S., and Fiander, A.. The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: An observational retrospective analysis of invasive cervical cancers. *International Journal of Cancer*. 2009;125(10):2425-2427.

Power, P., Gregoire, J., Duggan, M., and Nation, J.. Low-grade pap smears containing occasional high-grade cells as a predictor of high-grade dysplasia. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC*. 2006;28(10):884-887.

Prandi, S., Beccati, D., De, Aloysio G., Fulgenzi, P., Gabrielli, M., Ghirardini, C., Rivasi, F., Saragoni, L., de Bianchi, P. S., and Bucchi, L.. Applicability of the Bethesda System 2001 to a public health setting. *Cancer*. 2006;108(5):271-276.

Priest, P., Sadler, L., Sykes, P., Marshall, R., Peters, J., and Crengle, S.. Determinants of inequalities in cervical cancer stage at diagnosis and survival in New Zealand. *Cancer Causes and Control*. 2010;21(2):209-214.

Proca, D. M., Williams, J. D., Rofagha, S., Tranovich, V. L., and Keyhani-Rofagha, S.. Improved rate of high-grade cervical intraepithelial neoplasia detection in human papillomavirus DNA hybrid capture testing. *Analytical and Quantitative Cytology and Histology*. 2007;29(4):264-270.

Puig-Tintore, L. M., Torne, A., and Alonso, I.. Current techniques in screening for cervical cancer in Spain: Updated recommendations. *Gynecologic Oncology*. 2008;110(3 SUPPL.2):S8-S10.

Qiao, Y., Sellors, J. W., Eder, P. S., Bao, Y., Lim, J. M., Zhao, F., Weigl, B., Zhang, W., Peck, R. B., Li, L., Chen, F., Pan, Q., and Lorincz, A. T.. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. *The Lancet Oncology*. 2008;9(10):929-936.

Quddus, M., Neves, T., Reilly, M., Steinhoff, M., and Sung, C.. Does the ThinPrep Imaging System increase the detection of high-risk HPV-positive ASC-US and AGUS the Women and Infants Hospital experience with over 200,000 cervical cytology cases. *CytoJournal*. 2009;6 , 2009. Article Number: 15. Date of Publication: 2009.-.

Raab, S. S., Jones, B. A., Souers, R., and Tworek, J. A.. The effect of continuous monitoring of cytologic-histologic correlation data on cervical cancer screening performance. *Archives of Pathology and Laboratory Medicine*. 2008;132(1):16-22.

Rabelo-Santos, S. H., Derchain, S. F. M., Do Amaral Westin, M. C., Angelo-Andrade, L. A. L., Sarian, L. O. Z., Oliveira, E. R. Z. M., Morais, S. S., and Zeferino, L. C.. Endocervical glandular cell abnormalities in conventional cervical smears: Evaluation of the performance of cytomorphological criteria and HPV testing in predicting neoplasia. *Cytopathology*. 2008;19(1):34-43.

Raffle, A. E., Alden, B., Quinn, M., Babb, P. J., and Brett, M. T.. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented.[Erratum appears in *BMJ*. 2003 Aug 9;327(7410):325]. *BMJ*. 4-26-2003;326(7395):901-.

Ramsaroop, R. and Chu, I.. Accuracy of diagnosis of atypical glandular cells - Conventional and ThinPrep. *Diagnostic Cytopathology*. 2006;34(9):614-619.

Rebolj, M., van Ballegooijen M., Lynge, E., Looman, C., Essink-Bot, M.-L., Boer, R., and Habbema, D.. Incidence of cervical cancer after several negative smear results by age 50: Prospective observational study. *BMJ*. 2009;338(7702):1058-1060.

Reuschenbach, M., Clad, A., von Knebel, Doeberitz C., Wentzensen, N., Rahmsdorf, J., Schaffrath, F., Griesser, H., Freudenberg, N., and Von Knebel, Doeberitz M.. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. *Gynecologic Oncology*. 2010;119(1):98-105.

Rieck, G. C., Bhaumik, J., Beer, H. R., and Leeson, S. C.. Repeating cytology at initial colposcopy does not improve detection of high-grade abnormalities: A retrospective cohort study of 6595 women. *Gynecologic Oncology*. 2006;101(2):228-233.

Riethmuller, D., Gabelle, C., Ramanah, R., Sautiere, J.-L., Pretet, J.-L., Schaal, J.-P., Kantelip, B., Mouglin, C., and Maillet, R.. Importance of human papillomavirus (HPV) screening in the follow-up after CIN2-3 treatment. A study of 386 cases. [French]. *Journal de Gynecologie Obstetrique et Biologie de la Reproduction*. 2008;37(4):329-337.

Rijkaart, D. C., Berkhof, J., Van Kemenade, F. J., Rozendaal, L., Verheijen, R. H. M., Bulk, S., Herreilers, M. E., Verweij, W., Snijders, P. J. F., and Meijer, C. J. L. M.. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population-based cervical screening (VUSA-screen study). *International Journal of Cancer*. 2010;126(9):2175-2181.

Rijkaart, D. C., Coupe, V. M. H., Van Kemenade, F. J., Heideman, D. A. M., Hesselink, A. T., Verweij, W., Rozendaal, L., Verheijen, R. H., Snijders, P. J., Berkhof, J., and Meijer, C. J. L. M.. Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. *British Journal of Cancer*. 2010;103(7):939-946.

Roberts, J. M. and Thurloe, J. K.. Comparative sensitivities of ThinPrep and papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): Comparison with HSIL. *Cancer*. 2007;111(6):482-486.

Roberts, J. M., Thurloe, J. K., Bowditch, R. C., Hyne, S. G., Greenberg, M., Clarke, J. M., and Biro, C.. A three-armed trial of the thinprep imaging system. *Diagnostic Cytopathology*. 2007;35(2):96-102.

Roghaei, M. A., Afshar, Moghaddam N., Pooladkhan, Sh, and Roghaie, Sh. Adequacy criteria and cytomorphological changes in liqui-prep TM versus conventional cervical cytology. *Shiraz E Medical Journal*. 2010;11(4):173-182.

Rogoza, R. M., Ferko, N., Bentley, J., Meijer, C. J. L. M., Berkhof, J., Wang, K.-L., Downs, L., Smith, J. S., and Franco, E. L.. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. *Vaccine*. 2008;26(SUPPL.5):F46-F58.

Rooney, C. M., Hopkins, M. P., Oza, R., Nelson, K., and Alford, W.. The Efficacy of the ThinPrep Pap

Preparation Versus Conventional Means of Cervical Cancer Screening. *Journal of Pelvic Medicine and Surgery*. 2004;10(1):31-35.

Rosenthal, D. L., Geddes, S., Trimble, C. L., Carson, K. A., and Alli, P. M.. The PapSpin: A reasonable alternative to other, more expensive liquid-based Papanicolaou tests. *Cancer*. 2006;108(3):137-143.

Rossetti, D., Gerli, S., Saab, J.-C., and Di Renzo, G. C.. Atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) and histology. *Journal Medical Libanais*. 2000;48(3):127-130.

Rossi, P. G., Baiocchi, D., Ciatto, S., Cariaggi, P., Gustinucci, D., Camilli, I., Mancini, E., Montanari, G., Caprioglio, A., Parisio, F., Angeloni, C., Di, Gabriele G., Carantoni, A., Tinacci, G., Matteucci, M., Pontani, G., Collina, G., Carmelo, M., Biavati, P., Schincaglia, P., Serafini, M., Palma, P. D., Polla, E., Scarfanti, A. A., Schiboni, M. L., and Anghinoni, E.. Risk of CIN2 in women with a Pap test without endocervical cells vs. those with a negative Pap test with endocervical cells: A cohort study with 4.5 years of follow-up. *Acta Cytologica*. 2010;54(3):265-271.

Rughooputh, S., Parmar, K., and Greenwell, P.. Detection of human papillomavirus from liquid-based cytology specimens by in-house PCR: A pilot study. *British Journal of Biomedical Science*. 2004;61(1):22-25.

Rugpao, S., Koonlertkit, S., Ruengkrist, T., Lamlertkittikul, S., Pinjaroen, S., Limtrakul, A., Werawatakul, Y., and Sinchai, W.. ThinPrep Pap-smear and cervical intraepithelial neoplasia in reproductive-aged Thai women. *Journal of Obstetrics and Gynaecology Research*. 2009;35(3):551-554.

Sabath, A. P. and Kiviat, N. B.. Detection and classification of cervical Neoplasia in the era of HPV. *Pathology Case Reviews*. 2010;15(4):135-140.

Safaeian, M., Kiddugavu, M., Gravitt, P. E., Ssekasanvu, J., Murokora, D., Sklar, M., Serwadda, D., Wawer, M. J., Shah, K. V., and Gray, R.. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. *Sexually Transmitted Diseases*. 2007;34(7):429-436.

Sancho-Garnier, H.. Screening for breast and cervical cancers. [French]. *Oncologie*. 2002;4(8):493-498.

Saraiya, M., Berkowitz, Z., Yabroff, K. R., Wideroff, L., Kobrin, S., and Benard, V.. Cervical cancer screening with both human papillomavirus and papanicolaou testing vs papanicolaou testing alone: What screening intervals are physicians recommending?. *Archives of Internal Medicine*. 2010;170(11):977-986.

Saraiya, M., Martinez, G., Glaser, K., and Kulasingam, S.. Pap testing and sexual activity among young women in the united states. *Obstetrics and Gynecology*. 2009;114(6):1213-1219.

Sargent, A., Bailey, A., Turner, A., Almonte, M., Gilham, C., Baysson, H., Peto, J., Roberts, C., Thomson, C., Desai, M., Mather, J., and Kitchener, H.. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: Data from the ARTISTIC trial. *Journal of Clinical Microbiology*. 2010;48(2):554-558.

Sarode, V. R., Werner, C., Gander, R., Foster, B., Fulmer, A., Saboorian, M. H., and Ashfaq, R.. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: Focus on age-stratified clinical performance. *Cancer*. 2003;99(3):149-155.

Sasieni, P. and Adams, J.. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. *Lancet*. 2001;357(9267):1490-1493.

Sasieni, P., Adams, J., and Cuzick, J.. Benefit of cervical screening at different ages: Evidence from the UK audit of screening histories. *British Journal of Cancer*. 2003;89(1):88-93.

Sasieni, P., Castanon, A., and Cuzick, J.. Effectiveness of cervical screening with age: population based

case-control study of prospectively recorded data.[Erratum appears in BMJ. 2009;339:b3115]. BMJ. 2009;339:b2968-.

Sass, M. A.. Use of A Liquid-Based, Thin-Layer Pap Test in A Community Hospital: Impact on Cytology Performance and Productivity. *Acta Cytologica*. 2004;48(1):17-22.

Sawaya, G. F., McConnell, K. J., Kulasingam, S. L., Lawson, H. W., Kerlikowske, K., Melnikow, J., Lee, N. C., Gildengorin, G., Myers, E. R., and Washington, A. E.. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. *New England Journal of Medicine*. 2003;349(16):1501-1509.

Sawaya, G. F., Sung, H.-Y., Kearney, K. A., Miller, M., Kinney, W., Hiatt, R. A., and Mandelblatt, J.. Advancing age and cervical cancer screening and prognosis. *Journal of the American Geriatrics Society*. 2001;49(11):1499-1504.

Sayed, K., Korourian, S., Ellison, D. A., Kozlowski, K., Talley, L., Horn, H. V., Simpson, P., and Parham, D. M.. Diagnosing cervical biopsies in adolescents: The use of p16 immunohistochemistry to improve reliability and reproducibility. *Journal of Lower Genital Tract Disease*. 2007;11(3):141-146.

Scheiden, R., Knolle, U., Wagener, C., Wehenkel, A. M., and Capesius, C.. Cervical cancer screening in Luxembourg. *European Journal of Cancer*. 2000;36(17):2240-2243.

Schenck, U. and von, Karsa L.. Cervical cancer screening in Germany. *European Journal of Cancer*. 2000;36(17):2221-2226.

Schiffman, M., Khan, M. J., Solomon, D., Herrero, R., Wacholder, S., Hildesheim, A., Rodriguez, A. C., Bratti, M. C., Wheeler, C. M., and Burk, R. D.. A study of the impact of adding HPV types to cervical cancer screening and triage test. *Journal of the National Cancer Institute*. 2005;97(2):147-150.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Improvement of diagnostic accuracy and screening conditions with liquid-based cytology. *Diagnostic Cytopathology*. 2006;34(11):780-785.

Schledermann, D., Ejersbo, D., and Hoelund, B.. Significance of atypia in conventional Papanicolaou smears and liquid-based cytology: A follow-up study. *Cytopathology*. 2004;15(3):148-153.

Schneede, P., Hillemanns, P., Ziller, F., Hofstetter, A., Stockfleth, E., Arndt, R., and Meyer, T.. Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening. *Acta Obstetrica et Gynecologica Scandinavica*. 2001;80(8):750-752.

Schneider, A., Gleizes, O., Nieminen, P., Erdemoglu, E., Boselli, F., and Jenkins, D.. Implications of varied patterns of cervical cancer screening for introduction of human papillomavirus vaccines in Europe. *Journal of the Turkish German Gynecology Association Artemis*. 2009;10(2):61-67.

Schneider, A., Hoyer, H., Lotz, B., Leistritz, S., Kuhne-Heid, R., Nindl, I., Muller, B., Haerting, J., and Durst, M.. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. *International Journal of Cancer*. 2000;89(6):529-534.

Schopp, B., Holz, B., Zago, M., Stubenrauch, F., Petry, K.-U., Kjaer, S. K., and Iftner, T.. Evaluation of the performance of the novel PapilloCheck HPV genotyping test by comparison with two other genotyping systems and the HC2 test. *Journal of Medical Virology*. 2010;82(4):605-615.

Segnan, N., Ronco, G., and Ciatto, S.. Cervical cancer screening in Italy. *European Journal of Cancer*. 2000;36(17):2235-2239.

Sehgal, A. and Singh, V.. Human papillomavirus infection (hpv) & screening strategies for cervical cancer. *Indian Journal of Medical Research*. 2009;130(3):234-240.

Sharp, L. K., Zurawski, J. M., Roland, P. Y., O'Toole, C., and Hines, J.. Health literacy, cervical cancer risk factors, and distress in low-income African-American women seeking colposcopy. *Ethnicity &*

disease. 2002;12(4):541-546.

Sharpless, K. E., O'Sullivan, D. M., and Schnatz, P. F.. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology. *Journal of Lower Genital Tract Disease*. 2009;13(2):72-78.

Shastri, S. S., Dinshaw, K., Amin, G., Goswami, S., Patil, S., Chinoy, R., Kane, S., Kelkar, R., Muwonge, R., Mahe, C., Ajit, D., and Sankaranarayanan, R.. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. *Bulletin of the World Health Organization*. 2005;83(3):186-194.

Shastri, S. S.. Cervical cancer screening and vaccination in India. *Indian journal of medical ethics*. 2010;7(1):41-43.

Sheriff, S. K., Petry, K. U., Ikenberg, H., Crouse, G., Mazonson, P. D., and Santas, C. C.. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany. *European Journal of Health Economics*. 2007;8(2):153-160.

Sherlaw-Johnson, C. and Philips, Z.. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. *British Journal of Cancer*. 2004;91(1):84-91.

Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., and Schiffman, M.. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. *Journal of the National Cancer Institute*. 2003;95(1):46-52.

Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., Schiffman, M., and Helmerhorst, T.. Pap smear and HPV testing in combination were more accurate than either test alone for predicting the future development of CIN3 or cervical cancer. *Evidence-based Obstetrics and Gynecology*. 2003;5(3):137-138.

Shinn, E., Basen-Engquist, K., Le, T., Hansis-Diarte, A., Bostic, D., Martinez-Cross, J., Santos, A., and Follen, M.. Distress after an abnormal Pap smear result: Scale development and psychometric validation. *Preventive Medicine*. 2004;39(2):404-412.

Siddiqi, A., Spataro, M., McIntire, H., Akhtar, I., Baliga, M., Flowers, R., Lin, E., and Guo, M.. Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance Papanicolaou results in SurePath and ThinPrep specimens. *Cancer cytopathology*. 2009;117(5):318-325.

Siddiqui, M. T., Cohen, C., and Nassar, A.. Detecting high-grade cervical disease on ASC-H cytology: Role of BD ProEx C and digene hybrid capture II HPV DNA testing. *American journal of clinical pathology*. 2008;130(5):765-770.

Siebert, U., Sroczynski, G., Hillemanns, P., Engel, J., Stabenow, R., Stegmaier, C., Voigt, K., Gibis, B., Holzel, D., and Goldie, S. J.. The German Cervical Cancer Screening Model: Development and validation of a decision-analytic model for cervical cancer screening in Germany. *European Journal of Public Health*. 2006;16(2):185-192.

Siemens, F. C., Boon, M. E., Kuypers, J. C., and Kok, L. P.. Population-based cervical screening with a 5-year interval in the Netherlands: Stabilization of the incidence of squamous cell carcinoma and its precursor lesions in the screened population. *Acta Cytologica*. 2004;48(3):348-354.

Sigurdsson, K. and Sigvaldason, H.. Effectiveness of cervical cancer screening in Iceland, 1964-2002: A study on trends in incidence and mortality and the effect of risk factors. *Acta Obstetricia et Gynecologica Scandinavica*. 2006;85(3):343-349.

Sigurdsson, K. and Sigvaldason, H.. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. *European Journal of Cancer*. 2007;43(4):769-774.

Silverloo, I., Andrae, B., and Wilander, E.. Value of high-risk HPV-DNA testing in the triage of ASCUS. *Acta Obstetrica et Gynecologica Scandinavica*. 2009;88(9):1006-1010.

Simcock, B., Sykes, P., and Laney, M.. The impact of the National Cervical Screening Programme on the presentation of cancer of the cervix in Canterbury. *New Zealand Medical Journal*. 8-24-2001;114(1138):378-380.

Sireci, A. N., Crapanzano, J. P., Mansukhani, M., Wright, T., Babiac, A., Erroll, M., Vazquez, M., and Saqi, A.. Atypical Glandular Cells (AGC): ThinPrep Imaging System (TIS), Manual Screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. *Diagnostic Cytopathology*. 2010;38(10):705-709.

Sirovich, B. E. and Welch, H. G.. The frequency of Pap smear screening in the United States. *Journal of General Internal Medicine*. 2004;19(3):243-250.

Sirovich, B. E., Gottlieb, D. J., and Fisher, E. S.. The burden of prevention: Downstream consequences of Pap smear testing in the elderly. *Journal of medical screening*. 2003;10(4):189-195.

Smith, J. H. F.. The future of cervical screening in the UK. *Diagnostic Histopathology*. 2009;15(7):330-334.

Sodhani, P., Gupta, S., Singh, V., Sehgal, A., Halder, K., and Parashari, A.. Sensitivity of the pap test in detecting high grade lesions: What should be the acceptable cytologic threshold for colposcopic referral?. *Acta Cytologica*. 2006;50(2):181-184.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Acta Cytologica*. 2009;53(3):247-248.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *American journal of clinical pathology*. 2009;131(6):768-769.

Solomon, D., Papillo, J. L., and Davey, D. D.. Statement on HPV DNA test utilization. *Diagnostic Cytopathology*. 2009;37(7):542-543.

Solomon, D., Papillo, J., and Davis, Davey D.. Statement on HPV DNA test utilization. *Journal of Lower Genital Tract Disease*. 2009;13(3):135-136.

Solomon, D.. Chapter 14: Role of triage testing in cervical cancer screening. *Journal of the National Cancer Institute*. 2003;Monographs.(31):97-101.

Son, S., Noh, H. T., and An, S.. Human papillomavirus status in cervical scrapes and biopsy specimens using the HPV genotyping DNA microarray. *International Journal of Gynecology and Obstetrics*. 2006;93(3):258-259.

Soutter, W. P., Butler, J. S., and Tipples, M.. The role of colposcopy in the follow up of women treated for cervical intraepithelial neoplasia. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2006;113(5):511-514.

Sowjanya, A. P., Paul, P., Vedantham, H., Ramakrishna, G., Vidyadhari, D., Vijayaraghavan, K., Lakshmi, S., Sudula, M., Ronnett, B. M., Das, M., Shah, K. V., and Gravitt, P. E.. Suitability of self-collected vaginal samples for cervical cancer screening in Periurban Villages in Andhra Pradesh, India. *Cancer Epidemiology Biomarkers and Prevention*. 2009;18(5):1373-1378.

Spiryda, L. B., Brown, M., Creek, K. E., and Pirisi-Creek, L.. HSIL pap test and risk factors predicting acquisition of CIN 2/3 on colposcopy-directed biopsies. *Journal of the South Carolina Medical*

Association (1975). 2009;105(7):281-286.

Srodon, M., Parry, Dilworth H., and Ronnett, B. M.. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results. *Cancer*. 2006;108(1):32-38.

Stamataki, P., Papazafiropoulou, A., Elefsiniotis, I., Giannakopoulou, M., Brokalaki, H., Apostolopoulou, E., Sarafis, P., and Saroglou, G.. Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. *BMC infectious diseases*. 2010;10:27-.

Stein, S. R.. ThinPrep versus the conventional Papanicolaou test: A review of specimen adequacy, sensitivity, and cost-effectiveness. *Primary Care Update for Ob/Gyns*. 2003;10(6):310-313.

Stensson, E., Frberg, M., Hjerpe, A., Zethraeus, N., and Andersson, S.. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. *Acta Obstetrica et Gynecologica Scandinavica*. 2010;89(10):1316-1325.

Stinnett, B. A.. Use of Psychosocial Effects of Abnormal Pap Smears Questionnaire (PEAPS-Q) in a community hospital colposcopy clinic. *Journal of Lower Genital Tract Disease*. 2000;4(1):34-39.

Streiner, D. L. and Norman, G. R.. Mass screening: When does it make sense?. *Community Oncology*. 2010;7(2):93-95.

Sudha, S. and Muthumani, V.. Standardization of human papilloma virus DNA test correlation with pathology of cervical cancer. *Journal of Pure and Applied Microbiology*. 2010;4(1):243-246.

Symonds, I. M.. Screening for gynaecological conditions. *Foundation Years*. 2007;3(6):263-267.

Syrjanen, K., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Hammes, L. S., Sarian, L., Naud, P., Tatti, S., Branca, M., Erzen, M., Matos, J., Gontijo, R., Braganca, J., Arlindo, F., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among Latin American Women < 35 and >= 35 years of age: Experience from the Latin American Screening Study. *Acta Cytologica*. 2008;52(6):641-653.

Syrjanen, K., Naud, P., Derchain, S., Roteli-Martins, C., Longatto-Filho, A., Tatti, S., Branca, M., Erzen, M., Hammes, L. S., Matos, J., Gontijo, R., Sarian, L., Braganca, J., Arlindo, F. C., Maeda, M. Y. S., Lorincz, A., Dores, G. B., Costa, S., and Syrjanen, S.. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study. *Anticancer Research*. 2005;25(5):3469-3480.

Szarewski, A., Ambroisine, L., Cadman, L., Austin, J., Ho, L., Terry, G., Liddle, S., Dina, R., McCarthy, J., Buckley, H., Bergeron, C., Soutter, P., Lyons, D., and Cuzick, J.. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. *Cancer Epidemiology Biomarkers and Prevention*. 2008;17(11):3033-3042.

Szarewski, A.. Cervical screening by visual inspection with acetic acid. *Lancet*. 2007;370(9585):365-366.

Tang, N., Huang, S., Erickson, B., Mak, W.-B., Salituro, J., Robinson, J., and Abravaya, K.. High-risk HPV detection and concurrent HPV 16 and 18 typing with Abbott RealTime High Risk HPV test. *Journal of Clinical Virology*. 2009;45(SUPPL. 1):S25-S28.

Taoka, H., Yamamoto, Y., Sakurai, N., Fukuda, M., Asakawa, Y., Kurasaki, A., Oharaseki, T., and Kubushiro, K.. Comparison of conventional and liquid-based cytology, and human papillomavirus testing using SurePath preparation in Japan. *Human Cell*. 2010;23(4):126-133.

Taylor, R. J., Morrell, S. L., Mamoon, H. A., and Wain, G. V.. Effects of screening on cervical cancer incidence and mortality in New South Wales implied by influences of period of diagnosis and birth cohort. *Journal of Epidemiology & Community Health*. 2001;55(11):782-788.

Terret, C., Castel-Kremer, E., Albrand, G., and Droz, J. P.. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. *The Lancet Oncology*. 2009;10(1):80-87.

Thiryayi, S. A., Marshall, J., and Rana, D. N.. An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia. *Cytopathology*. 2010;21(4):223-228.

Thiryayi, S. A., Marshall, J., and Rana, D. N.. Differentiating between endocervical glandular neoplasia and high grade squamous intraepithelial lesions in endocervical crypts: Cytological features in ThinPrep and SurePath cervical cytology samples. *Diagnostic Cytopathology*. 2009;37(5):315-319.

Thrall, M. J., Pambuccian, S. E., Stelow, E. B., McKeon, D. M., Miller, L., Savik, K., and Gulbahce, H. E.. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda system on the sensitivity and specificity of the papanicolaou test: A 5-year follow-up study of papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria. *Cancer*. 2008;114(3):171-179.

Thrall, M. J., Russell, D. K., Facik, M. S., Yao, J. L., Warner, J. N., Bonfiglio, T. A., and Giampoli, E. J.. High-risk HPV testing in women 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up. *American journal of clinical pathology*. 2010;133(6):894-898.

Thrall, M. J., Smith, D. A., and Mody, D. R.. Women ≥ 30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: Should we reconsider HPV triage for LSIL in older women?. *Diagnostic Cytopathology*. 2010;38(6):407-412.

Thrall, M., Kjeldahl, K., Gulbahce, H. E., and Pambuccian, S. E.. Liquid-based papanicolaou test (SurePath) interpretations before histologic diagnosis of endometrial hyperplasias and carcinomas: Study of 272 cases classified by the 2001 Bethesda system. *Cancer*. 2007;111(4):217-223.

Tiews, S., Steinberg, W., Schneider, W., and Hanrath, C.. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: Preliminary data. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S11-S15.

Tinelli, A., Leo, G., Pisano, M., Storelli, F., Leo, S., Vergara, D., and Malvasi, A.. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. *Current Pharmaceutical Biotechnology*. 2009;10(8):767-771.

Treacy, A., Reynolds, J., Kay, E. W., Leader, M., and Grace, A.. Has the ThinPrep Method of Cervical Screening Maintained Its Improvement Over Conventional Smears in terms of Specimen Adequacy?. *Diagnostic Cytopathology*. 2009;37(4):239-240.

Trivers, K. F., Benard, V. B., Ehemann, C. R., Royalty, J. E., Ekwueme, D. U., and Lawson, H. W.. Repeat pap testing and colposcopic biopsies in the underserved. *Obstetrics and Gynecology*. 2009;114(5):1049-1056.

Troni, G. M., Cipparrone, I., Cariaggi, M. P., Ciatto, S., Miccinesi, G., Zappa, M., and Confortini, M.. Detection of false-negative pap smears using the PAPNET system. *Tumori*. 2000;86(6):455-457.

Tsai, H.-T., Tsai, Y.-M., Yang, S.-F., Lee, C.-H., Lin, L.-Y., Lee, S., and Wu, M.-T.. A notable accessory screening program for detection of cervical intraepithelial neoplasia. *Pathologie Biologie*. 2009;57(6):477-482.

Tsiodras, S., Georgoulakis, J., Chranioti, A., Voulgaris, Z., Psyrris, A., Tsvilika, A., Panayiotides, J., and Karakitsos, P.. Hybrid capture vs. PCR screening of cervical human papilloma virus infections.

Cytological and histological associations in 1270 women. *BMC Cancer*. 2010;10 , 2010. Article Number: 53. Date of Publication: 22 Feb 2010.:-.

Tuncer, Z. S., Basaran, M., Sezgin, Y., Firat, P., and Kuzey, G. M.. Clinical results of a split sample liquid-based cytology (ThinPrep) study of 4,322 patients in a Turkish institution. *European Journal of Gynaecological Oncology*. 2005;26(6):646-648.

Uyar, D. S., Eltabbakh, G. H., and Mount, S. L.. Positive predictive value of liquid-based and conventional cervical Papanicolaou smears reported as malignant. *Gynecologic Oncology*. 2003;89(2):227-232.

Valdini, A. and Esielionis, P.. Measurement of colposcopy-associated distress using the psychosocial effects of having an abnormal pap smear-questionnaire in a Latina population. *Journal of Lower Genital Tract Disease*. 2004;8(1):25-32.

Van Den Akker-Van Marle, van, Ballegooijen M., and Habbema, J. D. F.. Low risk of cervical cancer during a long period after negative screening in the Netherlands. *British Journal of Cancer*. 2003;88(7):1054-1057.

van der Aa, M. A., De Kok, I. M. C. M., Siesling, S., van, Ballegooijen M., and Coebergh, J. W. W.. Does lowering the screening age for cervical cancer in the Netherlands make sense?. *International Journal of Cancer*. 2008;123(6):1403-1406.

van der Aa, M. A., Schutter, E. M., Looijen-Salamon, M., Martens, J. E., and Siesling, S.. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of The Netherlands, 1992-2001. *European Journal of Obstetrics, Gynecology, & Reproductive Biology*. 2008;139(2):204-209.

Varnai, A. D., Bollmann, M., Bankfalvi, A., Speich, N., Schmitt, C., Griefingholt, H., Kovacs, K., Klozoris, C., and Bollmann, R.. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: Diagnostic and prognostic implications. *Oncology Reports*. 2008;19(2):457-465.

Vijayaraghavan, A., Efrusy, M. B., Mayrand, M. H., Santas, C. C., and Goggin, P.. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. *Canadian Journal of Public Health*. 2010;Revue canadienne de sante publique. 101(3):220-225.

Vijayaraghavan, A., Efrusy, M., Lindeque, G., Dreyer, G., and Santas, C.. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. *Gynecologic Oncology*. 2009;112(2):377-383.

Vollmer, R. T.. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. *Cancer*. 10-25-2002;96(5):316-318.

Voskanyan, M. A.. Precancerous cervical lesions: Diagnosis and treatment. *New Armenian Medical Journal*. 2009;3(3):49-56.

Voss, J. S., Kipp, B. R., Campion, M. B., Sokolova, I. A., Henry, M. R., Halling, K. C., and Clayton, A. C.. Assessment of fluorescence in situ hybridization and hybrid capture 2 analyses of cervical cytology specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia. *Analytical and Quantitative Cytology and Histology*. 2010;32(3):121-130.

Vrtacnik-Bokal, E., Rakar, S., Jancar, N., Mozina, A., and Poljak, M.. Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions. *European Journal of Gynaecological Oncology*. 2005;26(4):427-430.

Walter, L. C., Lewis, C. L., and Barton, M. B.. Screening for colorectal, breast, and cervical cancer in

the elderly: A review of the evidence. *American Journal of Medicine*. 2005;118(10):1078-1086.

Wang, K. L., Jeng, C. J., Yang, Y. C., Chen, C. A., Cheng, W. F., Chen, T. C., Mast, T. C., Wang, Y. C., and Hsieh, C. Y.. The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. *Journal of Psychosomatic Obstetrics & Gynecology*. 2010;31(1):16-23.

Wang, X., Zheng, B., Li, S., Zhang, R., Mulvihill, J. J., Chen, W. R., and Liu, H.. Automated detection and analysis of fluorescent in situ hybridization spots depicted in digital microscopic images of Pap-smear specimens. *Journal of biomedical optics*. 2009;14(2):021002-021Apr.

Warman, J.. Cervical cancer screening in young women: saving lives with prevention and detection. *Oncology nursing forum*. 2010;37(1):33-38.

Warren, J. B., Gullett, H., and King, V. J.. Cervical Cancer Screening and Updated Pap Guidelines. *Primary Care - Clinics in Office Practice*. 2009;36(1):131-149.

Wells, S. F.. Cervical cancer: an overview with suggested practice and policy goals. *Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses*. 2008;17(1):43-50.

Wentzensen, N., Bergeron, C., Cas, F., Vinokurova, S., and Von Knebel, Doeberitz M.. Triage of women with ASCUS and LSIL cytology: Use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. *Cancer*. 2007;111(1):58-66.

Wentzensen, N., Hampl, M., Herkert, M., Reichert, A., Trunk, M. J., Poremba, C., Ridder, R., and Von Knebel, Doeberitz M.. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. *Cancer*. 2006;107(9):2307-2313.

Werner, C. L., Griffith III, W. F., Ashfaq, R., Gossett, D., Wilkinson, E., Raab, S., Bambot, S., Mongin, D., and Faupel, M.. Comparison of human papilloma virus testing and spectroscopy combined with cervical cytology for the detection of high-grade cervical neoplasia. *Journal of Lower Genital Tract Disease*. 2007;11(2):73-79.

Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., Markman, M., Mayer, R., Pfister, D., Raghavan, D., Ramsey, S., Reaman, G., Sandler, H., Sawaya, R., Schuchter, L., Sweetenham, J., Vahdat, L., Schilsky, R. L., and Sweet, D.. Clinical cancer advances 2008: Major research advances in cancer treatment, prevention, and screening-a report from the american society of clinical oncology. *Journal of Clinical Oncology*. 2009;27(5):812-826.

Witt, A., Hudelist, G., Gregor, H., Kucera, E., Walchetseder, C., and Czerwenka, K.. The detection of HPV DNA improves the recognition of cervical intraepithelial lesions. *Archives of Gynecology and Obstetrics*. 2003;268(1):29-34.

Wong, A. K., Chan, R. C., Nichols, W. S., and Bose, S.. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance. *Cancer*. 2009;115(4):823-832.

Wongworapat, K., Keawvichit, R., Sirojorn, B., Dokuta, S., Ruangyuttikarn, C., Sriplienchan, S., Sontirat, A., Kla, K. T., Gravitt, P. E., and Celentano, D. D.. Detection of human papillomavirus from self-collected vaginal samples of women in Chiang Mai, Thailand. *Sexually Transmitted Diseases*. 2008;35(2):172-173.

Woo, P. P. S., Thach, T. Q., Choy, S. T. B., McGhee, S. M., and Leung, G. M.. Modelling the impact of population-based cytologic screening on cervical cancer incidence and mortality in Hong Kong: An age-period-cohort approach. *British Journal of Cancer*. 2005;93(9):1077-1083.

Wood, M. D., Horst, J. A., and Bibbo, M.. Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based pap tests: A review. *Diagnostic Cytopathology*. 2007;35(1):12-17.

- Wright, P. K., Marshall, J., and Desai, M.. Comparison of SurePath and ThinPrep liquid-based cervical cytology using positive predictive value, atypical predictive value and total predictive value as performance indicators. *Cytopathology*. 2010;21(6):374-378.
- Wu, S. F., Meng, L., Wang, S. X., and Ma, D.. A comparison of four screening methods for cervical neoplasia. *International Journal of Gynecology and Obstetrics*. 2005;91(2):189-193.
- Yang, B., Morrell, S., Zuo, Y., Roder, D., Tracey, E., and Jelfs, P.. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women. *Cancer Causes Control*. 2008;19(6):569-576.
- Yang, B., Pretorius, R. G., Belinson, J. L., Zhang, X., Burchette, R., and Qiao, Y.-L.. False negative colposcopy is associated with thinner cervical intraepithelial neoplasia 2 and 3. *Gynecologic Oncology*. 2008;110(1):32-36.
- Yapikakis, C., Adamopoulou, M., Antonopoulos, G., Koufaliotis, N., and Vairaktaris, E.. Prevalence of HPV types in a cohort of greeks with clinical indication of infection. *Anticancer Research*. 2008;28(4 B):2233-2237.
- Yeoh, G. P. S., Tse, M. P. Y., Chan, K. W., and Lord, L.. Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and follow-up patient group. *Acta Cytologica*. 2006;50(6):627-631.
- Yoon, J. H., Yoo, S. C., Kim, W. Y., Chang, S. J., Chang, K. H., and Ryu, H. S.. Role of HPV DNA testing for detection of high-grade cervical lesions in women with atypical squamous cells of undetermined significance: A prospective study in a Korean population. *European Journal of Gynaecological Oncology*. 2009;30(3):271-274.
- Young, T. K., Lee, J. M., Hur, S.-Y., Cho, C.-H., Kim, Y. T., Seung, C. K., and Kang, S. B.. Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. *International Journal of Cancer*. 2010;126(8):1903-1909.
- Yuan, Q. and Wilbur, D. C.. Original cervical cytology and follow-up biopsy results in positive high risk human papillomavirus DNA tests with high-level results. *Acta Cytologica*. 2008;52(5):557-562.
- Zhao, C. and Austin, R. M.. High-risk human papillomavirus DNA test results are useful for disease risk stratification in women with unsatisfactory liquid-based cytology pap test results. *Journal of Lower Genital Tract Disease*. 2009;13(2):79-84.
- Zhao, C., Florea, A., and Austin, R. M.. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. *Archives of pathology & laboratory medicine*. 2010;134(1):103-108.
- Zhao, C., Florea, A., Onisko, A., and Austin, R. M.. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: Results from a large academic womens hospital laboratory employing sensitive screening methods. *Gynecologic Oncology*. 2009;114(3):383-389.
- Zhu, J., Norman, I., Elfgren, K., Gaberi, V., Hagmar, B., Hjerpe, A., and Andersson, S.. A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. *Oncology Reports*. 2007;18(1):157-160.

Level 4: Population-Women are not between the ages of 15 and 70 years

- Sudha, S. and Muthumani, V.. Standardization of human papilloma virus DNA test correlation with pathology of cervical cancer. *Journal of Pure and Applied Microbiology*. 2010;4(1):243-246.
- Hoonhorst, F. and Hamon, A.. Cervical cancer and HPV screening. [French]. *IRBM News*. 2008;29(3-

4):19-21.

Level 4: Intervention - Conventional Pap tests, smear, liquid-based Pap test, HPV DNA testing or computer assisted screening.

Chan, P. G., Sung, H.-Y., and Sawaya, G. F.. Changes in cervical cancer incidence after three decades of screening US women less than 30 years old. *Obstetrics and Gynecology*. 2003;102(4):765-773.

Chan, P. K. S., Chang, A. R., Yu, M. Y., Li, W.-H., Chan, M. Y. M., Yeung, A. C. M., Cheung, T.-H., Yau, T.-N., Wong, S.-M., Yau, C.-W., and Ng, H.-K.. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. *International Journal of Cancer*. 2010;126(1):297-301.

Day, G. E., Lanier, A. P., Bulkow, L., Kelly, J. J., and Murphy, N.. Cancers of the breast, uterus, ovary and cervix among Alaska native women, 1974-2003. *International Journal of Circumpolar Health*. 2010;69(1):72-86.

Levi, F., Lucchini, F., Negri, E., Franceschi, S., and La, Vecchia C.. Cervical cancer mortality in young women in Europe patterns and trends. *European Journal of Cancer*. 2000;36(17):2266-2271.

Minelli, L., Stracci, F., Prandini, S., Moffa, I. F., and La, Rosa F.. Gynaecological cancers in Umbria (Italy): Trends of incidence, mortality and survival, 1978-1998. *European Journal of Obstetrics Gynecology and Reproductive Biology*. 2004;115(1):59-65.

Nincic, D., Mandic, A., Dugandzija, T., Zivaljevic, M., Rajovic, J., and Vojinovic, D.. Linear trend analysis of patients with cervical cancer treated at the Institute of Oncology Vojvodina in 2001-2007. *Journal of B*. 2009;U.ON.. 14(4):669-672.

Powell, N., Boyde, A., Tristram, A., Hibbitts, S., and Fiander, A.. The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: An observational retrospective analysis of invasive cervical cancers. *International Journal of Cancer*. 2009;125(10):2425-2427.

Sasieni, P. and Adams, J.. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. *Lancet*. 2001;357(9267):1490-1493.

Taylor, R. J., Morrell, S. L., Mamoon, H. A., and Wain, G. V.. Effects of screening on cervical cancer incidence and mortality in New South Wales implied by influences of period of diagnosis and birth cohort. *Journal of Epidemiology & Community Health*. 2001;55(11):782-788.

Level 4: Comparison - No screening, celibate or one partner women as low risk comparators, liquid-based pap test, conventional pap test or HPV DNA testing

Adab, P., McGhee, S. M., Yanova, J., Wong, C. M., and Hedley, A. J.. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. *Medical Care*. 2004;42(6):600-609.

Aklimunnessa, K., Mori, M., Khan, M. M. H., Sakauchi, F., Kubo, T., Fujino, Y., Suzuki, S., Tokudome, S., and Tamakoshi, A.. Effectiveness of cervical cancer screening over cervical cancer mortality among Japanese women. *Japanese journal of clinical oncology*. 2006;36(8):511-518.

Baay, M. F. D., Tjalma, W. A. A., Lambrechts, H. A. J., Pattyn, G. G. O., Lardon, F., Weyler, J., Van, Royen P., Van Marck, E. A. E., and Vermorken, J. B.. Combined Pap and HPV testing in primary screening for cervical abnormalities: Should HPV detection be delayed until age 35?. *European Journal*

of Cancer. 2005;41(17):2704-2708.

Bergeron, C.. Screening and early diagnosis of cervical cancer in a context of HPV vaccination. [French]. *Revue du Praticien*. 2010;60(2):214-215.

Blake, G., Hanchard, B., Gibson, T., Wolff, C., Samuels, E., Waugh, N., and Simpson, D.. Gynaecologic cancer incidence, Kingston and St Andrew, Jamaica, 1973-1997, and gynaecologic cancer mortality, Jamaica, 1999. *West Indian Medical Journal*. 2003;52(4):273-277.

Blanks, R. G., Moss, S. M., Addou, S., Coleman, D. A., and Swerdlow, A. J.. Risk of cervical abnormality after age 50 in women with previously negative smears. *British Journal of Cancer*. 2009;100(11):1832-1836.

Bray, F., Loos, A. H., McCarron, P., Weiderpass, E., Arbyn, M., Moller, H., Hakama, M., and Parkin, D. M.. Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. *Cancer Epidemiology Biomarkers and Prevention*. 2005;14(3):677-686.

Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H. M., and Meijer, C. J. L. M.. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. *International Journal of Cancer*. 2005;113(6):1005-1009.

Castle, P. E., Fetterman, B., Thomas, Cox J., Shaber, R., Poitras, N., Lorey, T., and Kinney, W.. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. *Obstetrics and Gynecology*. 2010;116(1):76-84.

Castle, P. E., Rodriguez, A. C., Burk, R. D., Herrero, R., Hildesheim, A., Solomon, D., Sherman, M. E., Jeronimo, J., Alfaro, M., Morales, J., Guillen, D., Hutchinson, M. L., Wacholder, S., and Schiffman, M.. Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. *International Journal of Cancer*. 2009;125(7):1649-1656.

Chen, Y.-Y., You, S.-L., Chen, C.-A., Shih, L.-Y., Koong, S.-L., Chao, K.-Y., Hsiao, M.-L., Hsieh, C.-Y., and Chen, C.-J.. Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences. *British Journal of Cancer*. 2009;101(1):174-177.

Coldman, A., Phillips, N., Kan, L., Maticic, J., Benedet, L., and Towers, L.. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives. *Journal of medical screening*. 2005;12(1):7-11.

Coldman, A., Phillips, N., Kan, L., Maticic, J., Benedet, L., and Towers, L.. Risk of invasive cervical cancer after three consecutive negative Pap smears. *Journal of medical screening*. 2003;10(4):196-200.

Comber, H. and Gavin, A.. Recent trends in cervical cancer mortality in Britain and Ireland: The case for population-based cervical cancer screening. *British Journal of Cancer*. 2004;91(11):1902-1904.

Deerasamee, S., Srivatanakul, P., Sriplung, H., Nilvachararung, S., Tansuwan, U., Pitakpraiwan, P., Kaewkungwal, J., Singhasivanon, P., Nimnakorn, P., and Sankaranarayanan, R.. Monitoring and evaluation of a model demonstration project for the control of cervical cancer in Nakhon Phanom province, Thailand. *Asian Pacific journal of cancer prevention : APJCP*. 2007;8(4):547-556.

Dunton, C. J., Dooley, M., and Holtz, D. O.. Early detection of cervical cancer by human papillomavirus DNA testing: Case reports. *Journal of Lower Genital Tract Disease*. 2006;10(4):256-257.

El, Gnaoui N., Saile, R., and Benomar, H.. Pap smear an inevitable test in the screening of the lesions of the cervix. [French]. *Journal Africain du Cancer*. 2010;2(1):9-13.

Escobedo, L. G., Zhong, Z., and Key, C.. Breast and cervical cancer screening and disease incidence and stage in New Mexico. *Cancer Causes and Control*. 2002;13(2):137-145.

Flori, M., Dupraz, C., Erpeldinger, S., and Le, Goaziou M. F.. Cervical smears among women after 65

years. One-year retrospective descriptive study. [French]. *Revue du Praticien*. 2009;59(10 SUPPL. 1):29-32.

Goldie, S. J., Kim, J. J., and Wright, T. C.. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. *Obstetrics and Gynecology*. 2004;103(4):619-631.

Gunnell, A. S., Ylitalo, N., Sandin, S., Sparen, P., Adami, H.-O., and Ripatti, S.. A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: Evidence of effectiveness and overtreatment. *Cancer Epidemiology Biomarkers and Prevention*. 2007;16(12):2641-2648.

Gupta, S., Sodhani, P., Halder, K., Chachra, K. L., Singh, V., and Sehgal, A.. Age trends in pre-cancerous and cancerous lesions of the uterine cervix in a cytology screening programme: What should be the target age group for a major thrust of screening in resource-limited settings?. *Cytopathology*. 2008;19(2):106-110.

Herbert, A., Gregory, M., Gupta, S. S., and Singh, N.. Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2009;116(6):854-859.

Herbert, A., Holdsworth, G., and Kubba, A. A.. Cervical screening: Why young women should be encouraged to be screened. *Journal of Family Planning and Reproductive Health Care*. 2008;34(1):21-25.

Igdbashian, S., Maggioni, A., Casadio, C., Boveri, S., Cristoforoni, P., and Sideri, M.. Sentinel Pap smears in 261 invasive cervical cancer patients in Italy. *Vaccine*. 2009;27(SUPPL. 1):A34-A38.

Ingemann-Hansen, O., Lidang, M., Niemann, I., Dinesen, J., Baandrup, U., Svanholm, H., and Petersen, L. K.. Screening history of women with cervical cancer: A 6-year study in Aarhus, Denmark. *British Journal of Cancer*. 2008;98(7):1292-1294.

Khuakoonratt, N., Tangjitgamol, S., Manusirivithaya, S., Khunnarong, J., Pataradule, K., Thavaramara, T., and Suekwattana, P.. Prevalence of high grade squamous intraepithelial lesion (HSIL) and invasive cervical cancer in patients with low grade squamous intraepithelial lesion (LSIL) at cervical pap smear. *Asian Pacific journal of cancer prevention : APJCP*. 2008;9(2):253-257.

Kinney, W., Sawaya, G. F., Sung, H. Y., Kearney, K. A., Miller, M., and Hiatt, R. A.. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. [Review] [27 refs]. *Acta Cytologica*. 2003;47(2):167-171.

Luyten, A., Scherbring, S., Reinecke-Luthge, A., Braun, B. E., Pietralla, M., Theiler, K., and Petry, K. U.. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany - Experience over 3 years. *Journal of Clinical Virology*. 2009;46(SUPPL. 3):S5-S10.

Misra, J. S., Gupta, H. P., and Das, V.. Assessing the feasibility of single lifetime PAP smear evaluation between 41-50 years of age as strategy for cervical cancer control in developing countries from our 32 years of experience of hospital-based routine cytological screening. *Diagnostic Cytopathology*. 2004;31(6):376-379.

Moore, G., Fetterman, B., Cox, J. T., Poitras, N., Lorey, T., Kinney, W., and Castle, P. E.. Lessons from practice: Risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24. *Journal of Lower Genital Tract Disease*. 2010;14(2):97-102.

Moreira, M. A. R., Longato-Filho, A., Taromaru, E., Queiroz, G., Jube, L. F., Pinto, S. A., and Schmitt, F. C.. Investigation of human papillomavirus by hybrid capture II in cervical carcinomas including 113 adenocarcinomas and related lesions. *International Journal of Gynecological Cancer*. 2006;16(2):586-

Ohl, M. and Kane, K. Y.. 3-Year interval between Pap smears adequate for women with prior negative results. *Journal of Family Practice*. 2004;53(3):172+175-.

Okewole, I. A., Fawole, A. O., Omigbodun, A. O., and Adewole, I. F.. Does screening for cervical intra-epithelial neoplasm in developing countries prevent invasive cervical cancer?. *African Journal of Medicine & Medical Sciences*. 2003;32(3):283-285.

Paci, E., Quaglia, A., Pannelli, F., and Budroni, M.. The impact of screening and early diagnosis on survival--results from the Italian cancer registries. *Epidemiologia e prevenzione*. 2001;25(3 Suppl):9-14.

Partridge, E. E., Abu-Rustum, N. R., Campos, S., Edelson, M., Fahey, P. J., Fiorica, J., Greer, B. E., Lieberman, R. W., Likes, W., Molpus, K. L., Nava, M. E., Reynolds, R. K., Singh, D. K., Smith-McCune, K., Soper, J., Teng, N., Trimble, C. L., and Wilczynski, S.. Cervical cancer screening clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2004;2(6):570-587.

Pirotta, M., Ung, L., Stein, A., Conway, E. L., Mast, T. C., Fairley, C. K., and Garland, S.. The psychosocial burden of human papillomavirus related disease and screening interventions. *Sexually Transmitted Infections*. 2009;85(7):508-513.

Qiao, Y., Sellors, J. W., Eder, P. S., Bao, Y., Lim, J. M., Zhao, F., Weigl, B., Zhang, W., Peck, R. B., Li, L., Chen, F., Pan, Q., and Lorincz, A. T.. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. *The Lancet Oncology*. 2008;9(10):929-936.

Rebolj, M., van, Ballegooijen M., Lynge, E., Looman, C., Essink-Bot, M.-L., Boer, R., and Habbema, D.. Incidence of cervical cancer after several negative smear results by age 50: Prospective observational study. *BMJ*. 2009;338(7702):1058-1060.

Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., Mielzynska-Lohnas, I., Rush, B. B., and Schiffman, M.. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. *Journal of the National Cancer Institute*. 2003;95(1):46-52.

Siemens, F. C., Boon, M. E., Kuypers, J. C., and Kok, L. P.. Population-based cervical screening with a 5-year interval in the Netherlands: Stabilization of the incidence of squamous cell carcinoma and its precursor lesions in the screened population. *Acta Cytologica*. 2004;48(3):348-354.

Sigurdsson, K. and Sigvaldason, H.. Effectiveness of cervical cancer screening in Iceland, 1964-2002: A study on trends in incidence and mortality and the effect of risk factors. *Acta Obstetricia et Gynecologica Scandinavica*. 2006;85(3):343-349.

Sigurdsson, K. and Sigvaldason, H.. Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseases. *European Journal of Cancer*. 2007;43(4):769-774.

Simcock, B., Sykes, P., and Laney, M.. The impact of the National Cervical Screening Programme on the presentation of cancer of the cervix in Canterbury. *New Zealand Medical Journal*. 8-24-2001;114(1138):378-380.

Trivers, K. F., Benard, V. B., Ehemann, C. R., Royalty, J. E., Ekwueme, D. U., and Lawson, H. W.. Repeat pap testing and colposcopic biopsies in the underserved. *Obstetrics and Gynecology*. 2009;114(5):1049-1056.

van der Aa, M. A., De Kok, I. M. C. M., Siesling, S., van, Ballegooijen M., and Coebergh, J. W. W.. Does lowering the screening age for cervical cancer in the Netherlands make sense?. *International*

Journal of Cancer. 2008;123(6):1403-1406.

van der Aa, M. A., Schutter, E. M., Looijen-Salamon, M., Martens, J. E., and Siesling, S.. Differences in screening history, tumour characteristics and survival between women with screen-detected versus not screen-detected cervical cancer in the east of The Netherlands, 1992-2001. *European Journal of Obstetrics, Gynecology, & Reproductive Biology*. 2008;139(2):204-209.

Level 4: Outcomes Of screening

Almonte, M., Ferreccio, C., Winkler, J. L., Cuzick, J., Tsu, V., Robles, S., Takahashi, R., and Sasieni, P.. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. *International Journal of Cancer*. 2007;121(4):796-802.

Patro, B. K. and Nongkynrih, B.. Review of screening and preventive strategies for cervical cancer in India. *Indian journal of public health*. 2007;51(4):216-221.

Petignat, P., Faltin, D., Coffin, F., Billieux, M.-H., Stucki, D., Sporri, S., and Vassilakos, P.. Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma. *Cancer*. 2005;105(3):126-132.

Tsiodras, S., Georgoulakis, J., Chranioti, A., Voulgaris, Z., Psyrris, A., Tsvilika, A., Panayiotides, J., and Karakitsos, P.. Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. *BMC Cancer*. 2010;10, 2010. Article Number: 53. Date of Publication: 22 Feb 2010.

Van Den Akker-Van Marle, van, Ballegooijen M., and Habbema, J. D. F.. Low risk of cervical cancer during a long period after negative screening in the Netherlands. *British Journal of Cancer*. 2003;88(7):1054-1057.

Level 4: Is this an appropriate study design: systematic review, meta-analysis, RCT or observational?

Canfell, K., Barnabas, R., Patnick, J., and Beral, V.. The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study. *British Journal of Cancer*. 2004;91(3):530-536.

Hemminki, K., Li, X., and Mutanen, P.. Age-incidence relationships and time trends in cervical cancer in Sweden. *European Journal of Epidemiology*. 2001;17(4):323-328.

Kahn, J. A., Slap, G. B., Bernstein, D. I., Kollar, L. M., Tissot, A. M., Hillard, P. A., and Rosenthal, S. L.. Psychological, behavioral, and interpersonal impact of human papillomavirus and pap test results. *Journal of Women's Health*. 2005;14(7):650-659.

Liu, S., Semenciw, R., Probert, A., and Mao, Y.. Cervical cancer in Canada: Changing patterns in incidence and mortality. *International Journal of Gynecological Cancer*. 2001;11(1):24-31.

Raffle, A. E., Alden, B., Quinn, M., Babb, P. J., and Brett, M. T.. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented.[Erratum appears in *BMJ*. 2003 Aug 9;327(7410):325]. *BMJ*. 4-26-2003;326(7395):901-

Woo, P. P. S., Thach, T. Q., Choy, S. T. B., McGhee, S. M., and Leung, G. M.. Modelling the impact of population-based cytologic screening on cervical cancer incidence and mortality in Hong Kong: An age-period-cohort approach. *British Journal of Cancer*. 2005;93(9):1077-1083.

